FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Landman, KZ
Tan, KR
Arguin, PM
AF Landman, Keren Z.
Tan, Kathrine R.
Arguin, Paul M.
TI Knowledge, Attitudes, and Practices Regarding Antimalarial
Chemoprophylaxis in US Peace Corps Volunteers - Africa, 2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID TRAVELERS
C1 [Landman, Keren Z.] CDC, Atlanta, GA 30333 USA.
[Landman, Keren Z.; Tan, Kathrine R.; Arguin, Paul M.] CDC, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Landman, KZ (reprint author), CDC, Atlanta, GA 30333 USA.
EM klandman@cdc.gov
NR 4
TC 6
Z9 7
U1 0
U2 0
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD JUN 13
PY 2014
VL 63
IS 23
BP 516
EP 517
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AJ4KN
UT WOS:000337645300003
PM 24918487
ER
PT J
AU Chiang, CF
Albarino, CG
Lo, MK
Spiropoulou, CF
AF Chiang, Cheng-Feng
Albarino, Cesar G.
Lo, Michael K.
Spiropoulou, Christina F.
TI Small Interfering RNA Inhibition of Andes Virus Replication
SO PLOS ONE
LA English
DT Article
ID HANTAVIRUS CARDIOPULMONARY SYNDROME; PULMONARY SYNDROME; NUCLEOCAPSID
PROTEIN; ANTIVIRAL IMMUNITY; MOSQUITO CELLS; DOUBLE-BLIND; TRANSMISSION;
INFECTIONS; RESISTANCE; RIBAVIRIN
AB Andes virus (ANDV) is the most common causative agent of hantavirus pulmonary syndrome (HPS) in the Americas, and is the only hantavirus associated with human-to-human transmission. Case fatality rates of ANDV-induced HPS are approximately 40%. There are currently no effective vaccines or antivirals against ANDV. Since HPS severity correlates with viral load, we tested small interfering RNA (siRNA) directed against ANDV genes as a potential antiviral strategy. We designed pools of 4 siRNAs targeting each of the ANDV genome segments (S, M, and L), and tested their efficacy in reducing viral replication in vitro. The siRNA pool targeting the S segment reduced viral transcription and replication in Vero-E6 cells more efficiently than those targeting the M and L segments. In contrast, siRNAs targeting the S, M, or L segment were similar in their ability to reduce viral replication in human lung microvascular endothelial cells. Importantly, these siRNAs inhibit ANDV replication even if given after infection. Taken together, our findings indicate that siRNAs targeting the ANDV genome efficiently inhibit ANDV replication, and show promise as a strategy for developing therapeutics against ANDV infection.
C1 [Chiang, Cheng-Feng; Albarino, Cesar G.; Lo, Michael K.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
RP Spiropoulou, CF (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
EM cspiropoulou@cdc.gov
OI Lo, Michael/0000-0002-0409-7896; Chiang, Cheng-Feng/0000-0002-3617-9124
FU Centers for Disease Control and Prevention (CDC)
FX This work was funded by Centers for Disease Control and Prevention (CDC)
core funding. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 37
TC 3
Z9 3
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 12
PY 2014
VL 9
IS 6
AR e99764
DI 10.1371/journal.pone.0099764
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK8TP
UT WOS:000338701300091
PM 24924189
ER
PT J
AU Pondo, T
Rose, CE
Martin, SW
Keitel, WA
Keyserling, HL
Babcock, J
Parker, S
Jacobson, RM
Poland, GA
McNeil, MM
AF Pondo, Tracy
Rose, Charles E., Jr.
Martin, Stacey W.
Keitel, Wendy A.
Keyserling, Harry L.
Babcock, Janiine
Parker, Scott
Jacobson, Robert M.
Poland, Gregory A.
McNeil, Michael M.
TI Evaluation of sex, race, body mass index and pre-vaccination serum
progesterone levels and post-vaccination serum anti-anthrax protective
immunoglobulin G on injection site adverse events following anthrax
vaccine adsorbed (AVA) in the CDC AVA human clinical trial
SO VACCINE
LA English
DT Article
DE Anthrax vaccine adsorbed; Anthrax vaccines/adverse events; Sex factors;
Race; Body mass index; Immunological response
ID IMMUNE-RESPONSES; RANDOMIZED-TRIAL; SAFETY PROFILE; IMMUNOGENICITY;
DISABILITY; IMMUNIZATION; PREGNANCY; HORMONES; GENDER; SYSTEM
AB Background: Anthrax vaccine adsorbed (AVA) administered intramuscularly (IM) results in fewer adverse events (AEs) than subcutaneous (SQ) administration. Women experience more AEs than men. Antibody response, female hormones, race, and body mass index (BMI) may contribute to increased frequency of reported injection site AEs.
Methods: We analyzed data from the CDC AVA human clinical trial. This double blind, randomized, placebo controlled trial enrolled 1563 participants and followed them through 8 injections (AVA or placebo) over a period of 42 months. For the trial's vaccinated cohort (n = 1267), we used multivariable logistic regression to model the effects of study group (SQ or IM), sex, race, study site, BMI, age, and post-vaccination serum anti-PA IgG on occurrence of AEs of any severity grade. Also, in a women-only subset (n = 227), we assessed effect of pre-vaccination serum progesterone level and menstrual phase on AEs.
Results: Participants who received SQ injections had significantly higher proportions of itching, redness, swelling, tenderness and warmth compared to the IM study group after adjusting for other risk factors. The proportions of redness, swelling, tenderness and warmth were all significantly lower in blacks vs. non-black participants. We found arm motion limitation, itching, pain, swelling and tenderness were more likely to occur in participants with the highest anti-PA IgG concentrations. In the SQ study group, redness and swelling were more common for obese participants compared to participants who were not overweight. Females had significantly higher proportions of all AEs compared to males. Menstrual phase was not associated with any AEs.
Conclusions: Female and non-black participants had a higher proportion of AVA associated AEs and higher anti-PA IgG concentrations. Antibody responses to other vaccines may also vary by sex and race. Further studies may provide better understanding for higher proportions of AEs in women and non-black participants. Published by Elsevier Ltd.
C1 [Pondo, Tracy; Rose, Charles E., Jr.; Martin, Stacey W.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30333 USA.
[McNeil, Michael M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Immunizat Safety Off, Atlanta, GA USA.
[Keitel, Wendy A.] Baylor Coll Med, Houston, TX 77030 USA.
[Keyserling, Harry L.] Emory Univ, Sch Med, Atlanta, GA USA.
[Babcock, Janiine] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA.
[Parker, Scott] Univ Alabama Birmingham, Birmingham, AL USA.
[Jacobson, Robert M.; Poland, Gregory A.] Mayo Clin, Rochester, MN USA.
RP Pondo, T (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30333 USA.
EM dio2@cdc.gov
FU CDC
FX The protocol for this study was approved by an Institutional Review
Board of the Centers for Disease Control and Prevention (CDC). The
funding for this study was provided solely by the CDC.
NR 44
TC 11
Z9 11
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUN 12
PY 2014
VL 32
IS 28
BP 3548
EP 3554
DI 10.1016/j.vaccine.2014.04.025
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AL0NC
UT WOS:000338822600012
PM 24768633
ER
PT J
AU Sudenga, SL
Wiener, HW
King, CC
Rompalo, AM
Cu-Uvin, S
Klein, RS
Shah, KV
Sobel, JD
Jamieson, DJ
Shrestha, S
AF Sudenga, Staci L.
Wiener, Howard W.
King, Caroline C.
Rompalo, Anne M.
Cu-Uvin, Susan
Klein, Robert S.
Shah, Keerti V.
Sobel, Jack D.
Jamieson, Denise J.
Shrestha, Sadeep
TI Dense Genotyping of Immune-Related Loci Identifies Variants Associated
with Clearance of HPV among HIV-Positive Women in the HIV Epidemiology
Research Study (HERS)
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; HUMAN-PAPILLOMAVIRUS INFECTION;
CERVICAL-CANCER; NATURAL-HISTORY; SUSCEPTIBILITY LOCI; G POLYMORPHISMS;
YOUNG-WOMEN; RISK; E6; DNA
AB Persistent high-risk human papillomavirus (HR-HPV) is a necessary and causal factor of cervical cancer. Most women naturally clear HPV infections; however, the biological mechanisms related to HPV pathogenesis have not been clearly elucidated. Host genetic factors that specifically regulate immune response could play an important role. All HIV-positive women in the HIV Epidemiology Research Study (HERS) with a HR-HPV infection and at least one follow-up biannual visit were included in the study. Cervicovaginal lavage samples were tested for HPV using type-specific HPV hybridization assays. Type-specific HPV clearance was defined as two consecutive HPV-negative tests after a positive test. DNA from participants was genotyped for 196,524 variants within 186 known immune related loci using the custom ImmunoChip microarray. To assess the influence of each single-nucleotide polymorphism (SNP) with HR-HPV clearance, the Cox proportional hazards model with the Wei-Lin-Weissfeld approach was used, adjusting for CD4+ count, low risk HPV (LR-HPV) co-infection, and relevant confounders. Three analytical models were performed: race-specific (African Americans (n = 258), European Americans (n = 87), Hispanics (n = 55), race-adjusted combined analysis, and meta-analysis of pooled independent race-specific analyses. Women were followed for a median time of 1,617 days. Overall, three SNPs (rs1112085, rs11102637, and rs12030900) in the MAGI-3 gene and one SNP (rs8031627) in the SMAD3 gene were associated with HR-HPV clearance (p<10(-6)). A variant (rs1633038) in HLA-G were also significantly associated in African American. Results from this study support associations of immune-related genes, having potential biological mechanism, with differential cervical HR-HPV infection outcomes.
C1 [Sudenga, Staci L.; Wiener, Howard W.; Shrestha, Sadeep] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35203 USA.
[King, Caroline C.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
[Rompalo, Anne M.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA.
[Cu-Uvin, Susan] Brown Univ, Dept Obstet & Gynecol & Med, Providence, RI 02912 USA.
[Klein, Robert S.] Mt Sinai Sch Med, New York, NY USA.
[Shah, Keerti V.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA.
[Sobel, Jack D.] Wayne State Univ, Sch Med, Detroit, MI USA.
RP Shrestha, S (reprint author), Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35203 USA.
EM sshrestha@uab.edu
RI Sudenga, Staci/A-7726-2015
FU Pilot Project Award from the Johns Hopkins Cervical Cancer SPORE
[(2P50CA098252]; NIH Cancer Prevention and Control Training Program
[R25CA47888]; Centers for Disease Control and Prevention [U64/CCU106795,
U64/CCU206798, U64/CCU306802, U64/CCU506831]
FX Genotyping efforts were supported by the Pilot Project Award (PI: Sadeep
Shrestha) from the Johns Hopkins Cervical Cancer SPORE (2P50CA098252 PI:
TC Wu). The work was supported in part by the NIH Cancer Prevention and
Control Training Program (R25CA47888 - fellowship of Staci Sudenga). The
HIV Epidemiology Research Study (HERS) was funded through Centers for
Disease Control and Prevention cooperative agreements U64/CCU106795,
U64/CCU206798, U64/CCU306802, and U64/CCU506831. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 46
TC 5
Z9 5
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 11
PY 2014
VL 9
IS 6
AR e99109
DI 10.1371/journal.pone.0099109
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK7TQ
UT WOS:000338631000048
PM 24918582
ER
PT J
AU Meyer, DA
Torres-Altoro, MI
Tan, ZJ
Tozzi, A
Di Filippo, M
DiNapoli, V
Plattner, F
Kansy, JW
Benkovic, SA
Huber, JD
Miller, DB
Greengard, P
Calabresi, P
Rosen, CL
Bibb, JA
AF Meyer, Douglas A.
Torres-Altoro, Melissa I.
Tan, Zhenjun
Tozzi, Alessandro
Di Filippo, Massimiliano
DiNapoli, Vincent
Plattner, Florian
Kansy, Janice W.
Benkovic, Stanley A.
Huber, Jason D.
Miller, Diane B.
Greengard, Paul
Calabresi, Paolo
Rosen, Charles L.
Bibb, James A.
TI Ischemic Stroke Injury Is Mediated by Aberrant Cdk5
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE biomarker; calpain; Cdk5; ischemia; neuroprotection; stroke
ID SYNAPTIC PLASTICITY; CEREBRAL-ISCHEMIA; CELL-DEATH; NEURODEGENERATIVE
DISEASES; HUNTINGTONS-DISEASE; IN-VITRO; NEURONS; VULNERABILITY;
MECHANISMS; DOPAMINE
AB Ischemic stroke is one of the leading causes of morbidity and mortality. Treatment options are limited and only a minority of patients receive acute interventions. Understanding the mechanisms that mediate neuronal injury and death may identify targets for neuroprotective treatments. Here we show that the aberrant activity of the protein kinase Cdk5 is a principal cause of neuronal death in rodents during stroke. Ischemia induced either by embolic middle cerebral artery occlusion (MCAO) in vivo or by oxygen and glucose deprivation in brain slices caused calpain-dependent conversion of the Cdk5-activating cofactor p35 to p25. Inhibition of aberrant Cdk5 during ischemia protected dopamine neurotransmission, maintained field potentials, and blocked excitotoxicity. Furthermore, pharmacological inhibition or conditional knock-out (CKO) of Cdk5 prevented neuronal death in response to ischemia. Moreover, Cdk5 CKO dramatically reduced infarctions following MCAO. Thus, targeting aberrant Cdk5 activity may serve as an effective treatment for stroke.
C1 [Meyer, Douglas A.; Torres-Altoro, Melissa I.; Plattner, Florian; Kansy, Janice W.; Bibb, James A.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
[Bibb, James A.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA.
[Tan, Zhenjun; DiNapoli, Vincent; Rosen, Charles L.] W Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA.
[Benkovic, Stanley A.; Miller, Diane B.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA.
[Tozzi, Alessandro; Di Filippo, Massimiliano; Calabresi, Paolo] Univ Perugia, Osped S Maria Misericordia, Neurol Clin, I-06156 Perugia, Italy.
[Tozzi, Alessandro; Di Filippo, Massimiliano; Calabresi, Paolo] Fdn Santa Lucia Ist Ricovero & Cura Carattere Sci, I-00184 Rome, Italy.
[Huber, Jason D.] W Virginia Univ, Sch Med, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA.
[Greengard, Paul] Rockefeller Univ, Lab Mol & Cellular Neurosci, New York, NY 10021 USA.
RP Bibb, JA (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
EM james.bibb@utsouthwestern.edu
OI Plattner, Florian/0000-0002-3150-1866
FU European Community [222918]; U.S. National Institutes of Health
[MH090963, DA10044, NS061954, MH79710, MH083711, DA016672, DA033485,
NS073855]; [DA0018343]
FX This work was supported by the European Community contract number 222918
(REPLACES) FP7-Thematic priority HEALTH to P. C., and U.S. National
Institutes of Health grants to P. G. (MH090963 and DA10044), J.D.H.
(NS061954), and J.A.B. (MH79710, MH083711, DA016672, DA033485,
NS073855). This work was also supported by DA0018343 Pilot Project
funding (J.A.B.). We thank W. Lai, X. Li, and M. Kouser, for technical
assistance, and F. Gillardon and Boehringer Ingelheim, for indolinone.
We thank P. Chambon and Universaire de Srasbourg, for Prp-ERT
transgenic mice, and A. Sonneborn, for help with manuscript preparation.
NR 44
TC 19
Z9 19
U1 0
U2 6
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUN 11
PY 2014
VL 34
IS 24
BP 8259
EP 8267
DI 10.1523/JNEUROSCI.4368-13.2014
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA AK3QB
UT WOS:000338338700019
PM 24920629
ER
PT J
AU Wiegert, K
Dinh, TH
Mushavi, A
Mugurungi, O
Kilmarx, PH
AF Wiegert, Katherine
Dinh, Thu-Ha
Mushavi, Angela
Mugurungi, Owen
Kilmarx, Peter H.
TI Integration of Prevention of Mother-to-Child Transmission of HIV (PMTCT)
Postpartum Services with Other HIV Care and Treatment Services within
the Maternal and Child Health Setting in Zimbabwe, 2012
SO PLOS ONE
LA English
DT Article
ID EARLY INFANT DIAGNOSIS; ANTIRETROVIRAL THERAPY; ANTENATAL CARE;
METAANALYSIS; MORTALITY; AFRICA
AB Background: We assessed the integration of PMTCT services during the postpartum period including early infant diagnosis of HIV (EID) and adult and pediatric antiretroviral therapy (ART) in maternal and child health (MCH) facilities in Zimbabwe
Methods and Findings: From August to December 2012 we conducted a cross-sectional survey of a nationally representative sample of 151 MCH facilities. A questionnaire was used to survey each site about staff training, dried blood spot sample (DBS) collection, turnaround time (TAT) for test results, PMTCT services, and HIV care and treatment linkages for HIV-infected mothers and children and HIV-exposed infants. Descriptive analyses were used. Of the facilities surveyed, all facilities were trained on DBS collection and 92% responded. Approximately, 99% of responding facilities reported providing DBS collection and a basic HIV-exposed infant service package including EID, extended nevirapine prophylaxis, and use of cotrimoxazole. DBS collection was integrated with immunisations at 83% of facilities, CD4 testing with point-of-care machines was available at 37% of facilities, and ART for both mothers and children was provided at 27% of facilities. More than 80% of facilities reported that DBS test results take >4 weeks to return; TAT did not have a direct association with any specific type of transport, distance to the lab, or intermediate stops for data to travel.
Conclusions: Zimbabwe has successfully scaled up and integrated the national EID and PMTCT programs into the existing MCH setting. The long TAT of infant DBS test results and the lack of integrated ART programs in the MCH setting could reduce effectiveness of the national PMTCT and ART programs. Addressing these important gaps will support successful implementation of the 2014 Zimbabwe's PMTCT guidelines under which all HIV-infected pregnant and breastfeeding women will be offered life-long ART and decentralized ART care.
C1 [Wiegert, Katherine] US Ctr Dis Control & Prevent, Atlanta, GA USA.
[Wiegert, Katherine] Duke Univ, Med Ctr, Durham, NC USA.
[Dinh, Thu-Ha; Kilmarx, Peter H.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA.
[Mushavi, Angela; Mugurungi, Owen] Minist Hlth & Child Care Zimbabwe, AIDS & TB Unit, Harare, Zimbabwe.
[Kilmarx, Peter H.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Harare, Zimbabwe.
RP Dinh, TH (reprint author), US Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA.
EM dvt1@cdc.gov
OI Kilmarx, Peter/0000-0001-6464-3345
FU President's Emergency Plan for AIDS Relief (PEPFAR) [U2GGH00315-01]
FX This work was supported by the President's Emergency Plan for AIDS
Relief (PEPFAR) under the Cooperative Agreement (U2GGH00315-01) between
the Centers for Disease Control and the University of
Zimbabwe/Department of Community Medicine. No funding bodies had any
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 19
TC 5
Z9 6
U1 2
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 10
PY 2014
VL 9
IS 6
AR e98236
DI 10.1371/journal.pone.0098236
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AN9SD
UT WOS:000340947700017
PM 24915422
ER
PT J
AU Mack, DG
Falta, MT
McKee, AS
Martin, AK
Simonian, PL
Crawford, F
Gordon, T
Mercer, RR
Hoover, MD
Marrack, P
Kappler, JW
Tuder, RM
Fontenot, AP
AF Mack, Douglas G.
Falta, Michael T.
McKee, Amy S.
Martin, Allison K.
Simonian, Philip L.
Crawford, Frances
Gordon, Terry
Mercer, Robert R.
Hoover, Mark D.
Marrack, Philippa
Kappler, John W.
Tuder, Rubin M.
Fontenot, Andrew P.
TI Regulatory T cells modulate granulomatous inflammation in an HLA-DP2
transgenic murine model of beryllium-induced disease
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE metal hypersensitivity; MHC presentation; genetic susceptibility
ID SUSCEPTIBILITY; TUBERCULOSIS; OXIDE; LUNG
AB Susceptibility to chronic beryllium disease (CBD) is linked to certain HLA-DP molecules, including HLA-DP2. To elucidate the molecular basis of this association, we exposed mice transgenic (Tg) for HLA-DP2 to beryllium oxide (BeO) via oropharyngeal aspiration. As opposed to WT mice, BeO-exposed HLA-DP2 Tg mice developed mononuclear infiltrates in a peribronchovascular distribution that were composed of CD4(+) T cells and included regulatory T (T-reg) cells. Beryllium-responsive, HLA-DP2-restricted CD4(+) T cells expressing IFN-gamma and IL-2 were present in BeO-exposed HLA-DP2 Tg mice and not in WT mice. Using Be-loaded HLA-DP2-peptide tetramers, we identified Be-specific CD4(+) T cells in the mouse lung that recognize identical ligands as CD4(+) T cells derived from the human lung. Importantly, a subset of HLA-DP2 tetramer-binding CD4(+) T cells expressed forkhead box P3, consistent with the expansion of antigen-specific T-reg cells. Depletion of T-reg cells in BeO-exposed HLA-DP2 Tg mice exacerbated lung inflammation and enhanced granuloma formation. These findings document, for the first time to our knowledge, the development of a Be-specific adaptive immune response in mice expressing HLA-DP2 and the ability of T-reg cells to modulate the beryllium-induced granulomatous immune response.
C1 [Mack, Douglas G.; Falta, Michael T.; McKee, Amy S.; Martin, Allison K.; Simonian, Philip L.; Tuder, Rubin M.; Fontenot, Andrew P.] Univ Colorado, Dept Med, Aurora, CO 80045 USA.
[Crawford, Frances; Marrack, Philippa; Kappler, John W.; Fontenot, Andrew P.] Univ Colorado, Dept Immunol, Aurora, CO 80045 USA.
[Gordon, Terry] NYU, Dept Environm Med, Tuxedo Pk, NY 10987 USA.
[Mercer, Robert R.; Hoover, Mark D.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA.
[Crawford, Frances; Marrack, Philippa; Kappler, John W.] Natl Jewish Hlth, Howard Hughes Med Inst, Denver, CO 80206 USA.
RP Kappler, JW (reprint author), Univ Colorado, Dept Immunol, Anschutz Med Campus, Aurora, CO 80045 USA.
EM kapplerj@njhealth.org; andrew.fontenot@ucdenver.edu
FU National Institutes of Health [HL62410, HL111760, ES11810, ES011473,
212-2010-M-35006, DE-FG02-08ER64670]
FX The authors thank Lisa Maier for helpful discussions and Ainsley Weston,
Sally Tinkle, and Edward Rubin for the generation of the HLA-DP2 Tg
mice. This work is supported by the following National Institutes of
Health Grants: HL62410, HL111760, and ES11810 (to A. P. F.); and
ES011473, 212-2010-M-35006, and DE-FG02-08ER64670 (to T. G.). The
findings and conclusions in this report are those of the authors and do
not necessarily represent the views of their respective organizations.
NR 23
TC 13
Z9 13
U1 1
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 10
PY 2014
VL 111
IS 23
BP 8553
EP 8558
DI 10.1073/pnas.1408048111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI6IJ
UT WOS:000336976000065
PM 24912188
ER
PT J
AU Tan, KR
Katalenich, BL
Mace, KE
Nambozi, M
Taylor, SM
Meshnick, SR
Wiegand, RE
Chalwe, V
Filler, SJ
Kamuliwo, M
Craig, AS
AF Tan, Kathrine R.
Katalenich, Bonnie L.
Mace, Kimberly E.
Nambozi, Michael
Taylor, Steve M.
Meshnick, Steven R.
Wiegand, Ryan E.
Chalwe, Victor
Filler, Scott J.
Kamuliwo, Mulakwa
Craig, Allen S.
TI Efficacy of sulphadoxine-pyrimethamine for intermittent preventive
treatment of malaria in pregnancy, Mansa, Zambia
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Pregnancy; Intermittent-preventive treatment;
Sulphadoxine-pyrimethamine
ID PLASMODIUM-FALCIPARUM MALARIA; MOLECULAR MARKERS; TREATMENT POLICY;
DRUG-RESISTANCE; WOMEN; GHANA; QUEERPAM; OUTCOMES; THERAPY; BENIN
AB Background: Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) decreases adverse effects of malaria during pregnancy. Zambia implemented its IPTp-SP programme in 2003. Emergence of SP-resistant Plasmodium falciparum threatens this strategy. The quintuple mutant haplotype (substitutions in N51I, C59R, S108N in dhfr and A437G and K540E in dhps genes), is associated with SP treatment failure in non-pregnant patients with malaria. This study examined efficacy of IPTp-SP and presence of the quintuple mutant among pregnant women in Mansa, Zambia.
Methods: In Mansa, an area with high malaria transmission, HIV-negative pregnant women presenting to two antenatal clinics for the 1st dose of IPTp-SP with asymptomatic parasitaemia were enrolled and microscopy for parasitaemia was done weekly for five weeks. Outcomes were parasitological failure and adequate parasitological response (no parasitaemia during follow-up). Polymerase chain reaction assays were employed to distinguish recrudescence from reinfection, and identify molecular markers of SP resistance. Survival analysis included those who had reinfection and incomplete follow-up (missed at least one follow-up).
Results: Of the 109 women included in the study, 58 (53%) completed all follow-up, 34 (31%) had incomplete follow-up, and 17 (16%) were lost to follow-up after day 0. Of those who had complete follow-up, 15 (26%, 95% confidence interval [CI] [16-38]) had parasitological failure. For the 92 women included in the survival analysis, median age was 20 years (interquartile range [IQR] 18-22), median gestational age was 22 weeks (IQR range 20-24), and 57% were primigravid. There was no difference in time to failure in primigravid versus multigravid women. Of the 84 women with complete haplotype data for the aforementioned loci of the dhfr and dhps genes, 53 (63%, 95% CI [50-70]) had quintuple mutants (two with an additional mutation in A581G of dhps). Among women with complete follow-up and quintuple mutants, 22% had parasitological failure versus 0% without (p = 0.44).
Conclusions: While underpowered, this study found 26% failure rates of SP given the moderate prevalence of the quintuple mutant haplotype. Despite the presence of resistance, SP retained some efficacy in clearing parasites in pregnant women, and may remain a viable option for IPTp in Zambia.
C1 [Tan, Kathrine R.; Mace, Kimberly E.; Wiegand, Ryan E.] US Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA 30333 USA.
[Katalenich, Bonnie L.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA.
[Nambozi, Michael] Trop Dis Res Ctr, Ndola, Zambia.
[Taylor, Steve M.] Duke Univ, Med Ctr, Durham, NC USA.
[Meshnick, Steven R.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
[Chalwe, Victor] Maina Soko Mil Hosp Lusaka, Lusaka, Zambia.
[Filler, Scott J.] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland.
[Kamuliwo, Mulakwa] Natl Malaria Control Ctr, Lusaka, Zambia.
[Craig, Allen S.] US Ctr Dis Control & Prevent, Vaccine Preventable Dis Eradicat & Eliminat Branc, Atlanta, GA USA.
RP Tan, KR (reprint author), US Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA 30333 USA.
EM ktan@cdc.gov
FU President's Malaria Initiative
FX This study was funded by the President's Malaria Initiative.
NR 35
TC 7
Z9 7
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUN 9
PY 2014
VL 13
AR 227
DI 10.1186/1475-2875-13-227
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AL1LP
UT WOS:000338887200001
PM 24909578
ER
PT J
AU McCann, RS
Messina, JP
MacFarlane, DW
Bayoh, MN
Vulule, JM
Gimnig, JE
Walker, ED
AF McCann, Robert S.
Messina, Joseph P.
MacFarlane, David W.
Bayoh, M. Nabie
Vulule, John M.
Gimnig, John E.
Walker, Edward D.
TI Modeling larval malaria vector habitat locations using landscape
features and cumulative precipitation measures
SO INTERNATIONAL JOURNAL OF HEALTH GEOGRAPHICS
LA English
DT Article
DE Random forest; Logistic regression; Anopheles gambiae; Larval habitats;
Predictive models
ID GAMBIAE COMPLEX DIPTERA; WESTERN KENYA HIGHLANDS;
HIGH-SPATIAL-RESOLUTION; ANOPHELES-GAMBIAE; LAND-COVER; CHILD-MORTALITY;
BREEDING HABITATS; CULICIDAE; AFRICA; RISK
AB Background: Predictive models of malaria vector larval habitat locations may provide a basis for understanding the spatial determinants of malaria transmission.
Methods: We used four landscape variables (topographic wetness index [TWI], soil type, land use-land cover, and distance to stream) and accumulated precipitation to model larval habitat locations in a region of western Kenya through two methods: logistic regression and random forest. Additionally, we used two separate data sets to account for variation in habitat locations across space and over time.
Results: Larval habitats were more likely to be present in locations with a lower slope to contributing area ratio (i.e. TWI), closer to streams, with agricultural land use relative to nonagricultural land use, and in friable clay/sandy clay loam soil and firm, silty clay/clay soil relative to friable clay soil. The probability of larval habitat presence increased with increasing accumulated precipitation. The random forest models were more accurate than the logistic regression models, especially when accumulated precipitation was included to account for seasonal differences in precipitation. The most accurate models for the two data sets had area under the curve (AUC) values of 0.864 and 0.871, respectively. TWI, distance to the nearest stream, and precipitation had the greatest mean decrease in Gini impurity criteria in these models.
Conclusions: This study demonstrates the usefulness of random forest models for larval malaria vector habitat modeling. TWI and distance to the nearest stream were the two most important landscape variables in these models. Including accumulated precipitation in our models improved the accuracy of larval habitat location predictions by accounting for seasonal variation in the precipitation. Finally, the sampling strategy employed here for model parameterization could serve as a framework for creating predictive larval habitat models to assist in larval control efforts.
C1 [McCann, Robert S.] Michigan State Univ, Dept Entomol, E Lansing, MI 48824 USA.
[Messina, Joseph P.] Michigan State Univ, Dept Geog, E Lansing, MI 48824 USA.
[MacFarlane, David W.] Michigan State Univ, Dept Forestry, E Lansing, MI 48824 USA.
[Bayoh, M. Nabie; Vulule, John M.] Ctr Dis Control & Prevent, Kenya Med Res Inst, Ctr Global Hlth Res, Kisumu, Kenya.
[Gimnig, John E.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA.
[Walker, Edward D.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.
RP McCann, RS (reprint author), Univ Wageningen & Res Ctr, Entomol Lab, POB 8031, NL-6700 EH Wageningen, Netherlands.
EM robert.mccann@wur.nl
OI Messina, Joseph/0000-0002-1978-0778; McCann, Robert/0000-0002-2195-6461
NR 48
TC 4
Z9 4
U1 5
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-072X
J9 INT J HEALTH GEOGR
JI Int. J. Health Geogr.
PD JUN 6
PY 2014
VL 13
AR 17
DI 10.1186/1476-072X-13-17
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AK1EF
UT WOS:000338157400001
PM 24903736
ER
PT J
AU Mazurek, JM
Syamlal, G
King, BA
Castellan, RM
AF Mazurek, Jacek M.
Syamlal, Girija
King, Brian A.
Castellan, Robert M.
TI Smokeless Tobacco Use Among Working Adults - United States, 2005 and
2010
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID PRODUCTS; SMOKERS
C1 [Mazurek, Jacek M.; Syamlal, Girija; Castellan, Robert M.] CDC, NIOSH, Div Resp Dis Studies, Atlanta, GA 30333 USA.
[King, Brian A.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Mazurek, JM (reprint author), CDC, NIOSH, Div Resp Dis Studies, Atlanta, GA 30333 USA.
EM acq8@cdc.gov
NR 10
TC 19
Z9 19
U1 1
U2 6
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD JUN 6
PY 2014
VL 63
IS 22
BP 477
EP 482
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI5OG
UT WOS:000336917800001
PM 24898164
ER
PT J
AU Epperson, S
Blanton, L
Kniss, K
Mustaquim, D
Steffens, C
Wallis, T
Dhara, R
Leon, M
Perez, A
Chaves, SS
Abd Elal, A
Gubareva, L
Xu, XY
Villanueva, J
Bresee, J
Cox, N
Finelli, L
Brammer, L
AF Epperson, Scott
Blanton, Lenee
Kniss, Krista
Mustaquim, Desiree
Steffens, Craig
Wallis, Teresa
Dhara, Rosaline
Leon, Michelle
Perez, Alejandro
Chaves, Sandra S.
Abd Elal, Anwar
Gubareva, Larisa
Xu, Xiyan
Villanueva, Julie
Bresee, Joseph
Cox, Nancy
Finelli, Lyn
Brammer, Lynnette
TI Influenza Activity - United States, 2013-14 Season and Composition of
the 2014-15 Influenza Vaccines
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID VIRUS
C1 [Epperson, Scott; Blanton, Lenee; Kniss, Krista; Mustaquim, Desiree; Steffens, Craig; Wallis, Teresa; Dhara, Rosaline; Leon, Michelle; Perez, Alejandro; Chaves, Sandra S.; Abd Elal, Anwar; Gubareva, Larisa; Xu, Xiyan; Villanueva, Julie; Bresee, Joseph; Cox, Nancy; Finelli, Lyn; Brammer, Lynnette] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Epperson, S (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM sepperson@cdc.gov
NR 6
TC 30
Z9 30
U1 0
U2 1
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD JUN 6
PY 2014
VL 63
IS 22
BP 483
EP 490
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI5OG
UT WOS:000336917800002
PM 24898165
ER
PT J
AU Hall, AJ
Wikswo, ME
Pringle, K
Gould, LH
Parashar, UD
AF Hall, Aron J.
Wikswo, Mary E.
Pringle, Kimberly
Gould, L. Hannah
Parashar, Umesh D.
TI Vital Signs: Foodborne Norovirus Outbreaks - United States, 2009-2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID NORWALK VIRUS; GASTROENTERITIS; ILLNESS
AB Introduction: Norovirus is the leading cause of acute gastroenteritis and foodborne disease in the United States, causing an estimated one in 15 U. S. residents to become ill each year as well as 56,000-71,000 hospitalizations and 570-800 deaths, predominantly among young children and the elderly. Whereas noroviruses often spread through person-to-person contact, foodborne transmission can cause widespread exposures and presents important prevention opportunities.
Methods: CDC analyzed 2009-2012 data on suspected and confirmed norovirus outbreaks reported by state, local, and territorial health departments through the National Outbreak Reporting System (NORS) to characterize the epidemiology of foodborne norovirus outbreaks.
Results: During 2009-2012, a total of 1,008 foodborne norovirus outbreaks were reported to NORS, constituting 48% of all foodborne outbreaks with a single known cause. Outbreaks were reported by 43 states and occurred year round. Restaurants were the most common setting (64%) of food preparation reported in outbreaks. Of 520 outbreaks with factors contributing to contamination reported, food workers were implicated as the source in 70%. Of 324 outbreaks with an implicated food, most resulted from food contaminated during preparation (92%) and food consumed raw (75%). Specific food categories were implicated in only 67 outbreaks; the most frequently named were vegetable row crops (e. g., leafy vegetables) (30%), fruits (21%), and mollusks (19%).
Conclusions: Noroviruses are the leading cause of reported foodborne disease outbreaks and most often associated with contamination of food in restaurants during preparation by infected food workers.
Implications for Public Health Practice: Improved adherence to appropriate hand hygiene, excluding ill staff members from working until >= 48 hours after symptom resolution, and supervision by certified kitchen managers are all recommended to reduce the incidence of foodborne norovirus disease.
C1 [Hall, Aron J.; Wikswo, Mary E.; Parashar, Umesh D.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Pringle, Kimberly] CDC, EIS, Atlanta, GA 30333 USA.
[Gould, L. Hannah] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA 30333 USA.
RP Hall, AJ (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM ajhall@cdc.gov
NR 17
TC 52
Z9 52
U1 2
U2 34
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD JUN 6
PY 2014
VL 63
IS 22
BP 491
EP 495
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI5OG
UT WOS:000336917800003
PM 24898166
ER
PT J
AU Gastanaduy, PA
Redd, SB
Fiebelkorn, AP
Rota, JS
Rota, PA
Bellini, WJ
Seward, JF
Wallace, GS
AF Gastanaduy, Paul A.
Redd, Susan B.
Fiebelkorn, Amy Parker
Rota, Jennifer S.
Rota, Paul A.
Bellini, William J.
Seward, Jane F.
Wallace, Gregory S.
TI Measles - United States, January 1-May 23, 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID CHILDREN
C1 [Gastanaduy, Paul A.; Redd, Susan B.; Fiebelkorn, Amy Parker; Rota, Jennifer S.; Rota, Paul A.; Bellini, William J.; Seward, Jane F.; Wallace, Gregory S.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Gastanaduy, PA (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM pgastanaduy@cdc.gov
NR 10
TC 52
Z9 53
U1 0
U2 6
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD JUN 6
PY 2014
VL 63
IS 22
BP 496
EP 499
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI5OG
UT WOS:000336917800004
PM 24898167
ER
PT J
AU Fischer, M
Staples, JE
AF Fischer, Marc
Staples, J. Erin
TI Chikungunya Virus Spreads in the Americas - Caribbean and South America,
2013-2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Fischer, Marc; Staples, J. Erin] CDC, Arboviral Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Fischer, M (reprint author), CDC, Arboviral Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM mfischer@cdc.gov
NR 4
TC 55
Z9 60
U1 1
U2 22
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD JUN 6
PY 2014
VL 63
IS 22
BP 500
EP 501
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI5OG
UT WOS:000336917800005
PM 24898168
ER
PT J
AU Ambuel, Y
Young, G
Brewoo, JN
Paykel, J
Weisgrau, KL
Rakasz, EG
Haller, AA
Royals, M
Huang, CYH
Capuano, S
Stinchcomb, DT
Partidos, CD
Osorio, JE
AF Ambuel, Yuping
Young, Ginger
Brewoo, Joseph N.
Paykel, Joanna
Weisgrau, Kim L.
Rakasz, Eva G.
Haller, Aurelia A.
Royals, Michael
Huang, Claire Y. -H.
Capuano, Saverio
Stinchcomb, Dan T.
Partidos, Charalambos D.
Osorio, Jorge E.
TI A rapid immunization strategy with a live-attenuated tetravalent dengue
vaccine elicits protective neutralizing antibody responses in non-human
primates
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE dengue; vaccine; non-human primates; neutralizing antibodies;
needle-free delivery; T cell responses
ID STRAIN 16681; VIRUS-VACCINE; PDK-53 VIRUS; EFFICACY; DENVAX;
PATHOGENESIS; VOLUNTEERS; VIREMIA
AB Dengue viruses (DENVs) cause approximately 390 million cases of DENV infections annually and over 3 billion people worldwide are at risk of infection. No dengue vaccine is currently available nor is there an antiviral therapy for DENV infections. We have developed a tetravalent live-attenuated DENV vaccine tetravalent dengue vaccine (TDV) that consists of a molecularly characterized attenuated DENV-2 strain (TDV-2) and three chimeric viruses containing the pre-membrane and envelope genes of DENV-1, -3, and -4 expressed in the context of the TDV-2 genome. To impact dengue vaccine delivery in endemic areas and immunize travelers, a simple and rapid immunization strategy (RIS) is preferred. We investigated RIS consisting of two full vaccine doses being administered subcutaneously or intradermally on the initial vaccination visit (day 0) at two different anatomical locations with a needle-free disposable syringe jet injection delivery devices (PharmaJet) in non-human primates. This vaccination strategy resulted in efficient priming and induction of neutralizing antibody responses to all four DENV serotypes comparable to those elicited by the traditional prime and boost (2 months later) vaccination schedule. In addition, the vaccine induced CD4(+) and CD8(+) T cells producing IFN-gamma, IL-2, and TNF-alpha, and targeting the DENV-2 NS1, NS3, and NS5 proteins. Moreover, vaccine-specific T cells were cross-reactive with the non-structural NS3 and NS5 proteins of DENV-4. When animals were challenged with DENV-2 they were protected with no detectable viremia, and exhibited sterilizing immunity (no increase of neutralizing titers post-challenge). RIS could decrease vaccination visits and provide quick immune response to all four DENV serotypes. This strategy could increase vaccination compliance and would be especially advantageous for travelers into endemic areas.
C1 [Ambuel, Yuping; Young, Ginger; Brewoo, Joseph N.; Paykel, Joanna; Partidos, Charalambos D.; Osorio, Jorge E.] Takeda Vaccines Inc, Madison, WI 53719 USA.
[Weisgrau, Kim L.; Rakasz, Eva G.; Capuano, Saverio] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI USA.
[Haller, Aurelia A.; Stinchcomb, Dan T.] Takeda Vaccines Inc, Ft Collins, CO USA.
[Royals, Michael] PharmaJet Inc, Golden, CO USA.
[Huang, Claire Y. -H.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA.
RP Partidos, CD (reprint author), Takeda Vaccines Inc, 504 S Rosa Rd,Suite 200, Madison, WI 53719 USA.
EM harry.partidos@takeda.com
OI Royals, Michael/0000-0003-3639-3101; Stinchcomb, Dan/0000-0002-3634-7503
FU Federal funds from the National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Department of Health and Human
Services [HH5N272201000034C]
FX This project has been funded in part with Federal funds from the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Department of Health and Human Services, under
Contract No. HH5N272201000034C.
NR 27
TC 9
Z9 9
U1 1
U2 3
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 5
PY 2014
VL 5
BP 1
EP 8
AR 263
DI 10.3389/fimmu.2014.00263
PG 8
WC Immunology
SC Immunology
GA CH8IG
UT WOS:000354279200001
PM 24926294
ER
PT J
AU Jiang, Y
Satten, GA
Han, YJ
Epstein, MP
Heinzen, EL
Goldstein, DB
Allen, AS
AF Jiang, Yu
Satten, Glen A.
Han, Yujun
Epstein, Michael P.
Heinzen, Erin L.
Goldstein, David B.
Allen, Andrew S.
TI Utilizing Population Controls in Rare-Variant Case-Parent Association
Tests
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID COMMON DISEASES; SEQUENCING DATA; FRAMEWORK; RISK
AB There is great interest in detecting associations between human traits and rare genetic variation. To address the low power implicit in single-locus tests of rare genetic variants, many rare-variant association approaches attempt to accumulate information across a gene, often by taking linear combinations of single-locus contributions to a statistic. Using the right linear combination is key an optimal test will up-weight true causal variants, down-weight neutral variants, and correctly assign the direction of effect for causal variants. Here, we propose a procedure that exploits data from population controls to estimate the linear combination to be used in an case-parent trio rare-variant association test. Specifically, we estimate the linear combination by comparing population control allele frequencies with allele frequencies in the parents of affected offspring: These estimates are then used to construct a rare-variant transmission disequilibrium test (rvTDT) in the case-parent data. Because the rvTDT is conditional on the parents' data, using parental data in estimating the linear combination does not affect the validity or asymptotic distribution of the rvTDT. By using simulation, we show that our new population-control-based rvTDT can dramatically improve power over rvTDTs that do not use population control information across a wide variety of genetic architectures. It also remains valid under population stratification. We apply the approach to a cohort of epileptic encephalopathy (EE) trios and find that dominant (or additive) inherited rare variants are unlikely to play a substantial role within EE genes previously identified through de novo mutation studies.
C1 [Jiang, Yu; Allen, Andrew S.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27710 USA.
[Satten, Glen A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Han, Yujun; Heinzen, Erin L.; Goldstein, David B.; Allen, Andrew S.] Duke Univ, Ctr Human Genome Variat, Sch Med, Durham, NC 27708 USA.
[Epstein, Michael P.] Emory Univ, Dept Human Genet, Sch Med, Atlanta, GA 30322 USA.
RP Allen, AS (reprint author), Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27710 USA.
EM andrew.s.allen@duke.edu
OI Satten, Glen/0000-0001-7275-5371
FU National Institute of Neurological Disorders and Stroke [NS053998,
NS077364, NS077274, NS077303, NS077276]; National Human Genome Research
Institute [HG007508]
FX We thank the patients and investigators of Epi4k and the Epilepsy
Phenome/Genome project for access to the epileptic encephalopathy data.
This work was supported by grants from the National Institute of
Neurological Disorders and Stroke (The Epilepsy Phenome/Genome Project
NS053998; Epi4K Project 1 - Epileptic Encephalopathies NS077364; Epi4K -
Administrative Core NS077274; Epi4K Sequencing, Biostatistics and
Bioinformatics Core NS077303; and Epi4K - Phenotyping and Clinical
Informatics Core NS077276). M.P.E. is a consultant for Amnion
Laboratories and was also supported by a grant from the National Human
Genome Research Institute (HG007508). The findings and conclusions in
this report are those of the authors and do not necessarily represent
the official position of the Centers for Disease Control and Prevention.
NR 27
TC 9
Z9 9
U1 1
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JUN 5
PY 2014
VL 94
IS 6
BP 845
EP 853
DI 10.1016/j.ajhg.2014.04.014
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA AJ0HK
UT WOS:000337331200005
PM 24836453
ER
PT J
AU Fernandes, EG
Sato, HK
Leshem, E
Flannery, B
Konstantyner, TCRD
Veras, MADM
Patel, MM
AF Fernandes, Eder Gatti
Sato, Helena Keico
Leshem, Eyal
Flannery, Brendan
Roma de Oliveira Konstantyner, Thais Claudia
de Sousa Mascena Veras, Maria Amelia
Patel, Manish M.
TI Impact of rotavirus vaccination on diarrhea-related hospitalizations
S(a) over tilde o paulo State, Brazil
SO VACCINE
LA English
DT Article
DE Rotavirus; Vaccine; Diarrhea; Brazil
ID UNITED-STATES; LATIN-AMERICA; CHILDREN; REDUCTION; MORTALITY; DISEASE
AB Introduction: Following introduction of routine infant rotavirus vaccination, severe diarrhea hospitalization rates declined among children aged <5 years throughout Brazil. Ensuring equity of rotavirus vaccine impact is important in countries that self-finance immunization programs. The objective of this study was to examine rotavirus vaccine impact on diarrhea admission rates among children aged <5 years in Brazil's public health system, according to area-based measures of human development in the state of S(a) over tilde o Paulo, Brazil.
Methods: Ecological analysis of public health system hospitalization rates for acute gastroenteritis among children aged <5 years in the state of S(a) over tilde o Paulo, Brazil, according to five categories of municipal development based on a modified Human Development Index for municipalities. Acute gastroenteritis hospitalization rates among children aged <5 years after national rotavirus vaccine introduction (2008-2011) were compared to rates in pre-vaccine years (2000-2005) to calculate percent decline in rates (1 - rate ratio) and 95% confidence intervals (Cl) for each municipal development category. Direct hospitalization costs during the two periods were compared.
Results: Annual rates declined by 40% (95% CI, 39-42%) from 631 diarrhea hospitalizations per 100,000 person years pre-rotavirus vaccination to 377 per 100,000 post-vaccination among children aged <5 years and 50% (95% CI, 48-52%) from 1009 to 505 per 100,000 among infants. Highest rates were observed in least developed municipalities. Significant declines of 26-52% among children <5 years and 41-63% among infants were observed in all categories of municipal development. Lower diarrhea hospitalization rates resulted in annual savings of approximately 2 million USD for the state of S(a) over tilde o Paulo. Savings in direct hospitalization costs benefitted municipalities in all five categories.
Conclusion: The introduction of rotavirus vaccination was associated with substantial reductions of diarrhea-related admissions at all levels of municipal development in S(a) over tilde o Paulo State, Brazil. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Fernandes, Eder Gatti; Roma de Oliveira Konstantyner, Thais Claudia] Secretaria Estado Saude Sao Paulo, Field Epidemiol Training Program Sao Paulo State, BR-01246000 Sao Paulo, Brazil.
[Sato, Helena Keico] Sao Paulo State Hlth Dept, Div Immunizat, BR-01246000 Sao Paulo, Brazil.
[Leshem, Eyal] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA.
[Flannery, Brendan] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[de Sousa Mascena Veras, Maria Amelia] Fac Ciencias Med Santa Casa Sao Paulo, Dept Social Med, BR-01221020 Sao Paulo, Brazil.
[Patel, Manish M.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
RP Fernandes, EG (reprint author), Secretaria Estado Saude Sao Paulo, Field Epidemiol Training Program Sao Paulo State, Ave Dr Arnaldo,35,6th Floor, BR-01246000 Sao Paulo, Brazil.
EM edergatti@hotmail.com.br; hsato@saude.sp.gov.br; wgp9@cdc.gov;
bif4@cdc.gov.br; tcroma@saude.sp.gov.br; maria.veras@gmail.com;
aul3@cdc.gov
NR 23
TC 13
Z9 14
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUN 5
PY 2014
VL 32
IS 27
BP 3402
EP 3408
DI 10.1016/j.vaccine.2014.04.015
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI8WT
UT WOS:000337208400010
PM 24736002
ER
PT J
AU Kading, RC
Biggerstaff, BJ
Young, G
Komar, N
AF Kading, Rebekah C.
Biggerstaff, Brad J.
Young, Ginger
Komar, Nicholas
TI Mosquitoes Used to Draw Blood for Arbovirus Viremia Determinations in
Small Vertebrates
SO PLOS ONE
LA English
DT Article
ID WEST-NILE-VIRUS; EQUINE ENCEPHALITIS-VIRUS; HIGHLANDS J-VIRUS;
EXPERIMENTAL-INFECTION; CHICKENS; STRAINS; BIRDS
AB Serial samples from the same individuals may be required for certain virological studies, however, some small animals cannot easily be blood-sampled. Therefore, we evaluated the use of Culex quinquefasciatus Say and Aedes albopictus Skuse mosquitoes as "biological syringes'' to draw blood for virus titer determinations in small vertebrates. Groups of chicks (Gallus gallus), hamsters (Mesocricetus auratus), and house sparrows (Passer domesticus) were experimentally infected with West Nile virus (WNV) or Highlands J virus (HJV). In general, good correlation was seen between mosquito-and syringe-derived blood samples at titers >= 5.0 log(10) pfu/mL serum as compared with titers < 5.0 log(10) pfu/mL serum for chicks, hamsters, and sparrows. Ninety-two percent (24/26) of sparrows with virus titers > 10(5) pfu/mL serum had mosquito-and syringe-derived titers within one log of each other. Sparrow viremia profiles generated from single mosquito blood meals and syringe were not significantly different (p > 0.05). This technique is valuable for assessing the roles of small vertebrates in the ecologies of arboviruses, and could be used in applications beyond virology and infectious diseases, when < 10 mu L of whole blood is required.
C1 [Kading, Rebekah C.; Biggerstaff, Brad J.; Young, Ginger; Komar, Nicholas] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
RP Kading, RC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
EM fxk7@cdc.gov
RI Kading, Rebekah/E-5633-2017
OI Kading, Rebekah/0000-0002-4996-915X
FU Centers for Disease Control and Prevention
FX We would like to thank the late Dr. Andrew Spielman for inspiring this
work. Animal care was provided by Verna O'Brien, Andrea Peterson, and
Dr. Paul Spurlock. Insectary support was provided by Andrea Peterson and
Erin Borland. Permission for sparrow capture was provided by Cozy Cow
Dairy, Windsor, CO. This project was financially supported by the
Centers for Disease Control and Prevention. The findings and conclusions
in this report are those of the authors only, and do not necessarily
reflect the views of the United States Government.
NR 29
TC 3
Z9 3
U1 2
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 5
PY 2014
VL 9
IS 6
AR e99342
DI 10.1371/journal.pone.0099342
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI4NF
UT WOS:000336841400120
PM 24901448
ER
PT J
AU Kourtis, AP
Read, JS
Jamieson, DJ
AF Kourtis, Athena P.
Read, Jennifer S.
Jamieson, Denise J.
TI Pregnancy and Infection
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Review
ID SURVEILLANCE NETWORK FOODNET; SIMPLEX-VIRUS HEPATITIS; VARICELLA-ZOSTER
VIRUS; INFLUENZA-A H1N1; RISK-FACTORS; PLASMODIUM-FALCIPARUM; MALARIA;
WOMEN; LISTERIOSIS; HERPES
AB BEFORE THE ADVENT OF ANTIBIOTIC AGENTS, PREGNANCY WAS A RECOGnized risk factor for severe complications of pneumococcal pneumonia, including death. 1 The influenza pandemic of 2009 provided a more recent reminder that certain infections may disproportionately affect pregnant women. Are pregnant women at increased risk for acquiring infections? Are pregnant women with infection at increased risk for severe disease? During pregnancy, several mechanical and pathophysiological changes occur (e. g., a decrease in respiratory volumes and urinary stasis due to an enlarging uterus), and immune adaptations are required to accommodate the fetus. In this article, we review and synthesize new knowledge about the severity of and susceptibility to infections in pregnant women. We focus on the infections for which there is evidence of increased severity or susceptibility during pregnancy that is not fully explained by mechanical or anatomical changes, and we discuss these infections in light of new findings on immunologic changes during pregnancy.
C1 [Kourtis, Athena P.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
[Read, Jennifer S.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Kourtis, AP (reprint author), 4770 Buford Hwy NE,MS F74, Atlanta, GA 30341 USA.
FU Intramural CDC HHS [CC999999]
NR 70
TC 65
Z9 68
U1 4
U2 25
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 5
PY 2014
VL 370
IS 23
BP 2211
EP 2218
DI 10.1056/NEJMra1213566
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI3AF
UT WOS:000336729900009
PM 24897084
ER
PT J
AU Bharaswadkar, S
Kanchar, A
Thakur, N
Shah, S
Patnaik, B
Click, ES
Kumar, AMV
Dewan, PK
AF Bharaswadkar, Sandeep
Kanchar, Avinash
Thakur, Narendra
Shah, Shubhangi
Patnaik, Brinda
Click, Eleanor S.
Kumar, Ajay M. V.
Dewan, Puneet Kumar
TI Tuberculosis Management Practices of Private Practitioners in Pune
Municipal Corporation, India
SO PLOS ONE
LA English
DT Article
ID DELHI
AB Background: Private Practitioners (PP) are the primary source of health care for patients in India. Limited representative information is available on TB management practices of Indian PP or on the efficacy of India's Revised National Tuberculosis Control Programme (RNTCP) to improve the quality of TB management through training of PP.
Methods: We conducted a cross-sectional survey of a systematic random sample of PP in one urban area in Western India (Pune, Maharashtra). We presented sample clinical vignettes and determined the proportions of PPs who reported practices consistent with International Standards of TB Care (ISTC). We examined the association between RNTCP training and adherence to ISTC by calculating odds ratios and 95% confidence intervals.
Results: Of 3,391 PP practicing allopathic medicine, 249 were interviewed. Of these, 55% had been exposed to RNTCP. For new pulmonary TB patients, 63% (158/249) of provider responses were consistent with ISTC diagnostic practices, and 34% (84/249) of responses were consistent with ISTC treatment practices. However, 48% (120/249) PP also reported use of serological tests for TB diagnosis. In the new TB case vignette, 38% (94/249) PP reported use of at least one second line anti-TB drug in the treatment regimen. RNTCP training was not associated with diagnostic or treatment practices.
Conclusion: In Pune, India, despite a decade of training activities by the RNTCP, high proportions of providers resorted to TB serology for diagnosis and second-line anti-TB drug use in new TB patients. Efforts to achieve universal access to quality TB management must account for the low quality of care by PP and the lack of demonstrated effect of current training efforts.
C1 [Bharaswadkar, Sandeep; Kanchar, Avinash; Dewan, Puneet Kumar] Off World Hlth Org WHO Representat India, New Delhi, India.
[Thakur, Narendra; Shah, Shubhangi] Pune Municipal Corp, Directorate Hlth Serv, Pune, Maharashtra, India.
[Patnaik, Brinda] MIMER Med Coll, Dept Community Med, Pune, Maharashtra, India.
[Click, Eleanor S.] Ctr Dis Control & Prevent CDC, Div TB Eliminat, Atlanta, GA USA.
[Kumar, Ajay M. V.] Int Union TB & Lung Dis, Reg Off Southeast, New Delhi, India.
RP Bharaswadkar, S (reprint author), Off World Hlth Org WHO Representat India, New Delhi, India.
EM bharaswadkars@rntcp.org
FU UNION-WHO-CTD-NTI Operational research Project
FX This operational research was funded under UNION-WHO-CTD-NTI Operational
research Project 2010-2011. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 15
TC 9
Z9 9
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 4
PY 2014
VL 9
IS 6
AR e97993
DI 10.1371/journal.pone.0097993
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK4YO
UT WOS:000338430700020
PM 24897374
ER
PT J
AU Gomez, PP
Gutman, J
Roman, E
Dickerson, A
Andre, ZH
Youll, S
Eckert, E
Hamel, MJ
AF Gomez, Patricia P.
Gutman, Julie
Roman, Elaine
Dickerson, Aimee
Andre, Zandra H.
Youll, Susan
Eckert, Erin
Hamel, Mary J.
TI Assessment of the consistency of national-level policies and guidelines
for malaria in pregnancy in five African countries
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Pregnancy; IPTp; SP; ITN; LLIN; Case management
AB Background: At least 39 sub-Saharan African countries have policies on preventing malaria in pregnancy (MIP), including use of long-lasting insecticidal nets (LLINs), intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) and case management. However, coverage of LLINs and IPTp-SP remains below international targets in most countries. One factor contributing to low coverage may be that MIP policies typically are developed by national malaria control programmes (NMCPs), but are implemented through national reproductive health (RH) programmes.
Methods: National-level MIP policies, guidelines, and training documents from NMCPs and RH programmes in Kenya, Mali, Mozambique, mainland Tanzania and Uganda were reviewed to assess whether they reflected WHO guidelines for prevention and treatment of MIP, and how consistent MIP content was across documents from the same country. Documents were compared for adherence to WHO guidance concerning IPTp-SP timing and dose, directly observed therapy, promotion and distribution of LLINs, linkages to HIV programmes and MIP case management.
Results: The five countries reviewed had national documents promoting IPTp-SP, LLINs and MIP case management. WHO guidance from 2004 frequently was not reflected: four countries recommended the first dose of IPTp-SP at 20 weeks or later (instead of 16 weeks), and three countries restricted the first and second IPTp-SP doses to specific gestational weeks. Documents from four countries provided conflicting guidance on MIP prevention for HIV-positive women, and none provided complete guidance on management of uncomplicated and severe malaria during pregnancy. In all countries, inconsistencies between NMCPs and RH programmes on the timing or dose of IPTp-SP were documented, as was the mechanism for providing LLINs. Inconsistencies also were found in training documents from NMCPs and RH programmes in a given country. Outdated, inconsistent guidelines have the potential to cause confusion and lead to incorrect practices among health workers who implement MIP programmes, contributing to low coverage of IPTp-SP and LLINs.
Conclusions: MIP policies, guidelines and training materials are outdated and/or inconsistent in the countries assessed. Updating and ensuring consistency among national MIP documents is needed, along with re-orientation and supervision of health workers to accelerate implementation of the 2012 WHO Global Malaria Programme policy recommendations for IPTp-SP.
C1 [Gomez, Patricia P.; Roman, Elaine; Dickerson, Aimee] Mat & Child Hlth Integrated Program, Baltimore, MD USA.
[Gutman, Julie; Hamel, Mary J.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA.
[Youll, Susan; Eckert, Erin] US Agcy Int Dev, Presidents Malaria Initiat, Bur Global Hlth, Washington, DC 20523 USA.
[Andre, Zandra H.] Ctr Dis Control & Prevent, Presidents Malaria Initiat, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA.
RP Gomez, PP (reprint author), Mat & Child Hlth Integrated Program, Baltimore, MD USA.
EM patricia.gomez@jhpiego.org
FU U.S. Agency for International Development (USAID) [GHS-A-00-08-00002-00]
FX This manuscript was made possible by the generous support of the
American people through the U.S. Agency for International Development
(USAID), under the terms of the Leader with Associates Cooperative
Agreement GHS-A-00-08-00002-00. The authors would like to thank various
experts collaborating on malaria programmes in Kenya, Madagascar,
Mainland Tanzania and Uganda for their responses to questions about MIP
in their countries.
NR 18
TC 9
Z9 9
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUN 3
PY 2014
VL 13
AR 212
DI 10.1186/1475-2875-13-212
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AL1PL
UT WOS:000338897300001
PM 24888703
ER
PT J
AU Andrade, AL
Ternes, YM
Vieira, MA
Moreira, WG
Lamaro-Cardoso, J
Kipnis, A
Cardoso, MR
Brandileone, MC
Moura, I
Pimenta, FC
Carvalho, MD
Saraiva, FO
Toscano, CM
Minamisava, R
AF Andrade, Ana Lucia
Ternes, Yves Mauro
Vieira, Maria Aparecida
Moreira, Weslley Garcia
Lamaro-Cardoso, Juliana
Kipnis, Andre
Cardoso, Maria Regina
Brandileone, Maria Cristina
Moura, Iaci
Pimenta, Fabiana C.
Carvalho, Maria da Gloria
Saraiva, Fabricia Oliveira
Toscano, Cristiana Maria
Minamisava, Ruth
TI Direct Effect of 10-Valent Conjugate Pneumococcal Vaccination on
Pneumococcal Carriage in Children Brazil
SO PLOS ONE
LA English
DT Article
ID STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; YOUNG-CHILDREN;
IMPACT; DISEASE; COLONIZATION; EFFICACY; VACCINES; PROGRAM
AB Background: 10-valent conjugate pneumococcal vaccine/PCV10 was introduced in the Brazilian National Immunization Program along the year of 2010. We assessed the direct effectiveness of PCV10 vaccination in preventing nasopharyngeal/NP pneumococcal carriage in infants.
Methods: A cross-sectional population-based household survey was conducted in Goiania Brazil, from December/2010-February/2011 targeting children aged 7-11 m and 15-18 m. Participants were selected using a systematic sampling. NP swabs, demographic data, and vaccination status were collected from 1,287 children during home visits. Main outcome and exposure of interest were PCV10 vaccine-type carriage and dosing schedules (3p+0, 2p+0, and one catch-up dose), respectively. Pneumococcal carriage was defined by a positive culture and serotyping was performed by Quellung reaction. Rate ratio/RR was calculated as the ratio between the prevalence of vaccine-types carriage in children exposed to different schedules and unvaccinated for PCV10. Adjusted RR was estimated using Poisson regression. PCV10 effectiveness/VE on vaccine-type carriage was calculated as 1-RR*100.
Results: The prevalence of pneumococcal carriage was 41.0% (95% CI: 38.4-43.7). Serotypes covered by PCV10 and PCV13 were 35.2% and 53.0%, respectively. Vaccine serotypes 6B (11.6%), 23F (7.8%), 14 (6.8%), and 19F (6.6%) were the most frequently observed. After adjusted for confounders, children who had received 2p+0 or 3p+0 dosing schedule presented a significant reduction in pneumococcal vaccine-type carriage, with PCV10 VE equal to 35.9% (95% CI: 4.2-57.1; p = 0.030) and 44.0% (95% CI: 14.-63.5; p = 0.008), respectively, when compared with unvaccinated children. For children who received one catch-up dose, no significant VE was detected (p = 0.905).
Conclusion: PCV10 was associated with high protection against vaccine-type carriage with 2p+0 and 3p+0 doses for children vaccinated before the second semester of life. The continuous evaluation of carriage serotypes distribution is likely to be useful for evaluating the long-term effectiveness and impact of pneumococcal vaccination on serotypes reduction.
C1 [Andrade, Ana Lucia; Ternes, Yves Mauro; Moreira, Weslley Garcia; Saraiva, Fabricia Oliveira; Toscano, Cristiana Maria] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil.
[Ternes, Yves Mauro] Secretariat Hlth Municipal Goiania, Epidemiol Branch, Goiania, Go, Brazil.
[Vieira, Maria Aparecida] Pontifical Catholic Univ Goias, Goiania, Go, Brazil.
[Moreira, Weslley Garcia; Lamaro-Cardoso, Juliana; Kipnis, Andre] Univ Fed Goias, Bacteriol Lab, Goiania, Go, Brazil.
[Cardoso, Maria Regina] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
[Brandileone, Maria Cristina] Adolfo Lutz Inst, Sao Paulo, Brazil.
[Moura, Iaci; Pimenta, Fabiana C.; Carvalho, Maria da Gloria] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA.
[Minamisava, Ruth] Univ Fed Goias, Fac Nursing, Goiania, Go, Brazil.
RP Andrade, AL (reprint author), Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil.
EM alssandrade@gmail.com
RI Andrade, Ana Lucia/L-5751-2013;
OI Minamisava, Ruth/0000-0001-9352-5567
FU National Council for Scientific and Technological Development (CNPq);
National Institute of Science and Technology for Health (IATS)
[573826/2008-0, 306096/2010-2]; Research Foundation of the Goias State/
FAPEG-GO, Brazil [PRONEX/07-2009]; Foundation for Research Support/
FUNAPE-GO, Federal University of Goias [34131]; Fogarty International
Center Global Infectious Diseases Research Training Program; National
Institutes of Health [D43TW006592]
FX Funding provided by National Council for Scientific and Technological
Development (CNPq) and National Institute of Science and Technology for
Health (IATS) (#573826/2008-0; 306096/2010-2); Research Foundation of
the Goias State/ FAPEG-GO, Brazil (Grant: PRONEX/07-2009); Foundation
for Research Support/ FUNAPE-GO, Federal University of Goias (#34131).
This work was supported in part by a Fogarty International Center Global
Infectious Diseases Research Training Program grant, National Institutes
of Health, to the University of Pittsburgh (D43TW006592). The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 46
TC 11
Z9 11
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 3
PY 2014
VL 9
IS 6
AR e98128
DI 10.1371/journal.pone.0098128
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI5ML
UT WOS:000336911400036
PM 24892409
ER
PT J
AU Shakoor, S
Kabir, F
Khowaja, AR
Qureshi, SM
Jehan, F
Qamar, F
Whitney, CG
Zaidi, AKM
AF Shakoor, Sadia
Kabir, Furqan
Khowaja, Asif R.
Qureshi, Shahida M.
Jehan, Fyezah
Qamar, Farah
Whitney, Cynthia G.
Zaidi, Anita K. M.
TI Pneumococcal Serotypes and Serogroups Causing Invasive Disease in
Pakistan, 2005-2013
SO PLOS ONE
LA English
DT Article
ID DETERMINING CAPSULAR SEROTYPES; SEQUENTIAL MULTIPLEX PCR;
STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; CHILDREN; SURVEILLANCE;
MENINGITIS
AB While pneumococcal conjugate vaccines have been implemented in most countries worldwide, use in Asia has lagged in part because of a lack of data on the amount of disease that is vaccine preventable in the region. We describe pneumococcal serotypes elicited from 111 episodes of invasive pneumococcal disease (IPD) from 2005 to 2013 among children and adults in Pakistan. Seventy-three percent (n = 81) of 111 IPD episodes were cases of meningitis (n = 76 in children 0-15 years and n = 5 among adults). Serotypes were determined by target amplification of DNA extracted from pneumococcal isolates (n = 52) or CSF specimens (n = 59). Serogroup 18 was the most common serogroup causing meningitis in children <5 years, accounting for 21% of cases (n = 13). The 10-valent pneumococcal conjugate vaccine (PCV 10) or PCV10- related serotypes were found in 61% (n = 47) of childhood (age 0-15 years) meningitis episodes. PCV-13 increased this coverage to 63% (one additional serotype 19A; n = 48). Our data indicate that use of PCVs would prevent a large proportion of serious pneumococcal disease.
C1 [Shakoor, Sadia; Kabir, Furqan; Khowaja, Asif R.; Qureshi, Shahida M.; Jehan, Fyezah; Qamar, Farah; Zaidi, Anita K. M.] Aga Khan Univ Hosp, Dept Pediat & Child Hlth, Karachi, Pakistan.
[Shakoor, Sadia] Aga Khan Univ Hosp, Dept Pathol & Microbiol, Karachi, Pakistan.
[Whitney, Cynthia G.] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Zaidi, AKM (reprint author), Aga Khan Univ Hosp, Dept Pediat & Child Hlth, Karachi, Pakistan.
EM anita.zaidi@aku.edu
FU Johns Hopkins University [PO2000273560]; National Institute of Health's
Fogarty International Center [1 D43 TW007585-01]
FX Collection of CSF samples used in the study was done through the
Johns-Hopkins and GAVI collaboration for the study: Impact of
Introduction of HiB Vaccine in selected districts of Pakistan. Grant No.
PO2000273560 Johns Hopkins University. Dr. Sadia Shakoor received
research training support from the National Institute of Health's
Fogarty International Center (1 D43 TW007585-01). The funders of this
primary study had no role in study design, data collection and analysis,
decision to publish, or preparation of this manuscript.
NR 23
TC 3
Z9 3
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 3
PY 2014
VL 9
IS 6
AR e98796
DI 10.1371/journal.pone.0098796
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI5ML
UT WOS:000336911400092
PM 24892937
ER
PT J
AU Greenwald, R
Bergin, MH
Yip, F
Boehmer, T
Kewada, P
Shafer, MM
Schauer, JJ
Sarnat, JA
AF Greenwald, Roby
Bergin, Michael H.
Yip, Fuyuen
Boehmer, Tegan
Kewada, Priya
Shafer, Martin M.
Schauer, James J.
Sarnat, Jeremy A.
TI On-Roadway In-Cabin Exposure to Particulate Matter: Measurement Results
Using Both Continuous and Time-Integrated Sampling Approaches
SO AEROSOL SCIENCE AND TECHNOLOGY
LA English
DT Article
ID POLYCYCLIC AROMATIC-HYDROCARBONS; ACUTE MYOCARDIAL-INFARCTION; SOLUBLE
ORGANIC-CARBON; HEART-RATE-VARIABILITY; URBAN AIR-POLLUTION;
LOS-ANGELES; ULTRAFINE PARTICLES; COMPOSITION DISTRIBUTIONS; ELEMENTAL
CARBON; OXIDATIVE DAMAGE
AB The Atlanta Commuters Exposure (ACE) Study was designed to measure in-cabin exposure to roadway particulate pollution and acute health response in a panel of adults with and without asthma following a 2-h scripted route along major highways in Atlanta. This article focuses on methods and results of both continuous and integrated approaches used to measure the concentration of PM2.5 mass, particle number concentration (PNC), black carbon (BC) mass, and particle-bound PAHs, in-cabin noise, PM elemental composition, elemental carbon, organic carbon, water-soluble organic carbon (WSOC) content, and speciation of a broad range of organic compounds including alkanes, hopanes, and PAHs. Speciated PM data indicates that in-cabin particles derive from three non-co-varying processes: the resuspension of road dust containing crustal elements and previously-deposited brake pad residue with a contribution of normal fuel combustion, incomplete combustion processes producing PAHs and carbon particles, and particles ablated from brake pads that have not previously deposited to the roadside environment. Most in-cabin pollutants were elevated during the warm season with the notable exception of PNC. PNC was not found to be correlated with most other pollutants. In-cabin concentrations were marginally higher when windows were open.
Copyright 2014 American Association for Aerosol Research
C1 [Greenwald, Roby; Kewada, Priya; Sarnat, Jeremy A.] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA.
[Bergin, Michael H.] Georgia Inst Technol, Dept Civil & Environm Engn, Atlanta, GA 30332 USA.
[Yip, Fuyuen; Boehmer, Tegan] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Atlanta, GA USA.
[Shafer, Martin M.; Schauer, James J.] Univ Wisconsin, Environm Chem & Technol Program, Madison, WI USA.
RP Greenwald, R (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.
EM roby.greenwald@emory.edu
FU Centers for Disease Control and Prevention; US EPA [R834799]
FX This study was made possible in part by funding from the Centers for
Disease Control and Prevention. The findings and conclusions in this
report are those of the author(s) and do not necessarily represent the
views of Centers for Disease Control and Prevention.; This publication
was made possible in part by US EPA grant R834799. This publication's
contents are solely the responsibility of the grantee and do not
necessarily represent the official views of the US EPA. Further, the US
EPA does not endorse the purchase of any commercial products or services
mentioned in the publication.
NR 72
TC 4
Z9 4
U1 6
U2 57
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 520 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0278-6826
EI 1521-7388
J9 AEROSOL SCI TECH
JI Aerosol Sci. Technol.
PD JUN 3
PY 2014
VL 48
IS 6
BP 664
EP 675
DI 10.1080/02786826.2014.912745
PG 12
WC Engineering, Chemical; Engineering, Mechanical; Environmental Sciences;
Meteorology & Atmospheric Sciences
SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric
Sciences
GA AH1DQ
UT WOS:000335860400004
ER
PT J
AU Abad, N
Baack, B
O'Leary, A
Lyles, C
AF Abad, Neetu
Baack, Brittney
O'Leary, Ann
Lyles, Cynthia
TI A REVIEW OF HIV/STD BEHAVIORAL PREVENTION INTERVENTIONS FOR FEMALE SEX
WORKERS IN THE UNITED STATES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Abad, Neetu; Baack, Brittney; Lyles, Cynthia] Ctr Dis Control & Prevent, Atlanta, GA USA.
[O'Leary, Ann] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Prevent Res Branch, Div HIV AIDS Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 70
BP S114
EP S114
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500403
ER
PT J
AU Alfonso, M
Flemming, T
Coursey, J
Furness, B
AF Alfonso, Maria
Flemming, Toni
Coursey, John
Furness, Bruce
TI ADDRESSING ANOTHER SILENT EPIDEMIC: HEPATITIS C SCREENING IN A SEXUALLY
TRANSMITTED DISEASES CLINIC
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Alfonso, Maria] DC Deparment Hlth, Washington, DC USA.
[Flemming, Toni; Furness, Bruce] Ctr Dis Control & Prevent, DSTDP, Washington, DC USA.
[Coursey, John] DC Dept Hlth, Washington, DC USA.
EM maria.alfonso@dc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 89
BP S63
EP S63
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500216
ER
PT J
AU Althaus, CL
Mishra, S
Spicknall, I
AF Althaus, Christian L.
Mishra, Sharmistha
Spicknall, Ian
TI MATHEMATICAL MODELING OF RISK BEHAVIORS, TRANSMISSION DYNAMICS AND
INTERVENTION IMPACT AND COST
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Althaus, Christian L.] Univ Bern, Inst Social & Prevent Med ISPM, Bern, Switzerland.
[Mishra, Sharmistha] Timmins & Dist Hosp, Timmins, ON, Canada.
[Spicknall, Ian] Ctr Dis Control & Prevent, DSTP, Hlth Serv Res & Evaluat Branch, Atlanta, GA USA.
RI Althaus, Christian/F-6008-2015
OI Althaus, Christian/0000-0002-5230-6760
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 1E
BP S10
EP S10
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500034
ER
PT J
AU Asbel, L
Anschuetz, G
Salmon, M
Lewis, F
Johnson, C
AF Asbel, Lenore
Anschuetz, Greta
Salmon, Melinda
Lewis, Felicia
Johnson, Caroline
TI SYPHILIS PARTNER SERVICES - CASE FINDING FOR HIV AND OTHER STDS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Asbel, Lenore; Anschuetz, Greta; Salmon, Melinda; Lewis, Felicia; Johnson, Caroline] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
[Lewis, Felicia] Ctr Dis Control & Prevent, Philadelphia, PA USA.
EM greta.anschuetz@phila.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 141
BP S133
EP S133
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500474
ER
PT J
AU Asbel, L
Anschuetz, G
Newbern, EC
Salmon, M
Lewis, F
Johnson, C
AF Asbel, Lenore
Anschuetz, Greta
Newbern, E. Claire
Salmon, Melinda
Lewis, Felicia
Johnson, Caroline
TI HIV SERODISCORDANT PARTNERSHIPS AMONG MSM DIAGNOSED WITH EARLY SYPHILIS
IN PHILADELPHIA
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Asbel, Lenore; Anschuetz, Greta; Newbern, E. Claire; Salmon, Melinda; Lewis, Felicia; Johnson, Caroline] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
[Lewis, Felicia] Ctr Dis Control & Prevent, Philadelphia, PA USA.
EM greta.anschuetz@phila.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 24
BP S102
EP S102
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500357
ER
PT J
AU Beltrami, J
Felton, C
Castellanos, T
Duncan, T
Dunbar, E
AF Beltrami, John
Felton, Chandra
Castellanos, Ted
Duncan, Ted
Dunbar, Erica
TI STATUS UPDATE ON CDC-FUNDED PS 12-1201 CATEGORY C DEMONSTRATION
PROJECTS: HIV TESTING, LINKAGE TO CARE, AND PARTNER SERVICES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Beltrami, John; Felton, Chandra; Castellanos, Ted; Duncan, Ted; Dunbar, Erica] CDC, Atlanta, GA 30333 USA.
EM hzb3@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 1
BP S96
EP S96
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500334
ER
PT J
AU Blank, S
Seyoum, S
Braunstein, S
Pathela, P
Nash, D
Schillinger, J
AF Blank, Susan
Seyoum, Selam
Braunstein, Sarah
Pathela, Preeti
Nash, Denis
Schillinger, Julia
TI IMPROVING HIV CARE OUTCOMES AMONG PERSONS NEWLY DIAGNOSED WITH HIV IN
THE NEW YORK CITY DEPARTMENT OF HEALTH & MENTAL HYGIENE SEXUALLY
TRANSMITTED DISEASE CLINICS, 2010 & 2011
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Blank, Susan; Braunstein, Sarah; Pathela, Preeti] New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA.
[Seyoum, Selam] Queens, New York City Dept Hlth & Mental Hyg, Bur HIV, New York, NY USA.
[Nash, Denis] CUNY, Sch Publ Hlth Hunter, New York, NY USA.
[Schillinger, Julia] Ctr Dis Control & Prevent, Queens, Div Sexually Transmitted Dis Prevent, Hyattsville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 2F2
BP S16
EP S16
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500054
ER
PT J
AU Blank, S
Borges, C
Pathela, P
Braunstein, S
Shepard, C
Schillinger, J
AF Blank, Susan
Borges, Christine
Pathela, Preeti
Braunstein, Sarah
Shepard, Colin
Schillinger, Julia
TI FINDING ACUTE HIV INFECTION AT NEW YORK CITY DEPARTMENT OF HEALTH AND
MENTAL HYGIENE'S SEXUALLY TRANSMITTED DISEASE CLINICS, 2010-2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Blank, Susan; Pathela, Preeti; Braunstein, Sarah] New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA.
[Borges, Christine] Dept Hlth & Mental Hyg, Long Isl City, NY USA.
[Shepard, Colin] New York City Dept Hlth & Mental Hyg, New York, NY USA.
[Schillinger, Julia] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Queens, Hyattsville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 2C4
BP S14
EP S15
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500049
ER
PT J
AU Bolan, G
Blanchard, J
AF Bolan, Gail
Blanchard, James
TI PROGRAM SCIENCE
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Bolan, Gail] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Blanchard, James] Univ Manitoba, Winnipeg, MB, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA P1
BP S1
EP S1
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500002
ER
PT J
AU Branson, B
Peeling, RW
Catania, J
AF Branson, Bernard
Peeling, Rosanna W.
Catania, Joseph
TI POINT OF CARE TESTS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Branson, Bernard] Ctr Dis Control & Prevent, Off Director, Div HIV AIDS Prevent, Atlanta, GA USA.
[Peeling, Rosanna W.] London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England.
[Catania, Joseph] Oregon State Univ, Coll Publ Hlth & Human Sci, Corvallis, OR 97331 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 6D
BP S39
EP S39
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500126
ER
PT J
AU Brookmeyer, K
AF Brookmeyer, Kathryn
TI VIOLENCE EXPOSURE, STD AND SEXUAL HEALTH RISK OUTCOMES: A NATIONALLY
REPRESENTATIVE STUDY FROM KENYA
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Brookmeyer, Kathryn] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM guul@cdc.gov
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 179
BP S87
EP S88
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500306
ER
PT J
AU Carrasco, S
Gorbach, P
Bhagwat, P
Parrish, A
Collins, T
Grauer, B
Bolan, R
Zimmerman, M
Markowitz, L
Kerndt, P
Meites, E
AF Carrasco, Steven
Gorbach, Pamina
Bhagwat, Priya
Parrish, Adam
Collins, Tom
Gratzer, Beau
Bolan, Robert
Zimmerman, Michael
Markowitz, Lauri
Kerndt, Peter
Meites, Elissa
TI HEALTH SYSTEM BARRIERS TO HUMAN PAPILLOMAVIRUS VACCINATION AMONG YOUNG
MEN WHO HAVE SEX WITH MEN IN TWO US CITIES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Carrasco, Steven; Gorbach, Pamina; Bhagwat, Priya] Univ Calif Los Angeles, Los Angeles, CA USA.
[Parrish, Adam; Collins, Tom] Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA.
[Gratzer, Beau] Howard Brown Hlth Ctr, Chicago, IL USA.
[Bolan, Robert] Los Angeles Gay & Lesbian Ctr, Los Angeles, CA USA.
[Zimmerman, Michael] AIDS Healthcare Fdn, Los Angeles, CA USA.
[Markowitz, Lauri; Meites, Elissa] Ctr Dis Control & Prevent Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
[Kerndt, Peter] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 29
BP S103
EP S103
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500362
ER
PT J
AU Carroll, S
Kirkcaldy, R
Fox, J
Kubin, G
Trees, D
AF Carroll, Serena
Kirkcaldy, Robert
Fox, Jan
Kubin, Grace
Trees, David
TI DECREASED SUSCEPTIBILITY TO CEFTRIAXONE IN NEISSERIA GONORRHOEAE IN THE
ABSENCE OF A MOSAIC PENICILLIN-BINDING PROTEIN 2 (PENA) ALLELE
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Carroll, Serena; Kirkcaldy, Robert; Trees, David] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Fox, Jan] Oklahoma Dept Hlth, Oklahoma City, OK USA.
[Kubin, Grace] Texas Dept State Hlth Serv, Austin, TX USA.
EM scarroll@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 145
BP S78
EP S78
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500272
ER
PT J
AU Charles, A
Michel, E
Friedman, A
Jackson, P
AF Charles, Abby
Michel, Elisabeth
Friedman, Allison
Jackson, Phronie
TI SEX PACT: EVALUATION OF AN INNOVATIVE APPROACH TO SEXUAL HEALTH
PROMOTION AMONG YOUNG AFRICAN AMERICAN MALES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Charles, Abby; Michel, Elisabeth] Inst Publ Hlth Informat, Washington, DC USA.
[Friedman, Allison] CDC, NCHHSTP, Atlanta, GA 30333 USA.
[Jackson, Phronie] Natl Council Negro Women, Washington, DC USA.
EM acharles@institutephi.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 59
BP S55
EP S55
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500186
ER
PT J
AU Charles, A
Michel, E
Friedman, A
AF Charles, Abby
Michel, Elisabeth
Friedman, Allison
TI EXPLORING THE REALITIES OF YOUNG AFRICAN AMERICAN MEN TO INFORM SEXUAL
HEALTH COMMUNICATION EFFORTS: FINDINGS FROM QUALITATIVE RESEARCH IN
WASHINGTON, D.C
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Charles, Abby; Michel, Elisabeth] Inst Publ Hlth Informat, Washington, DC USA.
[Friedman, Allison] CDC, NCHHSTP, Atlanta, GA 30333 USA.
EM acharles@institutephi.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 61
BP S56
EP S56
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500188
ER
PT J
AU Chen, CY
Gaydos, C
Grad, Y
Unemo, M
AF Chen, Cheng Y.
Gaydos, Charlotte
Grad, Yonatan
Unemo, Magnus
TI ADVANCES IN MOLECULAR DIAGNOSTICS AND GENOMICS OF AMR
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Chen, Cheng Y.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Gaydos, Charlotte] Johns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD USA.
[Grad, Yonatan] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Unemo, Magnus] Natl Reference Lab Pathogen Neisscria, Orebro, Sweden.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 1D
BP S10
EP S10
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500033
ER
PT J
AU Chesson, H
Markowitz, L
Dunne, E
AF Chesson, Harrell
Markowitz, Lauri
Dunne, Eileen
TI THE ESTIMATED IMPACT OF HPV VACCINATION COVERAGE ON LIFETIME CERVICAL
CANCER CASES AMONG GIRLS CURRENTLY AGED 12 YEARS AND YOUNGER IN THE
UNITED STATES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Chesson, Harrell; Dunne, Eileen] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Markowitz, Lauri] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
EM hbc7@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 46
BP S52
EP S52
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500173
ER
PT J
AU Choden, T
Hennessy, R
Schillinger, J
AF Choden, Tsering
Hennessy, Robin
Schillinger, Julia
TI THE FEASIBILITY OF USING HIV INFECTION AS THE SOLE CRITERION FOR
INITIATING FIELD INVESTIGATIONS AMONG PERSONS WITH REACTIVE SEROLOGIC
TESTS FOR SYPHILIS, NEW YORK CITY, 2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Choden, Tsering; Hennessy, Robin] New York City Dept Hlth & Mental Hyg, Queens, NY USA.
[Schillinger, Julia] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Queens, NY USA.
EM tchoden@health.nyc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 11
BP S98
EP S98
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500344
ER
PT J
AU Collins, C
Younge, S
Sales, J
DiClemente, R
AF Collins, Carmen
Younge, Sinead
Sales, Jessica
DiClemente, Ralph
TI EDUCATION, POWER, AND SEX: A QUALITATIVE STUDY ON THE INTERRELATIONSHIP
OF FACTORS THAT INFLUENCE THE SEXUAL BEHAVIOR OF AFRICAN AMERICAN WOMEN
ATTENDING A HISTORICALLY BLACK COLLEGE
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Collins, Carmen] CDC, Decatur, GA USA.
[Younge, Sinead] Morehouse Coll, Atlanta, GA USA.
[Sales, Jessica] Emory Univ, Atlanta, GA 30322 USA.
[DiClemente, Ralph] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 74
BP S115
EP S115
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500407
ER
PT J
AU Crain, C
Johnson, D
Tashima, N
Valentine, J
AF Crain, Cathleen
Johnson, David
Tashima, Nathaniel
Valentine, Jo
TI HEALTHY RELATIONSHIPS: CURRICULA FOR HISTORICALLY BLACK COLLEGE AND
UNIVERSITY STUDENTS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Crain, Cathleen] LTG & Associates Inc, Takoma Pk, MD USA.
[Johnson, David] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Tashima, Nathaniel] LTG Associates Inc, Turlock, CA USA.
[Valentine, Jo] Ctr Dis Control & Prevent, Div STD Prevent, NCHHSTP, Atlanta, GA USA.
EM partners@ltgassociates.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 40
BP S50
EP S50
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500167
ER
PT J
AU Cramer, R
Leichliter, J
Chesson, H
AF Cramer, Ryan
Leichliter, Jami
Chesson, Harrell
TI AN ASSESSMENT OF THE CHARACTERISTICS OF STATE LAWS CONCERNING DISEASE
INTERVENTION ACTIVITIES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Cramer, Ryan; Leichliter, Jami; Chesson, Harrell] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM rcramer@cdc.gov
NR 0
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 113
BP S126
EP S126
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500446
ER
PT J
AU Dlouhy, D
AF Dlouhy, Diane
TI DEVELOPMENT OF A STD COMMUNICATIONS TOOLKIT FOR PIOS/COMMUNICATORS IN
LOCAL AND STATE HEALTH DEPARTMENTS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Dlouhy, Diane] CDC, Div STD Prevent, Atlanta, GA 30333 USA.
EM IQU0@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 195
BP S92
EP S92
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500322
ER
PT J
AU Dumitru, G
AF Dumitru, Gema
TI RECENT FEDERAL GUIDANCE ABOUT SERVICES FOR PERSONS WITH HIV:
IMPLICATIONS FOR ACCESS TO STD PREVENTION AND CARE
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Dumitru, Gema] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 85
BP S118
EP S118
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500418
ER
PT J
AU Evans, L
Lawler, K
Moore, A
Bradford, J
AF Evans, Leigh
Lawler, Kelsey
Moore, Andrea
Bradford, Judith
TI BARRIERS TO IMPLEMENTING A RISK-REDUCTION PLAN AMONG MSM PARTICIPATING
IN A SINGLE-SESSION HIV PREVENTION INTERVENTION
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Evans, Leigh; Lawler, Kelsey; Bradford, Judith] Fenway Hlth, Boston, MA USA.
[Moore, Andrea] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 34
BP S105
EP S105
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500367
ER
PT J
AU Evans, L
Lawler, K
Moore, A
Bradford, J
AF Evans, Leigh
Lawler, Kelsey
Moore, Andrea
Bradford, Judith
TI MOVING FROM 2-SESSION TO 1-SESSION SEXUAL RISK-REDUCTION COUNSELING:
IMPLICATIONS FOR HIGHER-IMPACT HIV PREVENTION AMONG MSM
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Evans, Leigh; Lawler, Kelsey; Bradford, Judith] Fenway Hlth, Boston, MA USA.
[Moore, Andrea] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM levans@fenwayhealth.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 38
BP S49
EP S50
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500165
ER
PT J
AU Fakile, Y
Lupoli, K
AF Fakile, Yetunde
Lupoli, Kathryn
TI ESTABLISHING A QUALITY ASSURANCE PROGRAM FOR SYPHILIS SEROLOGY
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Fakile, Yetunde] Ctr Dis Control & Prevent, NCHHSTP, DSTDP, Atlanta, GA USA.
[Lupoli, Kathryn] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM yfakile@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP136
BP S76
EP S76
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500263
ER
PT J
AU Fanfair, RN
Fine, D
Grier, L
Salomon, S
Nakarsukasa-Ono, W
Blackburn, P
Torrone, E
Markowitz, L
AF Fanfair, Robyn Neblett
Fine, David
Grier, LaZetta
Salomon, Sarah
Nakarsukasa-Ono, Wendy
Blackburn, Patricia
Torrone, Elizabeth
Markowitz, Lauri
TI EVALUATING DIFFERENCES IN CHLAMYDIA SCREENING AMONG OLDER WOMEN
ATTENDING FAMILY PLANNING (FP) CLINICS BY US PUBLIC HEALTH SERVICE
(USPHS) REGION, 2010
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Fanfair, Robyn Neblett] CDC, Atlanta, GA 30333 USA.
Cardea Serv, Seattle, WA USA.
CDC, DHHS, OID, NCHHSTP,DSTDP,SDMB, Atlanta, GA 30333 USA.
Cardea, Oakland, CA USA.
Ctr Dis Control & Prevent, Atlanta, GA USA.
Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
EM iyo5@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 5
BP S41
EP S41
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500132
ER
PT J
AU Fine, D
Salomon, S
Bowen, V
Hughes, G
AF Fine, David
Salomon, Sarah
Bowen, Virginia
Hughes, Gwenda
TI MEASURING PROGRAM EFFECTIVENESS: SCREENING COVERAGE, TREATMENT, AND
PARTNER SERVICES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Fine, David; Salomon, Sarah] Cardea Serv, Seattle, WA USA.
[Bowen, Virginia] Ctr Dis Control & Prevent, Epidemiol & Stat Branch, Div STD Prevent, Atlanta, GA USA.
[Hughes, Gwenda] Publ Hlth England, HIV & STI Dept, Ctr Infect Dis Surveillance & Control, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 5E
BP S34
EP S35
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500113
ER
PT J
AU Fine, D
Fanfair, RN
Salomon, S
Nakatsukasa-Ono, W
Markowitz, L
AF Fine, David
Fanfair, Robyn Neblett
Salomon, Sarah
Nakatsukasa-Ono, Wendy
Markowitz, Lauri
TI CHLAMYDIA TRACHOMATIS (CT) IN OLDER FEMALE FAMILY PLANNING (FP) CLINIC
CLIENTS: ASSESSING EFFECTIVENESS AND EFFICIENCY OF SCREENING ALGORITHMS
BASED ON USPHS REGION X INFERTILITY PREVENTION PROJECT (IPP) RECORDS,
2009-2011
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Fine, David; Salomon, Sarah; Nakatsukasa-Ono, Wendy] Cardea Serv, Seattle, WA USA.
[Fanfair, Robyn Neblett] CDC, Atlanta, GA 30333 USA.
Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 1B2
BP S7
EP S8
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500024
ER
PT J
AU Flagg, EW
Weinstock, HS
AF Flagg, Elaine W.
Weinstock, Hillard S.
TI USE OF ADMINISTRATIVE HEALTH CARE DATA FOR SEXUALLY TRANSMITTED DISEASE
SURVEILLANCE
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Flagg, Elaine W.; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM ewf2@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 109
BP S68
EP S69
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500236
ER
PT J
AU Fleming, E
Hogben, M
AF Fleming, Eleanor
Hogben, Matthew
TI ASSESSING DIFFERENT PARTNER NOTIFICATION METHODS IN ASSURING PARTNER
TREATMENT FOR GONORRHEA
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Fleming, Eleanor] CDC, NCHHSTP, Atlanta, GA 30333 USA.
[Hogben, Matthew] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM efleming@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 113
BP S70
EP S70
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500240
ER
PT J
AU Flemming, T
Hess, P
Alfonso, M
Lum, G
Furness, B
AF Flemming, Toni
Hess, Paul
Alfonso, Maria
Lum, Garret
Furness, Bruce
TI BANG FOR THE BUCK: THE PARTNER SERVICES EXPERIENCE IN WASHINGTON, DC
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Flemming, Toni; Hess, Paul; Furness, Bruce] Ctr Dis Control & Prevent, DSTDP, Washington, DC USA.
[Alfonso, Maria; Lum, Garret] DC Dept Hlth, Washington, DC USA.
EM toni.flemming@dc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 9
BP S98
EP S98
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500342
ER
PT J
AU Friedman, A
Daniels, B
Uhrig, J
Gilbert, L
Poehlman, J
AF Friedman, Allison
Daniels, Booker
Uhrig, Jennifer
Gilbert, Lisa
Poehlman, Jon
TI UNDERSTANDING AFRICAN AMERICANS' PERCEPTIONS OF SEXUAL HEALTH: FINDINGS
FROM AN ONLINE NATIONAL SURVEY AND IMPLICATIONS FOR HEALTH COMMUNICATION
INTERVENTIONS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Friedman, Allison] NCHHSTP, CDC, Atlanta, GA USA.
[Daniels, Booker] CDC, Atlanta, GA 30333 USA.
[Uhrig, Jennifer; Gilbert, Lisa; Poehlman, Jon] RTI Int, Res Triangle Pk, NC USA.
EM alf8@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP198
BP S148
EP S148
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500531
ER
PT J
AU Friedman, M
Hennessy, R
Schillinger, J
Klingler, E
AF Friedman, Mark
Hennessy, Robin
Schillinger, Julia
Klingler, Ellen
TI IMPROVEMENTS IN TIMELINESS OF SYPHILIS SURVEILLANCE AND DISEASE
INTERVENTION ACTIVITIES FROM A NEWLY IMPLEMENTED SURVEILLANCE/CASE
MANAGEMENT SYSTEM
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Friedman, Mark; Klingler, Ellen] NYC Dept Hlth & Mental Hyg, Queens, NY USA.
[Hennessy, Robin] New York City Dept Hlth & Mental Hyg, Queens, NY USA.
[Schillinger, Julia] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Queens, NY USA.
EM mfmefriedman@msn.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 142
BP S77
EP S78
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500269
ER
PT J
AU Furness, B
Shah, Y
Kharfen, M
Dooley, D
AF Furness, Bruce
Shah, Yasir
Kharfen, Michael
Dooley, Danielle
TI INCORPORATING HIV TESTING INTO A CITY-WIDE SCHOOL-BASED STD SCREENING
PROGRAM
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Furness, Bruce] Ctr Dis Control & Prevent, DSTDP, Washington, DC USA.
[Shah, Yasir; Kharfen, Michael] DC Dept Hlth, Washington, DC USA.
[Dooley, Danielle] Unity Hlth Care Inc, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 53
BP S110
EP S110
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500386
ER
PT J
AU Gallo, M
Legardy-Williams, J
Steiner, M
Macaluso, M
Hobbs, M
Hylton-Kong, T
Anderson, C
Carter, M
Costenbader, E
Warner, L
AF Gallo, Maria
Legardy-Williams, Jennifer
Steiner, Markus
Macaluso, Maurizio
Hobbs, Marcia
Hylton-Kong, Tina
Anderson, Clive
Carter, Marion
Costenbader, Elizabeth
Warner, Lee
TI CONDOM USE SELF-EFFICACY AND EXPOSURE TO SEMEN AMONG FEMALE STI CLINIC
PATIENTS IN KINGSTON, JAMAICA
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Gallo, Maria] Ohio State Univ, Columbus, OH 43210 USA.
[Legardy-Williams, Jennifer] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
[Macaluso, Maurizio] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
[Hobbs, Marcia] Univ N Carolina, Chapel Hill, NC USA.
[Anderson, Clive] Univ W Indies, Off Vice Chancellor, Kingston, Jamaica.
[Carter, Marion] CDC, Hlth Serv Res & Evaluat Branch, Atlanta, GA 30333 USA.
[Warner, Lee] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM mgallo@cph.osu.edu
RI Macaluso, Maurizio/J-2076-2015
OI Macaluso, Maurizio/0000-0002-2977-9690
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 163
BP S83
EP S83
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500290
ER
PT J
AU Gallo, M
Margolis, A
Malotte, CK
Rietmeijer, C
Klausner, J
O'Donnell, L
Warner, L
AF Gallo, Maria
Margolis, Andrew
Malotte, C. Kevin
Rietmeijer, Cornelis
Klausner, Jeffrey
O'Donnell, Lydia
Warner, Lee
TI SEXUAL ABSTINENCE BY SEXUALLY TRANSMITTED CLINIC PATIENTS IMMEDIATELY
FOLLOWING A NEW STI DIAGNOSIS: SAFE IN THE CITY TRIAL
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Gallo, Maria] Ohio State Univ, Columbus, OH 43210 USA.
[Margolis, Andrew; Warner, Lee] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Malotte, C. Kevin] Calif State Univ Long Beach, Long Beach, CA 90840 USA.
[Rietmeijer, Cornelis] Denver Publ Hlth, Denver, CO USA.
[Klausner, Jeffrey] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Klausner, Jeffrey] Fielding Sch Publ Hlth, Los Angeles, CA USA.
[O'Donnell, Lydia] Educ Dev Ctr Inc, Newton, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 4C2
BP S27
EP S27
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500091
ER
PT J
AU Garbers, S
Friedman, A
Martinez, O
Scheinmann, R
Bermudez, D
Chiasson, MA
AF Garbers, Samantha
Friedman, Allison
Martinez, Omar
Scheinmann, Roberta
Bermudez, Dayana
Chiasson, Mary Ann
TI USING FORMATIVE RESEARCH TO ADAPT THE GYT CAMPAIGN FOR SEXUAL AND GENDER
MINORITY YOUTH OF COLOR IN NEW YORK CITY
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Garbers, Samantha; Scheinmann, Roberta; Bermudez, Dayana; Chiasson, Mary Ann] Publ Hlth Solut, New York, NY USA.
[Friedman, Allison] CDC, NCHHSTP, Atlanta, GA 30333 USA.
[Martinez, Omar] Columbia Univ, New York, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 45
BP S107
EP S108
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500378
ER
PT J
AU Garbers, S
Friedman, A
Scheinmann, R
Bermudez, D
Chiasson, MA
AF Garbers, Samantha
Friedman, Allison
Scheinmann, Roberta
Bermudez, Dayana
Chiasson, Mary Ann
TI IMPACT OF AN ADAPTED CAMPAIGN TO REACH STREET-ORIENTED SEXUAL & GENDER
MINORITY YOUTH IN NEW YORK CITY WITH STI TESTING MESSAGES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Garbers, Samantha; Scheinmann, Roberta; Bermudez, Dayana; Chiasson, Mary Ann] Publ Hlth Solut, New York, NY USA.
[Friedman, Allison] CDC, NCHHSTP, Atlanta, GA 30333 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 44
BP S107
EP S107
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500377
ER
PT J
AU Garon, J
Nelson, R
Torrone, E
Carey, D
AF Garon, Julie
Nelson, Robert
Torrone, Elizabeth
Carey, Delicia
TI REVISITING STD DATA RE-RELEASE GUIDELINES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Garon, Julie; Nelson, Robert; Torrone, Elizabeth; Carey, Delicia] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM wvd9@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 114
BP S70
EP S70
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500241
ER
PT J
AU Gift, T
Spence, O
AF Gift, Thomas
Spence, O'Mareen
TI INFERTILITY AND QUALITY OF LIFE: FINDINGS FROM A LITERATURE REVIEW
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Gift, Thomas] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Spence, O'Mareen] GDH Consulting, Alabama Medicaid Agcy, Montgomery, AL USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 72
BP S115
EP S115
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500405
ER
PT J
AU Goodwin, C
Hennessy, R
Schillinger, J
AF Goodwin, Christopher
Hennessy, Robin
Schillinger, Julia
TI TREATMENT VERIFICATION AMONG CASES OF GONORRHEA REPORTED FROM FEDERALLY
QUALIFIED HEALTH CENTERS, NEW YORK CITY, 2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Goodwin, Christopher] Ctr Dis Control & Prevent, Publ Hlth Associate Program, Queens, NY USA.
[Hennessy, Robin] New York City Dept Hlth & Mental Hyg, Queens, NY USA.
[Schillinger, Julia] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Queens, NY USA.
EM cgoodwin1@health.nyc.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 196
BP S92
EP S92
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500323
ER
PT J
AU Guarner, J
Pillay, A
Jost, H
Sun, YC
Cox, DL
Notenboom, R
Workowski, K
AF Guarner, Jeannette
Pillay, Allan
Jost, Heather
Sun, Yongcheng
Cox, David L.
Notenboom, Robert
Workowski, Kimberly
TI EVALUATION OF TREPONEMAL TESTS FOR IMPROVED DIAGNOSIS OF NEUROSYPHILIS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Guarner, Jeannette; Workowski, Kimberly] Emory Univ, Atlanta, GA 30322 USA.
[Pillay, Allan; Jost, Heather; Cox, David L.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Sun, Yongcheng] Syphilis Lab Reference & Res Branch, Atlanta, GA USA.
EM jguarne@emory.edu
RI Guarner, Jeannette/B-8273-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 149
BP S135
EP S135
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500482
ER
PT J
AU Gupta, A
Rogers, M
Abbott, S
Gorwitz, R
Dunne, E
Schillinger, J
AF Gupta, Akash
Rogers, Meighan
Abbott, Sharon
Gorwitz, Rachel
Dunne, Eileen
Schillinger, Julia
TI STD DIAGNOSIS AND MANAGEMENT PRACTICES IN FEDERALLY QUALIFIED HEALTH
CENTER CLINICS IN NEW YORK CITY, 2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Gupta, Akash; Gorwitz, Rachel; Dunne, Eileen] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Rogers, Meighan] New York City Dept Hlth & Mental Hyg, New York, NY USA.
[Abbott, Sharon] Cicatelli Associates Inc, New York, NY USA.
[Schillinger, Julia] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Queens, NY USA.
EM xix5@cdc.gov
NR 0
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 80
BP S61
EP S61
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500207
ER
PT J
AU Habel, MA
Leichliter, J
Torrone, E
AF Habel, Melissa A.
Leichliter, Jami
Torrone, Elizabeth
TI EXPLORING CHLAMYDIA POSITIVITY AMONG FEMALES ON COLLEGE CAMPUSES,
2008-2010
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Habel, Melissa A.; Leichliter, Jami; Torrone, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 3A4
BP S18
EP S19
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500061
ER
PT J
AU Haderxhanaj, L
Chesson, H
Aral, S
Leichliter, J
AF Haderxhanaj, Laura
Chesson, Harrell
Aral, Sevgi
Leichliter, Jami
TI THE DISTRIBUTION OF SEX PARTNERS IN THE UNITED STATES BY SEXUAL
IDENTITY, 2002 AND 2006-2010
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Haderxhanaj, Laura; Aral, Sevgi; Leichliter, Jami] CDC, Atlanta, GA 30333 USA.
[Chesson, Harrell] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM vzo6@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 114
BP S126
EP S126
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500447
ER
PT J
AU Haderxhanaj, L
Gift, T
Torrone, E
Behl, A
Romaguera, R
Leichliter, J
AF Haderxhanaj, Laura
Gift, Thomas
Torrone, Elizabeth
Behl, Ajay
Romaguera, Raul
Leichliter, Jami
TI ESTIMATING THE SIZE AND COST OF SERVICES OF THE SAFETY NET POPULATION
FOR STD PREVENTION
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Haderxhanaj, Laura; Leichliter, Jami] CDC, Atlanta, GA 30333 USA.
[Gift, Thomas; Torrone, Elizabeth; Romaguera, Raul] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Behl, Ajay] Hlth Partners Inst Educ & Res, Pingtung, Taiwan.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 3C2
BP S20
EP S21
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500069
ER
PT J
AU Ham, C
Fleischauer, A
Clymore, J
Leone, P
AF Ham, Cal
Fleischauer, Aaron
Clymore, Jacquelyn
Leone, Peter
TI OPPORTUNITIES FOR EXPANDED HIV AND STD MANAGEMENT IN FEDERALLY QUALIFIED
HEALTH CENTERS (FQHCS) - NORTH CAROLINA'S EXPERIENCE
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Ham, Cal] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Fleischauer, Aaron] Norht Carolina Div Publ Hlth, Raleigh, NC USA.
[Clymore, Jacquelyn] North Carolina Div Publ Hlth, Raleigh, NC USA.
[Leone, Peter] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
EM cal1477@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 138
BP S132
EP S132
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500471
ER
PT J
AU Ham, C
Guardado, M
Nieto, A
Northbrook, S
Kamb, M
AF Ham, Cal
Guardado, Maria
Nieto, Ana
Northbrook, Sanny
Kamb, Mary
TI FACTORS ASSOCIATED WITH HIV AMONG MEN WHO HAVE SEX WITH MEN IN 2 CITIES
IN EL SALVADOR: THE IMPORTANCE OF OTHER STIS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Ham, Cal; Kamb, Mary] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Guardado, Maria] TEPHINET, Guatemala City, Guatemala.
[Nieto, Ana] El Salvador Natl AIDS Program, San Salvador, El Salvador.
[Northbrook, Sanny] CDC Cent Amer, Guatemala City, Guatemala.
EM cal1477@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 161
BP S82
EP S83
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500288
ER
PT J
AU Hamarman, A
Mason, P
Kroeger, K
Alexander-Pender, C
AF Hamarman, Amelia
Mason, Patricia
Kroeger, Karen
Alexander-Pender, Carla
TI THE IMPACT OF BUDGET CUTS AMONG LOCAL STD PROGRAMS IN NEW JERSEY:
RESULTS OF A RAPID ETHNOGRAPHIC ASSESSMENT
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Hamarman, Amelia; Mason, Patricia] New Jersey Dept Hlth, Trenton, NJ USA.
[Kroeger, Karen; Alexander-Pender, Carla] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM knk2@cdc.gov
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 198
BP S93
EP S93
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500325
ER
PT J
AU Henning, T
Papp, J
McNicholl, J
Kersh, E
AF Henning, Tara
Papp, John
McNicholl, Janet
Kersh, Ellen
TI COINFECTION WITH TRICHOMONAS VAGINALIS AND CHLAMYDIA TRACHOMATIS WIDENS
THE SUSCEPTIBILITY WINDOW FOR SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS (SHIV)
ACQUISITION IN PIGTAIL MACAQUES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Henning, Tara; Papp, John; McNicholl, Janet; Kersh, Ellen] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM idz4@cdc.gov
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 146
BP S134
EP S135
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500479
ER
PT J
AU Hogben, M
Brookmeyer, K
Heyer, K
Kachur, R
Habel, M
Friedman, A
McFarlane, M
AF Hogben, Matthew
Brookmeyer, Kathryn
Heyer, Kate
Kachur, Rachel
Habel, Melissa
Friedman, Allison
McFarlane, Mary
TI YOUTH ATTITUDES TOWARD DIMENSIONS OF SEXUAL HEALTH
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Hogben, Matthew; Brookmeyer, Kathryn; Kachur, Rachel; Habel, Melissa; Friedman, Allison] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Heyer, Kate] NACCHO, Washington, DC USA.
[Friedman, Allison] CDC, NCHHSTP, Atlanta, GA 30333 USA.
[McFarlane, Mary] CDC, Atlanta, GA 30333 USA.
EM MHogben@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 45
BP S51
EP S52
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500172
ER
PT J
AU Hoover, KW
Parsell, B
Leichliter, J
Habel, M
Tao, GY
Heyer, K
Gift, T
AF Hoover, Karen W.
Parsell, Bradley
Leichliter, Jami
Habel, Melissa
Tao, Guoyu
Heyer, Kate
Gift, Tom
TI STD CLINICS ARE AN IMPORTANT PART OF THE US HEALTHCARE SAFETY NET
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Hoover, Karen W.; Leichliter, Jami; Habel, Melissa; Tao, Guoyu; Gift, Tom] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Parsell, Bradley] Univ Chicago, NORC, Chicago, IL 60637 USA.
[Heyer, Kate] NACCHO, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 104
BP S123
EP S123
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500437
ER
PT J
AU Howard, S
Pilgrim, N
Jennings, J
Sonenstein, F
Arrington-Sanders, R
Page, K
Dittius, P
Lousier, P
Marcell, A
AF Howard, Shalynn
Pilgrim, Nanlesta
Jennings, Jacky
Sonenstein, Freya
Arrington-Sanders, Renata
Page, Kathleen
Dittius, Patricia
Loosier, Penny
Marcell, Arik
TI PROJECT CONNECT BALTIMORE: HIV TESTING AT COMMUNITY-BASED YOUTH-SERVING
AGENCIES SERVING YOUNG MINORITY MALES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Howard, Shalynn; Marcell, Arik] Johns Hopkins Univ, Baltimore, MD USA.
[Pilgrim, Nanlesta; Sonenstein, Freya] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Jennings, Jacky; Page, Kathleen] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Arrington-Sanders, Renata] Johns Hopkins Sch Med, Baltimore, MD USA.
[Dittius, Patricia] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Loosier, Penny] CDC, Div STD Prevent, Atlanta, GA 30333 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 50
BP S109
EP S109
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500383
ER
PT J
AU Hoyte, T
Fisher, H
Flores, S
Dietz, P
Stratford, D
AF Hoyte, Tamika
Fisher, Holly
Flores, Stephen
Dietz, Patricia
Stratford, Dale
TI EVALUATING HIGH IMPACT HIV PREVENTION IN 12 US CITIES: LESSONS FOR THE
STD PROGRAM EVALUATOR
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Hoyte, Tamika; Fisher, Holly; Flores, Stephen; Dietz, Patricia; Stratford, Dale] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM thoyte@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 123
BP S72
EP S72
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500250
ER
PT J
AU Johnson, DM
Salomon, S
Warner, L
Carlon, A
Fine, D
AF Johnson, David M.
Salomon, Sarah
Warner, Lee
Carlon, Alfonso
Fine, David
TI MALE REPRODUCTIVE HEALTH PROJECT 2009-2013: PROGRAM IMPLEMENTATION,
RESEARCH RESULTS AND IMPLICATIONS FOR STD SERVICE DELIVERY
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Johnson, David M.] US DHHS Off Populat Affairs, Off Family Planning, Rockville, MD USA.
[Salomon, Sarah; Fine, David] Cardea Serv, Seattle, WA USA.
[Warner, Lee] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Carlon, Alfonso] Cardea Serv, Austin, TX USA.
EM david.johnson@hhs.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 6C3
BP S38
EP S38
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500124
ER
PT J
AU Kachur, R
AF Kachur, Rachel
TI DEVELOPMENT AND EVALUATION OF AN HIV/STD-FOCUSED MOTION COMIC FOR YOUNG
PEOPLE AGES 15-24 YEARS IN THE US
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Kachur, Rachel] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 59
BP S111
EP S111
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500392
ER
PT J
AU Kidd, S
Stenger, M
Llata, E
Weinstock, HS
AF Kidd, Sarah
Stenger, Mark
Llata, Eloisa
Weinstock, Hillard S.
TI BEYOND THE NATIONAL RATE: REGIONAL VARIATION IN GONORRHEA TRENDS-UNITED
STATES, 2009-2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Kidd, Sarah; Stenger, Mark; Llata, Eloisa] CDC, Atlanta, GA 30333 USA.
[Weinstock, Hillard S.] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM hgk9@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 193
BP S91
EP S91
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500320
ER
PT J
AU King, H
Holtzman, D
Xing, J
AF King, Hope
Holtzman, Deborah
Xing, Jian
TI HEPATITIS B VACCINATION AMONG HIGH-RISK ADULTS: RESULTS FROM THE
NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES), 2003-2010
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [King, Hope] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Holtzman, Deborah; Xing, Jian] Ctr Dis Control & Prevent, Div Vital Hepatitis, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 97
BP S121
EP S122
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500430
ER
PT J
AU Kirkcaldy, R
Papp, J
Soge, O
Hook, EW
del Rio, C
Harrington, S
Kubin, G
Weinstock, HS
AF Kirkcaldy, Robert
Papp, John
Soge, Olusegun
Hook, Edward W., III
del Rio, Carlos
Harrington, Susan
Kubin, Grace
Weinstock, Hillard S.
TI CEPHALOSPORIN ANTIMICROBIAL SUSCEPTIBILITY OF NEISSERIA GONORRHOEAE IN
THE UNITED STATES, 2009-2013
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Kirkcaldy, Robert; Papp, John; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Soge, Olusegun] Univ Washington, Seattle, WA 98195 USA.
[Hook, Edward W., III] Univ Alabama Birmingham, Birmingham, AL USA.
[del Rio, Carlos] Emory Univ, Atlanta, GA 30322 USA.
[Harrington, Susan] Cleveland Clin, Cleveland, OH USA.
[Kubin, Grace] Texas Dept State Hlth Serv, Austin, TX USA.
RI del Rio, Carlos/B-3763-2012
OI del Rio, Carlos/0000-0002-0153-3517
NR 0
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 6A2
BP S35
EP S36
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500115
ER
PT J
AU Kotzen, M
Schillinger, J
Greene, S
Cutler, B
Braunstein, S
Pathela, P
Hennessy, R
Isaac, B
Blank, S
Weiss, D
AF Kotzen, Mollie
Schillinger, Julia
Greene, Sharon
Cutler, Blayne
Braunstein, Sarah
Pathela, Preeti
Hennessy, Robin
Isaac, Beth
Blank, Susan
Weiss, Don
TI THE RELATIONSHIP BETWEEN SEXUALLY TRANSMITTED DISEASES AND INVASIVE
MENINGOCOCCAL DISEASE (IMD) IN NYC, 2000-2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Kotzen, Mollie; Greene, Sharon; Cutler, Blayne; Braunstein, Sarah; Pathela, Preeti; Isaac, Beth; Blank, Susan; Weiss, Don] New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA.
[Schillinger, Julia] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Queens, NY USA.
[Hennessy, Robin] New York City Dept Hlth & Mental Hyg, Queens, NY USA.
EM mkotzen@health.nyc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 126
BP S73
EP S73
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500253
ER
PT J
AU Kroeger, K
Humbert-Rico, T
Staatz, C
Alexander-Pender, C
Hamarman, A
Mason, P
AF Kroeger, Karen
Humbert-Rico, Tiffany
Staatz, Colleen
Alexander-Pender, Carla
Hamarman, Amelia
Mason, Patricia
TI "TIMES ARE CHANGING:" TRAINING DISEASE INTERVENTION SPECIALISTS (DIS) TO
CONDUCT RAPID ETHNOGRAPHIC ASSESSMENT: IMPLEMENTATION AND EVALUATION OF
A PILOT PROJECT IN NEW JERSEY
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Kroeger, Karen; Humbert-Rico, Tiffany; Staatz, Colleen; Alexander-Pender, Carla] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Hamarman, Amelia; Mason, Patricia] New Jersey Dept Hlth, Trenton, NJ USA.
EM knk2@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 197
BP S92
EP S92
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500324
ER
PT J
AU Lang, SG
Lobato, MN
Sosa, L
AF Lang, Simona G.
Lobato, Mark N.
Sosa, Lynn
TI EVALUATION OF GONORRHEA SURVEILLANCE - CONNECTICUT, 2011-2013
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Lobato, Mark N.] CDC, Atlanta, GA 30333 USA.
[Sosa, Lynn] Connecticut Dept Publ Hlth, Hartford, CT USA.
EM simona.lang@ct.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 124
BP S72
EP S73
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500251
ER
PT J
AU Leston, J
Tulloch, S
Reilley, B
AF Leston, Jessica
Tulloch, Scott
Reilley, Brigg
TI QUALITY IMPROVEMENT: A SYSTEMS APPROACH TO REDUCING HEALTH DISPARITIES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Leston, Jessica] Northwest Portland Area Indian Hlth Board, Portland, ME USA.
[Tulloch, Scott] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Reilley, Brigg] Indian Hlth Ser, Albuquerque, NM USA.
EM jleston@npaihb.org
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 144
BP S134
EP S134
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500477
ER
PT J
AU Lewis, F
Newman, D
Anschuerz, G
Mettey, A
Asbel, L
Walker-Baban, C
Richardson-Moore, R
Salmon, M
AF Lewis, Felicia
Newman, Daniel
Anschuerz, Greta
Mettey, Aaron
Asbel, Lenore
Walker-Baban, Cherie
Richardson-Moore, Regina
Salmon, Melinda
TI ANOTHER REASON TO STAY IN SCHOOL: PARTNER MEETING PLACE IS SIGNIFICANTLY
ASSOCIATED WITH CHLAMYDIA AND/OR GONORRHEA (CT/GC) INFECTION IN STUDENTS
TESTING IN A LARGE HIGH SCHOOL STD SCREENING PROGRAM-PHILADELPHIA,
2009-2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Lewis, Felicia; Newman, Daniel] Ctr Dis Control & Prevent, Philadelphia, PA USA.
[Lewis, Felicia; Anschuerz, Greta; Asbel, Lenore; Walker-Baban, Cherie; Richardson-Moore, Regina; Salmon, Melinda] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
[Mettey, Aaron] New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA.
EM felicia.lewis@phila.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 43
BP S51
EP S51
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500170
ER
PT J
AU Lewis, F
Eberhart, M
Anschuetz, G
Salmon, M
Terrell, C
Brady, K
AF Lewis, Felicia
Eberhart, Michael
Anschuetz, Greta
Salmon, Melinda
Terrell, Coleman
Brady, Kathleen
TI HIGH YIELD OF NEW HIV DIAGNOSES AND PATIENTS WITH HIGH VIRAL LOADS FROM
HIV PARTNER SERVICES, PHILADELPHIA DEPARTMENT OF PUBLIC HEALTH STD
CONTROL PROGRAM (STDCP) AND AIDS ACTIVITIES COORDINATING OFFICE (AACO),
2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Lewis, Felicia] Ctr Dis Control & Prevent, Philadelphia, PA USA.
[Lewis, Felicia; Eberhart, Michael; Anschuetz, Greta; Salmon, Melinda; Terrell, Coleman; Brady, Kathleen] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 5C5
BP S34
EP S34
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500111
ER
PT J
AU Liddon, N
Dunville, R
Barrios, L
AF Liddon, Nicole
Dunville, Richard
Barrios, Lisa
TI INCREASING ADOLESCENT ACCESS TO SEXUAL HEALTH SERVICES VIA SCHOOLS:
FINDINGS FROM AN EXPERT PANEL
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Liddon, Nicole; Dunville, Richard; Barrios, Lisa] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM ne16@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 49
BP S52
EP S53
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500176
ER
PT J
AU Lin, C
AF Lin, Carol
TI A SIMULATION STUDY OF USING COMPOSITE HPV GENOTYPING ASSAY RESULTS TO
MONITOR HUMAN PAPILLOMAVIRUS INFECTIONS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Lin, Carol] CDC, Atlanta, GA 30333 USA.
EM clin@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 143
BP S78
EP S78
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500270
ER
PT J
AU Lin, L
Benard, V
Greek, A
Roland, K
Hawkins, N
Saraiya, M
AF Lin, Lavinia
Benard, Vicki
Greek, April
Roland, Katherine
Hawkins, Nikki
Saraiya, Mona
TI RACIAL/ETHNIC DIFFERENCES IN HPV PREVALENCE, RISK FACTORS, AND KNOWLEDGE
AMONG PATIENTS IN FEDERALLY QUALIFIED HEALTH CENTERS (FQHCS)
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Lin, Lavinia; Benard, Vicki; Roland, Katherine; Hawkins, Nikki; Saraiya, Mona] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Greek, April] Battelle Mem Inst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 86
BP S118
EP S119
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500419
ER
PT J
AU Liu, G
Hariri, S
Bradley, H
Gottlieb, SL
Leichliter, J
Markowitz, L
AF Liu, Gui
Hariri, Susan
Bradley, Heather
Gottlieb, Sami L.
Leichliter, Jami
Markowitz, Lauri
TI TRENDS AND PATTERNS OF SEXUAL PRACTICES AMONG ADOLESCENTS AND ADULTS
AGED 14-59, UNITED STATES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Liu, Gui; Hariri, Susan; Bradley, Heather] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Leichliter, Jami] CDC, Atlanta, GA 30333 USA.
[Markowitz, Lauri] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
EM wrf8@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 123
BP S128
EP S128
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500456
ER
PT J
AU Llata, E
Schwebke, J
Schumacher, C
Pathela, P
Bernstein, K
Kerani, R
Weinstock, HS
AF Llata, Eloisa
Schwebke, Jane
Schumacher, Christina
Pathela, Preeti
Bernstein, Kyle
Kerani, Roxanne
Weinstock, Hillard S.
TI PELVIC INFLAMMATORY DISEASE MANAGEMENT AT SELECTED US STD CLINICS: STD
SURVEILLANCE NETWORK, 2010-2011
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Llata, Eloisa] CDC, Atlanta, GA 30333 USA.
[Schwebke, Jane] Univ Alabama Birmingham, Birmingham, AL USA.
[Schumacher, Christina] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA.
[Pathela, Preeti] New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA.
[Bernstein, Kyle] Johns Hopkins Sch Publ Hlth, San Francisco, CA USA.
[Kerani, Roxanne] Publ Hlth Seattle & King Cty, Seattle, WA USA.
[Weinstock, Hillard S.] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM gge3@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 66
BP S57
EP S57
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500193
ER
PT J
AU Marfel, M
Edilyong, J
Yinnifel, C
Farshy, C
Barrow, R
Papp, J
AF Marfel, Maria
Edilyong, James
Yinnifel, Cyril
Farshy, Carol
Barrow, Roxanne
Papp, John
TI ENHANCED LABORATORY TESTING REDUCES CHLAMYDIA TRACHOMATIS INFECTIONS IN
YAP, FEDERATED STATES OF MICRONESIA
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Marfel, Maria; Yinnifel, Cyril] Yap Minist Hlth, Colonia, Yap, Mexico.
Yap State Hlth Serv, Colonia, Yap, Mexico.
[Farshy, Carol; Papp, John] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Barrow, Roxanne] Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 4C5
BP S28
EP S28
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500094
ER
PT J
AU McFarlane, M
Kachur, R
Hogben, M
Brookmeyer, K
Heyer, K
Friedman, A
AF McFarlane, Mary
Kachur, Rachel
Hogben, Matthew
Brookmeyer, Kathryn
Heyer, Kate
Friedman, Allison
TI GYT AWARENESS AND STD TESTING BEHAVIORS AMONG YOUTH AND YOUNG ADULTS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [McFarlane, Mary] CDC, Atlanta, GA 30333 USA.
[Kachur, Rachel; Hogben, Matthew; Brookmeyer, Kathryn] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Heyer, Kate] NACCHO, Washington, DC USA.
[Friedman, Allison] CDC, NCHHSTP, Atlanta, GA 30333 USA.
EM xzm3@cdc.gov
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 44
BP S51
EP S51
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500171
ER
PT J
AU Meites, E
Markowitz, L
Paz-Bailey, G
Oster, A
AF Meites, Elissa
Markowitz, Lauri
Paz-Bailey, Gabriela
Oster, Alexandra
TI HPV VACCINE COVERAGE AMONG MEN WHO HAVE SEX WITH MEN - UNITED STATES,
2011
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Meites, Elissa; Markowitz, Lauri] Ctr Dis Control & Prevent Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
[Paz-Bailey, Gabriela; Oster, Alexandra] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM emeites@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 19
BP S100
EP S101
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500352
ER
PT J
AU Michaels, M
Gilbert, S
Ward, A
Pryzby, R
Loosier, P
AF Michaels, Maureen
Gilbert, Susan
Ward, Alana
Pryzby, Rachel
Loosier, Penny
TI TESTING SEXUAL HEALTH MESSAGES THAT PROMOTE BENEFITS AND ACTION STEPS:
RESULTS FROM END-USERS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Michaels, Maureen] Michaels Opin Res, New York, NY USA.
[Gilbert, Susan; Ward, Alana] Partnership Prevent, Washington, DC USA.
[Pryzby, Rachel; Loosier, Penny] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM plf4@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP195
BP S147
EP S147
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500528
ER
PT J
AU Nakatsukasa-Ono, W
Fanfair, RN
Salomon, S
Fine, D
Markowitz, L
AF Nakatsukasa-Ono, Wendy
Fanfair, Robyn Neblett
Salomon, Sarah
Fine, David
Markowitz, Lauri
TI HORMONAL CONTRACEPTIVE USE AND RISK OF CHLAMYDIA TRACHOMATIS (CT)
INFECTION IN USPHS REGION X FAMILY PLANNING (FP) FEMALE CLIENTS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Nakatsukasa-Ono, Wendy; Salomon, Sarah; Fine, David] Cardea Serv, Seattle, WA USA.
[Fanfair, Robyn Neblett] CDC, Atlanta, GA 30333 USA.
[Markowitz, Lauri] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
EM wono@carcleaservices.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 63
BP S56
EP S56
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500190
ER
PT J
AU Nelson, R
Torrone, E
Dooley-Edwards, S
Caron, J
Harvey, A
Kidd, S
Su, JR
Carey, D
AF Nelson, Robert
Torrone, Elizabeth
Dooley-Edwards, Sheila
Caron, Julie
Harvey, Alesia
Kidd, Sarah
Su, John R.
Carey, Delicia
TI STD CASE SURVEILLANCE DATA QUALITY UNITED STATES, 2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Nelson, Robert; Torrone, Elizabeth; Dooley-Edwards, Sheila; Caron, Julie; Harvey, Alesia; Su, John R.; Carey, Delicia] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Kidd, Sarah] CDC, Atlanta, GA 30333 USA.
EM rxn1@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 124
BP S128
EP S129
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500457
ER
PT J
AU Newman, D
Peterman, T
Shiver, S
AF Newman, Daniel
Peterman, Thomas
Shiver, Stacy
TI GONORRHEA REINFECTIONS IN WOMEN FROM FLORIDA 2000-2011
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Newman, Daniel; Peterman, Thomas] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Shiver, Stacy] Florida Dept Hlth, Tallahassee, FL USA.
EM dcn7@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 68
BP S57
EP S58
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500195
ER
PT J
AU Owusu-Edusei, K
Chesson, H
Gift, T
Gilbert, M
Brttnham, R
Bolan, G
AF Owusu-Edusei, Kwame, Jr.
Chesson, Harrell
Gift, Thomas
Gilbert, Mark
Brttnham, Robert
Bolan, Gail
TI EXPLORING THE COST-EFFECTIVENESS OF A HYPOTHETICAL CHLAMYDIA VACCINE FOR
YOUNG FEMALES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Owusu-Edusei, Kwame, Jr.] CDC, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Chesson, Harrell; Gift, Thomas; Bolan, Gail] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Gilbert, Mark; Brttnham, Robert] British Columbia Ctr Dis Control, Vancouver, BC, Canada.
EM kfo0@cdc.gov
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 116
BP S70
EP S71
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500243
ER
PT J
AU Papp, J
Rowlinson, MC
Razeq, J
Wholehan, J
Glennen, A
Walters, C
Iwen, P
Lee, L
Hagan, C
AF Papp, John
Rowlinson, Marie-Claire
Razeq, Jafar
Wholehan, Jason
Glennen, Anita
Walters, Chaney
Iwen, Peter
Lee, Lillian
Hagan, Celia
TI INTRA-LABORATORY VARIABILITY IN THE ETEST (R) METHOD FOR DETERMINING
ANTIBIOTIC SUSCEPTIBILITY OF NEISSERIA GONORRHOEAE TO CEFIXIME,
CEFTRIAXONE AND AZITHROMYCIN
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Papp, John] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Rowlinson, Marie-Claire] Bur Publ Hlth Labs, Baltimore, MD USA.
[Razeq, Jafar] Maryland Dept Hlth, Baltimore, MD USA.
[Wholehan, Jason] Michigan Dept Community Hlth, Lansing, MI USA.
[Glennen, Anita] Minnesota Dept Hlth, St Paul, MN USA.
[Walters, Chaney] Mississippi Publ Hlth Labs, Jackson, MS USA.
[Iwen, Peter] Nebraska Publ Hlth Lab, Omaha, NE USA.
[Lee, Lillian] New York City Dept Hlth & Mental Hyg, New York, NY USA.
[Hagan, Celia] Assoc Publ Hlth Labs, Silver Spring, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 5B4
BP S32
EP S32
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500105
ER
PT J
AU Parrish, A
Crosby, R
Collins, T
Gorbach, P
Carrasco, S
Kerndt, P
Gratzer, B
Markowitz, L
Meites, E
AF Parrish, Adam
Crosby, Richard
Collins, Tom
Gorbach, Pamina
Carrasco, Steven
Kerndt, Peter
Gratzer, Beau
Markowitz, Lauri
Meites, Elissa
TI INTERNALIZED HOMONEGATIVITY AND DISCLOSURE OF SAME-SEX SEXUAL BEHAVIOR
TO HEALTHCARE PROVIDERS AMONG YOUNG MEN WHO HAVE SEX WITH MEN
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Parrish, Adam; Crosby, Richard; Collins, Tom] Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA.
[Gorbach, Pamina; Carrasco, Steven] Univ Calif Los Angeles, Los Angeles, CA USA.
[Kerndt, Peter] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA.
[Gratzer, Beau] Howard Brown Hlth Ctr, Chicago, IL USA.
[Markowitz, Lauri; Meites, Elissa] Ctr Dis Control & Prevent Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
EM adam.parrish@uky.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 21
BP S101
EP S101
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500354
ER
PT J
AU Patel, C
Tao, GY
Gorwitz, R
Hoover, K
AF Patel, Chirag
Tao, Guoyu
Gorwitz, Rachel
Hoover, Karen
TI 1-2 GRAMS OF AZITHROMYCIN AND CARDIOVASCULAR DEATH AMONG COMMERCIALLY
INSURED PERSONS AGED 15-44 YEARS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Patel, Chirag; Hoover, Karen] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Tao, Guoyu; Hoover, Karen] CDC, Atlanta, GA 30333 USA.
EM wyp3@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 128
BP S130
EP S130
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500461
ER
PT J
AU Pathela, P
Braunstein, S
Shepard, C
Schillinger, J
AF Pathela, Preeti
Braunstein, Sarah
Shepard, Colin
Schillinger, Julia
TI INCIDENCE OF SEXUALLY TRANSMITTED DISEASES AMONG TRANSGENDER PERSONS
WITH HIV, NEW YORK CITY, 2000-2010
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Pathela, Preeti; Braunstein, Sarah] New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA.
[Shepard, Colin] New York City Dept Hlth & Mental Hyg, New York, NY USA.
[Schillinger, Julia] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Queens, NY USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 84
BP S118
EP S118
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500417
ER
PT J
AU Patton, M
So, JR
Nelson, R
Weinstock, H
AF Patton, Monica
So, John R.
Nelson, Robert
Weinstock, Hillard
TI PRIMARY AND SECONDARY SYPHILIS IN MEN - UNITED STATES, 2005-2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Patton, Monica; So, John R.; Nelson, Robert; Weinstock, Hillard] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM gnh9@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 26
BP S46
EP S46
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500153
ER
PT J
AU Perez, F
Hoover, K
Juarez, S
Salamanca, R
Ramos, G
Karem, K
Flores, F
Valencia, C
AF Perez, Freddy
Hoover, Karen
Juarez, Sandra
Salamanca, Roxana
Ramos, Gilvan
Karem, Kevin
Flores, Freddy
Valencia, Carola
TI INFORMING POLICY AND PROGRAM DECISIONS FOR SCALING UP SYPHILIS AND HIV
TESTING IN BOLIVIA THROUGH A JOINT TECHNICAL MISSION
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Perez, Freddy] Pan Amer Hlth Org, Washington, DC USA.
[Hoover, Karen; Karem, Kevin] CDC, Atlanta, GA 30333 USA.
[Salamanca, Roxana] PAHO Bolivia, La Paz, Bolivia.
[Ramos, Gilvan; Flores, Freddy; Valencia, Carola] Minist Hlth Bolivia, La Paz, Bolivia.
EM perezf@paho.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 164
BP S139
EP S139
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500497
ER
PT J
AU Peterman, T
Newman, D
Torrone, E
Shiver, S
AF Peterman, Thomas
Newman, Daniel
Torrone, Elizabeth
Shiver, Sracy
TI CUMULATIVE RISK OF REPORTED CHLAMYDIAL INFECTION AMONG WOMEN IN FLORIDA,
2000-2011
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Peterman, Thomas; Newman, Daniel; Torrone, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Shiver, Sracy] Florida Dept Hlth, Tallahassee, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 68
BP S114
EP S114
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500401
ER
PT J
AU Pillay, A
Kikkert, S
Kamb, ML
Broutet, N
Karem, K
AF Pillay, Allan
Kikkert, Susan
Kamb, Mary L.
Broutet, Nathalie
Karem, Kevin
TI WHO/PAHO COLLABORATING CENTRE FOR SYPHILIS SEROLOGY PROFICIENCY TESTING
PROGRAM AT THE CDC
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Pillay, Allan; Kikkert, Susan; Karem, Kevin] CDC, Atlanta, GA 30333 USA.
[Kamb, Mary L.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Broutet, Nathalie] WHO, Geneva, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 3F5
BP S23
EP S24
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500079
ER
PT J
AU Prior, M
Salmon, M
Walker-Baban, C
LaPollo, AB
Johnson, C
AF Prior, Matthew
Salmon, Melinda
Walker-Baban, Cherie
LaPollo, Archana Bodas
Johnson, Caroline
TI CONDOMS, CONDOMS EVERYWHERE! - EXAMINING THE REACH AND AWARENESS OF TAKE
CONTROL PHILLY! AT TWO YEARS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Prior, Matthew; Walker-Baban, Cherie; Johnson, Caroline] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
[Salmon, Melinda] Ctr Dis Control & Prevent, Atlanta, GA USA.
[LaPollo, Archana Bodas] Publ Hlth Management Corp, Philadelphia, PA USA.
EM matt.prior@phila.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 200
BP S93
EP S93
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500327
ER
PT J
AU Pryzby, R
AF Pryzby, Rachel
TI STD PREVENTION IN THE TWITTERSPHERE: FOUNDATIONAL ELEMENTS AND PRACTICAL
APPLICATIONS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Pryzby, Rachel] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM wwb8@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 140
BP S133
EP S133
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500473
ER
PT J
AU Pryzby, R
Kachur, R
AF Pryzby, Rachel
Kachur, Rachel
TI DEVELOPMENT AND EVALUATION OF AN STD TREATMENT MOBILE APPLICATION FOR
HEALTH CARE PROVIDERS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Pryzby, Rachel; Kachur, Rachel] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 6A4
BP S36
EP S36
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500117
ER
PT J
AU Raiford, J
Herbst, J
Carry, M
Browne, F
Doherty, I
Wechsberg, W
AF Raiford, Jerris
Herbst, Jeffrey
Carry, Monique
Browne, Felicia
Doherty, Irene
Wechsberg, Wendee
TI LOW PROSPECTS AND HIGH RISK: STRUCTURAL DETERMINANTS OF SEXUAL HEALTH
ASSOCIATED WITH SEXUAL RISK AMONG AN ECONOMICALLY DISADVANTAGED COHORT
OF YOUNG AFRICAN AMERICAN WOMEN
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Raiford, Jerris; Herbst, Jeffrey; Carry, Monique] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Browne, Felicia] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Doherty, Irene] Res Triangle Inst Int, Res Triangle Pk, NC USA.
[Wechsberg, Wendee] RTI Int, Res Triangle Pk, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 3A3
BP S18
EP S18
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500060
ER
PT J
AU Rasberry, C
Morris, E
Lesesne, C
Carver, L
Topete, P
Kroupa, E
Moore, W
Xu, Y
Stallworth, L
Robin, L
AF Rasberry, Catherine
Morris, Elana
Lesesne, Catherine
Carver, Lisa
Topete, Pablo
Kroupa, Elizabeth
Moore, William
Xu, Ye
Stallworth, LaSamuel
Robin, Leah
TI ACCESS TO AND WILLINGNESS TO USE SCHOOL-BASED HIV AND STD TESTING AND
PREVENTION SERVICES AMONG TEEN YOUNG MEN WHO HAVE SEX WITH MEN
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Rasberry, Catherine; Morris, Elana; Robin, Leah] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Lesesne, Catherine; Carver, Lisa; Topete, Pablo; Moore, William; Xu, Ye; Stallworth, LaSamuel] ICF Int, Atlanta, GA USA.
[Kroupa, Elizabeth] ICF Int, Seattle, WA USA.
EM crasberry@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 27
BP S103
EP S103
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500360
ER
PT J
AU Rorie, M
Zhang, H
Zhu, J
Song, W
Cesa, K
Essuon, A
Mulatu, M
Duffy, N
AF Rorie, Michele
Zhang, Hui
Zhu, Julia
Song, Wei
Cesa, Kristina
Essuon, Aba
Mulatu, Mesfin
Duffy, Nadezhda
TI MONITORING AND EVALUATION OF HIV PARTNER SERVICES PROGRAMS IN THE UNITED
STATES: APPROACHES, STRUCTURES, AND LESSONS LEARNED
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Rorie, Michele; Zhang, Hui; Zhu, Julia; Cesa, Kristina; Essuon, Aba; Mulatu, Mesfin; Duffy, Nadezhda] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Song, Wei] Northrop Grumman, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 3B5
BP S20
EP S20
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500067
ER
PT J
AU Ross, C
Hoover, K
Tao, GY
AF Ross, Christine
Hoover, Karen
Tao, Guoyu
TI PRENATAL SCREENING FOR CHLAMYDIA AND GONORRHEA AND THE ASSOCIATION WITH
PAPANICOLAOU TESTING AMONG MEDICAID-INSURED WOMEN UNITED STATES,
2009-2010
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Ross, Christine; Hoover, Karen; Tao, Guoyu] CDC, Atlanta, GA 30333 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 2B1
BP S12
EP S12
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500041
ER
PT J
AU Schillinger, J
Jamison, K
Rogers, M
AF Schillinger, Julia
Jamison, Kelly
Rogers, Meighan
TI POTENTIAL BIASES WHEN MEASURING REPEAT CHLAMYDIA TRACHOMATIS INFECTION
RATES TO ASSESS THE REAL-WORLD EFFECTIVENESS OF EXPEDITED PARTNER
THERAPY, NEW YORK CITY, 2011-2013
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Schillinger, Julia] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Queens, NY USA.
[Jamison, Kelly; Rogers, Meighan] New York City Dept Hlth & Mental Hyg, New York, NY USA.
EM jschilli@health.nyc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 109
BP S125
EP S125
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500442
ER
PT J
AU Schumacher, C
Kebede, S
Juberg, A
Muvva, RK
Nganga-good, C
Miazad, R
Marsiglia, V
Greiner, A
Jennings, J
AF Schumacher, Christina
Kebede, Samuel
Juberg, Arielle
Muvva, Ravikiran
Nganga-good, Carolyn
Miazad, Rafiq
Marsiglia, Vincent
Greiner, Amelia
Jennings, Jacky
TI CHARACTERISTICS ASSOCIATED WITH RECENT HIGH VIRAL LOAD AMONG
HIV-POSITIVE INDIVIDUALS IN BALTIMORE CITY
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Schumacher, Christina; Greiner, Amelia; Jennings, Jacky] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Kebede, Samuel] Johns Hopkins Univ, Baltimore, MD USA.
[Juberg, Arielle] US Ctr Dis Control & Prevent, Atlanta, GA USA.
[Muvva, Ravikiran] Johns Hopkins Sch Med, Baltimore City Hlth Dept, Baltimore, MD USA.
[Nganga-good, Carolyn; Miazad, Rafiq; Marsiglia, Vincent] Baltimore City Dept Hlth, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 55
BP S110
EP S110
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500388
ER
PT J
AU Seth, P
Wang, GS
Sizemore, E
Walker, T
Figueroa, A
Taylor, L
Hollis, N
Belcher, L
AF Seth, Puja
Wang, Guoshen
Sizemore, Erin
Walker, Tanja
Figueroa, Argelia
Taylor, La'Shan
Hollis, NaTasha
Belcher, Lisa
TI HIV SERVICE DELIVERY TO POPULATIONS AT HIGH RISK ATTENDING STD CLINICS,
55 HEALTH DEPARTMENT JURISDICTIONS, 2011
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Seth, Puja; Wang, Guoshen; Sizemore, Erin; Walker, Tanja; Figueroa, Argelia; Taylor, La'Shan; Hollis, NaTasha; Belcher, Lisa] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 2F1
BP S16
EP S16
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500053
ER
PT J
AU Snoeyenbos, G
Hoover, K
Tao, GY
Ault, K
Workowski, K
AF Snoeyenbos, Gretchen
Hoover, Karen
Tao, Guoyu
Ault, Kevin
Workowski, Kimberly
TI EVALUATION AND MANAGEMENT OF GENITAL ULCER DISEASE: NON-ADHERENCE TO CDC
GUIDELINES
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Snoeyenbos, Gretchen] Emory Univ, Atlanta, GA 30322 USA.
[Hoover, Karen; Tao, Guoyu] CDC, Atlanta, GA 30333 USA.
[Ault, Kevin; Workowski, Kimberly] Emory Univ Sch Med, Atlanta, GA USA.
EM gretchen.snoeyenbos@emory.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 110
BP S125
EP S125
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500443
ER
PT J
AU Spicknall, I
Gift, T
Manhart, LE
Golden, M
AF Spicknall, Ian
Gift, Thomas
Manhart, Lisa E.
Golden, Matthew
TI COST-EFFECTIVENESS ANALYSIS OF SCREENING FOR CHLAMYDIA, GONORRHEA, AND
M. GENITALIUM: MONOVALENT VERSUS MULTIVALENT TESTING
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Spicknall, Ian] CDC, Atlanta, GA 30333 USA.
[Gift, Thomas] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Manhart, Lisa E.; Golden, Matthew] Univ Washington, Seattle, WA 98195 USA.
EM xfu0@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 116
BP S126
EP S127
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500449
ER
PT J
AU Spicknall, I
Kirkcaldy, R
Gift, T
Chesson, H
Owusu-Edusei, K
AF Spicknall, Ian
Kirkcaldy, Robert
Gift, Thomas
Chesson, Harrell
Owusu-Edusei, Kwame, Jr.
TI MODELING THE IMPACT OF CEPHALOSPORIN-RESISTANT NEISSERIA GONORRHOEAE
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Spicknall, Ian] CDC, Atlanta, GA 30333 USA.
[Kirkcaldy, Robert; Gift, Thomas; Chesson, Harrell] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Owusu-Edusei, Kwame, Jr.] CDC, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM xfu0@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 115
BP S70
EP S70
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500242
ER
PT J
AU Steiner, R
Michael, S
Balaji, A
Dittos, P
Ethier, K
Liddon, N
Rapposelli, K
Romero, L
AF Steiner, Riley
Michael, Shannon
Balaji, Alexandra
Dittos, Patricia
Ethier, Kathleen
Liddon, Nicole
Rapposelli, Karina
Romero, Lisa
TI YOUTH HIV/STD PREVENTION AND SEXUAL HEALTH CONCEPTUAL FRAMEWORK: A GUIDE
FOR ASSESSMENT, PLANNING, AND COMMUNICATION
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Steiner, Riley; Michael, Shannon; Balaji, Alexandra; Dittos, Patricia; Ethier, Kathleen; Liddon, Nicole; Rapposelli, Karina; Romero, Lisa] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM rsteiner@cdc.gov
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 53
BP S53
EP S54
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500180
ER
PT J
AU Stenger, M
Anschuetz, G
Bernstein, KT
Eaglin, M
Pathela, P
Sosa, L
Reed, M
Samuel, M
Schumacher, C
Simon, J
Stover, J
Jespersen, M
Llata, E
Weinstock, HS
AF Stenger, Mark
Anschuetz, Greta
Bernstein, Kyle T.
Eaglin, Margaret
Pathela, Preeti
Sosa, Lynn
Reed, Mary
Samuel, Michael
Schumacher, Christina
Simon, Julie
Stover, Jeff
Jespersen, Megan
Llata, Eloisa
Weinstock, Hillard S.
TI DOES IT ALWAYS TAKE TWO TO TANGO? SEX PARTNER CHARACTERISTICS AMONG
PERSONS WITH GONORRHEA IN THE STD SURVEILLANCE NETWORK (SSUN), 2010-2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Stenger, Mark; Llata, Eloisa] CDC, Atlanta, GA 30333 USA.
[Anschuetz, Greta] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
[Bernstein, Kyle T.] San Francisco Dept Publ Hlth, San Francisco, CA USA.
[Eaglin, Margaret] City Chicago Dept Publ Hlth, Chicago, IL USA.
[Pathela, Preeti] New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA.
[Sosa, Lynn] Connecticut Dept Publ Hlth, Hartford, CT USA.
[Reed, Mary] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
[Samuel, Michael] Calif Dept Publ Hlth, Richmond, VA USA.
[Schumacher, Christina] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Simon, Julie] Washington State Dept Hlth, Olympia, WA USA.
[Stover, Jeff] Virginia Dept Hlth, Richmond, VA USA.
[Jespersen, Megan] LA Off Publ Hlth, New Orleans, LA USA.
[Weinstock, Hillard S.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 1A2
BP S6
EP S6
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500019
ER
PT J
AU Su, JR
Weinstock, HS
AF Su, John R.
Weinstock, Hillard S.
TI CO-INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) AMONG INDIVIDUALS
WITH EARLY SYPHILIS, BY STAGE OF SYPHILITIC INFECTION, 17 AREAS - US,
2009-2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Su, John R.; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM ezu2@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 29
BP S47
EP S47
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500156
ER
PT J
AU Swartzendruber, A
Sales, JM
Fasula, AM
Brown, JL
Gray, SC
Rose, ES
DiClemente, RJ
AF Swartzendruber, Andrea
Sales, Jessica M.
Fasula, Amy M.
Brown, Jennifer L.
Gray, Simone C.
Rose, Eve S.
DiClemente, Ralph J.
TI HISTORY OF LIVE BIRTH PREDICTS SEXUALLY TRANSMITTED INFECTION
ACQUISITION OVER 6 MONTHS OF FOLLOW-UP AMONG AFRICAN AMERICAN GIRLS
RECRUITED FROM JUVENILE DETENTION CENTERS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Swartzendruber, Andrea; Sales, Jessica M.; Rose, Eve S.; DiClemente, Ralph J.] Emory Univ, Atlanta, GA 30322 USA.
[Fasula, Amy M.; Gray, Simone C.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Brown, Jennifer L.] Texas Tech Univ, Lubbock, TX 79409 USA.
EM alswart@emory.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 50
BP S53
EP S53
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500177
ER
PT J
AU Tao, GY
Hoover, K
AF Tao, Guoyu
Hoover, Karen
TI PREVALENCE OF CHLAMYDIA TRACHOMATIS GENITAL INFECTIONS AMONG WOMEN
SEEKING ELECTIVE ABORTIONS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Tao, Guoyu; Hoover, Karen] CDC, Atlanta, GA 30333 USA.
EM gat3@cde.gov
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 67
BP S57
EP S57
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500194
ER
PT J
AU Taylor, M
Li, W
Skinner, J
Mickey, T
AF Taylor, Melanie
Li, Whitney
Skinner, Julia
Mickey, Tom
TI HIV VIRAL LOADS AMONG YOUNG HIV-INFECTED MEN WITH EARLY SYPHILIS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Taylor, Melanie] Ctr Dis Control, Phoenix, AZ USA.
[Li, Whitney] CDC, Los Angeles, CA USA.
[Skinner, Julia] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA.
[Mickey, Tom] Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA.
EM vqq8@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 20
BP S101
EP S101
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500353
ER
PT J
AU Taylor, M
Newman, D
Skinner, J
Mickey, T
Gonzales, J
AF Taylor, Melanie
Newman, Daniel
Skinner, Julia
Mickey, Tom
Gonzales, Jonathan
TI HIV STATUS AND VIRAL LOADS AMONG MEN TESTING POSITIVE FOR RECTAL
GONORRHEA AND CHLAMYDIA, MAR1COPA COUNTY, ARIZONA, 2011-2013
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Taylor, Melanie] Ctr Dis Control & Prevent, Phoenix, AZ USA.
[Newman, Daniel] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Skinner, Julia] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA.
[Mickey, Tom] Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA.
[Gonzales, Jonathan] ADHS, Phoenix, AZ USA.
EM MDT7@CDC.GOV
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 1
BP S40
EP S40
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500128
ER
PT J
AU Teodoro, N
Alfonso, M
Coursey, J
Hess, P
Furness, B
AF Teodoro, Nicholas
Alfonso, Maria
Coursey, John
Hess, Paul
Furness, Bruce
TI FROM PROBLEM FOCUSED TO HOLISTIC: MENTAL HEALTH AND SUBSTANCE ABUSE
SCREENING AT AN STD CLINIC
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Teodoro, Nicholas; Coursey, John] DC Dept Hlth, Washington, DC USA.
[Alfonso, Maria] DC Deparment Hlth, Washington, DC USA.
[Hess, Paul; Furness, Bruce] Ctr Dis Control & Prevent, DSTDP, Washington, DC USA.
EM nteodoro@gwu.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 88
BP S63
EP S63
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500215
ER
PT J
AU Thomas, C
Khan, A
Dunbar, K
Frasure-Williams, J
AF Thomas, Craig
Khan, Awal
Dunbar, Kevin
Frasure-Williams, Jessica
TI PERFORMANCE MEASUREMENT & PROGRAM IMPROVEMENT: WHERE SHOULD STD PROGRAMS
BE HEADING?
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Thomas, Craig] Ctr Dis Control & Prevent, OSTLTS, Atlanta, GA USA.
[Khan, Awal] Ctr Dis Control & Prevent, DTBE, Atlanta, GA USA.
[Dunbar, Kevin] Natl Chlamydia Screening Programme, Publ Hlth England, London, England.
[Frasure-Williams, Jessica] Calif Dept Publ Hlth, STD Control Program, Richmond, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 2E
BP S16
EP S16
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500052
ER
PT J
AU Torrone, E
Mayor, K
Taylor, M
Furness, B
Peterman, T
AF Torrone, Elizabeth
Mayor, Kelly
Taylor, Melanie
Furness, Bruce
Peterman, Thomas
TI SHARING HIV AND STD DATA TO INFORM AND TARGET PREVENTION
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Torrone, Elizabeth; Peterman, Thomas] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Mayor, Kelly] Natl Coalit STD Directors, Phoenix, AZ USA.
[Taylor, Melanie] Ctr Dis Control, Phoenix, AZ USA.
[Furness, Bruce] Ctr Dis Control & Prevent, DSTDP, Washington, DC USA.
EM ETorrone@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 112
BP S125
EP S126
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500445
ER
PT J
AU Torrone, E
Weinstock, HS
AF Torrone, Elizabeth
Weinstock, Hillard S.
TI PREVALENCE OF CHLAMYDIA TRACHOMATIS - UNITED STATES, 2007-2010
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Torrone, Elizabeth; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM ETorrone@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 4
BP S96
EP S97
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500337
ER
PT J
AU Townsend, J
Saraiya, M
Watson, M
Roland, K
AF Townsend, Julie
Saraiya, Mona
Watson, Meg
Roland, Katherine
TI COMPREHENSIVE CANCER CONTROL EFFORTS TO PROMOTE HUMAN PAPILLOMAVIRUS
VACCINATION
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Townsend, Julie; Saraiya, Mona; Watson, Meg; Roland, Katherine] Ctr Dis Control & Prevent, Atlanta, GA USA.
EM jtownsend@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 3
BP S96
EP S96
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500336
ER
PT J
AU Vaidya, S
Pathela, P
Klingler, E
Blank, S
Schillinger, J
AF Vaidya, Sheila
Pathela, Preen
Klingler, Ellen
Blank, Susan
Schillinger, Julia
TI SURVEY OF HEALTH CARE PROVIDERS SERVING MEN WHO HAVE SEX WITH MEN
SUGGESTS SUBOPTIMAL GONORRHEA DIAGNOSIS AND MANAGEMENT PRACTICES, NEW
YORK CITY 2012
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Vaidya, Sheila; Pathela, Preen] New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA.
[Blank, Susan; Schillinger, Julia] New York City Dept Hlth & Mental Hyg, Queens, NY USA.
[Blank, Susan] Ctr Dis Control & Prevent, Queens, NY USA.
EM smv2123@columbia.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA TP 33
BP S48
EP S48
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500160
ER
PT J
AU Walter, E
Dolor, R
Kemper, A
Unger, E
Panicker, G
Russell, K
Markowitz, L
Dunne, E
AF Walter, Emmanuel
Dolor, Rowena
Kemper, Alex
Unger, Elizabeth
Panicker, Gitika
Russell, Kate
Markowitz, Lauri
Dunne, Eileen
TI ANTIBODY TITERS FOLLOWING THE HPV4 SERIES ADMINISTERED AT DELAYED DOSING
INTERVALS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Walter, Emmanuel; Dolor, Rowena; Kemper, Alex; Russell, Kate] Duke Univ, Sch Med, Durham, NC 27706 USA.
[Unger, Elizabeth; Panicker, Gitika; Dunne, Eileen] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Markowitz, Lauri] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA 4C3
BP S27
EP S27
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500092
ER
PT J
AU Warner, L
Miller, K
Gavin, L
Macalso, M
AF Warner, Lee
Miller, Kim
Gavin, Lorrie
Macalso, Maurizio
TI FACTORS SURROUNDING LACK OF CONDOM USE AT FIRST INTERCOURSE AMONG
COLLEGE-AGE MEN
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Warner, Lee] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Miller, Kim; Gavin, Lorrie] CDC, Atlanta, GA 30333 USA.
[Macalso, Maurizio] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 60
BP S112
EP S112
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500393
ER
PT J
AU Westheimer, E
Pathela, P
Schillinger, J
Limratana, H
Blank, S
AF Westheimer, Emily
Pathela, Preeti
Schillinger, Julia
Limratana, Hellen
Blank, Susan
TI HIGH PREVALENCE OF OROPHARYNGEAL NEISSERIA GONORRHEA INFECTIONS DETECTED
BY NUCLEIC ACID AMPLIFICATION TESTING AMONG MEN WHO HAVE SEX WITH MEN
MENDING NEW YORK CITY SEXUALLY TRANSMITTED DISEASE CLINICS, 2013
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Westheimer, Emily; Limratana, Hellen] New York City Dept Hlth & Mental Hyg, Queens, NY USA.
[Pathela, Preeti; Blank, Susan] New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA.
[Schillinger, Julia] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Plevent, Queens, NY USA.
EM ewestheimer@health.nyc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 23
BP S102
EP S102
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500356
ER
PT J
AU Williams, SP
Hogben, M
Alexander-Pender, C
Simmons, D
Kinsey, J
Lloyd, PR
Mercurio, M
AF Williams, Samantha P.
Hogben, Matthew
Alexander-Pender, Carla
Simmons, Dee
Kinsey, Jennine
Lloyd, Patricia R.
Mercurio, Michael
CA Charlotte Reg Off Staff
TI A PILOT OF SEXUAL HEALTH GAP ANALYSIS TOOL AND METHODS
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Williams, Samantha P.; Hogben, Matthew; Alexander-Pender, Carla; Kinsey, Jennine] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Simmons, Dee] Ctr Dis Control & Prevent, Raleigh, NC USA.
[Lloyd, Patricia R.; Charlotte Reg Off Staff] North Carolina Dept Hlth & Human Serv, Charlotte, NC USA.
[Mercurio, Michael] Ctr Dis Control & Prevent, Charlotte, NC USA.
EM stw8@cdc.gov
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 121
BP S128
EP S128
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500454
ER
PT J
AU Wilmot, D
Yee, M
Burke, D
Garcia, C
Gans, A
Smith, L
Qiao, ML
Baldonado, M
Pierson, S
Champlin, C
Jasso, M
Bartok, A
Opperman, P
White, M
AF Wilmot, Duane
Yee, Margo
Burke, Daniel
Garcia, Carmelita
Gans, Andrew
Smith, Lewis
Qiao, Mianling
Baldonado, Michael
Pierson, Savannah
Champlin, Cheryl
Jasso, Merced
Bartok, Agnes
Opperman, Paul
White, Mary
TI VISUAL CASE ANALYSIS: DEVELOPMENT AND IMPLEMENTATION OF A FUNCTIONAL
COMPUTER-BASED VISUAL CASE ANALYSIS TOOL
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Meeting Abstract
CT STD Prevention Conference
CY JUN 09-12, 2014
CL Atlanta, GA
C1 [Wilmot, Duane; Smith, Lewis] Ctr Dis Control, Atlanta, GA 30333 USA.
[Yee, Margo; Burke, Daniel; Garcia, Carmelita; Smith, Lewis; Qiao, Mianling; Baldonado, Michael; Pierson, Savannah; Champlin, Cheryl; Jasso, Merced; Bartok, Agnes; Opperman, Paul] NM Dept Hlth, Santa Fe, NM USA.
[White, Mary] FL Dept Hlth, Bradenton, FL USA.
EM dfw1@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
SU 1
MA WP 136
BP S132
EP S132
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA CE7WB
UT WOS:000352051500469
ER
PT J
AU Folster, JP
Pecic, G
Stroika, S
Rickert, R
Whichard, JM
AF Folster, J. P.
Pecic, G.
Stroika, S.
Rickert, R.
Whichard, J. M.
TI Changing plasmid types responsible for extended-spectrum cephalosporin
resistance in Escherichia coli O157:H7 in the USA, 1996-2009
SO JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
LA English
DT Article
DE Antimicrobial resistance; Escherichia coli O157:H7; Resistance plasmid;
Cephalosporin resistance
ID HEMOLYTIC-UREMIC SYNDROME; UNITED-STATES; BETA-LACTAMASES; SALMONELLA;
O157-H7; INFECTION; RISK; ANIMALS; HUMANS; STRAIN
AB Escherichia coli O157 is a major cause of food-borne illness. Plasmids are genetic elements that mobilise antimicrobial resistance determinants, including bla(CMY) beta-lactamases that confer resistance to extended-spectrum cephalosporins (ESCs). ESCs are important for treating a variety of infections. IncA/C plasmids are found among diverse sources, including cattle, the principal source of E. coli 0157 infections in humans. IncI1 plasmids are common among E. coli and Salmonella from poultry and other avian sources. To broaden our understanding of the reservoirs of bla(CMY), the types of plasmids carrying bla(CMY) among E. coli O157 were determined. From 1996 to 2009, 3742 E. coli O157 isolates were tested. Eleven isolates (0.29%) were ceftriaxone-resistant and had a bla(CMY)-2-containing plasmid. All four isolates submitted before 2001 as well as a single 2001 isolate had bla(CMY) encoded on IncA/C plasmids, whilst all five isolates submitted after 2001 and a single 2001 isolate had bla(CMY) carried on IncI1 plasmids. The IncI1 plasmids were ST2, ST20 and ST23. We conclude that cephalosporin resistance among E. coli O157:H7 is due to plasmid-encoded bla(CMY) genes and that plasmid types appear to have shifted from IncA/C to Inch. This shift suggests either a change in plasmid type among animal reservoirs or that the organism has expanded into avian reservoirs. More analysis of human, retail meat and food animal isolates is necessary to broaden our understanding of the antimicrobial resistance determinants of ESC resistance among E. coli O157. Published by Elsevier Ltd on behalf of International Society for Chemotherapy of Infection and Cancer.
C1 [Folster, J. P.; Pecic, G.; Stroika, S.; Rickert, R.; Whichard, J. M.] US Ctr Dis Control & Prevent CDC, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA.
[Folster, J. P.; Pecic, G.] IHRC Inc, Atlanta, GA USA.
RP Folster, JP (reprint author), US Ctr Dis Control & Prevent CDC, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA.
EM gux8@cdc.gov
FU CDC; US Food and Drug Administration (FDA) Center for Veterinary
Medicine
FX This work was partially supported by an interagency agreement between
CDC and the US Food and Drug Administration (FDA) Center for Veterinary
Medicine.
NR 31
TC 2
Z9 2
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-7165
J9 J GLOB ANTIMICROB RE
JI J. Glob. Antimicrob. Resist.
PD JUN
PY 2014
VL 2
IS 2
BP 87
EP 91
DI 10.1016/j.jgar.2014.01.004
PG 5
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA CB9CG
UT WOS:000349929000005
PM 27873596
ER
PT J
AU Mullins, MM
DeLuca, JB
Crepaz, N
Lyles, CM
AF Mullins, Mary M.
DeLuca, Julia B.
Crepaz, Nicole
Lyles, Cynthia M.
TI Reporting quality of search methods in systematic reviews of HIV
behavioral interventions (2000-2010): are the searches clearly
explained, systematic and reproducible?
SO RESEARCH SYNTHESIS METHODS
LA English
DT Article
DE search reporting; reproducibility of results; systematic search;
systematic review; literature review; meta-analysis
ID SEXUALLY-TRANSMITTED INFECTIONS; RANDOMIZED CONTROLLED-TRIALS; HEALTH
TECHNOLOGY-ASSESSMENT; INJECTING DRUG-USERS; SUB-SAHARAN AFRICA;
PREVENTION PROGRAMS; PRISMA STATEMENT; RISK BEHAVIORS; SEX WORKERS;
REDUCE
AB Systematic reviews are an essential tool for researchers, prevention providers and policy makers who want to remain current with the evidence in the field. Systematic review must adhere to strict standards, as the results can provide a more objective appraisal of evidence for making scientific decisions than traditional narrative reviews. An integral component of a systematic review is the development and execution of a comprehensive systematic search to collect available and relevant information. A number of reporting guidelines have been developed to ensure quality publications of systematic reviews. These guidelines provide the essential elements to include in the review process and report in the final publication for complete transparency. We identified the common elements of reporting guidelines and examined the reporting quality of search methods in HIV behavioral intervention literature. Consistent with the findings from previous evaluations of reporting search methods of systematic reviews in other fields, our review shows a lack of full and transparent reporting within systematic reviews even though a plethora of guidelines exist. This review underscores the need for promoting the completeness of and adherence to transparent systematic search reporting within systematic reviews. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
C1 [Mullins, Mary M.; DeLuca, Julia B.; Crepaz, Nicole; Lyles, Cynthia M.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
RP Mullins, MM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, 1600 Clifton Rd,Mailstop E-37, Atlanta, GA 30333 USA.
EM mmullins@cdc.gov
NR 88
TC 4
Z9 4
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1759-2879
EI 1759-2887
J9 RES SYNTH METHODS
JI Res. Synth. Methods
PD JUN
PY 2014
VL 5
IS 2
BP 116
EP 130
DI 10.1002/jrsm.1098
PG 15
WC Mathematical & Computational Biology; Multidisciplinary Sciences
SC Mathematical & Computational Biology; Science & Technology - Other
Topics
GA CA0DK
UT WOS:000348585300003
PM 26052651
ER
PT J
AU Basler, CA
Bosch, SA
Behravesh, CB
AF Basler, Colin A.
Bosch, Stacey A.
Behravesh, Casey Barton
TI Clinical veterinarians can help protect the public's health
SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Basler, Colin A.; Bosch, Stacey A.; Behravesh, Casey Barton] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Basler, CA (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
FU Intramural CDC HHS [CC999999]
NR 5
TC 0
Z9 0
U1 0
U2 0
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA
SN 0003-1488
EI 1943-569X
J9 JAVMA-J AM VET MED A
JI JAVMA-J. Am. Vet. Med. Assoc.
PD JUN 1
PY 2014
VL 244
IS 11
BP 1245
EP 1245
PG 1
WC Veterinary Sciences
SC Veterinary Sciences
GA CA6CI
UT WOS:000348995600029
PM 24968461
ER
PT J
AU Savitt, TL
Smith, WR
Haywood, C
Creary, MS
AF Savitt, Todd L.
Smith, Wally R.
Haywood, Carlton, Jr.
Creary, Melissa S.
TI Use of the Word "Crisis" in Sickle Cell Disease: The Language of Sickle
Cell
SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
LA English
DT Article
DE sickle cell disease; crisis; history; pain
ID RED-BLOOD-CELLS; ABDOMINAL CRISES; HOME MANAGEMENT; PAINFUL CRISIS;
ANEMIA; CHILDREN; ADOLESCENTS; ADULTS; VASOOCCLUSION; SPLENECTOMY
AB Language matters. The Wards used to tiama,P,P1 desTIPP, disease phenomena are diefieCtien'af society. The authors the use at the Ward "crisis"i in SCD !-frcirro sociologic0),,,h1kION.01,:tePliPal:PP 1 patient PerSpeCtivei.-itieterrp,erisis7TOeComeosseciatedwithSickle cel disease in thernia,i9Os,'inore "than ii-deddeafterithe first description of the disease had been Cifiblished.TheTerm hod been used tar centuries in conlunction with fever and as a signifier of severe pain in certain diseases during the nineteenth century. The application of Jerre to thtk6w4p,,,,'disease in t`tiel92Cis'reirlted tram 1514,isiCkins; opservations. of their Patients :Lirgentsitt.;aiiens!ThouahcOMMonly used by tiealth'careorbyrdersand patients today "crisis" not be the appropriate term for sickle cell patients suffering se-vere pain. because people endure differinglemounts, of pain beforestating-they,are crisis." The can be undertreatment, of the Pain Or iniitrustjpetween`PhYsiCians and patient's about Use of 'strong (nbrcatiey Pain-relievers:Some patients believe the term is useful in communicating the severity P Of their pain and the urgency of their need - e.se for relief tram it, especially seeking at hospitaremergency, departments. while others believe "crisis" does not accurately'reflect-theii 4 - severity or seriousness of their situation.
C1 [Savitt, Todd L.] E Carolina Univ, Brody Sch Med, Dept Bioeth & Interdisciplinary Studies, Greenville, NC 27834 USA.
[Smith, Wally R.] Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA.
[Haywood, Carlton, Jr.] Johns Hopkins Berman Inst Bioeth, Baltimore, MD USA.
[Creary, Melissa S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA USA.
RP Savitt, TL (reprint author), E Carolina Univ, Brody Sch Med, Dept Bioeth & Interdisciplinary Studies, 600 Moye Blvd, Greenville, NC 27834 USA.
EM savittT@ecu.edu
OI Haywood Jr., Carlton/0000-0002-3574-7871
NR 68
TC 0
Z9 0
U1 1
U2 2
PU NATL MED ASSOC
PI WASHINGON
PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA
SN 0027-9684
J9 J NATL MED ASSOC
JI J. Natl. Med. Assoc.
PD SUM
PY 2014
VL 106
IS 1
BP 23
EP 30
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA AY6DL
UT WOS:000347657600004
PM 26744112
ER
PT J
AU Hamilton, JG
Edwards, HM
Khoury, MJ
Taplin, SH
AF Hamilton, Jada G.
Edwards, Heather M.
Khoury, Muin J.
Taplin, Stephen H.
TI Cancer Screening and Genetics: A Tale of Two Paradigms
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Editorial Material
ID SERVICES-TASK-FORCE; BREAST-CANCER; INCIDENTAL FINDINGS; SUSCEPTIBILITY
GENE; PERSONAL GENOMICS; OVARIAN-CANCER; PATIENT AUTONOMY;
RISK-ASSESSMENT; RECOMMENDATIONS; UPDATE
AB The long-standing medical tradition to "first do no harm" is reflected in population-wide evidence-based recommendations for cancer screening tests that focus primarily on reducing morbidity and mortality. The conventional cancer screening process is predicated on finding early-stage disease that can be treated effectively; yet emerging genetic and genomic testing technologies have moved the target earlier in the disease development process to identify a probabilistic predisposition to disease. Genetic risk information can have varying implications for the health and well-being of patients and their relatives, and has raised important questions about the evaluation and value of risk information. This article explores the paradigms that are being applied to the evaluation of conventional cancer screening tests and emerging genetic and genomic tests of cancer susceptibility, and how these perspectives are shifting and evolving in response to advances in our ability to detect cancer risks. We consider several challenges germane to the evaluation of both categories of tests, including defining benefits and harms in terms of personal and clinical utility, addressing healthcare consumers' information preferences, and managing scientific uncertainty. We encourage research and dialogue aimed at developing a better understanding of the value of all risk information, nongenetic and genetic, to people's lives. (C) 2014 AACR.
C1 [Hamilton, Jada G.] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY 10022 USA.
[Edwards, Heather M.] Frederick Natl Lab Canc Res, SAIC Frederick Inc, Clin Res Directorate CMRP, Frederick, MD USA.
[Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, NIH, Rockville, MD USA.
[Taplin, Stephen H.] NCI, Proc Care Res Branch, Div Canc Control & Populat Sci, NIH, Rockville, MD USA.
[Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA.
RP Hamilton, JG (reprint author), Mem Sloan Kettering Canc Ctr, 641 Lexington Ave,7th Floor, New York, NY 10022 USA.
EM hamiltoj@mskcc.org
FU CCR NIH HHS [HHSN261200800001C]; Intramural NIH HHS [Z99 CA999999]; NCI
NIH HHS [HHSN261201300091C, HHSN261200800001E]
NR 60
TC 3
Z9 3
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JUN
PY 2014
VL 23
IS 6
BP 909
EP 916
DI 10.1158/1055-9965.EPI-13-1016
PG 8
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA AT9UD
UT WOS:000345270800003
PM 24706727
ER
PT J
AU Stepman, HCM
Tiikkainen, U
Stockl, D
Vesper, HW
Edwards, SH
Laitinen, H
Pelanti, J
Thienpont, LM
AF Stepman, Hedwig C. M.
Tiikkainen, Ulla
Stockl, Dietmar
Vesper, Hubert W.
Edwards, Selvin H.
Laitinen, Harri
Pelanti, Jonna
Thienpont, Linda M.
CA Participating Labs
TI Measurements for 8 Common Analytes in Native Sera Identify Inadequate
Standardization among 6 Routine Laboratory Assays
SO CLINICAL CHEMISTRY
LA English
DT Article
ID EXTERNAL QUALITY ASSESSMENT; CANDIDATE REFERENCE METHODS; INTERNAL
ACCURACY CONTROL; DETERMINING TARGET VALUES; SINGLE-DONATION SERA;
OF-THE-ART; ASSESSMENT SCHEMES; URIC-ACID; CHOLESTEROL; HARMONIZATION
AB BACKGROUND: External quality assessment (EQA) with commutable samples is essential for assessing the quality of assays performed by laboratories, particularly when the emphasis is on their standardization status and interchangeability of results.
METHODS: We used a panel of 20 fresh-frozen singledonation serum samples to assess assays for the measurement of creatinine, glucose, phosphate, uric acid, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. The commercial random access platforms included: Abbott Architect, Beckman Coulter AU, Ortho Vitros, Roche Cobas, Siemens Advia, and Thermo Scientific Konelab. The assessment was done at the peer group level and by comparison against the all-method trimmed mean or reference method values, where available. The considered quality indicators were intraassay imprecision, combined imprecision (including sample-matrix interference), bias, and total error. Fail/pass decisions were based on limits reflecting state-of-the-art performance, but also limits related to biological variation.
RESULTS: Most assays showed excellent peer performance attributes, except for HDL- and LDL cholesterol. Cases in which individual assays had biases exceeding the used limits were the Siemens Advia creatinine (-4.2%), Ortho Vitros phosphate (8.9%), Beckman Coulter AU triglycerides (5.4%), and Thermo Scientific Konelab uric acid (6.4%), which lead to considerable interassay discrepancies. Additionally, large laboratory effects were observed that caused interlaboratory differences of >30%.
CONCLUSIONS: The design of the EQA study was well suited for monitoring different quality attributes of as-says performed in daily laboratory practice. There is a need for improvement, even for simple clinical chemistry analytes. In particular, the interchangeability of results remains jeopardized both by assay standardization issues and individual laboratory effects. (C) 2014 American Association for Clinical Chemistry.
C1 [Stepman, Hedwig C. M.; Thienpont, Linda M.] Univ Ghent, Fac Pharmaceut Sci, Analyt Chem Lab, B-9000 Ghent, Belgium.
[Tiikkainen, Ulla; Laitinen, Harri; Pelanti, Jonna] Labquality, Helsinki, Finland.
[Stockl, Dietmar] STT Consulting, Horebeke, Belgium.
[Vesper, Hubert W.; Edwards, Selvin H.] Ctr Dis Control & Prevent CDC, Div Sci Lab, Atlanta, GA USA.
RP Thienpont, LM (reprint author), Univ Ghent, Fac Pharmaceut Sci, Analyt Chem Lab, Harelbekestr 72, B-9000 Ghent, Belgium.
EM linda.thienpont@ugent.be
NR 34
TC 18
Z9 18
U1 0
U2 8
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD JUN
PY 2014
VL 60
IS 6
BP 855
EP 863
DI 10.1373/clinchem.2013.220376
PG 9
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA AT2QG
UT WOS:000344778600012
PM 24687951
ER
PT J
AU Keck, JW
Miernyk, KM
Bulkow, LR
Kelly, JJ
McMahon, BJ
Sacco, F
Hennessy, TW
Bruce, MG
AF Keck, James W.
Miernyk, Karen M.
Bulkow, Lisa R.
Kelly, Janet J.
McMahon, Brian J.
Sacco, Frank
Hennessy, Thomas W.
Bruce, Michael G.
TI Helicobacter pylori infection and markers of gastric cancer risk in
Alaska Native persons: A retrospective case-control study
SO CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Alaska Native; cagA; Gastric cancer; Helicobacter pylori; Pepsinogen I
ID SERUM PEPSINOGEN; HIGH-PREVALENCE; CAGA; ANTIBODY; CARCINOGENESIS;
ADENOCARCINOMA; ASSOCIATION; RESISTANCE
AB BACKGROUND: Alaska Native persons experience gastric cancer incidence and mortality rates that are three to four times higher than in the general United States population.
OBJECTIVE: To evaluate pepsinogen I, pepsinogen I/II ratio, anti-Helicobacter pylori and cytotoxin-associated gene A (CagA) antibody levels, and blood group for their associations with gastric cancer development in Alaska Native people.
METHODS: The present analysis was a retrospective case-control study that matched gastric cancers reported to the Alaska Native Tumor Registry from 1969 to 2008 to three controls on known demographic risk factors for H pylori infection, using sera from the Alaska Area Specimen Bank. Conditional logistic regression evaluated associations between serum markers and gastric cancer.
RESULTS: A total of 122 gastric cancer cases were included, with sera predating cancer diagnosis (mean = 13 years) and 346 matched controls. One hundred twelve cases (91.8%) and 285 controls (82.4%) had evidence of previous or ongoing H pylori infection as measured by anti-H pylori antibody levels. Gastric cancer cases had a 2.63-fold increased odds of having positive anti-H pylori antibodies compared with their matched controls (P=0.01). In a multivariate model, non-cardia gastric cancer (n=94) was associated with anti-H pylori antibodies (adjusted OR 3.92; P=0.004) and low pepsinogen I level (adjusted OR 6.04; P=0.04). No association between gastric cancer and blood group, anti-CagA antibodies or pepsinogen I/II ratio was found.
CONCLUSION: Alaska Native people with gastric cancer had increased odds of previous H pylori infection. Low pepsinogen I level may function as a precancer marker for noncardia cancer.
C1 [Keck, James W.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA.
[Keck, James W.; Miernyk, Karen M.; Bulkow, Lisa R.; McMahon, Brian J.; Hennessy, Thomas W.; Bruce, Michael G.] Ctr Dis Control & Prevent, Arctic Investigat Program, Anchorage, AK 99508 USA.
[Miernyk, Karen M.; Kelly, Janet J.; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA.
[Sacco, Frank] Alaska Native Med Ctr, Dept Surg, Anchorage, AK USA.
RP Keck, JW (reprint author), Ctr Dis Control & Prevent, Arctic Investigat Program, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.
EM jameswkeck@gmail.com
NR 34
TC 3
Z9 4
U1 0
U2 0
PU PULSUS GROUP INC
PI OAKVILLE
PA 2902 S SHERIDAN WAY, OAKVILLE, ONTARIO L6J 7L6, CANADA
SN 0835-7900
J9 CAN J GASTROENTEROL
JI Can. J. Gastroenterol. Hepatol.
PD JUN
PY 2014
VL 28
IS 6
BP 305
EP 310
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AR9FX
UT WOS:000343879300003
PM 24945184
ER
PT J
AU Curry, DW
Perry, HB
Tirmizi, SN
Goldstein, AL
Lynch, MC
AF Curry, Dora Ward
Perry, Henry B.
Tirmizi, Syed N.
Goldstein, Allison L.
Lynch, Meg C.
TI Assessing the Effectiveness of House-to-House Visits on Routine Oral
Polio Immunization Completion and Tracking of Defaulters
SO JOURNAL OF HEALTH POPULATION AND NUTRITION
LA English
DT Article
DE Community health workers; Defaulter tracking; Home visits; Oral polio
immunization; Polio eradication; Routine immunization
ID SOCIAL MOBILIZATION; ERADICATION; COMMUNICATION; COUNTRIES; PROGRAMS;
LESSONS; INDIA
AB Strengthening routine immunization is one of the four prongs of the Global Polio Eradication Initiative. Using data collected through 30-cluster sample household surveys of caretakers of children aged 12-23 months, this paper assessed the effectiveness of house-to-house visits on routine oral polio immunization completion, using simple frequency tables, bivariate and multivariate logistic regression analyses. Logistic regression results demonstrated that children in households where the caregivers reported receiving a household visit by health workers were more likely to be fully immunized for polio through routine immunization than other children, although results were significant only after correcting for confounders. In Ethiopia and India, children of caregivers who remembered a house-to-house visit were significantly and positively associated with routine polio vaccination completion (OR=2.2 and OR=2.2 respectively). In Angola, the association was positive, though not significant (OR=1.3). The evidence suggests that targeting high-risk areas for house-to-house visits played a role in increasing routine polio vaccination.
C1 [Curry, Dora Ward; Tirmizi, Syed N.] CARE USA, Atlanta, GA 30303 USA.
[Perry, Henry B.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
[Goldstein, Allison L.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Curry, DW (reprint author), CARE USA, 151 Ellis St NE, Atlanta, GA 30303 USA.
EM dcurry@care.org
NR 13
TC 1
Z9 1
U1 0
U2 2
PU ICDDR B
PI DHAKA
PA MOHAKHALI, 1212 DHAKA, BANGLADESH
SN 1606-0997
EI 2072-1315
J9 J HEALTH POPUL NUTR
JI J. Heatlh Popul. Nutr.
PD JUN
PY 2014
VL 32
IS 2
BP 356
EP 366
PG 11
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AR7GB
UT WOS:000343746400019
PM 25076672
ER
PT J
AU DeSisto, CL
Kim, SY
Sharma, AJ
AF DeSisto, Carla L.
Kim, Shin Y.
Sharma, Andrea J.
TI Prevalence Estimates of Gestational Diabetes Mellitus in the United
States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007-2010
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID INTERNATIONAL ASSOCIATION; GLUCOSE-INTOLERANCE; OBESITY;
RECOMMENDATIONS; CLASSIFICATION; METAANALYSIS; DISPARITIES; DIAGNOSIS;
DELIVERY; CRITERIA
AB Introduction
The true prevalence of gestational diabetes mellitus (GDM) is unknown. The objective of this study was 1) to provide the most current GDM prevalence reported on the birth certificate and the Pregnancy Risk Assessment Monitoring System (PRAMS) questionnaire and 2) to compare GDM prevalence from PRAMS across 2007-2008 and 2009-2010.
Methods
We examined 2010 GDM prevalence reported on birth certificate or PRAMS questionnaire and concordance between the sources. We included 16 states that adopted the 2003 revised birth certificate. We also examined trends from 2007 through 2010 and included 21 states that participated in PRAMS for all 4 years. We combined GDM prevalence across 2-year intervals and conducted t tests to examine differences. Data were weighted to represent all women delivering live births in each state.
Results
GDM prevalence in 2010 was 4.6% as reported on the birth certificate, 8.7% as reported on the PRAMS questionnaire, and 9.2% as reported on either the birth certificate or questionnaire. The agreement between sources was 94.1% (percent positive agreement = 3.7%, percent negative agreement = 90.4%). There was no significant difference in GDM prevalence between 2007-2008 (8.1%) and 2009-2010 (8.5%, P = .15).
Conclusion
Our results indicate that GDM prevalence is as high as 9.2% and is more likely to be reported on the PRAMS questionnaire than the birth certificate. We found no statistical difference in GDM prevalence between the 2 phases. Further studies are needed to understand discrepancies in reporting GDM by data source.
C1 [DeSisto, Carla L.] Ctr Dis Control & Prevent, El Paso, TX 79912 USA.
[Kim, Shin Y.; Sharma, Andrea J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP DeSisto, CL (reprint author), Ctr Dis Control & Prevent, 601 Sunland Pk Dr,Suite 200, El Paso, TX 79912 USA.
EM cdesisto@cdc.gov
OI Sharma, Andrea/0000-0003-0385-0011
NR 30
TC 22
Z9 23
U1 1
U2 6
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD JUN
PY 2014
VL 11
AR 130415
DI 10.5888/pcd11.130415
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AR3XI
UT WOS:000343522100010
ER
PT J
AU Pearson, WS
Goates, SA
Harrykissoon, SD
Miller, SA
AF Pearson, W. S.
Goates, S. A.
Harrykissoon, S. D.
Miller, S. A.
TI State-Based Medicaid Costs for Pediatric Asthma Emergency Department
Visits
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID UNITED-STATES; PROGRAM; CARE
AB Introduction
The prevalence of childhood asthma in the United States increased from 8.7% in 2001 to 9.5% in 2011. This increased prevalence adds to the costs incurred by state Medicaid programs. We provide state-based cost estimates of pediatric asthma emergency department (ED) visits and highlight an opportunity for states to reduce these costs through a recently changed Centers for Medicare and Medicaid Services (CMS) regulation.
Methods
We used a cross-sectional design across multiple data sets to produce state-based cost estimates for asthma-related ED visits among children younger than 18, where Medicaid/CHIP (Children's Health Insurance Program) was the primary payer.
Results
There were approximately 629,000 ED visits for pediatric asthma for Medicaid/CHIP enrollees, which cost $272 million in 2010. The average cost per visit was $433. Costs ranged from $282,000 in Alaska to more than $25 million in California.
Conclusions
Costs to states for pediatric asthma ED visits vary widely. Effective January 1, 2014, the CMS rule expanded which type of providers can be reimbursed for providing preventive services to Medicaid/CHIP beneficiaries. This rule change, in combination with existing flexibility for states to define practice setting, allows state Medicaid programs to reimburse for asthma interventions that use nontraditional providers (such as community health workers or certified asthma educators) in a nonclinical setting, as long as the service was initially recommended by a physician or other licensed practitioner. The rule change may help states reduce Medicaid costs of asthma treatment and the severity of pediatric asthma.
C1 [Pearson, W. S.] Ctr Dis Control & Prevent, Off Associate Director Policy, Atlanta, GA 30329 USA.
[Goates, S. A.; Harrykissoon, S. D.; Miller, S. A.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
RP Pearson, WS (reprint author), Ctr Dis Control & Prevent, Off Associate Director Policy, 1600 Clifton Rd NE,Mailstop E-02, Atlanta, GA 30329 USA.
EM Wpearson@cdc.gov
NR 21
TC 4
Z9 4
U1 0
U2 2
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD JUN
PY 2014
VL 11
AR 140139
DI 10.5888/pcd11.140139
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AR3XI
UT WOS:000343522100017
ER
PT J
AU Ruiz, S
Brady, TJ
Glasgow, RE
Birkel, R
Spafford, M
AF Ruiz, Sarah
Brady, Teresa J.
Glasgow, Russell E.
Birkel, Richard
Spafford, Michelle
TI Chronic Condition Self-Management Surveillance: What Is and What Should
Be Measured?
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID CARE; FRAMEWORK; DISEASE
AB Introduction
The rapid growth in chronic disease prevalence, in particular the prevalence of multiple chronic conditions, poses a significant and increasing burden on the health of Americans. Maximizing the use of proven self-management (SM) strategies is a core goal of the US Department of Health and Human Services. Yet, there is no systematic way to assess how much SM or self-management support (SMS) is occurring in the United States. The purpose of this project was to identify appropriate concepts or measures to incorporate into national SM and SMS surveillance.
Methods
A multistep process was used to identify candidate concepts, assess existing measures, and select high-priority concepts for further development. A stakeholder survey, an environmental scan, subject matter expert feedback, and a stakeholder priority-setting exercise were all used to select the high-priority concepts for development.
Results
The stakeholder survey gathered feedback on 32 candidate concepts; 9 concepts were endorsed by more than 66% of respondents. The environmental scan indicated few existing measures that adequately reflected the candidate concepts, and those that were identified were generally specific to a defined condition and not gathered on a population basis. On the basis of the priority setting exercises and environmental scan, we selected 1 concept from each of 5 levels of behavioral influence for immediate development as an SM or SMS indicator.
Conclusion
The absence of any available measures to assess SM or SMS across the population highlights the need to develop chronic condition SM surveillance that uses national surveys and other data sources to measure national progress in SM and SMS.
C1 [Ruiz, Sarah; Spafford, Michelle] Univ Chicago, NORC, Bethesda, MD 20814 USA.
[Brady, Teresa J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Glasgow, Russell E.] Univ Colorado, Sch Med, Aurora, CO USA.
[Birkel, Richard] Natl Council Aging, Washington, DC USA.
RP Ruiz, S (reprint author), Univ Chicago, NORC, 4350 East-West Hwy, Bethesda, MD 20814 USA.
EM ruiz-sarah@norc.org
RI Ruiz, Sarah/B-3456-2017
OI Ruiz, Sarah/0000-0002-6428-2321
FU Sanofi
FX This project was supported by an award from Sanofi to the National
Council on Aging. The findings and conclusions in this report are those
of the authors and do not necessarily represent the official position of
the National Institutes of Health.
NR 28
TC 2
Z9 2
U1 0
U2 2
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD JUN
PY 2014
VL 11
AR 130328
DI 10.5888/pcd11.130328
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AR3XI
UT WOS:000343522100004
PM 24945239
ER
PT J
AU St Pierre, J
Bach, J
Duquette, D
Oehlke, K
Nystrom, R
Silvey, K
Zlot, A
Giles, R
Johnson, J
Anders, HM
Gwinn, M
Bowen, S
Khoury, MJ
AF St Pierre, Jeanette
Bach, Janice
Duquette, Debra
Oehlke, Kristen
Nystrom, Robert
Silvey, Kerry
Zlot, Amy
Giles, Rebecca
Johnson, Jenny
Anders, H. Mack
Gwinn, Marta
Bowen, Scott
Khoury, Muin J.
TI Strategies, Actions, and Outcomes of Pilot State Programs in Public
Health Genomics, 2003-2008
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID CARE PROVIDER PRACTICE; FAMILY-HISTORY; PATIENT BEHAVIOR; OREGONIANS;
DISEASE
AB State health departments in Michigan, Minnesota, Oregon, and Utah explored the use of genomic information, including family health history, in chronic disease prevention programs. To support these explorations, the Office of Public Health Genomics at the Centers for Disease Control and Prevention provided cooperative agreement funds from 2003 through 2008. The 4 states' chronic disease programs identified advocates, formed partnerships, and assessed public data; they integrated genomics into existing state plans for genetics and chronic disease prevention; they developed projects focused on prevention of asthma, cancer, cardiovascular disease, diabetes, and other chronic conditions; and they created educational curricula and materials for health workers, policymakers, and the public. Each state's program was different because of the need to adapt to existing culture, infrastructure, and resources, yet all were able to enhance their chronic disease prevention programs with the use of family health history, a low-tech "genomic tool." Additional states are drawing on the experience of these 4 states to develop their own approaches.
C1 [St Pierre, Jeanette; Bowen, Scott; Khoury, Muin J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Bach, Janice; Duquette, Debra] Michigan Dept Community Hlth, Lansing, MI USA.
[Oehlke, Kristen] Minnesota Dept Hlth, St Paul, MN USA.
[Nystrom, Robert; Silvey, Kerry; Zlot, Amy] Oregon Hlth Author, Portland, OR USA.
[Giles, Rebecca; Johnson, Jenny] Utah Dept Hlth, Salt Lake City, UT USA.
[Anders, H. Mack; Gwinn, Marta] McKing Consulting Corp, Atlanta, GA USA.
RP Bowen, S (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA.
EM msb4@cdc.gov
FU CDC
FX Timothy Baker and Jean Chabut convened the 2002 Chronic Disease
Directors' Summit, which inspired the work described here. It was
supported by a CDC cooperative agreement.
NR 39
TC 0
Z9 0
U1 0
U2 4
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD JUN
PY 2014
VL 11
AR 130267
DI 10.5888/pcd11.130267
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AR3XI
UT WOS:000343522100002
ER
PT J
AU Stahre, M
Roeber, J
Kanny, D
Brewer, RD
Zhang, XY
AF Stahre, Mandy
Roeber, Jim
Kanny, Dafna
Brewer, Robert D.
Zhang, Xingyou
TI Contribution of Excessive Alcohol Consumption to Deaths and Years of
Potential Life Lost in the United States
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID BINGE DRINKING; US; METAANALYSIS; FREQUENCY
AB Introduction
Excessive alcohol consumption is a leading cause of premature mortality in the United States. The objectives of this study were to update national estimates of alcohol-attributable deaths (AAD) and years of potential life lost (YPLL) in the United States, calculate age-adjusted rates of AAD and YPLL in states, assess the contribution of AAD and YPLL to total deaths and YPLL among working-age adults, and estimate the number of deaths and YPLL among those younger than 21 years.
Methods
We used the Centers for Disease Control and Prevention's Alcohol-Related Disease Impact application for 2006-2010 to estimate total AAD and YPLL across 54 conditions for the United States, by sex and age. AAD and YPLL rates and the proportion of total deaths that were attributable to excessive alcohol consumption among working-age adults (2064 y) were calculated for the United States and for individual states.
Results
From 2006 through 2010, an annual average of 87,798 (27.9/100,000 population) AAD and 2 5 million (831.6/100,000) YPLL occurred in the United States. Age-adjusted state AAD rates ranged from 51.2/100,000 in New Mexico to 19.1/100,000 in New Jersey. Among working-age adults, 9.8% of all deaths in the United States during this period were attributable to excessive drinking, and 69% of all AAD involved working-age adults.
Conclusions
Excessive drinking accounted for 1 in 10 deaths among working-age adults in the United States. AAD rates vary across states, but excessive drinking remains a leading cause of premature mortality nationwide. Strategies recommended by the Community Preventive Services Task Force can help reduce excessive drinking and harms related to it.
C1 [Stahre, Mandy] Washington State Dept Hlth, Olympia, WA 98504 USA.
[Roeber, Jim] New Mexico Dept Hlth, Santa Fe, NM USA.
[Kanny, Dafna; Brewer, Robert D.; Zhang, Xingyou] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Stahre, M (reprint author), Washington State Dept Hlth, Olympia, WA 98504 USA.
EM mandy.stahre@doh.wa.gov
FU Robert Wood Johnson Foundation [044149, 059738]
FX This article is dedicated to Ron Davis, MD, MA, for his visionary
leadership and commitment to the prevention of excessive alcohol use. We
thank Henry Wechsler, PhD, retired, Harvard School of Public Health,
Harvard University. The development of the ARDI application was
supported by generous grants (nos. 044149 and 059738) from the Robert
Wood Johnson Foundation to the CDC Foundation.
NR 21
TC 43
Z9 44
U1 2
U2 18
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD JUN
PY 2014
VL 11
AR 130293
DI 10.5888/pcd11.130293
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AR3XI
UT WOS:000343522100003
ER
PT J
AU Cope, JR
Frost, M
Li, RC
Xie, RQ
AF Cope, James R.
Frost, Melinda
Li Richun
Xie, Ruiqian
TI Assessing Knowledge and Application of Emergency Risk Communication
Principles Among Public Health Workers in China
SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
LA English
DT Article
DE risk communication; China; policy making; public health practice;
emergency response
AB Objective: Since 2003, the Chinese National Health and Family Planning Commission (formerly the Ministry of Health) has implemented changes to more effectively communicate risk during public health emergencies. In spite of ongoing improvements, provincial and sub-provincial leaders face barriers, such as established modes of operation, lack of training, shortage of trained risk communicators, and limited understanding and willingness of recipients to mitigate risks.
Methods: We assessed the current status of and barriers to risk communication knowledge and practice among public health practitioners in China. We designed the survey questionnaire to capture information related to the risk communication core capacities required by international health regulations and common risk communication principles.
Results: Our findings showed that risk communication training has successfully developed an awareness of risk communication principles and the ability to implement those principles in practice in China.
Conclusions: Future efforts should focus on areas such as a dedicated risk communication workforce, requirements that public health agencies develop a risk communication plan, and additional training for public health practitioners and their partners. It is critical that the infectious diseases prevention and control law be amended to grant provincial and local public health agencies more autonomy to release information.
C1 [Cope, James R.; Frost, Melinda] US Ctr Dis Control & Prevent, Ctr Global Hlth, Global Dis Detect Branch, Atlanta, GA 30333 USA.
[Li Richun] China Emerging Infect Dis Program, Beijing, Peoples R China.
[Xie, Ruiqian] Chinese Ctr Hlth Educ, Beijing, Peoples R China.
RP Cope, JR (reprint author), US Ctr Dis Control & Prevent, Ctr Global Hlth, 1600 Clifton Rd, Atlanta, GA 30333 USA.
EM voz4@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 16
TC 1
Z9 3
U1 0
U2 8
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1935-7893
EI 1938-744X
J9 DISASTER MED PUBLIC
JI Dis. Med. Public Health Prep.
PD JUN
PY 2014
VL 8
IS 3
BP 199
EP 205
DI 10.1017/dmp.2014.29
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ9NO
UT WOS:000343182500005
PM 24785302
ER
PT J
AU Leary, AD
Schwartz, MD
Kirk, MA
Ignacio, JS
Wencil, EB
Cibulsky, SM
AF Leary, Adam D.
Schwartz, Michael D.
Kirk, Mark A.
Ignacio, Joselito S.
Wencil, Elaine B.
Cibulsky, Susan M.
TI Evidence-Based Patient Decontamination: An Integral Component of Mass
Exposure Chemical Incident Planning and Response
SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
LA English
DT Article
DE decontamination; chemical hazard release; chemical warfare; emergency
preparedness; hazardous substances
ID 1-PERCENT SOAPY WATER; SKIN DECONTAMINATION; 0.5-PERCENT BLEACH;
REDUCTION PASTE; WARFARE AGENTS; DOMESTIC SWINE; EFFICACY; BURNS; VX;
STRATEGIES
AB Decontaminating patients who have been exposed to hazardous chemicals can directly benefit the patients' health by saving lives and reducing the severity of toxicity. While the importance of decontaminating patients to prevent the spread of contamination has long been recognized, its role in improving patient health outcomes has not been as widely appreciated. Acute chemical toxicity may manifest rapidly-often minutes to hours after exposure. Patient decontamination and emergency medical treatment must be initiated as early as possible to terminate further exposure and treat the effects of the dose already absorbed. In a mass exposure chemical incident, responders and receivers are faced with the challenges of determining the type of care that each patient needs (including medical treatment, decontamination, and behavioral health support), providing that care within the effective window of time, and protecting themselves from harm. The US Department of Health and Human Services and Department of Homeland Security have led the development of national planning guidance for mass patient decontamination in a chemical incident to help local communities meet these multiple, time-sensitive health demands. This report summarizes the science on which the guidance is based and the principles that form the core of the updated approach.
C1 [Leary, Adam D.; Wencil, Elaine B.; Cibulsky, Susan M.] US Dept HHS, Med Countermeasure Strategy & Requirements Div, Off Policy & Planning, Off Assistant Secretary Preparedness & Response, Washington, DC 20201 USA.
[Schwartz, Michael D.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, US Dept HHS, Washington, DC USA.
[Kirk, Mark A.; Ignacio, Joselito S.] US Dept Homeland Secur, Chem Def Program, Off Hlth Affairs, Washington, DC USA.
RP Cibulsky, SM (reprint author), JFK Fed Bldg,15 New Sudbury St,Ste 2126, Boston, MA 02203 USA.
EM susan.cibulsky@hhs.gov
NR 35
TC 2
Z9 3
U1 0
U2 8
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1935-7893
EI 1938-744X
J9 DISASTER MED PUBLIC
JI Dis. Med. Public Health Prep.
PD JUN
PY 2014
VL 8
IS 3
BP 260
EP 266
DI 10.1017/dmp.2014.41
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ9NO
UT WOS:000343182500014
PM 24867089
ER
PT J
AU Yen, C
Tate, JE
Hyde, TB
Cortese, MM
Lopman, BA
Jiang, BM
Glass, RI
Parashar, UD
AF Yen, Catherine
Tate, Jacqueline E.
Hyde, Terri B.
Cortese, Margaret M.
Lopman, Benjamin A.
Jiang, Baoming
Glass, Roger I.
Parashar, Umesh D.
TI Rotavirus vaccines Current status and future considerations
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Review
DE rotavirus; diarrhea; gastroenteritis; rotavirus vaccines; vaccine impact
ID 1ST 2 YEARS; DIARRHEA-ASSOCIATED HOSPITALIZATIONS; CHILDREN LESS-THAN-5
YEARS; ALL-CAUSE GASTROENTERITIS; UNITED-STATES; US CHILDREN;
INTUSSUSCEPTION RISK; IMMUNIZATION PROGRAM; INDIRECT PROTECTION;
HEALTH-BENEFITS
AB Rotavirus is the leading cause of severe diarrhea among children <5 years worldwide. Currently licensed rotavirus vaccines have been efficacious and effective, with many countries reporting substantial declines in diarrheal and rotavirus-specific morbidity and mortality. However, the full public health impact of these vaccines has not been realized. Most countries, including those with the highest disease burden, have not yet introduced rotavirus vaccines into their national immunization programs. Research activities that may help inform vaccine introduction decisions include (1) establishing effectiveness, impact, and safety for rotavirus vaccines in low-income settings; (2) identifying potential strategies to improve performance of oral rotavirus vaccines in developing countries, such as zinc supplementation; and (3) pursuing alternate approaches to oral vaccines, such as parenteral immunization. Policy-and program-level barriers, such as financial implications of new vaccine introductions, should be addressed to ensure that countries are able to make informed decisions regarding rotavirus vaccine introduction.
C1 [Yen, Catherine; Tate, Jacqueline E.; Cortese, Margaret M.; Lopman, Benjamin A.; Jiang, Baoming; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
[Yen, Catherine; Hyde, Terri B.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
[Glass, Roger I.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
RP Yen, C (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
EM cyen@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 101
TC 13
Z9 13
U1 1
U2 4
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD JUN
PY 2014
VL 10
IS 6
BP 1436
EP 1448
DI 10.4161/hv.28857
PG 13
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA AQ4JV
UT WOS:000342763200011
PM 24755452
ER
PT J
AU Callahan, T
AF Callahan, Tegan
TI APPLIED PUBLIC HEALTH TRAINING: A GRADUATE'S PERSPECTIVE
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Letter
ID MPH EDUCATION; CURRICULUM
C1 [Callahan, Tegan] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Callahan, T (reprint author), 159 Murray Hill Ave NE, Atlanta, GA 30317 USA.
EM tegan.callahan@gmail.com
NR 2
TC 0
Z9 0
U1 0
U2 0
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
IS 6
BP E1
EP E1
DI 10.2105/AJPH.2014.301913
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AP0YC
UT WOS:000341791500001
PM 24825221
ER
PT J
AU Griffin, SO
Jones, K
Crespin, M
AF Griffin, Susan O.
Jones, Kari
Crespin, Matthew
TI Calculating averted caries attributable to school-based sealant programs
with a minimal data set
SO JOURNAL OF PUBLIC HEALTH DENTISTRY
LA English
DT Article
DE pit and fissure sealants; Markov chains; program evaluation
ID COST-EFFECTIVENESS; TEETH
AB ObjectivesWe describe a methodology for school-based sealant programs (SBSP) to estimate averted cavities, (i.e., difference in cavities without and with SBSP) over 9 years using a minimal data set.
MethodsA Markov model was used to estimate averted cavities. SBSP would input estimates of their annual attack rate (AR) and 1-year retention rate. The model estimated retention 2+ years after placement with a functional form obtained from the literature. Assuming a constant AR, SBSP can estimate their AR with child-level data collected prior to sealant placement on sealant presence, number of decayed/filled first molars, and age. We demonstrate the methodology with data from the Wisconsin SBSP. Finally, we examine how sensitive averted cavities obtained with this methodology is if an SBSP were to over or underestimate their AR or 1-year retention.
ResultsDemonstrating the methodology with estimated AR (=7 percent) and 1-year retention (=92 percent) from the Wisconsin SBSP data, we found that placing 31,324 sealants averted 10,718 cavities. Sensitivity analysis indicated that for any AR, the magnitude of the error (percent) in estimating averted cavities was always less than the magnitude of the error in specifying the AR and equal to the error in specifying the 1-year retention rate. We also found that estimates of averted cavities were more robust to misspecifications of AR for higher- versus lower-risk children.
ConclusionsWith Excel (Microsoft Corporation, Redmond, WA, USA) spreadsheets available upon request, SBSP can use this methodology to generate reasonable estimates of their impact with a minimal data set.
C1 [Griffin, Susan O.] Ctr Dis Control, Div Oral Hlth, Atlanta, GA 30341 USA.
[Jones, Kari] Quantitat Hlth Res Inc, Tampa, FL USA.
[Crespin, Matthew] Childrens Hlth Alliance Wisconsin, Milwaukee, WI USA.
RP Griffin, SO (reprint author), Ctr Dis Control, Div Oral Hlth, 3005 Chamblee Tucker Rd,MSF10, Atlanta, GA 30341 USA.
EM sig1@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 14
TC 2
Z9 2
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4006
EI 1752-7325
J9 J PUBLIC HEALTH DENT
JI J. Public Health Dent.
PD SUM
PY 2014
VL 74
IS 3
BP 202
EP 209
DI 10.1111/jphd.12047
PG 8
WC Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational
Health
SC Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational
Health
GA AP5TG
UT WOS:000342141000005
PM 24423023
ER
PT J
AU Dye, BA
Li, XF
Lewis, BG
Iafolla, T
Beltran-Aguilar, ED
Eke, PI
AF Dye, Bruce A.
Li, Xianfen
Lewis, Brenda G.
Iafolla, Tim
Beltran-Aguilar, Eugenio D.
Eke, Paul I.
TI Overview and quality assurance for the oral health component of the
National Health and Nutrition Examination Survey (NHANES), 2009-2010
SO JOURNAL OF PUBLIC HEALTH DENTISTRY
LA English
DT Article
DE NHANES; oral health; data reliability; epidemiology; surveillance;
periodontal disease; quality assurance; dental public health
ID CASE DEFINITIONS; SURVEILLANCE; PERIODONTITIS; POPULATION
AB ObjectiveIn 2009-2010, the oral health component for the National Health and Nutrition Examination Survey (NHANES) focused on adult periodontal health and included a full mouth periodontal examination as well as a series of questions adminis during the home interview. During this period, intraoral assessments were conducted by dental hygienists.
MethodsThis report provides oral health content information and results of dental examiner reliability for data collected during NHANES 2009-2010 on 7,189 persons aged 3-19 years and 30 years and older representing the US civilian, noninstitutionalized population in these age groups.
ResultsFor caries and dental sealant assessments, Kappa statistics ranged from 0.71 to 1.00. Kappa scores for moderate and severe periodontitis using the Centers for Disease Control and Prevention/American Academy of Periodontology case definition guidelines was 0.70, but were lower for other periodontal status definitions. When defining moderate or severe periodontitis based on the NHANES 2003-2004 study, protocols using data from only three facial periodontal sites, the Kappa scores were 0.64 and 0.55. Interclass correlation coefficients (ICCs) for mean attachment loss were 0.80 or higher for both examiners. Site-specific mean attachment loss ICCs were generally higher for interproximal measurements compared with mid-facial and mid-lingual measurements.
ConclusionOverall, the data reliability analyses conducted for 2009-2010 indicate an acceptable level of data quality and that examiner (dental hygienist) performance in this data collection cycle is similar to prior survey periods since the NHANES continuous survey began in 1999.
C1 [Dye, Bruce A.; Lewis, Brenda G.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
[Li, Xianfen] Harris Corp, Fairfax, VA USA.
[Iafolla, Tim] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA.
[Beltran-Aguilar, Eugenio D.; Eke, Paul I.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Oral Hlth, Atlanta, GA USA.
RP Dye, BA (reprint author), CDC NCHS NHANES Program, 3311 Toledo Rd,RM 4416, Hyattsville, MD 20782 USA.
EM bfd1@cdc.gov
FU NHANES
FX The 2009-2010 NHANES oral health component was a funding and content
collaborative effort between the NIH / National Institute of Dental and
Craniofacial Research, the CDC / National Center for Health Promotion
and Disease Prevention Division of Oral Health, and the CDC / National
Center for Health Statistics.
NR 16
TC 9
Z9 9
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4006
EI 1752-7325
J9 J PUBLIC HEALTH DENT
JI J. Public Health Dent.
PD SUM
PY 2014
VL 74
IS 3
BP 248
EP 256
DI 10.1111/jphd.12056
PG 9
WC Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational
Health
SC Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational
Health
GA AP5TG
UT WOS:000342141000011
PM 24849242
ER
PT J
AU Anderson, RN
Copeland, G
Hayes, JM
AF Anderson, Robert N.
Copeland, Glenn
Hayes, John Mosely
TI Linkages to Improve Mortality Data for American Indians and Alaska
Natives: A New Model for Death Reporting?
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Editorial Material
ID NATIONAL LONGITUDINAL MORTALITY; RACE; IDENTIFICATION; CERTIFICATE;
ETHNICITY; PATTERNS; QUALITY; HEALTH
AB Racial misclassification is a well-documented weakness of mortality data taken from death certificates. As a result, mortality statistics for American Indians and Alaska Natives (AI/ANs) present, at best, an inaccurate and misleading assessment of mortality in this population.
Studies evaluating the quality of race/ethnicity reporting on death certificates have linked data from death certificates to other data sources collected when the decedent was still alive (e. g., Census, Current Population Survey). Such studies have shown substantial misclassification of AI/AN decedents.
Despite limitations, linking mortality data from death certificates with data from other sources collected when decedents were living provides opportunities to evaluate and correct misclassification of populations such as AI/AN persons and facilitates the calculation and presentation of more accurate mortality statistics.
C1 [Anderson, Robert N.] Ctr Dis Control & Prevent, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA.
[Copeland, Glenn] Michigan Dept Community Hlth, Div Vital Records & Hlth Stat, Lansing, MI USA.
[Hayes, John Mosely] United South & Eastern Tribes, Tribal Epidemiol Ctr, Nashville, TN USA.
RP Anderson, RN (reprint author), Div Vital Stat, 3311 Toledo Rd,Room 7318, Hyattsville, MD 20782 USA.
EM RNAnderson@cdc.gov
NR 37
TC 1
Z9 1
U1 1
U2 1
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S258
EP S262
DI 10.2105/AJPH.2013.301647
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300006
PM 24754614
ER
PT J
AU Arias, E
Xu, JQ
Jim, MA
AF Arias, Elizabeth
Xu, Jiaquan
Jim, Melissa A.
TI Period Life Tables for the Non-Hispanic American Indian and Alaska
Native Population, 2007-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID OLDER AGES; MORTALITY
AB Objectives. We estimated complete period life tables for the non-Hispanic American Indian and Alaska Native (AI/AN) population residing in Contract Health Service Delivery Area (CHSDA) counties for the period 2007-2009.
Methods. We used National Vital Statistics System mortality data files for years 2007-2009 corrected for AI/AN misclassification on death certificates, midyear 2008 revised census bridged race intercensal population estimates, and National Vital Statistics System birth data for years 2006-2009. We used the same methodology as that used to estimate official US annual life tables, with some minor modifications.
Results. For the period 2007-2009, the non-Hispanic AI/AN population in CHSDA counties had the lowest life expectancy at birth (71.1 years) of any racial/ethnic group for which official US life tables are estimated. By comparison, in 2008, life expectancy at birth was 73.9 years for the non-Hispanic Black population, 78.4 years for the non-Hispanic White population, and 80.8 years for the Hispanic population.
Conclusions. The life tables showed a clear mortality disadvantage for the non-Hispanic AI/AN population in CHSDA counties relative to other national populations. The findings suggested that further research is necessary to explore the causes behind these disadvantages.
C1 [Arias, Elizabeth; Xu, Jiaquan] Ctr Dis Control & Prevent, Mortal Stat Branch, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA.
[Jim, Melissa A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Arias, E (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 7330, Hyattsville, MD 20782 USA.
EM EArias@cdc.gov
NR 19
TC 4
Z9 5
U1 0
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S312
EP S319
DI 10.2105/AJPH.2013.301635
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300013
PM 24754553
ER
PT J
AU Bauer, UE
Plescia, M
AF Bauer, Ursula E.
Plescia, Marcus
TI Addressing Disparities in the Health of American Indian and Alaska
Native People: The Importance of Improved Public Health Data
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Editorial Material
C1 [Bauer, Ursula E.] US Ctr Dis Control & Prevent CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Bauer, UE (reprint author), 4770 Buford Hwy NE MS F-80, Atlanta, GA 30341 USA.
EM ubauer@cdc.gov
NR 11
TC 2
Z9 2
U1 0
U2 2
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S255
EP S257
DI 10.2105/AJPH.2013.301602
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300005
PM 24754654
ER
PT J
AU Burrows, NR
Cho, P
Bullard, KM
Narva, AS
Eggers, PW
AF Burrows, Nilka Rios
Cho, Pyone
Bullard, Kai McKeever
Narva, Andrew S.
Eggers, Paul W.
TI Survival on Dialysis Among American Indians and Alaska Natives With
Diabetes in the United States, 1995-2010
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID STAGE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; HEMODIALYSIS-PATIENTS;
CARDIOVASCULAR-DISEASE; ETHNIC-DIFFERENCES; NUTRITIONAL-STATUS;
RISK-FACTOR; RACE; MORTALITY; POPULATION
AB Objectives. We assessed survival in American Indians and Alaska Natives (AI/ANs) with end-stage renal disease attributed to diabetes who initiated hemodialysis between 1995 and 2009.
Methods. Follow-up extended from the first date of dialysis in the United States Renal Data System until December 31, 2010, kidney transplantation, or death. We used the Kaplan-Meier method to compute survival on dialysis by age and race/ethnicity and Cox regression analysis to compute adjusted hazard ratios (HRs).
Results. Our study included 510 666 persons-48% Whites, 2% AI/AN persons, and 50% others. Median follow-up was 2.2 years (interquartile range = 1.1-4.1 years). At any age, AI/AN persons survived longer on hemodialysis than Whites; this finding persisted after adjusting for baseline differences. Among AI/AN individuals, those with full Indian blood ancestry had the lowest adjusted risk of death compared with Whites (HR = 0.58; 95% confidence interval = 0.55, 0.61). The risk increased with declining proportion of AI/AN ancestry.
Conclusions. Survival on dialysis was better among AI/AN than White persons with diabetes. Among AI/AN persons, the inverse relationship between risk of death and level of AI/AN ancestry suggested that cultural or hereditary factors played a role in survival.
C1 [Burrows, Nilka Rios; Cho, Pyone; Bullard, Kai McKeever] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
[Narva, Andrew S.; Eggers, Paul W.] NIDDK, NIH, Bethesda, MD 20892 USA.
RP Burrows, NR (reprint author), 4770 Buford Highway NE,Mailstop F73, Atlanta, GA 30341 USA.
EM nrios@cdc.gov
NR 31
TC 1
Z9 1
U1 1
U2 4
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S490
EP S495
DI 10.2105/AJPH.2014.301942
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300034
PM 24754656
ER
PT J
AU Cheek, JE
Holman, RC
Redd, JT
Haberling, D
Hennessy, TW
AF Cheek, James E.
Holman, Robert C.
Redd, John T.
Haberling, Dana
Hennessy, Thomas W.
TI Infectious Disease Mortality Among American Indians and Alaska Natives,
1999-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID UNITED-STATES; RESPIRATORY-TRACT; HOSPITALIZATIONS; TRENDS; POPULATION;
CANCER; MISCLASSIFICATION; DISPARITIES; INFANTS; DEATH
AB Objectives. We described death rates and leading causes of death caused by infectious diseases (IDs) in American Indian/Alaska Native (AI/AN) persons.
Methods. We analyzed national mortality data, adjusted for AI/AN race by linkage with Indian Health Service registration records, for all US counties and Contract Health Service Delivery Area (CHSDA) counties. The average annual 1999 to 2009 ID death rates per 100 000 persons for AI/AN persons were compared with corresponding rates for Whites.
Results. The ID death rate in AI/AN populations was significantly higher than that of Whites. A reported 8429 ID deaths (rate 86.2) in CHSDA counties occurred among AI/AN persons; the rate was significantly higher than the rate in Whites (44.0; rate ratio [RR] = 1.96; 95% confidence interval [CI] = 1.91, 2.00). The rates for the top 10 ID underlying causes of death were significantly higher for AI/AN persons than those for Whites. Lower respiratory tract infection and septicemia were the top-ranked causes. The greatest relative rate disparity was for tuberculosis (RR = 13.51; 95% CI = 11.36, 15.93).
Conclusions. Health equity might be furthered by expansion of interventions to reduce IDs among AI/AN communities.
C1 [Cheek, James E.] Univ New Mexico, Sch Med, Dept Family & Community Med, Albuquerque, NM 87131 USA.
[Holman, Robert C.; Haberling, Dana] Ctr Dis Control & Prevent CDC, NCEZID, Atlanta, GA USA.
[Redd, John T.] Indian Hlth Serv HIS, Santa Fe, NM USA.
[Hennessy, Thomas W.] CDC, Arctic Invest Program, NCEZID, Anchorage, AK 99508 USA.
RP Hennessy, TW (reprint author), CDC, Arctic Invest Program, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.
EM tbh0@cdc.gov
NR 43
TC 2
Z9 2
U1 0
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S446
EP S452
DI 10.2105/AJPH.2013.301721
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300029
PM 24754622
ER
PT J
AU Cho, P
Geiss, LS
Burrows, NR
Roberts, DL
Bullock, AK
Toedt, ME
AF Cho, Pyone
Geiss, Linda S.
Burrows, Nilka Rios
Roberts, Diana L.
Bullock, Ann K.
Toedt, Michael E.
TI Diabetes-Related Mortality Among American Indians and Alaska Natives,
1990-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID UNITED-STATES; DEATH CERTIFICATE; CANCER RATES; US ADULTS; PREVALENCE;
TRENDS
AB Objectives. We assessed diabetes-related mortality for American Indians and Alaska Natives (AI/ANs) and Whites.
Methods. Study populations were non-Hispanic AI/AN and White persons in Indian Health Service (IHS) Contract Health Service Delivery Area counties; Hispanics were excluded. We used 1990 to 2009 death certificate data linked to IHS patient registration records to identify AI/AN decedents aged 20 years or older. We examined disparities and trends in mortality related to diabetes as an underlying cause of death (COD) and as a multiple COD.
Results. After increasing between 1990 and 1999, rates of diabetes as an underlying COD and a multiple COD subsequently decreased in both groups. However, between 2000 and 2009, age-adjusted rates of diabetes as an underlying COD and a multiple COD remained 2.5 to 3.5 times higher among AI/AN persons than among Whites for all age groups (20-44, 45-54, 55-64, 65-74, and 75 years), both sexes, and every IHS region except Alaska.
Conclusions. Declining trends in diabetes-related mortality in both AI/AN and White populations are consistent with recent improvements in their health status. Reducing persistent disparities in diabetes mortality will require developing effective approaches to not only control but also prevent diabetes among AI/AN populations.
C1 [Cho, Pyone; Geiss, Linda S.; Burrows, Nilka Rios] Ctr Dis Control & Prevent CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
[Roberts, Diana L.] Indian Hlth Serv IHS, Alaska Area Native Hlth Serv, Anchorage, AK USA.
[Bullock, Ann K.] IHS, Div Diabet Treatment & Prevent, Albuquerque, NM USA.
[Toedt, Michael E.] Cherokee Indian Hosp, Cherokee, NC USA.
RP Cho, P (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F-73, Atlanta, GA 30341 USA.
EM pcho@cdc.gov
NR 47
TC 7
Z9 7
U1 2
U2 7
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S496
EP S503
DI 10.2105/AJPH.2014.301968
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300035
PM 24754621
ER
PT J
AU Cobb, N
Espey, D
King, J
AF Cobb, Nathaniel
Espey, David
King, Jessica
TI Health Behaviors and Risk Factors Among American Indians and Alaska
Natives, 2000-2010
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID NORTHERN PLAINS; UNITED-STATES; DISEASE; PREVALENCE
AB Objectives. We provided contextual risk factor information for a special supplement on causes of death among American Indians and Alaska Natives (AI/ANs). We analyzed 11 years of Behavioral Risk Factor Surveillance System (BRFSS) data for AI/AN respondents in the United States.
Methods. We combined BRFSS data from 2000 to 2010 to determine the prevalence of selected risk factors for AI/AN and White respondents residing in Indian Health Service Contract Health Service Delivery Area counties. Regional prevalence estimates for AI/AN respondents were compared with the estimates for White respondents for all regions combined; respondents of Hispanic origin were excluded.
Results. With some regional exceptions, AI/AN people had high prevalence estimates of tobacco use, obesity, and physical inactivity, and low prevalence estimates of fruit and vegetable consumption, cancer screening, and seatbelt use.
Conclusions. These behavioral risk factors were consistent with observed patterns of mortality and chronic disease among AI/AN persons. All are amenable to public health intervention.
C1 [Cobb, Nathaniel] Indian Hlth Serv, Div Epidemiol & Dis Prevent, Albuquerque, NM USA.
[Espey, David; King, Jessica] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA.
RP Espey, D (reprint author), 1720 Louisiana Blvd NE, Albuquerque, NM 87110 USA.
EM dke0@cdc.gov
NR 36
TC 30
Z9 30
U1 3
U2 14
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S481
EP S489
DI 10.2105/AJPH.2014.301879
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300033
PM 24754662
ER
PT J
AU Espey, DK
Jim, MA
Cobb, N
Bartholomew, M
Becker, T
Haverkamp, D
Plescia, M
AF Espey, David K.
Jim, Melissa A.
Cobb, Nathaniel
Bartholomew, Michael
Becker, Tom
Haverkamp, Don
Plescia, Marcus
TI Leading Causes of Death and All-Cause Mortality in American Indians and
Alaska Natives
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID UNITED-STATES; METABOLIC SYNDROME; CANCER RATES; PREVALENCE; PATTERNS;
TRENDS
AB Objectives. We present regional patterns and trends in all-cause mortality and leading causes of death in American Indians and Alaska Natives (AI/ANs).
Methods. US National Death Index records were linked with Indian Health Service (IHS) registration records to identify AI/AN deaths misclassified as non-AI/AN. We analyzed temporal trends for 1990 to 2009 and comparisons between non-Hispanic AI/AN and non-Hispanic White persons by geographic region for 1999 to 2009. Results focus on IHS Contract Health Service Delivery Area counties in which less race misclassification occurs.
Results. From 1990 to 2009 AI/AN persons did not experience the significant decreases in all-cause mortality seen for Whites. For 1999 to 2009 the all-cause death rate in CHSDA counties for AI/AN persons was 46% more than that for Whites. Death rates for AI/AN persons varied as much as 50% among regions. Except for heart disease and cancer, subsequent ranking of specific causes of death differed considerably between AI/AN and White persons.
Conclusions. AI/AN populations continue to experience much higher death rates than Whites. Patterns of mortality are strongly influenced by the high incidence of diabetes, smoking prevalence, problem drinking, and social determinants. Much of the observed excess mortality can be addressed through known public health interventions.
C1 [Espey, David K.; Jim, Melissa A.; Haverkamp, Don; Plescia, Marcus] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
[Cobb, Nathaniel] Indian Hlth Serv, Div Epidemiol & Dis Prevent, Rockville, MD USA.
[Becker, Tom] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Espey, DK (reprint author), Div Epidemiol & Dis Prevent, 1720 Louisiana Blvd NE, Albuquerque, NM 87110 USA.
EM dke0@cdc.gov
NR 54
TC 31
Z9 31
U1 2
U2 16
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S303
EP S311
DI 10.2105/AJPH.2013.301798
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300012
PM 24754554
ER
PT J
AU Groom, AV
Hennessy, TW
Singleton, RJ
Butler, JC
Holve, S
Cheek, JE
AF Groom, Amy V.
Hennessy, Thomas W.
Singleton, Rosalyn J.
Butler, Jay C.
Holve, Stephen
Cheek, James E.
TI Pneumonia and Influenza Mortality Among American Indian and Alaska
Native People, 1990-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID INVASIVE PNEUMOCOCCAL DISEASE; RESPIRATORY-TRACT INFECTION; WOOD-BURNING
STOVES; UNITED-STATES; A H1N1; SYNCYTIAL VIRUS; RISK-FACTORS;
POLYSACCHARIDE VACCINE; ETHNIC DISPARITIES; HEALTH BEHAVIORS
AB Objectives. We compared pneumonia and influenza death rates among American Indian/Alaska Native (AI/AN) people with rates among Whites and examined geographic differences in pneumonia and influenza death rates for AI/AN persons.
Methods. We adjusted National Vital Statistics Surveillance mortality data for racial misclassification of AI/AN people through linkages with Indian Health Service (IHS) registration records. Pneumonia and influenza deaths were defined as those who died from 1990 through 1998 and 1999 through 2009 according to codes for pneumonia and influenza from the International Classification of Diseases, 9th and 10th Revision, respectively. We limited the analysis to IHS Contract Health Service Delivery Area counties, and compared pneumonia and influenza death rates between AI/ANs and Whites by calculating rate ratios for the 2 periods.
Results. Compared with Whites, the pneumonia and influenza death rate for AI/AN persons in both periods was significantly higher. AI/AN populations in the Alaska, Northern Plains, and Southwest regions had rates more than 2 times higher than those of Whites. The pneumonia and influenza death rate for AI/AN populations decreased from 39.6 in 1999 to 2003 to 33.9 in 2004 to 2009.
Conclusions. Although progress has been made in reducing pneumonia and influenza mortality, disparities between AI/AN persons and Whites persist. Strategies to improve vaccination coverage and address risk factors that contribute to pneumonia and influenza mortality are needed.
C1 [Groom, Amy V.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Hennessy, Thomas W.] Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA.
[Singleton, Rosalyn J.; Butler, Jay C.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA.
[Holve, Stephen] Indian Hlth Serv, Tuba City Reg Hlth Care, Tuba City, AZ USA.
[Cheek, James E.] Univ New Mexico, Albuquerque, NM 87131 USA.
RP Groom, AV (reprint author), MPH Native Diabet Wellness Program, 1720 Louisiana Blvd NE,Suite 208, Albuquerque, NM 87110 USA.
EM Amy.Groom@ihs.gov
NR 65
TC 7
Z9 7
U1 3
U2 6
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S460
EP S469
DI 10.2105/AJPH.2013.301740
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300031
PM 24754620
ER
PT J
AU Hoffman, RM
Li, J
Henderson, JA
Ajani, UA
Wiggins, C
AF Hoffman, Richard M.
Li, Jun
Henderson, Jeffrey A.
Ajani, Umed A.
Wiggins, Charles
TI Prostate Cancer Deaths and Incident Cases Among American Indian/Alaska
Native Men, 1999-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID ALASKA-NATIVES; RADICAL PROSTATECTOMY; UNITED-STATES; NEW-MEXICO;
FOLLOW-UP; INDIANS; MORTALITY; RATES; US; SURVEILLANCE
AB Objectives. We linked databases to improve identification of American Indians/Alaska Natives (AI/ANs) in determining prostate cancer death and incidence rates.
Methods. We linked prostate cancer mortality and incidence data with Indian Health Service (IHS) patient records; analyses focused on residents of IHS Contract Health Service Delivery Area (CHSDA) counties. We calculated age-adjusted incidence and death rates for AI/AN and White men for 1999 to 2009; men of Hispanic origin were excluded.
Results. Prostate cancer death rates were higher for AI/AN men than for White men. Death rates declined for White men (-3.0% per year) but not for AI/AN men. AI/AN men had lower prostate cancer incidence rates than White men. Incidence rates declined among Whites (-2.2% per year) and AI/ANs (-1.9% per year).
Conclusions. AI/AN men had higher prostate cancer death rates and lower prostate cancer incidence rates than White men. Disparities in accessing health care could contribute to mortality differences, and incidence differences could be related to lower prostate-specific antigen testing rates among AI/AN men.
C1 [Hoffman, Richard M.; Wiggins, Charles] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA.
[Hoffman, Richard M.; Wiggins, Charles] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA.
[Hoffman, Richard M.] New Mexico VA Hlth Care Syst, Albuquerque, NM 87108 USA.
[Li, Jun; Ajani, Umed A.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
[Henderson, Jeffrey A.] Black Hills Ctr Amer Indian Hlth, Rapid City, SD USA.
RP Hoffman, RM (reprint author), New Mexico VA Hlth Care Syst, Mailstop 111,1501 San Pedro Dr SE, Albuquerque, NM 87108 USA.
EM rhoffman@unm.edu
FU US Department of Veterans Affairs; National Institutes of
Health/National Institute of General Medical Sciences/Indian Health
Service [1S06GM092240]; National Institutes of Health, National Cancer
Institute [1P50CA148110]
FX R. M. H. is supported by the US Department of Veterans Affairs. J. A. H.
is supported by the National Institutes of Health/National Institute of
General Medical Sciences/Indian Health Service (1S06GM092240) and the
National Institutes of Health, National Cancer Institute (1P50CA148110).
NR 42
TC 4
Z9 4
U1 0
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S439
EP S445
DI 10.2105/AJPH.2013.301690
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300028
PM 24754659
ER
PT J
AU Jim, MA
Arias, E
Seneca, DS
Hoopes, MJ
Jim, CC
Johnson, NJ
Wiggins, CL
AF Jim, Melissa A.
Arias, Elizabeth
Seneca, Dean S.
Hoopes, Megan J.
Jim, Cheyenne C.
Johnson, Norman J.
Wiggins, Charles L.
TI Racial Misclassification of American Indians and Alaska Natives by
Indian Health Service Contract Health Service Delivery Area
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID END RESULTS PROGRAM; DEATH CERTIFICATES; UNITED-STATES; SURVEILLANCE
DATA; CANCER REGISTRY; EPIDEMIOLOGY; RATES; ACCURACY; NATION; RACE
AB Objectives. We evaluated the racial misclassification of American Indians and Alaska Natives (AI/ANs) in cancer incidence and all-cause mortality data by Indian Health Service (IHS) Contract Health Service Delivery Area (CHSDA).
Methods. We evaluated data from 3 sources: IHS-National Vital Statistics System (NVSS), IHS-National Program of Cancer Registries (NPCR)/Surveillance, Epidemiology and End Results (SEER) program, and National Longitudinal Mortality Study (NLMS). We calculated, within each data source, the sensitivity and classification ratios by sex, IHS region, and urban-rural classification by CHSDA county.
Results. Sensitivity was significantly greater in CHSDA counties (IHS-NVSS: 83.6%; IHS-NPCR/SEER: 77.6%; NLMS: 68.8%) than non-CHSDA counties (IHS-NVSS: 54.8%; IHS-NPCR/SEER: 39.0%; NLMS: 28.3%). Classification ratios indicated less misclassification in CHSDA counties (IHS-NVSS: 1.20%; IHS-NPCR/SEER: 1.29%; NLMS: 1.18%) than non-CHSDA counties (IHS-NVSS: 1.82%; IHS-NPCR/SEER: 2.56%; NLMS: 1.81%). Race misclassification was less in rural counties and in regions with the greatest concentrations of AI/AN persons (Alaska, Southwest, and Northern Plains).
Conclusions. Limiting presentation and analysis to CHSDA counties helped mitigate the effects of race misclassification of AI/AN persons, although a portion of the population was excluded.
C1 [Jim, Melissa A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Albuquerque, NM USA.
[Arias, Elizabeth] Ctr Dis Control & Prevent, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA.
[Seneca, Dean S.] Ctr Dis Control & Prevent, Div Publ Hlth Capac Dev, Off State Tribal Local & Terr Support, Atlanta, GA USA.
[Hoopes, Megan J.] Northwest Portland Area Indian Hlth Board, Northwest Tribal Epidemiol Ctr, Portland, OR USA.
[Jim, Cheyenne C.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Albuquerque, NM USA.
[Johnson, Norman J.] US Bur Census, Natl Longitudinal Mortal Study Branch, Suitland, MD USA.
[Wiggins, Charles L.] Univ New Mexico, Ctr Canc, New Mexico Tumor Registry, Albuquerque, NM 87131 USA.
RP Jim, MA (reprint author), CDC, Div Canc Prevent & Control, Albuquerque, NM 87110 USA.
EM melissa.jim@ihs.gov
OI Hoopes, Megan/0000-0001-7941-254X
NR 56
TC 24
Z9 24
U1 2
U2 8
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S295
EP S302
DI 10.2105/AJPH.2014.301933
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300011
PM 24754617
ER
PT J
AU Li, J
Weir, HK
Jim, MA
King, SM
Wilson, R
Master, VA
AF Li, Jun
Weir, Hannah K.
Jim, Melissa A.
King, Sallyann M.
Wilson, Reda
Master, Viraj A.
TI Kidney Cancer Incidence and Mortality Among American Indians and Alaska
Natives in the United States, 1990-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID RENAL-CELL CANCER; PHYSICAL-ACTIVITY; HEALTH BEHAVIORS; RISING
INCIDENCE; RISK-FACTORS; EPIDEMIOLOGY; PATTERNS; OBESITY; TRENDS; WOMEN
AB Objectives. We describe rates and trends in kidney cancer incidence and mortality and identify disparities between American Indian/Alaska Native (AI/AN) and White populations.
Methods. To improve identification of AI/AN race, incidence and mortality data were linked with Indian Health Service (IHS) patient records. Analysis focused on residents of IHS Contract Health Service Delivery Area counties; Hispanics were excluded. We calculated age-adjusted kidney cancer incidence (2001-2009) and death rates (1990-2009) by sex, age, and IHS region.
Results. AI/AN persons have a 1.6 times higher kidney cancer incidence and a 1.9 times higher kidney cancer death rate than Whites. Despite a significant decline in kidney cancer death rates for Whites (annual percentage change [APC] = -0.3; 95% confidence interval [CI] = -0.5, 0.0), death rates for AI/AN persons remained stable (APC = 0.4; 95% CI = -0.7, 1.5). Kidney cancer incidence rates rose more rapidly for AI/AN persons (APC = 3.5; 95% CI = 1.2, 5.8) than for Whites (APC = 2.1; 95% CI = 1.4, 2.8).
Conclusions. AI/AN individuals have greater risk of developing and dying of kidney cancers. Incidence rates have increased faster in AI/AN populations than in Whites. Death rates have decreased slightly in Whites but remained stable in AI/AN populations. Racial disparities in kidney cancer are widening.
C1 [Li, Jun; Weir, Hannah K.; Jim, Melissa A.; Wilson, Reda] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
[King, Sallyann M.] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Master, Viraj A.] Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA.
[Master, Viraj A.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA.
RP Li, J (reprint author), CDC, Div Canc Prevent & Control, 4770 Buford Highway,MS K55, Atlanta, GA 30341 USA.
EM ffa2@cdc.gov
NR 44
TC 4
Z9 4
U1 0
U2 1
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S396
EP S403
DI 10.2105/AJPH.2013.301616
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300023
PM 24754655
ER
PT J
AU Murphy, T
Pokhrel, P
Worthington, A
Billie, H
Sewell, M
Bill, N
AF Murphy, Tierney
Pokhrel, Pallavi
Worthington, Anne
Billie, Holly
Sewell, Mack
Bill, Nancy
TI Unintentional Injury Mortality Among American Indians and Alaska Natives
in the United States, 1990-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID OLDER PERSONS; DEATHS; POPULATIONS; OVERDOSES; FALLS
AB Objectives. We describe the burden of unintentional injury (UI) deaths among American Indian and Alaska Native (AI/AN) populations in the United States.
Methods. National Death Index records for 1990 to 2009 were linked with Indian Health Service registration records to identify AI/AN deaths misclassified as non-AI/AN deaths. Most analyses were restricted to Contract Health Service Delivery Area counties in 6 geographic regions of the United States. We compared age-adjusted death rates for AI/AN persons with those for Whites; Hispanics were excluded.
Results. From 2005 to 2009, the UI death rate for AI/AN people was 2.4 times higher than for Whites. Death rates for the 3 leading causes of UI death-motor vehicle traffic crashes, poisoning, and falls-were 1.4 to 3 times higher among AI/AN persons than among Whites. UI death rates were higher among AI/AN males than among females and highest among AI/AN persons in Alaska, the Northern Plains, and the Southwest.
Conclusions. AI/AN persons had consistently higher UI death rates than did Whites. This disparity in overall rates coupled with recent increases in unintentional poisoning deaths requires that injury prevention be a major priority for improving health and preventing death among AI/AN populations.
C1 [Murphy, Tierney; Pokhrel, Pallavi; Worthington, Anne] New Mexico Dept Hlth, Epidemiol & Response Div, Santa Fe, NM 87502 USA.
[Billie, Holly] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
[Sewell, Mack] Wyoming Dept Workforce Serv, Cheyenne, WY USA.
[Bill, Nancy] Indian Hlth Serv, Rockville, MD USA.
RP Murphy, T (reprint author), New Mexico Dept Hlth, Epidemiol & Response Div, 1190 St Francis Dr,N1110,POB 26110, Santa Fe, NM 87502 USA.
EM tierney.murphy@state.nm.us
NR 43
TC 10
Z9 10
U1 0
U2 1
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S470
EP S480
DI 10.2105/AJPH.2013.301854
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300032
PM 24754624
ER
PT J
AU Perdue, DG
Haverkamp, D
Perkins, C
Daley, CM
Provost, E
AF Perdue, David G.
Haverkamp, Donald
Perkins, Carin
Daley, Christine Makosky
Provost, Ellen
TI Geographic Variation in Colorectal Cancer Incidence and Mortality, Age
of Onset, and Stage at Diagnosis Among American Indian and Alaska Native
People, 1990-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID UNITED-STATES; SURVEILLANCE; HEALTH; TRENDS; RATES; DISPARITIES
AB Objectives. We characterized estimates of colorectal cancer (CRC) in American Indians/Alaska Natives (AI/ANs) compared with Whites using a linkage methodology to improve AI/AN classification in incidence and mortality data.
Methods. We linked incidence and mortality data to Indian Health Service enrollment records. Our analyses were restricted to Contract Health Services Delivery Area counties. We analyzed death and incidence rates of CRC for AI/AN persons and Whites by 6 regions from 1999 to 2009. Trends were described using linear modeling.
Results. The AI/AN colorectal cancer incidence was 21% higher and mortality 39% higher than in Whites. Although incidence and mortality significantly declined among Whites, AI/AN incidence did not change significantly, and mortality declined only in the Northern Plains. AI/AN persons had a higher incidence of CRC than Whites in all ages and were more often diagnosed with late stage CRC than Whites.
Conclusions. Compared with Whites, AI/AN individuals in many regions had a higher burden of CRC and stable or increasing CRC mortality. An understanding of the factors driving these regional disparities could offer critical insights for prevention and control programs.
C1 [Perdue, David G.] Amer Indian Canc Fdn, Minneapolis, MN USA.
[Perdue, David G.] Minnesota Gastroenterol PA, Minneapolis, MN 55414 USA.
[Haverkamp, Donald] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
[Perkins, Carin] Minnesota Canc Surveillance Syst, Minneapolis, MN USA.
[Daley, Christine Makosky] Univ Kansas, Med Ctr, Ctr Amer Indian Community Hlth, Kansas City, KS USA.
[Provost, Ellen] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA.
RP Perdue, DG (reprint author), Minnesota Gastroenterol PA, POB 14909, Minneapolis, MN 55414 USA.
EM dperdue@mngastro.com
NR 47
TC 12
Z9 12
U1 2
U2 5
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S404
EP S414
DI 10.2105/AJPH.2013.301654
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300024
PM 24754657
ER
PT J
AU Plescia, M
Henley, SJ
Pate, A
Underwood, JM
Rhodes, K
AF Plescia, Marcus
Henley, Sarah Jane
Pate, Anne
Underwood, J. Michael
Rhodes, Kris
TI Lung Cancer Deaths Among American Indians and Alaska Natives, 1990-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID CURRENT CIGARETTE-SMOKING; UNITED-STATES; TOBACCO CONTROL; MORTALITY;
SURVEILLANCE; TRENDS; RATES; DISPARITIES; ADULTS; PATTERNS
AB Objectives. We examined regional differences in lung cancer among American Indians/Alaska Natives (AI/ANs) using linked data sets to minimize racial misclassification.
Methods. On the basis of federal lung cancer incidence data for 1999 to 2009 and deaths for 1990 to 2009 linked with Indian Health Service (IHS) registration records, we calculated age-adjusted incidence and death rates for non-Hispanic AI/AN and White persons by IHS region, focusing on Contract Health Service Delivery Area (CHSDA) counties. We correlated death rates with cigarette smoking prevalence and calculated mortality-to-incidence ratios.
Results. Lung cancer death rates among AI/AN persons in CHSDA counties varied across IHS regions, from 94.0 per 100 000 in the Northern Plains to 15.2 in the Southwest, reflecting the strong correlation between smoking and lung cancer. For every 100 lung cancers diagnosed, there were 6 more deaths among AI/AN persons than among White persons. Lung cancer death rates began to decline in 1997 among AI/AN men and are still increasing among AI/AN women.
Conclusions. Comparison of regional lung cancer death rates between AI/AN and White populations indicates disparities in tobacco control and prevention interventions. Efforts should be made to ensure that AI/AN persons receive equal benefit from current and emerging lung cancer prevention and control interventions.
C1 [Plescia, Marcus; Henley, Sarah Jane; Underwood, J. Michael] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA.
[Pate, Anne] Oklahoma Dept Hlth, Chron Dis Serv, Oklahoma City, OK USA.
[Rhodes, Kris] Amer Indian Canc Fdn, Minneapolis, MN USA.
RP Plescia, M (reprint author), 249 Billingsley Rd, Charlotte, NC 28211 USA.
EM Marcus.Plescia@mecklenburgcountync.gov
NR 50
TC 14
Z9 14
U1 2
U2 7
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S388
EP S395
DI 10.2105/AJPH.2013.301609
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300022
PM 24754613
ER
PT J
AU Reilley, B
Bloss, E
Byrd, KK
Iralu, J
Neel, L
Cheek, J
AF Reilley, Brigg
Bloss, Emily
Byrd, Kathy K.
Iralu, Jonathan
Neel, Lisa
Cheek, James
TI Death Rates From Human Immunodeficiency Virus and Tuberculosis Among
American Indians/Alaska Natives in the United States, 1990-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID INFECTIOUS-DISEASE MORTALITY; ALASKA-NATIVES; ANTIRETROVIRAL THERAPY;
RACIAL MISCLASSIFICATION; HIV INCIDENCE; RISK-FACTORS; HEALTH; HIV/AIDS;
TRENDS; CANCER
AB Objectives. We used race-corrected data and comprehensive diagnostic codes to better compare HIV and tuberculosis (TB) mortality from 1999 to 2009 between American Indian/Alaska Natives (AI/ANs) and Whites.
Methods. National Vital Statistics Surveillance System mortality data were adjusted for AI/AN racial misclassification through linkage with Indian Health Service registration records. We compared average annual 1990 to 2009 HIV and TB death rates (per 100 000 people) for AI/AN persons with those for Whites; Hispanics were excluded.
Results. Although death rates from HIV in AI/AN persons were significantly lower than those in Whites from 1990 to 1998 (4.2 vs 7.0), they were significantly higher than those in Whites from 1999 to 2009 (3.6 vs 2.0). Death rates from TB in AI/AN persons were significantly higher than those in Whites, with a significant disparity during both 1990 to 1998 (3.3 vs 0.3) and 1999 to 2009 (1.5 vs 0.1).
Conclusions. The decrease in death rates from HIV and TB was greater among Whites, and death rates remained significantly higher among AI/AN individuals. Public health interventions need to be prioritized to reduce the TB and HIV burden and mortality in AI/AN populations.
C1 [Reilley, Brigg; Iralu, Jonathan; Neel, Lisa] Indian Hlth Serv, Albuquerque, NM 87110 USA.
[Bloss, Emily; Byrd, Kathy K.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Cheek, James] Univ New Mexico, Dept Family & Community Med, Albuquerque, NM 87131 USA.
RP Reilley, B (reprint author), Indian Hlth Serv, 5300 Homestead Dr NE, Albuquerque, NM 87110 USA.
EM Brigg.Reilley@ihs.gov
NR 59
TC 2
Z9 2
U1 1
U2 4
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S453
EP S459
DI 10.2105/AJPH.2013.301746
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300030
PM 24754664
ER
PT J
AU Schieb, LJ
Ayala, C
Valderrama, AL
Veazie, MA
AF Schieb, Linda J.
Ayala, Carma
Valderrama, Amy L.
Veazie, Mark A.
TI Trends and Disparities in Stroke Mortality by Region for American
Indians and Alaska Natives
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID DISEASE RISK-FACTORS; FACTOR SURVEILLANCE SYSTEM;
CARDIOVASCULAR-DISEASE; UNITED-STATES; HEART-ASSOCIATION; HEALTH
BEHAVIORS; CANCER; CARE; POPULATIONS; CHALLENGES
AB Objectives. We evaluated trends and disparities in stroke death rates for American Indians and Alaska Natives (AI/ANs) and White people by Indian Health Service region.
Methods. We identified stroke deaths among AI/AN persons and Whites (adults aged 35 years or older) using National Vital Statistics System data for 1990 to 2009. We used linkages with Indian Health Service patient registration data to adjust for misclassification of race for AI/AN persons. Analyses excluded Hispanics and focused on Contract Health Service Delivery Area (CHSDA) counties.
Results. Stroke death rates among AI/AN individuals were higher than among Whites for both men and women in CHSDA counties and were highest in the youngest age groups. Rates and AI/AN: White rate ratios varied by region, with the highest in Alaska and the lowest in the Southwest. Stroke death rates among AI/AN persons decreased in all regions beginning in 2001.
Conclusions. Although stroke death rates among AI/AN populations have decreased over time, rates are still higher for AI/AN persons than for Whites. Interventions that address reducing stroke risk factors, increasing awareness of stroke symptoms, and increasing access to specialty care for stroke may be more successful at reducing disparities in stroke death rates.
C1 [Schieb, Linda J.; Ayala, Carma; Valderrama, Amy L.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA.
[Veazie, Mark A.] Phoenix Area Indian Hlth Serv, Phoenix, AZ USA.
RP Schieb, LJ (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy NE,MS F-72, Atlanta, GA 30341 USA.
EM lschieb@cdc.gov
NR 54
TC 4
Z9 4
U1 0
U2 0
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S368
EP S376
DI 10.2105/AJPH.2013.301698
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300020
PM 24754653
ER
PT J
AU Singh, SD
Ryerson, AB
Wu, MX
Kaur, JS
AF Singh, Simple D.
Ryerson, A. Blythe
Wu, Manxia
Kaur, Judith S.
TI Ovarian and Uterine Cancer Incidence and Mortality in American Indian
and Alaska Native Women, United States, 1999-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID INCIDENCE RATES; SURVEILLANCE; POPULATION; HEALTH; TRENDS; EPIDEMIOLOGY;
HYSTERECTOMY; ETHNICITY; PATTERNS; REGISTRY
AB Objectives. We examined geographic differences and trends in incidence and mortality of ovarian and uterine cancer in American Indian/Alaska Native (AI/AN) women.
Methods. We linked mortality data (1990-2009) and incidence data (1999-2009) to Indian Health Service (IHS) records. Death (and incidence) rates for ovarian and uterine cancer were examined for AI/AN and White women; Hispanics were excluded. Analyses focused on Contract Health Service Delivery Area (CHSDA) counties.
Results. AI/AN and White women had similar ovarian and uterine cancer death rates. Ovarian and uterine cancer incidence and death rates were higher for AI/ANs residing in CHSDA counties than for all US counties. We also observed geographic differences, regardless of CHSDA residence, in ovarian and uterine cancer incidence and death rates in AI/AN women by IHS region; Pacific Coast and Southern Plains women had higher ovarian cancer death rates and Northern Plains women had higher uterine cancer death rates.
Conclusions. Regional differences in the incidence and mortality of ovarian and uterine cancers among AI/AN women in the United States were significant. More research among correctly classified AI/AN women is needed to understand these differences.
C1 [Singh, Simple D.; Ryerson, A. Blythe; Wu, Manxia] Ctr Dis Control & Prevent, Canc Surveillance Branch, Div Canc Prevent & Control, Atlanta, GA USA.
[Kaur, Judith S.] Mayo Clin, Dept Oncol, Rochester, MN USA.
RP Singh, SD (reprint author), 4770 Buford Highway NE,Mailstop F-76, Atlanta, GA 30341 USA.
EM hjv3@cdc.gov
NR 57
TC 3
Z9 3
U1 1
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S423
EP S431
DI 10.2105/AJPH.2013.301781
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300026
PM 24754663
ER
PT J
AU Suryaprasad, A
Byrd, KK
Redd, JT
Perdue, DG
Manos, M
McMahon, BJ
AF Suryaprasad, Anil
Byrd, Kathy K.
Redd, John T.
Perdue, David G.
Manos, Michele
McMahon, Brian J.
TI Mortality Caused by Chronic Liver Disease Among American Indians and
Alaska Natives in the United States, 1999-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID HEPATITIS-C INFECTION; VIRUS-INFECTION; VIRAL-HEPATITIS; CANCER RATES;
PREVALENCE; TRENDS; ADULTS; RISK; US
AB Objectives. We compared chronic liver disease (CLD) mortality from 1999 to 2009 between American Indians and Alaska Natives (AI/ANs) and Whites in the United States after improving CLD case ascertainment and AI/AN race classification.
Methods. We defined CLD deaths and causes by comprehensive death certificate-based diagnostic codes. To improve race classification, we linked US mortality data to Indian Health Service enrollment records, and we restricted analyses to Contract Health Service Delivery Areas and to non-Hispanic populations. We calculated CLD death rates (per 100 000) in 6 geographic regions. We then described trends using linear modeling.
Results. CLD mortality increased from 1999 to 2009 in AI/AN persons and Whites. Overall, the CLD death rate ratio (RR) of AI/ANindividuals to Whites was 3.7 and varied by region. The RR was higher in women (4.7), those aged 25 to 44 years (7.4), persons residing in the Northern Plains (6.4), and persons dying of cirrhosis (4.0) versus hepatocellular carcinoma (2.5), particularly those aged 25 to 44 years (7.7).
Conclusions. AI/AN persons had greater CLD mortality, particularly from premature cirrhosis, than Whites, with variable mortality by region. Comprehensive prevention and care strategies are urgently needed to stem the CLD epidemic among AI/AN individuals.
C1 [Suryaprasad, Anil; Byrd, Kathy K.] Ctr Dis Control & Prevent CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, US Dept HHS, Atlanta, GA 30329 USA.
[Redd, John T.] Santa Fe Publ Hlth Serv Indian, Indian Hlth Serv, US Dept Hlth & Human Serv, Santa Fe, NM USA.
[Perdue, David G.] Amer Indian Canc Fdn, Minneapolis, MN USA.
[Perdue, David G.] Minnesota Gastroenterol PA, Minneapolis, MN USA.
[Manos, Michele] Kaiser Permanente, Div Res, Oakland, CA USA.
[McMahon, Brian J.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA.
RP Suryaprasad, A (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mailstop G-37, Atlanta, GA 30329 USA.
EM asuryaprasad@cdc.gov
FU Centers for Disease Control and Prevention (CDC); Indian Health Service
(IHS)
FX This study was supported by the Centers for Disease Control and
Prevention (CDC) and the Indian Health Service (IHS).
NR 43
TC 7
Z9 7
U1 0
U2 1
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S350
EP S358
DI 10.2105/AJPH.2013.301645
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300018
PM 24754616
ER
PT J
AU Veazie, M
Ayala, C
Schieb, L
Dai, SF
Henderson, JA
Cho, P
AF Veazie, Mark
Ayala, Carma
Schieb, Linda
Dai, Shifan
Henderson, Jeffrey A.
Cho, Pyone
TI Trends and Disparities in Heart Disease Mortality Among American
Indians/Alaska Natives, 1990-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID ALASKA-NATIVES; CARDIOVASCULAR-DISEASE; UNITED-STATES; CANCER; DEATH;
PREVALENCE; QUALITY; RATES
AB Objectives. We evaluated heart disease death rates among American Indians and Alaska Natives (AI/ANs) and Whites after improving identification of AI/AN populations.
Methods. Indian Health Service (IHS) registration data were linked to the National Death Index for 1990 to 2009 to identify deaths among AI/AN persons aged 35 years and older with heart disease listed as the underlying cause of death (UCOD) or 1 of multiple causes of death (MCOD). We restricted analyses to IHS Contract Health Service Delivery Areas and to non-Hispanic populations.
Results. Heart disease death rates were higher among AI/AN persons than Whites from 1999 to 2009 (1.21 times for UCOD, 1.30 times for MCOD). Disparities were highest in younger age groups and in the Northern Plains, but lowest in the East and Southwest. In AI/AN persons, MCOD rates were 84% higher than UCOD rates. From 1990 to 2009, UCOD rates declined among Whites, but only declined significantly among AI/AN persons after 2003.
Conclusions. Analysis with improved race identification indicated that AI/AN populations experienced higher heart disease death rates than Whites. Better prevention and more effective care of heart disease is needed for AI/AN populations.
C1 [Veazie, Mark] Phoenix Area Indian Hlth Serv, Flagstaff, AZ USA.
[Ayala, Carma; Schieb, Linda] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA.
[Dai, Shifan] Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA USA.
[Henderson, Jeffrey A.] Black Hills Ctr Amer Indian Hlth, Rapid City, SD USA.
[Cho, Pyone] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA.
RP Veazie, M (reprint author), 1215 N Beaver St Suite 201, Flagstaff, AZ 86001 USA.
EM mark.veazie@ihs.gov
FU National Institutes of Health [1S06GM092240, 1P50CA148110]
FX J. H.'s contribution was supported by the National Institutes of Health
(grants 1S06GM092240 [NIH/NIGMS/IHS] and 1P50CA148110 [NIH/NCI]).
NR 48
TC 10
Z9 10
U1 2
U2 5
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S359
EP S367
DI 10.2105/AJPH.2013.301715
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300019
PM 24754556
ER
PT J
AU Watson, M
Benard, V
Thomas, C
Brayboy, A
Paisano, R
Becker, T
AF Watson, Meg
Benard, Vicki
Thomas, Cheryll
Brayboy, Annie
Paisano, Roberta
Becker, Thomas
TI Cervical Cancer Incidence and Mortality Among American Indian and Alaska
Native Women, 1999-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID UNITED-STATES; HUMAN-PAPILLOMAVIRUS; VACCINATION COVERAGE;
HEALTH-SERVICE; RATES; PATTERNS; SURVEILLANCE; PROGRAM; TRENDS
AB Objectives. We analyzed cervical cancer incidence and mortality data in American Indian and Alaska Native (AI/AN) women compared with women of other races.
Methods. We improved identification of AI/AN race, cervical cancer incidence, and mortality data using Indian Health Service (IHS) patient records; our analyses focused on residents of IHS Contract Health Service Delivery Area (CHSDA) counties. Age-adjusted incidence and death rates were calculated for AI/AN and White women from 1999 to 2009.
Results. AI/AN women in CHSDA counties had a death rate from cervical cancer of 4.2, which was nearly twice the rate in White women (2.0; rate ratio [RR] = 2.11). AI/AN women also had higher incidence rates of cervical cancer compared with White women (11.0 vs 7.1; RR = 1.55) and were more often diagnosed with later-stage disease (RR = 1.84 for regional stage and RR = 1.74 for distant stage). Death rates decreased for AI/AN women from 1990 to 1993 (-25.8%/year) and remained stable thereafter.
Conclusions. Although rates decreased over time, AI/AN women had disproportionately higher cervical cancer incidence and mortality. The persistently higher rates among AI/AN women compared with White women require continued improvements in identifying and treating cervical cancer and precancerous lesions.
C1 [Watson, Meg; Benard, Vicki; Thomas, Cheryll; Brayboy, Annie] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Atlanta, GA USA.
[Paisano, Roberta] Indian Hlth Serv, Albuquerque, NM USA.
[Becker, Thomas] Oregon Hlth & Sci Univ, Sch Med, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
RP Watson, M (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy,MS-F76, Atlanta, GA 30341 USA.
EM EZE5@cdc.gov
NR 53
TC 11
Z9 11
U1 0
U2 2
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S415
EP S422
DI 10.2105/AJPH.2013.301681
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300025
PM 24754650
ER
PT J
AU White, A
Richardson, LC
Li, CY
Ekwueme, DU
Kaur, JS
AF White, Arica
Richardson, Lisa C.
Li, Chunyu
Ekwueme, Donatus U.
Kaur, Judith S.
TI Breast Cancer Mortality Among American Indian and Alaska Native Women,
1990-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID UNITED-STATES; RATES; DISPARITIES; SURVIVAL; PATTERNS; PROGRAM; TRENDS;
US
AB Objectives. We compared breast cancer death rates and mortality trends among American Indian/Alaska Native (AI/AN) and White women using data for which racial misclassification was minimized.
Methods. We used breast cancer deaths and cases linked to Indian Health Service (IHS) data to calculate age-adjusted rates and 95% confidence intervals (CIs) by IHS-designated regions from 1990 to 2009 for AI/AN and White women; Hispanics were excluded. Mortality-to-incidence ratios (MIR) were calculated for 1999 to 2009 as a proxy for prognosis after diagnosis.
Results. Overall, the breast cancer death rate was lower in AI/AN women (21.6 per 100 000) than in White women (26.5). However, rates in AI/ANs were higher than rates in Whites for ages 40 to 49 years in the Alaska region, and ages 65 years and older in the Southern Plains region. White death rates significantly decreased (annual percent change [APC] = -2.1; 95% CI = -2.3, -2.0), but regional and overall AI/AN rates were unchanged (APC = 0.9; 95% CI = 0.1, 1.7). AI/AN women had higher MIRs than White women.
Conclusions. There has been no improvement in death rates among AI/AN women. Targeted screening and timely, high-quality treatment are needed to reduce mortality from breast cancer in AI/AN women.
C1 [White, Arica; Richardson, Lisa C.; Li, Chunyu; Ekwueme, Donatus U.] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis & Hlth Promot, Atlanta, GA USA.
[Kaur, Judith S.] Mayo Clin, Rochester, MN USA.
RP White, A (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, 4770 Buford Hwy NE,Mailstop F76, Atlanta, GA 30341 USA.
EM awhite5@cdc.gov
NR 34
TC 8
Z9 8
U1 2
U2 4
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S432
EP S438
DI 10.2105/AJPH.2013.301720
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300027
PM 24754658
ER
PT J
AU White, MC
Espey, DK
Swan, J
Wiggins, CL
Eheman, C
Kaur, JS
AF White, Mary C.
Espey, David K.
Swan, Judith
Wiggins, Charles L.
Eheman, Christie
Kaur, Judith S.
TI Disparities in Cancer Mortality and Incidence Among American Indians and
Alaska Natives in the United States
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID EARLY-DETECTION PROGRAM; END RESULTS PROGRAM; TO-INCIDENCE RATIOS;
UNDERSERVED WOMEN; NATIONAL BREAST; SCREENING NEEDS; HEPATITIS-B;
HEALTH; SURVEILLANCE; POPULATION
AB Objectives. We used improved data on American Indian and Alaska Native (AI/AN) ancestry to provide an updated and comprehensive description of cancer mortality and incidence among AI/AN populations from 1990 to 2009.
Methods. We linked the National Death Index and central cancer registry records independently to the Indian Health Service (IHS) patient registration database to improve identification of AI/AN persons in cancer mortality and incidence data, respectively. Analyses were restricted to non-Hispanic persons residing in Contract Health Service Delivery Area counties in 6 geographic regions of the United States. We compared age-adjusted mortality and incidence rates for AI/AN populations with White populations using rate ratios and mortality-to-incidence ratios. Trends were described using joinpoint analysis.
Results. Cancer mortality and incidence rates for AI/AN persons compared with Whites varied by region and type of cancer. Trends in death rates showed that greater progress in cancer control was achieved for White populations compared with AI/AN populations over the last 2 decades.
Conclusions. Spatial variations in mortality and incidence by type of cancer demonstrated both persistent and emerging challenges for cancer control in AI/AN populations.
C1 [White, Mary C.; Espey, David K.; Eheman, Christie] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA.
[Swan, Judith] NCI, Surveillance Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Wiggins, Charles L.] Univ New Mexico, Ctr Canc, New Mexico Tumor Registry, Albuquerque, NM 87131 USA.
[Kaur, Judith S.] Mayo Clin, Native Amer Programs, Rochester, MN USA.
RP White, MC (reprint author), CDC, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, 4770 Buford Highway NE,F76, Atlanta, GA 30341 USA.
EM mxw5@cdc.gov
RI White, Mary /C-9242-2012
OI White, Mary /0000-0002-9826-3962
FU National Cancer Institute (NCI), National Institutes of Health
[HHSN261201000033C]; University of New Mexico Cancer Center
[P30-CA118100]
FX C. L. Wiggins received support under contract HHSN261201000033C from the
National Cancer Institute (NCI), National Institutes of Health and from
the University of New Mexico Cancer Center, as a recipient of NCI Cancer
Support Grant P30-CA118100.
NR 61
TC 27
Z9 27
U1 2
U2 9
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S377
EP S387
DI 10.2105/AJPH.2013.301673
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300021
PM 24754660
ER
PT J
AU Wong, CA
Gachupin, FC
Holman, RC
MacDorman, MF
Cheek, JE
Holve, S
Singleton, RJ
AF Wong, Charlene A.
Gachupin, Francine C.
Holman, Robert C.
MacDorman, Marian F.
Cheek, James E.
Holve, Steve
Singleton, Rosalyn J.
TI American Indian and Alaska Native Infant and Pediatric Mortality, United
States, 1999-2009
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID INFECTIOUS-DISEASE HOSPITALIZATIONS; AGED 0-19 YEARS; RISK-FACTORS;
RESPIRATORY-TRACT; POSTNEONATAL MORTALITY; UNINTENTIONAL INJURY;
DEATH-SYNDROME; SUBSTANCE USE; HEALTH; CHILDREN
AB Objectives. We described American Indian/Alaska Native (AI/AN) infant and pediatric death rates and leading causes of death.
Methods. We adjusted National Vital Statistics System mortality data for AI/AN racial misclassification by linkage with Indian Health Service (IHS) registration records. We determined average annual death rates and leading causes of death for 1999 to 2009 for AI/AN versus White infants and children. We limited the analysis to IHS Contract Health Service Delivery Area counties.
Results. The AI/AN infant death rate was 914 (rate ratio [RR] = 1.61; 95% confidence interval [CI] = 1.55, 1.67). Sudden infant death syndrome, unintentional injuries, and influenza or pneumonia were more common in AI/AN versus White infants. The overall AI/AN pediatric death rates were 69.6 for ages 1 to 4 years (RR = 2.56; 95% CI = 2.38, 2.75), 28.9 for ages 5 to 9 years (RR = 2.12; 95% CI = 1.92, 2.34), 37.3 for ages 10 to 14 years (RR = 2.22; 95% CI = 2.04, 2.40), and 158.4 for ages 15 to 19 years (RR = 2.71; 95% CI = 2.60, 2.82). Unintentional injuries and suicide occurred at higher rates among AI/AN youths versus White youths.
Conclusions. Death rates for AI/AN infants and children were higher than for Whites, with regional disparities. Several leading causes of death in the AI/AN pediatric population are potentially preventable.
C1 [Wong, Charlene A.] Univ Washington, Dept Pediat, Seattle Childrens Hosp, Seattle, WA 98195 USA.
[Gachupin, Francine C.] Univ Arizona, Coll Med, Dept Family & Community Med, Tucson, AZ USA.
[Holman, Robert C.] Ctr Dis Control & Prevent CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
[MacDorman, Marian F.] Natl Ctr Hlth Stat, Reprod Stat Branch, Div Vital Stat, Hyattsville, MD 20782 USA.
[Cheek, James E.] Univ New Mexico, Sch Med, Publ Hlth Program, Dept Family & Community Med, Albuquerque, NM 87131 USA.
[Holve, Steve] Tuba City Reg Healthcare Corp, Indian Hlth Serv, Tuba City, AZ USA.
[Singleton, Rosalyn J.] CDC, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA.
RP Wong, CA (reprint author), Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, 1303 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM charwong@upenn.edu
NR 70
TC 9
Z9 9
U1 1
U2 7
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2014
VL 104
SU 3
BP S320
EP S328
DI 10.2105/AJPH.2013.301598
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO5DL
UT WOS:000341362300014
PM 24754619
ER
PT J
AU Ponder-Brookins, P
Witt, J
Steward, J
Greenwell, D
Chew, GL
Samuel, Y
Kennedy, C
Brown, MJ
AF Ponder-Brookins, Paris
Witt, Joyce
Steward, John
Greenwell, Douglas
Chew, Ginger L.
Samuel, Yvette
Kennedy, Chinaro
Brown, Mary Jean
TI Incorporating Community-Based Participatory Research Principles Into
Environmental Health Research: Challenges and Lessons Learned From a
Housing Pilot Study
SO JOURNAL OF ENVIRONMENTAL HEALTH
LA English
DT Article
ID PARTNERSHIP; EXPOSURE; SEATTLE; PROJECT; ASTHMA; HOME
AB In environmental health research, a community-based participatory research (CBPR) approach can effectively involve community members, researchers, and representatives from nonprofit, academic, and governmental agencies as equal partners throughout the research process. The authors sought to use CBPR principles in a pilot study; its purpose was to investigate how green construction practices might affect indoor exposures to chemicals and biological agents. Information from this pilot informed the development of a methodology for a nationwide study of low-income urban multifamily housing. The authors describe here 1) the incorporation of CBPR principles into a pilot study comparing green vs. conventionally built urban housing, 2) the resulting implementation and reporting challenges, and 3) lessons learned and implications for increased community participation in environmental health research.
C1 [Ponder-Brookins, Paris; Witt, Joyce; Chew, Ginger L.; Kennedy, Chinaro; Brown, Mary Jean] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Steward, John] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30303 USA.
[Greenwell, Douglas] Atlanta Reg Hlth Forum, Atlanta, GA USA.
[Samuel, Yvette] ZAP Asthma, Atlanta, GA USA.
RP Ponder-Brookins, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D-29, Atlanta, GA 30333 USA.
EM fpd6@cdc.gov
NR 27
TC 1
Z9 1
U1 1
U2 4
PU NATL ENVIRON HEALTH ASSOC
PI DENVER
PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA
SN 0022-0892
J9 J ENVIRON HEALTH
JI J. Environ. Health
PD JUN
PY 2014
VL 76
IS 10
BP 8
EP 17
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AO7NU
UT WOS:000341540700002
PM 24988659
ER
PT J
AU Anderson, DJ
Podgorny, K
Berrios-Torres, SI
Bratzler, DW
Dellinger, EP
Greene, L
Nyquist, AC
Saiman, L
Yokoe, DS
Maragakis, LL
Kaye, KS
AF Anderson, Deverick J.
Podgorny, Kelly
Berrios-Torres, Sandra I.
Bratzler, Dale W.
Dellinger, E. Patchen
Greene, Linda
Nyquist, Ann-Christine
Saiman, Lisa
Yokoe, Deborah S.
Maragakis, Lisa L.
Kaye, Keith S.
TI Strategies to Prevent Surgical Site Infections in Acute Care Hospitals:
2014 Update
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; RANDOMIZED CONTROLLED-TRIAL; STERNAL
WOUND INFECTIONS; GENTAMICIN-COLLAGEN SPONGE; BYPASS GRAFT-SURGERY;
SUPPLEMENTAL PERIOPERATIVE OXYGEN; TOTAL PARENTERAL-NUTRITION;
TRICLOSAN-COATED SUTURES; TOTAL HIP-ARTHROPLASTY; OPEN-HEART-SURGERY
C1 [Anderson, Deverick J.] Duke Univ, Med Ctr, Durham, NC 27710 USA.
[Podgorny, Kelly] Int Joint Commiss, Oak Brook Terrace, IL USA.
[Berrios-Torres, Sandra I.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Bratzler, Dale W.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Dellinger, E. Patchen] Univ Washington, Med Ctr, Seattle, WA 98195 USA.
[Greene, Linda] Highland Hosp, Rochester, NY USA.
[Greene, Linda] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Nyquist, Ann-Christine] Childrens Hosp Colorado, Aurora, CO USA.
[Nyquist, Ann-Christine] Univ Colorado, Sch Med, Aurora, CO USA.
[Saiman, Lisa] Columbia Univ, Med Ctr, New York, NY USA.
[Yokoe, Deborah S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Yokoe, Deborah S.] Harvard Univ, Sch Med, Boston, MA USA.
[Maragakis, Lisa L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Kaye, Keith S.] Detroit Med Ctr, Detroit, MI USA.
[Kaye, Keith S.] Wayne State Univ, Detroit, MI USA.
RP Anderson, DJ (reprint author), Duke Univ, Med Ctr, Div Infect Dis, Box 102359, Durham, NC 27710 USA.
EM deverick.anderson@duke.edu
FU Tetraphase; Sage Products
FX E.P.D. reports serving as an advisor/consultant for Merck, Baxter,
Ortho-McNeil, Targanta, Rib-X, Affinium, 3M, Schering-Plough, Astellas,
CareFusion, Durata, Pfizer, and Applied Medical and receiving grant
support from Tetraphase. L.G. reports receiving honoraria from Premier,
CareFusion, and Infection Control Today. K.S.K. reports receiving grant
support and serving as an advisor/consultant for Sage Products. D.J.A.,
K.P., D.W.B., S.I.B.-T., A.-C.N., L.L.M., L.S., and D.S.Y. report no
relevant conflicts of interest.
NR 233
TC 0
Z9 0
U1 1
U2 7
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD JUN 1
PY 2014
VL 35
IS 6
BP 605
EP 627
DI 10.1086/676022
PG 23
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AG8UK
UT WOS:000335693500001
ER
PT J
AU Dubberke, ER
Carling, P
Carrico, R
Donskey, CJ
Loo, VG
McDonald, LC
Maragakis, LL
Sandora, TJ
Weber, DJ
Yokoe, DS
Gerding, DN
AF Dubberke, Erik R.
Carling, Philip
Carrico, Ruth
Donskey, Curtis J.
Loo, Vivian G.
McDonald, L. Clifford
Maragakis, Lisa L.
Sandora, Thomas J.
Weber, David J.
Yokoe, Deborah S.
Gerding, Dale N.
TI Strategies to Prevent Clostridium difficile Infections in Acute Care
Hospitals: 2014 Update
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; HIGH-RISK ANTIBIOTICS; ENVIRONMENTAL
CONTAMINATION; HYPOCHLORITE SOLUTION; COLONIZED PATIENTS; CONTACT
ISOLATION; TOXIN PRODUCTION; ISOLATION ROOMS; UNITED-STATES;
NORTH-AMERICA
C1 [Dubberke, Erik R.] Washington Univ, Sch Med, St Louis, MO 63110 USA.
[Carling, Philip] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Carrico, Ruth] Univ Louisville, Sch Med, Div Infect Dis, Louisville, KY 40292 USA.
[Donskey, Curtis J.] Case Western Reserve Univ, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA.
[Loo, Vivian G.] McGill Univ, McGill Univ Hlth Ctr, Montreal, PQ, Canada.
[McDonald, L. Clifford] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA.
[Maragakis, Lisa L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Sandora, Thomas J.] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA USA.
[Weber, David J.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Yokoe, Deborah S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Yokoe, Deborah S.] Harvard Univ, Sch Med, Boston, MA USA.
[Gerding, Dale N.] Edward Hines Jr Vet Affairs Hosp, Hines, IL USA.
[Gerding, Dale N.] Loyola Univ, Stritch Sch Med, Chicago, IL 60611 USA.
RP Dubberke, ER (reprint author), Washington Univ, Sch Med, 660 South Euclid Ave,Box 8051, St Louis, MO 63110 USA.
EM edubberk@dom.wustl.edu
FU Sanofi Pasteur; ViroPharma; Optimer; Merck; Rebiotix; Steris; Pfizer;
GOJO Industries
FX E.R.D. reports serving as an advisor/consultant for Sanofi Pasteur,
Merck, and Pfizer and receiving research grants/contracts from Sanofi
Pasteur, ViroPharma, Optimer, Merck, and Rebiotix. P.C. reports serving
as an advisor/consultant for Steris and holding a
patent/copyright/license with Ecolab. R.C. reports serving on the
speakers' bureau for Sanofi Pasteur, MedImmune, Abbott Diabetes Care,
and 3M; performing technical writing for Ketchum; and receiving research
grants/contracts from Sanofi Pasteur. C.J.D. reports serving as an
advisor/consultant for Steris, GOJO Industries, and 3M; receiving
honoraria from Ecolab; and receiving research grants/contracts from
Merck, ViroPharma, Steris, and Pfizer. V.G.L. reports serving as an
advisor/consultant for Optimer Pharmaceuticals. D.J.W. reports serving
as an advisor/consultant for Johnson & Johnson and Clorox. D.N.G.
reports serving as an advisor/consultant for Merck, Cubist, Novartis,
Cangene, Actelion, ViroPharma, Rebiotix, and Sanofi Pasteur; receiving
honoraria from Robert Michael; holding a patent/license (no royalties)
with ViroPharma; and receiving research grant/contracts from GOJO
Industries. L.C.M., L.L.M., T.J.S., and D.S.Y. report no conflicts of
interest.
NR 122
TC 0
Z9 0
U1 2
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD JUN 1
PY 2014
VL 35
IS 6
BP 628
EP 645
DI 10.1086/676023
PG 18
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AG8UK
UT WOS:000335693500002
ER
PT J
AU Sanchez, GV
Hicks, LA
AF Sanchez, Guillermo V.
Hicks, Lauri A.
TI Acute Sinusitis and Pharyngitis as Inappropriate Indications for
Antibiotic Use
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Letter
ID CLINICAL-PRACTICE GUIDELINE; RHINOSINUSITIS; CHILDREN; ADULTS
C1 [Sanchez, Guillermo V.; Hicks, Lauri A.] Ctr Dis Control & Prevent, Get Smart Know Antibiot Work Program, Atlanta, GA 30333 USA.
RP Sanchez, GV (reprint author), Ctr Dis Control & Prevent, Get Smart Know Antibiot Work Program, Atlanta, GA 30333 USA.
EM xkv4@cdc.gov
NR 4
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2014
VL 58
IS 6
BP 3572
EP 3572
DI 10.1128/AAC.02696-14
PG 1
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AK9VP
UT WOS:000338776900081
PM 24829387
ER
PT J
AU Stoddard, RA
Quinn, CP
Schiffer, JM
Boyer, AE
Goldstein, J
Bagarozzi, DA
Soroka, SD
Dauphin, LA
Hoffmaster, AR
AF Stoddard, Robyn A.
Quinn, Conrad P.
Schiffer, Jarad M.
Boyer, Anne E.
Goldstein, Jason
Bagarozzi, Dennis A.
Soroka, Stephen D.
Dauphin, Leslie A.
Hoffmaster, Alex R.
TI Detection of anthrax protective antigen (PA) using europium labeled
anti-PA monoclonal antibody and time-resolved fluorescence
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE Bacillus anthracis; Protective antigen; Anthrax toxin; Europium;
Immunoassays; Time resolved fluorescence
ID LINKED-IMMUNOSORBENT-ASSAY; INHALATION ANTHRAX; LETHAL FACTOR;
BACILLUS-ANTHRACIS; MASS-SPECTROMETRY; IMMUNOGLOBULIN-G; TOXIN; MODEL;
BINDING; MARKER
AB Inhalation anthrax is a rare but acute infectious disease following adsorption of Bacillus anthracis spores through the lungs. The disease has a high fatality rate if untreated, but early and correct diagnosis has a significant impact on case patient recovery. The early symptoms of inhalation anthrax are, however, non-specific and current anthrax diagnostics are primarily dependent upon culture and confirmatory real-time PCR. Consequently, there may be a significant delay in diagnosis and targeted treatment. Rapid, culture-independent diagnostic tests are therefore needed, particularly in the context of a large scale emergency response.
The aim of this study was to evaluate the ability of monoclonal antibodies to detect anthrax toxin proteins that are secreted early in the course of B. anthracis infection using a time-resolved fluorescence (TRF) immunoassay. We selected monoclonal antibodies that could detect protective antigen (PA), as PA83 and also PA63 and LF in the lethal toxin complex. The assay reliable detection limit (RDL) was 6.63 x 10(-6) mu M (0.551 ng/ml) for PA83 and 2.51 x 10(-5) mu M (1.58 ng/ml) for PA63. Despite variable precision and accuracy of the assay, PA was detected in 9 out of 10 sera samples from anthrax confirmed case patients with cutaneous (n = 7), inhalation (n = 2), and gastrointestinal (n = 1) disease. Anthrax Immune Globulin (AIG), which has been used in treatment of clinical anthrax, interfered with detection of PA. This study demonstrates a culture-independent method of diagnosing anthrax through the use of monoclonal antibodies to detect PA and LF in the lethal toxin complex. Published by Elsevier B.V.
C1 [Stoddard, Robyn A.; Quinn, Conrad P.; Schiffer, Jarad M.; Boyer, Anne E.; Goldstein, Jason; Bagarozzi, Dennis A.; Soroka, Stephen D.; Dauphin, Leslie A.; Hoffmaster, Alex R.] CDC, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Stoddard, RA (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Bacterial Special Pathogens Branch, Zoonoses & Select Agent Lab, Mail Stop G-34,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM RAStoddard@cdc.gov
FU Biomedical Advanced Research and Development Authority (BARDA)
FX The authors would like to thank Hanan Dababneh, Panagiotis Maniatis,
Maribel Gallegos Candela, Renato C. Lins, and John R. Barr for their
assistance with sample testing and reagent acquisition; Todd Parker and
Elke Saile for their technical assistance; and Yon Yu for reviewing the
manuscript. A portion of this work was funded by a Biomedical Advanced
Research and Development Authority (BARDA) interagency agreement.
NR 29
TC 6
Z9 6
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD JUN
PY 2014
VL 408
BP 78
EP 88
DI 10.1016/j.jim.2014.05.008
PG 11
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA AM0JU
UT WOS:000339532700009
PM 24857756
ER
PT J
AU Savic, RM
Lu, YH
Bliven-Sizemore, E
Weiner, M
Nuermberger, E
Burman, W
Dorman, SE
Dooley, KE
AF Savic, Radojka M.
Lu, Yanhui
Bliven-Sizemore, Erin
Weiner, Marc
Nuermberger, Eric
Burman, William
Dorman, Susan E.
Dooley, Kelly E.
TI Population Pharmacokinetics of Rifapentine and Desacetyl Rifapentine in
Healthy Volunteers: Nonlinearities in Clearance and Bioavailability
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID PULMONARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; BACTERICIDAL
ACTIVITY; RIFAMPIN; MODEL; DISPOSITION; METABOLISM; ABSORPTION;
RIFAMYCINS; MG
AB Rifapentine is under active investigation as a potent drug that may help shorten the tuberculosis (TB) treatment duration. A previous rifapentine dose escalation study with daily dosing indicated a possible decrease in bioavailability as the dose increased and an increase in clearance over time for rifapentine and its active metabolite, desacetyl rifapentine. This study aimed to assess the effects of increasing doses on rifapentine absorption and bioavailability and to evaluate the clearance changes over 14 days. A population analysis was performed with nonlinear mixed-effects modeling. Absorption, time-varying clearance, bioavailability, and empirical and semimechanistic autoinduction models were investigated. A one-compartment model linked to a transit compartment absorption model best described the data. The bioavailability of rifapentine decreased linearly by 2.5% for each 100-mg increase in dose. The autoinduction model suggested a dose-independent linear increase in clearance of the parent drug and metabolite over time from 1.2 and 3.1 liters.h(-1), respectively, after a single dose to 2.2 and 5.0 liters.h(-1), respectively, after 14 once-daily doses, with no plateau being reached by day 14. In clinical trial simulations using the final model, rifapentine demonstrated less-than-dose-proportional pharmacokinetics, but there was no plateau in exposures over the dose range tested (450 to 1,800 mg), and divided dosing increased exposures significantly. Thus, the proposed compartmental model incorporating daily dosing of rifapentine over a wide range of doses and time-related changes in bioavailability and clearance provides a useful tool for estimation of drug exposure that can be used to optimize rifapentine dosing for TB treatment.
C1 [Savic, Radojka M.] UCSF, Sch Pharm Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
[Lu, Yanhui; Nuermberger, Eric; Dorman, Susan E.; Dooley, Kelly E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Bliven-Sizemore, Erin] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA.
[Weiner, Marc] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Weiner, Marc] VAMC, San Antonio, TX USA.
[Burman, William] Denver Publ Hlth, Denver, CO USA.
RP Savic, RM (reprint author), UCSF, Sch Pharm Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
EM Rada.Savic@ucsf.edu
FU Tuberculosis Trials Consortium (TBTC) of the Centers for Disease Control
and Prevention (CDC); UCSF-CTSI [KL2 TR000143-07]; [K23AI080842]
FX We acknowledge the Tuberculosis Trials Consortium (TBTC) of the Centers
for Disease Control and Prevention (CDC) for its support of this
secondary analysis of TBTC study 29B data. Support was also provided by
K23AI080842 (to K. E. D.) and UCSF-CTSI grant number KL2 TR000143-07 (to
R.M.S.).
NR 29
TC 6
Z9 6
U1 0
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2014
VL 58
IS 6
BP 3035
EP 3042
DI 10.1128/AAC.01918-13
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AK9VP
UT WOS:000338776900006
PM 24614383
ER
PT J
AU Flint, M
McMullan, LK
Dodd, KA
Bird, BH
Khristova, ML
Nichol, ST
Spiropoulou, CF
AF Flint, Mike
McMullan, Laura K.
Dodd, Kimberly A.
Bird, Brian H.
Khristova, Marina L.
Nichol, Stuart T.
Spiropoulou, Christina F.
TI Inhibitors of the Tick-Borne, Hemorrhagic Fever-Associated Flaviviruses
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HEPATITIS-C VIRUS; WEST-NILE-VIRUS; KYASANUR-FOREST-DISEASE; ANTIVIRAL
COMPOUNDS; RNA-POLYMERASE; PROTEASE INHIBITORS; NUCLEOSIDE ANALOGS;
REPLICON CELLS; DENGUE VIRUS; REPLICATION
AB No antiviral therapies are available for the tick-borne flaviviruses associated with hemorrhagic fevers: Kyasanur Forest disease virus (KFDV), both classical and the Alkhurma hemorrhagic fever virus (AHFV) subtype, and Omsk hemorrhagic fever virus (OHFV). We tested compounds reported to have antiviral activity against members of the Flaviviridae family for their ability to inhibit AHFV replication. 6-Azauridine (6-azaU), 2'-C-methylcytidine (2'-CMC), and interferon alpha 2a (IFN-alpha 2a) inhibited the replication of AHFV and also KFDV, OHFV, and Powassan virus. The combination of IFN-alpha 2a and 2'-CMC exerted an additive antiviral effect on AHFV, and the combination of IFN-alpha 2a and 6-azaU was moderately synergistic. The combination of 2'-CMC and 6-azaU was complex, being strongly synergistic but with a moderate level of antagonism. The antiviral activity of 6-azaU was reduced by the addition of cytidine but not guanosine, suggesting that it acted by inhibiting pyrimidine biosynthesis. To investigate the mechanism of action of 2'-CMC, AHFV variants with reduced susceptibility to 2'-CMC were selected. We used a replicon system to assess the substitutions present in the selected AHFV population. A double NS5 mutant, S603T/C666S, and a triple mutant, S603T/C666S/M644V, were more resistant to 2'-CMC than the wild-type replicon. The S603T/C666S mutant had a reduced level of replication which was increased when M644V was also present, although the replication of this triple mutant was still below that of the wild type. The S603 and C666 residues were predicted to lie in the active site of the AHFV NS5 polymerase, implicating the catalytic center of the enzyme as the binding site for 2'-CMC.
C1 [Flint, Mike; McMullan, Laura K.; Dodd, Kimberly A.; Bird, Brian H.; Khristova, Marina L.; Nichol, Stuart T.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
[Dodd, Kimberly A.] Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA.
RP Spiropoulou, CF (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
EM ccs8@cdc.gov
OI Flint, Michael/0000-0002-5373-787X
NR 48
TC 9
Z9 9
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2014
VL 58
IS 6
BP 3206
EP 3216
DI 10.1128/AAC.02393-14
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AK9VP
UT WOS:000338776900028
PM 24663025
ER
PT J
AU Marinucci, GD
Luber, G
Uejio, CK
Saha, S
Hess, JJ
AF Marinucci, Gino D.
Luber, George
Uejio, Christopher K.
Saha, Shubhayu
Hess, Jeremy J.
TI Building Resilience against Climate Effects-A Novel Framework to
Facilitate Climate Readiness in Public Health Agencies
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE adaptation; climate change; public health agency; public health;
resilience
ID HEAT-RELATED MORTALITY; TIME-SERIES; DECISION-MAKING; CASE-CROSSOVER;
UNITED-STATES; VULNERABILITY; ADAPTATION; LESSONS; RISKS; INTERVENTIONS
AB Climate change is anticipated to have several adverse health impacts. Managing these risks to public health requires an iterative approach. As with many risk management strategies related to climate change, using modeling to project impacts, engaging a wide range of stakeholders, and regularly updating models and risk management plans with new information-hallmarks of adaptive management-are considered central tenets of effective public health adaptation. The Centers for Disease Control and Prevention has developed a framework, entitled Building Resilience Against Climate Effects, or BRACE, to facilitate this process for public health agencies. Its five steps are laid out here. Following the steps laid out in BRACE will enable an agency to use the best available science to project likely climate change health impacts in a given jurisdiction and prioritize interventions. Adopting BRACE will also reinforce public health's established commitment to evidence-based practice and institutional learning, both of which will be central to successfully engaging the significant new challenges that climate change presents.
C1 [Marinucci, Gino D.; Luber, George; Uejio, Christopher K.; Saha, Shubhayu; Hess, Jeremy J.] Ctr Dis Control & Prevent, Climate & Hlth Program, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
[Uejio, Christopher K.] Florida State Univ, Dept Geog, Tallahassee, FL 32306 USA.
[Hess, Jeremy J.] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA.
[Hess, Jeremy J.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA.
RP Hess, JJ (reprint author), Ctr Dis Control & Prevent, Climate & Hlth Program, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
EM ipx1@cdc.gov; gcl4@cdc.gov; cuejio@fsu.edu; hsf5@cdc.gov;
jhess@emory.edu
NR 100
TC 9
Z9 9
U1 3
U2 13
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUN
PY 2014
VL 11
IS 6
BP 6433
EP 6458
DI 10.3390/ijerph110606433
PG 26
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AK8FL
UT WOS:000338662600055
PM 24991665
ER
PT J
AU Dodd, KA
McElroy, AK
Jones, TL
Zaki, SR
Nichol, ST
Spiropoulou, CF
AF Dodd, Kimberly A.
McElroy, Anita K.
Jones, Tara L.
Zaki, Sherif R.
Nichol, Stuart T.
Spiropoulou, Christina F.
TI Rift Valley Fever Virus Encephalitis Is Associated with an Ineffective
Systemic Immune Response and Activated T Cell Infiltration into the CNS
in an Immunocompetent Mouse Model
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; NSS PROTEIN; JAPANESE
ENCEPHALITIS; INTRANASAL INFECTION; NEUROLOGIC DISEASE; MURINE MODEL;
MICE; TRANSCRIPTION; CHALLENGE
AB Background: Rift Valley fever virus (RVFV) causes outbreaks of severe disease in livestock and humans throughout Africa and the Arabian Peninsula. In people, RVFV generally causes a self-limiting febrile illness but in a subset of individuals, it progresses to more serious disease. One manifestation is a delayed-onset encephalitis that can be fatal or leave the afflicted with long-term neurologic sequelae. In order to design targeted interventions, the basic pathogenesis of RVFV encephalitis must be better understood.
Methodology/Principal Findings: To characterize the host immune responses and viral kinetics associated with fatal and nonfatal infections, mice were infected with an attenuated RVFV lacking NSs (Delta NSs) that causes lethal disease only when administered intranasally (IN). Following IN infection, C57BL/6 mice developed severe neurologic disease and succumbed 7-9 days post-infection. In contrast, inoculation of Delta NSs virus subcutaneously in the footpad (FP) resulted in a subclinical infection characterized by a robust immune response with rapid antibody production and strong T cell responses. IN-inoculated mice had delayed antibody responses and failed to clear virus from the periphery. Severe neurological signs and obtundation characterized end stage-disease in IN-inoculated mice, and within the CNS, the development of peak virus RNA loads coincided with strong proinflammatory responses and infiltration of activated T cells. Interestingly, depletion of T cells did not significantly alter survival, suggesting that neurologic disease is not a by-product of an aberrant immune response.
Conclusions/Significance: Comparison of fatal (IN-inoculated) and nonfatal (FP-inoculated) DNSs RVFV infections in the mouse model highlighted the role of the host immune response in controlling viral replication and therefore determining clinical outcome. There was no evidence to suggest that neurologic disease is immune-mediated in RVFV infection. These results provide important insights for the future design of vaccines and therapeutic options.
C1 [Dodd, Kimberly A.; McElroy, Anita K.; Nichol, Stuart T.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
[Dodd, Kimberly A.] Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA.
[McElroy, Anita K.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
[Jones, Tara L.; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA.
RP Dodd, KA (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
EM ccs8@cdc.gov
FU Pediatric Infectious Disease Society-St. Jude Fellowship award; Atlanta
Pediatric Scholars Program; NIH
FX AKM is supported by the Pediatric Infectious Disease Society-St. Jude
Fellowship award and the Atlanta Pediatric Scholars Program, and is also
the recipient of an NIH loan repayment award. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 48
TC 10
Z9 10
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2014
VL 8
IS 6
AR e2874
DI 10.1371/journal.pntd.0002874
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AL0VW
UT WOS:000338846100017
PM 24922480
ER
PT J
AU Ahn, KW
Kosoy, M
Chan, KS
AF Ahn, Kwang Woo
Kosoy, Michael
Chan, Kung-Sik
TI An approach for modeling cross-immunity of two strains, with application
to variants of Bartonella in terms of genetic similarity
SO EPIDEMICS
LA English
DT Article
DE Bartonella; Conditional least squares; Cross-immunity; SIR model
ID CITRATE SYNTHASE GENE; INFLUENZA; POPULATION; DYNAMICS; RODENTS
AB We developed a two-strain susceptible-infected-recovered (SIR) model that provides a framework for inferring the cross-immunity between two strains of a bacterial species in the host population with discretely sampled co-infection time-series data. Moreover, the model accounts for seasonality in host reproduction. We illustrate an approach using a dataset describing co-infections by several strains of bacteria circulating within a population of cotton rats (Sigmodon hispidus). Bartonella strains were clustered into three genetically close groups, between which the divergence is correspondent to the accepted level of separate bacterial species. The proposed approach revealed no cross-immunity between genetic clusters while limited cross-immunity might exist between subgroups within the clusters. (C) 2014 Published by Elsevier B.V.
C1 [Ahn, Kwang Woo] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA.
[Kosoy, Michael] Ctr Dis Control & Prevent, Ft Collins, CO USA.
[Chan, Kung-Sik] Univ Iowa, Dept Stat & Actuarial Sci, Iowa City, IA 52242 USA.
RP Ahn, KW (reprint author), Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA.
EM kwooahn@mcw.edu; mck3@cdc.gov; kung-sik-chan@uiowa.edu
FU U.S. National Science Foundation [DMS-1021896]
FX This work was partially supported by the U.S. National Science
Foundation (DMS-1021896). The authors would like to thank Dr. Jennifer
Le-Rademacher and two anonymous reviewers for their helpful comments and
suggestions, which significantly improved the manuscript and Mr. Franco
Mendolia for his computational assistance.
NR 23
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1755-4365
J9 EPIDEMICS-NETH
JI Epidemics
PD JUN
PY 2014
VL 7
BP 7
EP 12
DI 10.1016/j.epidem.2014.03.001
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA AK8UU
UT WOS:000338704900002
PM 24928664
ER
PT J
AU Spears, DR
McNeil, C
Warnock, E
Trapp, J
Oyinloye, O
Whitehurst, V
Decker, KC
Chapman, S
Campbell, M
Meechan, P
AF Spears, D. Ross
McNeil, Carrie
Warnock, Eli
Trapp, Jonathan
Oyinloye, Oluremi
Whitehurst, Vanessa
Decker, K. C.
Chapman, Sandy
Campbell, Morris
Meechan, Paul
TI Predicting Temporal Trends in Total Absenteeism Rates for Civil Service
Employees of a Federal Public Health Agency
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID SICKNESS ABSENCE; LEAVE
AB Objective: This study evaluates the predictability in temporal absences trends due to all causes (total absenteeism) among employees at a federal agency. The objective is to determine how leave trends vary within the year, and determine whether trends are predictable. Methods: Ten years of absenteeism data from an attendance system were analyzed for rates of total absence. Results: Trends over a 10-year period followed predictable and regular patterns during a given year that correspond to major holiday periods. Temporal trends in leave among small, medium, and large facilities compared favorably with the agency as a whole. Conclusions: Temporal trends in total absenteeism rates for an organization can be determined using its attendance system. The ability to predict employee absenteeism rates can be extremely helpful for management in optimizing business performance and ensuring that an organization meets its mission.
C1 [Spears, D. Ross; McNeil, Carrie; Warnock, Eli; Meechan, Paul] Ctr Dis Control & Prevent, Environm Safety & Hlth Compliance Off, Atlanta, GA 30333 USA.
[Trapp, Jonathan] Ctr Dis Control & Prevent, Off Safety Secur & Asset Management, Atlanta, GA 30333 USA.
[Oyinloye, Oluremi; Whitehurst, Vanessa; Decker, K. C.] Booz Allen & Hamilton Inc, Mclean, VA 22102 USA.
[Chapman, Sandy] Ctr Dis Control & Prevent, Program Grants Off, Atlanta, GA 30333 USA.
[Campbell, Morris] Ctr Dis Control & Prevent, Management Syst Informat Off, Atlanta, GA 30333 USA.
RP Spears, DR (reprint author), Ctr Dis Control & Prevent, US Publ Hlth Serv, 1600 Clifton Rd NE,MS F-05, Atlanta, GA 30333 USA.
EM ava3@cdc.gov
FU Centers for Disease Control and Prevention, Atlanta, Georgia
FX Source of funding is the Centers for Disease Control and Prevention,
Atlanta, Georgia.
NR 21
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-2752
EI 1536-5948
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD JUN
PY 2014
VL 56
IS 6
BP 632
EP 638
DI 10.1097/JOM.0000000000000155
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AK9PX
UT WOS:000338760100011
PM 24854256
ER
PT J
AU Greer, S
Kramer, MR
Cook-Smith, JN
Casper, ML
AF Greer, Sophia
Kramer, Michael R.
Cook-Smith, Jessica N.
Casper, Michele L.
TI Metropolitan Racial Residential Segregation and Cardiovascular
Mortality: Exploring Pathways
SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE
LA English
DT Article
DE Residential segregation; Racial segregation; Metropolitan; Heart
disease; Stroke; Cardiovascular disease; Social context; Economic
context
ID SOCIAL-DISORGANIZATION THEORY; STROKE MORTALITY; DISPARITIES; HEALTH;
DIRECTIONS; DISEASE; BLACKS; WHITES; POLICY; CARE
AB Racial residential segregation has been associated with an increased risk for heart disease and stroke deaths. However, there has been little research into the role that candidate mediating pathways may play in the relationship between segregation and heart disease or stroke deaths. In this study, we examined the relationship between metropolitan statistical area (MSA)-level segregation and heart disease and stroke mortality rates, by age and race, and also estimated the effects of various educational, economic, social, and health-care indicators (which we refer to as pathways) on this relationship. We used Poisson mixed models to assess the relationship between the isolation index in 265 U.S. MSAs and county-level (heart disease, stroke) mortality rates. All models were stratified by race (non-Hispanic black, non-Hispanic white), age group (35-64 years, a parts per thousand yen65 years), and cause of death (heart disease, stroke). We included each potential pathway in the model separately to evaluate its effect on the segregation-mortality association. Among blacks, segregation was positively associated with heart disease mortality rates in both age groups but only with stroke mortality rates in the older age group. Among whites, segregation was marginally associated with heart disease mortality rates in the younger age group and was positively associated with heart disease mortality rates in the older age group. Three of the potential pathways we explored attenuated relationships between segregation and mortality rates among both blacks and whites: percentage of female-headed households, percentage of residents living in poverty, and median household income. Because the percentage of female-headed households can be seen as a proxy for the extent of social disorganization, our finding that it has the greatest attenuating effect on the relationship between racial segregation and heart disease and stroke mortality rates suggests that social disorganization may play a strong role in the elevated rates of heart disease and stroke found in racially segregated metropolitan areas.
C1 [Greer, Sophia; Casper, Michele L.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA.
[Kramer, Michael R.; Cook-Smith, Jessica N.] Emory Univ, Atlanta, GA 30322 USA.
RP Greer, S (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy NE,MS F-72, Atlanta, GA 30341 USA.
EM sgreer@cdc.gov
FU Research Participation Program at CDC
FX Dr. Kramer was supported in part by the Research Participation Program
at CDC administered by the Oak Ridge Institute of Science and Education.
NR 31
TC 1
Z9 1
U1 3
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1099-3460
EI 1468-2869
J9 J URBAN HEALTH
JI J. Urban Health
PD JUN
PY 2014
VL 91
IS 3
BP 499
EP 509
DI 10.1007/s11524-013-9834-7
PG 11
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AK8HI
UT WOS:000338667900008
PM 24154933
ER
PT J
AU Shurin, MR
Yanamala, N
Kisin, ER
Tkach, AV
Shurin, GV
Murray, AR
Leonard, HD
Reynolds, JS
Gutkin, DW
Star, A
Fadeel, B
Savolainen, K
Kagan, VE
Shvedova, AA
AF Shurin, Michael R.
Yanamala, Naveena
Kisin, Elena R.
Tkach, Alexey V.
Shurin, Galina V.
Murray, Ashley R.
Leonard, Howard D.
Reynolds, Jeffrey S.
Gutkin, Dmirtiy W.
Star, Alexander
Fadeel, Bengt
Savolainen, Kai
Kagan, Valerian E.
Shvedova, Anna A.
TI Graphene Oxide Attenuates Th2-Type Immune Responses, but Augments Airway
Remodeling and Hyperresponsiveness in a Murine Model of Asthma
SO ACS NANO
LA English
DT Article
DE Th2 responses; macrophage activation; IgE-independent AHR; chitinases
ID CHITINASE-LIKE PROTEIN; ACIDIC MAMMALIAN CHITINASE; MULTIWALLED CARBON
NANOTUBES; INDUCED TOXICITY FOCUS; EPITHELIAL-CELLS; DIFFERENTIAL
EXPRESSION; ACTIVATED MACROPHAGES; SIGNALING PATHWAYS; PRISTINE
GRAPHENE; BRONCHIAL-ASTHMA
AB Several lines of evidence indicate that exposure to nanoparticles (NPs) is able to modify airway immune responses, thus facilitating the development of respiratory diseases. Graphene oxide (GO) is a promising carbonaceous nanomaterial with unique physicochemical properties, envisioned for a multitude of medical and industrial applications. In this paper, we determined how exposure to GO modulates the allergic pulmonary response. Using a murine model of ovalbumin (OVA)-induced asthma, we revealed that GO, given at the sensitization stage, augmented airway hyperresponsiveness and airway remodeling in the form of goblet cell hyperplasia and smooth muscle hypertrophy. At the same time, the levels of the cytokines IL-4, IL-5, and IL-13 were reduced in broncho-alveolar lavage (BAL) fluid in GO-exposed mice. Exposure to GO during sensitization with OVA decreased eosinophil accumulation and increased recruitment of macrophages in BAL fluid. In line with the cytokine profiles, sensitization with OVA in the presence of GO stimulated the production of OVA-specific IgG2a and down-regulated the levels of IgE and IgG1. Moreover, exposure to GO increased the macrophage production of the mammalian chitinases, CHI3L1 and AMCase, whose expression is associated with asthma. Finally, molecular modeling has suggested that GO may directly interact with chitinase, affecting AMCase activity, which has been directly proven in our studies. Thus, these data show that GO exposure attenuates Th2 immune response in a model of OVA-induced asthma, but leads to potentiation of airway remodeling and hyperresponsiveness, with the induction of mammalian chitinases.
C1 [Shurin, Michael R.; Shurin, Galina V.; Gutkin, Dmirtiy W.] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15260 USA.
[Yanamala, Naveena; Kisin, Elena R.; Tkach, Alexey V.; Murray, Ashley R.; Leonard, Howard D.; Reynolds, Jeffrey S.; Shvedova, Anna A.] NIOSH, Pathol & Physiol Res Branch, CDC, Morgantown, WV 26505 USA.
[Star, Alexander] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA.
[Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA.
[Fadeel, Bengt] Karolinska Inst, Inst Environm Med, Div Mol Toxicol, S-17177 Stockholm, Sweden.
[Savolainen, Kai] Finnish Inst Occupat Hlth, Nanosafety Res Ctr, Helsinki 02500, Finland.
[Shvedova, Anna A.] W Virginia Univ, Dept Physiol & Pharmacol, Morgantown, WV 26505 USA.
RP Shvedova, AA (reprint author), NIOSH, Pathol & Physiol Res Branch, CDC, Morgantown, WV 26505 USA.
EM ats1@cdc.gov
FU NIOSH [OH008282]; NORA [0HELD015]; EC-FP-7-NANOSOLUTIONS; NIEHS
[R01ES019304]
FX This work was supported by NIOSH OH008282, NORA 0HELD015,
EC-FP-7-NANOSOLUTIONS, and NIEHS R01ES019304. The authors are grateful
to M. Farcas, M. Hatfield, S. Stanley, A. Cumpston, J. Cumpston, and D.
Schwegler-Berry for the technical assistance.
NR 68
TC 11
Z9 12
U1 6
U2 29
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD JUN
PY 2014
VL 8
IS 6
BP 5585
EP 5599
DI 10.1021/nn406454u
PG 15
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AK0FV
UT WOS:000338089200023
PM 24847914
ER
PT J
AU Yadav, K
Mathur, G
Ford, B
Miller, R
AF Yadav, K.
Mathur, G.
Ford, B.
Miller, R.
CA CDC Working Grp
TI A Case Cluster of Lymphocytic Choriomeningitis Virus Transmitted Via
Organ Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Yadav, K.; Mathur, G.; Ford, B.; Miller, R.] Univ Iowa, Carver Coll Med, Iowa City, IA USA.
[CDC Working Grp] Ctr Dis Control, Atlanta, GA 30333 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2381
BP 768
EP 768
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303389
ER
PT J
AU Guy, GP
Yabroff, KR
Ekwueme, DU
Smith, AW
Dowling, EC
Rechis, R
Nutt, S
Richardson, LC
AF Guy, Gery P., Jr.
Yabroff, K. Robin
Ekwueme, Donatus U.
Smith, Ashley Wilder
Dowling, Emily C.
Rechis, Ruth
Nutt, Stephanie
Richardson, Lisa C.
TI Estimating The Health And Economic Burden Of Cancer Among Those
Diagnosed As Adolescents And Young Adults
SO HEALTH AFFAIRS
LA English
DT Article
ID UNITED-STATES; SURVIVORS; PRODUCTIVITY; PREVALENCE; IMPACT; CHALLENGES;
COSTS; CARE
AB Adolescent and young adult cancer survivors-those who were ages 15-39 at their first cancer diagnosis-have important health limitations. These survivors are at risk for higher health care expenditures and lost productivity, compared to adults without a history of cancer. Using Medical Expenditure Panel Survey data, we present nationally representative estimates of the economic burden among people who were diagnosed with cancer in adolescence or young adulthood. Our findings demonstrate that surviving cancer at this age is associated with a substantial economic burden. Compared to adults without a history of cancer, adolescent and young adult cancer survivors had excess annual medical expenditures of $3,170 per person and excess annual productivity losses of $2,250 per person. Multifaceted prevention strategies, including education and sustained intervention programs to ensure access to lifelong risk-based follow-up care, may be effective ways to improve the economic outcomes associated with cancer survivorship in this population.
C1 [Guy, Gery P., Jr.] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA.
[Yabroff, K. Robin; Smith, Ashley Wilder] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Ekwueme, Donatus U.] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA.
[Dowling, Emily C.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Rechis, Ruth] LIVESTRONG Fdn, Austin, TX USA.
[Nutt, Stephanie] LIVESTRONG Fdn, Res & Evaluat Team, Austin, TX USA.
[Richardson, Lisa C.] CDC, Div Blood Disorders, Atlanta, GA 30333 USA.
RP Guy, GP (reprint author), Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA.
EM irm2@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 31
TC 17
Z9 18
U1 7
U2 14
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD JUN
PY 2014
VL 33
IS 6
BP 1024
EP 1031
DI 10.1377/hlthaff.2013.1425
PG 8
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AK1PL
UT WOS:000338187200014
PM 24889952
ER
PT J
AU Scott, RD
Sinkowitz-Cochran, R
Wise, ME
Baggs, J
Goates, S
Solomon, SL
McDonald, LC
Jernigan, JA
AF Scott, R. Douglas, II
Sinkowitz-Cochran, Ronda
Wise, Matthew E.
Baggs, James
Goates, Scott
Solomon, Steven L.
McDonald, L. Clifford
Jernigan, John A.
TI CDC Central-Line Bloodstream Infection Prevention Efforts Produced Net
Benefits Of At Least $640 Million During 1990-2008
SO HEALTH AFFAIRS
LA English
DT Article
ID CARE-ASSOCIATED INFECTIONS; UNITED-STATES; GUIDELINES
AB The prevention of central line-associated bloodstream infections in patients in hospital critical care units has been a target of efforts by the Centers for Disease Control and Prevention (CDC) since the 1960s. We developed a historical economic model to measure the net economic benefits of preventing these infections in Medicare and Medicaid patients in critical care units for the period 1990-2008-a time when reductions attributable to federal investment resulted primarily from CDC efforts-using the cost perspective of the federal government as a third-party payer. The estimated net economic benefits ranged from $640 million to $1.8 billion, with the corresponding net benefits per case averted ranging from $15,780 to $24,391. The per dollar rate of return on the CDC's investments ranged from $3.88 to $23.85. These findings suggest that investments in CDC programs targeting other health care-associated infections also have the potential to produce savings by lowering Medicare and Medicaid reimbursements.
C1 [Scott, R. Douglas, II] Ctr Dis Control & Prevent CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
[Sinkowitz-Cochran, Ronda; Baggs, James; McDonald, L. Clifford] CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
[Wise, Matthew E.] CDC, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA.
[Goates, Scott] CDC, Atlanta, GA 30333 USA.
[Solomon, Steven L.] CDC, Div Healthcare Qual Promot, Off Antimicrobial Resistance, Atlanta, GA 30333 USA.
[Jernigan, John A.] CDC, Div Healthcare Qual Promot, Off Prevent Res & Evaluat, Atlanta, GA 30333 USA.
RP Scott, RD (reprint author), Ctr Dis Control & Prevent CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
EM DScott1@cdc.gov
OI Baggs, James/0000-0003-0757-4683
NR 28
TC 5
Z9 6
U1 1
U2 3
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD JUN
PY 2014
VL 33
IS 6
BP 1040
EP 1047
DI 10.1377/hlthaff.2013.0865
PG 8
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AK1PL
UT WOS:000338187200016
PM 24889954
ER
PT J
AU Shapiro-Mendoza, CK
AF Shapiro-Mendoza, Carrie K.
TI Commentary: Mediation and moderation analyses: a novel approach to
exploring the complex pathways between maternal medical conditions,
preterm birth and associated newborn morbidity risk
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
C1 Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA.
RP Shapiro-Mendoza, CK (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, MS F74,4770 Buford Highway,NE, Atlanta, GA 30333 USA.
EM ayn9@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 10
TC 1
Z9 1
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD JUN
PY 2014
VL 43
IS 3
BP 815
EP 817
DI 10.1093/ije/dyt285
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AK0SZ
UT WOS:000338127000022
PM 24464191
ER
PT J
AU Buchanan, ND
Block, R
Smith, AW
Tai, E
AF Buchanan, Natasha D.
Block, Rebecca
Smith, Ashley Wilder
Tai, Eric
TI Psychosocial Barriers and Facilitators to Clinical Trial Enrollment and
Adherence for Adolescents With Cancer
SO PEDIATRICS
LA English
DT Article
DE adherence; adolescent; cancer survivors; clinical trial; enrollment;
psychosocial
ID EDUCATION SHARE PROGRAM; YOUNG-ADULT CANCER; CHILDHOOD-CANCER;
LYMPHOBLASTIC-LEUKEMIA; SURVIVOR HEALTH; CONSENT FORMS; PARTICIPATION;
CHILDREN; ISSUES; EXPERIENCES
AB Adolescents (aged 15-19 years) have not experienced the same survival gains as children and older adults diagnosed with cancer. Poor clinical trial enrollment and adherence rates among adolescents may account for some of this disparity. Although biological, regulatory, systemic, and practice-related challenges to clinical trial enrollment and adherence have been examined, studies of psychosocial factors, which can serve as barriers or facilitators to enrollment and adherence, are limited. To bring attention to these psychological factors, we reviewed existing literature on psychosocial barriers and facilitators that can affect an adolescent's decision to enroll and adhere to a clinical trial. We also provide potential strategies to address psychosocial factors affecting clinical trial accrual and adherence.
C1 [Buchanan, Natasha D.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30341 USA.
[Tai, Eric] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Comprehens Canc Control Branch, Atlanta, GA 30341 USA.
[Block, Rebecca] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Smith, Ashley Wilder] NCI, Outcomes Res Branch, Bethesda, MD 20892 USA.
RP Buchanan, ND (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS K-55, Atlanta, GA 30341 USA.
EM nbuchanan@cdc.gov
NR 64
TC 3
Z9 3
U1 1
U2 4
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2014
VL 133
SU 3
BP S123
EP S130
DI 10.1542/peds.2014-01221
PG 8
WC Pediatrics
SC Pediatrics
GA AK3TG
UT WOS:000338347000008
PM 24918211
ER
PT J
AU Tai, E
Buchanan, N
Eliman, D
Westervelt, L
Beaupin, L
Lawvere, S
Bleyer, A
AF Tai, Eric
Buchanan, Natasha
Eliman, Dena
Westervelt, Lauren
Beaupin, Lynda
Lawvere, Silvana
Bleyer, Archie
TI Understanding and Addressing the Lack of Clinical Trial Enrollment Among
Adolescents With Cancer
SO PEDIATRICS
LA English
DT Article
DE adolescents; cancer; clinical trial enrollment; oncology; teens; youth
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; YOUNG-ADULT CANCER; SURVIVORS; CARE;
ONCOLOGY; PARTICIPATION; SURVEILLANCE; CHALLENGES; CHILDHOOD; PROTOCOLS
AB Despite overall improvement in survival, morbidity, and quality of life of US patients with cancer, this progress is less prevalent in the population of adolescent and young adult patients with cancer, including those between the ages of 15 and 19 years. Evidence suggests that participation in clinical trials is associated with better survival outcomes among children and adolescents with cancer; however, adolescents have lower clinical trial participation rates compared with younger age cohorts. To better understand the unique concerns among adolescent patients with cancer, the Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention convened a workgroup of researchers and health care providers in the field of adolescent and young adult oncology and cancer survivorship to examine the barriers and challenges limiting the participation of adolescents in clinical trials and to define ways to improve upon these concerns. This article summarizes the activities of the workgroup and their suggestions for enhanced accrual.
C1 [Tai, Eric; Buchanan, Natasha] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA.
[Eliman, Dena; Westervelt, Lauren] SciMetrika LLC, Res Triangle Pk, NC USA.
[Beaupin, Lynda] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Lawvere, Silvana] Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA.
[Bleyer, Archie] St Charles Hlth Syst, Qual Dept, Bend, OR USA.
RP Tai, E (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy,MS-F76, Atlanta, GA 30341 USA.
EM etai@cdc.gov
NR 36
TC 7
Z9 7
U1 0
U2 0
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2014
VL 133
SU 3
BP S98
EP S103
DI 10.1542/peds.2014-0122D
PG 6
WC Pediatrics
SC Pediatrics
GA AK3TG
UT WOS:000338347000003
PM 24918214
ER
PT J
AU Tai, E
Buchanan, N
Westervelt, L
Elimam, D
Lawvere, S
AF Tai, Eric
Buchanan, Natasha
Westervelt, Lauren
Elimam, Dena
Lawvere, Silvana
TI Treatment Setting, Clinical Trial Enrollment, and Subsequent Outcomes
Among Adolescents With Cancer: A Literature Review
SO PEDIATRICS
LA English
DT Review
DE clinical trial enrollment; cancer; adolescents; oncology
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; YOUNG-ADULT SURVIVORS; AYA ONCOLOGY
PATIENTS; CHILDHOOD-CANCER; OLDER ADOLESCENTS; CHILDREN; AGE; PROGRAM;
CARE; PROTOCOLS
AB BACKGROUND: There has been an overall improvement in survival rates for persons with cancer over the past 35 years. However, these gains are less prevalent among adolescents with cancer aged 15 to 19 years, which may be due to lower clinical trial enrollment among adolescents with cancer.
METHODS: We conducted a literature review to assess current research regarding clinical trial enrollment and subsequent outcomes among adolescents with cancer. The search included English-language publications that reported original data from January 1985 to October 2011.
RESULTS: The search identified 539 records. Of these 539 records, there were 30 relevant original research articles. Multiple studies reported that adolescents with cancer are enrolled in clinical trials at lower rates compared with younger children and older adults. Treatment setting, physician type, and institution type may all be factors in the low enrollment rate among adolescents. Few data focused solely on adolescents, with many studies combining adolescents with young adults. The number of available studies related to this topic was limited, with significant variability in study design, methods, and outcomes.
CONCLUSIONS: This literature review suggests that adolescents with cancer are not treated at optimal settings and are enrolled in clinical trials at low rates. This may lead to inferior treatment and poor subsequent medical and psychosocial outcomes. The scarcity in data further validates the need for additional research focusing on this population.
C1 [Tai, Eric; Buchanan, Natasha] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA.
[Westervelt, Lauren; Elimam, Dena] SciMetrika LLC, Res Triangle Pk, NC USA.
[Lawvere, Silvana] Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA.
RP Tai, E (reprint author), Ctr Dis Control & Prevent, Div Canc Control & Prevent, 4770 Buford Hwy,MS-F76, Atlanta, GA 30341 USA.
EM etai@cdc.gov
NR 49
TC 4
Z9 4
U1 1
U2 2
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2014
VL 133
SU 3
BP S91
EP S97
DI 10.1542/peds.2014-0122C
PG 7
WC Pediatrics
SC Pediatrics
GA AK3TG
UT WOS:000338347000002
PM 24918213
ER
PT J
AU Tai, E
Beaupin, L
Bleyer, A
AF Tai, Eric
Beaupin, Lynda
Bleyer, Archie
TI Clinical Trial Enrollment Among Adolescents With Cancer: Supplement
Overview
SO PEDIATRICS
LA English
DT Article
DE clinical trial; enrollment; adolescent
ID YOUNG-ADULT SURVIVORS; CHILDHOOD-CANCER; OLDER ADOLESCENTS; AYA
ONCOLOGY; DIAGNOSIS; PATTERNS; OUTCOMES; PROGRAM; CARE; SITE
AB BACKGROUND: Survival rates for children with cancer have significantly increased over the past 35 years. However, adolescents with cancer aged 15 to 19 years have had less progress in survival prolongation compared with younger children, which may be due to lower clinical trial enrollment among adolescents with cancer. To help address this issue, the Centers for Disease Control and Prevention (CDC) convened a series of webinars to identify salient issues and measures to address this problem. This supplement is intended to raise awareness about the unique challenges of clinical trial enrollment among adolescents with cancer.
METHODS: The CDC convened a workgroup of researchers and health care providers in the field of adolescent and young adult oncology and cancer survivorship to examine the barriers and challenges limiting the participation of adolescents in clinical trials and to define ways to improve on these concerns.
RESULTS: The workgroup identified 3 distinct issues affecting clinical trial enrollment among adolescents with cancer: (1) many adolescents with cancer are not referred to institutions where clinical trials are offered, (2) there are limited numbers of clinical trials for adolescents with cancer, and (3) psychosocial barriers impede adolescents with cancer from enrolling in clinical trials.
CONCLUSIONS: Adolescents with cancer have the smallest proportion and least number of patients enrolled in clinical trials in pediatric oncology. Successfully addressing this challenge requires improving referral to existing clinical trials, addressing regulatory barriers to clinical trial enrollment, increasing the number of clinical trials for adolescents, and addressing unique psychosocial barriers to clinical trial enrollment.
C1 [Tai, Eric] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA.
[Beaupin, Lynda] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Bleyer, Archie] St Charles Hlth Syst, Qual Dept, Bend, OR USA.
RP Tai, E (reprint author), Ctr Dis Control & Prevent, Div Canc Control & Prevent, 4770 Buford Hwy,MS-F76, Atlanta, GA 30341 USA.
EM etai@cdc.gov
NR 26
TC 5
Z9 5
U1 1
U2 1
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2014
VL 133
SU 3
BP S85
EP S90
DI 10.1542/peds.2014-0122B
PG 6
WC Pediatrics
SC Pediatrics
GA AK3TG
UT WOS:000338347000001
PM 24918212
ER
PT J
AU Magadan, JG
Altman, MO
Ince, WL
Hickman, HD
Stevens, J
Chevalier, A
Baker, D
Wilson, PC
Ahmed, R
Bennink, JR
Yewdell, JW
AF Magadan, Javier G.
Altman, Meghan O.
Ince, William L.
Hickman, Heather D.
Stevens, James
Chevalier, Aaron
Baker, David
Wilson, Patrick C.
Ahmed, Rafi
Bennink, Jack R.
Yewdell, Jonathan W.
TI Biogenesis of Influenza A Virus Hemagglutinin Cross-Protective Stem
Epitopes
SO PLOS PATHOGENS
LA English
DT Article
ID STALK-SPECIFIC ANTIBODIES; MEMORY B-CELLS; MONOCLONAL-ANTIBODIES;
INTRACELLULAR-TRANSPORT; RECEPTOR-BINDING; IMMUNE-RESPONSE;
GLYCOPROTEIN; NEUTRALIZATION; VACCINATION; TRIMERIZATION
AB Antigenic variation in the globular domain of influenza A virus (IAV) hemagglutinin (HA) precludes effective immunity to this major human pathogen. Although the HA stem is highly conserved between influenza virus strains, HA stem-reactive antibodies (StRAbs) were long considered biologically inert. It is now clear, however, that StRAbs reduce viral replication in animal models and protect against pathogenicity and death, supporting the potential of HA stem-based immunogens as drift-resistant vaccines. Optimally designing StRAb-inducing immunogens and understanding StRAb effector functions require thorough comprehension of HA stem structure and antigenicity. Here, we study the biogenesis of HA stem epitopes recognized in cells infected with various drifted IAV H1N1 strains using mouse and human StRAbs. Using a novel immunofluorescence (IF)-based assay, we find that human StRAbs bind monomeric HA in the endoplasmic reticulum (ER) and trimerized HA in the Golgi complex (GC) with similar high avidity, potentially good news for producing effective monomeric HA stem immunogens. Though HA stem epitopes are nestled among several N-linked oligosaccharides, glycosylation is not required for full antigenicity. Rather, as N-linked glycans increase in size during intracellular transport of HA through the GC, StRAb binding becomes temperature-sensitive, binding poorly to HA at 4 degrees C and well at 37 degrees C. A de novo designed, 65-residue protein binds the mature HA stem independently of temperature, consistent with a lack of N-linked oligosaccharide steric hindrance due to its small size. Likewise, StRAbs bind recombinant HA carrying simple N-linked glycans in a temperature-independent manner. Chemical cross-linking experiments show that N-linked oligosaccharides likely influence StRAb binding by direct local effects rather than by globally modifying the conformational flexibility of HA. Our findings indicate that StRAb binding to HA is precarious, raising the possibility that sufficient immune pressure on the HA stem region could select for viral escape mutants with increased steric hindrance from N-linked glycans.
C1 [Magadan, Javier G.; Altman, Meghan O.; Ince, William L.; Hickman, Heather D.; Bennink, Jack R.; Yewdell, Jonathan W.] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
[Stevens, James] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Chevalier, Aaron; Baker, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
[Wilson, Patrick C.] Univ Chicago, Knapp Ctr Lupus & Immunol Res, Dept Med, Sect Rheumatol,Comm Immunol, Chicago, IL 60637 USA.
[Ahmed, Rafi] Emory Univ, Sch Med, Dept Microbiol & Immunol, Emory Vaccine Ctr, Atlanta, GA 30322 USA.
RP Magadan, JG (reprint author), NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
EM jyewdell@niaid.nih.gov
RI Altman, Meghan/J-2975-2015
OI Altman, Meghan/0000-0002-8910-9074
FU Division of Intramural Research of the National Institute of Allergy and
Infectious Diseases
FX This work was supported by the Division of Intramural Research of the
National Institute of Allergy and Infectious Diseases. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 62
TC 2
Z9 2
U1 2
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUN
PY 2014
VL 10
IS 6
AR e1004204
DI 10.1371/journal.ppat.1004204
PG 12
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA AK1SV
UT WOS:000338197400038
PM 24945804
ER
PT J
AU Carrieri, M
Bartolucci, GB
Lee, T
Barbero, A
Harper, M
AF Carrieri, Mariella
Bartolucci, Giovanni Battista
Lee, Taekhee
Barbero, Ana
Harper, Martin
TI Chemical Markers of Occupational Exposure to Teak Wood Dust
SO ANNALS OF OCCUPATIONAL HYGIENE
LA English
DT Article
DE deoxylapachol; lapachol; occupational exposure; teak dust; wood dust
ID TECTONA-GRANDIS; CONTACT-DERMATITIS; ANTIFUNGAL ACTIVITY; SINONASAL
CANCER; NASAL CAVITY; LAPACHOL; NAPHTHOQUINONES; ANTIBACTERIAL;
QUINONES; PLANTS
AB A novel high-performance liquid chromatographic/ultraviolet method was developed to detect lapachol (LP) and deoxylapachol (DLP) in wood dust as chemical markers of teak wood (a suspected human carcinogen). The specificity of this analysis was determined by noting the absence of LP and DLP in 12 other specimens of different woods belonging to the angiosperm family. The consistency was examined by analyzing teak from three different sources, where the percentages (wt/wt) of the chemicals ranged from 0.006 to 0.261 for LP and from 0.038 to 0.497 for DLP, respectively. Although the LP and DLP components of teak varied according to source, a very high correlation coefficient (r(2) > 0.98 always) was found between the content of the two markers in the bulk specimens and in bulk dust derived from them. The method was then applied to teak dust collected on polyvinylchloride filters from aerosol in an exposure chamber in the range of mass loadings between 0.03 and 3.65 mg, which corresponds to a dust exposure between 0.124 and 8.703 mg m(-3) for a sampling time of 2 h. A field test was also carried out in a small factory where teak was used. A good correlation was confirmed between LP and DLP versus the dust collected on the filter in both cases. LP and DLP can be markers to estimate the true quantities of teak dust inhaled in a workplace with mixed wood dust, provided the results are matched to the content of LP and DLP in the bulk wood. LP and DLP have also been proposed as the agents responsible for allergic reaction to teak dust. Therefore, it would be useful to evaluate the exposure to these two substances even without a relationship to teak dust exposure.
C1 [Carrieri, Mariella; Bartolucci, Giovanni Battista] Univ Padua, Dept Cardiol Thorac & Vasc Sci, I-35128 Padua, Italy.
[Lee, Taekhee; Barbero, Ana; Harper, Martin] NIOSH, Exposure Assessment Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA.
RP Carrieri, M (reprint author), Univ Padua, Dept Cardiol Thorac & Vasc Sci, Via Giustiniani 2, I-35128 Padua, Italy.
EM mariella.carrieri@unipd.it
FU INAIL - The Workers Compensation Authority [15/2009]
FX This work was partly supported by INAIL - The Workers Compensation
Authority (15/2009).
NR 36
TC 1
Z9 1
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0003-4878
EI 1475-3162
J9 ANN OCCUP HYG
JI Ann. Occup. Hyg.
PD JUN
PY 2014
VL 58
IS 5
BP 566
EP 578
DI 10.1093/annhyg/meu016
PG 13
WC Public, Environmental & Occupational Health; Toxicology
SC Public, Environmental & Occupational Health; Toxicology
GA AK0MN
UT WOS:000338107300004
PM 24671613
ER
PT J
AU Vo, E
Zhuang, ZQ
Birch, E
Zhao, Q
Horvatin, M
Liu, YW
AF Vo, Evanly
Zhuang, Ziqing
Birch, Eileen
Zhao, Qi
Horvatin, Matthew
Liu, Yuewei
TI Measurement of Mass-Based Carbon Nanotube Penetration through Filtering
Facepiece Respirator Filtering Media
SO ANNALS OF OCCUPATIONAL HYGIENE
LA English
DT Article
DE aerosol respirator testing system; elemental carbon; filtering facepiece
respirators; mass-based penetration; multiwalled carbon nanotubes;
single-walled carbon nanotubes
ID OCCUPATIONAL-EXPOSURE ASSESSMENT; ELEMENTAL CARBON; SECONDARY
MANUFACTURERS; NANOFIBER PRIMARY; PULMONARY; AEROSOL; SYSTEM; MICE;
PERFORMANCE; RESPONSES
AB Recent studies suggest that a wide range of human health effects could result from exposure to carbon nanotubes (CNTs). A National Institute for Occupational Safety and Health survey of the carbonaceous nanomaterial industry found that 77% of the companies used respiratory protection, such as filtering facepiece respirators (FFRs). Despite CNT studies in some occupational settings being reported, the literature for mass-based penetration of CNTs through FFRs is lacking. The aim of this study was to conduct a quantitative study of single-walled CNT (SWCNT) and multiwalled CNT (MWCNT) penetration through FFRs. A CNT aerosol respirator testing system was used to generate charge-neutralized airborne SWCNTs and MWCNTs for this study. The size distribution was 20-10 000 nm, with 99% of the particles between 25 and 2840 nm. Mass median diameters were 598 and 634 nm with geometric standard deviations of 1.34 and 1.48 for SWCNTs and MWCNTs, respectively. Upstream and downstream CNTs were collected simultaneously using closed-face 3.7-cm-diameter filter cassettes. These samples were subsequently analyzed for organic carbon and elemental carbon (EC), with EC as a measure of mass-based CNTs. The mass-based penetration of SWCNTs and MWCNTs through six FFR models at constant flow rates of 30 l min(-1) (LPM) was determined. Generally, the penetrations of SWCNTs and MWCNTs at 30 LPM had a similar trend and were highest for the N95 FFRs, followed by N99 and P100 FFRs. The mass-based penetration of MWCNTs through six FFR models at two constant flow rates of 30 and 85 LPM was also determined. The penetration of MWCNTs at 85 LPM was greater compared with the values of MWCNTs at 30 LPM.
C1 [Vo, Evanly; Zhuang, Ziqing; Liu, Yuewei] NIOSH, Natl Personal Protect Technol Lab, Pittsburgh, PA 15236 USA.
[Birch, Eileen; Zhao, Qi] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA.
[Horvatin, Matthew] URS Corp, Pittsburgh, PA 15236 USA.
RP Vo, E (reprint author), NIOSH, Natl Personal Protect Technol Lab, 626 Cochrans Mill Rd,POB 18070, Pittsburgh, PA 15236 USA.
EM eav8@cdc.gov
RI Zhuang, Ziqing/K-5462-2012
NR 33
TC 3
Z9 3
U1 2
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0003-4878
EI 1475-3162
J9 ANN OCCUP HYG
JI Ann. Occup. Hyg.
PD JUN
PY 2014
VL 58
IS 5
BP 646
EP 656
DI 10.1093/annhyg/meu005
PG 11
WC Public, Environmental & Occupational Health; Toxicology
SC Public, Environmental & Occupational Health; Toxicology
GA AK0MN
UT WOS:000338107300010
PM 24802251
ER
PT J
AU Harper, M
Key-Schwartz, R
AF Harper, Martin
Key-Schwartz, Rosa
TI Analysis of Crystalline Silica in Bulk Materials
SO ANNALS OF OCCUPATIONAL HYGIENE
LA English
DT Letter
C1 [Harper, Martin] NIOSH, Exposure Assessment Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA.
[Key-Schwartz, Rosa] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA.
RP Harper, M (reprint author), NIOSH, Exposure Assessment Branch, Hlth Effects Lab Div, 1095 Willowdale Rd,MS-3030, Morgantown, WV 26505 USA.
EM mharper@cdc.gov; rjk9@cdc.gov
NR 4
TC 1
Z9 1
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0003-4878
EI 1475-3162
J9 ANN OCCUP HYG
JI Ann. Occup. Hyg.
PD JUN
PY 2014
VL 58
IS 5
BP 657
EP 658
DI 10.1093/annhyg/meu020
PG 2
WC Public, Environmental & Occupational Health; Toxicology
SC Public, Environmental & Occupational Health; Toxicology
GA AK0MN
UT WOS:000338107300011
PM 24681562
ER
PT J
AU Skuladottir, H
Wilcox, AJ
Ma, C
Lammer, EJ
Rasmussen, SA
Werler, MM
Shaw, GM
Carmichael, SL
AF Skuladottir, Hildur
Wilcox, Allen J.
Ma, Chen
Lammer, Edward J.
Rasmussen, Sonja A.
Werler, Martha M.
Shaw, Gary M.
Carmichael, Suzan L.
TI Corticosteroid Use and Risk of Orofacial Clefts
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article
DE orofacial clefts; cleft lip and palate; corticosteroids; birth defects;
pregnancy
ID BIRTH-DEFECTS PREVENTION; TOPICAL CORTICOSTEROIDS; ORAL CLEFTS;
DRUG-USE; PREGNANCY; PALATE; EXPOSURE; LIP
AB Background: Maternal use of corticosteroids during early pregnancy has been inconsistently associated with orofacial clefts in the offspring. A previous report from the National Birth Defect Prevention Study (NBDPS), using data from 1997 to 2002, found an association with cleft lip and palate (odds ratio, 1.7; 95% confidence interval [CI], 1.1-2.6), but not cleft palate only (odds ratio, 0.5, 95% CI, 0.2-1.3). From 2003 to 2009, the study population more than doubled in size, and our objective was to assess this association in the more recent data. Methods: The NBDPS is an ongoing multi-state population-based case-control study of birth defects, with ascertainment of cases and controls born since 1997. We assessed the association of corticosteroids and orofacial clefts using data from 2372 cleft cases and 5922 controls born from 2003 to 2009. Maternal corticosteroid exposure was based on telephone interviews. Results: The overall association of corticosteroids and cleft lip and palate in the new data was 1.0 (95% CI, 0.7-1.4). There was little evidence of associations between specific corticosteroid components or timing and clefts. Conclusion: In contrast to the 1997 to 2002 data from the NBDPS, the 2003 to 2009 data show no association between maternal corticosteroid use and cleft lip and palate in the offspring. (C) 2014 The Authors Birth Defects Research Part A: Clinical and Molecular Teratology Published by Wiley Periodicals, Inc.
C1 [Skuladottir, Hildur] Haukeland Hosp, Dept Plast Surg, N-5021 Bergen, Norway.
[Skuladottir, Hildur] Univ Bergen, Dept Global Publ Hlth & Primary Care, N-5020 Bergen, Norway.
[Wilcox, Allen J.] NIEHS, NIH, Durham, NC USA.
[Ma, Chen; Shaw, Gary M.; Carmichael, Suzan L.] Stanford Univ, Dept Pediat, Div Neonatol & Dev Med, Sch Med, Stanford, CA 94305 USA.
[Lammer, Edward J.] Childrens Hosp Oakland Res Inst, Oakland, CA USA.
[Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Werler, Martha M.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA.
RP Skuladottir, H (reprint author), Haukeland Hosp, Dept Plast Surg, Jonas Lies Vei 67, N-5021 Bergen, Norway.
EM hildur.skuladottir@gmail.com
OI Wilcox, Allen/0000-0002-3376-1311
FU NCBDD CDC HHS [U01-DD-001033, U01-DD-000489]
NR 24
TC 12
Z9 12
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD JUN
PY 2014
VL 100
IS 6
BP 499
EP 506
DI 10.1002/bdra.23248
PG 8
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AJ9MU
UT WOS:000338036300006
PM 24777675
ER
PT J
AU Lewin, AB
Mink, JW
Bitsko, RH
Holbrook, JR
Parker-Athill, EC
Hanks, C
Storch, EA
Augustine, EF
Adams, HR
Vierhile, AE
Thatcher, AR
Murphy, TK
AF Lewin, Adam B.
Mink, Jonathan W.
Bitsko, Rebecca H.
Holbrook, Joseph R.
Parker-Athill, E. Carla
Hanks, Camille
Storch, Eric A.
Augustine, Erika F.
Adams, Heather R.
Vierhile, Amy E.
Thatcher, Alyssa R.
Murphy, Tanya K.
TI Utility of the Diagnostic Interview Schedule for Children for Assessing
Tourette Syndrome in Children
SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
LA English
DT Article
ID TIC DISORDERS; DISC-IV; ADOLESCENTS; RELIABILITY; SEVERITY; PARENT;
POPULATION; PREVALENCE
AB Objective: The Diagnostic Interview Schedule for Children IV (DISC) has been used extensively in research and screening. Despite wide use, little information exists on the validity of the DISC for diagnosing tic disorders. Methods: Participants were 181 youth with expert clinician-diagnosed Tourette syndrome (TS). Results: Using expert clinician-diagnosed TS as the gold standard, the sensitivity of the DISC-Y (youth, 0.27) and DISC-P (parent, 0.44) was poor. The DISC-Y identified 29.7% of youth with diagnosed TS whereas the DISC-P identified 47.4% of cases. Only 54% of cases of TS were detected by either the DISC-Y or -P. Diagnostic agreement between the DISC and expert clinician diagnosis was poor. The DISC-Y/P results did not differ as a function of tic severity. Conclusions: Despite utility for assessing child psychiatric disorders, the sensitivity of the DISC for detecting TS appears poor. This study suggests that DISC has low agreement with expert clinician diagnosis of TS. Findings highlight the need for modification of the DISC and/or the identification and development of more sensitive measures for TS screening.
C1 [Lewin, Adam B.; Parker-Athill, E. Carla; Hanks, Camille; Storch, Eric A.; Murphy, Tanya K.] Univ S Florida, Dept Pediat, St Petersburg, FL 33701 USA.
[Lewin, Adam B.; Parker-Athill, E. Carla; Hanks, Camille; Storch, Eric A.; Murphy, Tanya K.] Univ S Florida, Dept Psychiat Behav Neurosci, St Petersburg, FL 33701 USA.
[Mink, Jonathan W.; Augustine, Erika F.; Adams, Heather R.; Vierhile, Amy E.; Thatcher, Alyssa R.] Univ Rochester, Dept Neurol, Rochester, NY USA.
[Bitsko, Rebecca H.; Holbrook, Joseph R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Lewin, AB (reprint author), USF Pediat, 880 6th St South Suite 460 Box 7523, St Petersburg, FL 33701 USA.
EM alewin@health.usf.edu
FU Centers for Disease Control and Prevention [U01DD000509, U01DD000510]
FX This study was sponsored by Centers for Disease Control and Prevention
cooperative agreements U01DD000509 (TKM) and U01DD000510 (JWM). The
findings and conclusions in this report are those of the authors and do
not necessarily represent the official position of the Centers for
Disease Control and Prevention.
NR 36
TC 1
Z9 1
U1 4
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5463
EI 1557-8992
J9 J CHILD ADOL PSYCHOP
JI J. Child Adolesc. Psychopharmacol.
PD JUN
PY 2014
VL 24
IS 5
BP 275
EP 284
DI 10.1089/cap.2013.0128
PG 10
WC Pediatrics; Pharmacology & Pharmacy; Psychiatry
SC Pediatrics; Pharmacology & Pharmacy; Psychiatry
GA AJ9EP
UT WOS:000338010400007
PM 24813854
ER
PT J
AU Athey, TBT
Teatero, S
Li, AM
Marchand-Austin, A
Beall, BW
Fittipaldi, N
AF Athey, Taryn B. T.
Teatero, Sarah
Li, Aimin
Marchand-Austin, Alex
Beall, Bernard W.
Fittipaldi, Nahuel
TI Deriving Group A Streptococcus Typing Information from Short-Read
Whole-Genome Sequencing Data
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID HORIZONTAL GENE-TRANSFER; EMM-LIKE GENES; M-PROTEIN; OPACITY-FACTOR;
PYOGENES; PATHOGENESIS; EVOLUTION; DISEASE; BINDING; CLONE
AB Typing of group A Streptococcus (GAS) is crucial for infection control and epidemiology. While whole-genome sequencing (WGS) is revolutionizing the way that bacterial organisms are typed, it is necessary to provide backward compatibility with currently used typing schemas to facilitate comparisons and understanding of epidemiological trends. Here, we sequenced the genomes of 191 GAS isolates representing 42 different emm types and used bioinformatics tools to derive commonly used GAS typing information directly from the short-read WGS data. We show that emm typing and multilocus sequence typing can be achieved rapidly and efficiently using this approach, which also permits the determination of the presence or absence of genes associated with GAS tissue tropism. We also report on how the WGS data analysis was instrumental in identifying ambiguities present in the commonly used emm type database hosted by the U.S. Centers for Disease Control and Prevention.
C1 [Athey, Taryn B. T.; Teatero, Sarah; Li, Aimin; Marchand-Austin, Alex; Fittipaldi, Nahuel] Publ Hlth Ontario, Toronto, ON, Canada.
[Marchand-Austin, Alex; Fittipaldi, Nahuel] Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
[Beall, Bernard W.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA.
RP Fittipaldi, N (reprint author), Publ Hlth Ontario, Toronto, ON, Canada.
EM nahuel.fittipaldi@oahpp.ca
OI Marchand-Austin, Alex/0000-0001-5932-2037
FU Public Health Ontario
FX This work was funded by Public Health Ontario.
NR 34
TC 8
Z9 8
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2014
VL 52
IS 6
BP 1871
EP 1876
DI 10.1128/JCM.00029-14
PG 6
WC Microbiology
SC Microbiology
GA AJ7YZ
UT WOS:000337919500010
PM 24648555
ER
PT J
AU Yakrus, MA
Driscoll, J
Lentz, AJ
Sikes, D
Hartline, D
Metchock, B
Starks, AM
AF Yakrus, Mitchell A.
Driscoll, Jeffrey
Lentz, Allison J.
Sikes, David
Hartline, Denise
Metchock, Beverly
Starks, Angela M.
TI Concordance between Molecular and Phenotypic Testing of Mycobacterium
tuberculosis Complex Isolates for Resistance to Rifampin and Isoniazid
in the United States
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID STRAINS
AB Multidrug-resistant (MDR) isolates of Mycobacterium tuberculosis complex (MTBC) are defined by resistance to at least rifampin (RMP) and isoniazid (INH). Rapid and accurate detection of multidrug resistance is essential for effective treatment and interruption of disease transmission of tuberculosis (TB). Overdiagnosis of MDR TB may result in treatment with second-line drugs that are more costly, less effective, and more poorly tolerated than first-line drugs. CDC offers rapid confirmation of MDR TB by the molecular detection of drug resistance (MDDR) for mutations associated with resistance to RMP and INH along with analysis for resistance to other first-line and second-line drugs. Simultaneously, CDC does growth-based phenotypic drug susceptibility testing (DST) by the indirect agar proportion method for a panel of first-line and second-line antituberculosis drugs. We reviewed discordance between molecular and phenotypic DST for INH and RMP for 285 isolates submitted as MTBC to CDC from September 2009 to February 2011. We compared CDC's results with those from the submitting public health laboratories (PHL). Concordances between molecular and phenotypic testing at CDC were 97.4% for RMP and 92.5% for INH resistance. Concordances between CDC's molecular testing and PHL DST results were 93.9% for RMP and 90.0% for INH. Overall concordance between CDC molecular and PHL DST results was 91.7% for RMP and INH collectively. Discordance was primarily attributable to the absence of known INH resistance mutations in isolates found to be INH resistant by DST and detection of mutations associated with low-level RMP resistance in isolates that were RMP susceptible by phenotypic DST. Both molecular and phenotypic test results should be considered for the diagnosis of MDR TB.
C1 [Yakrus, Mitchell A.; Driscoll, Jeffrey; Lentz, Allison J.; Sikes, David; Hartline, Denise; Metchock, Beverly; Starks, Angela M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Yakrus, MA (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM may2@cdc.gov
NR 12
TC 3
Z9 3
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2014
VL 52
IS 6
BP 1932
EP 1937
DI 10.1128/JCM.00417-14
PG 6
WC Microbiology
SC Microbiology
GA AJ7YZ
UT WOS:000337919500018
PM 24648563
ER
PT J
AU Lim, SM
Brault, AC
van Amerongen, G
Sewbalaksing, VD
Osterhaus, ADME
Martina, BEE
Koraka, P
AF Lim, Stephanie M.
Brault, Aaron C.
van Amerongen, Geert
Sewbalaksing, Varsha D.
Osterhaus, Albert D. M. E.
Martina, Byron E. E.
Koraka, Penelope
TI Susceptibility of European jackdaws (Corvus monedula) to experimental
infection with lineage 1 and 2 West Nile viruses
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID NEW-YORK; AMERICAN CROWS; PATHOGENICITY; TRANSMISSION; VIRULENCE;
MOSQUITOS; OUTBREAK; STRAINS; HUMANS; BIRDS
AB Mass bird mortality has been observed in North America after the introduction of West Nile virus (WNV), most notably massive die-offs of American crows (Corvus brachyrhynchos). In contrast, WNV epidemic activity in Europe has been characterized by very low incidences of bird mortality. As the general susceptibility of European corvids to strains of WNV remains in question, European jackdaws (Corvus monedula) were inoculated with WNV strains circulating currently in Greece (Greece-10), Italy (FIN and Ita09) and Hungary (578/10), as well as a North American (NY99) genotype with a demonstrated corvid virulence phenotype. Infection with all strains except WNV-FIN resulted in mortality. Viraemia was observed for birds inoculated with all strains and virus was detected in a series of organs upon necropsy. These results suggested that jackdaws could potentially function as a sentinel for following WNV transmission in Europe; however, elicited viraemia levels might be too low to allow for efficient transmission of virus to mosquitoes.
C1 [Lim, Stephanie M.; van Amerongen, Geert; Sewbalaksing, Varsha D.; Osterhaus, Albert D. M. E.; Martina, Byron E. E.; Koraka, Penelope] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
[Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA.
RP Koraka, P (reprint author), Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
EM p.koraka@erasmusmc.nl
FU European Community [261466]
FX We thank Vittorio Sambri, Luisa Barzon, Giorgio Palu and Tamas Bakonyi
for providing the low-passage isolates used in this study. We would also
like to thank Tanja Schouten and Angela Gomersbach for their excellent
technical assistance. We thank Jeroen Roose and Peter van Run for their
technical assistance with the immunohistochemistry, and Thijs Kuiken for
his assistance with the analysis of the histological staining. The
research leading to these results has received complete funding from the
European Community's Seventh Framework Programme (FP7/2007-2013) under
the project 'VECTORIE' (EC grant agreement 261466). The funders had no
role in study design, data collection and analysis, decision to publish
or preparation of the manuscript. Permission for trapping European
jackdaws was obtained from the Ministry of Agriculture (registered under
number FF/75A/2011/031). Experimental inoculations were performed under
protocol number 122-12-12 with permission obtained from the Animal
Ethics Committee of Erasmus Medical Centre. All efforts were made to
minimize animal suffering.
NR 38
TC 9
Z9 9
U1 3
U2 13
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
BERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD JUN
PY 2014
VL 95
BP 1320
EP 1329
DI 10.1099/vir.0.063651-0
PN 6
PG 10
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA AK1LN
UT WOS:000338176700013
PM 24671752
ER
PT J
AU Corrigan, JD
Kreider, S
Cuthbert, J
Whyte, J
Dams-O'Connor, K
Faul, M
Harrison-Felix, C
Whiteneck, G
Pretz, CR
AF Corrigan, John D.
Kreider, Scott
Cuthbert, Jeffrey
Whyte, John
Dams-O'Connor, Kristen
Faul, Mark
Harrison-Felix, Cynthia
Whiteneck, Gale
Pretz, Christopher R.
TI Components of Traumatic Brain Injury Severity Indices
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE AIS; Barell matrix; craniocerebral trauma; GCS; MCA; TBI
ID GLASGOW COMA SCALE; PROGNOSTIC VALUE; MOTOR SCORE; HEAD-INJURY;
PREDICTION; TOMOGRAPHY; DIAGNOSIS; OUTCOMES
AB The purpose of this study was to determine whether there are underlying dimensions common among traditional traumatic brain injury (TBI) severity indices and, if so, the extent to which they are interchangeable when predicting short-term outcomes. This study had an observational design, and took place in United States trauma centers reporting to the National Trauma Data Bank (NTDB). The sample consisted of 77,470 unweighted adult cases reported to the NTDB from 2007 to 2010, with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) TBI codes. There were no interventions. Severity indices used were the Emergency Department Glasgow Coma Scale (GCS) Total score and each of the subscales for eye opening (four levels), verbal response (five levels), and motor response (six levels); the worst Abbreviated Injury Scale (AIS) severity score for the head (six levels); and the worst Barell index type (three categories). Prediction models were computed for acute care length of stay (days), intensive care unit length of stay (days), hospital discharge status (alive or dead), and, if alive, discharge disposition (home versus institutional). Multiple correspondence analysis (MCA) indicated a two dimensional relationship among items of severity indexes. The primary dimension reflected overall injury severity. The second dimension seemed to capture volitional behavior without the capability for cogent responding. Together, they defined two vectors around which most of the items clustered. A scale that took advantage of the order of items along these vectors proved to be the most consistent index for predicting short-term health outcomes. MCA provided useful insight into the relationships among components of traditional TBI severity indices. The two vector pattern may reflect the impact of injury on different cortical and subcortical networks. Results are discussed in terms of score substitution and the ability to impute missing values.
C1 [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.
[Kreider, Scott; Cuthbert, Jeffrey; Harrison-Felix, Cynthia; Whiteneck, Gale; Pretz, Christopher R.] Craig Hosp, Res Dept, Englewood, CO USA.
[Dams-O'Connor, Kristen] Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Elkins Pk, PA USA.
[Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA.
[Faul, Mark] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
RP Corrigan, JD (reprint author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.
EM corrigan.1@osu.edu
FU Intramural CDC HHS [CC999999]
NR 28
TC 3
Z9 3
U1 1
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
EI 1557-9042
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUN 1
PY 2014
VL 31
IS 11
BP 1000
EP 1007
DI 10.1089/neu.2013.3145
PG 8
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA AJ7RS
UT WOS:000337895300002
PM 24521197
ER
PT J
AU Uejio, CK
Hayden, MH
Zielinski-Gutierrez, E
Lopez, JLR
Barrera, R
Amador, M
Thompson, G
Waterman, SH
AF Uejio, Christopher K.
Hayden, Mary H.
Zielinski-Gutierrez, Emily
Robles Lopez, Jose Luis
Barrera, Roberto
Amador, Manuel
Thompson, Gregory
Waterman, Stephen H.
TI BIOLOGICAL CONTROL OF MOSQUITOES IN SCRAP TIRES IN BROWNSVILLE, TEXAS,
USA AND MATAMOROS, TAMAULIPAS, MEXICO
SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION
LA English
DT Article
DE Aedes; Mesocyclops; Toxorhynchites; tires; United States-Mexico border
ID MESOCYCLOPS-LONGISETUS COPEPODA; TOXORHYNCHITES-RUTILUS-RUTILUS;
LONGITUDINAL DATA-ANALYSIS; AEDES-AEGYPTI; DENGUE; TRANSMISSION;
CYCLOPIDAE; CONTAINERS; CYCLOPOIDA; FEVER
AB Dengue periodically circulates in southern Texas and neighboring Tamaulipas, Mexico; thus, a closer examination of human and vector ecology at the northern limits of North American transmission may improve prevention activities. Scrap tires produce large mosquito populations and increase the risk of dengue transmission. Some households choose not to pay tire disposal fees, and many tires are illegally dumped in residential areas. Biological control may provide low-cost and environmentally friendly mosquito control. This pilot study evaluated the ability of Mesocyclops longisetus to reduce mosquito populations in existing residential scrap tire piles. Mosquito populations were measured by the number of all mosquito pupae within tires or adult Aedes aegypti and Ae. albopictus near piles. Mesocyclops longisetus-treated piles did not significantly reduce total mosquito pupae (P = 0.07) in Matamoros, Mexico. The study also evaluated the efficacy of native Toxorhynchites moctezuma which preferentially colonized tire piles under vegetation cover in Brownsville, TX. Toxorhynchites moctezuma larvae significantly reduced total mosquito pupae, but the strength of control diminished over time.
C1 [Uejio, Christopher K.] Florida State Univ, Dept Geog, Tallahassee, FL 32306 USA.
[Hayden, Mary H.] Natl Ctr Atmospher Res, Res Applicat Lab, Boulder, CO 80307 USA.
[Zielinski-Gutierrez, Emily] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
[Barrera, Roberto; Amador, Manuel] Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR 00920 USA.
[Thompson, Gregory] New Orleans Mosquito Rodent & Termite Control Boa, New Orleans Mosquito Control Dist, New Orleans, LA 70122 USA.
[Waterman, Stephen H.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, San Diego, CA 92110 USA.
RP Uejio, CK (reprint author), Florida State Univ, Dept Geog, 113 Collegiate Loop, Tallahassee, FL 32306 USA.
FU Pan American Health Organization/World Health Organization/US
Environmental Protection Agency Grant
FX We acknowledge the following institutions that aided the project:
Jurisdiccion Sanitaria No. III de Matamoros, Brownsville Public Health
Department, Harris County Public Health and Environmental Services, and
University of Texas School of Public Health-Brownsville. Josh Ramirez,
Vicente Anguiano, Victor Herrera, Juan Manuel Becerra Guevara, and
Ildefonso Salas assisted with site selection and mosquito collection. We
thank Frank Ramberg and Thomas Zavortink for confirming the
Toxorhynchites moctezuma identification. This project was funded by the
Pan American Health Organization/World Health Organization/US
Environmental Protection Agency Grant.
NR 33
TC 0
Z9 0
U1 1
U2 16
PU AMER MOSQUITO CONTROL ASSOC
PI MOUNT LAUREL
PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA
SN 8756-971X
EI 1943-6270
J9 J AM MOSQUITO CONTR
JI J. Am. Mosq. Control Assoc.
PD JUN
PY 2014
VL 30
IS 2
BP 130
EP 135
PG 6
WC Entomology
SC Entomology
GA AK0GN
UT WOS:000338091000010
PM 25102598
ER
PT J
AU Yi, SH
Baggs, J
Gould, CV
Scott, RD
Jernigan, JA
AF Yi, Sarah H.
Baggs, James
Gould, Carolyn V.
Scott, Robert D., II
Jernigan, John A.
TI Medicare Reimbursement Attributable to Catheter-associated Urinary Tract
Infection in the Inpatient Setting A Retrospective Cohort Analysis
SO MEDICAL CARE
LA English
DT Article
DE catheter-associated urinary tract infection; Medicare; reimbursement;
health care-associated infection; claims data; health care costs;
mortality; regression analysis
ID NETWORK NHSN REPORT; SURGICAL PATIENTS; CARE; COSTS; BENEFICIARIES;
MORTALITY
AB Background:Most catheter-associated urinary tract infections (CAUTIs) are considered preventable and thus a potential target for health care quality improvement and cost savings.Objectives:We sought to estimate excess Medicare reimbursement, length of stay, and inpatient death associated with CAUTI among hospitalized beneficiaries.Research Design:Using a retrospective cohort design with linked Medicare inpatient claims and National Healthcare Safety Network data from 2009, we compared Medicare reimbursement between Medicare beneficiaries with and without CAUTIs.Subjects:Fee-for-service Medicare beneficiaries aged 65 years or older with continuous coverage of parts A (hospital insurance) and B (supplementary medical insurance).Results:We found that beneficiaries with CAUTI had higher median Medicare reimbursement [intensive care unit (ICU): $8548, non-ICU: $1479) and length of stay (ICU: 8.1 d, non-ICU: 3.6 d) compared with those without CAUTI controlling for potential confounding factors. Odds of inpatient death were higher among beneficiaries with versus without CAUTI only among those with an ICU stay (ICU: odds ratio 1.37).Conclusions:Beneficiaries with CAUTI had increased Medicare reimbursement and length of stay compared with those without CAUTI after adjusting for potential confounders.
C1 [Yi, Sarah H.; Baggs, James; Gould, Carolyn V.; Scott, Robert D., II; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
RP Yi, SH (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM sarahyi@cdc.gov
NR 35
TC 8
Z9 10
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD JUN
PY 2014
VL 52
IS 6
BP 469
EP 478
DI 10.1097/MLR.0000000000000106
PG 10
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AJ5LK
UT WOS:000337723900002
PM 24699236
ER
PT J
AU Rasmussen, SA
Watson, AK
Kennedy, ED
Broder, KR
Jamieson, DJ
AF Rasmussen, Sonja A.
Watson, Amelia K.
Kennedy, Erin D.
Broder, Karen R.
Jamieson, Denise J.
TI Vaccines and pregnancy: Past, present, and future
SO SEMINARS IN FETAL & NEONATAL MEDICINE
LA English
DT Review
DE Newborns; Pregnant women; Safety; Vaccine
ID IMMUNIZATION PRACTICES ACIP; INFLUENZA VACCINATION COVERAGE; ACELLULAR
PERTUSSIS-VACCINE; ADVISORY-COMMITTEE; UNITED-STATES; SEASONAL
INFLUENZA; BIRTH-DEFECTS; SPONTANEOUS-ABORTION; PRETERM DELIVERY;
ANTHRAX VACCINE
AB Vaccination during pregnancy with certain vaccines can prevent morbidity and mortality in pregnant women and their infants. However, previous recommendations often focused on the potential risks of vaccines to the fetus when used during pregnancy. In recent years, additional data have become available on the absence of increased risks for adverse events associated with vaccines when administered during pregnancy and on their benefits to mothers and infants. Currently two vaccines - (i) inactivated influenza, and (ii) tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) - are recommended for use by all pregnant women by the United States Advisory Committee on Immunization Practices. Here we review the history of vaccination during pregnancy, the current status of recommendations for vaccination during pregnancy in the USA, and the potential for future advances in this area, including key barriers that must be overcome to accommodate these advances. Published by Elsevier Ltd.
C1 [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Influenza Coordinat Unit, Off Infect Dis, Atlanta, GA USA.
[Watson, Amelia K.] Univ Georgia, Athens, GA 30602 USA.
[Kennedy, Erin D.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Broder, Karen R.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
[Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Rasmussen, SA (reprint author), CDC, 1600 Clifton Rd,MS A-28, Atlanta, GA 30333 USA.
EM skr9@cdc.gov
OI Rasmussen, Sonja/0000-0002-0574-4928
NR 97
TC 23
Z9 24
U1 0
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1744-165X
EI 1878-0946
J9 SEMIN FETAL NEONAT M
JI Semin. Fetal Neonatal Med.
PD JUN
PY 2014
VL 19
IS 3
BP 161
EP 169
DI 10.1016/j.siny.2013.11.014
PG 9
WC Pediatrics
SC Pediatrics
GA AJ8ZQ
UT WOS:000337997000004
PM 24355683
ER
PT J
AU Bartholomew, ML
Heffernan, RT
Wright, JG
Klos, RF
Monson, T
Khan, S
Trees, E
Sabol, A
Willems, RA
Flynn, R
Deasy, MP
Jones, B
Davis, JP
AF Bartholomew, Michael L.
Heffernan, Richard T.
Wright, Jennifer G.
Klos, Rachel F.
Monson, Timothy
Khan, Sofiya
Trees, Eija
Sabol, Ashley
Willems, Robert A.
Flynn, Raymond
Deasy, Marshall P.
Jones, Benjamen
Davis, Jeffrey P.
TI Multistate Outbreak of Salmonella enterica Serotype Enteritidis
Infection Associated with Pet Guinea Pigs
SO VECTOR-BORNE AND ZOONOTIC DISEASES
LA English
DT Article
DE Salmonellosis; Salmonella enteritidis; Guinea pigs
ID FIELD GEL-ELECTROPHORESIS; UNITED-STATES; EXOTIC PETS; TYPHIMURIUM;
CONTACT; ILLNESS; TRANSPORTATION; FOOD
AB Salmonella causes about one million illnesses annually in the United States. Although most infections result from foodborne exposures, animal contact is an important mode of transmission. We investigated a case of Salmonella enterica serotype Enteritidis (SE) sternal osteomyelitis in a previously healthy child who cared for two recently deceased guinea pigs (GPs). A case was defined as SE pulsed-field gel electrophoresis (PFGE) XbaI pattern JEGX01.0021, BlnI pattern JEGA26.0002 (outbreak strain) infection occurring during 2010 in a patient who reported GP exposure. To locate outbreak strain isolates, PulseNet and the US Department of Agriculture National Veterinary Service Laboratories (NVSL) databases were queried. Outbreak strain isolates underwent multilocus variable-number tandem repeat analysis (MLVA). Traceback and environmental investigations were conducted at homes, stores, and breeder or broker facilities. We detected 10 cases among residents of eight states and four NVSL GP outbreak strain isolates. One patient was hospitalized; none died. The median patient age was 9.5 (range, 1-61) years. Among 10 patients, two purchased GPs at independent stores, and three purchased GPs at different national retail chain (chain A) store locations; three were chain A employees and two reported GP exposures of unknown characterization. MLVA revealed four related patterns. Tracebacks identified four distributors and 92 sources supplying GPs to chain A, including one breeder potentially supplying GPs to all case-associated chain A stores. All environmental samples were Salmonella culture-negative. A definitive SE-contaminated environmental source was not identified. Because GPs can harbor Salmonella, consumers and pet industry personnel should be educated regarding risks.
C1 [Bartholomew, Michael L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA.
[Bartholomew, Michael L.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA USA.
[Bartholomew, Michael L.] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA.
[Bartholomew, Michael L.; Heffernan, Richard T.; Klos, Rachel F.; Davis, Jeffrey P.] Wisconsin Div Publ Hlth, Madison, WI 53701 USA.
[Wright, Jennifer G.; Khan, Sofiya; Trees, Eija; Sabol, Ashley] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
[Monson, Timothy] Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA.
[Willems, Robert A.; Flynn, Raymond] Anim & Plant Hlth Inspect Serv, USDA, Raleigh, NC USA.
[Deasy, Marshall P.] Penn Dept Hlth, Harrisburg, PA 17108 USA.
[Jones, Benjamen] Waukesha Cty Hlth & Human Serv Dept, Publ Hlth Div, Waukesha, WI USA.
RP Bartholomew, ML (reprint author), Wisconsin Div Publ Hlth, 1 West Wilson St,Room 318, Madison, WI 53701 USA.
EM michael.l.bartholomew@gmail.com
FU Wisconsin Division of Public Health; Center for Disease Control and
Prevention's Public Health Emergency Response; Center for Epidemiology
and Laboratory Capacity
FX This work is dedicated in memory of Richard Thomas Burch Heffernan, a
dedicated epidemiologist, trusted colleague, strong leader, mentor, and
dear friend. We are indebted to the many local and state public health
officials, clinicians, infection preventionists, and laboratory staff
who submitted case reports and provided information to support this
investigation. This work was supported by the Wisconsin Division of
Public Health with funding from the Centers for Disease Control and
Prevention's Public Health Emergency Response and Epidemiology and
Laboratory Capacity cooperative agreements.
NR 36
TC 5
Z9 5
U1 0
U2 15
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-3667
EI 1557-7759
J9 VECTOR-BORNE ZOONOT
JI Vector-Borne Zoonotic Dis.
PD JUN
PY 2014
VL 14
IS 6
BP 414
EP 421
DI 10.1089/vbz.2013.1506
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AJ8MI
UT WOS:000337958500006
PM 24866204
ER
PT J
AU Denny, CH
Hungerford, DW
McKnight-Eily, LR
Green, PP
Dang, EP
Cannon, MJ
Cheal, NE
Sniezek, J
AF Denny, C. H.
Hungerford, D. W.
McKnight-Eily, L. R.
Green, P. P.
Dang, E. P.
Cannon, M. J.
Cheal, N. E.
Sniezek, J.
TI SELF-REPORTED PREVALENCE OF SCREENING FOR ALCOHOL MISUSE AMONG UNITED
STATES ADULTS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Denny, C. H.; Hungerford, D. W.; McKnight-Eily, L. R.; Green, P. P.; Dang, E. P.; Cannon, M. J.; Cheal, N. E.; Sniezek, J.] Ctr Dis Control & Prevent, Prevent Res Branch, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0821
BP 206A
EP 206A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701021
ER
PT J
AU Elliott, JC
Aharonovich, E
O'Leary, A
Johnston, B
Hasin, DS
AF Elliott, J. C.
Aharonovich, E.
O'Leary, A.
Johnston, B.
Hasin, D. S.
TI PERCEIVED MEDICAL RISKS OF DRINKING AMONG HIV-INFECTED PATIENTS WITH AND
WITHOUT HEPATITIS C
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Columbia Univ, Med Ctr, New York, NY 10032 USA.
Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 1082
BP 271A
EP 271A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701281
ER
PT J
AU Doligalski, CT
Benedict, K
Cleveland, AA
Park, B
Derado, G
Pappas, PG
Baddley, JW
Zaas, DW
Harris, MT
Alexander, BD
AF Doligalski, C. T.
Benedict, K.
Cleveland, A. A.
Park, B.
Derado, G.
Pappas, P. G.
Baddley, J. W.
Zaas, D. W.
Harris, M. T.
Alexander, B. D.
TI Epidemiology of Invasive Mold Infections in Lung Transplant Recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Epidemiology; infection; lung transplant; mold
ID FUNGAL-INFECTIONS; ANTIFUNGAL PROPHYLAXIS; RISK-FACTORS; ASPERGILLOSIS;
STRATEGIES
AB Invasive mold infections (IMIs) are a major source of morbidity and mortality among lung transplant recipients (LTRs), yet information regarding the epidemiology of IMI in this population is limited. From 2001 to 2006, multicenter prospective surveillance for IMIs among LTR was conducted by the Transplant-Associated Infection Surveillance Network. The epidemiology of IMI among all LTRs in the cohort is reported. Twelve percent (143/ 1173) of LTRs under surveillance at 15 US centers developed IMI infections. The 12-month cumulative incidence of IMIs was 5.5%; 3-month all-cause mortality was 21.7%. Aspergillus caused the majority (72.7%) of IMIs; non-Aspergillus infections (39, 27.3%) included Scedosporium (5, 3.5%), mucormycosis (3, 2.1%) and "unspecified'' or "other'' mold infections (31, 21.7%). Late-onset IMI was common: 52% occurred within 1 year posttransplant (median 11 months, range 0-162 months). IMIs are common late-onset complications with substantial mortality in LTRs. LTRs should be monitored for late-onset IMIs and prophylactic agents should be optimized based on likely pathogen.
C1 [Doligalski, C. T.] Tampa Gen Hosp, Dept Pharm, Tampa, FL 33606 USA.
[Benedict, K.; Cleveland, A. A.; Park, B.] US Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA.
[Derado, G.] US Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
[Pappas, P. G.; Baddley, J. W.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Zaas, D. W.; Alexander, B. D.] Duke Univ Hosp, Dept Med, Durham, NC 27710 USA.
[Harris, M. T.] Duke Univ Hosp, Dept Pharm, Durham, NC USA.
[Alexander, B. D.] Duke Univ Hosp, Dept Pathol, Durham, NC USA.
RP Alexander, BD (reprint author), Duke Univ Hosp, Dept Med, Durham, NC 27710 USA.
EM Barbara.alexander@duke.edu
FU Centers for Disease Control [5U01C1000286-05]; NIH NIAID [K24 AI072522]
FX This work was supported in part by the Centers for Disease Control
(grant no. 5U01C1000286-05) and NIH NIAID K24 AI072522 (BDA).
NR 20
TC 13
Z9 13
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
IS 6
BP 1328
EP 1333
DI 10.1111/ajt.12691
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ2UP
UT WOS:000337519500014
PM 24726020
ER
PT J
AU Gupte, AA
Hocevar, SN
Lea, AS
Kulkarni, RD
Schain, DC
Casey, MJ
Zendejas-Ruiz, IR
Chung, WK
Mbaeyi, C
Roy, SL
Visvesvara, GS
da Silva, AJ
Tallaj, J
Eckhoff, D
Baddley, JW
AF Gupte, A. A.
Hocevar, S. N.
Lea, A. S.
Kulkarni, R. D.
Schain, D. C.
Casey, M. J.
Zendejas-Ruiz, I. R.
Chung, W. K.
Mbaeyi, C.
Roy, S. L.
Visvesvara, G. S.
da Silva, A. J.
Tallaj, J.
Eckhoff, D.
Baddley, J. W.
TI Transmission of Balamuthia mandrillaris Through Solid Organ
Transplantation: Utility of Organ Recipient Serology to Guide Clinical
Management
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Amebic encephalitis; Balamuthia mandrillaris; donor-derived infection;
miltefosine
ID FREE-LIVING AMEBAS; NAEGLERIA-FOWLERI; ACANTHAMOEBA SPP.; ENCEPHALITIS;
MENINGOENCEPHALITIS; PATIENT; INFECTION; AGENT; PCR
AB A liver, heart, iliac vessel and two kidneys were recovered from a 39-year-old man who died of traumatic head injury and were transplanted into five recipients. The liver recipient 18 days posttransplantation presented with headache, ataxia and fever, followed by rapid neurologic decline and death. Diagnosis of granulomatous amebic encephalitis was made on autopsy. Balamuthia mandrillaris infection was confirmed with immunohistochemical and polymerase chain reaction (PCR) assays. Donor and recipients' sera were tested for B. mandrillaris antibodies. Donor brain was negative for Balamuthia by immunohistochemistry and PCR; donor serum Balamuthia antibody titer was positive (1:64). Antibody titers in all recipients were positive (range, 1:64-1:512). Recipients received a four-to five-drug combination of miltefosine or pentamidine, azithromycin, albendazole, sulfadiazine and fluconazole. Nausea, vomiting, elevated liver transaminases and renal insufficiency were common. All other recipients survived and have remained asymptomatic 24 months posttransplant. This is the third donor-derived Balamuthia infection cluster described in solid organ transplant recipients in the United States. As Balamuthia serologic testing is only available through a national reference laboratory, it is not feasible for donor screening, but may be useful to determine exposure status in recipients and to help guide chemotherapy.
C1 [Gupte, A. A.; Kulkarni, R. D.; Schain, D. C.; Casey, M. J.; Zendejas-Ruiz, I. R.] Univ Florida, Coll Med, Gainesville, FL USA.
[Hocevar, S. N.; Mbaeyi, C.; Roy, S. L.; Visvesvara, G. S.; da Silva, A. J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Lea, A. S.; Chung, W. K.] Univ Texas Med Branch, Galveston, TX 77555 USA.
[Tallaj, J.; Eckhoff, D.; Baddley, J. W.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
RP Baddley, JW (reprint author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
EM jbaddley@uab.edu
FU Intramural CDC HHS [CC999999]
NR 25
TC 7
Z9 8
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
IS 6
BP 1417
EP 1424
DI 10.1111/ajt.12726
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ2UP
UT WOS:000337519500024
PM 24840013
ER
PT J
AU Schafer, IJ
Miller, R
Stroher, U
Knust, B
Nichol, ST
Rollin, PE
AF Schafer, Ilana J.
Miller, Rachel
Stroeher, Ute
Knust, Barbara
Nichol, Stuart T.
Rollin, Pierre E.
TI Notes From the Field: A Cluster of Lymphocytic Choriomeningitis Virus
Infections Transmitted Through Organ Transplantation-Iowa, 2013
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Editorial Material
C1 [Schafer, Ilana J.] CDC, Atlanta, GA 30333 USA.
[Miller, Rachel] Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA.
[Stroeher, Ute; Knust, Barbara; Nichol, Stuart T.; Rollin, Pierre E.] CDC, Viral Special Pathogens Branch, Natl Ctr Emerging, Atlanta, GA 30333 USA.
RP Schafer, IJ (reprint author), CDC, Atlanta, GA 30333 USA.
EM ischafer@cdc.gov
NR 3
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
IS 6
BP 1459
EP 1459
DI 10.1111/ajt.12802
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ2UP
UT WOS:000337519500030
PM 24854024
ER
PT J
AU Miller, CH
Rice, AS
Garrett, K
Stein, SF
AF Miller, Connie H.
Rice, Anne S.
Garrett, Katherine
Stein, Sidney F.
TI Gender, race and diet affect platelet function tests in normal subjects,
contributing to a high rate of abnormal results
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE platelets; platelet function tests; platelet aggregation; ristocetin;
flavonoids
ID LIGHT TRANSMISSION AGGREGOMETRY; REFERENCE INTERVALS;
HEALTHY-VOLUNTEERS; AGGREGATION; BLOOD; SEX; INDIVIDUALS; VARIABLES;
CONSENSUS; TIME
AB To assess sources of variability in platelet function tests in normal subjects, 64 healthy young adults were tested on 2-6 occasions at 2week intervals using four methods: platelet aggregation (AGG) in platelet-rich plasma (PRP) in the Bio/Data PAP-4 Aggregometer (BD) and Chrono-Log Lumi-Aggregometer (CL); and AGG in whole blood (WB) in the CL and Multiplate Platelet Function Analyser (MP), with ATP release (REL) in CL-PRP and CL-WB. Food and medication exposures were recorded prospectively for 2weeks prior to each blood draw. At least one AGG abnormality was seen in 21% of 81 drug-free specimens with CL-PRP, 15% with CL-WB, 13% with BD-PRP and 6% with MP-WB, increasing with inclusion of REL to 28% for CL-PRP and 30% for CL-WB. Epinephrine AGG and REL were significantly reduced in males (P<00001). Ristocetin AGG and collagen and thrombin REL were significantly reduced in Blacks (P<00001). One-third of specimens drawn following flavonoid-rich food exposures had aberrant results, compared to 85% of specimens without such exposures (P=00035). PRP tests had less intra-individual variation than WB tests. Gender, race, diet and test system affected results of platelet function testing in healthy subjects, suggesting caution when interpreting the results of platelet function testing in patients.
C1 [Miller, Connie H.; Rice, Anne S.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Garrett, Katherine; Stein, Sidney F.] Emory Univ, Sch Med, Atlanta, GA USA.
RP Miller, CH (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS D-02, Atlanta, GA 30333 USA.
EM cmiller2@cdc.gov
OI Miller, Connie H/0000-0002-3989-7973
FU Association of Teachers of Preventive Medicine
FX The study was supported by a cooperative agreement with the Association
of Teachers of Preventive Medicine. The findings and conclusions in this
report are those of the authors and do not necessarily represent the
views of the Centers for Disease Control and Prevention.
NR 31
TC 7
Z9 8
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD JUN
PY 2014
VL 165
IS 6
BP 842
EP 853
DI 10.1111/bjh.12827
PG 12
WC Hematology
SC Hematology
GA AJ2UY
UT WOS:000337520600014
PM 24617520
ER
PT J
AU Mesquita, JR
Delgado, I
Costantini, V
Heenemann, K
Vahlenkamp, TW
Vinje, J
Nascimento, MSJ
AF Mesquita, Joao R.
Delgado, Ines
Costantini, Veronica
Heenemann, Kristin
Vahlenkamp, Thomas W.
Vinje, Jan
Nascimento, Maria S. J.
TI Seroprevalence of Canine Norovirus in 14 European Countries
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID DOGS; OUTBREAK
AB To investigate the prevalence of the recently described genogroup VI canine noroviruses (CNVs) in dogs in Europe, we tested 510 serum samples from dogs in 14 European countries for anti-IgG CNV antibodies. Seropositive dogs were found throughout Europe. Dogs with antibodies against human noroviruses were also found.
C1 [Mesquita, Joao R.] Polytech Inst, Agrarian Super Sch, Viseu, Portugal.
[Mesquita, Joao R.; Nascimento, Maria S. J.] Univ Porto, Ctr Invest Biodiversidade & Recursos Genet, Viseu, Portugal.
[Delgado, Ines; Nascimento, Maria S. J.] Univ Porto, Fac Pharm, P-4100 Oporto, Portugal.
[Costantini, Veronica; Vinje, Jan] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Heenemann, Kristin; Vahlenkamp, Thomas W.] Univ Leipzig, Fac Vet, D-04109 Leipzig, Germany.
RP Mesquita, JR (reprint author), Polytech Inst, Agrarian Super Sch, Viseu, Portugal.
EM jmesquita@esav.ipv.pt
RI Mesquita, Joao/B-6960-2016;
OI Mesquita, Joao/0000-0001-8769-8103; Delgado, Ines/0000-0002-7369-2883;
Costantini, Veronica/0000-0002-1532-4345
FU FEDER funds through the Programa Operacional Factores de
Competividade-COMPETE; Fundacao para a Ciencia e Tecnologia (FCT)
[PTDC/CVT/113218/2009]; FCT [SFRH/BD/45407/2008]
FX This work was supported by FEDER funds through the Programa Operacional
Factores de Competividade-COMPETE and funding through the Fundacao para
a Ciencia e Tecnologia (FCT) (project PTDC/CVT/113218/2009). J.R.M. was
supported by a Ph.D. grant (SFRH/BD/45407/2008) from the FCT.
NR 12
TC 2
Z9 3
U1 2
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD JUN
PY 2014
VL 21
IS 6
BP 898
EP 900
DI 10.1128/CVI.00048-14
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AJ0NW
UT WOS:000337352500016
PM 24671552
ER
PT J
AU Li, R
Barker, LE
Shrestha, S
Zhang, P
Duru, OK
Pearson-Clarke, T
Gregg, EW
AF Li, Rui
Barker, Lawrence E.
Shrestha, Sundar
Zhang, Ping
Duru, O. Kenrick
Pearson-Clarke, Tony
Gregg, Edward W.
TI Changes Over Time in High Out-of-Pocket Health Care Burden in US Adults
With Diabetes, 2001-2011
SO DIABETES CARE
LA English
DT Article
ID MEDICARE PART D; FINANCIAL BURDEN; EXPENDITURE BURDENS; PRESCRIPTION
DRUGS; TRENDS; BENEFICIARIES; POPULATION; COSTS
AB OBJECTIVE
High out-of-pocket (OOP) costs can be an obstacle to health care access and treatment compliance. This study investigated trends in high OOP health care burden in people with diabetes.
RESEARCH DESIGN AND METHODS
Using Medical Expenditure Panel Survey 2001-2011 data, we examined trends in the proportion of people aged 18-64 years with diabetes facing a high OOP burden. We also examined whether the trend differed by insurance status (private insurance, public insurance, or no insurance) or by income level (poor and near poor, low income, middle income, or high income).
RESULTS
In 2011, 23% of people with diabetes faced high OOP burden. Between 2001-2002 and 2011, the proportion of people facing high OOP burden fell by 5 percentage points (P < 0.01). The proportion of those who were publicly insured decreased by 22 percentage points (P < 0.001) and of those who were uninsured by 12 percentage points (P = 0.01). Among people with diabetes who were poor and near poor and those with low income, the proportion facing high OOP burden decreased by 21 (P < 0.001) and 13 (P = 0.01) percentage points, respectively; no significant change occurred in the proportion with private insurance or middle and high incomes between 2001-2002 and 2011.
CONCLUSIONS
The past decade has seen a narrowing of insurance coverage and income-related disparities in high OOP burden in people with diabetes; yet, almost one-fourth of all people with diabetes still face a high OOP burden.
C1 [Li, Rui; Barker, Lawrence E.; Shrestha, Sundar; Zhang, Ping; Pearson-Clarke, Tony; Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA.
[Duru, O. Kenrick] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Li, R (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA.
EM eok8@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 28
TC 6
Z9 6
U1 0
U2 1
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD JUN
PY 2014
VL 37
IS 6
BP 1629
EP 1635
DI 10.2337/dc13-1997
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AJ5RX
UT WOS:000337746100038
PM 24667459
ER
PT J
AU Tamma, PD
Srinivasan, A
Cosgrove, SE
AF Tamma, Pranita D.
Srinivasan, Arjun
Cosgrove, Sara E.
TI Preface
SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
LA English
DT Editorial Material
C1 [Tamma, Pranita D.; Cosgrove, Sara E.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA.
[Srinivasan, Arjun] Ctr Dis Control & Prevent, Atlanta, GA 30322 USA.
RP Tamma, PD (reprint author), Johns Hopkins Univ, Sch Med, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM ptamma1@jhmi.edu; asrinivasan@cdc.gov; scosgro1@jhmi.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0891-5520
EI 1557-9824
J9 INFECT DIS CLIN N AM
JI Infect. Dis. Clin. North Am.
PD JUN
PY 2014
VL 28
IS 2
BP XI
EP XII
DI 10.1016/j.idc.2014.04.001
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AJ0HE
UT WOS:000337330300001
PM 24857396
ER
PT J
AU Rhee, SM
Stone, ND
AF Rhee, Susan M.
Stone, Nimalie D.
TI Antimicrobial Stewardship in Long-term Care Facilities
SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
DE Long-term care; Antimicrobial stewardship; Antimicrobial resistance;
Elderly; Infection prevention
ID NURSING-HOME RESIDENTS; URINARY-TRACT-INFECTION; ANTIBIOTIC USE;
ASYMPTOMATIC BACTERIURIA; CRITERIA; SURVEILLANCE; INTERVENTION;
DEFINITIONS; HOSPITALS; MORTALITY
AB Although antimicrobial stewardship has been shown to improve microbiologic susceptibility patterns, decrease drug toxicities, and lower overall drug costs in acute care inpatient, there are few studies assessing programs in the long-term care (LTC) setting. Implementing antimicrobial stewardship programs in LTC settings can be challenging as the LTC setting houses a unique population of frail and older adults with several preexisting conditions and multiple risk factors for colonization with multidrug-resistant organisms. Antimicrobial stewardship has an important role in decreasing inappropriate antibiotic use, encouraging targeted treatment of specific disease states, and limiting the untoward effects and costs of antimicrobials in this vulnerable population.
C1 [Rhee, Susan M.] Johns Hopkins Bayview Med Ctr, Div Infect Dis, Baltimore, MD 21224 USA.
[Stone, Nimalie D.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
RP Rhee, SM (reprint author), Johns Hopkins Bayview Med Ctr, Div Infect Dis, 5200 Eastern Ave,MFL Ctr Tower,3rd Floor, Baltimore, MD 21224 USA.
EM srhee9@jhmi.edu
NR 50
TC 11
Z9 11
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0891-5520
EI 1557-9824
J9 INFECT DIS CLIN N AM
JI Infect. Dis. Clin. North Am.
PD JUN
PY 2014
VL 28
IS 2
BP 237
EP +
DI 10.1016/j.idc.2014.01.001
PG 11
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AJ0HE
UT WOS:000337330300006
PM 24857390
ER
PT J
AU Bitsko, RH
Holbrook, JR
Visser, SN
Mink, JW
Zinner, SH
Ghandour, RM
Blumberg, SJ
AF Bitsko, Rebecca H.
Holbrook, Joseph R.
Visser, Susanna N.
Mink, Jonathan W.
Zinner, Samuel H.
Ghandour, Reem M.
Blumberg, Stephen J.
TI A National Profile of Tourette Syndrome, 2011-2012
SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS
LA English
DT Article
DE epidemiology; prevalence; health care; comorbidity; parenting
ID HEALTH-CARE NEEDS; TIC DISORDERS; CHILDREN; PREVALENCE; EPIDEMIOLOGY;
COMORBIDITY; RISK
AB Objective: To provide recent estimates of the prevalence of Tourette syndrome among a nationally representative sample of US children and to describe the association of Tourette syndrome with indicators of health and functioning. Methods: Data on 65,540 US children aged 6 to 17 years from the 20112012 National Survey of Children's Health were analyzed. Parents reported whether a health care provider had ever told them their child had Tourette syndrome or other neurobehavioral or chronic health conditions and whether their child had current Tourette syndrome. Results: Based on parents' report, 0.19% of US children had Tourette syndrome; the average age of diagnosis was 8.1 years. Children with Tourette syndrome, compared with those without, were more likely to have co-occurring neurobehavioral and other health conditions, meet criteria for designation as having a special health care need, receive mental health treatment, have unmet mental health care needs, and have parents with high parenting aggravation and parents who were contacted about school problems; they were less likely to receive effective care coordination or have a medical home. After controlling for co-occurring neurobehavioral conditions, the findings on parents being contacted about school problems and children having unmet mental health care needs were no longer significant. Conclusions: Tourette syndrome is characterized by co-occurring neurobehavioral and other health conditions, and poorer health, education, and family relationships. The findings support previous recommendations to consider co-occurring conditions in the diagnosis and treatment of Tourette syndrome. Future research may explore whether having a medical home improves outcomes among children with Tourette syndrome.
C1 [Bitsko, Rebecca H.; Holbrook, Joseph R.; Visser, Susanna N.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, NCBDDD, Atlanta, GA USA.
[Mink, Jonathan W.] Univ Rochester, Dept Neurol, Rochester, NY USA.
[Mink, Jonathan W.] Univ Rochester, Dept Neurobiol & Anat, Rochester, NY USA.
[Mink, Jonathan W.] Univ Rochester, Dept Brain & Cognit Sci, Rochester, NY USA.
[Mink, Jonathan W.] Univ Rochester, Dept Pediat, Rochester, NY USA.
[Zinner, Samuel H.] Univ Washington, Dept Pediat, Div Dev Med, Seattle, WA 98195 USA.
[Ghandour, Reem M.] Maternal & Child Hlth Bur, Off Epidemiol & Res, US Hlth Resources & Serv Adm, Rockville, MD USA.
[Blumberg, Stephen J.] Ctr Dis Control & Prevent, Div Hlth Interview Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA.
RP Bitsko, RH (reprint author), CDC, NCBDDD, 1600 Clifton Rd,MS E-88, Atlanta, GA 30333 USA.
EM dvk2@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 34
TC 11
Z9 11
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0196-206X
EI 1536-7312
J9 J DEV BEHAV PEDIATR
JI J. Dev. Behav. Pediatr.
PD JUN
PY 2014
VL 35
IS 5
BP 317
EP 322
PG 6
WC Behavioral Sciences; Psychology, Developmental; Pediatrics
SC Behavioral Sciences; Psychology; Pediatrics
GA AJ0PL
UT WOS:000337357400002
PM 24906033
ER
PT J
AU Osadebe, LU
Li, Y
Damon, IK
Reynolds, MG
Muyombwe, A
Gappy, C
AF Osadebe, Lynda U.
Li, Yu
Damon, Inger K.
Reynolds, Mary G.
Muyombwe, Anthony
Gappy, Christopher
TI Ocular Molluscum Contagiosum Atypical Clinical Presentation
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
C1 [Osadebe, Lynda U.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, DHCPP,Poxvirus & Rabies Branch, Atlanta, GA 30333 USA.
[Li, Yu; Damon, Inger K.; Reynolds, Mary G.] Ctr Dis Control & Prevent, DHCPP, Poxvirus & Rabies Branch, Atlanta, GA USA.
[Muyombwe, Anthony] Michigan Dept Community Hlth, Bur Labs, Lansing, MI USA.
[Gappy, Christopher] Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48109 USA.
RP Osadebe, LU (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, DHCPP,Poxvirus & Rabies Branch, Atlanta, GA 30333 USA.
NR 8
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUN
PY 2014
VL 33
IS 6
BP 668
EP 668
DI 10.1097/INF.0000000000000258
PG 1
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AJ0OL
UT WOS:000337354400030
PM 24830519
ER
PT J
AU Dharan, NJ
Sokolow, LZ
Cheng, PY
Gargiullo, P
Gershman, K
Lynfield, R
Morin, C
Thomas, A
Meek, J
Farley, MM
Arnold, KE
Reingold, A
Craig, AS
Schaffner, W
Bennett, NM
Zansky, S
Baumbach, J
Lathrop, S
Kamimoto, L
Shay, DK
AF Dharan, Nila J.
Sokolow, Leslie Z.
Cheng, Po-Yung
Gargiullo, Paul
Gershman, Ken
Lynfield, Ruth
Morin, Craig
Thomas, Ann
Meek, James
Farley, Monica M.
Arnold, Kathryn E.
Reingold, Arthur
Craig, Allen S.
Schaffner, William
Bennett, Nancy M.
Zansky, Shelley
Baumbach, Joan
Lathrop, Sarah
Kamimoto, Laurie
Shay, David K.
TI Child, Household, and Caregiver Characteristics Associated with
Hospitalization for Influenza Among Children 6-59 Months of Age An
Emerging Infections Program Study
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE influenza; risk factors; hospitalization; children; household
ID RESPIRATORY SYNCYTIAL VIRUS; TEST-NEGATIVE DESIGN; RISK-FACTORS;
UNITED-STATES; YOUNG-CHILDREN; INFANTS; SURVEILLANCE; DISPARITIES;
DISEASE; VACCINE
AB Background: Young children are at increased risk of severe outcomes from influenza illness, including hospitalization. We conducted a case-control study to identify risk factors for influenza-associated hospitalizations among children in US Emerging Infections Program sites.
Methods: Cases were children 6-59 months of age hospitalized for laboratory-confirmed influenza infections during 2005-2008. Age- and zip-code-matched controls were enrolled. Data on child, caregiver and household characteristics were collected from parents and medical records. Conditional logistic regression was used to identify independent risk factors for hospitalization.
Results: We enrolled 290 (64%) of 454 eligible cases and 1089 (49%) of 2204 eligible controls. Risk for influenza hospitalization increased with maternal age <26 years [odds ratio (OR): 1.8, 95% confidence interval (CI): 1.1-2.9]; household income below the poverty threshold (OR: 2.2, 95% CI: 1.4-3.6); smoking by >50% of household members (OR: 2.9, 95% CI: 1.4-6.6); lack of household influenza vaccination (OR: 1.8, 95% CI: 1.2-2.5) and presence of chronic illnesses, including hematologic/oncologic (OR: 11.8, 95% CI: 4.5-31.0), pulmonary (OR: 2.9, 95% CI: 1.9-4.4) and neurologic (OR: 3.8, 95% CI: 1.6-9.2) conditions. Full influenza immunization decreased the risk among children 6-23 months of age (OR: 0.5, 95% CI: 0.3-0.9) but not among those 24-59 months of age (OR: 1.5, 95% CI: 0.8-3.0; P value for difference = 0.01).
Conclusions: Chronic illnesses, young maternal age, poverty, household smoking and lack of household influenza vaccination increased the risk of influenza hospitalization. These characteristics may help providers to identify young children who are at greatest risk for severe outcomes from influenza illness.
C1 [Dharan, Nila J.; Sokolow, Leslie Z.; Cheng, Po-Yung; Gargiullo, Paul; Kamimoto, Laurie; Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
[Sokolow, Leslie Z.] Battelle Mem Inst, Atlanta, GA USA.
[Gershman, Ken] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
[Lynfield, Ruth; Morin, Craig] Minnesota Dept Hlth, St Paul, MN USA.
[Thomas, Ann] Oregon Publ Hlth Div, Portland, OR USA.
[Meek, James] Connecticut Emerging Infect Program, New Haven, CT USA.
[Farley, Monica M.] Emory Univ, Sch Med, Atlanta, GA USA.
[Farley, Monica M.] Atlanta VA Med Ctr, Atlanta, GA USA.
[Arnold, Kathryn E.] Georgia Emerging Infect Program, Atlanta, GA USA.
[Reingold, Arthur] Calif Emerging Infect Program, Oakland, CA USA.
[Craig, Allen S.] Tennessee Dept Hlth, Nashville, TN USA.
[Craig, Allen S.; Schaffner, William] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA.
[Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA.
[Zansky, Shelley] New York State Dept Hlth, Albany, NY USA.
[Baumbach, Joan] New Mexico Dept Hlth, Santa Fe, NM USA.
[Lathrop, Sarah] Univ New Mexico, Albuquerque, NM 87131 USA.
RP Dharan, NJ (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, 185 South Orange Ave,MSB 1-689, Newark, NJ 07103 USA.
EM Dharannj@njms.rutgers.edu
OI Shay, David/0000-0001-9619-4820
FU Centers for Disease Control and Prevention
FX The EIP is a collaboration of state health departments, academic
institutions and local partners and is funded by the Centers for Disease
Control and Prevention. Members of the EIP sites were involved in the
design and conduct of the study; collection, management, analysis and
interpretation of the data and preparation, review or approval of the
manuscript.
NR 33
TC 6
Z9 6
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUN
PY 2014
VL 33
IS 6
BP E141
EP E150
DI 10.1097/INF.0000000000000283
PG 10
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AJ0OL
UT WOS:000337354400002
PM 24642518
ER
PT J
AU Richards, TB
White, MC
Caraballo, RS
AF Richards, Thomas B.
White, Mary C.
Caraballo, Ralph S.
TI Lung Cancer Screening with Low-Dose Computed Tomography for Primary Care
Providers
SO PRIMARY CARE
LA English
DT Article
DE Lung neoplasms; Screening; Computed tomography; Primary health care;
Practice guidelines; Smoking cessation; Shared decision making
ID CLINICAL-PRACTICE GUIDELINES; ED AMERICAN-COLLEGE; 1-YEAR FOLLOW-UP;
UNITED-STATES; SMOKING-CESSATION; PULMONARY NODULES; DECISION-MAKING;
TRIAL PARTICIPANTS; FLEISCHNER-SOCIETY; PROSPECTIVE COHORT
AB This review provides an update on lung cancer screening with low-dose computed tomography (LDCT) and its implications for primary care providers. One of the unique features of lung cancer screening is the potential complexity in patient management if an LDCT scan reveals a small pulmonary nodule. Additional tests, consultation with multiple specialists, and follow-up evaluations may be needed to evaluate whether lung cancer is present. Primary care providers should know the resources available in their communities for lung cancer screening with LDCT and smoking cessation, and the key points to be addressed in informed and shared decision-making discussions with patients.
C1 [Richards, Thomas B.; White, Mary C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Caraballo, Ralph S.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
RP Richards, TB (reprint author), Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Bldg 107,F-76,4770 Buford Highway Northeast, Atlanta, GA 30341 USA.
EM TRichards@cdc.gov
RI White, Mary /C-9242-2012
OI White, Mary /0000-0002-9826-3962
FU Intramural CDC HHS [CC999999]
NR 121
TC 4
Z9 4
U1 0
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0095-4543
EI 1558-299X
J9 PRIMARY CARE
JI Primary Care
PD JUN
PY 2014
VL 41
IS 2
BP 307
EP +
DI 10.1016/j.pop.2014.02.007
PG 26
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA AJ0HC
UT WOS:000337330100009
PM 24830610
ER
PT J
AU Wilson, JR
Tzeng, WP
Spesock, A
Music, N
Guo, Z
Barrington, R
Stevens, J
Donis, RO
Katz, JM
York, IA
AF Wilson, Jason R.
Tzeng, Wen-Pin
Spesock, April
Music, Nedzad
Guo, Zhu
Barrington, Robert
Stevens, James
Donis, Ruben O.
Katz, Jacqueline M.
York, Ian A.
TI Diversity of the murine antibody response targeting influenza
A(H1N1pdm09) hemagglutinin
SO VIROLOGY
LA English
DT Article
DE Influenza; Antibody; Germline; Repertoire; Affinity; Cloning
ID DEPENDENT CELLULAR CYTOTOXICITY; VIRUS A/PR/8/34 HEMAGGLUTININ; HUMAN
MONOCLONAL-ANTIBODIES; SPECIES RICHNESS ESTIMATION; CAPTURE
PROBABILITIES VARY; RECEPTOR-BINDING; A VIRUSES; NEUTRALIZING EPITOPE;
ANTIGENIC VARIATION; MAXIMUM-LIKELIHOOD
AB We infected mice with the 2009 influenza A pandemic virus (H1N1pdm09), boosted with an inactivated vaccine, and cloned immunoglobulins (Igs) from HA-specific B cells. Based on the redundancy in germline gene utilization, we inferred that between 72-130 unique IgH VDJ and 35 different IgL VJ combinations comprised the anti-HA recall response. The IgH VH1 and IgL VK14 variable gene families were employed most frequently. A representative panel of antibodies were cloned and expressed to confirm reactivity with H1N1pdm09 HA. The majority of the recombinant antibodies were of high avidity and capable of inhibiting H1N1pdm09 hemagglutination. Three of these antibodies were subtype-specific cross-reactive, binding to the HA of A/South Carolina/1/1918(H1N1), and one further reacted with A/swine/Iowa/15/1930(H1N1). These results help to define the genetic diversity of the influenza anti-HA antibody repertoire profile induced following infection and vaccination, which may facilitate the development of influenza vaccines that are more protective and broadly neutralizing.
Importance: Protection against influenza viruses is mediated mainly by antibodies, and in most cases this antibody response is narrow, only providing protection against closely related viruses. In spite of this limited range of protection, recent findings indicate that individuals immune to one influenza virus may contain antibodies (generally a minority of the overall response) that are more broadly reactive. These findings have raised the possibility that influenza vaccines could induce a more broadly protective response, reducing the need for frequent vaccine strain changes. However, interpretation of these observations is hampered by the lack of quantitative characterization of the antibody repertoire. In this study, we used single-cell cloning of influenza HA-specific B cells to assess the diversity and nature of the antibody response to influenza hemagglutinin in mice. Our findings help to put bounds on the diversity of the anti-hemagglutinin antibody response, as well as characterizing the cross-reactivity, affinity, and molecular nature of the antibody response. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Wilson, Jason R.; Tzeng, Wen-Pin; Spesock, April; Music, Nedzad; Guo, Zhu; Stevens, James; Donis, Ruben O.; Katz, Jacqueline M.; York, Ian A.] Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
[Barrington, Robert] Univ S Alabama, Mobile, AL 36688 USA.
RP York, IA (reprint author), Influenza Div, MS G-16,1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM ite1@cdc.gov
OI York, Ian/0000-0002-3478-3344
FU Oak Ridge Institute for Science and Education, Oak Ridge, TN; Centers
for Disease Control and Prevention (CDC)
FX This work was supported by the Centers for Disease Control and
Prevention (CDC). J.R.W. received financial support for this work from
the Oak Ridge Institute for Science and Education, Oak Ridge, TN.
NR 55
TC 2
Z9 2
U1 1
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUN
PY 2014
VL 458
BP 114
EP 124
DI 10.1016/j.virol.2014.04.011
PG 11
WC Virology
SC Virology
GA AJ4RZ
UT WOS:000337664800012
PM 24928044
ER
PT J
AU Yangco, BG
Buchacz, K
Baker, R
Palella, FJ
Armon, C
Brooks, JT
AF Yangco, Bienvenido G.
Buchacz, Kate
Baker, Rose
Palella, Frank J.
Armon, Carl
Brooks, John T.
CA HIV Outpatient Study Investigators
TI Is Primary Mycobacterium avium Complex Prophylaxis Necessary in Patients
with CD4 < 50 Cells/mu L Who Are Virologically Suppressed on cART?
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID OPPORTUNISTIC ILLNESSES; ANTIRETROVIRAL THERAPY; INFECTION; COHORT; AIDS
AB We analyzed 369 patients with no prior Mycobacterium avium complex (MAC) infection and CD4 < 50 cells/mu L (baseline), while on combination antiretroviral therapy(cART), for incidence rates of primary MAC infection during the 6 months after baseline, by prophylaxis status. Of participants (median age, 40 years old), most were male (81%) and about half were non-white; at baseline, 81% of participants were on cART > 60 days and 19% had HIV RNA < 1000 copies/mL, whereas 65% had HIV RNA > 10,000 copies/mL. Eleven patients had MAC infection within 6 months baseline (rate = 0.6/100 person months): 4/175 on MAC prophylaxis vs. 7/194, no MAC prophylaxis (p = 0.64). Of the 11 patients, seven had HIV RNA > 10,000, and three > 1000-9999 copies/mL at baseline (one missing). Median time to MAC infection was 62 days (IQR 43-126, maximum 139 days). No MAC infection occurred among 71 (19%) patients virologically suppressed (HIV RNA < 1000 copies/mL) at baseline, including 41 patients with no MAC prophylaxis during follow-up. A small number of eligible virologically suppressed participants and the lack of data on cART/MAC prophylaxis adherence limited our observational nonrandomized study. Primary MAC prophylaxis may not be required for cART-virologically suppressed patients with CD4 < 50 cells/mL.
C1 [Yangco, Bienvenido G.] Infect Dis Res Inst Inc, Tampa, FL 33614 USA.
[Buchacz, Kate; Brooks, John T.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
[Baker, Rose; Armon, Carl] Cerner Corp, Vienna, Austria.
[Palella, Frank J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Yangco, BG (reprint author), Infect Dis Res Inst Inc, 4620 N Habana Ave Suite 203, Tampa, FL 33614 USA.
EM bgy@yangcomd.com
FU Centers for Disease Control and Prevention [200-2001-00133,
200-2006-18797, 200-2011-41872]
FX This work was supported by the Centers for Disease Control and
Prevention (contract Nos. 200-2001-00133, 200-2006-18797 and
200-2011-41872)
NR 15
TC 2
Z9 2
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD JUN
PY 2014
VL 28
IS 6
BP 280
EP 283
DI 10.1089/apc.2013.0270
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AI9CG
UT WOS:000337224700002
PM 24833016
ER
PT J
AU Davis, JC
Verhagen, E
Bryan, S
Liu-Ambrose, T
Borland, J
Buchner, D
Hendriks, MRC
Weiler, R
Morrow, JR
van Mechelen, W
Blair, SN
Pratt, M
Windt, J
al-Tunaiji, H
Macri, E
Khan, KM
AF Davis, Jennifer C.
Verhagen, Evert
Bryan, Stirling
Liu-Ambrose, Teresa
Borland, Jeff
Buchner, David
Hendriks, Marike R. C.
Weiler, Richard
Morrow, James R., Jr.
van Mechelen, Willem
Blair, Steven N.
Pratt, Mike
Windt, Johann
al-Tunaiji, Hashel
Macri, Erin
Khan, Karim M.
CA EPIC Grp
TI 2014 Consensus Statement from the first Economics of Physical Inactivity
Consensus (EPIC) Conference (Vancouver)
SO BRITISH JOURNAL OF SPORTS MEDICINE
LA English
DT Article
ID COST-EFFECTIVENESS; CARDIOVASCULAR-DISEASE; ACTIVITY INTERVENTIONS;
LIFE-STYLE; PREVENTION; NUTRITION; OBESITY; PROMOTION; PROGRAMS; NEGLECT
AB This article describes major topics discussed from the 'Economics of Physical Inactivity Consensus Workshop' (EPIC), held in Vancouver, Canada, in April 2011. Specifically, we (1) detail existing evidence on effective physical inactivity prevention strategies; (2) introduce economic evaluation and its role in health policy decisions; (3) discuss key challenges in establishing and building health economic evaluation evidence (including accurate and reliable costs and clinical outcome measurement) and (4) provide insight into interpretation of economic evaluations in this critically important field. We found that most methodological challenges are related to (1) accurately and objectively valuing outcomes; (2) determining meaningful clinically important differences in objective measures of physical inactivity; (3) estimating investment and disinvestment costs and (4) addressing barriers to implementation. We propose that guidelines specific for economic evaluations of physical inactivity intervention studies are developed to ensure that related costs and effects are robustly, consistently and accurately measured. This will also facilitate comparisons among future economic evidence.
C1 [Davis, Jennifer C.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada.
[Davis, Jennifer C.; Bryan, Stirling] Univ British Columbia, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1M9, Canada.
[Verhagen, Evert; Hendriks, Marike R. C.; van Mechelen, Willem] Vrije Univ Amsterdam Med Ctr, Dept Publ & Occupat Hlth, Amsterdam, Netherlands.
[Verhagen, Evert; Hendriks, Marike R. C.; van Mechelen, Willem] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
[Liu-Ambrose, Teresa; al-Tunaiji, Hashel; Macri, Erin] Univ British Columbia, Dept Phys Therapy, Ctr Hip Hlth, Vancouver, BC V5Z 1M9, Canada.
[Borland, Jeff] Univ Melbourne, Melbourne, Vic 3010, Australia.
[Buchner, David] MC 588 Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL USA.
[Hendriks, Marike R. C.] Maastricht Univ, Sch Nutr Toxicol & Metab, NUTRIM, Dept Human Movement Sci, NL-6200 MD Maastricht, Netherlands.
[Weiler, Richard] Univ Coll London Hosp NHS Fdn Trust, Inst Sport Exercise & Hlth, London, England.
[Morrow, James R., Jr.] Univ N Texas, Denton, TX 76203 USA.
[Blair, Steven N.] Univ S Carolina, Dept Exercise Sci, Columbia, SC 29208 USA.
[Pratt, Mike] Ctr Dis Control & Prevent, NCCDPHP, Atlanta, GA USA.
[Windt, Johann] Univ British Columbia, Dept Expt Med, Abbotsford, BC, Canada.
[Khan, Karim M.] Univ British Columbia, Dept Family Practice, Vancouver, BC V5Z 1M9, Canada.
[Khan, Karim M.] Aspetar Orthopaed & Sports Med Hosp, Doha, Qatar.
RP Davis, JC (reprint author), Univ British Columbia, Dept Hlth Care & Epidemiol, 828 West 10th Ave, Vancouver, BC V5Z 1M9, Canada.
EM jennifer.davis@ubc.ca
RI Verhagen, Evert/A-1502-2013
OI Verhagen, Evert/0000-0001-9227-8234
FU Canadian Institutes of Health Research-Mobility in Aging/CHHM Team in
Vulnerable Seniors, BMJ Group, CHHM Walk the Talk Team; Canadian
Institutes of Health Research (CIHR) [MAT-92025]
FX The Economics of Physical Inactivity Consensus (EPIC) Symposium was
funded by the Canadian Institutes of Health Research-Mobility in
Aging/CHHM Team in Vulnerable Seniors, BMJ Group, CHHM Walk the Talk
Team. Canadian Institutes of Health Research (CIHR)-Emerging Team Grant
in Mobility in Aging MAT-92025.
NR 42
TC 15
Z9 16
U1 2
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-3674
EI 1473-0480
J9 BRIT J SPORT MED
JI Br. J. Sports Med.
PD JUN
PY 2014
VL 48
IS 12
BP 947
EP +
DI 10.1136/bjsports-2014-093575
PG 6
WC Sport Sciences
SC Sport Sciences
GA AJ0GV
UT WOS:000337329300006
PM 24859181
ER
PT J
AU Majowicz, SE
Scallan, E
Jones-Bitton, A
Sargeant, JM
Stapleton, J
Angulo, FJ
Yeung, DH
Kirk, MD
AF Majowicz, Shannon E.
Scallan, Elaine
Jones-Bitton, Andria
Sargeant, Jan M.
Stapleton, Jackie
Angulo, Frederick J.
Yeung, Derrick H.
Kirk, Martyn D.
TI Global Incidence of Human Shiga Toxin-Producing Escherichia coli
Infections and Deaths: A Systematic Review and Knowledge Synthesis
SO FOODBORNE PATHOGENS AND DISEASE
LA English
DT Article
ID UNITED-STATES; CHILDHOOD DIARRHEA; VTEC INFECTION; RISK-FACTORS; BURDEN;
POPULATION; GASTROENTERITIS; SURVEILLANCE; PATHOGENS; BACTERIAL
AB Objectives: Shiga toxin-producing Escherichia coli (STEC) are an important cause of foodborne disease, yet global estimates of disease burden do not exist. Our objective was to estimate the global annual number of illnesses due to pathogenic STEC, and resultant hemolytic uremic syndrome (HUS), end-stage renal disease (ESRD), and death.
Materials: We searched Medline, Scopus, SIGLE/OpenGrey, and CABI and World Health Organization (WHO) databases for studies of STEC incidence in the general population, published between January 1, 1990 and April 30, 2012, in all languages. We searched health institution websites for notifiable disease data and reports, cross-referenced citations, and consulted international knowledge experts. We employed an a priori hierarchical study selection process and synthesized results using a stochastic simulation model to account for uncertainty inherent in the data.
Results: We identified 16 articles and databases from 21 countries, from 10 of the 14 WHO Sub-Regions. We estimated that STEC causes 2,801,000 acute illnesses annually (95% Credible Interval [Cr. I.]: 1,710,000; 5,227,000), and leads to 3890 cases of HUS (95% Cr. I.: 2400; 6700), 270 cases of ESRD (95% Cr. I.: 20; 800), and 230 deaths (95% Cr. I.: 130; 420). Sensitivity analyses indicated these estimates are likely conservative.
Conclusions: These are the first estimates of the global incidence of STEC-related illnesses, which have not been explicitly included in previous global burden of disease estimations. Compared to other pathogens with a foodborne transmission component, STEC appears to cause more cases than alveolar echinococcosis each year, but less than typhoid fever, foodborne trematodes, and nontyphoidal salmonellosis.
Applications: Given the persistence of STEC globally, efforts aimed at reducing the burden of foodborne disease should consider the relative contribution of STEC in the target population.
C1 [Majowicz, Shannon E.; Yeung, Derrick H.] Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON N2L 3G1, Canada.
[Scallan, Elaine] Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO USA.
[Jones-Bitton, Andria; Sargeant, Jan M.] Univ Guelph, Dept Populat Med, Guelph, ON N1G 2W1, Canada.
[Jones-Bitton, Andria; Sargeant, Jan M.] Univ Guelph, Ctr Publ Hlth & Zoonoses, Guelph, ON N1G 2W1, Canada.
[Stapleton, Jackie] Univ Waterloo Lib, Waterloo, ON, Canada.
[Angulo, Frederick J.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA.
[Kirk, Martyn D.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Acton, ACT, Australia.
RP Majowicz, SE (reprint author), Univ Waterloo, Sch Publ Hlth & Hlth Syst, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
EM smajowicz@uwaterloo.ca
FU School of Public Health and Health Systems; World Health Organization's
Foodborne Diseases Epidemiology Reference Group (FERG); Faculty of
Applied Health Sciences (University of Waterloo)
FX The authors thank Janet Harris (Public Health Agency of Canada) for
assistance creating the search strings and conducting the review and
extraction. The School of Public Health and Health Systems and the
Faculty of Applied Health Sciences (University of Waterloo) and the
World Health Organization's Foodborne Diseases Epidemiology Reference
Group (FERG) supported this work. FERG was consulted during study
design, assisted with obtaining identified references, provided feedback
on preliminary results, and had the opportunity to comment on the final
manuscript.
NR 49
TC 28
Z9 28
U1 4
U2 30
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1535-3141
EI 1556-7125
J9 FOODBORNE PATHOG DIS
JI Foodborne Pathog. Dis.
PD JUN
PY 2014
VL 11
IS 6
BP 447
EP 455
DI 10.1089/fpd.2013.1704
PG 9
WC Food Science & Technology
SC Food Science & Technology
GA AI8OA
UT WOS:000337177400005
PM 24750096
ER
PT J
AU Dubey, JP
Jones, JL
AF Dubey, Jitender P.
Jones, Jeffrey L.
TI Comments on "Detection of Toxoplasma gondii in Raw Caprine, Ovine,
Buffalo, Bovine, and Camel Milk Using Cell Cultivation, Cat Bioassay,
Capture ELISA, and PCR Methods in Iran''
SO FOODBORNE PATHOGENS AND DISEASE
LA English
DT Letter
ID UNITED-STATES; INFECTION; GOATS
C1 [Dubey, Jitender P.] ARS, Beltsville Agr Res Ctr, Anim Parasit Dis Lab, USDA, Beltsville, MD 20705 USA.
[Jones, Jeffrey L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA.
RP Dubey, JP (reprint author), ARS, Beltsville Agr Res Ctr, Anim Parasit Dis Lab, USDA, Bldg 1001, Beltsville, MD 20705 USA.
EM jitender.dubey@ars.usda.gov
NR 11
TC 5
Z9 5
U1 0
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1535-3141
EI 1556-7125
J9 FOODBORNE PATHOG DIS
JI Foodborne Pathog. Dis.
PD JUN
PY 2014
VL 11
IS 6
BP 500
EP 501
DI 10.1089/fpd.2014.1786
PG 2
WC Food Science & Technology
SC Food Science & Technology
GA AI8OA
UT WOS:000337177400013
PM 24886069
ER
PT J
AU Koziel, J
Bryzek, D
Sroka, A
Maresz, K
Glowczyk, I
Bielecka, E
Kantyka, T
Pyrc, K
Svoboda, P
Pohl, J
Potempa, J
AF Koziel, Joanna
Bryzek, Danuta
Sroka, Aneta
Maresz, Katarzyna
Glowczyk, Izabela
Bielecka, Ewa
Kantyka, Tomasz
Pyrc, Krzysztof
Svoboda, Pavel
Pohl, Jan
Potempa, Jan
TI Citrullination Alters Immunomodulatory Function of LL-37 Essential for
Prevention of Endotoxin-Induced Sepsis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ANTIMICROBIAL PEPTIDE LL-37; NEUTROPHIL EXTRACELLULAR TRAPS;
PEPTIDYLARGININE DEIMINASE; CATHELICIDIN FAMILY; POSTTRANSLATIONAL
MODIFICATION; TISSUE INFLAMMATION; HUMAN SKIN; ANTIBACTERIAL;
EXPRESSION; CELLS
AB Cathelicidin LL-37 plays an essential role in innate immunity by killing invading microorganisms and regulating the inflammatory response. These activities depend on the cationic character of the peptide, which is conferred by arginine and lysine residues. At inflammatory foci in vivo, LL-37 is exposed to peptidyl arginine deiminase (PAD), an enzyme released by inflammatory cells. Therefore, we hypothesized that PAD-mediated citrullination of the arginine residues within LL-37 will abrogate its immunomodulatory functions. We found that, when citrullinated, LL-37 was at least 40 times less efficient at neutralizing the proinflammatory activity of LPS due to a marked decrease in its affinity for endotoxin. Also, the ability of citrullinated LL-37 to quench macrophage responses to lipoteichoic acid and poly(I:C) signaling via TLR2 and TLR3, respectively, was significantly reduced. Furthermore, in stark contrast to native LL-37, the modified peptide completely lost the ability to prevent morbidity and mortality in a mouse model of D-galactosamine-sensitized endotoxin shock. In fact, administration of citrullinated LL-37 plus endotoxin actually exacerbated sepsis due to the inability of LL-37 to neutralize LPS and the subsequent enhancement of systemic inflammation due to increased serum levels of IL-6. Importantly, serum from septic mice showed increased PAD activity, which strongly correlated with the level of citrullination, indicating that PAD-driven protein modification occurs in vivo. Because LL-37 is a potential treatment for sepsis, its administration should be preceded by a careful analysis to ensure that the citrullinated peptide is not generated in treated patients.
C1 [Koziel, Joanna; Bryzek, Danuta; Sroka, Aneta; Maresz, Katarzyna; Glowczyk, Izabela; Bielecka, Ewa; Kantyka, Tomasz; Pyrc, Krzysztof; Potempa, Jan] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Microbiol, PL-30387 Krakow, Poland.
[Svoboda, Pavel; Pohl, Jan] Ctr Dis Control & Prevent, Div Sci Resources, Atlanta, GA 30333 USA.
[Potempa, Jan] Univ Louisville, Sch Dent, Ctr Oral Hlth & System Dis, Louisville, KY 40202 USA.
RP Koziel, J (reprint author), Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Microbiol, Gronostajowa 7 St, PL-30387 Krakow, Poland.
EM joanna.koziel@uj.edu.pl
OI Pyrc, Krzysztof/0000-0002-3867-7688
FU European Community [FP7-HEALTH-2010261460, FP7-HEALTH-F3-2012-306029,
FP7-PEOPLE-2011-ITN-290246]; National Institutes of Health [DE 022597];
National Science Center, Poland [UMO-2011/01/B/NZ6/00268,
2011/03/B/NZ6/00053]; Foundation for Polish Science TEAM Project
[DPS/424-329/10]; Polish Ministry of Science and Higher Education
[137/7.PR-EU/2011/2]; European Union [POIG. 02.01.00-12-064/08]
FX This work was supported by European Community Grants
FP7-HEALTH-2010261460 "Gums&Joints," FP7-HEALTH-F3-2012-306029
"TRIGGER," and FP7-PEOPLE-2011-ITN-290246 "RAPID"; National Institutes
of Health Grant DE 022597; National Science Center, Poland Grants
UMO-2011/01/B/NZ6/00268 and 2011/03/B/NZ6/00053 (to J. Potempa and J.K.,
respectively); Foundation for Polish Science TEAM Project
DPS/424-329/10; and Polish Ministry of Science and Higher Education
Grant 137/7.PR-EU/2011/2. The Faculty of Biochemistry, Biophysics, and
Biotechnology of the Jagiellonian University is a beneficiary of
structural funds from the European Union (POIG. 02.01.00-12-064/08).
NR 40
TC 11
Z9 11
U1 1
U2 9
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD JUN 1
PY 2014
VL 192
IS 11
BP 5363
EP 5372
DI 10.4049/jimmunol.1303062
PG 10
WC Immunology
SC Immunology
GA AI8MT
UT WOS:000337171800047
PM 24771854
ER
PT J
AU Eke, PI
Page, RC
Wei, L
Thornton-Evans, G
Genco, RJ
AF Eke, Paul I.
Page, Roy C.
Wei, Liang
Thornton-Evans, Gina
Genco, Robert J.
TI Re: Update of the Case Definitions for PopulationBased Surveillance of
Periodontitis. Eke PI, Page RC, Wei L, Thornton-Evans G, Genco RJ. (J
Periodontol 2012; 83: 1449-1454.) Response
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Letter
C1 [Eke, Paul I.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA 30333 USA.
[Page, Roy C.] Univ Washington, Sch Med & Dent, Reg Clin Dent Res Ctr, Seattle, WA 98195 USA.
[Wei, Liang; Thornton-Evans, Gina] Ctr Dis Control & Prevent, Div Oral Hlth, Atlanta, GA USA.
[Genco, Robert J.] SUNY Buffalo, Sch Dent Med, Buffalo, NY 14260 USA.
[Genco, Robert J.] SUNY Buffalo, Sch Med, Buffalo, NY 14260 USA.
[Genco, Robert J.] SUNY Buffalo, Sch Biomed Sci, Buffalo, NY 14260 USA.
RP Eke, PI (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA 30333 USA.
NR 5
TC 0
Z9 0
U1 0
U2 2
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA
SN 0022-3492
EI 1943-3670
J9 J PERIODONTOL
JI J. Periodont.
PD JUN
PY 2014
VL 85
IS 6
BP 766
EP 767
DI 10.1902/jop.2014.130676
PG 3
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA AI8HJ
UT WOS:000337151800011
PM 24875013
ER
PT J
AU Simon, TR
Ikeda, RM
Smith, EP
Reese, LE
Rabiner, DL
Miller, S
Winn, DM
Dodge, KA
Asher, SR
Horne, AM
Orpinas, P
Martin, R
Quinn, WH
Tolan, PH
Gorman-Smith, D
Henry, DB
Gay, FN
Schoeny, M
Farrell, AD
Meyer, AL
Sullivan, TN
Allison, KW
AF Simon, Thomas R.
Ikeda, Robin M.
Smith, Emilie Phillips
Reese, Le'Roy E.
Rabiner, David L.
Miller, Shari
Winn, Donna-Marie
Dodge, Kenneth A.
Asher, Steven R.
Horne, Arthur M.
Orpinas, Pamela
Martin, Roy
Quinn, William H.
Tolan, Patrick H.
Gorman-Smith, Deborah
Henry, David B.
Gay, Franklin N.
Schoeny, Michael
Farrell, Albert D.
Meyer, Aleta L.
Sullivan, Terri N.
Allison, Kevin W.
CA Multisite Violence Prevention
TI Targeting High-Risk, Socially Influential Middle School Students to
Reduce Aggression: Universal Versus Selective Preventive Intervention
Effects
SO JOURNAL OF RESEARCH ON ADOLESCENCE
LA English
DT Article
ID MULTISITE VIOLENCE PREVENTION; EARLY ADOLESCENTS; RANDOMIZED-TRIAL;
PROBLEM-BEHAVIOR; CONDUCT PROBLEMS; PEER-GROUPS; PROGRAM; FAMILIES;
CHILDHOOD; IMPACT
AB Early adolescence may be an opportune time for violence prevention, particularly if shifts in risk patterns and the importance of peer influence are considered. An important question is whether to target high-risk students or the entire population. Thirty-seven schools were randomized to four conditions: universal classroom intervention; selective family intervention; combined interventions; or control to test effects on a high-risk sample (N=1,805) of sixth graders targeted due to elevated aggression and social influence. Intent-to-treat and dosage-weighted growth comparisons through two years of postintervention revealed selective intervention benefits for physical aggression, aggressive strategies, and targeted family characteristics. Universal and combined interventions affected valuing academic achievement. Implications for middle school prevention, particularly selective targeting of socially influential high-risk youth, are discussed.
C1 [Simon, Thomas R.; Ikeda, Robin M.; Smith, Emilie Phillips; Reese, Le'Roy E.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
[Rabiner, David L.; Miller, Shari; Winn, Donna-Marie; Dodge, Kenneth A.; Asher, Steven R.] Duke Univ, Durham, NC 27706 USA.
Univ Georgia, Athens, GA 30602 USA.
[Horne, Arthur M.; Orpinas, Pamela; Martin, Roy; Quinn, William H.] Univ Illinois, Chicago, IL USA.
[Tolan, Patrick H.; Gorman-Smith, Deborah; Henry, David B.; Gay, Franklin N.; Schoeny, Michael; Farrell, Albert D.; Meyer, Aleta L.; Sullivan, Terri N.; Allison, Kevin W.] Virginia Commonwealth Univ, Richmond, VA 23284 USA.
RP Tolan, PH (reprint author), Univ Virginia, Youth Nex Ctr, POB 400281, Charlottesville, VA 22904 USA.
EM pht6t@virginia.edu
OI Tolan, Patrick/0000-0001-5669-8442
NR 62
TC 4
Z9 4
U1 5
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1050-8392
EI 1532-7795
J9 J RES ADOLESCENCE
JI J. Res. Adolesc.
PD JUN
PY 2014
VL 24
IS 2
SI SI
BP 364
EP 382
DI 10.1111/jora.12067
PG 19
WC Family Studies; Psychology, Developmental
SC Family Studies; Psychology
GA AJ3MU
UT WOS:000337571500013
ER
PT J
AU Cooper, CP
Gelb, CA
Chu, J
AF Cooper, Crystale Purvis
Gelb, Cynthia A.
Chu, Jennifer
TI What's the Appeal? Testing Public Service Advertisements to Raise
Awareness About Gynecologic Cancer
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
AB In 2013, the Centers for Disease Control and Prevention's (CDC) Inside Knowledge: Get the Facts About Gynecologic Cancer campaign tested creative concepts for English-and Spanish-language video advertisements (for use on television and the Internet) with women aged 35-64 years. Sixteen English and nine Spanish focus groups were conducted in four U. S. cities. CDC used animatics (a series of photographs edited together with a sound track) to simulate produced advertisements, without having to incur the high cost of filming and production. Advertisement concepts consistently resonating with participants featured cancer survivors, were straightforward, included information about cancer symptoms, displayed Inside Knowledge educational materials, and featured diverse women. In the general population focus groups, a primacy testing order effect was observed in which the concept tested first tended to be the most favorably received. Varying the order in which concepts were tested and considering testing order when interpreting results was critical.
C1 [Cooper, Crystale Purvis] Soltera Ctr Canc Prevent & Control, Tucson, AZ USA.
[Gelb, Cynthia A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Chu, Jennifer] Ogilvy Washington, Washington, DC USA.
RP Gelb, CA (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway,Bldg 107,MS F76, Atlanta, GA 30341 USA.
EM cgelb@cdc.gov
FU Division of Cancer Prevention and Control, National Center for Chronic
Disease Prevention and Health Promotion, Centers for Disease Control and
Prevention
FX Funding for the research described here was provided by the Division of
Cancer Prevention and Control, National Center for Chronic Disease
Prevention and Health Promotion, Centers for Disease Control and
Prevention. The findings and conclusions in this report are those of the
authors and do not necessarily represent the official position of the
Centers for Disease Control and Prevention. The authors thank Wendy
Child and Jackeline Fernandez for their assistance with developing the
focus group discussion guide and facilitating the groups.
NR 4
TC 3
Z9 3
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUN
PY 2014
VL 23
IS 6
BP 488
EP 492
DI 10.1089/jwh.2014.4759
PG 5
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA AI9BT
UT WOS:000337222700003
PM 24707839
ER
PT J
AU Derosset, L
Mullenix, A
Flores, A
Mattia-Dewey, D
Mai, CT
AF deRosset, Leslie
Mullenix, Amy
Flores, Alina
Mattia-Dewey, Daniel
Mai, Cara T.
TI Promotora de Salud: Promoting Folic Acid Use Among Hispanic Women
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID UNITED-STATES; SPINA-BIFIDA; FORTIFICATION; INTERVENTION; DEFECTS
AB Background: The U. S. Public Health Service recommends that all women in the United States capable of becoming pregnant consume 400 mu g of folic acid daily to reduce their risk of having a pregnancy affected by a neural tube defect (NTD). However, disparities exist in the consumption of folic acid, with Hispanic women having lower rates of folic acid consumption than non-Hispanic white women.
Methods: A community-based feasibility study was designed to assess the utility of the promotora de salud model to promote consumption of multivitamins containing folic acid for the prevention of NTDs among Spanish-speaking Hispanic women in North Carolina. The study consisted of an educational intervention given by a promotora (a lay, community health worker), with data collection occurring at baseline and four months post-intervention to measure changes in knowledge and behavior. Overall, 52% (n = 303) of participants completed all components of the study.
Results: Self-reported daily multivitamin consumption increased from 24% at baseline to 71% four months post-intervention. During the same time frame, awareness of folic acid increased from 78% to 98% and knowledge of the role of folic acid in the prevention of birth defects increased from 82% to 92%.
Conclusions: The results of this study indicate that the promotora de salud model may be effective in reaching a subpopulation of women with the folic acid message. Additional studies with larger population sizes are warranted to validate these findings.
C1 [deRosset, Leslie] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Maternal Child Hlth, Chapel Hill, NC 27599 USA.
[deRosset, Leslie; Mullenix, Amy] March Dimes North Carolina Preconcept Hlth Campai, Raleigh, NC USA.
[Flores, Alina; Mattia-Dewey, Daniel; Mai, Cara T.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
RP Derosset, L (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Maternal Child Hlth, 170 Roseanau Hall,CB 7400,135 Dauer Dr, Chapel Hill, NC 27599 USA.
EM derosset@email.unc.edu
FU National Center on Birth Defects and Developmental Disabilities, Centers
for Disease Control and Prevention; North Carolina March of Dimes
Chapter [200-2009-M-32674]
FX Funding for the project was obtained from the National Center on Birth
Defects and Developmental Disabilities, Centers for Disease Control and
Prevention and the North Carolina March of Dimes Chapter (Contract No.
200-2009-M-32674).
NR 24
TC 2
Z9 2
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUN
PY 2014
VL 23
IS 6
BP 525
EP 531
DI 10.1089/jwh.2013.4695
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA AI9BT
UT WOS:000337222700009
PM 24707879
ER
PT J
AU Haley, DF
Golin, C
El-Sadr, W
Hughes, JP
Wang, J
Isler, MR
Mannheimer, S
Kuo, I
Lucas, J
DiNenno, E
Justman, J
Frew, PM
Emel, L
Rompalo, A
Polk, S
Adimora, AA
Rodriquez, L
Soto-Torres, L
Hodder, S
AF Haley, Danielle F.
Golin, Carol
El-Sadr, Wafaa
Hughes, James P.
Wang, Jing
Isler, Malika Roman
Mannheimer, Sharon
Kuo, Irene
Lucas, Jonathan
DiNenno, Elizabeth
Justman, Jessica
Frew, Paula M.
Emel, Lynda
Rompalo, Anne
Polk, Sarah
Adimora, Adaora A.
Rodriquez, Lorenna
Soto-Torres, Lydia
Hodder, Sally
CA HIV Prevention Trials Network HPTN
TI Venue-Based Recruitment of Women at Elevated Risk for HIV: An HIV
Prevention Trials Network Study
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID SEXUALLY-TRANSMITTED INFECTIONS; BEHAVIORAL SURVEILLANCE SYSTEM; VACCINE
EFFICACY TRIALS; AFRICAN-AMERICAN WOMEN; UNITED-STATES; CLINICAL-TRIALS;
INCARCERATION RATES; HEALTH DISPARITIES; SEX PARTNERS; US
AB Background: The challenge of identifying and recruiting U. S. women at elevated risk for HIV acquisition impedes prevention studies and services. HIV Prevention Trials Network (HPTN) 064 was a U. S. multisite, longitudinal cohort study designed to estimate HIV incidence among women living in communities with prevalent HIV and poverty. Venue-based sampling (VBS) methodologies and participant and venue characteristics are described.
Methods: Eligible women were recruited from 10 U. S. communities with prevalent HIV and poverty using VBS. Participant eligibility criteria included age 18-44 years, residing in a designated census tract/zip code, and self-report of at least one high-risk personal and/or male sexual partner characteristic associated with HIV acquisition (e. g., incarceration history). Ethnography was conducted to finalize recruitment areas and venues.
Results: Eight thousand twenty-nine women were screened and 2,099 women were enrolled (88% black, median age 29 years) over 14 months. The majority of participants were recruited from outdoor venues (58%), retail spaces (18%), and social service organizations (13%). The proportion of women recruited per venue category varied by site. Most participants (73%) had both individual and partner characteristics that qualified them for the study; 14% were eligible based on partner risk only.
Conclusion: VBS is a feasible and effective approach to rapidly recruit a population of women at enhanced risk for HIV in the United States. Such a recruitment approach is needed in order to engage women most at risk and requires strong community engagement.
C1 [Haley, Danielle F.; Lucas, Jonathan] FHI 360, Durham, NC USA.
[Haley, Danielle F.; Frew, Paula M.] Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, Atlanta, GA 30033 USA.
[Golin, Carol; Adimora, Adaora A.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Golin, Carol; Adimora, Adaora A.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
[El-Sadr, Wafaa; Justman, Jessica] Columbia Univ, Mailman Sch Publ Hlth, Int Ctr AIDS Care & Treatment Programs, New York, NY USA.
[Hughes, James P.; Wang, Jing; Emel, Lynda] Fred Hutchinson Canc Res Ctr, Dept Biostat, Seattle, WA 98104 USA.
[Hughes, James P.] Univ Washington, Div Infect Dis, Seattle, WA 98195 USA.
[Isler, Malika Roman] Univ N Carolina, Sch Med, Dept Social Med, Chapel Hill, NC USA.
[Isler, Malika Roman] Univ N Carolina, North Carolina Translat & Clin Sci Inst, Chapel Hill, NC USA.
[Mannheimer, Sharon] Columbia Univ, Harlem Hosp Ctr, New York, NY USA.
[Mannheimer, Sharon] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
[Kuo, Irene] George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC USA.
[DiNenno, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Frew, Paula M.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30033 USA.
[Rompalo, Anne; Polk, Sarah] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Rodriquez, Lorenna] Bronx Lebanon Hosp Ctr, New York, NY USA.
[Soto-Torres, Lydia] NIAID, NIH, Bethesda, MD 20892 USA.
[Hodder, Sally] Rutgers State Univ, New Jersey Med Sch, Newark, NJ 07102 USA.
RP Haley, DF (reprint author), Emory Univ, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd Northeast, Atlanta, GA 30033 USA.
EM dfhaley@emory.edu
OI Frew, Paula/0000-0002-3078-9124
FU National Institute of Allergy and Infectious Diseases, National
Institute on Drug Abuse; National Institute of Mental Health [UM1
AI068619, U01-AI068613, UM1-AI068613]; Centers for Innovative Research
to Control AIDS, Mailman School of Public Health, Columbia University
[5U1Al069466]; University of North Carolina Clinical Trials Unit
[AI069423]; University of North Carolina Clinical Trials Research Center
of the Clinical and Translational Science Award [RR 025747]; University
of North Carolina Center for AIDS Research [AI050410]; Emory University
HIV/AIDS Clinical Trials Unit [5UO1AI069418]; Center for AIDS Research
[P30 AI050409]; Clinical and Translational Science Award [UL1 RR025008];
Terry Beirn Community Programs for Clinical Research on AIDS Clinical
Trials Unit [5 UM1 AI069503-07]; Johns Hopkins Adult AIDS Clinical Trial
Unit [AI069465]; Johns Hopkins Clinical and Translational Science Award
[UL1 RR 25005]; HPTN Scholars Program; National Institute of Allergy and
Infectious Disease; National Institute of Mental Health; Emory
University Laney Graduate School Robert W. Woodruff Pre-Doctoral
Fellowship; National Institute of Allergy and Infectious Diseases;
National Institutes of Health; Centers for Disease Control and
Prevention; HPTN
FX Funding for this study provided through grants from the National
Institute of Allergy and Infectious Diseases, National Institute on Drug
Abuse, and National Institute of Mental Health (UM1 AI068619,
U01-AI068613, and UM1-AI068613); Centers for Innovative Research to
Control AIDS, Mailman School of Public Health, Columbia University
(5U1Al069466); University of North Carolina Clinical Trials Unit
(AI069423); University of North Carolina Clinical Trials Research Center
of the Clinical and Translational Science Award (RR 025747); University
of North Carolina Center for AIDS Research (AI050410); Emory University
HIV/AIDS Clinical Trials Unit (5UO1AI069418), Center for AIDS Research
(P30 AI050409), and Clinical and Translational Science Award (UL1
RR025008); The Terry Beirn Community Programs for Clinical Research on
AIDS Clinical Trials Unit(5 UM1 AI069503-07); The Johns Hopkins Adult
AIDS Clinical Trial Unit (AI069465); The Johns Hopkins Clinical and
Translational Science Award (UL1 RR 25005); and the HPTN Scholars
Program funded by the National Institute of Allergy and Infectious
Disease and the National Institute of Mental Health. The primary
author's time has been supported in part by the Emory University Laney
Graduate School Robert W. Woodruff Pre-Doctoral Fellowship.; The views
expressed herein are those of the authors and do not necessarily
represent the views of the National Institute of Allergy and Infectious
Diseases, the National Institute of Mental Health, the National
Institutes of Health, the Centers for Disease Control and Prevention,
the HPTN, or its funders.
NR 58
TC 4
Z9 4
U1 1
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUN
PY 2014
VL 23
IS 6
BP 541
EP 551
DI 10.1089/jwh.2013.4654
PG 11
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA AI9BT
UT WOS:000337222700011
PM 24742266
ER
PT J
AU Daniels, RD
Kubale, TL
Yiin, JH
Dahm, MM
Hales, TR
Baris, D
Zahm, SH
Beaumont, JJ
Waters, KM
Pinkerton, LE
AF Daniels, Robert D.
Kubale, Travis L.
Yiin, James H.
Dahm, Matthew M.
Hales, Thomas R.
Baris, Dalsu
Zahm, Shelia H.
Beaumont, James J.
Waters, Kathleen M.
Pinkerton, Lynne E.
TI Mortality and cancer incidence in a pooled cohort of US firefighters
from San Francisco, Chicago and Philadelphia (1950-2009)
SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID FLORIDA PROFESSIONAL FIREFIGHTERS; HEALTH INTERVIEW SURVEY; CENTRAL
UNITED-STATES; TABLE ANALYSIS SYSTEM; FIRE FIGHTERS; OCCUPATIONAL
EXPOSURES; INCIDENCE RATES; ALCOHOL-USE; TOBACCO USE; OBESITY
AB Objectives To examine mortality patterns and cancer incidence in a pooled cohort of 29 993 US career firefighters employed since 1950 and followed through 2009.
Methods Mortality and cancer incidence were evaluated by life table methods with the US population referent. Standardised mortality (SMR) and incidence (SIR) ratios were determined for 92 causes of death and 41 cancer incidence groupings. Analyses focused on 15 outcomes of a priori interest. Sensitivity analyses were conducted to examine the potential for significant bias.
Results Person-years at risk totalled 858 938 and 403 152 for mortality and incidence analyses, respectively. All-cause mortality was at expectation (SMR = 0.99, 95% CI 0.97 to 1.01, n = 12 028). There was excess cancer mortality (SMR = 1.14, 95% CI 1.10 to 1.18, n = 3285) and incidence (SIR = 1.09, 95% CI 1.06 to 1.12, n = 4461) comprised mainly of digestive (SMR = 1.26, 95% CI 1.18 to 1.34, n = 928; SIR = 1.17, 95% CI 1.10 to 1.25, n = 930) and respiratory (SMR= 1.10, 95% CI 1.04 to 1.17, n = 1096; SIR = 1.16, 95% CI 1.08 to 1.24, n = 813) cancers. Consistent with previous reports, modest elevations were observed in several solid cancers; however, evidence of excess lymphatic or haematopoietic cancers was lacking. This study is the first to report excess malignant mesothelioma (SMR= 2.00, 95% CI 1.03 to 3.49, n = 12; SIR = 2.29, 95% CI 1.60 to 3.19, n = 35) among US firefighters. Results appeared robust under differing assumptions and analytic techniques.
Conclusions Our results provide evidence of a relation between firefighting and cancer. The new finding of excess malignant mesothelioma is noteworthy, given that asbestos exposure is a known hazard of firefighting.
C1 [Daniels, Robert D.; Kubale, Travis L.; Yiin, James H.; Dahm, Matthew M.; Hales, Thomas R.; Waters, Kathleen M.; Pinkerton, Lynne E.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA.
[Baris, Dalsu; Zahm, Shelia H.] NCI, Div Canc Epidemiol & Genet, Gaithersburg, MD USA.
[Beaumont, James J.] UC Davis Dept Publ Hlth Sci, Sacramento, CA USA.
RP Daniels, RD (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,Mailstop R-13, Cincinnati, OH 45226 USA.
EM rtd2@cdc.gov
RI Zahm, Shelia/B-5025-2015
FU National Institute for Occupational Safety and Health (NIOSH) by
National Occupational Research Agenda (NORA); US Fire Administration
(USFA); National Institutes of Health (NIH), National Cancer Institute
(NCI)
FX Research funding was provided by the National Institute for Occupational
Safety and Health (NIOSH) by intramural award under the National
Occupational Research Agenda (NORA), and by the US Fire Administration
(USFA). This research was also supported, in part, by the intramural
research programme of the National Institutes of Health (NIH), National
Cancer Institute (NCI).
NR 45
TC 28
Z9 29
U1 2
U2 19
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1351-0711
EI 1470-7926
J9 OCCUP ENVIRON MED
JI Occup. Environ. Med.
PD JUN
PY 2014
VL 71
IS 6
BP 388
EP 397
DI 10.1136/oemed-2013-101662
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI9MV
UT WOS:000337257600003
PM 24142974
ER
PT J
AU Yong, LC
Luckhaupt, SE
Li, J
Calvert, GM
AF Yong, Lee C.
Luckhaupt, Sara E.
Li, Jia
Calvert, Geoffrey M.
TI Quit interest, quit attempt and recent cigarette smoking cessation in
the US working population, 2010
SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID HEALTH INTERVIEW SURVEY; UNITED-STATES; STOP SMOKING; WORKPLACE;
PREDICTORS; BEHAVIORS; SMOKERS; IMPACT; ADULTS; PRODUCTIVITY
AB Objectives To determine the prevalence of cigarette smoking cessation and examine the association between cessation and various factors among workers in a nationally representative sample of US adults.
Methods Data were derived from the 2010 National Health Interview Survey. Prevalence rates were calculated for interest in quitting smoking, making an attempt to quit smoking, and successful smoking cessation (defined as smokers who had quit for 6-12 months). Logistic regression analyses were used to identify factors associated with cessation after adjustment for demographic characteristics (age group, race/ethnicity, educational level and marital status).
Results Data were available for 17 524 adults who were employed in the 12 months prior to interview. The prevalence of quit interest, quit attempt and recent cessation was 65.2%, 53.8% and 6.8%, respectively. Quit interest was less likely among workers with long work hours, but more likely among workers with job insecurity, or frequent workplace skin and/or respiratory exposures. Quit attempt was more likely among workers with a hostile work environment but less likely among workers living in a home that permitted smoking or who smoked >= 11 cigarettes/day. Recent smoking cessation was less likely among workers with frequent exposure to others smoking at work or living in a home that permitted smoking, but more likely among workers with health insurance.
Conclusions Factors associated with cessation interest or attempt differed from those associated with successful cessation. Cessation success might be improved by reducing exposure to others smoking at work and home, and by improving access to health insurance.
C1 [Yong, Lee C.; Luckhaupt, Sara E.; Li, Jia; Calvert, Geoffrey M.] NIOSH, Surveillance Branch, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA.
RP Yong, LC (reprint author), NIOSH, Surveillance Branch, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,Mail Stop R-15, Cincinnati, OH 45226 USA.
EM LAY7@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 40
TC 7
Z9 7
U1 1
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1351-0711
EI 1470-7926
J9 OCCUP ENVIRON MED
JI Occup. Environ. Med.
PD JUN
PY 2014
VL 71
IS 6
BP 405
EP 414
DI 10.1136/oemed-2013-101852
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI9MV
UT WOS:000337257600005
PM 24497440
ER
PT J
AU Alshaarawy, O
Zhu, MT
Ducatman, AM
Conway, B
Andrew, ME
AF Alshaarawy, Omayma
Zhu, Motao
Ducatman, Alan M.
Conway, Baqiyyah
Andrew, Michael E.
TI Urinary polycyclic aromatic hydrocarbon biomarkers and diabetes mellitus
SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID OXIDATIVE STRESS; EXPOSURE; RISK; INFLAMMATION; ASSOCIATION; EXCRETION;
COTININE; SMOKING; MARKERS; WORKERS
AB Objective The aim of the current study is to investigate the association of polycyclic aromatic hydrocarbons (PAHs), a group of environmental pollutants, with diabetes mellitus. Animal studies link PAHs to inflammation and subsequent development of diabetes mellitus. In addition, occupational studies suggest that exposure to other aromatic hydrocarbons such as dioxins may be associated with diabetes risk in humans.
Design We examined participants from the merged National Health and Nutrition Examination Survey 2001-2002, 2003-2004 and 2005-2006. Exposures of interest were eight urinary monohydroxy-PAHs. Our outcome was diabetes mellitus defined as a glycohemoglobin level (HbA1c) >= 6.5%, a self-reported physician diagnosis of diabetes or use of oral hypoglycaemic medication or insulin. Analyses were adjusted for age, sex, body mass index, race, alcohol consumption, poverty-income ratio, total cholesterol and serum cotinine.
Results We observed a positive association between urinary biomarkers of 1 and 2-hydroxynapthol, 2-hydroxyphenanthrene and summed low molecular weight (LMW) PAH biomarkers, and diabetes mellitus. Compared with participants with summed LMW PAH biomarkers in the lowest quartile, the multivariable-adjusted OR of diabetes mellitus among those in the highest quartile was 3.1 (95% CI 1.6 to 5.8).
Conclusions Urinary biomarkers of 1 and 2-hydroxynapthol, 2-hydroxyphenanthrene and summed LMW PAH biomarkers are associated with diabetes mellitus in US adults 20-65 years of age. The association of a one-time biomarker of PAH exposure has limitations commonly associated with cross-sectional studies, yet is consistent with experimental animal data and is worthy of additional consideration.
C1 [Alshaarawy, Omayma] Michigan State Univ, Dept Epidemiol & Biostat, Sch Med, E Lansing, MI 48824 USA.
[Zhu, Motao; Conway, Baqiyyah] W Virginia Univ, Dept Epidemiol, Sch Publ Hlth, Morgantown, WV 26506 USA.
[Ducatman, Alan M.] W Virginia Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, Morgantown, WV 26506 USA.
[Andrew, Michael E.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA.
RP Alshaarawy, O (reprint author), Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA.
EM oalshaarawy@epi.msu.edu
RI Tuomisto, Jouko/J-7450-2012
FU Intramural CDC HHS [CC999999]
NR 32
TC 12
Z9 12
U1 1
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1351-0711
EI 1470-7926
J9 OCCUP ENVIRON MED
JI Occup. Environ. Med.
PD JUN
PY 2014
VL 71
IS 6
BP 437
EP 441
DI 10.1136/oemed-2013-101987
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI9MV
UT WOS:000337257600009
PM 24638887
ER
PT J
AU Boyle, CA
Bocchini, JA
Kelly, J
AF Boyle, Coleen A.
Bocchini, Joseph A., Jr.
Kelly, James
TI Reflections on 50 Years of Newborn Screening
SO PEDIATRICS
LA English
DT Editorial Material
DE newborn screening
ID HERITABLE DISORDERS; ADVISORY-COMMITTEE; STATEMENT; SECRETARY; CHILDREN;
HEALTH
C1 [Boyle, Coleen A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Bocchini, Joseph A., Jr.] Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, Shreveport, LA 71105 USA.
[Kelly, James] Hunters Hope Fdn, Orchard Pk, NY USA.
RP Boyle, CA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM cboyle@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 7
TC 6
Z9 6
U1 1
U2 3
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2014
VL 133
IS 6
BP 961
EP 963
DI 10.1542/peds.2013-3658
PG 3
WC Pediatrics
SC Pediatrics
GA AI8MY
UT WOS:000337172600043
PM 24843062
ER
PT J
AU Quinlan, K
Shults, RA
Rudd, RA
AF Quinlan, Kyran
Shults, Ruth A.
Rudd, Rose A.
TI Child Passenger Deaths Involving Alcohol-Impaired Drivers
SO PEDIATRICS
LA English
DT Article
DE motor vehicle accidents; accident prevention; child passenger safety;
epidemiology-injury; injury prevention and control
ID INTERVENTIONS; POLICY
AB BACKGROUND AND OBJECTIVE: Approximately 1 in 5 child passenger deaths in the United States involves an alcohol-impaired driver, most commonly the child's own driver. The objective of this study was to document recent trends and state-specific rates of these deaths.
METHODS: A descriptive analysis of 2001-2010 Fatality Analysis Reporting System data for child passengers aged <15 years killed in alcohol-impaired driving crashes. Driver impairment was defined as a blood alcohol concentration of >= 0.08 g/dL.
RESULTS: During 2001-2010, 2344 children <15 years were killed in crashes involving at least 1 alcohol-impaired driver. Of these children, 1515 (65%) were riding with an impaired driver. Annual deaths among children riding with an alcohol-impaired driver decreased by 41% over the decade. Among the 37 states included in the state-level analysis, Texas (272) and California (135) had the most children killed while riding with an impaired driver and South Dakota (0.98) and New Mexico (0.86) had the highest annualized child passenger death rates (per 100 000 children). Most (61%) child passengers of impaired drivers were unrestrained at the time of the crash. One-third of the impaired drivers did not have a valid driver's license.
CONCLUSIONS: Alcohol-impaired driving remains a substantial threat to the safety of child passengers in the United States, and typically involves children being driven by impaired drivers. This risk varies meaningfully among states. To make further progress, states and communities could consider increased use of effective interventions and efforts aimed specifically at protecting child passengers from impaired drivers.
C1 [Quinlan, Kyran] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Div Community Based Primary Care, Chicago, IL 60611 USA.
[Quinlan, Kyran] Erie Family Hlth Ctr, Chicago, IL 60622 USA.
[Shults, Ruth A.; Rudd, Rose A.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
RP Quinlan, K (reprint author), Erie Family Hlth Ctr, 1701 W Super St, Chicago, IL 60622 USA.
EM kquinlan@eriefamilyhealth.org
NR 21
TC 7
Z9 7
U1 0
U2 1
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2014
VL 133
IS 6
BP 966
EP 972
DI 10.1542/peds.2013-2318
PG 7
WC Pediatrics
SC Pediatrics
GA AI8MY
UT WOS:000337172600045
PM 24799550
ER
PT J
AU Hambidge, SJ
Newcomer, SR
Narwaney, KJ
Glanz, JM
Daley, MF
Xu, S
Shoup, A
Rowhani-Rahbar, A
Klein, NP
Lee, GM
Nelson, JC
Lugg, M
Naleway, AL
Nordin, JD
Weintraub, E
DeStefano, F
AF Hambidge, Simon J.
Newcomer, Sophia R.
Narwaney, Komal J.
Glanz, Jason M.
Daley, Matthew F.
Xu, Stan
Shoup, Ann
Rowhani-Rahbar, Ali
Klein, Nicola P.
Lee, Grace M.
Nelson, Jennifer C.
Lugg, Marlene
Naleway, Allison L.
Nordin, James D.
Weintraub, Eric
DeStefano, Frank
TI Timely Versus Delayed Early Childhood Vaccination and Seizures
SO PEDIATRICS
LA English
DT Article
DE vaccine safety; immunization; vaccine; seizures; vaccine delay
ID INFLUENZAE TYPE-B; ACELLULAR PERTUSSIS; FEBRILE SEIZURES; INACTIVATED
POLIOVIRUS; IMMUNIZATION SAFETY; PARENTAL REFUSAL; YOUNG-CHILDREN;
UNITED-STATES; RISK; VACCINES
AB BACKGROUND: Little is known regarding the timing of childhood vaccination and postvaccination seizures.
METHODS: In a cohort of 323 247 US children from the Vaccine Safety Datalink born from 2004 to 2008, we analyzed the association between the timing of childhood vaccination and the first occurrence of seizure with a self-controlled case series analysis of the first doses of individual vaccines received in the first 2 years of life.
RESULTS: In infants, there was no association between the timing of infant vaccination and postvaccination seizures. In the second year of life, the incident rate ratio (IRR) for seizures after receipt of the first measles-mumps-rubella vaccine (MMR) dose at 12 to 15 months was 2.65 (95% confidence interval [CI] 1.99-3.55); the IRR after an MMR dose at 16 to 23 months was 6.53 (95% CI 3.15-13.53). The IRR for seizures after receipt of the first measles-mumps-rubella-varicella vaccine (MMRV) dose at 12 to 15 months was 4.95 (95% CI 3.68-6.66); the IRR after an MMRV dose at 16 to 23 months was 9.80 (95% CI 4.35-22.06).
CONCLUSIONS: There is no increased risk of postvaccination seizure in infants regardless of timing of vaccination. In year 2, delaying MMR vaccine past 15 months of age results in a higher risk of seizures. The strength of the association is doubled with MMRV vaccine. These findings suggest that on-time vaccination is as safe with regard to seizures as delayed vaccination in the first year of life, and that delayed vaccination in the second year of life is associated with more postvaccination seizures than on-time vaccination.
C1 [Hambidge, Simon J.; Newcomer, Sophia R.; Narwaney, Komal J.; Glanz, Jason M.; Daley, Matthew F.; Xu, Stan; Shoup, Ann] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
[Hambidge, Simon J.] Denver Hlth, Dept Community Hlth Serv, Denver, CO USA.
[Hambidge, Simon J.; Daley, Matthew F.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA.
[Hambidge, Simon J.; Glanz, Jason M.] Univ Colorado, Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA.
[Rowhani-Rahbar, Ali] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Klein, Nicola P.] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA.
[Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA.
[Lee, Grace M.] Harvard Univ, Sch Med, Boston, MA USA.
[Lee, Grace M.] Boston Childrens Hosp, Div Infect Dis, Boston, MA USA.
[Lee, Grace M.] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA.
[Nelson, Jennifer C.] Grp Hlth Res Inst, Seattle, WA USA.
[Lugg, Marlene] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.
[Naleway, Allison L.] Kaiser Fdn Hosp Ctr Hlth Res, Portland, OR USA.
[Nordin, James D.] Hlth Partners Res Fdn, Minneapolis, MN USA.
[Weintraub, Eric; DeStefano, Frank] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Atlanta, GA USA.
RP Hambidge, SJ (reprint author), Denver Hlth Mailcode 1914,660 Bannock St, Denver, CO 80204 USA.
EM simon.hambidge@dhha.org
OI Naleway, Allison/0000-0001-5747-4643
FU Vaccine Safety Surveillance and Assessment Project [200-2002-00732];
American's Health Insurance Plans - Centers for Disease Control and
Prevention
FX This study was supported through the Vaccine Safety Surveillance and
Assessment Projects (contract 200-2002-00732) with American's Health
Insurance Plans, funded by the Centers for Disease Control and
Prevention. The Centers for Disease Control and Prevention coauthors (Mr
Weintraub and Dr DeStefano) were involved in the design and conduct of
the study; analysis and interpretation of the data; and review and
approval of the manuscript.
NR 41
TC 13
Z9 13
U1 1
U2 10
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2014
VL 133
IS 6
BP E1492
EP E1499
DI 10.1542/peds.2013-3429
PG 8
WC Pediatrics
SC Pediatrics
GA AI8MY
UT WOS:000337172600002
PM 24843064
ER
PT J
AU Middleman, AB
Baker, CJ
Kozinetz, CA
Kamili, S
Nguyen, C
Hu, DJ
Spradling, PR
AF Middleman, Amy B.
Baker, Carol J.
Kozinetz, Claudia A.
Kamili, Saleem
Chi Nguyen
Hu, Dale J.
Spradling, Philip R.
TI Duration of Protection After Infant Hepatitis B Vaccination Series
SO PEDIATRICS
LA English
DT Article
DE infant immunization; hepatitis B vaccine; hepatitis B; adolescent
immunization
ID LONG-TERM IMMUNOGENICITY; ADOLESCENTS; VACCINES; IMMUNITY; BOOSTER;
PERSISTENCE; CHILDREN; BIRTH; MODELS; GENES
AB BACKGROUND: Little is known about duration of protection after the infant primary series of hepatitis B (HB) vaccine in settings of low HB endemicity. This study sought to determine the proportion of adolescents immunized as infants who had protective titers of antibody to hepatitis B surface antigen (anti-HBs) before and after a challenge dose of vaccine.
METHODS: US-born 16-through 19-year-olds who received a recombinant HB vaccine 3-dose series initiated within 7 days of birth (group 1) or at >= 4 weeks of age (group 2) and completed by 12 months of age were enrolled. Participants had serologic testing before and 2 weeks after randomization to receive a challenge dose of 10 mu g or 20 mg of Engerix-B. Baseline and postchallenge levels of anti-HBs were compared by group, challenge dosage, and demographic and behavioral characteristics.
RESULTS: At baseline, 24% had protective anti-HBs levels of >= 10 IU/mL; 92% achieved protective levels after challenge dose. Although group 1 had a lower proportion of seroprotection at baseline, group and challenge dosage were not associated with postchallenge proportion of seroprotection. Being in group 2, higher test dosage, higher baseline geometric mean titer, and nonwhite race were associated with significantly higher geometric mean titer after challenge dose.
CONCLUSIONS: More than 90% of study participants immunized against HB as infants exhibited a seroprotective response to a challenge dose of vaccine. Duration of protection from the primary infant HB vaccine series extended through the adolescent years in the setting of low HB endemicity.
C1 [Middleman, Amy B.] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73190 USA.
[Baker, Carol J.; Kozinetz, Claudia A.; Chi Nguyen] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
[Kamili, Saleem; Hu, Dale J.; Spradling, Philip R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Middleman, AB (reprint author), OU Childrens Phys, Dept Pediat, 1200 Childrens Ave,Ste 12200, Oklahoma City, OK 73104 USA.
EM amym@ouhsc.edu
FU Centers for Disease Control and Prevention project [00HCVJHB-2009-67553]
FX This project was contracted and funded by the Centers for Disease
Control and Prevention project 00HCVJHB-2009-67553.
NR 26
TC 9
Z9 12
U1 0
U2 4
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2014
VL 133
IS 6
BP E1500
EP E1507
DI 10.1542/peds.2013-2940
PG 8
WC Pediatrics
SC Pediatrics
GA AI8MY
UT WOS:000337172600003
PM 24843060
ER
PT J
AU Pettersson, E
Mendle, J
Turkheimer, E
Horn, EE
Ford, DC
Simms, LJ
Clark, LA
AF Pettersson, Erik
Mendle, Jane
Turkheimer, Eric
Horn, Erin E.
Ford, Derek C.
Simms, Leonard J.
Clark, Lee Anna
TI Do Maladaptive Behaviors Exist at One or Both Ends of Personality
Traits?
SO PSYCHOLOGICAL ASSESSMENT
LA English
DT Article
DE personality pathology; personality disorders; general factor;
evaluation; social desirability
ID 5-FACTOR MODEL; GENERAL FACTOR; SOCIAL DESIRABILITY; ADAPTIVE
PERSONALITY; PSYCHIATRIC-PATIENT; EMPIRICAL SUPPORT; DIMENSIONAL MODEL;
EEG ASYMMETRY; DISORDERS; SELF
AB In the Diagnostic and Statistical Manual of Mental Disorders (5th ed.; American Psychiatric Association, 2013) personality disorder trait model, maladaptive behavior is located at one end of continuous scales. Widiger and colleagues, however, have argued that maladaptive behavior exists at both ends of trait continua. We propose that the role of evaluative variance differentiates these two perspectives and that once evaluation is isolated, maladaptive behaviors emerge at both ends of nonevaluative trait dimensions. In Study 1, we argue that evaluative variance is worthwhile to measure separately from descriptive content because it clusters items by valence regardless of content (e. g., lazy and workaholic; apathetic and anxious; gullible and paranoid; timid and hostile, etc.), which is unlikely to describe a consistent behavioral style. We isolate evaluation statistically (Study 2) and at the time of measurement (Study 3) to show that factors unrelated to valence evidence maladaptive behavior at both ends. We argue that nonevaluative factors, which display maladaptive behavior at both ends of continua, may better approximate ways in which individuals actually behave.
C1 [Pettersson, Erik] Karolinska Inst, S-17177 Stockholm, Sweden.
[Mendle, Jane] Cornell Univ, Dept Human Dev, Ithaca, NY 14853 USA.
[Turkheimer, Eric; Horn, Erin E.] Univ Virginia, Dept Psychol, Charlottesville, VA 22903 USA.
[Ford, Derek C.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Simms, Leonard J.] SUNY Buffalo, Dept Psychol, Buffalo, NY 14260 USA.
[Clark, Lee Anna] Univ Notre Dame, Dept Psychol, Notre Dame, IN 46556 USA.
RP Pettersson, E (reprint author), Karolinska Inst, Box 281, S-17177 Stockholm, Sweden.
EM erik.pettersson@ki.se
NR 82
TC 4
Z9 4
U1 3
U2 9
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1040-3590
EI 1939-134X
J9 PSYCHOL ASSESSMENT
JI Psychol. Assess.
PD JUN
PY 2014
VL 26
IS 2
BP 433
EP 446
DI 10.1037/a0035587
PG 14
WC Psychology, Clinical
SC Psychology
GA AJ5EU
UT WOS:000337706000009
PM 24490679
ER
PT J
AU Moro, PL
Museru, OI
Niu, M
Lewis, P
Broder, K
AF Moro, Pedro L.
Museru, Oidda I.
Niu, Manette
Lewis, Paige
Broder, Karen
TI Reports to the Vaccine Adverse Event Reporting System after hepatitis A
and hepatitis AB vaccines in pregnant women
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE hepatitis A hepatitis B combined vaccine; hepatitis A vaccine;
pregnancy; surveillance; vaccine safety
ID B-VACCINE; SAFETY; VAERS; IMMUNIZATION; SURVEILLANCE
AB OBJECTIVE: To characterize adverse events (AEs) after hepatitis A vaccines (Hep A) and hepatitis A and hepatitis B combination vaccine (Hep AB) in pregnant women reported to the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system.
STUDY DESIGN: We searched VAERS for AEs reports in pregnant women who received Hep A or Hep AB from Jan. 1, 1996-April 5, 2013. Clinicians reviewed all reports and available medical records.
RESULTS: VAERS received 139 reports of AEs in pregnant women; 7 (5.0%) were serious; no maternal or infant deaths were identified. Sixty-five (46.8%) did not describe any AEs. For those women whose gestational age was available, most were vaccinated during the first trimester, 50/60 (83.3%) for Hep A and 18/21 (85.7%) for Hep AB. The most common pregnancy-specific outcomes following Hep A or Hep AB vaccinations were spontaneous abortion in 15 (10.8%) reports, elective termination in 10 (7.2%), and preterm delivery in 7 (5.0%) reports. The most common nonpregnancy specific outcome was urinary tract infection and nausea/vomiting with 3 (2.2%) reports each. One case of amelia of the lower extremities was reported in an infant following maternal Hep A immunization.
CONCLUSION: This review of VAERS reports did not identify any concerning pattern of AEs in pregnant women or their infants following maternal Hep A or Hep AB immunizations during pregnancy.
C1 [Moro, Pedro L.; Museru, Oidda I.; Lewis, Paige; Broder, Karen] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
[Niu, Manette] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA.
RP Moro, PL (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
NR 26
TC 4
Z9 4
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD JUN
PY 2014
VL 210
IS 6
AR 561.e1
DI 10.1016/j.ajog.2013.12.036
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AI1CS
UT WOS:000336588000022
PM 24378675
ER
PT J
AU Mixson-Hayden, T
Lee, D
Ganova-Raeva, L
Drobeniuc, J
Stauffer, WM
Teshale, E
Kamili, S
AF Mixson-Hayden, Tonya
Lee, Deborah
Ganova-Raeva, Lilia
Drobeniuc, Jan
Stauffer, William M.
Teshale, Eyasu
Kamili, Saleem
TI Hepatitis B Virus and Hepatitis C Virus Infections in United
States-Bound Refugees from Asia and Africa
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; INTERNATIONAL MIGRANTS; GEOSENTINEL CLINICS;
VIRAL-HEPATITIS; HBV INFECTION; PREVALENCE; GENOTYPES; THAILAND;
SPECTRUM; ILLNESS
AB The aim of this study was to determine the prevalence of active hepatitis B and C virus infections among refugees from various countries in Africa and Asia. Pre-admission serum samples collected during 2002-2007 from refugees originating from Bhutan (N = 755), Myanmar (N = 1076), Iraq (N = 1137), Laos (N = 593), Thailand (N = 622), and Somalia (N = 707) were tested for hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA. The HBV DNA (genotypes A, B, C, and G) was detected in 12.1% of samples negative for anti-HBs. Highest HBV prevalence was found among Hmong; lowest among Bhutanese. The HCV RNA (genotypes 1a, 1b, 1c, 3b, 6n, and 6m) was detected in 1.3% of the samples. Highest HCV prevalence was found among Hmong from Thailand; lowest among Iraqis. Screening specific refugee groups at high risk for viral hepatitis infections will identify infected individuals who could benefit from referral to care and treatment and prevent further transmissions.
C1 [Mixson-Hayden, Tonya; Lee, Deborah; Ganova-Raeva, Lilia; Drobeniuc, Jan; Teshale, Eyasu; Kamili, Saleem] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA.
[Stauffer, William M.] Univ Minnesota, Div Infect Dis & Int Med, Minneapolis, MN USA.
RP Mixson-Hayden, T (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd,MS A33, Atlanta, GA 30333 USA.
EM zdy0@cdc.gov; dpl2@cdc.gov; lkg7@cdc.gov; jqd6@cdc.gov;
stauf005@umn.edu; eht4@cdc.gov; sek6@cdc.gov
NR 41
TC 5
Z9 5
U1 2
U2 9
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUN
PY 2014
VL 90
IS 6
BP 1014
EP 1020
DI 10.4269/ajtmh.14-0068
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AI4FD
UT WOS:000336820200007
PM 24732462
ER
PT J
AU Scobie, HM
Nilles, E
Kama, M
Kool, JL
Mintz, E
Wannemuehler, KA
Hyde, TB
Dawainavesi, A
Singh, S
Korovou, S
Jenkins, K
Date, K
AF Scobie, Heather M.
Nilles, Eric
Kama, Mike
Kool, Jacob L.
Mintz, Eric
Wannemuehler, Kathleen A.
Hyde, Terri B.
Dawainavesi, Akanisi
Singh, Sheetalpreet
Korovou, Samuel
Jenkins, Kylie
Date, Kashmira
TI Impact of a Targeted Typhoid Vaccination Campaign Following Cyclone
Tomas, Republic of Fiji, 2010
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID FEVER; EXPERIENCE; BURDEN; TRIAL
AB After a category 4 cyclone that caused extensive population displacement and damage to water and sanitation infrastructure in Fiji in March 2010, a typhoid vaccination campaign was conducted as part of the post-disaster response. During June-December 2010, 64,015 doses of typhoid Vi polysaccharide vaccine were administered to persons >= 2 years of age, primarily in cyclone-affected areas that were typhoid endemic. Annual typhoid fever incidence decreased during the post-campaign year (2011) relative to preceding years (2008-2009) in three subdivisions where a large proportion of the population was vaccinated (incidence rate ratios and 95% confidence intervals: 0.23, 0.13-0.41; 0.24, 0.14-0.41; 0.58, 0.40-0.86), and increased or remained unchanged in 12 subdivisions where little to no vaccination occurred. Vaccination played a role in reducing typhoid fever incidence in high-incidence areas after a disaster and should be considered in endemic settings, along with comprehensive control measures, as recommended by the World Health Organization.
C1 [Scobie, Heather M.; Nilles, Eric; Wannemuehler, Kathleen A.; Hyde, Terri B.; Date, Kashmira] Ctr Dis Control & Prevent, Global Immunizat Div, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.
[Nilles, Eric] World Hlth Org, Div Pacific Tech Support, Suva, Fiji.
[Scobie, Heather M.; Mintz, Eric; Wannemuehler, Kathleen A.; Hyde, Terri B.; Date, Kashmira] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA.
[Kama, Mike; Dawainavesi, Akanisi] Fiji Ctr Communicable Dis Control, Suva, Fiji.
[Singh, Sheetalpreet] Minist Hlth, Hlth Informat Unit, Suva, Fiji.
Fiji Minist Hlth, Labasa, Fiji.
[Jenkins, Kylie] Minist Hlth, Fiji Hlth Sect Improvement Program, Suva, Fiji.
RP Scobie, HM (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS A04, Atlanta, GA 30333 USA.
EM vih8@cdc.gov; nillese@wpro.who.int; mnkama02@gmail.com;
koolj@wpro.whoint; edm1@cdc.gov; kpw9@cdc.gov; tkh4@cdc.gov;
dawainavesia@wpro.who.int; sheetal.nagra@gmail.com; skorokou@yahoo.uk;
kylie.jenkins@fhssp.org.fj; gln7@cdc.gov
OI Nilles, Eric/0000-0001-7044-5257; Kool, Jacob/0000-0002-9605-2918
FU Centers for Disease Control and Prevention; World Health Organization
FX Funding was provided by the Centers for Disease Control and Prevention
and World Health Organization.
NR 21
TC 7
Z9 7
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUN
PY 2014
VL 90
IS 6
BP 1031
EP 1038
DI 10.4269/ajtmh.13-0728
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AI4FD
UT WOS:000336820200010
PM 24710618
ER
PT J
AU Duval, BD
Elrod, MG
Gee, JE
Chantratita, N
Tandhavanant, S
Limmathurotsakul, D
Hoffmaster, AR
AF Duval, Brea D.
Elrod, Mindy G.
Gee, Jay E.
Chantratita, Narisara
Tandhavanant, Sarunporn
Limmathurotsakul, Direk
Hoffmaster, Alex R.
TI Short Report: Evaluation of a Latex Agglutination Assay for the
Identification of Burkholderia pseudomallei and Burkholderia mallei
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PSEUDOMONAS-PSEUDOMALLEI; INFECTION
AB Cases of melioidosis and glanders are rare in the United States, but the etiologic agents of each disease (Burkholderia pseudomallei and Burkholderia mallei, respectively) are classified as Tier 1 select agents because of concerns about their potential use as bioterrorism agents. A rapid, highly sensitive, and portable assay for clinical laboratories and field use is required. Our laboratory has further evaluated a latex agglutination assay for its ability to identify B. pseudomallei and B. mallei isolates. This assay uses a monoclonal antibody that specifically recognizes the capsular polysaccharide produced by B. pseudomallei and B. mallei, but is absent in closely related Burkholderia species. A total of 110 B. pseudomallei and B. mallei were tested, and 36 closely related Burkholderia species. The latex agglutination assay was positive for 109 of 110 (99.1% sensitivity) B. pseudomallei and B. mallei isolates tested.
C1 Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Atlanta, GA 30333 USA.
Mahidol Univ, Fac Trop Med, Dept Microbiol & Immunol, Bangkok, Thailand.
Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.
Mahidol Univ, Fac Trop Med, Dept Trop Hyg, Bangkok, Thailand.
RP Hoffmaster, AR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS G34, Atlanta, GA 30333 USA.
EM BDuval@cdc.gov; MGElrod@cdc.gov; JGeel@cdc.gov; Narisara@tropmedres.ac;
Sarunporn@tropmedres.ac; Direk@tropmedres.ac; amh9@cdc.gov
NR 12
TC 3
Z9 3
U1 0
U2 4
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUN
PY 2014
VL 90
IS 6
BP 1043
EP 1046
DI 10.4269/ajtmh.14-0025
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AI4FD
UT WOS:000336820200012
PM 24710616
ER
PT J
AU Eisen, RJ
MacMillan, K
Atiku, LA
Mpanga, JT
Zielinski-Gutierrez, E
Graham, CB
Boegler, KA
Enscore, RE
Gage, KL
AF Eisen, Rebecca J.
MacMillan, Katherine
Atiku, Linda A.
Mpanga, Joseph T.
Zielinski-Gutierrez, Emily
Graham, Christine B.
Boegler, Karen A.
Enscore, Russell E.
Gage, Kenneth L.
TI Identification of Risk Factors for Plague in the West Nile Region of
Uganda
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID FLEAS CTENOCEPHALIDES-FELIS; EARLY-PHASE TRANSMISSION; ENDEMIC REGION;
NORTHWESTERN UGANDA; YERSINIA-PESTIS; TANZANIA; RODENTS; SIPHONAPTERA;
PREDICTORS; VILLAGES
AB Plague is an often fatal, primarily flea-borne rodent-associated zoonosis caused by Yersinia pestis. We sought to identify risk factors for plague by comparing villages with and without a history of human plague cases within a model-defined plague focus in the West Nile Region of Uganda. Although rat (Rattus rattus) abundance was similar inside huts within case and control villages, contact rates between rats and humans (as measured by reported rat bites) and host-seeking flea loads were higher in case villages. In addition, compared with persons in control villages, persons in case villages more often reported sleeping on reed or straw mats, storing food in huts where persons sleep, owning dogs and allowing them into huts where persons sleep, storing garbage inside or near huts, and cooking in huts where persons sleep. Compared with persons in case villages, persons in control villages more commonly reported replacing thatch roofing, and growing coffee, tomatoes, onions, and melons in agricultural plots adjacent to their homesteads. Rodent and flea control practices, knowledge of plague, distance to clinics, and most care-seeking practices were similar between persons in case villages and persons in control villages. Our findings reinforce existing plague prevention recommendations and point to potentially advantageous local interventions.
C1 [Eisen, Rebecca J.; MacMillan, Katherine; Zielinski-Gutierrez, Emily; Graham, Christine B.; Boegler, Karen A.; Enscore, Russell E.; Gage, Kenneth L.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80522 USA.
[Atiku, Linda A.; Mpanga, Joseph T.] Uganda Virus Res Inst, Plague Sect, Entebbe, Uganda.
RP Eisen, RJ (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, POB 2087, Ft Collins, CO 80522 USA.
EM dyn2@cdc.gov; iky4@cdc.gov; l.atikupraise@yahoo.com; joe1ug@msn.com;
ezb0@cdc.gov; hyb4@cdc.gov; kje5@cdc.gov; renscore@cdc.gov; klg0@cdc.gov
FU United States Agency for International Development Emerging Pandemic
Threat Program
FX This study was supported in part by the United States Agency for
International Development Emerging Pandemic Threat Program.
NR 51
TC 3
Z9 3
U1 1
U2 16
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUN
PY 2014
VL 90
IS 6
BP 1047
EP 1058
DI 10.4269/ajtmh.14-0035
PG 12
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AI4FD
UT WOS:000336820200013
PM 24686743
ER
PT J
AU Martin, DL
Marks, M
Galdos-Cardenas, G
Gilman, RH
Goodhew, B
Ferrufino, L
Halperin, A
Sanchez, G
Verastegui, M
Escalante, P
Naquira, C
Levy, MZ
Bern, C
AF Martin, Diana L.
Marks, Morgan
Galdos-Cardenas, Gerson
Gilman, Robert H.
Goodhew, Brook
Ferrufino, Lisbeth
Halperin, Anthony
Sanchez, Gerardo
Verastegui, Manuela
Escalante, Patricia
Naquira, Cesar
Levy, Michael Z.
Bern, Caryn
TI Regional Variation in the Correlation of Antibody and T-Cell Responses
to Trypanosoma cruzi
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID CHAGAS-DISEASE; GENETIC-VARIABILITY; IMMUNE-RESPONSES; INTERFERON-GAMMA;
INFECTION; BLOOD; ARGENTINA; TRANSMISSION; PATHOGENESIS; POPULATIONS
AB Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a major cause of morbidity and mortality in Central and South America. Geographic variations in the sensitivity of serologic diagnostic assays to T. cruzi may reflect differences in T cruzi exposure. We measured parasite-specific T-cell responses among seropositive individuals in two populations from South America with widely varying antibody titers against T. cruzi. Antibody titers among seropositive individuals were significantly lower in Arequipa, Peru compared with Santa Cruz, Bolivia. Similarly, the proportion of seropositive individuals with positive T-cell responses was lower in Peru than Bolivia, resulting in overall lower frequencies of interferon-gamma (IFN gamma)-secreting cells from Peruvian samples. However, the magnitude of the IFN gamma response was similar among the IFN gamma responders in both locations. These data indicate that immunological discrepancies based on geographic region are reflected in T-cell responses as well as antibody responses.
C1 [Martin, Diana L.; Goodhew, Brook] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
NIH, Bethesda, MD 20892 USA.
Johns Hopkins Univ, Baltimore, MD USA.
[Galdos-Cardenas, Gerson; Ferrufino, Lisbeth] Hosp Univ Japones, Santa Cruz, Bolivia.
[Galdos-Cardenas, Gerson; Ferrufino, Lisbeth] Asociac Benef PRISMA, Lima, Peru.
[Gilman, Robert H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Naquira, Cesar] Arequipa Minist Hlth, Arequipa, Peru.
[Levy, Michael Z.] Univ Penn, Philadelphia, PA 19104 USA.
[Sanchez, Gerardo; Verastegui, Manuela] Univ Peruana Cayetano Heredia, Lima, Peru.
RP Martin, DL (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, MS D-65,1600 Clifton Rd NE, Atlanta, GA 30329 USA.
EM hzx3@cdc.gov; mmarkster@gmail.com; gerson_galdos@yahoo.es;
gilmanabob@gmail.com; isd6@cdc.gov; lisbeth_ferrufino@yahoo.es;
gjsg2@hotmail.com; mveraste@jhsph.edu; patriciaeem2008@gmail.com;
cesar.naquira@gmail.com; rnzlevy@mail.med.upenn.edu;
Caryn.Bern2@ucsf.edu
FU National Institutes of Health Tropical Medical Research Center [P50
AI074285]; National Institutes of Health Fogarty Scholars Program [R24
TW007988]
FX This work was funded by National Institutes of Health Tropical Medical
Research Center Grant P50 AI074285 and National Institutes of Health
Fogarty Scholars Program Grant R24 TW007988.
NR 35
TC 1
Z9 1
U1 1
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUN
PY 2014
VL 90
IS 6
BP 1074
EP 1081
DI 10.4269/ajtmh.13-0391
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AI4FD
UT WOS:000336820200016
PM 24710614
ER
PT J
AU Rodrigues, PT
Alves, JMP
Santamaria, AM
Calzada, JE
Xayavong, M
Parise, M
da Silva, AJ
Ferreira, MU
AF Rodrigues, Priscila T.
Alves, Joao Marcelo P.
Maria Santamaria, Ana
Calzada, Jose E.
Xayavong, Maniphet
Parise, Monica
da Silva, Alexandre J.
Ferreira, Marcelo U.
TI Using Mitochondrial Genome Sequences to Track the Origin of Imported
Plasmodium vivax Infections Diagnosed in the United States
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID ANCIENT POPULATION EXPANSION; FALCIPARUM-MALARIA; EVOLUTIONARY HISTORY;
GEOGRAPHIC STRUCTURE; SRI-LANKA; RISK; TRANSMISSION; ELIMINATION;
STRATEGIES; DIVERSITY
AB Although the geographic origin of malaria cases imported into the United States can often be inferred from travel histories, these histories may be lacking or incomplete. We hypothesized that mitochondrial haplotypes could provide region-specific molecular barcodes for tracing the origin of imported Plasmodium vivax infections. An analysis of 348 mitochondrial genomes from worldwide parasites and new sequences from 69 imported malaria cases diagnosed across the United States allowed for a geographic assignment of most infections originating from the Americas, southeast Asia, east Asia, and Melanesia. However, mitochondrial lineages from Africa, south Asia, central Asia, and the Middle East, which altogether contribute the vast majority of imported malaria cases in the United States, were closely related to each other and could not be reliably assigned to their geographic origins. More mitochondrial genomes are required to characterize molecular barcodes of P. vivax from these regions.
C1 [Rodrigues, Priscila T.; Alves, Joao Marcelo P.; Ferreira, Marcelo U.] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, BR-05508900 Sao Paulo, Brazil.
[Maria Santamaria, Ana; Calzada, Jose E.] Gorgas Mem Inst Hlth, Dept Parasitol, Panama City, Panama.
[Xayavong, Maniphet; Parise, Monica; da Silva, Alexandre J.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA USA.
RP Ferreira, MU (reprint author), Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Av Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.
EM priscilathihara@usp.br; alvesjmp@gmail.com; asantamaria@gorgas.gob.pa;
jcalzada@gorgas.gob.pa; max1@cdc.gov; mep0l@cdc.gov; abs8@cdc.gov;
muferrei@usp.br
RI Alves, Joao/G-8927-2011; Ferreira, Marcelo/G-8289-2011
OI Alves, Joao/0000-0001-5914-2087; Ferreira, Marcelo/0000-0002-5293-9090
FU National Institutes of Health, United States [R01 AI 075416]; Centers
for Disease Control and Prevention, United States; Fundacao de Amparo a
Pesquisa do Estado de Sao Paulo (FAPESP), Brazil [2010/50333-8];
Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
Brazil [590106/2011-2]; Coordenacao de Aperfeicoamento de Pessoal de
Nivel Superior (CAPES), Brazil; CNPq; FAPESP
FX This research was supported by funds from the National Institutes of
Health, United States (Grant R01 AI 075416), the Centers for Disease
Control and Prevention, United States, the Fundacao de Amparo a Pesquisa
do Estado de Sao Paulo (FAPESP), Brazil (Grant 2010/50333-8), and
Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
Brazil (Grant 590106/2011-2). P.T.R. received a scholarship from the
Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
Brazil and is currently supported by CNPq. J.M.P.A. is currently
supported by FAPESP. M.U.F. received a senior research scholarship from
CNPq, Brazil.
NR 37
TC 9
Z9 9
U1 0
U2 4
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUN
PY 2014
VL 90
IS 6
BP 1102
EP 1108
DI 10.4269/ajtmh.13-0588
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AI4FD
UT WOS:000336820200021
PM 24639297
ER
PT J
AU Jones, JL
Kruszon-Moran, D
Rivera, HN
Price, C
Wilkins, PP
AF Jones, Jeffrey L.
Kruszon-Moran, Deanna
Rivera, Hilda N.
Price, Courtney
Wilkins, Patricia P.
TI Toxoplasma gondii Seroprevalence in the United States 2009-2010 and
Comparison with the Past Two Decades
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID NATIONAL-HEALTH; MOOD DISORDERS; TISSUE CYSTS; RISK-FACTORS; INFECTION;
SCHIZOPHRENIA; PORK
AB Toxoplasma gondii is a ubiquitous parasite that can cause neurologic and ocular disease. We tested sera from 7,072 people >= 6 years of age in the 2009-2010 National Health and Nutrition Examination Survey (NHANES) for immunoglobulin G antibodies and compared these results with two previous NHANES studies. The overall T. gondii antibody seroprevalence among persons >= 6 years of age in 2009-2010 was 13.2% (95% confidence limit [CL] 11.8%, 14.5%) and age-adjusted seroprevalence was 12.4% (95% CL 11.1%, 13.7%); age-adjusted seroprevalence among women 15-44 years of age was 9.1% (95% CL 7.2%, 11.1%). In U.S. born persons 12-49 years of age, the age-adjusted T. gondii seroprevalence decreased from 14.1% (95% CL 12.7%, 15.5%) in NHANES III (1988-1994) to 9.0% (95% CL 7.6%, 10.5%) in NHANES 1999-2004 to 6.7% (95% CL 5.3%, 8.2%) in NHANES 2009-2010 (P < 0.001 linear trend). Although T. gondii antibody presence is still relatively common, the prevalence in the United States has continued to decline.
C1 [Jones, Jeffrey L.; Rivera, Hilda N.; Price, Courtney; Wilkins, Patricia P.] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Kruszon-Moran, Deanna] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
RP Jones, JL (reprint author), Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Bld 24,1600 Clifton Rd,NE,Mailstop A-06, Atlanta, GA 30333 USA.
EM jlj1@cdc.gov; ddko@cdc.gov; igi2@cdc.gov; www4@cdc.gov; pma1@cdc.gov
NR 27
TC 25
Z9 25
U1 0
U2 9
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUN
PY 2014
VL 90
IS 6
BP 1135
EP 1139
DI 10.4269/ajtmh.14-0013
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AI4FD
UT WOS:000336820200027
PM 24710615
ER
PT J
AU Sibai, AM
Tohme, RA
Almedawar, MM
Itani, T
Yassine, SI
Nohra, EA
Isma'eel, HA
AF Sibai, Abla M.
Tohme, Rania A.
Almedawar, Mohamad M.
Itani, Taha
Yassine, Sara I.
Nohra, Eden A.
Isma'eel, Hussain A.
TI Lifetime cumulative exposure to waterpipe smoking is associated with
coronary artery disease
SO ATHEROSCLEROSIS
LA English
DT Article
DE Waterpipe smoking; Coronary artery disease; Heart disease; Case-control
study
ID HEART-RATE-VARIABILITY; TOBACCO SMOKING; PIPE SMOKING; RISK; ATTITUDES;
BEHAVIOR; BELIEFS
AB Objective: Globally, waterpipe (WP) smoking is becoming a more prevalent form of tobacco consumption. Whilst research so far has demonstrated a significant link between WP use and a number of health outcomes, little is known of its association with heart disease. We examine in this study the association of WP smoking with angiographically confirmed coronary artery disease (CAD).
Methods: A total of 1210 patients, aged 40 years and over and free from smoking-associated illnesses or history of cardiovascular procedures, admitted for coronary angiography at four major hospitals in Lebanon, were included. The extent of CAD was summarized in two ways, firstly as diseased (>= 50% and >= 70% occlusion in at least one main coronary artery) versus non-diseased (entirely normal coronaries), and secondly, as CAD cumulative score based on Duke CAD Prognostic Index. A score of WP-years, capturing intensity and lifetime duration of exposure, was estimated for each individual.
Results: Lifetime exposure exceeding 40 WP-years was associated with a threefold significant increase in the odds of having severe stenosis (>= 70%) compared to non-smokers (OR = 2.94, 95% CI = 1.04-8.33) as well as with the CAD Index (beta = 7.835, p-value = 0.027), net of the effect of socio-demographic characteristics, health behaviors and co-morbidity. A dose-response relationship between WP-years and percent stenosis was also established. WP smoking status (never, past and current) did not associate with CAD.
Conclusions: Cumulative exposure to WP smoking is significantly associated with severe CAD. There is a need to monitor WP use among cardiac patients and include this information in their medical charts in the same manner cigarettes smoking is documented. This is likely to increase awareness of the hazards of WP smoking and prompt physicians to target WP tobacco control by providing advice to their patients on WP smoking cessation. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Sibai, Abla M.; Tohme, Rania A.; Yassine, Sara I.] Amer Univ Beirut, Fac Hlth Sci, Dept Epidemiol & Populat Hlth, Beirut 11072020, Lebanon.
[Tohme, Rania A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Almedawar, Mohamad M.; Isma'eel, Hussain A.] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut 11072020, Lebanon.
[Almedawar, Mohamad M.; Isma'eel, Hussain A.] Amer Univ Beirut, Med Ctr, Vasc Med Program, Beirut 11072020, Lebanon.
[Itani, Taha] Univ Bielefeld, Sch Publ Hlth, Dept Publ Hlth Med, D-33615 Bielefeld, Germany.
[Nohra, Eden A.] Amer Univ Beirut, Med Ctr, Dept Surg, Beirut 11072020, Lebanon.
RP Isma'eel, HA (reprint author), Amer Univ Beirut, Med Ctr, Cairo St,POB 11-0236, Beirut 11072020, Lebanon.
EM hi09@aub.edu.lb
OI Sibai, Abla/0000-0002-1851-5606
FU International Development Research Centre (IDRC-EDR) [103436-001]
FX This work was supported by the International Development Research Centre
(IDRC-EDR) [grant number 103436-001] to [AMS]. The funding source had no
role in the study design, conduct or analysis; in the writing of the
paper or the decision to submit the paper for publication.
NR 29
TC 15
Z9 15
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2014
VL 234
IS 2
BP 454
EP 460
DI 10.1016/j.atherosclerosis.2014.03.036
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AH9CT
UT WOS:000336439000032
PM 24814409
ER
PT J
AU Ellis, MW
Schlett, CD
Millar, EV
Wilkins, KJ
Crawford, KB
Morrison-Rodriguez, SM
Pacha, LA
Gorwitz, RJ
Lanier, JB
Tribble, DR
AF Ellis, Michael W.
Schlett, Carey D.
Millar, Eugene V.
Wilkins, Kenneth J.
Crawford, Katrina B.
Morrison-Rodriguez, Stephanie M.
Pacha, Laura A.
Gorwitz, Rachel J.
Lanier, Jeffrey B.
Tribble, David R.
TI Hygiene Strategies to Prevent Methicillin-Resistant Staphylococcus
aureus Skin and Soft Tissue Infections: A Cluster-Randomized Controlled
Trial Among High-Risk Military Trainees
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Staphylococcus aureus; methicillin-resistant Staphylococcus aureus
(MRSA); skin and soft tissue infection; chlorhexidine; military
ID HOUSEHOLD CONTACTS; MARINE RECRUITS; UNITED-STATES; COLONIZATION;
EPIDEMIOLOGY; CELLULITIS; CHILDREN; PREVALENCE; CALIFORNIA; MUPIROCIN
AB Background. Effective measures are needed to prevent methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs) in high-risk community settings. The study objective was to evaluate the effect of personal hygiene-based strategies on rates of overall SSTI and MRSA SSTI.
Methods. We conducted a prospective, field-based, cluster-randomized trial in US Army Infantry trainees from May 2010 through January 2012. There were 3 study groups with incrementally increased education and hygiene-based interventions: standard (S), enhanced standard (ES), and chlorhexidine (CHG). The primary endpoints were incidence of overall SSTI and MRSA SSTI.
Results. The study included 30 209 trainees constituting 540 platoons (168 S, 192 ES, and 180 CHG). A total of 1203 (4%) participants developed SSTI, 316 (26%) due to MRSA. The overall SSTI rate was 4.15 (95% confidence interval [CI], 3.77-4.58) per 100 person-cycles. SSTI rates by study group were 3.48 (95% CI, 2.87-4.22) for S, 4.18 (95% CI, 3.56-4.90) for ES, and 4.71 (95% CI, 4.03-5.50) for CHG. The MRSA SSTI rate per 100 person-cycles for all groups was 1.10 (95% CI,.91-1.32). MRSA SSTI rates by study group were 1.0 (95% CI,.70-1.42) for S, 1.29 (95% CI,.98-1.71) for ES, and 0.97 (95% CI,.70-1.36) for CHG.
Conclusions. Personal hygiene and education measures, including once-weekly use of chlorhexidine body wash, did not prevent overall SSTI or MRSA SSTI in a high-risk population of military trainees.
C1 [Ellis, Michael W.] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA.
[Schlett, Carey D.; Millar, Eugene V.; Crawford, Katrina B.; Morrison-Rodriguez, Stephanie M.; Tribble, David R.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Infect Dis Clin Res Program, Bethesda, MD 20814 USA.
[Wilkins, Kenneth J.] NIDDK, NIH, Bethesda, MD 20892 USA.
[Pacha, Laura A.] US Army Publ Hlth Command, Army Inst Publ Hlth, Aberdeen Proving Ground, MD USA.
[Gorwitz, Rachel J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Lanier, Jeffrey B.] Martin Army Community Hosp, Ft Benning, GA USA.
RP Ellis, MW (reprint author), Uniformed Serv Univ Hlth Sci, Dept Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.
EM michael.ellis@usuhs.edu
FU Infectious Disease Clinical Research Program, a DoD program through the
Uniformed Services University of the Health Sciences; National Institute
of Allergy and Infectious Diseases, National Institutes of Health
[Y1-AI-5072]; CDC, National Center for Emerging and Zoonotic Infectious
Diseases, Division of Healthcare Quality Promotion [09FED914272]; DoD
Global Emerging Infections Surveillance program [C0366-11-HS]
FX The work was supported by the Infectious Disease Clinical Research
Program, a DoD program executed through the Uniformed Services
University of the Health Sciences. This project has been funded in
whole, or in part, with federal funds from the National Institute of
Allergy and Infectious Diseases, National Institutes of Health
(Interagency Agreement Y1-AI-5072). Additional funding was provided by
CDC, National Center for Emerging and Zoonotic Infectious Diseases,
Division of Healthcare Quality Promotion (Interagency Agreement
(09FED914272 to M. W. E.), and the DoD Global Emerging Infections
Surveillance program (C0366-11-HS to M. W. E.).
NR 38
TC 15
Z9 15
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 1
PY 2014
VL 58
IS 11
BP 1540
EP 1548
DI 10.1093/cid/ciu166
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AI7AL
UT WOS:000337031200009
PM 24633684
ER
PT J
AU Patton, ME
Kidd, S
Llata, E
Stenger, M
Braxton, J
Asbel, L
Bernstein, K
Gratzer, B
Jespersen, M
Kerani, R
Mettenbrink, C
Mohamed, M
Pathela, P
Schumacher, C
Stirland, A
Stover, J
Tabidze, I
Kirkcaldy, RD
Weinstock, H
AF Patton, Monica E.
Kidd, Sarah
Llata, Eloisa
Stenger, Mark
Braxton, Jim
Asbel, Lenore
Bernstein, Kyle
Gratzer, Beau
Jespersen, Megan
Kerani, Roxanne
Mettenbrink, Christie
Mohamed, Mukhtar
Pathela, Preeti
Schumacher, Christina
Stirland, Ali
Stover, Jeff
Tabidze, Irina
Kirkcaldy, Robert D.
Weinstock, Hillard
TI Extragenital Gonorrhea and Chlamydia Testing and Infection Among Men Who
Have Sex With Men-STD Surveillance Network, United States, 2010-2012
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE extragenital gonorrhea; extragenital chlamydia; men who have sex with
men (MSM); STD
ID NEISSERIA-GONORRHOEAE; HIV-INFECTION; GONOCOCCAL INFECTION; RECTAL
GONORRHEA; HOMOSEXUAL-MEN; SAN-FRANCISCO; BISEXUAL MEN; TRACHOMATIS;
PHARYNGEAL; HEALTH
AB Background. Gonorrhea (GC) and chlamydia (CT) are the most commonly reported notifiable diseases in the United States. The Centers for Disease Control and Prevention recommends that men who have sex with men (MSM) be screened for urogenital GC/CT, rectal GC/CT, and pharyngeal GC. We describe extragenital GC/CT testing and infections among MSM attending sexually transmitted disease (STD) clinics.
Methods. The STD Surveillance Network collects patient data from 42 STD clinics. We assessed the proportion of MSM attending these clinics during July 2011-June 2012 who were tested and positive for extragenital GC/CT at their most recent visit or in the preceding 12 months and the number of extragenital infections that would have remained undetected with urethral screening alone.
Results. Of 21 994 MSM, 83.9% were tested for urogenital GC, 65.9% for pharyngeal GC, 50.4% for rectal GC, 81.4% for urogenital CT, 31.7% for pharyngeal CT, and 45.9% for rectal CT. Of MSM tested, 11.1% tested positive for urogenital GC, 7.9% for pharyngeal GC, 10.2% for rectal GC, 8.4% for urogenital CT, 2.9% for pharyngeal CT, and 14.1% for rectal CT. More than 70% of extragenital GC infections and 85% of extragenital CT infections were associated with negative urethral tests at the same visit and would not have been detected with urethral screening alone.
Conclusions. Extragenital GC/CT was common among MSM attending STD clinics, but many MSM were not tested. Most extragenital infections would not have been identified, and likely would have remained untreated, with urethral screening alone. Efforts are needed to facilitate implementation of extragenital GC/CT screening recommendations for MSM.
C1 [Patton, Monica E.; Kidd, Sarah; Llata, Eloisa; Stenger, Mark; Braxton, Jim; Kirkcaldy, Robert D.; Weinstock, Hillard] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30316 USA.
[Patton, Monica E.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30316 USA.
[Asbel, Lenore] Philadelphia Hlth Dept, Philadelphia, PA USA.
[Bernstein, Kyle] San Francisco Dept Publ Hlth, San Francisco, CA USA.
[Gratzer, Beau] Howard Brown Hlth Ctr, Chicago, IL USA.
[Jespersen, Megan] Louisiana Off Publ Hlth, Baton Rouge, LA USA.
[Kerani, Roxanne] Publ Hlth Seattle & King Cty, Seattle, WA USA.
[Kerani, Roxanne] Univ Washington, Seattle, WA 98195 USA.
[Mettenbrink, Christie] Denver Publ Hlth Dept, Denver, CO USA.
[Mohamed, Mukhtar] Connecticut Dept Publ Hlth, Hartford, CT USA.
[Pathela, Preeti] New York City Dept Hlth & Mental Hyg, New York, NY USA.
[Schumacher, Christina] Baltimore City Dept Hlth, Baltimore, MD USA.
[Schumacher, Christina] Johns Hopkins Sch Med, Baltimore, MD USA.
[Stirland, Ali] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA.
[Stover, Jeff] Virginia Dept Hlth, Richmond, VA USA.
[Tabidze, Irina] Chicago Div Publ Hlth, Chicago, IL USA.
RP Patton, ME (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E02, Atlanta, GA 30316 USA.
EM gnh9@cdc.gov
FU Centers for Disease Control and Prevention, Division of STD Prevention,
STD Surveillance Network [CDC RFA PS08-865]
FX This work was supported by the Centers for Disease Control and
Prevention, Division of STD Prevention, STD Surveillance Network (CDC
RFA PS08-865).
NR 31
TC 30
Z9 30
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 1
PY 2014
VL 58
IS 11
BP 1564
EP 1570
DI 10.1093/cid/ciu184
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AI7AL
UT WOS:000337031200012
PM 24647015
ER
PT J
AU Wagenaar, JA
van Bergen, MAP
Blaser, MJ
Tauxe, RV
Newell, DG
van Putten, JPM
AF Wagenaar, Jaap A.
van Bergen, Marcel A. P.
Blaser, Martin J.
Tauxe, Robert V.
Newell, Diane G.
van Putten, Jos P. M.
TI Campylobacter fetus Infections in Humans: Exposure and Disease
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Campylobacter fetus; food safety; exposure; immunocompromised
ID SUBSP FETUS; CLINICAL-FEATURES; S-LAYER; BACTEREMIA; SPP.;
IDENTIFICATION; CONTAMINATION; PATHOGENESIS; PREVALENCE; MECHANISMS
AB Campylobacter fetus can cause intestinal illness and, occasionally, severe systemic infections. Infections mainly affect persons at higher risk, including elderly and immunocompromised individuals and those with occupational exposure to infected animals. Outbreaks are infrequent but have provided insight into sources. Source attribution of sporadic cases through case-control interviews has not been reported. The reservoirs for C. fetus are mainly cattle and sheep. Products from these animals are suspected as sources for human infections. Campylobacter fetus is rarely isolated from food, albeit selective isolation methods used in food microbiology are not suited for its detection. We hypothesize that the general population is regularly exposed to C. fetus through foods of animal origin, cross-contaminated foodstuffs, and perhaps other, as yet unidentified, routes. Campylobacter fetus infection should be suspected particularly in patients with nonspecific febrile illness who are immunocompromised or who may have been occupationally exposed to ruminants.
C1 [Wagenaar, Jaap A.; van Putten, Jos P. M.] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Lelystad, Netherlands.
[Wagenaar, Jaap A.; van Bergen, Marcel A. P.] Wageningen UR, Cent Vet Inst, Lelystad, Netherlands.
[Wagenaar, Jaap A.; van Bergen, Marcel A. P.; van Putten, Jos P. M.] World Hlth Org Collaborating Ctr Campylobacter, OIE Reference Lab Campylobacteriosis, Utrecht, Netherlands.
[Blaser, Martin J.] NYU, Sch Med, Dept Med, New York, NY USA.
[Tauxe, Robert V.] Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, Atlanta, GA USA.
[Newell, Diane G.] Food Borne Zoonoses Consultancy, Wherwell, Andover, England.
RP Wagenaar, JA (reprint author), Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, POB 80-165, NL-3508 TD Utrecht, Netherlands.
EM j.wagenaar@uu.nl
OI van Putten, Jos/0000-0002-4126-8172
FU Diane Belfer Program in Human Microbial Ecology
FX This work was supported in part by the Diane Belfer Program in Human
Microbial Ecology.
NR 61
TC 13
Z9 13
U1 1
U2 25
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 1
PY 2014
VL 58
IS 11
BP 1579
EP 1586
DI 10.1093/cid/ciu085
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AI7AL
UT WOS:000337031200015
PM 24550377
ER
PT J
AU Hinton, CF
Mai, CT
Nabukera, SK
Botto, LD
Feuchtbaum, L
Romitti, PA
Wang, Y
Piper, KN
Olney, RS
AF Hinton, Cynthia F.
Mai, Cara T.
Nabukera, Sarah K.
Botto, Lorenzo D.
Feuchtbaum, Lisa
Romitti, Paul A.
Wang, Ying
Piper, Kimberly Noble
Olney, Richard S.
TI Developing a public health-tracking system for follow-up of newborn
screening metabolic conditions: a four-state pilot project structure and
initial findings
SO GENETICS IN MEDICINE
LA English
DT Article
DE long-term follow-up; newborn streening metabolic disorders; public
health surveillance
ID SERVICES ADVISORY-COMMITTEE; HERITABLE DISORDERS; INFORMATION-SYSTEM;
UNITED-STATES; US SECRETARY; CHILDREN; COLLECTION; GUIDELINES;
DIAGNOSIS; PROGRAMS
AB Purpose: The aim of this study was to describe the methods, cases, and initial results of a pilot project using existing public health data collection programs (birth defect surveillance or newborn screening) to conduct long-term follow-up of children with metabolic disorders.
Methods: California, Iowa, New York, and Utah expanded birth defect surveillance or newborn screening programs to collect long-term follow-up data on 19 metabolic disorders. Data elements to monitor health status and services delivered were identified, and record abstraction and data linkages were conducted. Children were followed up through to the age of 3 years.
Results: A total of 261 metabolic cases were diagnosed in 1,343,696 live births (19.4 cases/100,000; 95% confidence interval = 17.1-21.8). Four deaths were identified. Children with fatty acid oxidation disorders had a higher percentage of health service encounters compared with children with other disorders of at least one health service encounter (hospitalization, emergency room, metabolic clinic, genetic service provider, or social worker) except for hospitalizations; children with organic acid disorders had a higher percentage of at least one hospitalization during their third year of life than children with other disorders.
Conclusion: Existing public health data programs can be leveraged to conduct population-based newborn screening long-term follow-up. This approach is flexible according to state needs and resources. These data will enable the states in assessing health burden, assuring access to services, and supporting policy development.
C1 [Hinton, Cynthia F.; Mai, Cara T.; Olney, Richard S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Nabukera, Sarah K.] Social & Sci Syst, Silver Spring, MD USA.
[Botto, Lorenzo D.] Univ Utah, Dept Pediat, Div Med Genet, Salt Lake City, UT USA.
[Feuchtbaum, Lisa] Calif Dept Publ Hlth, Genet Dis Screening Program, Sacramento, CA USA.
[Romitti, Paul A.] Univ Iowa, Iowa City, IA USA.
[Wang, Ying] New York State Dept Hlth, Albany, NY USA.
[Piper, Kimberly Noble] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA.
RP Hinton, CF (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM chinton@cdc.gov
FU National Center on Birth Defects and Developmental Disabilities, Centers
for Disease Control and Prevention (CDC) [DD08-810]
FX This project was supported in part by the cooperative agreement. no.
DD08-810 from the National Center on Birth Defects and Developmental
Disabilities, Centers for Disease Control and Prevention (CDC). We
acknowledge key individuals who contributed to the project: Christopher
Johnson and Marilyn Sango-Jordan for newborn screening data and
preparing the final data set in New York; Sunaina Dowray and Jennifer
Carter for data coordination and management in California; Aliese
Franck, Marcia L. Feldkamp, Amy E. Nance, and Miland Palmer for data
abstraction and database preparation and support in Utah; Jan
Vanderflugt, Florence Foo, and Carrie Fall for data abstraction in Iowa.
In addition, we thank Coleen Boyle, Margaret Honein, Harry Hannon, and
Carla Cuthbert from the CDC for their support of the project.
NR 24
TC 4
Z9 4
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
EI 1530-0366
J9 GENET MED
JI Genet. Med.
PD JUN
PY 2014
VL 16
IS 6
BP 484
EP 490
DI 10.1038/gim.2013.177
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA AI6UF
UT WOS:000337011800009
PM 24310309
ER
PT J
AU Conklin, L
Sejvar, JJ
Kieszak, S
Sabogal, R
Sanchez, C
Flanders, D
Tulloch, F
Victoria, G
Rodriguez, G
Sosa, N
McGeehin, MA
Schier, JG
AF Conklin, Laura
Sejvar, James J.
Kieszak, Stephanie
Sabogal, Raquel
Sanchez, Carlos
Flanders, Dana
Tulloch, Felicia
Victoria, Gerardo
Rodriguez, Giselle
Sosa, Nestor
McGeehin, Michael A.
Schier, Joshua G.
TI Long-term Renal and Neurologic Outcomes Among Survivors of Diethylene
Glycol Poisoning
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID METABOLITE; INGESTION; EPIDEMIC; TOXICITY; PANAMA
AB IMPORTANCE At least 13 medication-associated diethylene glycol (DEG) mass poisonings have occurred since 1937. To our knowledge, this is the first longitudinal study characterizing long-term health outcomes among survivors beyond the acute poisoning period.
OBJECTIVE To characterize renal and neurologic outcomes among survivors of a 2006 DEG mass-poisoning event in Panama for 2 years after exposure.
DESIGN, SETTING, AND PARTICIPANTS This prospective longitudinal study used descriptive statistics and mixed-effects repeated-measures analysis to evaluate DEG-poisoned survivors at 4 consecutive 6-month intervals (0, 6, 12, and 18 months). Case patients included outbreak survivors with a history of (1) ingestion of DEG-contaminated medication, (2) hospitalization for DEG poisoning, and (3) an unexplained serum creatinine level of 1.5 mg/dL or higher (to convert to micromoles per liter, multiply by 88.4) during acute illness or unexplained exacerbation of preexisting end-stage renal disease.
MAIN OUTCOMES AND MEASURES Demographics, mortality, dialysis dependence, renal function, neurologic signs and symptoms, and nerve conduction studies.
RESULTS Of the 32 patients enrolled, 5 (15.6%) died and 1 was lost to follow-up, leaving 26 patients at 18 months. Three (9.4%) missed 1 or more evaluations. The median age was 62 years (range, 15-88 years), and 59.4% were female. Three (9.4%) patients had preexisting renal failure. Enrollment evaluations occurred at a median of 108 days (range, 65-154 days) after acute illness. The median serum creatinine level for the 22 patients who were not dialysis dependent at time 0 was 5.9 mg/dL (range, 1.8-17.1 mg/dL) during acute illness and 1.8 mg/dL (range, 0.9-5.9 mg/dL) at time 0. Among non-dialysis-dependent patients, there were no significant differences in the log of serum creatinine or estimated glomerular filtration rate over time. The number of patients with subjective generalized weakness declined significantly over time (P < .001). A similar finding was observed for any sensory loss (P = .05). The most common deficits at enrollment were bilateral lower extremity numbness in 13 patients (40.6%) and peripheral facial nerve motor deficits in 7 (21.9%). All patients with neurologic deficits at enrollment demonstrated improvement in motor function over time. Among 28 patients (90.3%) with abnormal nerve conduction study findings at enrollment, 10 (35.7%) had motor axonal involvement, the most common primary abnormality.
CONCLUSIONS AND RELEVANCE Neurologic findings of survivors tended to improve over time. Renal function generally improved among non-dialysis-dependent patients between acute illness and the first evaluation with little variability thereafter. No evidence of delayed-onset neurologic or renal disease was observed.
C1 [Conklin, Laura; Kieszak, Stephanie; Sabogal, Raquel; Sanchez, Carlos; Flanders, Dana; McGeehin, Michael A.; Schier, Joshua G.] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.
[Sejvar, James J.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA 30333 USA.
[Rodriguez, Giselle] Caja Seguro Social, Panama City, Panama.
[Sosa, Nestor] Gorgas Mem Inst, Panama City, Panama.
[Schier, Joshua G.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA USA.
RP Conklin, L (reprint author), Ctr Dis Control & Prevent, Mail Stop A-04,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM lconklin@cdc.gov
FU Conklin; Tulloch; Schier
FX Obtained funding: Conklin, Tulloch, Schier.
NR 13
TC 6
Z9 6
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN
PY 2014
VL 174
IS 6
BP 912
EP 917
DI 10.1001/jamainternmed.2014.344
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI4OA
UT WOS:000336843500023
PM 24819553
ER
PT J
AU Decker, SL
Kenney, GM
Long, SK
AF Decker, Sandra L.
Kenney, Genevieve M.
Long, Sharon K.
TI Characteristics of Uninsured Low-Income Adults in States Expanding vs
Not Expanding Medicaid
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Decker, Sandra L.] Ctr Dis Control & Prevent, Hyattsville, MD 20782 USA.
[Kenney, Genevieve M.; Long, Sharon K.] Urban Inst, Washington, DC 20037 USA.
RP Decker, SL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA.
EM sdecker@cdc.gov
NR 2
TC 4
Z9 4
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN
PY 2014
VL 174
IS 6
BP 988
EP 989
DI 10.1001/jamainternmed.2014.518
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI4OA
UT WOS:000336843500038
PM 24710741
ER
PT J
AU Reis, G
Ritter, J
Bellini, W
Bollen, A
AF Reis, Gerald
Ritter, Jana
Bellini, William
Bollen, Andrew
TI A 29-year-old Pregnant Woman with Worsening Left Hemiparesis,
Encephalopathy, and Hemodynamic Instability: A Case of SSPE
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Meeting Abstract
CT 90th Annual Meeting of the American-Association-of-Neuropathologists-Inc
CY JUN 12-15, 2014
CL Portland, OR
SP Amer Assoc Neuropathologists Inc
C1 [Reis, Gerald; Bollen, Andrew] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Ritter, Jana; Bellini, William] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
EI 1554-6578
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD JUN
PY 2014
VL 73
IS 6
MA 66
BP 602
EP 603
PG 2
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA AI3AZ
UT WOS:000336732100074
ER
PT J
AU Su, KC
Vinters, H
Khanlou, N
Yong, W
Wu, A
Shieh, WJ
Blau, D
Muehlenbachs, A
AF Su, Keng-Chih
Vinters, Harry
Khanlou, Negar
Yong, William
Wu, Annie
Shieh, Wun-Ju
Blau, Dianna
Muehlenbachs, Atis
TI Balamuthia Amoebic Encephalitis, Diagnostic Challenges from Surgical
Pathology to Autopsy: A Case Report
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Meeting Abstract
CT 90th Annual Meeting of the American-Association-of-Neuropathologists-Inc
CY JUN 12-15, 2014
CL Portland, OR
SP Amer Assoc Neuropathologists Inc
C1 [Su, Keng-Chih; Vinters, Harry; Khanlou, Negar; Yong, William; Wu, Annie] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neuropathol, Los Angeles, CA 90095 USA.
[Shieh, Wun-Ju; Blau, Dianna; Muehlenbachs, Atis] Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
EI 1554-6578
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD JUN
PY 2014
VL 73
IS 6
MA 67
BP 603
EP 603
PG 1
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA AI3AZ
UT WOS:000336732100077
ER
PT J
AU Fleischer, NL
Melstrom, P
Yard, E
Brubaker, M
Thomas, T
AF Fleischer, N. L.
Melstrom, P.
Yard, E.
Brubaker, M.
Thomas, T.
TI The epidemiology of falling-through-the-ice in Alaska, 1990-2010
SO JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE morbidity and mortality; public health; social determinants
ID CLIMATE-CHANGE; HEALTH
AB Climate change has contributed to increasing temperatures, earlier snowmelts and thinning ice packs in the Arctic, where crossing frozen bodies of water is essential for transportation and subsistence living. In some Arctic communities, anecdotal reports indicate a growing belief that falling-through-the-ice (FTI) are increasing. The objective of this study was to describe the morbidity and mortality associated with unintentional FTIs in Alaska.
We searched newspaper reports to identify FTI events from 1990 to 2010. We also used data from a trauma registry, occupational health and law enforcement registries and vital statistics to supplement the newspaper reports. Morbidity and mortality rates were calculated for Alaska Native (AN) people and all Alaskans.
During the 21-year period, we identified 307 events, affecting at least 449 people. Events ranged from no morbidity to fatalities of five people. More than half of the events involved transportation by snow machine. Mortality rates were markedly higher for AN people than that for all Alaskans.
We provide a numeric estimate of the importance of FTI events in Alaska. FTIs may represent an adverse health outcome related to climate changes in the Arctic, and may be particularly critical for vulnerable populations such as AN people.
C1 [Fleischer, N. L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv Assigned, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.
[Melstrom, P.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Yard, E.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.
[Brubaker, M.] Alaska Native Tribal Hlth Consortium, Ctr Climate & Hlth, Anchorage, AK 99508 USA.
[Thomas, T.] Alaska Native Tribal Hlth Consortium, Anchorage, AK 99508 USA.
RP Fleischer, NL (reprint author), Univ S Carolina, Dept Epidemiol & Biostat, Arnold Sch Publ Hlth, 800 Sumter St, Columbia, SC 29208 USA.
EM nfleischer@sc.edu
FU Health Studies Branch, National Center for Environmental Health, CDC
FX This work was supported by funding from the Health Studies Branch,
National Center for Environmental Health, CDC.
NR 25
TC 3
Z9 3
U1 2
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1741-3842
EI 1741-3850
J9 J PUBLIC HEALTH-UK
JI J. Public Health
PD JUN
PY 2014
VL 36
IS 2
BP 235
EP 242
DI 10.1093/pubmed/fdt081
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI7NB
UT WOS:000337077300009
PM 23995713
ER
PT J
AU Levings, JL
Gunn, JP
AF Levings, Jessica Lee
Gunn, Janelle Peralez
TI The Imbalance of Sodium and Potassium Intake: Implications for Dietetic
Practice
SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS
LA English
DT Article
ID STOP HYPERTENSION DIET; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; TRIALS;
METAANALYSIS; PREVENTION; MORTALITY; CHILDREN; STROKE; ADULTS
C1 [Levings, Jessica Lee; Gunn, Janelle Peralez] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Levings, JL (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
NR 33
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-2672
J9 J ACAD NUTR DIET
JI J. Acad. Nutr. Diet.
PD JUN
PY 2014
VL 114
IS 6
BP 838
EP 841
DI 10.1016/j.jand.2014.02.015
PG 4
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AI7LD
UT WOS:000337071200003
PM 24742901
ER
PT J
AU Clarke, DK
Nasar, F
Chong, S
Johnson, JE
Coleman, JW
Lee, M
Witko, SE
Kotash, CS
Abdullah, R
Megati, S
Luckay, A
Nowak, B
Lackner, A
Price, RE
Little, P
Kalyan, N
Randolf, V
Javadian, A
Zamb, TJ
Parks, CL
Egan, MA
Eldridge, J
Hendry, M
Udem, SA
AF Clarke, David K.
Nasar, Farooq
Chong, Siew
Johnson, J. Erik
Coleman, John W.
Lee, Margaret
Witko, Susan E.
Kotash, Cheryl S.
Abdullah, Rashed
Megati, Shakuntala
Luckay, Amara
Nowak, Becky
Lackner, Andrew
Price, Roger E.
Little, Peter
Kalyan, Narender
Randolf, Valerie
Javadian, Ali
Zamb, Timothy J.
Parks, Christopher L.
Egan, Michael A.
Eldridge, John
Hendry, Michael
Udem, Stephen A.
TI Neurovirulence and Immunogenicity of Attenuated Recombinant Vesicular
Stomatitis Viruses in Nonhuman Primates
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID RESPIRATORY SYNCYTIAL VIRUS; TEMPERATURE-SENSITIVE MUTANTS;
CENTRAL-NERVOUS-SYSTEM; MATRIX PROTEIN; GENE-EXPRESSION; VACCINIA VIRUS;
MUMPS-VIRUS; IN-VIVO; PHLEBOTOMINE SANDFLIES; BOOST VACCINATION
AB In previous work, a prototypic recombinant vesicular stomatitis virus Indiana serotype (rVSIV) vector expressing simian immunodeficiency virus (SIV) gag and human immunodeficiency virus type 1 (HIV-1) env antigens protected nonhuman primates (NHPs) from disease following challenge with an HIV-1/SIV recombinant (SHIV). However, when tested in a stringent NHP neurovirulence (NV) model, this vector was not adequately attenuated for clinical evaluation. For the work described here, the prototypic rVSIV vector was attenuated by combining specific G protein truncations with either N gene translocations or mutations (M33A and M51A) that ablate expression of subgenic M polypeptides, by incorporation of temperature-sensitive mutations in the N and L genes, and by deletion of the VSIV G gene to generate a replicon that is dependent on trans expression of G protein for in vitro propagation. When evaluated in a series of NHP NV studies, these attenuated rVSIV variants caused no clinical disease and demonstrated a very significant reduction in neuropathology compared to wild-type VSIV and the prototypic rVSIV vaccine vector. In spite of greatly increased in vivo attenuation, some of the rVSIV vectors elicited cell-mediated immune responses that were similar in magnitude to those induced by the much more virulent prototypic vector. These data demonstrate novel approaches to the rational attenuation of VSIV NV while retaining vector immunogenicity and have led to identification of an rVSIV N4CT1gag1 vaccine vector that has now successfully completed phase I clinical evaluation.
C1 [Clarke, David K.; Nowak, Becky; Egan, Michael A.; Eldridge, John] Profectus Biosci, Tarrytown, NY 10591 USA.
[Nasar, Farooq] Univ Texas Med Branch, Galveston, TX 77555 USA.
[Chong, Siew; Johnson, J. Erik; Lee, Margaret; Witko, Susan E.; Kotash, Cheryl S.; Abdullah, Rashed; Megati, Shakuntala; Luckay, Amara; Kalyan, Narender; Randolf, Valerie; Javadian, Ali; Zamb, Timothy J.; Udem, Stephen A.] Pfizer Pharmaceut Inc, Pearl River, NY USA.
[Coleman, John W.; Parks, Christopher L.] AIDS Vaccine Design & Dev Lab, Int AIDS Vaccine Initiat, Brooklyn, NY USA.
[Lackner, Andrew] Tulane Univ, Tulane Natl Primate Res Ctr, New Orleans, LA 70118 USA.
[Price, Roger E.] Vet Pathol Serv, Houston, TX USA.
[Little, Peter] EPL Inc, Res Triangle Pk, NC USA.
[Hendry, Michael] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA.
RP Clarke, DK (reprint author), Profectus Biosci, Tarrytown, NY 10591 USA.
EM DClarke@profectusbiosciences.net
FU HVDDT [HHSN272200800061C]; NIH
FX This work was supported by HVDDT contract HHSN272200800061C, awarded by
the NIH.
NR 89
TC 7
Z9 7
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUN
PY 2014
VL 88
IS 12
BP 6690
EP 6701
DI 10.1128/JVI.03441-13
PG 12
WC Virology
SC Virology
GA AI5HF
UT WOS:000336895600015
PM 24696472
ER
PT J
AU Camp, KM
Parisi, MA
Acosta, PB
Berry, GT
Bilder, DA
Blau, N
Bodamer, OA
Brosco, JP
Brown, CS
Burlina, AB
Burton, BK
Chang, CS
Coates, PM
Cunningham, AC
Dobrowolski, SF
Ferguson, JH
Franklin, TD
Frazier, DM
Grange, DK
Greene, CL
Groft, SC
Harding, CO
Howell, RR
Huntington, KL
Hyatt-Knorr, HD
Jevaji, IP
Levy, HL
Lichter-Konecki, U
Lindegren, ML
Lloyd-Puryear, MA
Matalon, K
MacDonald, A
McPheeters, ML
Mitchell, JJ
Mofidi, S
Moseley, KD
Mueller, CM
Mulberg, AE
Nerurkar, LS
Ogata, BN
Pariser, AR
Prasad, S
Pridjian, G
Rasmussen, SA
Reddy, UM
Rohr, FJ
Singh, RH
Sirrs, SM
Stremer, SE
Tagle, DA
Thompson, SM
Urv, TK
Utz, JR
van Spronsen, F
Vockley, J
Waisbren, SE
Weglicki, LS
White, DA
Whitley, CB
Wilfond, BS
Yannicelli, S
Young, JM
AF Camp, Kathryn M.
Parisi, Melissa A.
Acosta, Phyllis B.
Berry, Gerard. T.
Bilder, Deborah A.
Blau, Nenad
Bodamer, Olaf A.
Brosco, Jeffrey P.
Brown, Christine S.
Burlina, Alberto B.
Burton, Barbara K.
Chang, Christine S.
Coates, Paul M.
Cunningham, Amy C.
Dobrowolski, Steven F.
Ferguson, John H.
Franklin, Thomas D.
Frazier, Dianne M.
Grange, Dorothy K.
Greene, Carol L.
Groft, Stephen C.
Harding, Cary O.
Howell, R. Rodney
Huntington, Kathleen L.
Hyatt-Knorr, Henrietta D.
Jevaji, Indira P.
Levy, Harvey L.
Lichter-Konecki, Uta
Lindegren, Mary Lou
Lloyd-Puryear, Michele A.
Matalon, Kimberlee
MacDonald, Anita
McPheeters, Melissa L.
Mitchell, John J.
Mofidi, Shideh
Moseley, Kathryn D.
Mueller, Christine M.
Mulberg, Andrew E.
Nerurkar, Lata S.
Ogata, Beth N.
Pariser, Anne R.
Prasad, Suyash
Pridjian, Gabriella
Rasmussen, Sonja A.
Reddy, Uma M.
Rohr, Frances J.
Singh, Rani H.
Sirrs, Sandra M.
Stremer, Stephanie E.
Tagle, Danilo A.
Thompson, Susan M.
Urv, Tiina K.
Utz, Jeanine R.
van Spronsen, Francjan
Vockley, Jerry
Waisbren, Susan E.
Weglicki, Linda S.
White, Desiree A.
Whitley, Chester B.
Wilfond, Benjamin S.
Yannicelli, Steven
Young, Justin M.
TI Phenylketonuria Scientific Review Conference: State of the science and
future research needs
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Phenylketonuria; Sapropterin; Hyperphenylalaninemia; Maternal PIN; Large
neutral amino acids; Glycomacropeptide
ID PHENYLALANINE-HYDROXYLASE DEFICIENCY; NEUTRAL AMINO-ACIDS;
DIHYDROPTERIDINE REDUCTASE DEFICIENCY; CONTINUOUSLY TREATED
PHENYLKETONURIA; TETRAHYDROBIOPTERIN LOADING TEST; GENOTYPE-PHENOTYPE
CORRELATIONS; THERAPEUTIC LIVER REPOPULATION; MATERNAL BLOOD
PHENYLALANINE; ENZYME REPLACEMENT THERAPY; TANDEM MASS-SPECTROMETRY
AB New developments in the treatment and management of phenylketonuria (PKU) as well as advances in molecular testing have emerged since the National Institutes of Health 2000 PKU Consensus Statement was released. An NIH State-of-the-Science Conference was convened in 2012 to address new findings, particularly the use of the medication sapropterin to treat some individuals with PKU, and to develop a research agenda. Prior to the 2012 conference, five working groups of experts and public members met over a 1-year period. The working groups addressed the following: long-term outcomes and management across the lifespan; PKU and pregnancy; diet control and management; pharmacologic interventions; and molecular testing, new technologies, and epidemiologic considerations. In a parallel and independent activity, an Evidence-based Practice Center supported by the Agency for Healthcare Research and Quality conducted a systematic review of adjuvant treatments for PKU; its conclusions were presented at the conference. The conference included the findings of the working groups, panel discussions from industry and international perspectives, and presentations on topics such as emerging treatments for PKU, transitioning to adult care, and the U.S. Food and Drug Administration regulatory perspective. Over 85 experts participated in the conference through information gathering and/or as presenters during the conference, and they reached several important conclusions. The most serious neurological impairments in PKU are preventable with current dietary treatment approaches. However, a variety of more subtle physical, cognitive, and behavioral consequences of even well-controlled PKU are now recognized. The best outcomes in maternal PKU occur when blood phenylalanine (Phe) concentrations are maintained between 120 and 360 Rtnol/L before and during pregnancy. The dietary management treatment goal for individuals with PKU is a blood Phe concentration between 120 and 360 [tmol/L. The use of genotype information in the newborn period may yield valuable insights about the severity of the condition for infants diagnosed before maximal Phe levels are achieved. While emerging and established genotype-phenotype correlations may transform our understanding of PKU, establishing correlations with intellectual outcomes is more challenging. Regarding the use of sapropterin in PKU, there are significant gaps in predicting response to treatment; at least half of those with PKU will have either minimal or no response. A coordinated approach to PKU treatment improves long-term outcomes for those with PKU and facilitates the conduct of research to improve diagnosis and treatment. New drugs that are safe, efficacious, and impact a larger proportion of individuals with PKU are needed. However, it is imperative that treatment guidelines and the decision processes for determining access to treatments be tied to a solid evidence base with rigorous standards for robust and consistent data collection. The process that preceded the PKU State-of-the-Science Conference, the conference itself, and the identification of a research agenda have facilitated the development of clinical practice guidelines by professional organizations and serve as a model for other inborn errors of metabolism.
C1 [Camp, Kathryn M.; Coates, Paul M.; Lloyd-Puryear, Michele A.] NIH, Off Dietary Supplements, Bethesda, MD 20982 USA.
[Parisi, Melissa A.; Reddy, Uma M.; Urv, Tiina K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD 20892 USA.
[Acosta, Phyllis B.; Singh, Rani H.] Emory Univ, Atlanta, GA 30033 USA.
[Berry, Gerard. T.; Levy, Harvey L.; Waisbren, Susan E.] Harvard Univ, Boston Childrens Hosp, Sch Med, Boston, MA 02115 USA.
[Bilder, Deborah A.] Univ Utah, Dept Psychiat, Salt Lake City, UT 84108 USA.
[Blau, Nenad] Univ Childrens Hosp, Heidelberg, Germany.
[Blau, Nenad] Univ Childrens Hosp, Zurich, Switzerland.
[Bodamer, Olaf A.; Howell, R. Rodney] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
[Brosco, Jeffrey P.] Univ Miami, Mailman Ctr Child Dev, Miami, FL 33101 USA.
[Brown, Christine S.; Franklin, Thomas D.] Natl PKU Alliance, Encinitas, CA USA.
[Burlina, Alberto B.] Univ Hosp, I-35128 Padua, Italy.
[Burton, Barbara K.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA.
[Chang, Christine S.] Agcy Healthcare Res & Qual, Rockville, MD 20850 USA.
[Cunningham, Amy C.; Pridjian, Gabriella] Tulane Univ, Sch Med, Hayward Genet Ctr, New Orleans, LA 70112 USA.
[Dobrowolski, Steven F.; Vockley, Jerry] Univ Pittsburgh, Pittsburgh, PA 15224 USA.
[Ferguson, John H.; Groft, Stephen C.; Hyatt-Knorr, Henrietta D.; Nerurkar, Lata S.] NIH, Off Rare Dis Res, Natl Ctr Adv Translat Sci, Bethesda, MD 20982 USA.
[Frazier, Dianne M.] Univ N Carolina, Chapel Hill, NC 27599 USA.
[Grange, Dorothy K.] Washington Univ, St Louis Childrens Hosp, Sch Med, St Louis, MO 63110 USA.
[Greene, Carol L.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Harding, Cary O.; Huntington, Kathleen L.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Jevaji, Indira P.] NIH, Off Res Womens Hlth, Bethesda, MD 20817 USA.
[Lichter-Konecki, Uta] George Washington Univ, Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Lindegren, Mary Lou] Vanderbilt Univ, Sch Med, Nashville, TN 37203 USA.
[Matalon, Kimberlee] Univ Houston, Houston, TX 77204 USA.
[MacDonald, Anita] Birmingham Childrens Hosp, Birmingham B4 6NH, W Midlands, England.
[McPheeters, Melissa L.] Inst Med & Publ Hlth, Vanderbilt Evidence Based Practice Ctr, Nashville, TN 37203 USA.
[Mitchell, John J.] McGill Univ, Ctr Hlth, Montreal, PQ H3H 1P3, Canada.
[Mofidi, Shideh] Maria Fareri Childrens Hosp, Westchester Med Ctr, Valhalla, NY 10595 USA.
[Moseley, Kathryn D.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Mueller, Christine M.] US FDA, Off Orphan Prod Dev, Silver Spring, MD 20993 USA.
[Mulberg, Andrew E.; Pariser, Anne R.] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA.
[Ogata, Beth N.] Univ Washington, Seattle, WA 98195 USA.
[Prasad, Suyash] BioMarin Pharmaceut Inc, San Rafael, CA 94901 USA.
[Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Rohr, Frances J.] Boston Childrens Hosp, Boston, MA 02115 USA.
[Sirrs, Sandra M.] Univ British Columbia, Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada.
[Burlina, Alberto B.] PKU & Allied Disorders Wisconsin, Madison, WI 53705 USA.
[Tagle, Danilo A.] NIH, Natl Ctr Adv Translat Sci, Bethesda, MD 20892 USA.
[Thompson, Susan M.] Childrens Hosp Westrnead, Sydney, NSW 2145, Australia.
[Utz, Jeanine R.; Whitley, Chester B.] Univ Minnesota, Minneapolis, MN 55455 USA.
[van Spronsen, Francjan] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, NL-9700 AB Groningen, Netherlands.
[Weglicki, Linda S.] NINR, NIH, Bethesda, MD 20892 USA.
[White, Desiree A.] Washington Univ, Dept Psychol, St Louis, MO 63130 USA.
[Wilfond, Benjamin S.] Univ Washington, Seattle Childrens Res Inst, Sch Med, Seattle, WA 98101 USA.
[Yannicelli, Steven] Nutricia North Amer, Rockville, MD 20850 USA.
[Young, Justin M.] Young Face Facial Plast & Reconstruct Surg, Cumming, GA 30041 USA.
RP Camp, KM (reprint author), 6100 Execut Blvd, Rockville, MD 20892 USA.
EM campkm@od.nih.gov; parisima@mail.nih.gov; pja1933@gmail.com;
gerard.berry@childrens.harvard.edu; deborah.bilder@hsc.utah.edu;
nenad.blau@med.uni-heidelberg.de; obodamer@med.miami.edu;
jbrosco@med.miami.edu; christine.brown@npkua.org;
alberto.burlina@unipd.it; bburton@luriechildrens.org;
christine.chang@ahrq.hhs.gov; coatesp@od.nih.gov; acunnin@tulane.edu;
dobrowolskis@upmc.edu; jferg@helix.nih.gov; tom.franklin@npkua.org;
dianne_frazier@med.unc.edu; grange_d@kids.wustl.edu;
cgreene@peds.umaryland.edu; stephen.groft@nih.gov; hardingc@ohsu.edu;
rhowell@miami.edu; huntingt@ohsu.edu; henrietta.hyatt-knorr@nih.gov;
indira.jevaji@cms.hhs.gov; harvey.levy@childrens.harvard.edu;
ulichter@cnmc.org; marylou.lindegren@vanderbilt.edu;
lloydpuryearma@od.nih.gov; kmatalon@uh.edu; anita.macdonald@bch.nhs.uk;
melissa.mcpheeters@vanderbilt.edu; john.mitchell@muhc.mcgill.ca;
shideh_mofidi@nymc.edu; kmoseley@usc.edu; christine.mueller@nih.gov;
andrew.mulberg@fda.hhs.gov; lnerurkar@gmail.com; bogata@uw.edu;
anne.pariser@fda.hhs.gov; sprasad@bmrn.com; pridjian@tulane.edu;
skr9@cdc.gov; reddyu@mail.nih.gov; frances.rohr@childrens.harvard.edu;
rsingh@emory.edu; sandra.sirrs@vch.ca; sstremer@yahoo.com;
danilo.tagle@nih.gov; sue.thompson@health.nsw.gov.au;
urvtiin@mail.nih.gov; jutz1@fairview.org; f.j.van.spronsen@umcg.nl;
vockleyg@upmc.edu; susan.waisbren@childrens.harvard.edu;
weglickils@mail.nih.gov; dawhite@wustl.edu; whitley@umn.edu;
benjamin.wilfond@seattlechildrens.org; steven.yannicelli@nutricia.com;
jmichaelyoung@yahoo.com
OI Berry, Gerard/0000-0001-5299-3313; Vockley, Jerry/0000-0002-8180-6457
NR 336
TC 43
Z9 43
U1 5
U2 73
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD JUN
PY 2014
VL 112
IS 2
BP 87
EP 122
DI 10.1016/j.ymgme.2014.02.013
PG 36
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
Medicine
GA AI7KF
UT WOS:000337067900002
PM 24667081
ER
PT J
AU Goldstein, BD
Brooks, BW
Cohen, SD
Gates, AE
Honeycutt, ME
Morris, JB
Orme-Zavaleta, J
Penning, TM
Snawder, J
AF Goldstein, Bernard D.
Brooks, Bryan W.
Cohen, Steven D.
Gates, Alexander E.
Honeycutt, Michael E.
Morris, John B.
Orme-Zavaleta, Jennifer
Penning, Trevor M.
Snawder, John
TI The Role of Toxicological Science in Meeting the Challenges and
Opportunities of Hydraulic Fracturing
SO TOXICOLOGICAL SCIENCES
LA English
DT Editorial Material
DE hydraulic fracturing; mixtures; shale gas; methane; benzene; radon
ID RATIONAL MOLECULAR DESIGN; MARCELLUS SHALE REGION; NATURAL-GAS
EXTRACTION; DRINKING-WATER WELLS; METHANE CONTAMINATION; AQUATIC
TOXICITY; RISK-ASSESSMENT; WASTE-WATER; IMPACTS; PENNSYLVANIA
AB We briefly describe how toxicology can inform the discussion and debate of the merits of hydraulic fracturing by providing information on the potential toxicity of the chemical and physical agents associated with this process, individually and in combination. We consider upstream activities related to bringing chemical and physical agents to the site, on-site activities including drilling of wells and containment of agents injected into or produced from the well, and downstream activities including the flow/removal of hydrocarbon products and of produced water from the site. A broad variety of chemical and physical agents are involved. As the industry expands this has raised concern about the potential for toxicological effects on ecosystems, workers, and the general public. Response to these concerns requires a concerted and collaborative toxicological assessment. This assessment should take into account the different geology in areas newly subjected to hydraulic fracturing as well as evolving industrial practices that can alter the chemical and physical agents of toxicological interest. The potential for ecosystem or human exposure to mixtures of these agents presents a particular toxicological and public health challenge. These data are essential for developing a reliable assessment of the potential risks to the environment and to human health of the rapidly increasing use of hydraulic fracturing and deep underground horizontal drilling techniques for tightly bound shale gas and other fossil fuels. Input from toxicologists will be most effective when employed early in the process, before there are unwanted consequences to the environment and human health, or economic losses due to the need to abandon or rework costly initiatives.
C1 [Goldstein, Bernard D.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15261 USA.
[Brooks, Bryan W.] Baylor Univ, Dept Environm Sci, Waco, TX 76798 USA.
[Cohen, Steven D.] Massachusetts Coll Pharm & Hlth Sci, Sch Pharm Worcester Manchester, Worcester, MA 01608 USA.
[Gates, Alexander E.] Rutgers State Univ, Dept Earth & Environm Sci, Newark, NJ 07102 USA.
[Honeycutt, Michael E.] Texas Commiss Environm Qual, Div Toxicol, Austin, TX 78711 USA.
[Morris, John B.] Univ Connecticut, Sch Pharm, Storrs, CT 06269 USA.
[Orme-Zavaleta, Jennifer] US EPA, Off Res & Dev, Res Triangle Pk, NC 27711 USA.
[Penning, Trevor M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA.
[Snawder, John] Natl Inst Occupat Safety & Hlth Appl Res & Techno, Ctr Dis Control & Prevent, Williamstown, KY 41097 USA.
RP Goldstein, BD (reprint author), 130 DeSoto St,A710 Crabtree Hall, Pittsburgh, PA 15261 USA.
EM bdgold@pitt.edu
RI Brooks, Bryan/B-2612-2010; Guenat, Heather/H-6528-2014;
OI Brooks, Bryan/0000-0002-6277-9852; Penning, Trevor/0000-0002-3937-1066
FU NIEHS NIH HHS [P30 ES013508, P30-ES013508]
NR 66
TC 17
Z9 17
U1 3
U2 85
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096-6080
EI 1096-0929
J9 TOXICOL SCI
JI Toxicol. Sci.
PD JUN
PY 2014
VL 139
IS 2
BP 271
EP 283
DI 10.1093/toxsci/kfu061
PG 13
WC Toxicology
SC Toxicology
GA AI7MO
UT WOS:000337075900001
PM 24706166
ER
PT J
AU Soucie, JM
Miller, CH
Kelly, FM
Aschman, D
DiMichele, D
Konkle, BA
Kulkarni, R
Monahan, PE
AF Soucie, J. Michael
Miller, Connie H.
Kelly, Fiona M.
Aschman, Diane
DiMichele, Donna
Konkle, Barbara A.
Kulkarni, Roshni
Monahan, Paul E.
CA CDC Inhibitor Surveillance Working
TI National surveillance for hemophilia inhibitors in the United States:
Summary report of an expert meeting
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID FACTOR-VIII INHIBITORS; NIJMEGEN MODIFICATION; BETHESDA ASSAY; IX
INHIBITORS; C INHIBITORS; POPULATION; DIAGNOSIS; KINGDOM
AB On March 12, 2012, the Centers for Disease Control and Prevention (CDC) held a meeting of its partners in hemophilia treatment, community-based organizations, industry, and government to review data and discuss implementation issues relevant to planned United States (U.S.) national inhibitor surveillance. Issues discussed included the current status of inhibitor surveillance in the United Kingdom (UK) and the US, the results of a US inhibitor surveillance feasibility study, proposed national surveillance schemes, laboratory testing and reporting issues and potential opportunities for future inhibitor-related research. It was concluded that implementation of a national program of inhibitor surveillance using standardized testing through an established public health registry along with patient and care provider education and targeted research provide the best opportunity to inform efforts to develop and evaluate effective prevention strategies.Am. J. Hematol. 89:621-625, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Soucie, J. Michael; Miller, Connie H.; Kelly, Fiona M.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA USA.
[Aschman, Diane] Amer Thrombosis & Hemostasis Network, Chicago, IL USA.
[DiMichele, Donna] NHLBI, NIH, Bethesda, MD 20892 USA.
[Konkle, Barbara A.] Puget Sound Blood Ctr, Seattle, WA 98104 USA.
[Kulkarni, Roshni] Michigan State Univ, Dept Pediat & Human Dev, E Lansing, MI 48824 USA.
[Monahan, Paul E.] Univ N Carolina, Dept Pediat, Div Hematol Oncol, Chapel Hill, NC USA.
RP Soucie, JM (reprint author), Div Blood Disorders, 1600 Clifton Rd,MS E64, Atlanta, GA 30333 USA.
EM msoucie@cdc.gov
OI Miller, Connie H/0000-0002-3989-7973
FU Intramural CDC HHS [CC999999]
NR 15
TC 2
Z9 2
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD JUN
PY 2014
VL 89
IS 6
BP 621
EP 625
DI 10.1002/ajh.23704
PG 5
WC Hematology
SC Hematology
GA AI1NU
UT WOS:000336618600212
PM 24616187
ER
PT J
AU Grosse, SD
Presley, RJ
Yusuf, HR
Richardson, LC
Amin, A
AF Grosse, Scott D.
Presley, Rodney J.
Yusuf, Hussain R.
Richardson, Lisa C.
Amin, Alpesh
TI INCREASED USE OF ANTICOAGULANT THROMBOPROPHYLAXIS IN US HOSPITALS,
2006-2010
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Grosse, Scott D.; Presley, Rodney J.; Yusuf, Hussain R.; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA.
[Amin, Alpesh] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD JUN
PY 2014
VL 89
IS 6
MA 4
BP E2
EP +
PG 2
WC Hematology
SC Hematology
GA AI1NU
UT WOS:000336618600005
ER
PT J
AU Manco-Johnson, MJ
Dudley, B
Recht, M
Byams, V
Kapica, S
Aschman, D
Cooke, B
Oakley, M
AF Manco-Johnson, Marilyn J.
Dudley, Becky
Recht, Michael
Byams, Vanessa
Kapica, Suzanne
Aschman, Diane
Cooke, Brandi
Oakley, Michele
TI COMMUNITY COUNTS: A NATIONAL SURVEILLANCE SYSTEM FOR BLEEDING AND
CLOTTING DISORDERS
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Manco-Johnson, Marilyn J.] Univ Colorado, Aurora, CO USA.
[Dudley, Becky; Aschman, Diane] Amer Thrombosis & Hemostasis Network, Greenrivers, IL USA.
[Recht, Michael] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Byams, Vanessa; Cooke, Brandi; Oakley, Michele] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Kapica, Suzanne] Hemophilia Fdn Michigan, Ypsilanti, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD JUN
PY 2014
VL 89
IS 6
MA 7
BP E4
EP E4
PG 1
WC Hematology
SC Hematology
GA AI1NU
UT WOS:000336618600008
ER
PT J
AU Soucie, JM
Grosse, SD
Siddiqi, AEA
Byams, V
Thierry, J
Zack, M
Shapiro, A
Duncan, N
AF Soucie, J. Michael
Grosse, Scott D.
Siddiqi, Azfar-E-Alam
Byams, Vanessa
Thierry, JoAnn
Zack, Matthew
Shapiro, Amy
Duncan, Natalie
TI DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE AMONG PERSONS WITH SEVERE
HEMOPHILIA A IN THE UNITED STATES
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Soucie, J. Michael; Grosse, Scott D.; Siddiqi, Azfar-E-Alam; Byams, Vanessa; Thierry, JoAnn; Zack, Matthew] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Shapiro, Amy; Duncan, Natalie] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD JUN
PY 2014
VL 89
IS 6
MA 100
BP E48
EP E48
PG 1
WC Hematology
SC Hematology
GA AI1NU
UT WOS:000336618600098
ER
PT J
AU Lo, MK
Nichol, ST
Spiropoulou, CF
AF Lo, Michael K.
Nichol, Stuart T.
Spiropoulou, Christina F.
TI Evaluation of luciferase and GFP-expressing Nipah viruses for rapid
quantitative antiviral screening
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Henipavirus; Nipah virus; Antiviral screening; Luciferase; GFP;
High-throughput screening
ID INFECTION; HENDRA; ESTABLISHMENT; REPLICATION; INHIBITION; INTERFERON;
VALIDATION; GENERATION; CELLS; GENE
AB Nipah virus (NiV) outbreaks have occurred in Malaysia, India, and Bangladesh, and the virus continues to cause annual outbreaks of fatal human encephalitis in Bangladesh due to spillover from its bat host reservoir. Due to its high pathogenicity, its potential use for bio/agro-terrorism, and to the current lack of approved therapeutics, NiV is designated as an overlap select agent requiring biosafety level-4 containment. Although the development of therapeutic monoclonal antibodies and soluble protein subunit vaccines have shown great promise, the paucity of effective antiviral drugs against NiV merits further exploration of compound libraries using rapid quantitative antiviral assays. As a proof-of-concept study, we evaluated the use of fluorescent and luminescent reporter NiVs for antiviral screening. We constructed and rescued NiVs expressing either Renilla luciferase or green fluorescent protein, and characterized their reporter signal kinetics in different cell types as well as in the presence of several inhibitors. The 50% effective concentrations (EC(50)s) derived for inhibitors against both reporter viruses are within range of EC50s derived from virus yield-based dose-response assays against wild-type NiV (within 1 Log(10)), thus demonstrating that both reporter NiVs can serve as robust antiviral screening tools. Utilizing these live NiV-based reporter assays requires modest instrumentation, and circumvents the time and labor-intensive steps associated with cytopathic effect or viral antigen-based assays. These reporter NiVs will not only facilitate antiviral screening, but also the study of host cell components that influence the virus life cycle. Published by Elsevier B.V.
C1 [Lo, Michael K.; Nichol, Stuart T.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30333 USA.
RP Lo, MK (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, 1600 Clifton Rd,Mailstop G-14, Atlanta, GA 30333 USA.
EM mko2@cdc.gov; ccs8@cdc.gov
OI Lo, Michael/0000-0002-0409-7896
FU Intramural CDC HHS [CC999999]
NR 31
TC 8
Z9 8
U1 0
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD JUN
PY 2014
VL 106
BP 53
EP 60
DI 10.1016/j.antiviral.2014.03.011
PG 8
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA AI4IA
UT WOS:000336827700007
PM 24680955
ER
PT J
AU Uebelhoer, LS
Albarino, CG
McMullan, LK
Chakrabarti, AK
Vincent, JP
Nichol, ST
Towner, JS
AF Uebelhoer, Luke S.
Albarino, Cesar G.
McMullan, Laura K.
Chakrabarti, Ayan K.
Vincent, Joel P.
Nichol, Stuart T.
Towner, Jonathan S.
TI High-throughput, luciferase-based reverse genetics systems for
identifying inhibitors of Marburg and Ebola viruses
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Filovirus; Marburg virus; Ebola virus; Luciferase; Reverse genetics;
Antiviral screen
ID SPECTRUM ANTIVIRAL ACTIVITY; HEMORRHAGIC FEVERS; RNA INTERFERENCE;
IN-VITRO; REPLICATION; TRANSCRIPTION; PROTEIN; IDENTIFICATION;
INFECTION; VP35
AB Marburg virus (MARV) and Ebola virus (EBOV), members of the family Filoviridae, represent a significant challenge to global public health. Currently, no licensed therapies exist to treat filovirus infections, which cause up to 90% mortality in human cases. To facilitate development of antivirals against these viruses, we established two distinct screening platforms based on MARV and EBOV reverse genetics systems that express secreted Gaussia luciferase (gLuc). The first platform is a mini-genome replicon to screen viral replication inhibitors using gLuc quantification in a BSL-2 setting. The second platform is complementary to the first and expresses gLuc as a reporter gene product encoded in recombinant infectious MARV and EBOV, thereby allowing for rapid quantification of viral growth during treatment with antiviral compounds. We characterized these viruses by comparing luciferase activity to virus production, and validated luciferase activity as an authentic real-time measure of viral growth. As proof of concept, we adapt both mini-genome and infectious virus platforms to high-throughput formats, and demonstrate efficacy of several antiviral compounds. We anticipate that both approaches will prove highly useful in the development of anti-filovirus therapies, as well as in basic research on the filovirus life cycle. Published by Elsevier B.V.
C1 [Uebelhoer, Luke S.; Albarino, Cesar G.; McMullan, Laura K.; Chakrabarti, Ayan K.; Vincent, Joel P.; Nichol, Stuart T.; Towner, Jonathan S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Towner, JS (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM jit8@cdc.gov
FU Research Participation Program at the Centers for Disease Control and
Prevention (CDC); Centers for Disease Control and Prevention (CDC)
FX The authors would like to thank Karl-Klaus Conzelmann
(Max-von-Pettenkofer-Institut, Munich, Germany) for providing BSR-T7/5
cells, Marina Khristova for assistance with genome sequencing of clones,
Tatyana Klimova for critical editing of the manuscript, and Michael
Flint for providing inhibitory compounds and excellent technical advice.
Luke Uebelhoer holds a fellowship supported by the Research
Participation Program at the Centers for Disease Control and Prevention
(CDC) administered by the Oak Ridge Institute for Science and Education
(ORISE) through an interagency agreement between the U.S. Department of
Energy (DOE) and CDC.
NR 40
TC 29
Z9 32
U1 3
U2 44
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD JUN
PY 2014
VL 106
BP 86
EP 94
DI 10.1016/j.antiviral.2014.03.018
PG 9
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA AI4IA
UT WOS:000336827700011
PM 24713118
ER
PT J
AU Lee, S
Ward, TJ
Graves, LM
Tarr, CL
Siletzky, RM
Kathariou, S
AF Lee, Sangmi
Ward, Todd J.
Graves, Lewis M.
Tarr, Cheryl L.
Siletzky, Robin M.
Kathariou, Sophia
TI Population Structure of Listeria monocytogenes Serotype 4b Isolates from
Sporadic Human Listeriosis Cases in the United States from 2003 to 2008
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID BENZALKONIUM CHLORIDE RESISTANCE; MULTILOCUS GENOTYPING ASSAY; FIELD
GEL-ELECTROPHORESIS; TURKEY-PROCESSING PLANTS; GENETIC-CHARACTERIZATION;
EPIDEMIC CLONES; HEAVY-METAL; FOOD SAFETY; STRAINS; OUTBREAK
AB Listeria monocytogenes can cause severe food-borne disease (listeriosis). Numerous outbreaks have involved three serotype 4b epidemic clones (ECs): ECI, ECII, and ECIa. However, little is known about the population structure of L. monocytogenes serotype 4b from sporadic listeriosis in the United States, even though most cases of human listeriosis are in fact sporadic. Here we analyzed 136 serotype 4b isolates from sporadic cases in the United States, 2003 to 2008, utilizing multiple tools including multilocus genotyping, pulsed-field gel electrophoresis, and sequence analysis of the inlAB locus. ECI, ECII, and ECIa were frequently encountered (32, 17, and 7%, respectively). However, annually 30 to 68% of isolates were outside these ECs, and several novel clonal groups were identified. An estimated 33 and 17% of the isolates, mostly among the ECs, were resistant to cadmium and arsenic, respectively, but resistance to benzalkonium chloride was uncommon (3%) among the sporadic isolates. The frequency of clonal groups fluctuated within the 6-year study period, without consistent trends. However, on several occasions, temporal clusters of isolates with indistinguishable genotypes were detected, suggesting the possibility of hidden multistate outbreaks. Our analysis suggests a complex population structure of serotype 4b L. monocytogenes from sporadic disease, with important contributions by ECs and several novel clonal groups. Continuous monitoring will be needed to assess long-term trends in clonality patterns and population structure of L. monocytogenes from sporadic listeriosis.
C1 [Lee, Sangmi; Siletzky, Robin M.; Kathariou, Sophia] N Carolina State Univ, Dept Food Bioproc & Nutr Sci, Raleigh, NC 27695 USA.
[Ward, Todd J.] ARS, Bacterial Foodborne Pathogens & Mycol Res Unit, USDA, Peoria, IL USA.
[Graves, Lewis M.; Tarr, Cheryl L.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
RP Lee, S (reprint author), N Carolina State Univ, Dept Food Bioproc & Nutr Sci, Raleigh, NC 27695 USA.
EM slee19@ncsu.edu
FU USDA [2006-35201-17377]; U.S. Department of Agriculture's Agricultural
Research Service
FX This study was partially supported by USDA grant 2006-35201-17377 and
the U.S. Department of Agriculture's Agricultural Research Service.
NR 47
TC 5
Z9 5
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0099-2240
EI 1098-5336
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD JUN
PY 2014
VL 80
IS 12
BP 3632
EP 3644
DI 10.1128/AEM.00454-14
PG 13
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA AI3EX
UT WOS:000336744000010
PM 24705322
ER
PT J
AU Campo, DS
Skums, P
Dimitrova, Z
Vaughan, G
Forbi, JC
Teol, CG
Khudyakov, Y
Lau, DTY
AF Campo, D. S.
Skums, P.
Dimitrova, Z.
Vaughan, G.
Forbi, J. C.
Teol, C. G.
Khudyakov, Y.
Lau, D. T-Y
TI Drug Resistance of a Viral Population and Its Individual Intrahost
Variants During the First 48 Hours of Therapy
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID CHRONIC HEPATITIS-C; ANTIVIRAL TREATMENT; INTERFERON; RIBAVIRIN; VIRUS;
PHYLOGENIES; INFECTION
AB Using hepatitis C virus (HCV) and interferon (IFN) resistance as a Proof of concept, we have devised a new method for calculating the effect of a drug on a viral population, as well as the resistance of the population's individual intrahost variants. By means of next-generation sequencing, HCV variants were obtained from sera collected at nine time points from 16 patients during the first 48h after injection of IFN-alpha. IFN-resistance coefficients were calculated for individual variants using changes in their relative frequencies, and for the entire intrahost viral population using changes in viral titer. Population-wide resistance and presence of IFN-resistant variants were highly associated with pegylated IFN-alpha 2a/ribavirin treatment outcome at week 12 (P = 3.78 x 10(-5) and 0.0114, respectively). This new method allows an accurate measurement of resistance based solely on changes in viral titer or the relative frequency of intrahost viral variants during a short observation time.
C1 [Campo, D. S.; Skums, P.; Dimitrova, Z.; Vaughan, G.; Forbi, J. C.; Teol, C. G.; Khudyakov, Y.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA.
[Lau, D. T-Y] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Liver Ctr,Div Gastroenterol, Boston, MA 02215 USA.
RP Campo, DS (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA.
EM fyv6@cdc.gov
OI Campo, David S./0000-0002-8970-3436
FU National Institutes of Health [R01 DK068598-01, M01-RR-01032]
FX This study was supported by National Institutes of Health grants R01
DK068598-01 (to D.T.-Y.L.), M01-RR-01032, and M01-RR-01032 (to the
General Clinical Research Center).
NR 30
TC 4
Z9 5
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD JUN
PY 2014
VL 95
IS 6
BP 627
EP 635
DI 10.1038/clpt.2014.20
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AH8VC
UT WOS:000336415300026
PM 24488144
ER
PT J
AU Ford, ES
Mannino, DM
Giles, WH
Wheaton, AG
Liu, Y
Croft, JB
AF Ford, Earl S.
Mannino, David M.
Giles, Wayne H.
Wheaton, Anne G.
Liu, Yong
Croft, Janet B.
TI Prescription Practices for Chronic Obstructive Pulmonary Disease:
Findings from the National Ambulatory Medical Care Survey 1999-2010
SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
LA English
DT Article
DE COPD; prescriptions; therapeutics; trends
ID CLINICAL-PRACTICE GUIDELINE; AMERICAN-COLLEGE; TIOTROPIUM;
EXACERBATIONS; EPIDEMIOLOGY; PREVENTION; PHYSICIANS; PROPIONATE;
SALMETEROL; MANAGEMENT
AB Recent trends in prescriptions for medicines used to treat chronic obstructive pulmonary disease (COPD) in the United States have received little attention. Our objective was to examine trends in prescribing practices for medications used to treat COPD. We examined data from surveys of national samples of office visits to non-federal employed office-based physicians in the United States by patients aged >= 40 years with COPD recorded by the National Ambulatory Medical Care Survey from 1999 to 2010. From three diagnostic codes, office visits by patients with COPD were identified. Prescribed medications were identified from up to 8 recorded medications. The percentage of these visits during which a prescription for any medication used to treat COPD was issued increased from 27.0% in 1999 to 49.1% in 2010 (p trend < 0.001). Strong increases were noted for short-acting beta-2 agonists (17.6% in 1999 to 24.7% in 2010; p trend < 0.001), long-acting beta-2 agonists as single agents or combination products (6.2% in 1999 to 28.3% in 2010; p trend < 0.001), inhaled corticosteroids as single agents or combination products (10.9% in 1999 to 30.9% in 2010; p trend < 0.001), and tiotropium (3.8% in 2004 to 17.2% in 2010; p trend < 0.001). Since 1999, prescription patterns for medicines used to treat COPD have changed profoundly in the United States.
C1 [Ford, Earl S.; Giles, Wayne H.; Wheaton, Anne G.; Liu, Yong; Croft, Janet B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA.
[Mannino, David M.] Univ Kentucky, Coll Publ Hlth, Dept Prevent Med & Environm Hlth, Lexington, KY USA.
RP Ford, ES (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS F78, Atlanta, GA 30341 USA.
EM eford@cdc.gov
OI Mannino, David/0000-0003-3646-7828
FU GlaxoSmithKline plc; Novartis Pharmaceuticals; Pfizer Inc.; AstraZeneca
PLC; Forest Laboratories Inc.; Creative Educational Concepts
FX Dr. Mannino has received honoraria/consulting fees and served on speaker
bureaus for GlaxoSmithKline plc, Novartis Pharmaceuticals, Pfizer Inc.,
AstraZeneca PLC, Forest Laboratories Inc., and Creative Educational
Concepts. Furthermore, he has received royalties from Up-to-Date. The
other authors report no conflicts of interest. The authors alone are
responsible for the content and writing of the paper.
NR 20
TC 3
Z9 3
U1 0
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1541-2555
EI 1541-2563
J9 COPD
JI COPD-J. Chronic Obstr. Pulm. Dis.
PD JUN
PY 2014
VL 11
IS 3
BP 247
EP 255
DI 10.3109/15412555.2013.840570
PG 9
WC Respiratory System
SC Respiratory System
GA AI0AI
UT WOS:000336507800002
PM 24568285
ER
PT J
AU Pleasants, RA
Ohar, JA
Croft, JB
Liu, Y
Kraft, M
Mannino, DM
Donohue, JF
Herrick, HL
AF Pleasants, Roy A.
Ohar, Jill A.
Croft, Janet B.
Liu, Yong
Kraft, Monica
Mannino, David M.
Donohue, James F.
Herrick, Harry L.
TI Chronic Obstructive Pulmonary Disease and Asthma - Patient
Characteristics and Health Impairment
SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
LA English
DT Article
DE chronic obstructive pulmonary disease; asthma; overlap syndrome;
Behavioral Risk factor Surveillance System; health impairment
ID QUALITY-OF-LIFE; UNITED-STATES; CARDIOVASCULAR-DISEASE;
SOCIOECONOMIC-STATUS; COPD PATIENTS; PHYSICAL-ACTIVITY; GLOBAL BURDEN;
RISK-FACTORS; POPULATION; PREVALENCE
AB Background: Persons with chronic obstructive pulmonary disease (COPD) and/or asthma have great risk for morbidity. There has been sparse state-specific surveillance data to estimate the impact of COPD or COPD with concomitant asthma (overlap syndrome) on health-related impairment. Methods: The North Carolina (NC) Behavioral Risk Factor Surveillance System (BRFSS) was used to assess relationships between COPD and asthma with health impairment indicators. Five categories [COPD, current asthma, former asthma, overlap syndrome, and neither] were defined for 24,073 respondents. Associations of these categories with health impairments (physical or mental disability, use of special equipment, mental or physical distress) and with co-morbidities (diabetes, coronary heart disease, stroke, arthritis, and high blood pressure) were assessed. Results: Fifteen percent of NC adults reported a COPD and/or asthma history. The overall age-adjusted prevalence of any self-reported COPD and current asthma were 5.6% and 7.6%, respectively; 2.4% reported both. In multivariable analyses, adults with overlap syndrome, current asthma only, and COPD only were twice as likely as those with neither disease to report health impairments (p < 0.05). Compared to those with neither disease, adults with overlap syndrome and COPD were more likely to have co-morbidities (p < 0.05). The prevalence of the five co-morbid conditions was highest in overlap syndrome; comparisons with the other groups were significant (p < 0.05) only for diabetes, stroke, and arthritis. Conclusions: The BRFSS demonstrates different levels of health impairment among persons with COPD, asthma, overlap syndrome, and those with neither disease. Persons reporting overlap syndrome had the most impairment and highest prevalence of co-morbidities.
C1 [Pleasants, Roy A.] Campbell Univ, Coll Pharm & Hlth Sci, Durham, NC USA.
[Pleasants, Roy A.] Duke Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA.
[Ohar, Jill A.] Wake Forest Univ, Sch Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27109 USA.
[Croft, Janet B.; Liu, Yong] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA.
[Kraft, Monica] Duke Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA.
[Mannino, David M.] Univ Kentucky, Pulm Epidemiol Res Lab, Div Pulm Crit Care & Sleep Med, Lexington, KY USA.
[Donohue, James F.] Univ N Carolina, Dept Med, Div Pulm Dis & Crit Care, Chapel Hill, NC USA.
[Herrick, Harry L.] North Carolina Div Publ Hlth, State Ctr Hlth Stat, Raleigh, NC USA.
RP Pleasants, RA (reprint author), Duke Univ, Duke Univ Hosp, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA.
EM roy.pleasants@duke.edu
OI Mannino, David/0000-0003-3646-7828
FU National Institutes of Health; Genentech; GlaxoSmithKline; Merck;
Asthmatx (Boston Scientific); Eumedics; Novartis; American thoracic
Society for leadership role; Research Grant Aerocrine
FX The authors report the following: RAP: Speaker for Astra Zeneca,
Boehringer Ingelheim, Novartis, Pfizer: JOA: Advisory Board for Astra
Zeneca and Glaxo Smith Kline; JBC: No conflicts of interest; YL: No
conflicts of interest; MK: Research Grants: National Institutes of
Health, Genentech, GlaxoSmithKline, Merck, Asthmatx (Boston Scientific),
Eumedics, and Novartis. Stipend from American thoracic Society for
leadership role; JFD: Consultant/advisor: Glaxo Smith Kline, Boehringer
Ingelheim, Forest, Novartis, Mylan, and Sunovion. Research Grant
Aerocrine; and HLK: No conflicts of interest.
NR 53
TC 24
Z9 25
U1 1
U2 6
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1541-2555
EI 1541-2563
J9 COPD
JI COPD-J. Chronic Obstr. Pulm. Dis.
PD JUN
PY 2014
VL 11
IS 3
BP 256
EP 266
DI 10.3109/15412555.2013.840571
PG 11
WC Respiratory System
SC Respiratory System
GA AI0AI
UT WOS:000336507800003
PM 24152212
ER
PT J
AU Patel, JC
Taylor, SM
Juliao, PC
Parobek, CM
Janko, M
Gonzalez, LD
Ortiz, L
Padilla, N
Tshefu, AK
Emch, M
Udhayakumar, V
Lindblade, K
Meshnick, SR
AF Patel, Jaymin C.
Taylor, Steve M.
Juliao, Patricia C.
Parobek, Christian M.
Janko, Mark
Gonzalez, Luis Demetrio
Ortiz, Lucia
Padilla, Norma
Tshefu, Antoinette K.
Emch, Michael
Udhayakumar, Venkatachalam
Lindblade, Kim
Meshnick, Steven R.
TI Genetic Evidence of Importation of Drug-Resistant Plasmodium falciparum
to Guatemala from the Democratic Republic of the Congo
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID MICROSATELLITE MARKERS; ANOPHELES-ALBIMANUS; POPULATION; MALARIA;
TRANSMISSION; ELIMINATION; PREVALENCE; REVEAL
AB Imported malaria threatens control and elimination efforts in countries that have low rates of transmission. In 2010, an outbreak of Plasmodium falciparum malaria was reported among United Nations peacekeeping soldiers from Guatemala who had recently returned from the Democratic Republic of the Congo (DRC). Epidemiologic evidence suggested that the soldiers were infected in the DRC, but local transmission could not be ruled out in all cases. We used population genetic analyses of neutral microsatellites to determine the outbreak source. Genetic relatedness was compared among parasites found in samples from the soldiers and parasite populations collected in the DRC and Guatemala; parasites identified in the soldiers were more closely related to those from the DRC. A phylogenetic clustering analysis confirms this identification with >99.9% confidence. Thus, results support the hypothesis that the soldiers likely imported malaria from the DRC. This study demonstrates the utility of molecular genotyping in outbreak investigations.
C1 [Patel, Jaymin C.; Taylor, Steve M.; Parobek, Christian M.; Janko, Mark; Emch, Michael; Meshnick, Steven R.] Univ N Carolina, Chapel Hill, NC 27599 USA.
[Juliao, Patricia C.; Udhayakumar, Venkatachalam; Lindblade, Kim] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Gonzalez, Luis Demetrio] Mil Med Ctr, Guatemala City, Guatemala.
[Ortiz, Lucia; Padilla, Norma] Univ Valle Guatemala, Guatemala City, Guatemala.
[Tshefu, Antoinette K.] Univ Kinshasa, Kinshasa, Congo.
RP Patel, JC (reprint author), Univ N Carolina, 135 Dauer Dr,3206 Michael Hooker Res Bldg, Chapel Hill, NC 27599 USA.
EM jaymin86@email.unc.edu
FU Gillings Innovation Laboratory award from the UNC Gillings School of
Global Public Health; National Institutes of Health (NIH) [NIAID
1R56AI097609-01]; National Science Foundation (NSF) [BSC-13339949]
FX This work was supported by a Gillings Innovation Laboratory award from
the UNC Gillings School of Global Public Health and by grants from the
National Institutes of Health (NIH) (NIAID 1R56AI097609-01) and National
Science Foundation (NSF) (BSC-13339949).
NR 39
TC 8
Z9 8
U1 0
U2 4
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUN
PY 2014
VL 20
IS 6
BP 932
EP 940
DI 10.3201/eid2006.131204
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AI0SZ
UT WOS:000336561600002
PM 24856348
ER
PT J
AU Watson, JT
Hall, AJ
Erdman, DD
Swerdlow, DL
Gerber, SI
AF Watson, John T.
Hall, Aron J.
Erdman, Dean D.
Swerdlow, David L.
Gerber, Susan I.
TI Unraveling the Mysteries of Middle East Respiratory Syndrome Coronavirus
SO EMERGING INFECTIOUS DISEASES
LA English
DT Editorial Material
ID DROMEDARY CAMELS; MERS CORONAVIRUS; SAUDI-ARABIA; ANTIBODIES; LIVESTOCK
C1 [Watson, John T.; Hall, Aron J.; Erdman, Dean D.; Swerdlow, David L.; Gerber, Susan I.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Watson, JT (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd NE,Mailstop A34, Atlanta, GA 30333 USA.
EM acq4@cdc.gov
NR 19
TC 2
Z9 2
U1 0
U2 7
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUN
PY 2014
VL 20
IS 6
BP 1054
EP 1056
DI 10.3201/eid2006.140322
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AI0SZ
UT WOS:000336561600024
PM 24983095
ER
PT J
AU Breedlove, B
AF Breedlove, Byron
TI Quiet Moment around the Campfire
SO EMERGING INFECTIOUS DISEASES
LA English
DT Editorial Material
C1 [Breedlove, Byron] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA.
RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, EID Journal, 1600 Clifton Rd NE,Mailstop C14, Atlanta, GA 30329 USA.
EM wbb1@cdc.gov
OI Breedlove, Byron/0000-0002-1026-1963
NR 7
TC 0
Z9 0
U1 0
U2 3
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUN
PY 2014
VL 20
IS 6
BP 1092
EP 1093
DI 10.3201/eid2006.AC2006
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AI0SZ
UT WOS:000336561600042
ER
PT J
AU Kramarow, E
Warner, M
Chen, LH
AF Kramarow, Ellen
Warner, Margaret
Chen, Li-Hui
TI Food-related choking deaths among the elderly
SO INJURY PREVENTION
LA English
DT Article
ID ASPIRATION
AB During 2007-2010 in the USA, 2214 deaths among people aged >= 65 were attributed to choking on food. The death rate for this cause is higher among the elderly than among any other age group. Using data from the US National Vital Statistics System, we examined the relationship between food suffocation and other causes of death listed on the death certificate. Among decedents aged >= 65, the three most common additional conditions listed on the death certificate were heart disease, dementia and diabetes. However, after estimating the expected joint frequency of other causes based on the overall distribution of all causes of death, we find that three causes-dementia (including Alzheimer's disease), Parkinson's disease and pneumonitis-are most strongly associated with deaths from choking on food among older people.
C1 [Kramarow, Ellen; Chen, Li-Hui] Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
[Warner, Margaret] Ctr Dis Control & Prevent, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
RP Kramarow, E (reprint author), Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA.
EM ekramarow@cdc.gov
NR 22
TC 1
Z9 1
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1353-8047
EI 1475-5785
J9 INJURY PREV
JI Inj. Prev.
PD JUN
PY 2014
VL 20
IS 3
BP 200
EP 203
DI 10.1136/injuryprev-2013-040795
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI3CE
UT WOS:000336735700013
PM 24003082
ER
PT J
AU Cooper, CP
Gelb, CA
Rodriguez, J
Hawkins, NA
AF Cooper, Crystale Purvis
Gelb, Cynthia A.
Rodriguez, Juan
Hawkins, Nikki A.
TI Promoting Gynecologic Cancer Awareness at a Critical Juncture-Where
Women and Providers Meet
SO JOURNAL OF CANCER EDUCATION
LA English
DT Article
DE Primary care; Health promotion; Prevention; Patient education;
Gynecologic cancer
ID OVARIAN-CANCER; UNITED-STATES; US WOMEN; SYMPTOMS; CARE; PHYSICIANS;
KNOWLEDGE; SEEKING
AB Given the absence of effective population-based screening tests for ovarian, uterine, vaginal, and vulvar cancers, early detection can depend on women and health care providers recognizing the potential significance of symptoms. In 2008, the Centers for Disease Control and Prevention's (CDC) Inside Knowledge campaign began distributing consumer education materials promoting awareness of gynecologic cancer symptoms. We investigated providers' in-office use of CDC gynecologic cancer materials and their recognition of the symptoms highlighted in the materials. We analyzed data from a national 2012 survey of US primary care physicians, nurse practitioners, and gynecologists (N = 1,380). Less than a quarter of providers (19.4 %) reported using CDC gynecologic cancer education materials in their offices. The provider characteristics associated with the use of CDC materials were not consistent across specialties. However, recognition of symptoms associated with gynecologic cancers was consistently higher among providers who reported using CDC materials. The possibility that providers were educated about gynecologic cancer symptoms through the dissemination of materials intended for their patients is intriguing and warrants further investigation. Distributing consumer education materials in health care provider offices remains a priority for the Inside Knowledge campaign, as the setting where women and health care providers interact is one of the most crucial venues to promote awareness of gynecologic cancer symptoms.
C1 [Cooper, Crystale Purvis] Soltera Ctr Canc Prevent & Control, Tucson, AZ 85704 USA.
[Gelb, Cynthia A.; Rodriguez, Juan; Hawkins, Nikki A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Gelb, Cynthia A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Chamblee, GA 30341 USA.
RP Gelb, CA (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 3719 North Peachtree,MS F75,Chamblee Bldg 107, Chamblee, GA 30341 USA.
EM cgelb@cdc.gov
FU Division of Cancer Prevention and Control, National Center for Chronic
Disease Prevention and Health Promotion, Centers for Disease Control and
Prevention
FX Funding for this study was provided by the Division of Cancer Prevention
and Control, National Center for Chronic Disease Prevention and Health
Promotion, Centers for Disease Control and Prevention, which licensed
the 2012 DocStyles data analyzed from Porter Novelli (Washington DC).
The authors thank Pedro J. Rodriguez, Northrop Grumman Corporation, for
extracting the web site materials download data. The findings and
conclusions in this report are those of the authors and do not
necessarily represent the official position of the Centers for Disease
Control and Prevention.
NR 14
TC 0
Z9 0
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-8195
EI 1543-0154
J9 J CANCER EDUC
JI J. Cancer Educ.
PD JUN
PY 2014
VL 29
IS 2
BP 247
EP 251
DI 10.1007/s13187-013-0580-z
PG 5
WC Oncology; Education, Scientific Disciplines; Public, Environmental &
Occupational Health
SC Oncology; Education & Educational Research; Public, Environmental &
Occupational Health
GA AH8LZ
UT WOS:000336390600009
PM 24214840
ER
PT J
AU Gaglani, M
Spencer, S
Ball, S
Song, J
Naleway, A
Henkle, E
Bozeman, S
Reynolds, S
Sessions, W
Hancock, K
Thompson, M
AF Gaglani, Manjusha
Spencer, Sarah
Ball, Sarah
Song, Juhee
Naleway, Allison
Henkle, Emily
Bozeman, Sam
Reynolds, Sue
Sessions, Wendy
Hancock, Kathy
Thompson, Mark
TI Antibody Response to Influenza A(H1N1)pdm09 Among Healthcare Personnel
Receiving Trivalent Inactivated Vaccine: Effect of Prior Monovalent
Inactivated Vaccine
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE hemagglutination inhibition antibody; influenza vaccine immunogenicity
or response; healthcare workers; 2009 influenza pandemic H1N1; influenza
vaccine
ID IMMUNIZATION PRACTICES ACIP; SELF-RATED HEALTH; A H1N1 VACCINE;
UNITED-STATES; VIRUS VACCINE; ADVISORY-COMMITTEE; CONSECUTIVE YEARS;
IMMUNE-RESPONSE; ELDERLY ADULTS; EFFICACY
AB Background. Few data are available on the immunogenicity of repeated annual doses of influenza A(H1N1) pdm09-containing vaccines.
Methods.aEuro integral We enrolled healthcare personnel (HCP) in direct patient care during the autumn of 2010 at 2 centers with voluntary immunization. We verified the receipt of A(H1N1)pdm09-containing monovalent inactivated influenza vaccine (MIIV) and 2010-2011 trivalent inactivated vaccine (TIV). We performed hemagglutination inhibition antibody (HI) assays on preseason, post-TIV, and end-of-season serum samples. We compared the proportion of HCPs with HI titer a parts per thousand yen40 against A(H1N1)pdm09 per receipt of prior-season MIIV, current-season TIV, both, or neither.
Results.aEuro integral At preseason (n = 1417), HI a parts per thousand yen 40 was significantly higher among those who received MIIV (34%) vs those who did not (14%) (adjusted relative risk [ARR], 3.26; 95% confidence interval [CI], 2.72-3.81). At post-TIV (n = 865), HI a parts per thousand yen 40 was lower among HCP who received MIIV and TIV (66%) than among those receiving only TIV (85%) (ARR, 0.93 [95% CI, .84-.997]). At end-of-season (n = 1254), HI a parts per thousand yen 40 was 40% among those who received both MIIV and TIV and 67% among those receiving only TIV (ARR, 0.76 [95% CI, .65-.88]), 52% among those who received MIIV only, and 12% among those receiving neither.
Conclusions.aEuro integral HCP immunization programs should consider effects of host immune response and vaccine antigenic distance on immunogenicity of repeated annual doses of influenza vaccines.
C1 [Gaglani, Manjusha] Scott & White Healthcare, Texas A&M Hlth Sci Ctr, Div Pediat Infect Dis, Temple, TX USA.
[Song, Juhee] Scott & White Healthcare, Texas A&M Hlth Sci Ctr, Div Res, Temple, TX USA.
[Spencer, Sarah; Reynolds, Sue; Sessions, Wendy; Thompson, Mark] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Atlanta, GA USA.
[Hancock, Kathy] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Bozeman, Sam] Abt Associates Inc, Cambridge, MA USA.
[Naleway, Allison; Henkle, Emily] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA.
RP Gaglani, M (reprint author), McLane Childrens Hosp, Scott & White Healthcare, Texas A&M HSC COM, 2401 S 31st St, Temple, TX 76508 USA.
EM mgaglani@sw.org
OI Naleway, Allison/0000-0001-5747-4643
FU CDC [200-2010-F-33396]
FX This work was supported by the CDC (contract 200-2010-F-33396 to Abt
Associates Inc). This research was supported in part by an appointment
to the Research Participation Program at the CDC administered by the Oak
Ridge Institute for Science and Education through an interagency
agreement between the US Department of Energy and the CDC.
NR 50
TC 7
Z9 7
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2014
VL 209
IS 11
BP 1705
EP 1714
DI 10.1093/infdis/jit825
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AH9TP
UT WOS:000336485900006
PM 24363436
ER
PT J
AU Fowlkes, A
Giorgi, A
Erdman, D
Temte, J
Goodin, K
Di Lonardo, S
Sun, YM
Martin, K
Feist, M
Linz, R
Boulton, R
Bancroft, E
McHugh, L
Lojo, J
Filbert, K
Finelli, L
AF Fowlkes, Ashley
Giorgi, Andrea
Erdman, Dean
Temte, Jon
Goodin, Kate
Di Lonardo, Steve
Sun, Yumei
Martin, Karen
Feist, Michelle
Linz, Rachel
Boulton, Rachelle
Bancroft, Elizabeth
McHugh, Lisa
Lojo, Jose
Filbert, Kimberly
Finelli, Lyn
CA IISP Working Grp
TI Viruses Associated With Acute Respiratory Infections and Influenza-like
Illness Among Outpatients From the Influenza Incidence Surveillance
Project, 2010-2011
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE influenza; respiratory virus; influenza-like illness; acute respiratory
illness; seasonality; epidemiology
ID SYNCYTIAL VIRUS; UNITED-STATES; YOUNG-CHILDREN; TRACT INFECTIONS; US
CHILDREN; BURDEN; PCR; DISEASE; TIME; EPIDEMIOLOGY
AB Background. The Influenza Incidence Surveillance Project (IISP) monitored outpatient acute respiratory infection (ARI; defined as the presence of >= 2 respiratory symptoms not meeting ILI criteria) and influenza-like illness (ILI) to determine the incidence and contribution of associated viral etiologies.
Methods.aEuro integral From August 2010 through July 2011, 57 outpatient healthcare providers in 12 US sites reported weekly the number of visits for ILI and ARI and collected respiratory specimens on a subset for viral testing. The incidence was estimated using the number of patients in the practice as the denominator, and the virus-specific incidence of clinic visits was extrapolated from the proportion of patients testing positive.
Results.aEuro integral The age-adjusted cumulative incidence of outpatient visits for ARI and ILI combined was 95/1000 persons, with a viral etiology identified in 58% of specimens. Most frequently detected were rhinoviruses/enteroviruses (RV/EV) (21%) and influenza viruses (21%); the resulting extrapolated incidence of outpatient visits was 20 and 19/1000 persons respectively. The incidence of influenza virus-associated clinic visits was highest among patients aged 2-17 years, whereas other viruses had varied patterns among age groups.
Conclusions.aEuro integral The IISP provides a unique opportunity to estimate the outpatient respiratory illness burden by etiology. Influenza virus infection and RV/EV infection(s) represent a substantial burden of respiratory disease in the US outpatient setting, particularly among children.
C1 [Fowlkes, Ashley; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
[Erdman, Dean] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
[Giorgi, Andrea] Council State & Territorial Epidemiologists, Atlanta, GA USA.
[Temte, Jon] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[Goodin, Kate] Florida Dept Hlth, Tallahassee, FL USA.
[Di Lonardo, Steve] New York City Dept Hlth & Mental Hyg, New York, NY USA.
[Sun, Yumei] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA.
[Martin, Karen] Minnesota Dept Hlth, Minneapolis, MN 55414 USA.
[Feist, Michelle] North Dakota Dept Hlth, Bismarck, ND USA.
[Linz, Rachel] Oregon Publ Hlth Div, Portland, OR USA.
[Boulton, Rachelle] Utah Dept Hlth, Salt Lake City, UT 84116 USA.
[Bancroft, Elizabeth] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA.
[McHugh, Lisa] New Jersey State Dept Hlth, Trenton, NJ 08625 USA.
[Lojo, Jose] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
[Filbert, Kimberly] Virgina Dept Hlth, Richmond, VA USA.
RP Fowlkes, A (reprint author), 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30333 USA.
EM afowlkes@cdc.gov
OI Lang, Brian/0000-0002-9362-0086
FU Council of State and Territorial Epidemiologists (Centers for Disease
Control and Prevention). [5U38HM000414-04]
FX This work was supported by the Council of State and Territorial
Epidemiologists (cooperative agreement 5U38HM000414-04 from the Centers
for Disease Control and Prevention).
NR 36
TC 17
Z9 17
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2014
VL 209
IS 11
BP 1715
EP 1725
DI 10.1093/infdis/jit806
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AH9TP
UT WOS:000336485900007
PM 24338352
ER
PT J
AU Steinau, M
Hariri, S
Gillison, ML
Broutian, TR
Dunne, EF
Tong, ZY
Markowitz, LE
Unger, ER
AF Steinau, Martin
Hariri, Susan
Gillison, Maura L.
Broutian, Tatevic R.
Dunne, Eileen F.
Tong, Zhen-yue
Markowitz, Lauri E.
Unger, Elizabeth R.
TI Prevalence of Cervical and Oral Human Papillomavirus Infections Among US
Women
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE human papillomavirus; cervix; oral cavity; HPV prevalence; NHANES
ID UNITED-STATES; HPV INFECTION; NATIONAL-HEALTH; NEGATIVE WOMEN; FEMALES;
CANCER
AB Data from the National Health and Nutrition Examination Survey, 2009-2010, indicated that the prevalence of human papillomavirus (HPV) infection among women was 42.7% in the cervix and 3.8% in the oral cavity. The prevalence of oral HPV infection was 5-fold higher among women with than among those without cervical HPV infection (7.0% vs 1.4%; prevalence ratio, 4.9 [95% confidence interval, 2.7-8.7]). Among the 3% of women with HPV detected at both sites, complete type concordance was detected in 6.6%, and partial agreement was detected in 37.7%. These data suggest that HPV infections at these 2 sites are not independent, although type-specific concordance is low.
C1 [Steinau, Martin; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Hariri, Susan; Dunne, Eileen F.; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Gillison, Maura L.; Broutian, Tatevic R.; Tong, Zhen-yue] Ohio State Univ, Columbus, OH 43210 USA.
RP Steinau, M (reprint author), Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA.
EM MSteinau@cdc.gov
FU Division of STD Prevention, National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention; National Center for Health
Statistics, Centers for Disease Control and Prevention; Ohio State
University Comprehensive Cancer Center; Merck; John and Nina Cassils;
National Cancer Institute
FX This work was supported by the Division of STD Prevention, National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, and the
National Center for Health Statistics, Centers for Disease Control and
Prevention; work conducted at Ohio State University was supported by the
Ohio State University Comprehensive Cancer Center, Merck, John and Nina
Cassils, and the Intramural Research Program of the National Cancer
Institute.
NR 15
TC 13
Z9 14
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2014
VL 209
IS 11
BP 1739
EP 1743
DI 10.1093/infdis/jit799
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AH9TP
UT WOS:000336485900010
PM 24319284
ER
PT J
AU Zetola, NM
Modongo, C
Moonan, PK
Ncube, R
Matlhagela, K
Sepako, E
Collman, RG
Bisson, GP
AF Zetola, Nicola M.
Modongo, Chawangwa
Moonan, Patrick K.
Ncube, Ronald
Matlhagela, Keikantse
Sepako, Enoch
Collman, Ronald G.
Bisson, Gregory P.
TI Clinical Outcomes Among Persons With Pulmonary Tuberculosis Caused by
Mycobacterium tuberculosis Isolates With Phenotypic Heterogeneity in
Results of Drug-Susceptibility Tests
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Tuberculosis; multidrug-resistant tuberculosis; mixed infection;
heteroresistance; treatment outcome; drug susceptibility testing
ID MULTIDRUG-RESISTANT TUBERCULOSIS; EXOGENOUS REINFECTION; MIXED
INFECTION; SOUTH-AFRICA; BOTSWANA; STRAIN; HOUSEHOLDS; EVOLUTION;
THERAPY; ADULTS
AB Background. Patients with multidrug- resistant (MDR) tuberculosis may have phenotypic heterogeneity in results of drug-susceptibility tests (DSTs). However, the impact of this on clinical outcomes among patients treated for MDR tuberculosis is unknown.
Methods.aEuro integral Phenotypic DST heterogeneity was defined as presence of at least 1 Mycobacterium tuberculosis isolate susceptible to rifampicin and isoniazid recovered < 3 months after MDR tuberculosis treatment initiation from a patient with previous documented tuberculosis due to M. tuberculosis resistant to at least rifampicin and isoniazid. The primary outcome was defined as good (ie, cure or treatment completion) or poor (ie, treatment failure, treatment default, or death). A secondary outcome was time to culture conversion. Cox proportional hazard models were used to determine the association between phenotypic DST heterogeneity and outcomes.
Results.aEuro integral Phenotypic DST heterogeneity was identified in 33 of 475 patients (7%) with MDR tuberculosis. Poor outcome occurred in 126 patients (28%). Overall, patients with MDR tuberculosis who had phenotypic DST heterogeneity were at greater risk of poor outcome than those with MDR tuberculosis but no phenotypic DST heterogeneity (adjusted hazard ratio [aHR], 2.1; 95% confidence interval [CI], 1.2-3.6). Among HIV-infected patients with MDR tuberculosis, the adjusted hazard for a poor outcome for those with phenotypic DST heterogeneity was 2.4 (95% CI, 1.3-4.2) times that for those without phenotypic DST heterogeneity, whereas among HIV-negative patients with MDR tuberculosis, the adjusted hazard for those with phenotypic DST heterogeneity was 1.5 (95% CI, .5-4.3) times that for those without phenotypic DST heterogeneity. HIV-infected patients with MDR tuberculosis with phenotypic DST heterogeneity also had a longer time to culture conversion than with HIV-infected patients with MDR tuberculosis without phenotypic DST heterogeneity (aHR, 2.9; 95% CI, 1.4-6.0).
Conclusions.aEuro integral Phenotypic DST heterogeneity among persons with HIV infection who are being treated for MDR tuberculosis is associated with poor outcomes and longer times to culture conversion.
C1 [Zetola, Nicola M.; Bisson, Gregory P.] Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA.
[Collman, Ronald G.] Univ Penn, Div Pulm & Crit Care Med, Philadelphia, PA 19104 USA.
[Moonan, Patrick K.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Zetola, Nicola M.; Modongo, Chawangwa; Bisson, Gregory P.] Botswana Univ Pennsylvania Partnership, Gaborone, Botswana.
[Zetola, Nicola M.] Univ Botswana, Dept Med, Gaborone, Botswana.
[Matlhagela, Keikantse; Sepako, Enoch] Univ Botswana, Dept Biol Sci, Gaborone, Botswana.
[Zetola, Nicola M.; Modongo, Chawangwa] Princess Marina Referral Hosp, Gaborone, Botswana.
[Ncube, Ronald] Botswana Natl TB Programme, Gaborone, Botswana.
RP Zetola, NM (reprint author), Botswana UPenn Partnership, 214 Independence Ave, Gaborone, Botswana.
EM nzetola@gmail.com
OI Moonan, Patrick/0000-0002-3550-2065
FU National Institutes of Health [R01AI097045, P30AI45008]
FX This work was supported by the National Institutes of Health (grants
R01AI097045 and P30AI45008 to the Penn Centre for AIDS Research).
NR 35
TC 12
Z9 12
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2014
VL 209
IS 11
BP 1754
EP 1763
DI 10.1093/infdis/jiu040
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AH9TP
UT WOS:000336485900012
PM 24443546
ER
PT J
AU Mei, ZG
Serdula, MK
Liu, JM
Flores-Ayala, RC
Wang, LL
Ye, RW
Grummer-Strawn, LM
AF Mei, Zuguo
Serdula, Mary K.
Liu, Jian-meng
Flores-Ayala, Rafael C.
Wang, Linlin
Ye, Rongwei
Grummer-Strawn, Laurence M.
TI Iron-Containing Micronutrient Supplementation of Chinese Women with No
or Mild Anemia during Pregnancy Improved Iron Status but Did Not Affect
Perinatal Anemia
SO JOURNAL OF NUTRITION
LA English
DT Article
ID SERUM TRANSFERRIN RECEPTOR; REFERENCE RANGES; DEFICIENCY
AB Universal prenatal daily iron folic acid (IFA) and multiple micronutrient (MM) supplements are recommended to reduce the risk of low birth weight, maternal anemia, and iron deficiency (ID) during pregnancy, but the evidence of their effect on iron status among women with mild or no anemia is limited. The aim of this study was to-describe the iron status [serum ferritin (SF), serum soluble transferrin receptor (sTfR), and body iron (BI)] before and after micronutrient supplementation during pregnancy. We examined 834 pregnant women with hemoglobin > 100 g/L at enrollment before 20 wk of gestation and with iron measurement data from a subset of a randomized, double-blind trial in China. Women were randomly assigned to take daily 400 mu g of folic acid (FA) (control), FA plus 30 mg of iron, or FA, iron, plus 13 additional MMs provided before 20 wk of gestation to delivery. Venous blood was collected in this subset during study enrollment (before 20 wk of gestation) and 28-32 wk of gestation. We found that, at 28-32 wk of-gestation, compared with the FA group, both the IFA and MM groups had significantly lower prevalence of ID regardless of which indicator (SF, sTfR, or BI) was used for defining ID. The prevalence of ID at 28-32 wk of gestation for IFA, MM, and FA were 35.3%, 42.7%, and 59.6% by using low SF, 53.6%, 59.9%, and 69.9% by using high sTfR, and 34.5%, 41.2%, and 59.6% by using low BI, respectively. However, there was no difference in anemia prevalence (hemoglobin < 110 g/L) between FA and IFA or MM groups. We concluded that, compared with FA alone, prenatal IFA and MM supplements provided to women with no or mild anemia improved iron status later during pregnancy but did not affect perinatal anemia. This trial was registered at clinicaltrials.gov as NCT00137744.
C1 [Mei, Zuguo; Serdula, Mary K.; Flores-Ayala, Rafael C.; Grummer-Strawn, Laurence M.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Liu, Jian-meng; Wang, Linlin; Ye, Rongwei] Peking Univ, Hlth Sci Ctr, Inst Reprod & Child Hlth, Minist Hlth,Key Lab Reprod Hlth, Beijing 100871, Peoples R China.
RP Ye, RW (reprint author), Peking Univ, Hlth Sci Ctr, Inst Reprod & Child Hlth, Minist Hlth,Key Lab Reprod Hlth, Beijing 100871, Peoples R China.
EM yerw@bjmu.edu.cn
FU Peking University Health Science Center; CDC
FX Supported by,a cooperative agreement between Peking University Health
Science Center and the CDC. The findings and conclusions in this report
are those-of the authors and do not necessarily represent the official
position of the CDC.
NR 15
TC 5
Z9 5
U1 4
U2 8
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD JUN
PY 2014
VL 144
IS 6
BP 943
EP 948
DI 10.3945/jn.113.189894
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AH9LZ
UT WOS:000336465200022
PM 24744317
ER
PT J
AU Valenzuela, JM
Seid, M
Waitzfelder, B
Anderson, AM
Beavers, DP
Dabelea, DM
Dolan, LM
Imperatore, G
Marcovina, S
Reynolds, K
Yi-Frazier, J
Mayer-Davis, EJ
AF Valenzuela, Jessica M.
Seid, Michael
Waitzfelder, Beth
Anderson, Andrea M.
Beavers, Daniel P.
Dabelea, Dana M.
Dolan, Lawrence M.
Imperatore, Giuseppina
Marcovina, Santica
Reynolds, Kristi
Yi-Frazier, Joyce
Mayer-Davis, Elizabeth J.
CA SEARCH Diabet Youth Study Grp
TI Prevalence of and Disparities in Barriers to Care Experienced by Youth
with Type 1 Diabetes
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID HEALTH-CARE; PROSPECTIVE COHORT; GLYCEMIC CONTROL; CHILDREN; NEEDS;
QUALITY; ACCESS; QUESTIONNAIRE; ADOLESCENTS; INSURANCE
AB Objective To describe the prevalence of access and process barriers to health care and to examine their relationship to sociodemographic and disease factors in a large and diverse cohort of US youth with type 1 diabetes.
Study design A cross-sectional analysis of 780 youth who participated in the SEARCH for Diabetes in Youth Study and were diagnosed with type 1 diabetes in 2002-2005. Experience of barriers to care was collected from parent report on questionnaires. Analyses included multivariate regression models to predict the presence of specific barriers to care.
Results Overall, 81.7% of participants reported at least one barrier; the 3 most common were costs (47.5%), communication (43.0%), and getting needed information (48.4%). Problems with access to care, not having a regular provider, and receiving contextual care (care that takes into account personal and family context) were associated with poorer glycated hemoglobin levels. Adjusted multivariate models indicated that barriers related to access (regular provider, cost) were most likely for youth with low family income and those without public health insurance. Barriers associated with the processes of quality care (contextual care, communication) were more likely for Hispanic youth and those whose parents had less education.
Conclusions This study indicates that a large proportion of youth with type 1 diabetes experience substantial barriers to care. Barriers to access and those associated with processes of quality care differed by sociodemographic characteristics. Future investigators should expand knowledge of the systemic processes that lead to disparate outcomes for some youth with diabetes and assess potential solutions.
C1 [Valenzuela, Jessica M.] Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA.
[Seid, Michael] Cincinnati Childrens Hosp Med Ctr, Div Pulm Med, Cincinnati, OH 45229 USA.
[Seid, Michael] Cincinnati Childrens Hosp Med Ctr, James M Anderson Ctr Hlth Syst Excellence, Cincinnati, OH 45229 USA.
[Waitzfelder, Beth] Pacific Hlth Res Inst, Honolulu, HI USA.
[Waitzfelder, Beth] Kaiser Permanente Ctr Hlth Res Hawaii, Honolulu, HI USA.
[Anderson, Andrea M.; Beavers, Daniel P.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA.
[Dabelea, Dana M.] Univ Colorado, Dept Epidemiol, Colorado Sch Publ Hlth, Denver, CO 80202 USA.
[Dolan, Lawrence M.] Cincinnati Childrens Hosp Med Ctr, Div Endocrinol, Cincinnati, OH 45229 USA.
[Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
[Marcovina, Santica] Univ Washington, Dept Med, Seattle, WA USA.
[Reynolds, Kristi] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.
[Yi-Frazier, Joyce] Seattle Childrens Hosp, Seattle, WA USA.
[Mayer-Davis, Elizabeth J.] Univ N Carolina, Dept Nutr, Gillings Sch Global Publ, Chapel Hill, NC USA.
[Mayer-Davis, Elizabeth J.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
RP Valenzuela, JM (reprint author), Nova SE Univ, Ctr Psychol Studies, 3301 Coll Ave, Ft Lauderdale, FL 33314 USA.
EM Jessica.Valenzuela@nova.edu
RI Beavers, Daniel/G-5338-2016; Dagostino Jr, Ralph/C-4060-2017
OI Dagostino Jr, Ralph/0000-0002-3550-8395
FU NCATS NIH HHS [UL1 TR000077, UL1 TR001082, UL1 TR000423, UL1 TR000154];
NCCDPHP CDC HHS [U01 DP000246, DP-05-069, DP-10-001, U18DP002710-01, U01
DP000250, U18DP002714, U18DP002708-01, U18DP000247-06A1, U01 DP000244,
U01 DP000247, U01 DP000254, U01 DP000248, U01 DP000245, 1U18DP002709];
NCRR NIH HHS [UL1RR029882, M01 RR00069, UL1 RR029882, M01RR00037,
1UL1RR026314-01]; NIDDK NIH HHS [P30 DK57516, P30 DK057516, K23
DK089017]; PHS HHS [U58/CCU019235-4, U48/CCU819241-3, U48/CCU519239,
200-2010-35171, U48/CCU419249, 00097, U58CCU919256, U48/CCU919219]
NR 29
TC 16
Z9 16
U1 3
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD JUN
PY 2014
VL 164
IS 6
BP 1369
EP +
DI 10.1016/j.jpeds.2014.01.035
PG 8
WC Pediatrics
SC Pediatrics
GA AH9YX
UT WOS:000336503200029
PM 24582008
ER
PT J
AU Li, GW
Zhang, P
Wang, JP
An, YL
Gong, QH
Gregg, EW
Yang, WY
Zhang, B
Shuai, Y
Hong, J
Engelgau, MM
Li, H
Roglic, G
Hu, Y
Bennett, PH
AF Li, Guangwei
Zhang, Ping
Wang, Jinping
An, Yali
Gong, Qiuhong
Gregg, Edward W.
Yang, Wenying
Zhang, Bo
Shuai, Ying
Hong, Jing
Engelgau, Michael M.
Li, Hui
Roglic, Gojka
Hu, Yinghua
Bennett, Peter H.
TI Cardiovascular mortality, all-cause mortality, and diabetes incidence
after lifestyle intervention for people with impaired glucose tolerance
in the Da Qing Diabetes Prevention Study: a 23-year follow-up study
SO LANCET DIABETES & ENDOCRINOLOGY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIALS; FASTING GLUCOSE; ADULT DEATHS; METFORMIN;
MELLITUS; PROGRAM; IMPACT; CHINA; RISK; METAANALYSIS
AB Background Lifestyle interventions among people with impaired glucose tolerance reduce the incidence of diabetes, but their effect on all-cause and cardiovascular disease mortality is unclear. We assessed the long-term effect of lifestyle intervention on long-term outcomes among adults with impaired glucose tolerance who participated in the Da Qing Diabetes Prevention Study.
Methods The study was a cluster randomised trial in which 33 clinics in Da Qing, China-serving 577 adults with impaired glucose tolerance-were randomised (1: 1: 1: 1) to a control group or lifestyle intervention groups (diet or exercise or both). Patients were enrolled in 1986 and the intervention phase lasted for 6 years. In 2009, we followed up participants to assess the primary outcomes of cardiovascular mortality, all-cause mortality, and incidence of diabetes in the intention-to-treat population.
Findings Of the 577 patients, 439 were assigned to the intervention group and 138 were assigned to the control group (one refused baseline examination). 542 (94%) of 576 participants had complete data for mortality and 568 (99%) contributed data to the analysis. 174 participants died during the 23 years of follow-up (121 in the intervention group vs 53 in the control group). Cumulative incidence of cardiovascular disease mortality was 11.9% (95% CI 8.8-15.0) in the intervention group versus 19.6% (12.9-26.3) in the control group (hazard ratio [HR] 0.59, 95% CI 0.36-0 96; p=0.033). All-cause mortality was 28.1% (95% CI 23.9-32 4) versus 38.4% (30.3-46.5; HR 0 71, 95% CI 0.51-0.99; p=0.049). Incidence of diabetes was 72.6% (68.4-76.8) versus 89.9% (84.9-94.9; HR 0.55, 95% CI 0.40-0.76; p=0.001).
Interpretation A 6-year lifestyle intervention programme for Chinese people with impaired glucose tolerance can reduce incidence of cardiovascular and all-cause mortality and diabetes. These findings emphasise the long-term clinical benefits of lifestyle intervention for patients with impaired glucose tolerance and provide further justification for adoption of lifestyle interventions as public health measures to control the consequences of diabetes.
C1 [Li, Guangwei; Yang, Wenying; Zhang, Bo; Shuai, Ying; Hong, Jing] China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China.
[Li, Guangwei; An, Yali; Gong, Qiuhong] Natl Ctr Cardiol, Ctr Endocrinol & Cardiovasc Dis, Beijing, Peoples R China.
[Li, Guangwei; An, Yali; Gong, Qiuhong] Fuwai Hosp, Beijing, Peoples R China.
[Zhang, Ping; Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA.
[Engelgau, Michael M.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30341 USA.
[Wang, Jinping; Li, Hui; Hu, Yinghua] Da Qing First Hosp, Dept Cardiol, Da Qing, Peoples R China.
[Roglic, Gojka] WHO, Dept Management Noncommunicable Dis, CH-1211 Geneva, Switzerland.
[Bennett, Peter H.] NIDDK, Phoenix Epidemiol & Clin Res Branch, Phoenix, AZ USA.
RP Li, GW (reprint author), Dept Endocrinol, 167 Beilishi Rd, Beijing 100037, Peoples R China.
EM guangwei_li@medmail.com.cn; pzhang@cdc.gov
FU CDC/WHO [U58/CCU424123-01-02]; China-Japan Friendship Hospital
FX Supported by CDC/WHO Cooperative Agreement No. U58/CCU424123-01-02 and
the China-Japan Friendship Hospital. We thank the participants in the
original Da Qing Diabetes Prevention Study and their proxies who
contributed to the follow-up study. We also thank Lingzhi Kong, China
Ministry of Health, the leadership at the China-Japan Friendship
Hospital, Da Qing First Hospital, the Da Qing City Health Bureau, and
the Beijing and West Pacific Regional Office of WHO for their general
support. We thank Xilin Yang (Tianjin Medical University), Yang Yang
(National Center of Cardiology and Fuwai Hospital, China), and Ted
Thompson (Centers for Disease Control and Prevention, USA) for
statistical advice. Our special thanks go to the late Prof Xiaoren Pan
as this study would not have been possible without his leadership in the
design and implementation of the original Da Qing Diabetes Prevention
Study. The contents of this report are solely the responsibility of the
authors and do not necessarily represent the official positions of the
Centers for Disease Control and Prevention, the National Institute of
Diabetes and Digestive and Kidney Diseases, or WHO.
NR 33
TC 128
Z9 138
U1 11
U2 41
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2213-8587
J9 LANCET DIABETES ENDO
JI Lancet Diabetes Endocrinol.
PD JUN
PY 2014
VL 2
IS 6
BP 474
EP 480
DI 10.1016/S2213-8587(14)70057-9
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AI2YE
UT WOS:000336724300024
PM 24731674
ER
PT J
AU Domingues, CMAS
Verani, JR
Renoiner, EIM
Brandileone, MCD
Flannery, B
de Oliveira, LH
Santos, JB
de Moraes, JC
AF Domingues, Carla Magda Allan S.
Verani, Jennifer R.
Montenegro Renoiner, Ernesto Issac
de Cunto Brandileone, Maria Cristina
Flannery, Brendan
de Oliveira, Lucia Helena
Santos, Joao Barberino
de Moraes, Jose Cassio
CA Brazilian Pneumococcal Conjugate
TI Effectiveness of ten-valent pneumococcal conjugate vaccine against
invasive pneumococcal disease in Brazil: a matched case-control study
SO LANCET RESPIRATORY MEDICINE
LA English
DT Article
ID STREPTOCOCCUS-PNEUMONIAE; PHID-CV; ANTIMICROBIAL RESISTANCE; CHILDREN;
IMMUNOGENICITY; IMPACT; SEROTYPES; CARRIAGE; COVERAGE; BURDEN
AB Background In March 2010, Brazil introduced the ten-valent pneumococcal conjugate vaccine (PCV10), which was licensed based on non-inferiority of immunological correlates of protection compared with the seven-valent vaccine. The schedule comprised three primary doses at ages 2 months, 4 months, and 6 months, and a booster dose at age 12 months. A single catch-up dose was offered for children aged 12-23 months at the time of introduction. We assessed PCV10 effectiveness against invasive pneumococcal disease in Brazilian children.
Methods Invasive pneumococcal disease, defined as isolation of Streptococcus pneumoniae from blood, cerebrospinal fluid, or another normally sterile site, was identified in children age-eligible for at least one PCV10 dose through laboratory-based and hospital-based surveillance in ten states in Brazil from March 1, 2010, until Dec 31, 2012. We aimed to identify four age-matched and neighbourhood-matched controls for each case. We used conditional logistic regression and calculated PCV10 effectiveness as (1-adjusted matched odds ratio) x 100% for vaccine-type and vaccine-related serotypes (ie, in the same serogroup as a vaccine serotype).
Findings In 316 cases (median age 13.2 months, range 2.6-53.1) and 1219 controls (13.3 months, 2.6-53.1), the adjusted effectiveness of an age-appropriate PCV10 schedule was 83.8% (95% CI 65.9-92.3) against vaccine serotypes, and 77.9% (41.0-91.7) against vaccine-related serotypes. Serotype-specific effectiveness was shown for the two most common vaccine serotypes-14 (87.7%, 60.8-96.1) and 6B (82.8%, 23.8-96.1)-and serotype 19A (82.2%, 10.7-96.4), a serotype related to vaccine serotype 19F. A single catch-up dose in children aged 12-23 months was effective against vaccine-type disease (68.0%, 17.6-87.6). No significant effectiveness was shown against non-vaccine serotypes for age-appropriate or catch-up schedules.
Interpretation In the routine immunisation programme in Brazil, PCV10 prevents invasive disease caused by vaccine serotypes. PCV10 might provide cross-protection against some vaccine-related serotypes.
C1 [Domingues, Carla Magda Allan S.; Montenegro Renoiner, Ernesto Issac] Minist Hlth, Natl Immunizat Program, Secretariat Hlth Surveillance, Brasilia, DF, Brazil.
[Domingues, Carla Magda Allan S.; Santos, Joao Barberino] Univ Brasilia, Ctr Trop Med, Brasilia, DF, Brazil.
[Verani, Jennifer R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[de Cunto Brandileone, Maria Cristina] Secretary Hlth State Sao Paulo, Natl Reference Lab Meningitis & Pneumococcal Infe, Bacteriol Ctr, Adolfo Lutz Inst, Sao Paulo, Brazil.
[Flannery, Brendan] Pan Amer Hlth Org, Brasilia, DF, Brazil.
[de Oliveira, Lucia Helena] Pan Amer Hlth Org, Washington, DC USA.
[de Moraes, Jose Cassio] Sch Med Sci Santa Casa, Dept Social Med, Sao Paulo, Brazil.
RP Domingues, CMAS (reprint author), Programa Nacl Imunizacoes, Brasilia, DF, Brazil.
EM carla.domingues@saude.gov.br
FU Brazilian Ministry of Health; Pan American Health Organization
FX Surveillance of invasive pneumococcal disease was funded by the
Brazilian Ministry of Health, with support from the Pan American Health
Organization. Support for the national reference laboratory for invasive
bacterial diseases was provided by the Pan American Health Organization
through the regional surveillance for new vaccines (SIREVA II) project.
We thank the children and their parents whose participation made this
study possible; surveillance units, hospital staff, meningitis and
pneumonia surveillance personnel, and public health laboratory staff at
the local, state, and federal levels; and Cyndy Whitney (US Centers for
Disease Control and Prevention) for valuable input to the manuscript.
The findings and conclusions in this report are those of the authors and
do not necessarily represent the views of the Centers for Disease
Control and Prevention.
NR 29
TC 53
Z9 55
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD JUN
PY 2014
VL 2
IS 6
BP 464
EP 471
DI 10.1016/S2213-2600(14)70060-8
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AI2WA
UT WOS:000336717900017
PM 24726406
ER
PT J
AU Holman, DM
Berkowitz, Z
Guy, GP
Hartman, AM
Perna, FM
AF Holman, Dawn M.
Berkowitz, Zahava
Guy, Gery P., Jr.
Hartman, Anne M.
Perna, Frank M.
TI The association between demographic and behavioral characteristics and
sunburn among U.S. adults - National Health Interview Survey, 2010
SO PREVENTIVE MEDICINE
LA English
DT Article
DE Sunburn; Skin neoplasms; Primary prevention; Health behavior; Adult
ID SKIN-CANCER RISK; CUTANEOUS MALIGNANT-MELANOMA; UNITED-STATES; SUN
PROTECTION; WOMEN; METAANALYSIS; POPULATION; PREVALENCE; PREVENTION;
SUNSCREEN
AB Objective. To examine the association between demographic and behavioral characteristics and sunburn among U.S. adults.
Method We used 2010 National Health Interview Survey data (N = 24,970) to conduct multivariable logistic regressions examining associations with having 1 or more sunburns in the past year and having 4 or more sunburns in the past year.
Results. Overall, 37.1% of adults experienced sunburn in the past year. The adjusted prevalence of sunburn was particularly common among adults aged 18-29 years (52.0%), those who repeatedly burn or freckle after 2 weeks in the sun (45.9%), whites (443%), indoor tanners (44.1%), those with a family history of melanoma (43.9%), and those who are US-born (39.5%). Physical activity, alcohol consumption, and overweight/obesity were positively associated with sunburn (all P < 0.001); sun protection behaviors were not significantly associated with sunburn (P = 0.35). Among those who were sunburned in the past year, 12.1% experienced 4 or more sunburns.
Conclusion. Sunburn is common, particularly among younger adults, those with a more sun-sensitive skin type, whites, those with a family history of melanoma, the highly physically active, and indoor tanners. Efforts are needed to facilitate sun-safety during outdoor recreation, improve the consistency of sun protection practices, and prevent sunburn, particularly among these subgroups. Published by Elsevier Inc.
C1 [Holman, Dawn M.; Berkowitz, Zahava; Guy, Gery P., Jr.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA.
[Hartman, Anne M.; Perna, Frank M.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
RP Holman, DM (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway,NE Chamblee Bldg 107,MS F76, Atlanta, GA 30341 USA.
EM dholman@cdc.gov; zab3@cdc.gov; irm2@cdc.gov; hartmana@mail.nih.gov;
pernafm@mail.nih.gov
FU Intramural CDC HHS [CC999999]
NR 39
TC 22
Z9 22
U1 4
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
EI 1096-0260
J9 PREV MED
JI Prev. Med.
PD JUN
PY 2014
VL 63
BP 6
EP 12
DI 10.1016/j.ypmed.2014.02.018
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AI0TM
UT WOS:000336562900002
PM 24589442
ER
PT J
AU Pesko, MF
Xu, X
Tynan, MA
Gerzoff, RB
Malarcher, AM
Pechacek, TF
AF Pesko, Michael F.
Xu, Xin
Tynan, Michael A.
Gerzoff, Robert B.
Malarcher, Ann M.
Pechacek, Terry F.
TI Per-pack price reductions available from different cigarette purchasing
strategies: United States, 2009-2010
SO PREVENTIVE MEDICINE
LA English
DT Article
DE Price reduction; Cigarette purchasing strategy; United States
ID 4 COUNTRY SURVEY; MINIMIZATION STRATEGIES; SMOKING-CESSATION; TOBACCO
USE; BEHAVIORS; SMOKERS; TAXES; PATTERNS; INTERNET
AB Objective. Following cigarette excise tax increases, smokers may use cigarette price minimization strategies to continue their usual cigarette consumption rather than reducing consumption or quitting. This reduces the public health benefits of the tax increase. This paper estimates the price reductions for a wide-range of strategies, compensating for overlapping strategies.
Method. We performed regression analysis on the 2009-2010 National Adult Tobacco Survey (N = 13,394) to explore price reductions that smokers in the United States obtained from purchasing cigarettes. We examined five cigarette price minimization strategies: 1) purchasing discount brand cigarettes, 2) using price promotions, 3) purchasing cartons, 4) purchasing on Indian reservations, and 5) purchasing online. Price reductions from these strategies were estimated jointly to compensate for overlapping strategies.
Results. Each strategy provided price reductions between 26 and 99 cents per pack. Combined price reductions were possible. Additionally, price promotions were used with regular brands to obtain larger price reductions than when price promotions were used with generic brands.
Conclusion. Smokers can realize large price reductions from price minimization strategies, and there are many strategies available. Policymakers and public health officials should be aware of the extent that these strategies can reduce cigarette prices. Published by Elsevier Inc.
C1 [Pesko, Michael F.] Cornell Univ, Weill Cornell Med Coll, Dept Healthcare Policy & Res, New York, NY 10065 USA.
[Xu, Xin; Gerzoff, Robert B.; Malarcher, Ann M.; Pechacek, Terry F.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA.
[Tynan, Michael A.] Oregon Hlth Author, Publ Hlth Div, Portland, OR 97232 USA.
RP Xu, X (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Highway,Mailstop K-50, Atlanta, GA 30341 USA.
EM xinxu@cdc.gov
FU Research Participation Program at the Centers for Disease Control and
Prevention (CDC); U.S. Department of Energy [DE-AC05-06OR23100]; CDC
[DE-AC05-06OR23100]
FX This project was supported in part by an appointment to the Research
Participation Program at the Centers for Disease Control and Prevention
(CDC) administered by the Oak Ridge Institute for Science and Education
through an interagency agreement between the U.S. Department of Energy
and the CDC (Grant DE-AC05-06OR23100).
NR 28
TC 5
Z9 5
U1 3
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
EI 1096-0260
J9 PREV MED
JI Prev. Med.
PD JUN
PY 2014
VL 63
BP 13
EP 19
DI 10.1016/j.ypmed.2014.02.017
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AI0TM
UT WOS:000336562900003
PM 24594102
ER
PT J
AU Haderxhanaj, LT
Leichliter, JS
Aral, SO
Chesson, HW
AF Haderxhanaj, Laura T.
Leichliter, Jami S.
Aral, Sevgi O.
Chesson, Harrell W.
TI Sex in a Lifetime: Sexual Behaviors in the United States by Lifetime
Number of Sex Partners, 2006-2010
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID MODEL-BASED ANALYSIS; TRANSMITTED-DISEASES; HEALTH; WOMEN; AGE; US
AB Using data from the 2006-2010 National Survey of Family Growth, we found that lifetime number of vaginal sex partners is positively associated with the number of sex partners in the past 12 months and negatively associated with age at first vaginal intercourse among 15- to 44-year-old male and female respondents.
C1 [Haderxhanaj, Laura T.; Leichliter, Jami S.; Aral, Sevgi O.; Chesson, Harrell W.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Haderxhanaj, LT (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,Mailstop E-02, Atlanta, GA 30333 USA.
EM LHaderxhanaj@cdc.gov
FU US Department of Energy; Centers for Disease Control and Prevention
FX This research was supported in part by an appointment to the Research
Participation Program at the Centers for Disease Control and Prevention
administered by the Oak Ridge Institute for Science and Education
through an interagency agreement between the US Department of Energy and
Centers for Disease Control and Prevention.
NR 25
TC 1
Z9 1
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
IS 6
BP 345
EP 352
DI 10.1097/OLQ.0000000000000132
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA AI2EA
UT WOS:000336669000001
PM 24825330
ER
PT J
AU Hoots, BE
Lewis, FMT
Anschuetz, G
Schillinger, JA
Blank, S
Foskey, T
Stover, JA
Peterman, TA
AF Hoots, Brooke E.
Lewis, Felicia M. T.
Anschuetz, Greta
Schillinger, Julia A.
Blank, Susan
Foskey, Tammy
Stover, Jeffrey A.
Peterman, Thomas A.
TI Would Targeting Increase Efficiency of Syphilis Partner Services
Programs?-Data From New York City, Philadelphia, Texas, and Virginia
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID CASE-FINDING EFFECTIVENESS; NOTIFICATION; MEN; SEX; ATTITUDES; COSTS;
HIV
AB Background: Targeted partner notification (PN), or limiting PN to groups in which efforts are most successful, has been suggested as a potentially cost-effective alternative to providing PN for all syphilis case-patients. The purpose of this study was to identify index case characteristics associated with highest yield partner elicitation and subsequent case finding to determine whether some groups could be reasonably excluded from PN efforts.
Methods: We examined index case characteristics and PN metrics from syphilis case management records of 4 sexually transmitted disease control programs-New York City, Philadelphia, Texas, and Virginia. Partner elicitation was considered successful when a case-patient named 1 or more partners during interview. Case finding was considered successful when a case-patient had 1 or more partners who were tested and had serologic evidence of syphilis exposure. Associations between case characteristics and proportion of pursued case-patients with successful partner elicitation and case finding were evaluated using chi(2) tests.
Results: Successful partner elicitation and new case finding was most likely for index case-patients who were younger and diagnosed at public sexually transmitted disease clinics. However, most characteristics of index case-patients were related to success at only a few sites, or varied in the direction of the relationship by site. Other than late latent case-patients, few demographic groups had a yield far below average.
Conclusions: If implemented, targeted PN will require site-specific data. Sites may consider eliminating PN for late latent case-patients. The lack of demographic groups with a below average yield suggests that sites should not exclude other groups from PN.
C1 [Hoots, Brooke E.; Lewis, Felicia M. T.; Schillinger, Julia A.; Blank, Susan; Peterman, Thomas A.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30329 USA.
[Hoots, Brooke E.] Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Div Appl Sci, Atlanta, GA USA.
[Lewis, Felicia M. T.; Anschuetz, Greta] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
[Schillinger, Julia A.; Blank, Susan] New York City Dept Hlth & Mental Hyg, New York, NY USA.
[Foskey, Tammy] Texas Dept State Hlth Serv, HIV STD Prevent & Care Branch, Austin, TX USA.
[Stover, Jeffrey A.] Virginia Dept Hlth, Div Dis Prevent, Richmond, VA USA.
RP Hoots, BE (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mailstop E-46, Atlanta, GA 30329 USA.
EM bhoots@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 18
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD JUN
PY 2014
VL 41
IS 6
BP 407
EP 412
DI 10.1097/OLQ.0000000000000130
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA AI2EA
UT WOS:000336669000012
PM 24825340
ER
PT J
AU Lehman, JS
Carr, MH
Nichol, AJ
Ruisanchez, A
Knight, DW
Langford, AE
Gray, SC
Mermin, JH
AF Lehman, J. Stan
Carr, Meredith H.
Nichol, Allison J.
Ruisanchez, Alberto
Knight, David W.
Langford, Anne E.
Gray, Simone C.
Mermin, Jonathan H.
TI Prevalence and Public Health Implications of State Laws that Criminalize
Potential HIV Exposure in the United States
SO AIDS AND BEHAVIOR
LA English
DT Review
DE HIV prevention; HIV-specific criminal laws; Public health law research;
Public health policy; Structural interventions; State laws
ID PREVENTION; DISCLOSURE; TRANSMISSION; ATTITUDES; IMPACT; MEN
AB For the past three decades, legislative approaches to prevent HIV transmission have been used at the national, state, and local levels. One punitive legislative approach has been enactment of laws that criminalize behaviors associated with HIV exposure (HIV-specific criminal laws). In the USA, HIV-specific criminal laws have largely been shaped by state laws. These laws impose criminal penalties on persons who know they have HIV and subsequently engage in certain behaviors, most commonly sexual activity without prior disclosure of HIV-positive serostatus. These laws have been subject to intense public debate. Using public health law research methods, data from the legal database WestlawNextA (c) were analyzed to describe the prevalence and characteristics of laws that criminalize potential HIV exposure in the 50 states (plus the District of Columbia) and to examine the implications of these laws for public health practice. The first state laws were enacted in 1986; as of 2011 a total of 67 laws had been enacted in 33 states. By 1995, nearly two-thirds of all laws had been enacted; by 2000, 85 % of laws had been enacted; and since 2000, an additional 10 laws have been enacted. Twenty-four states require persons who are aware that they have HIV to disclose their status to sexual partners and 14 states require disclosure to needle-sharing partners. Twenty-five states criminalize one or more behaviors that pose a low or negligible risk for HIV transmission. Nearly two-thirds of states in the USA have legislation that criminalizes potential HIV exposure. Many of these laws criminalize behaviors that pose low or negligible risk for HIV transmission. The majority of laws were passed before studies showed that antiretroviral therapy (ART) reduces HIV transmission risk and most laws do not account for HIV prevention measures that reduce transmission risk, such as condom use, ART, or pre-exposure prophylaxis. States with HIV-specific criminal laws are encouraged to use the findings of this paper to re-examine those laws, assess the laws' alignment with current evidence regarding HIV transmission risk, and consider whether the laws are the best vehicle to achieve their intended purposes.
C1 [Lehman, J. Stan; Carr, Meredith H.; Gray, Simone C.; Mermin, Jonathan H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Carr, Meredith H.] ORISE, Atlanta, GA USA.
[Nichol, Allison J.; Ruisanchez, Alberto; Knight, David W.; Langford, Anne E.] US Dept Justice, Civil Rights Div, Washington, DC 20530 USA.
RP Lehman, JS (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS D21, Atlanta, GA 30333 USA.
EM slehman@cdc.gov
NR 33
TC 27
Z9 27
U1 1
U2 9
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JUN
PY 2014
VL 18
IS 6
BP 997
EP 1006
DI 10.1007/s10461-014-0724-0
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA AH5YF
UT WOS:000336206400001
PM 24633716
ER
PT J
AU Jenkins, MM
Reefhuis, J
Gallagher, ML
Mulle, JG
Hoffmann, TJ
Koontz, DA
Sturchio, C
Rasmussen, SA
Witte, JS
Richter, P
Honein, MA
AF Jenkins, Mary M.
Reefhuis, Jennita
Gallagher, Margaret L.
Mulle, Jennifer G.
Hoffmann, Thomas J.
Koontz, Deborah A.
Sturchio, Cynthia
Rasmussen, Sonja A.
Witte, John S.
Richter, Patricia
Honein, Margaret A.
CA Natl Birth Defects Prevention
TI Maternal smoking, xenobiotic metabolizing enzyme gene variants, and
gastroschisis risk
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE maternal smoking; CYP; NAT; genetic epidemiology; risk factors;
gastroschisis
ID BIRTH-DEFECTS; TOBACCO-SMOKE; UNITED-STATES; WALL DEFECTS;
POLYMORPHISMS; CAFFEINE; PREVALENCE; EXPOSURE; CYP1A1; NAT2
AB Maternal smoking during pregnancy is one proposed risk factor for gastroschisis, but reported associations have been modest, suggesting that differences in genetic susceptibility might play a role. We included 108 non-Hispanic white and 62 Hispanic families who had infants with gastroschisis, and 1,147 non-Hispanic white and 337 Hispanic families who had liveborn infants with no major structural birth defects (controls) in these analyses. DNA was extracted from buccal cells collected from infants and mothers, and information on periconceptional smoking history was obtained from maternal interviews, as part of the National Birth Defects Prevention Study. We analyzed five polymorphisms in three genes that code for enzymes involved in metabolism of some cigarette smoke constituents (CYP1A1, CYP1A2, and NAT2). Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) independently for maternal smoking and maternal and infant gene variants, and to assess joint associations of maternal smoking and maternal or infant gene variants with gastroschisis. In analyses adjusted for maternal age at delivery and stratified by maternal race-ethnicity, we identified three suggestive associations among 30 potential associations with sufficient numbers to calculate ORs: CYP1A1*2A for non-Hispanic white mothers who smoked periconceptionally (aOR = 0.38, 95% CI 0.15-0.98), and NAT2*6 for Hispanic non-smoking mothers (aOR = 2.17, 95% CI 1.12-4.19) and their infants (aOR = 2.11, 95% CI 1.00-4.48). This analysis does not support the occurrence of effect modification between periconceptional maternal smoking and most of the xenobiotic metabolizing enzyme gene variants assessed. (c) 2014 Wiley Periodicals, Inc.
C1 [Jenkins, Mary M.; Reefhuis, Jennita; Gallagher, Margaret L.; Koontz, Deborah A.; Rasmussen, Sonja A.; Richter, Patricia; Honein, Margaret A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Mulle, Jennifer G.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Hoffmann, Thomas J.; Witte, John S.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Hoffmann, Thomas J.; Witte, John S.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
[Sturchio, Cynthia] Battelle Ctr Publ Hlth Res & Evaluat, Columbus, OH USA.
RP Jenkins, MM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,M-S E-86, Atlanta, GA 30333 USA.
EM mmjenkins@cdc.gov
FU CDC's National Office of Public Health Genomics
FX Grant sponsor: CDC's National Office of Public Health Genomics.
NR 45
TC 4
Z9 4
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD JUN
PY 2014
VL 164
IS 6
BP 1454
EP 1463
DI 10.1002/ajmg.a.36478
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA AH2BV
UT WOS:000335926600013
PM 24668907
ER
PT J
AU Lairson, DR
Chang, YC
Byrd, TL
Smith, JL
Fernandez, ME
Wilson, KM
AF Lairson, David R.
Chang, Yu-Chia
Byrd, Theresa L.
Smith, Judith Lee
Fernandez, Maria E.
Wilson, Katherine M.
TI Cervical Cancer Screening with AMIGAS A Cost-Effectiveness Analysis
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID HISPANIC WOMEN; INTERVENTION; BREAST; SERVICES; STATES
AB Background: Hispanic women have a higher incidence of cervical cancer than all other races and ethnicities. In Hispanic subgroups, Mexican American women were among the least likely to have received cervical cancer screening. In a recent RCT, Ayudando a las Mujeres con Informacion, Guia, y Amor para su Salud (AMIGAS) was shown to increase cervical cancer screening rates among women of Mexican descent at 6 months in all intervention arms compared to the control arm. Limited information exists about the economics of interventions to increase cervical cancer screening rates among women of Mexican descent.
Purpose: This study aims to estimate the cost-effectiveness of the alternative AMIGAS intervention methods for increasing cervical cancer screening among low-income women of Mexican descent in three U.S. communities.
Methods: Cost data were collected from 2008 to 2011 alongside the AMIGAS study of 613 women. Receipt of Pap test within 6 months of intervention was the primary outcome measure in the cost-effectiveness analysis, conducted during 2012-2013.
Results: The cost per additional woman screened comparing the video-only intervention to usual care was $980. The cost increased to $1,309 with participant time cost included. With an additional cost per participant of $3.90 compared to flipchart only, the full AMIGAS program (video plus flipchart) yielded 6.8% additional women screened.
Conclusions: Results on the average and incremental cost-effectiveness of the AMIGAS program elements may assist health policymakers and program managers to select and appropriately budget for interventions shown to increase cervical cancer screening among low-income women of Mexican descent. (C) 2014 American Journal of Preventive Medicine. All rights reserved.
C1 [Lairson, David R.; Chang, Yu-Chia; Fernandez, Maria E.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX 77030 USA.
[Fernandez, Maria E.] Univ Texas Hlth Sci Ctr Houston, Ctr Hlth Promot & Prevent Res, Houston, TX 77030 USA.
[Byrd, Theresa L.] Texas Tech Univ, Paul L Foster Sch Med, Lubbock, TX 79409 USA.
[Smith, Judith Lee] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA.
[Wilson, Katherine M.] CDC, Epidemiol & Anal Program Off, Atlanta, GA 30333 USA.
RP Lairson, DR (reprint author), Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, 1200 Herman Pressler, Houston, TX 77030 USA.
EM david.r.lairson@uth.tmc.edu
FU CDC [U48-DP000057]
FX Research for this publication was supported by the CDC cooperative
agreement U48-DP000057 to the University of Texas, School of Public
Health at El Paso. The findings and conclusions in this report are those
of the authors and do not necessarily represent the official position of
the CDC.
NR 37
TC 2
Z9 2
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD JUN
PY 2014
VL 46
IS 6
BP 617
EP 623
DI 10.1016/j.amepre.2014.01.020
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA AH5SC
UT WOS:000336190400009
PM 24842738
ER
PT J
AU McNicholl, JM
Henning, TC
Vishwanathan, SA
Kersh, EN
AF McNicholl, Janet M.
Henning, Tara C.
Vishwanathan, Sundaram A.
Kersh, Ellen N.
TI Non-Human Primate Models of Hormonal Contraception and HIV
SO AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
LA English
DT Article
DE Acquisition risk; immune; macaque; progesterone; simian immunodeficiency
viruses (SIV); SIVs expressing HIV genes
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED-DISEASES; FEMALE
REPRODUCTIVE-TRACT; SIV VAGINAL TRANSMISSION; PIG-TAILED MACAQUES;
RHESUS MACAQUES; MACACA-NEMESTRINA; MENSTRUAL-CYCLE; ANIMAL-MODELS;
SIMIAN-HUMAN
AB ProblemRecent concerns that hormonal contraception (HC) may increase risk of HIV acquisition has led to keen interest in using non-human primates (NHP) to understand the underlying mechanism and the magnitude of the risk. This is, in part, because some experiments which would be difficult or logistically impossible in women are more easily conducted in NHP.
Method of studyNHP models of HIV can inform HIV acquisition and pathogenesis research and identify and evaluate biomedical preventions and treatments for HIV/AIDS. Widely used species include rhesus, pigtail, and cynomolgous macaques.
ResultsThis paper reviews past, current and proposed NHP research around the intersection of HIV and HC.
ConclusionNHP research may lead to the identification of hormonally regulated biomarkers that correlate with HIV-acquisition risk, to a ranking of existing or next-generation HC along an HIV-acquisition risk profile, and inform research around new biomedical preventions for HIV.
C1 [McNicholl, Janet M.; Henning, Tara C.; Vishwanathan, Sundaram A.; Kersh, Ellen N.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA.
RP McNicholl, JM (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, MS A25, Atlanta, GA 30329 USA.
EM jkm7@cdc.gov
FU CDC; CDC [AAI 12041]; NIH/NIAID [AAI 12041]
FX We thank David Garber and Mark Lewis for assistance with Table II and
for helpful comments on the manuscript. Prachi Sharma and Ai Tsuki
helped with vaginal histology. Some of the work cited in this article
was funded by CDC and by an Interagency Agreement AAI 12041 between CDC
and NIH/NIAID.
NR 89
TC 10
Z9 10
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1046-7408
EI 1600-0897
J9 AM J REPROD IMMUNOL
JI Am. J. Reprod. Immunol.
PD JUN
PY 2014
VL 71
IS 6
SI SI
BP 513
EP 522
DI 10.1111/aji.12246
PG 10
WC Immunology; Reproductive Biology
SC Immunology; Reproductive Biology
GA AH1YK
UT WOS:000335917600005
PM 24716832
ER
PT J
AU Schwebel, DC
Lewis, T
Simon, TR
Elliott, MN
Toomey, SL
Tortolero, SR
Cuccaro, PM
Schuster, MA
AF Schwebel, David C.
Lewis, Terri
Simon, Thomas R.
Elliott, Marc N.
Toomey, Sara L.
Tortolero, Susan R.
Cuccaro, Paula M.
Schuster, Mark A.
TI Prevalence and Correlates of Firearm Ownership in the Homes of Fifth
Graders: Birmingham, AL, Houston, TX, and Los Angeles, CA
SO HEALTH EDUCATION & BEHAVIOR
LA English
DT Article
DE firearms; guns; injury; safety
ID STORAGE PRACTICES; HOUSEHOLD FIREARMS; PEDIATRIC POPULATION; CHILDREN;
RISK; INJURIES; ADOLESCENTS; DISPARITIES; PATTERNS; ACCESS
AB Firearms in the home are associated with increased injury risk, especially when loaded and unlocked. In this study, 5,010 fifth-graders and their caregivers in three U.S. metropolitan areas participated in the 2004-2006 Healthy Passages study on adolescent health. Firearm ownership and storage patterns were examined by four self-reported sociodemographic characteristics (child's race/ethnicity, child's gender, family socioeconomic status, and study site) and reasons for ownership. Eighteen percent (n = 880) of the families reported firearms in the home. Families with African American and Hispanic children had lower odds of owning firearms than families with non-Hispanic White children. The most common reasons for ownership were protection from crime and hunting. Six percent (n = 56) of the families with firearms stored at least one firearm unlocked, assembled, without a trigger lock, and with unlocked ammunition. Compared with families with non-Hispanic White children, families with African American children engaged in safer storage practices. Results can inform childhood firearm injury prevention activities.
C1 [Schwebel, David C.; Lewis, Terri] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Simon, Thomas R.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
[Elliott, Marc N.; Schuster, Mark A.] RAND Corp, Santa Monica, CA USA.
[Toomey, Sara L.; Schuster, Mark A.] Boston Childrens Hosp, Div Gen Pediat, Boston, MA USA.
[Toomey, Sara L.; Schuster, Mark A.] Harvard Univ, Sch Med, Boston, MA USA.
[Tortolero, Susan R.; Cuccaro, Paula M.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
RP Schwebel, DC (reprint author), Univ Alabama Birmingham, Dept Psychol, 1300 Univ Blvd,HHB 571, Birmingham, AL 35294 USA.
EM schwebel@uab.edu
OI Cuccaro, Paula/0000-0002-9551-4789
FU Intramural CDC HHS [CC999999]; NCCDPHP CDC HHS [U19DP002663, U19
DP002663, U19 DP002664, U19 DP002665, U19DP002664, U19DP002665]
NR 30
TC 2
Z9 2
U1 2
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1090-1981
EI 1552-6127
J9 HEALTH EDUC BEHAV
JI Health Educ. Behav.
PD JUN
PY 2014
VL 41
IS 3
BP 299
EP 306
DI 10.1177/1090198113512126
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH6DW
UT WOS:000336221900008
PM 24419969
ER
PT J
AU Nguyen, DC
Sanghvi, R
Scinicariello, F
Pulit-Penaloza, J
Hill, N
Attanasio, R
AF Nguyen, Doan C.
Sanghvi, Rashesh
Scinicariello, Franco
Pulit-Penaloza, Joanna
Hill, Nicole
Attanasio, Roberta
TI Cynomolgus and pigtail macaque IgG subclasses: characterization of IGHG
genes and computational analysis of IgG/Fc receptor binding affinity
SO IMMUNOGENETICS
LA English
DT Article
DE IGHG genes; Nonhuman primate (NHP); Macaque; Macfas; Macnem; IMGT
ID FC-GAMMA-RI; PRE-B-CELLS; RHESUS MACAQUES; IMMUNOGLOBULIN; REGION; SITE;
ANTIBODY; IDENTIFICATION; HETEROGENEITY; COMPLEMENT
AB Macaques are the most widely used experimental nonhuman primate (NHP) species. Rhesus (Macaca mulatta, Macmul), cynomolgus (Macaca fascicularis, Macfas), and pigtail (Macaca nemestrina, Macnem) macaques continue to be popular models for vaccine and infectious diseases research, especially HIV infection and AIDS, and for the development of antibody-based therapeutic strategies. Increased understanding of the immune system of these species is necessary for their optimal use as models of human infections and intervention. In the past few years, the antibody/Fc receptor system has been characterized in a stepwise manner in these species. We have continued this characterization by identifying the four IG heavy gamma (IGHG) genes of Macfas and Macnem in this study. Our results show that these genes share a high degree of similarity with those from other NHP species, while presenting consistent differences when compared to human IGHG genes. Furthermore, comparison of Macfas IGHG genes with those described in other studies suggests the existence of polymorphism. Using sequence- and structure-based computational tools, we performed in silico analysis on multiple polymorphic Macfas IgG and their interactions with human IgG Fc receptors (Fc gamma R), thus predicting that Macfas IGHG polymorphisms influence IgG protein stability and/or binding affinity towards Fc gamma R. The presence of macaque IGHG polymorphisms and macaque/human amino acid changes at locations potentially involved in antibody functional properties indicate the need for cautious design and data interpretation of studies in these models, possibly requiring the characterization of antibody/Fc receptor interactions at the individual level.
C1 [Nguyen, Doan C.; Sanghvi, Rashesh; Pulit-Penaloza, Joanna; Hill, Nicole; Attanasio, Roberta] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA.
[Scinicariello, Franco] Ctr Dis Control & Prevent, Div Toxicol & Environm Med, Agcy Tox Subst & Dis Registry, Atlanta, GA 30333 USA.
RP Attanasio, R (reprint author), Georgia State Univ, Dept Biol, POB 4010, Atlanta, GA 30303 USA.
EM rattanasio@gsu.edu
FU NIH [R21 AI078855]; Research Program Enhancement from the Georgia State
University Office of Research and Sponsored Programs; Georgia Research
Alliance; Molecular Basis of Disease (MBD) program at Georgia State
University
FX This work was supported in part by NIH grant R21 AI078855, by the
Research Program Enhancement from the Georgia State University Office of
Research and Sponsored Programs, and by the Georgia Research Alliance.
Support for Doan C. Nguyen was provided by the Molecular Basis of
Disease (MBD) program at Georgia State University.
NR 45
TC 5
Z9 5
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0093-7711
EI 1432-1211
J9 IMMUNOGENETICS
JI Immunogenetics
PD JUN
PY 2014
VL 66
IS 6
BP 361
EP 377
DI 10.1007/s00251-014-0775-4
PG 17
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA AH6VM
UT WOS:000336270000002
PM 24811270
ER
PT J
AU Shepardson, D
Mac Kenzie, WR
AF Shepardson, Dylan
Mac Kenzie, William R.
TI Update on cost-effectiveness of a 12-dose regimen for latent tuberculous
infection at new rifapentine prices
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Letter
C1 [Shepardson, Dylan] Mt Holyoke Coll, S Hadley, MA 01075 USA.
[Mac Kenzie, William R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Shepardson, D (reprint author), Mt Holyoke Coll, S Hadley, MA 01075 USA.
EM wrm0@cdc.gov
NR 3
TC 6
Z9 6
U1 1
U2 1
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
EI 1815-7920
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD JUN
PY 2014
VL 18
IS 6
BP 751
EP 751
DI 10.5588/ijtld.14.0052
PG 1
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA AH5VH
UT WOS:000336198700022
PM 24903950
ER
PT J
AU York, L
Janet, L
Lanasa, S
AF York, Liz
Janet, Laura
Lanasa, Suzanne
TI Go Green, Get Healthy: An Agencywide Effort to Reduce Energy Use and
Move the Centers for Disease Control and Prevention toward
Sustainability
SO JOURNAL OF ENERGY ENGINEERING
LA English
DT Article
DE Centers for Disease Control and Prevention; Healthy environment; Energy
consumption; Sustainable behaviors; Carbon footprint; Greenhouse gas;
Power management; Alternative energy; Healthier worksite; Environmental
stewardship
ID CONSERVATION; INFORMATION; PSYCHOLOGY
AB Americans look to the Centers for Disease Control and Prevention (CDC) to lead by providing an example of healthy people in healthy environments. Recognizing the synergy between environmental health and personal health and well-being, the CDC formed the Go Green, Get Healthy (GGGH) initiative. The GGGH rolls healthier worksite initiatives, quality-of-work-life programs, and internal environmental protection efforts into a coordinated campaign for widespread cultural change with energy conservation as one of the major goals. The CDC hopes that this success will be a model for other agencies and organizations. The Office of Sustainability at the CDC actively engages the entire agency in environmental stewardship and specifically, energy conservation (in the GGGH initiative) by providing a vision with leadership support, education for every individual, effective communication methods, and a robust tracking system for comprehensive data and feedback. The campaign works effectively by breaking down the task of greening the agency into sectors. Each sector needs support of CDC leadership and work of responsible offices, complimented by the grassroots dedication of individuals in the GGGH workgroups and collaborative external partnerships. Several low/no-cost examples are included to demonstrate progress toward a sustainable CDC and these can be used to help other organizations discover a greener and healthier model for their sustainability and conservation efforts with a minimal outlay of funds. Through physical changes, culture changes, and policy/operational changes, energy and water can be saved. This paper seeks to convey the following main learning points: (1)identify low/no-cost ways to reduce energy and water consumption; (2)describe ways to influence workers to adopt more sustainable behaviors; and (3)discuss ways to integrate energy-management decision-making processes and standard operating procedures. (C) 2013 American Society of Civil Engineers.
C1 [York, Liz; Janet, Laura; Lanasa, Suzanne] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Lanasa, S (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM SLanasa@cdc.gov
NR 10
TC 0
Z9 0
U1 2
U2 14
PU ASCE-AMER SOC CIVIL ENGINEERS
PI RESTON
PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA
SN 0733-9402
EI 1943-7897
J9 J ENERG ENG
JI J. Energy Eng.-ASCE
PD JUN
PY 2014
VL 140
IS 2
DI 10.1061/(ASCE)EY.1943-7897.0000132
PG 7
WC Energy & Fuels; Engineering, Civil
SC Energy & Fuels; Engineering
GA AH6PD
UT WOS:000336252100007
ER
PT J
AU Pelaez-Carvajal, D
Cotes-Cantillo, K
Paternina-Caicedo, A
Gentsch, J
de la Hoz-Restrepo, F
Patel, M
AF Pelaez-Carvajal, Dioselina
Cotes-Cantillo, Karol
Paternina-Caicedo, Angel
Gentsch, Jon
de la Hoz-Restrepo, Fernando
Patel, Manish
TI Characterization of Rotavirus Genotypes Before and After the
Introduction of a Monovalent Rotavirus Vaccine in Colombia
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE rotavirus; vaccine; strains; serotype; diarrhea
ID DIARRHEA; MEXICO; PROTECTION; STRAINS; BRAZIL
AB Strain monitoring for emergence of novel strains after the introduction of rotavirus vaccine is an integral component of routine rotavirus immunization programs. Using a laboratory based strain surveillance system between 2008 and 2012, a wide variation in strain pattern in Colombia was founded both before and after the introduction of a monovalent rotavirus vaccine in 2009. G2P[4], a strain fully heterotypic to the vaccine was predominant before vaccine introduction in 2008 (47%) and after vaccine introduction in 2010 (54%), 2011 (86%), and 2012 (32%). The presence of this strain before the introduction of vaccine and decreasing prevalence during the most recent surveillance year suggests secular variation rather than vaccine pressure as a cause for this fluctuation. While strain monitoring can be valuable after vaccine introduction, these surveillance data alone without information on disease incidence or strain specific vaccine effectiveness can be prone to misinterpretation with regard to the role of vaccine pressure on emergence of new or persistent strains. J. Med. Virol. 86:1083-1086, 2014. (c) 2017 Wiley Periodicals, Inc.
C1 [Pelaez-Carvajal, Dioselina; de la Hoz-Restrepo, Fernando] Natl Inst Hlth Colombia, Bogota, Colombia.
[Cotes-Cantillo, Karol] Univ Nacl Colombia, Bogota, Colombia.
[Paternina-Caicedo, Angel] Univ Cartagena, Cartagena De Indias, Colombia.
[Gentsch, Jon; Patel, Manish] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Cotes-Cantillo, K (reprint author), Univ Nacl Colombia, Fac Med, Ciudad Univ,Fac Med Of 150, Bogota, Colombia.
EM karpatri@hotmail.com
RI Paternina-Caicedo, Angel/N-4496-2015
OI Paternina-Caicedo, Angel/0000-0002-6332-5174
FU National Institute of Health of Colombia; Administrative Department of
Science Technology and Innovation of Colombia (COLCIENCIAS)
FX Grant sponsor: National Institute of Health of Colombia; Grant sponsor:
Administrative Department of Science Technology and Innovation of
Colombia (COLCIENCIAS)
NR 13
TC 4
Z9 4
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD JUN
PY 2014
VL 86
IS 6
BP 1083
EP 1086
DI 10.1002/jmv.23899
PG 4
WC Virology
SC Virology
GA AE1XX
UT WOS:000333768200024
PM 24616018
ER
PT J
AU King, SC
Pollack, LA
Li, J
King, JB
Master, VA
AF King, Sallyann Coleman
Pollack, Lori A.
Li, Jun
King, Jessica B.
Master, Viraj A.
TI Continued Increase in Incidence of Renal Cell Carcinoma, Especially in
Young Patients and High Grade Disease: United States 2001 to 2010
SO JOURNAL OF UROLOGY
LA English
DT Article
DE kidney; carcinoma, renal cell; young adult; SEER program; epidemiology
ID CIGARETTE-SMOKING; KIDNEY CANCER; RISK; NUTRITION; ADULTS; TRENDS; CARE
AB Purpose: More than 50,000 Americans were diagnosed with kidney and renal pelvis cancer in 2010. The National Program of Cancer Registries and SEER (Surveillance, Epidemiology and End Results) combined data include cancer incidences from the entire United States. Our study presents updated incidence data, evaluates trends and adds geographic distribution to the literature.
Materials and Methods: We examined invasive, microscopically confirmed kidney and renal pelvis cancers diagnosed from 2001 to 2010 that met United States Cancer Statistics reporting criteria for each year, excluding cases diagnosed by autopsy or death certificate. Histology codes classified cases as renal cell carcinoma. Rates and trends were estimated using SEER*Stat.
Results: A total of 342,501 renal cell carcinoma cases were diagnosed. The renal cell carcinoma incidence rate increased from 10.6/100,000 individuals in 2001 to 12.4/100,000 in 2010 and increased with age until ages 70 to 74 years. The incidence rate in men was almost double that in women. The annual percent change was higher in women than in men, in those 20 to 24 years old and in grade III tumors.
Conclusions: The annual percent change incidence increased from 2001 to 2010. Asian/Pacific Islanders and 20 to 24-year-old individuals had the highest annual percent change. While some increase resulted from localized disease, the highest annual percent change was in grade III tumors, indicating more aggressive disease. Continued monitoring of trends and epidemiological study are warranted to determine risk factors.
C1 [Master, Viraj A.] Emory Univ, Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30322 USA.
[Master, Viraj A.] Emory Univ, Dept Urol, Atlanta, GA 30322 USA.
[Master, Viraj A.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA.
RP King, SC (reprint author), 4770 Buford Hwy Northeast,Mailstop F-72, Atlanta, GA 30341 USA.
EM fjq9@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 29
TC 29
Z9 33
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD JUN
PY 2014
VL 191
IS 6
BP 1665
EP 1670
DI 10.1016/j.juro.2013.12.046
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA AI0IS
UT WOS:000336531100008
PM 24423441
ER
PT J
AU Pettygrove, S
Lu, ZQ
Andrews, JG
Meaney, FJ
Sheehan, DW
Price, ET
Fox, DJ
Pandya, S
Ouyang, LJ
Apkon, SD
Powis, Z
Cunniff, C
AF Pettygrove, Sydney
Lu, Zhenqiang
Andrews, Jennifer G.
Meaney, F. John
Sheehan, Daniel W.
Price, Elinora T.
Fox, Deborah J.
Pandya, Shree
Ouyang, Lijing
Apkon, Susan D.
Powis, Zoe
Cunniff, Christopher
TI SIBLING CONCORDANCE FOR CLINICAL FEATURES OF DUCHENNE AND BECKER
MUSCULAR DYSTROPHIES
SO MUSCLE & NERVE
LA English
DT Article
DE nerve conduction studies; electromyography; radiculopathy; F-waves;
latency
ID SCOLIOSIS; MANAGEMENT; SURVIVAL
AB Introduction: The utility of F-waves in assessing radiculopathies is debated. The aim of this study is to determine the frequency of abnormal minimum tibial F-wave latencies compared to an F-estimate and an absolute reference value in patients with electromyography (EMG) confirmed S1 radiculopathies. Methods: A retrospective review of F-waves in patients with an EMG-confirmed isolated S1 radiculopathy was performed. The minimum and mean latencies of 8 tibial F-waves were compared with the calculated F-estimate and to an absolute reference value, and the frequencies of abnormal responses were determined. Results: Of the 50 patients with an S1 radiculopathy, 4% had prolongation of the minimum reproducible F-wave latency, and 8% had prolongation of the mean latency relative to the calculated F-estimate. Conclusions: The minimum and mean F-wave latencies are infrequently abnormal when compared with an estimated F-wave latency in S1 radiculopathies and are insensitive in the assessment of S1 nerve root injury. Muscle Nerve 49: 809-813, 2014
C1 [Pettygrove, Sydney] Univ Arizona, Coll Publ Hlth, Tucson, AZ 85724 USA.
[Lu, Zhenqiang; Andrews, Jennifer G.; Meaney, F. John; Price, Elinora T.; Powis, Zoe; Cunniff, Christopher] Univ Arizona, Coll Med, Dept Pediat, Tucson, AZ 85724 USA.
[Lu, Zhenqiang] Univ Arizona, Inst Bio5, Tucson, AZ 85724 USA.
[Sheehan, Daniel W.] SUNY Buffalo, Dept Pediat, Buffalo, NY USA.
[Fox, Deborah J.] New York State Dept Hlth, Albany, NY USA.
[Pandya, Shree] Univ Rochester, Dept Neurol, Rochester, NY USA.
[Ouyang, Lijing] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Apkon, Susan D.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
RP Cunniff, C (reprint author), Univ Arizona, Coll Med, Dept Pediat, 1501 N Campbell Ave,Box 245073, Tucson, AZ 85724 USA.
EM ccunniff@peds.arizona.edu
FU Centers for Disease Control and Prevention [DD000187]
FX This study was funded by the Centers for Disease Control and Prevention
Cooperative Agreement DD000187 for Surveillance and Epidemiologic
Research of Duchenne and Becker Muscular Dystrophy. The findings and
conclusions in this report are those of the author(s) and do not
necessarily represent the views of the Centers for Disease Control and
Prevention.
NR 17
TC 3
Z9 3
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD JUN
PY 2014
VL 49
IS 6
BP 814
EP 821
DI 10.1002/mus.23992
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AH2MA
UT WOS:000335954400005
PM 24030636
ER
PT J
AU Seth, P
Kidder, D
Pals, S
Parent, J
Mbatia, R
Chesang, K
Mbilinyi, D
Koech, E
Nkingwa, M
Katuta, F
Ng'ang'a, A
Bachanas, P
AF Seth, Puja
Kidder, Daniel
Pals, Sherri
Parent, Julie
Mbatia, Redempta
Chesang, Kipruto
Mbilinyi, Deogratius
Koech, Emily
Nkingwa, Mathias
Katuta, Frieda
Ng'ang'a, Anne
Bachanas, Pamela
TI Psychosocial Functioning and Depressive Symptoms Among HIV-Positive
Persons Receiving Care and Treatment in Kenya, Namibia, and Tanzania
SO PREVENTION SCIENCE
LA English
DT Article
DE Depression; Psychosocial; Health; HIV-positive; Africa
ID SUB-SAHARAN AFRICA; SELF-REPORTED ADHERENCE; CD4 CELL COUNT;
SOUTH-AFRICA; MENTAL-HEALTH; ALCOHOL-USE; ANTIRETROVIRAL THERAPY;
INFECTED INDIVIDUALS; DISEASE PROGRESSION; PARTNER VIOLENCE
AB In sub-Saharan Africa, the prevalence of depressive symptoms among people living with HIV (PLHIV) is considerably greater than that among members of the general population. It is particularly important to treat depressive symptoms among PLHIV because they have been associated with poorer HIV care-related outcomes. This study describes overall psychosocial functioning and factors associated with depressive symptoms among PLHIV attending HIV care and treatment clinics in Kenya, Namibia, and Tanzania. Eighteen HIV care and treatment clinics (six per country) enrolled approximately 200 HIV-positive patients (for a total of 3,538 participants) and collected data on patients' physical and mental well-being, medical/health status, and psychosocial functioning. Although the majority of participants did not report clinically significant depressive symptoms (72 %), 28 % reported mild to severe depressive symptoms, with 12 % reporting severe depressive symptoms. Regression models indicated that greater levels of depressive symptoms were associated with: (1) being female, (2) younger age, (3) not being completely adherent to HIV medications, (4) likely dependence on alcohol, (5) disclosure to three or more people (versus one person), (6) experiences of recent violence, (7) less social support, and (8) poorer physical functioning. Participants from Kenya and Namibia reported greater depressive symptoms than those from Tanzania. Approximately 28 % of PLHIV reported clinically significant depressive symptoms. The scale-up of care and treatment services in sub-Saharan Africa provides an opportunity to address psychosocial and mental health needs for PLHIV as part of comprehensive care.
C1 [Seth, Puja; Kidder, Daniel; Pals, Sherri; Bachanas, Pamela] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Parent, Julie; Katuta, Frieda] Minist Hlth & Social Serv, Windhoek, Namibia.
[Mbatia, Redempta] Tanzania Hlth Promot Support, Dar Es Salaam, Tanzania.
[Chesang, Kipruto] US Ctr Dis Control & Prevent, Nairobi, Kenya.
[Mbilinyi, Deogratius] US Ctr Dis Control & Prevent, Dar Es Salaam, Tanzania.
[Koech, Emily] ICAP, Nairobi, Kenya.
[Nkingwa, Mathias] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania.
[Ng'ang'a, Anne] Minist Hlth & Social Welf, Nairobi, Kenya.
RP Seth, P (reprint author), US Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, 1600 Clifton Rd,MS E04, Atlanta, GA 30333 USA.
EM pseth@cdc.gov
FU Intramural CDC HHS [CC999999]; PEPFAR
NR 62
TC 5
Z9 5
U1 1
U2 7
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-4986
EI 1573-6695
J9 PREV SCI
JI Prev. Sci.
PD JUN
PY 2014
VL 15
IS 3
BP 318
EP 328
DI 10.1007/s11121-013-0420-8
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH7AB
UT WOS:000336283200007
PM 23868419
ER
PT J
AU Knight, KR
Das, M
DeMicco, E
Raiford, JL
Matheson, T
Shook, A
Antunez, E
Santos, GM
Dadasovich, R
Dilley, JW
Colfax, GN
Herbst, JH
AF Knight, Kelly R.
Das, Moupali
DeMicco, Erin
Raiford, Jerris L.
Matheson, Tim
Shook, Alic
Antunez, Erin
Santos, Glenn-Milo
Dadasovich, Rand
Dilley, James W.
Colfax, Grant N.
Herbst, Jeffrey H.
TI A Roadmap for Adapting an Evidence-Based HIV Prevention Intervention:
Personal Cognitive Counseling (PCC) for Episodic Substance-Using Men Who
Have Sex with Men
SO PREVENTION SCIENCE
LA English
DT Article
DE HIV prevention; Evidence-based intervention; Adaptation; Episodic
substance use; MSM
ID UNPROTECTED ANAL INTERCOURSE; GAY MEN; BISEXUAL MEN; RISK BEHAVIORS;
METHAMPHETAMINE USE; CONTROLLED-TRIAL; SELF-EFFICACY; AIDS;
TRANSMISSION; DEPENDENCE
AB Episodic (less than weekly) drug use and binge drinking increase HIV-related sexual risk behaviors among men who have sex with men (MSM), yet no evidence-based interventions exist for these men. We describe an adaptation process of the Personalized Cognitive Counseling (PCC) intervention for utilization with high-risk, HIV-negative episodic, substance-using MSM. Participants (N = 59) were racially diverse, and reported unprotected anal intercourse and concurrent binge drinking (85 %), use of poppers (36 %), methamphetamine (20 %) and cocaine (12 %). Semi-structured interviews with 20 episodic, substance-using MSM elicited sexual narratives for engaging in unprotected anal intercourse while using alcohol or drugs. Emergent qualitative themes were translated into self-justifications and included in a revised PCC self-justification elicitation instrument (SJEI). The adapted SJEI was pretested with 19 episodic, substance-using MSM, and the final adapted PCC was pilot-tested for acceptability and feasibility with 20 episodic, substance-using MSM. This process can be used as a roadmap for adapting PCC for other high-risk populations of MSM.
C1 [Knight, Kelly R.] Univ Calif San Francisco, Dept Anthropol Hist & Social Med, San Francisco, CA 94143 USA.
[Das, Moupali; DeMicco, Erin; Matheson, Tim; Shook, Alic; Antunez, Erin; Santos, Glenn-Milo; Dadasovich, Rand; Colfax, Grant N.] San Francisco Dept Publ Hlth, HIV Prevent Sect, Subst Use Res Unit, San Francisco, CA USA.
[Dilley, James W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Dilley, James W.] San Francisco Gen Hosp, San Francisco, CA 94110 USA.
[Raiford, Jerris L.; Herbst, Jeffrey H.] CDC, Prevent Res Branch, Div HIV AIDS Prevent, NCHHSTP, Atlanta, GA 30333 USA.
RP Knight, KR (reprint author), Univ Calif San Francisco, Dept Anthropol Hist & Social Med, 3333 Calif St,Suite 485, San Francisco, CA 94143 USA.
EM kelly.knight@ucsf.edu
FU Intramural CDC HHS [CC999999]; NCHHSTP CDC HHS [UR6PS000684, UR6
PS000684]
NR 55
TC 8
Z9 8
U1 3
U2 9
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-4986
EI 1573-6695
J9 PREV SCI
JI Prev. Sci.
PD JUN
PY 2014
VL 15
IS 3
BP 364
EP 375
DI 10.1007/s11121-013-0364-z
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH7AB
UT WOS:000336283200011
PM 23412947
ER
PT J
AU Pearce, BD
Kruszon-Moran, D
Jones, JL
AF Pearce, Brad D.
Kruszon-Moran, Deanna
Jones, Jeffrey L.
TI The association of Toxoplasma gondii infection with neurocognitive
deficits in a population-based analysis
SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
LA English
DT Article
DE Infection; Cognition; Neuroimmunology; Population-based study
ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; NEUROBEHAVIORAL
TEST-PERFORMANCE; RISK-FACTORS; COGNITIVE FUNCTION; BEHAVIORAL-CHANGES;
TRAFFIC ACCIDENTS; KYNURENIC ACID; UNITED-STATES; NHANES-III
AB To examine the relationship between infection with Toxoplasma gondii (toxo) and cognition.
Multivariate logistic regression was used to test the association of toxo seropositivity with indices of cognitive function among over 4,200 adults in the third National Health and Nutrition Examination Survey.
Toxo-seropositive participants were more likely than seronegative participants to score in the worst quartile of the simple reaction time test (OR 1.3, 95 % CI 1.0, 1.6), symbol-digit substitution test (SDST, OR 1.5, 95 % CI 1.2, 1.9) and the serial-digit learning test (trials to criterion) (SDLTNT, OR 1.4, 95 % CI 1.1, 1.8) in models adjusted for age, race/ethnicity, gender and foreign birth. After further adjustment for all cofactors, the association between toxo seropositivity and these outcomes was no longer significant. However, seropositivity was associated with worse scores on the SDST (OR 2.9, 95 % CI 1.8, 4.8) among those in the lowest income category and the SDLTNT (OR 1.5, 95 % CI 1.1, 2.5) among those foreign born.
Toxo seropositivity may be associated with poor cognitive test scores in certain subgroups; however, causation cannot be established in this cross-sectional study.
C1 [Pearce, Brad D.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Kruszon-Moran, Deanna] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
[Jones, Jeffrey L.] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Pearce, BD (reprint author), Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, 1518-002-3BB, Atlanta, GA 30322 USA.
EM bpearce@emory.edu
FU National Institutes of Health (National Institute of Mental Health,
National Institute of Child Health and Human Development); March of
Dimes; NARSAD; Emory Neuroscience Initiative
FX We thank Dr. Nancy Bliwise for helpful input on the early phase of this
project and Dr. Myfawny Hopkins for her critical reading of the
manuscript. Dr. Pearce reports grant support from the National
Institutes of Health (National Institute of Mental Health, National
Institute of Child Health and Human Development), The March of Dimes,
NARSAD, and the Emory Neuroscience Initiative.
NR 39
TC 8
Z9 8
U1 3
U2 12
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0933-7954
EI 1433-9285
J9 SOC PSYCH PSYCH EPID
JI Soc. Psychiatry Psychiatr. Epidemiol.
PD JUN
PY 2014
VL 49
IS 6
BP 1001
EP 1010
DI 10.1007/s00127-014-0820-5
PG 10
WC Psychiatry
SC Psychiatry
GA AH7BR
UT WOS:000336287900016
PM 24477344
ER
PT J
AU Kosa, KM
Cates, SC
Hall, AJ
Brophy, JE
Frasier, A
AF Kosa, Katherine M.
Cates, Sheryl C.
Hall, Aron J.
Brophy, Jenna E.
Frasier, Angela
TI Knowledge of norovirus prevention and control among infection
preventionists
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Survey; Core competency
ID UNITED-STATES; DISEASE; GASTROENTERITIS; EFFICACY
AB A Web-based survey was administered to infection preventionists (IPs) (N = 941) to characterize awareness and knowledge of norovirus (NoV). Only 44% of respondents correctly identified NoV as one of the 3 most common foodborne pathogens in the United States, and 5% correctly identified the 3 most common settings for NoV outbreaks. Several gaps in IPs' knowledge of NoV were identified; specifically, IPs could benefit from learning more about the natural history of NoV, modes of transmission, and cleaning and disinfection processes. Copyright (C) 2014 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Kosa, Katherine M.; Cates, Sheryl C.; Brophy, Jenna E.] RTI Int, Food & Nutr Policy Res, Res Triangle Pk, NC 27709 USA.
[Hall, Aron J.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
[Frasier, Angela] Clemson Univ, Dept Food Nutr & Packaging Sci, Clemson, SC USA.
RP Kosa, KM (reprint author), RTI Int, Food & Nutr Policy Res, 3040 Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA.
EM kkosa@rti.org
FU Agriculture and Food Research Initiative (AFRI) Competitive Grant from
the US Department of Agriculture, National Institute of Food and
Agriculture [2011-68003-30395]; Association for Professionals in
Infection Control and Epidemiology Research Program
FX Supported by the Agriculture and Food Research Initiative (AFRI)
Competitive Grant No. 2011-68003-30395 from the US Department of
Agriculture, National Institute of Food and Agriculture, and by the
Association for Professionals in Infection Control and Epidemiology
Research Program.
NR 14
TC 2
Z9 2
U1 1
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD JUN
PY 2014
VL 42
IS 6
BP 676
EP 678
DI 10.1016/j.ajic.2014.02.004
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AH1UB
UT WOS:000335905500022
PM 24837119
ER
PT J
AU Ruch-Ross, HS
Zapata, LB
Williams, JL
Ruhl, C
AF Ruch-Ross, Holly S.
Zapata, Lauren B.
Williams, Jennifer L.
Ruhl, Catherine
TI General influenza infection control policies and practices during the
2009 H1N1 influenza pandemic: A survey of women's health, obstetric, and
neonatal nurses
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Hospital policy and practice; H1N1 pandemic; Labor and delivery;
Hospital nursery; CDC guidance
ID APRIL-MAY 2009; CARE WORKERS; UNITED-STATES; PREGNANT-WOMEN; SOUTHERN
CALIFORNIA; VIRUS-INFECTIONS; VACCINATION; PERSONNEL; ILLNESS;
TRANSMISSION
AB Background: An evaluation of infection control practices was conducted following the release of the Centers for Disease Control and Prevention (CDC) guidance regarding the care of pregnant women during the 2009 H1N1 influenza pandemic. This paper describes 9 general hospital practices.
Methods: A questionnaire was distributed electronically to 12,612 members of the Association of Women's Health, Obstetric, and Neonatal Nurses (AWHONN). Respondents (N = 2,304) who reported working in obstetric or neonatal settings during the pandemic completed the questionnaire.
Results: Most (73%) respondents considered the Centers for Disease Control and Prevention's guidance very useful. Significantly more reported a written hospital policy for each practice during versus before the pandemic. Six of the 9 practices were implemented most of the time by at least 70% of respondents; the practices least often implemented were mandatory vaccination of health care personnel involved (52%) and not involved (34%) in direct patient care and offering vaccination to close contacts of newborns prior to discharge (22%). The most consistent factor associated with implementation was the presence of a written policy supporting the practice at the respondent's hospital.
Conclusion: We offer a descriptive account of general hospital infection control policies and practices during the 2009 H1N1 pandemic. Factors associated with reported implementation may be useful to inform planning to protect women and children for future public health emergencies. Copyright (C) 2014 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Zapata, Lauren B.; Williams, Jennifer L.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Ruhl, Catherine] Assoc Womens Hlth Obstetr & Neonatal Nurses, Washington, DC USA.
RP Ruch-Ross, HS (reprint author), 9345 Avers Ave, Evanston, IL 60203 USA.
EM hruchross@aol.com
FU Intramural CDC HHS [CC999999]
NR 34
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD JUN
PY 2014
VL 42
IS 6
BP E65
EP E70
DI 10.1016/j.ajic.2014.02.022
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AH1UB
UT WOS:000335905500001
PM 24837128
ER
PT J
AU Botelho, JC
Ribera, A
Cooper, HC
Vesper, HW
AF Botelho, Julianne Cook
Ribera, Ashley
Cooper, Hans C.
Vesper, Hubert W.
TI CDC Standardization Programs - Testosterone, Estradiol, and Vitamin D
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Botelho, Julianne Cook; Ribera, Ashley; Cooper, Hans C.; Vesper, Hubert W.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA SAT-0265
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805106006
ER
PT J
AU Boehme, AK
McGwin, G
Andes, DR
Lyon, GM
Chiller, T
Pappas, PG
Baddley, JW
AF Boehme, Amelia K.
McGwin, Gerald
Andes, David R.
Lyon, G. Marshall
Chiller, Tom
Pappas, Peter G.
Baddley, John W.
TI RACE AND INVASIVE FUNGAL INFECTION IN SOLID ORGAN TRANSPLANT RECIPIENTS
SO ETHNICITY & DISEASE
LA English
DT Article
DE Invasive Fungal Infection; Solid Organ Transplant; Aspergillosis;
Candidiasis; Cryptococcosis
ID SURVEILLANCE NETWORK TRANSNET; LIVER-TRANSPLANTATION; ETHNIC
DISPARITIES; RISK-FACTORS; COCCIDIOIDOMYCOSIS; SURVIVAL; ACCESS
AB Health disparities in access to solid organ transplantation (SOT) and graft survival are well recognized, but there are limited data on the relationship of race to risk of invasive fungal infection (IFI) among SOT recipients. We conducted a case-control study using data from the Transplant-Associated Infection Surveillance Network (TRANSNET) to investigate race and IFI. Cases (n=1,214) and controls (n=16,550) were compared on demographic variables using chi-square, and the relationship between race and IFI was assesses with unconditional logistic regression. Compared to White transplant patients, Blacks had similar odds of developing IFI (OR=.97, 95% CI 0.82-1.15, P=.7125), while participants who identified as other ethnicity were less likely to develop IFI (OR=.56, 95% CI .41-.75, P<.001). Blacks, when compared to White patients, were at increased odds of developing cryptococcal infection (OR 2.19, 95%CI 1.35-3.54, P=.002). Despite pharmacogenetic differences, Black transplant recipients were not more likely overall to develop IFI compared to White transplant recipients.
C1 [Boehme, Amelia K.] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA.
[Andes, David R.] Univ Wisconsin, Madison, WI 53706 USA.
[Lyon, G. Marshall] Emory Univ, Sch Med, Atlanta, GA 30322 USA.
[Chiller, Tom] Ctr Dis Control, Atlanta, GA 30333 USA.
[Pappas, Peter G.; Baddley, John W.] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA.
[Baddley, John W.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
RP Baddley, JW (reprint author), Univ Alabama Birmingham, Div Infect Dis, 1900 Univ Blvd,THT 229, Birmingham, AL 35294 USA.
EM jbaddley@uab.edu
FU CDC; Astellas; Pfizer; Merck; Schering Plough
FX TRANSNET was sponsored by the CDC, Astellas, Pfizer, Merck, and Schering
Plough. We would like to thank the following TRANSNET Investigators:
Barbara Alexander, MD, Duke University; Elias Anaissie, MD, University
of Arkansas; Michael Boeckh, MD, Fred Hutchinson Cancer Research Center;
Janice Brown, MD, Stanford University; Lisa Brumble, MD, Mayo
Clinic-Jacksonville; Alison Freifeld, MD, University of Nebraska; Yoav
Golan, MD, and Susan Hadley, MD, Tufts University; Loreen Herwaldt, MD,
University of Iowa; James Ito, MD, City of Hope National Medical Center;
Carol Kauffman, MD, University of Michigan; Katherine Knapp, MD, St.
Jude Children's Hospital; Dimitrios Kontoyiannis, MD, MD Anderson Cancer
Center; Kieren Marr, MD and Trish Perl, MD, Johns Hopkins Medical
Institute; Vicki Morrison, MD, University of Minnesota; Genovefa
Papanicolaou, MD, Memorial Sloan-Kettering Cancer Center; Tom Patterson,
MD, University of Texas HSC-San Antonio; Mindy Schuster, MD, University
of Pennsylvania; Randall Walker, MD, Mayo Clinic-Rochester; Tom Walsh,
MD, Weill Cornell Medical College; John Wingard, MD, University of
Florida.
NR 17
TC 1
Z9 1
U1 0
U2 0
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
EI 1945-0826
J9 ETHNIC DIS
JI Ethn. Dis.
PD SUM
PY 2014
VL 24
IS 3
BP 382
EP 385
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CU7KT
UT WOS:000363717300018
PM 25065083
ER
PT J
AU Moreno-Madrinan, MJ
Crosson, WL
Eisen, L
Estes, SM
Estes, MG
Hayden, M
Hemmings, SN
Irwin, DE
Lozano-Fuentes, S
Monaghan, AJ
Quattrochi, D
Welsh-Rodriguez, CM
Zielinski-Gutierrez, E
AF Moreno-Madrinan, Max J.
Crosson, William L.
Eisen, Lars
Estes, Sue M.
Estes, Maurice G., Jr.
Hayden, Mary
Hemmings, Sarah N.
Irwin, Dan E.
Lozano-Fuentes, Saul
Monaghan, Andrew J.
Quattrochi, Dale
Welsh-Rodriguez, Carlos M.
Zielinski-Gutierrez, Emily
TI Correlating Remote Sensing Data with the Abundance of Pupae of the
Dengue Virus Mosquito Vector, Aedes aegypti, in Central Mexico
SO ISPRS INTERNATIONAL JOURNAL OF GEO-INFORMATION
LA English
DT Article
DE MODIS; TRMM; DEM; Aqua; remote sensing; elevation; mosquito; rainfall;
temperature
ID LIFE TABLE MODEL; RIO-DE-JANEIRO; CLIMATE-CHANGE; INFECTIOUS-DISEASES;
HELMINTH INFECTIONS; POTENTIAL INFLUENCE; BORNE DISEASES; UNITED-STATES;
HUMAN HEALTH; VARIABILITY
AB Using a geographic transect in Central Mexico, with an elevation/climate gradient, but uniformity in socio-economic conditions among study sites, this study evaluates the applicability of three widely-used remote sensing (RS) products to link weather conditions with the local abundance of the dengue virus mosquito vector, Aedes aegypti (Ae. aegypti). Field-derived entomological measures included estimates for the percentage of premises with the presence of Ae. aegypti pupae and the abundance of Ae. aegypti pupae per premises. Data on mosquito abundance from field surveys were matched with RS data and analyzed for correlation. Daily daytime and nighttime land surface temperature (LST) values were obtained from Moderate Resolution Imaging Spectroradiometer (MODIS)/Aqua cloud-free images within the four weeks preceding the field survey. Tropical Rainfall Measuring Mission (TRMM)-estimated rainfall accumulation was calculated for the four weeks preceding the field survey. Elevation was estimated through a digital elevation model (DEM). Strong correlations were found between mosquito abundance and RS-derived night LST, elevation and rainfall along the elevation/climate gradient. These findings show that RS data can be used to predict Ae. aegypti abundance, but further studies are needed to define the climatic and socio-economic conditions under which the correlations observed herein can be assumed to apply.
C1 [Moreno-Madrinan, Max J.] Indiana Univ, IUPUI, Fairbanks Sch Publ Hlth, Dept Environm Hlth, Indianapolis, IN 46202 USA.
[Crosson, William L.; Hemmings, Sarah N.] USRA, Inst Sci & Technol, Huntsville, AL 35805 USA.
[Eisen, Lars; Lozano-Fuentes, Saul] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
[Estes, Sue M.; Estes, Maurice G., Jr.] Univ Alabama, Earth & Syst Sci Ctr, Huntsville, AL 35805 USA.
[Hayden, Mary; Monaghan, Andrew J.] Natl Ctr Atmospher Res, Res Applicat Lab, Boulder, CO 80307 USA.
[Hemmings, Sarah N.] NASA Headquarters, Div Earth Sci, Appl Sci Program, Washington, DC 20024 USA.
[Irwin, Dan E.; Quattrochi, Dale] NASA Marshall Space Flight Ctr, Earth Sci, Huntsville, AL 35811 USA.
[Welsh-Rodriguez, Carlos M.] Veracruz Univ, Ctr Earth Sci, Xalapa 91090, Veracruz, Mexico.
[Zielinski-Gutierrez, Emily] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA.
RP Moreno-Madrinan, MJ (reprint author), Indiana Univ, IUPUI, Fairbanks Sch Publ Hlth, Dept Environm Hlth, Indianapolis, IN 46202 USA.
EM mmorenom@iu.edu; bill.crosson@nasa.gov; lars.eisen@colostate.edu;
sue.m.estes@nasa.gov; maury.estes@nsstc.uah.edu; monaghan@ucar.edu;
sarah.n.hemmings@nasa.gov; daniel.irwin@nasa.gov;
saul.lozano-fuentes@colostate.edu; mhayden@ucar.edu;
dale.quattrochi@nasa.gov; cwelsh@uv.mx; Ebz0@cdc.gov
OI Monaghan, Andrew/0000-0002-8170-2359
FU National Aeronautic and Space Administration (NASA); National Science
Foundation (NSF); NASA through ROSES: Earth Science Applications
Feasibility Studies: Public Health [A.31]; NASA [10-PHFEAS10-0010]; NSF
[GEO-1010204]; SERVIR
FX This study was funded by grants from the National Aeronautic and Space
Administration (NASA) and the National Science Foundation (NSF). The
NASA funds were granted through ROSES-2010: Earth Science Applications
Feasibility Studies: Public Health (A.31); and to the Applied Earth
Sciences group at the Marshall Space Flight Center (MSFC)
(10-PHFEAS10-0010). The NSF funds were granted to the University
Corporation for Atmospheric Research (GEO-1010204). The National Center
for Atmospheric Research is partially funded by NSF. A partial
contribution was provided by an appointment to the NASA Postdoctoral
Program at the Marshall Space Flight Center/National Space Science and
Technology Center/NASA Global Hydrology and Climate Center in
Huntsville, AL, USA; administered by Oak Ridge Associated Universities
through a contract with NASA. We express our appreciation to Douglas
Rickman and Mohammad Z. Al-Hamdan for their guidance in the processing
of remote sensing applications, as well as to SERVIR for providing
logistics and support. We thank Gina Wade for helping with the proposal.
We also thank Carolina Ochoa-Martinez and Berenice Tapia-Santos for
running the field teams and to Kevin Kobylinski and Chris Uejio for
helping out in the field. Lastly but not the least we thank the students
from Veracruz University who helped with the field work completing the
survey and collecting the in situ data.
NR 61
TC 1
Z9 2
U1 2
U2 11
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2220-9964
J9 ISPRS INT J GEO-INF
JI ISPRS Int. Geo-Inf.
PD JUN
PY 2014
VL 3
IS 2
BP 732
EP 749
DI 10.3390/ijgi3020732
PG 18
WC Geography, Physical; Remote Sensing
SC Physical Geography; Remote Sensing
GA CO1RO
UT WOS:000358933100018
ER
PT J
AU Kershaw, KN
Brenes, GA
Charles, LE
Coday, M
Daviglus, ML
Denburg, NL
Kroenke, CH
Safford, MM
Savla, T
Tindle, HA
Tinker, LF
Van Horn, L
AF Kershaw, Kiarri N.
Brenes, Gretchen A.
Charles, Luenda E.
Coday, Mace
Daviglus, Martha L.
Denburg, Natalie L.
Kroenke, Candyce H.
Safford, Monika M.
Savla, Tina
Tindle, Hilary A.
Tinker, Lesley F.
Van Horn, Linda
TI Associations of Stressful Life Events and Social Strain With Incident
Cardiovascular Disease in the Women's Health Initiative
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE cardiovascular diseases; epidemiology; stress
AB Background-Epidemiologic studies have yielded mixed findings on the association of psychosocial stressors with cardiovascular disease (CVD) risk. In this study, we examined associations of stressful life events (SLE) and social strain with incident coronary heart disease (CHD) and stroke (overall, and for hemorrhagic and ischemic strokes) independent of sociodemographic characteristics, and we evaluated whether these relationships were explained by traditional behavioral and biological risk factors.
Methods and Results-Data from approximately 82 000 Women's Health Initiative Observational Study participants were used for the SLE and social strain analyses, respectively. Participants were followed for events for up to 18.0 years (median, 14.0). Separate Cox proportional hazards models were generated to estimate associations of each stress measure with incident CVD. After adjusting for sociodemographic characteristics and depressive symptoms, higher SLE and social strain were associated with higher incident CHD and stroke (each P trend <0.05). Hazard ratios and 95% confidence intervals were 1.12 (1.01, 1.25) for incident CHD and 1.14 (1.01, 1.28) for incident stroke among participants reporting high versus low SLE. Findings were similar for social strain. Associations were attenuated with further adjustment for mediating behavioral and biological risk factors. Findings were similar for associations of SLE with ischemic stroke and hemorrhagic stroke, but social strain was only associated with ischemic stroke.
Conclusions-Higher SLE and social strain were associated with higher incident CVD independent of sociodemographic factors and depressive symptoms, but not behavioral and biological risk factors.
C1 [Kershaw, Kiarri N.; Daviglus, Martha L.; Van Horn, Linda] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
[Brenes, Gretchen A.] Wake Forest Sch Med, Dept Psychiat, Winston Salem, NC USA.
[Charles, Luenda E.] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Morgantown, WV USA.
[Coday, Mace] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA.
[Coday, Mace] Univ Tennessee, Ctr Hlth Sci, Dept Psychiat, Memphis, TN 38163 USA.
[Daviglus, Martha L.] Univ Illinois, Dept Med, Chicago, IL USA.
[Denburg, Natalie L.] Univ Iowa, Carver Coll Med, Dept Neurol, Des Moines, IA USA.
[Kroenke, Candyce H.] Kaiser Permanente, Div Res, Oakland, CA USA.
[Safford, Monika M.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Savla, Tina] Virginia Polytech Inst & State Univ, Dept Human Dev, Blacksburg, VA 24061 USA.
[Tindle, Hilary A.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA.
[Tinker, Lesley F.] Fred Hutchinson Canc Res Ctr, Womens Hlth Initiat, Seattle, WA 98104 USA.
RP Kershaw, KN (reprint author), Northwestern Univ, 680 N Lake Shore Dr,Suite 1400, Chicago, IL 60611 USA.
EM k-kershaw@northwestern.edu
RI Savla, Jyoti/J-7125-2015
OI Savla, Jyoti/0000-0001-7142-3770
FU NIH [N01-HC-95164]; National Heart, Lung and Blood Institute, National
Institutes of Health, U.S. Department of Health and Human Services
[HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]
FX Dr Kershaw is funded by NIH grant N01-HC-95164. The WHI program is
funded by the National Heart, Lung and Blood Institute, National
Institutes of Health, U.S. Department of Health and Human Services
through contracts HHSN268201100046C, HHSN268201100001C,
HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and
HHSN271201100004C.
NR 37
TC 8
Z9 9
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JUN
PY 2014
VL 3
IS 3
AR e000687
DI 10.1161/JAHA.113.000687
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA V41RD
UT WOS:000209562400015
PM 24973226
ER
PT J
AU Sieber, WK
Robinson, CF
Birdsey, J
Chen, GX
Hitchcock, EM
Lincoln, JE
Nakata, A
Sweeney, MH
AF Sieber, W. Karl
Robinson, Cynthia F.
Birdsey, Jan
Chen, Guang X.
Hitchcock, Edward M.
Lincoln, Jennifer E.
Nakata, Akinori
Sweeney, Marie H.
TI Obesity and other risk factors: The National Survey of U.S. Long-Haul
Truck Driver Health and Injury
SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE
LA English
DT Article
DE work practices; survey; risk factor; health; intervention; truck driver;
surveillance
ID PHYSICAL-ACTIVITY; INDUSTRY WORKERS; ACCIDENT RISK; UNITED-STATES;
POPULATION; MORTALITY; DISEASES; ADULTS
AB Background
Drivers of heavy and tractor-trailer trucks accounted for 56% of all production and nonsupervisory employees in the truck transportation industry in 2011. There are limited data for illness and injury in long-haul truck drivers, which prompted a targeted national survey.
Methods
Interviewers collected data during 2010 from 1,670 long-haul truck drivers at 32 truck stops across the 48 contiguous United States that were used to compute prevalence estimates for self-reported health conditions and risk factors.
Results
Obesity (69% vs. 31%, P < 0.01) and current smoking (51% vs. 19%, P < 0.01) were twice as prevalent in long-haul truck drivers as in the 2010 U.S. adult working population. Sixty-one percent reported having two or more of the risk factors: hypertension, obesity, smoking, high cholesterol, no physical activity, 6 or fewer hours of sleep per 24-hr period.
Conclusion
Survey findings suggest a need for targeted interventions and continued surveillance for long-haul truck drivers. Am. J. Ind. Med. 57:615-626, 2014. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
C1 [Sieber, W. Karl; Robinson, Cynthia F.; Birdsey, Jan; Sweeney, Marie H.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
[Chen, Guang X.; Lincoln, Jennifer E.] NIOSH, Div Safety Res, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA.
[Hitchcock, Edward M.] NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
[Nakata, Akinori] Univ Occupat & Environm Hlth, Sch Hlth Sci, Fukuoka, Japan.
RP Sieber, WK (reprint author), NIOSH, MSR 17,4476 Columbia Pkwy, Cincinnati, OH 45226 USA.
EM wsieber@cdc.gov
FU National Institute for Occupational Safety and Health; Federal Motor
Carrier Safety Administration, U.S. Department of Transportation
FX This work was supported by the National Institute for Occupational
Safety and Health with partial funding from the Federal Motor Carrier
Safety Administration, U.S. Department of Transportation. We wish to
thank Albert Alvarez, Rebecca Brewster, Dale Belman, Michael Belzer,
LaMont Byrd, Gerald Donaldson, Eric Garshick, Jim Helmkamp, Gerald
Krueger, Scott Madar, Anne McCartt, Stephanie Pratt, Roger Rosa, Andy
Schaudt, John Sestito, Aaron Sussell, Thomas Weakley, Martin Walker, Ann
Williamson, and Eric Wood for their helpful comments and/or guidance in
development of our survey and questionnaire. Teri Jacobs, Hovi Nguyen
and Matthew Groenewold prepared maps. We in particular wish to thank the
participating truck stops and drivers without whom this data collection
would not have been possible. Westat Inc. provided data collection and
statistical support. The findings and conclusions in this report are
those of the author(s) and do not necessarily represent the views of the
National Institute for Occupational Safety and Health.
NR 65
TC 37
Z9 37
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0271-3586
EI 1097-0274
J9 AM J IND MED
JI Am. J. Ind. Med.
PD JUN
PY 2014
VL 57
IS 6
BP 615
EP 626
DI 10.1002/ajim.22293
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AG4JU
UT WOS:000335386600001
PM 24390804
ER
PT J
AU Steege, AL
Boiano, JM
Sweeney, MH
AF Steege, Andrea L.
Boiano, James M.
Sweeney, Marie H.
TI NIOSH Health and Safety Practices Survey of Healthcare Workers: Training
and awareness of employer safety procedures
SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE
LA English
DT Article
DE self-report; healthcare worker; web-based survey; employer safe handling
procedures; training; cognitive testing; professional practice
organization
ID PROTECTION; EXPOSURE
AB Background
The Health and Safety Practices Survey of Healthcare Workers describes current practices used to minimize chemical exposures and barriers to using recommended personal protective equipment for the following: antineoplastic drugs, anesthetic gases, high level disinfectants, surgical smoke, aerosolized medications (pentamidine, ribavirin, and antibiotics), and chemical sterilants.
Methods
Twenty-one healthcare professional practice organizations collaborated with NIOSH to develop and implement the web-based survey.
Results
Twelve thousand twenty-eight respondents included professional, technical, and support occupations which routinely come in contact with the targeted hazardous chemicals. Chemical-specific safe handling training was lowest for aerosolized antibiotics (52%, n = 316), and surgical smoke (57%, n = 4,747). Reported employer procedures for minimizing exposure was lowest for surgical smoke (32%, n = 4,746) and anesthetic gases (56%, n = 3,604).
Conclusions
Training and having procedures in place to minimize exposure to these chemicals is one indication of employer and worker safety awareness. Safe handling practices for use of these chemicals will be reported in subsequent papers. Am. J. Ind. Med. 57:640-652, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Steege, Andrea L.; Boiano, James M.; Sweeney, Marie H.] NIOSH, Surveillance Branch, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA.
RP Steege, AL (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,MSR 18, Cincinnati, OH 45226 USA.
EM asteege@cdc.gov
RI Steege, Andrea/H-8900-2016
OI Steege, Andrea/0000-0001-5665-2559
FU National Institute for Occupational Safety and Health
FX Contract grant sponsor: National Institute for Occupational Safety and
Health.
NR 26
TC 13
Z9 13
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0271-3586
EI 1097-0274
J9 AM J IND MED
JI Am. J. Ind. Med.
PD JUN
PY 2014
VL 57
IS 6
BP 640
EP 652
DI 10.1002/ajim.22305
PG 13
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AG4JU
UT WOS:000335386600003
PM 24549581
ER
PT J
AU Lara, J
Purdy, MA
Khudyakov, YE
AF Lara, James
Purdy, Michael A.
Khudyakov, Yury E.
TI Genetic host specificity of hepatitis E virus
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Hepatitis E virus; Prediction; HEV ORFs; Adaptation; Bayesian network;
Coevolution
ID RISK-FACTORS; C VIRUS; ZOONOTIC TRANSMISSION; DRUG-RESISTANCE;
INFECTION; GENOTYPE; CHINA; EPIDEMIOLOGY; SEQUENCE; NETWORKS
AB Hepatitis E virus (HEV) causes epidemic and sporadic cases of hepatitis worldwide. HEV genotypes 3 (HEV3) and 4 (HEV4) infect humans and animals, with swine being the primary reservoir. The relevance of HEV genetic diversity to host adaptation is poorly understood. We employed a Bayesian network (BN) analysis of HEV3 and HEV4 to detect epistatic connectivity among protein sites and its association with the host specificity in each genotype. The data imply coevolution among similar to 70% of polymorphic sites from all HEV proteins and association of numerous coevolving sites with adaptation to swine or humans. BN models for individual proteins and domains of the nonstructural polyprotein detected the host origin of HEV strains with accuracy of 74-93% and 63-87%, respectively. These findings, taken together with lack of phylogenetic association to host, suggest that the HEV host specificity is a heritable and convergent phenotypic trait achievable through variety of genetic pathways (abundance), and explain a broad host range for HEV3 and HEV4. Published by Elsevier B.V.
C1 [Lara, James; Purdy, Michael A.; Khudyakov, Yury E.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA.
RP Lara, J (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA.
EM jlara@cdc.gov
NR 69
TC 5
Z9 5
U1 1
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JUN
PY 2014
VL 24
BP 127
EP 139
DI 10.1016/j.meegid.2014.03.011
PG 13
WC Infectious Diseases
SC Infectious Diseases
GA AG4GG
UT WOS:000335376800015
PM 24667049
ER
PT J
AU Roebling, AD
Johnson, D
Blanton, JD
Levin, M
Slate, D
Fenwick, G
Rupprecht, CE
AF Roebling, A. D.
Johnson, D.
Blanton, J. D.
Levin, M.
Slate, D.
Fenwick, G.
Rupprecht, C. E.
TI Rabies Prevention and Management of Cats in the Context of
Trap-Neuter-Vaccinate-Release Programmes
SO ZOONOSES AND PUBLIC HEALTH
LA English
DT Article
DE trap; release; vaccination; Cat; TNR
ID FELINE IMMUNODEFICIENCY VIRUS; UNITED-STATES; FERAL CATS;
TOXOPLASMA-GONDII; POSTEXPOSURE PROPHYLAXIS; LEUKEMIA-VIRUS; DOMESTIC
CATS; RETURN; POPULATIONS; EPIDEMIOLOGY
AB Domestic cats are an important part of many Americans' lives, but effective control of the 60-100 million feral cats living throughout the country remains problematic. Although trap-neuter-vaccinate-return (TNVR) programmes are growing in popularity as alternatives to euthanizing feral cats, their ability to adequately address disease threats and population growth within managed cat colonies is dubious. Rabies transmission via feral cats is a particular concern as demonstrated by the significant proportion of rabies post-exposure prophylaxis associated with exposures involving cats. Moreover, TNVR has not been shown to reliably reduce feral cat colony populations because of low implementation rates, inconsistent maintenance and immigration of unsterilized cats into colonies. For these reasons, TNVR programmes are not effective methods for reducing public health concerns or for controlling feral cat populations. Instead, responsible pet ownership, universal rabies vaccination of pets and removal of strays remain integral components to control rabies and other diseases.
C1 [Roebling, A. D.; Johnson, D.; Blanton, J. D.; Levin, M.; Rupprecht, C. E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Slate, D.] US Anim & Plant Hlth Inspect Serv, USDA, Wildlife Serv, Manchester, NH USA.
[Fenwick, G.] Amer Bird Conservancy, The Plains, VA USA.
RP Blanton, JD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS G33, Atlanta, GA 30333 USA.
EM Asi5@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 41
TC 2
Z9 2
U1 3
U2 34
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1863-1959
EI 1863-2378
J9 ZOONOSES PUBLIC HLTH
JI Zoonoses Public Health
PD JUN
PY 2014
VL 61
IS 4
BP 290
EP 296
DI 10.1111/zph.12070
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases;
Veterinary Sciences
SC Public, Environmental & Occupational Health; Infectious Diseases;
Veterinary Sciences
GA AF4JP
UT WOS:000334678400008
PM 23859607
ER
PT J
AU Ayinmode, AB
Zhang, H
Dada-Adegbola, HO
Xiao, L
AF Ayinmode, A. B.
Zhang, H.
Dada-Adegbola, H. O.
Xiao, L.
TI Cryptosporidium hominis Subtypes and Enterocytozoon bieneusi Genotypes
in HIV-Infected Persons in Ibadan, Nigeria
SO ZOONOSES AND PUBLIC HEALTH
LA English
DT Article
DE microsporidiosis; cryptosporidiosis; diarrhoea; Enterocytozoon bieneusi;
HIV; opportunistic infection; epidemiology; Cryptosporidium
ID ACTIVE ANTIRETROVIRAL THERAPY; INTESTINAL MICROSPORIDIOSIS; PERU;
HIV/AIDS; DIARRHEA; VIRUS; HAART; LIMA
AB Cryptosporidium and Enterocytozoon are common opportunistic pathogens in HIV+ patients in developing countries, especially those do not have access to antiretroviral therapy. To determine the distribution of genotypes/subtypes of Cryptosporidium and Enterocytozoon bieneusi, faecal specimens were collected from 132 HIV+ persons attending a tertiary hospital in Ibadan, Nigeria. By polymerase chain reaction, eight and ten patients were identified as positive for Cryptosporidium spp. and E.bieneusi, respectively. Seven of the Cryptosporidium specimens were identified as C.hominis, while the remaining one as the new species C.viatorum recently identified in the United Kingdom. DNA sequencing of the 60-kDa glycoprotein gene showed that the C.hominis belonged to three common subtype families: Ia (in three patients), Ib (in one patient) and Ie (in one patient). In contrast, DNA sequencing of the E.bieneusi internal transcribed spacer products showed the occurrence of genotypes associated with both humans (Peru 8 in one patient, Nig2 in two patients and a new genotype in one patient) and animals (D in one patient and Type IV in five patients). Low CD4+ cell count was identified as a risk factor for both cryptosporidiosis and microsporidiosis.
C1 [Ayinmode, A. B.] Univ Ibadan, Dept Vet Microbiol & Parasitol, Fac Vet Med, Ibadan, Nigeria.
[Zhang, H.] Henan Ctr Dis Prevent & Control, Inst Parasite Dis Prevent & Control, Zhengzhou, Peoples R China.
[Dada-Adegbola, H. O.] Univ Coll Hosp, Dept Med Microbiol & Parasitol, Ibadan, Nigeria.
[Xiao, L.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA.
RP Xiao, L (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Mail Stop D66,1600 Clifton Rd, Atlanta, GA 30329 USA.
EM lxiao@cdc.gov
RI Xiao, Lihua/B-1704-2013
OI Xiao, Lihua/0000-0001-8532-2727
FU PEP-FAR Grant
FX We thank Dele Ajayi and Awoyemi E. J. Awosanya for technical assistance.
This work was supported in part by PEP-FAR 2010 Grant to the University
of Ibadan. The findings and conclusions in this report are those of the
authors and do not necessarily represent the views of the Centers for
Disease Control and Prevention.
NR 28
TC 7
Z9 7
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1863-1959
EI 1863-2378
J9 ZOONOSES PUBLIC HLTH
JI Zoonoses Public Health
PD JUN
PY 2014
VL 61
IS 4
BP 297
EP 303
DI 10.1111/zph.12072
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases;
Veterinary Sciences
SC Public, Environmental & Occupational Health; Infectious Diseases;
Veterinary Sciences
GA AF4JP
UT WOS:000334678400009
PM 23870732
ER
PT J
AU Henning, T
Butler, K
Mitchell, J
Ellis, S
Deyounks, F
Farshy, C
Phillips, C
Papp, J
Patton, D
Caldwell, H
Sturdevant, G
McNicholl, J
Kersh, E
AF Henning, Tara
Butler, Katherine
Mitchell, James
Ellis, Shanon
Deyounks, Frank
Farshy, Carol
Phillips, Christi
Papp, John
Patton, Dorothy
Caldwell, Harlan
Sturdevant, Gail
McNicholl, Janet
Kersh, Ellen
TI Development of a rectal sexually transmitted infection - HIV coinfection
model utilizing Chlamydia trachomatis and SHIVSF162p3
SO JOURNAL OF MEDICAL PRIMATOLOGY
LA English
DT Article
DE men who have sex with men; STD
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NEISSERIA-GONORRHOEAE; NONHUMAN-PRIMATES;
MACAQUE MODEL; GENITAL-TRACT; TRANSMISSION; SEX; MEN; TENOFOVIR; SYSTEM
AB BackgroundRectal sexually transmitted infections (STIs) may increase HIV susceptibility in men who have sex with men (MSM), and Chlamydia trachomatis is prevalent among HIV-positive MSM. To study STIs and HIV infection in MSM, we first evaluated whether cynomolgus macaques can sustain both C.trachomatis and SHIVSF162p3 infections(.)
MethodsFour SHIVSF162p3-positive male cynomolgus macaques were used (n=3 rectally inoculated with 10(6) IFU; n=1 control). Systemic and rectal SHIV RNA levels and cytokines were measured by real-time PCR and Luminex assays, respectively.
ResultsMacaques were successfully Chlamydia infected. Rectal SHIV shedding (P=0.02 (2)) and levels of G-CSF, IL-1ra, IL-6, IL-8, IFN-, and TNF- (P0.01, Mann-Whitney) in rectal secretions increased following infection.
ConclusionsThese pilot data successfully demonstrate rectal C.trachomatis-SHIV coinfection in cynomolgus macaques and suggest the feasibility of a rectal C.trachomatis model for SHIV susceptibility and biomedical prevention studies in the context of rectal STIs.
C1 [Henning, Tara; Butler, Katherine; Mitchell, James; Ellis, Shanon; Deyounks, Frank; McNicholl, Janet; Kersh, Ellen] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
[Farshy, Carol; Phillips, Christi; Papp, John] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA.
[Patton, Dorothy] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA.
[Caldwell, Harlan; Sturdevant, Gail] NIAID, Intracellular Parasites Lab, Rocky Mt Labs, NIH, Hamilton, MT USA.
RP Kersh, E (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS A-25, Atlanta, GA 30333 USA.
EM ekersh@cdc.gov
FU CDC [Y1-A1-0681-02]; NIH [Y1-A1-0681-02]
FX The authors thank Dr. John Brooks and Dr. Pragna Patel for advisement on
rectal pathogens. The authors thank Patty Guenthner for her assistance
with macaques' SHIV infection data from the previous titration study.
This work was funded by CDC and an interagency agreement (Y1-A1-0681-02)
between CDC and NIH.
NR 27
TC 3
Z9 3
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0047-2565
EI 1600-0684
J9 J MED PRIMATOL
JI J. Med. Primatol.
PD JUN
PY 2014
VL 43
IS 3
BP 135
EP 143
DI 10.1111/jmp.12103
PG 9
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA AF2EF
UT WOS:000334524700001
PM 24460742
ER
PT J
AU Haider, N
Rahman, MS
Khan, SU
Mikolon, A
Gurley, ES
Osmani, MG
Shanta, IS
Paul, SK
Macfarlane-Berry, L
Islam, A
Desmond, J
Epstein, JH
Daszak, P
Azim, T
Luby, SP
Zeidner, N
Rahman, MZ
AF Haider, N.
Rahman, M. S.
Khan, S. U.
Mikolon, A.
Gurley, E. S.
Osmani, M. G.
Shanta, I. S.
Paul, S. K.
Macfarlane-Berry, L.
Islam, A.
Desmond, J.
Epstein, J. H.
Daszak, P.
Azim, T.
Luby, S. P.
Zeidner, N.
Rahman, M. Z.
TI Identification and Epidemiology of a Rare HoBi-Like Pestivirus Strain in
Bangladesh
SO TRANSBOUNDARY AND EMERGING DISEASES
LA English
DT Article
DE BVDV-3; HoBi-like pestivirus; Bangladesh; cattle
ID VIRAL DIARRHEA VIRUS; INFECTION; SUBSTITUTIONS; CATTLE
AB The genus pestivirus of the family flaviviridae consists of four recognized species: bovine viral diarrhoea virus 1 (BVDV-1), bovine viral diarrhoea virus 2 (BVDV-2), classical swine fever virus and border disease virus. A new putative pestivirus species tentatively named as either 'HoBi-like pestivirus' or BVDV-3 has recently been identified in Brazil, Italy and Thailand. Despite reports of serological evidence of BVDV in Bangladesh, the types of the virus circulating in cattle have not been identified. We conducted surveillance in cattle from May 2009 to August 2010 in three government veterinary hospitals to characterize BVDV in cattle of Bangladesh. We tested serum for BVDV using an antigen-capture ELISA. Of 638 cattle samples, 3% (16/638) tested positive for BVDV antigen. The ELISA-positive samples were selected for further molecular detection and characterization of BVDV. Molecular analysis of the partial 5 ' untranslated region (UTR) nucleotide sequences of BVDV-positive samples identified the rare HoBi-like pestivirus or BVDV-3 virus circulating in cattle of Bangladesh. The identification of this rare HoBi-like pestivirus or BVDV-3 strain in Bangladesh warrants further surveillance to evaluate its impact on livestock production.
C1 [Haider, N.; Rahman, M. S.; Khan, S. U.; Gurley, E. S.; Shanta, I. S.; Paul, S. K.; Macfarlane-Berry, L.; Azim, T.; Luby, S. P.; Zeidner, N.; Rahman, M. Z.] Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh.
[Khan, S. U.] Univ Florida, Coll Publ Hlth & Hlth Profess, Gainesville, FL USA.
[Mikolon, A.] USDA, Hawthorne, CA USA.
[Osmani, M. G.] Minist Fisheries, Dept Livestock Serv, Dhaka, Bangladesh.
[Osmani, M. G.] Minist Livestock, Dept Livestock Serv, Dhaka, Bangladesh.
[Islam, A.; Desmond, J.; Epstein, J. H.; Daszak, P.] EcoHlth Alliance, New York, NY USA.
[Luby, S. P.] Stanford Univ, Stanford, CA 94305 USA.
[Zeidner, N.] US Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Rahman, MZ (reprint author), Icddr B, Ctr Communicable Dis, Virol Lab, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.
EM mzrahman@icddrb.org
RI Haider, Najmul/F-6083-2015; Gurley, Emily/B-7903-2010;
OI Haider, Najmul/0000-0002-5980-3460; Gurley, Emily/0000-0002-8648-9403;
Luby, Stephen/0000-0001-5385-899X
FU Google; Rockefeller foundation through EcoHealth Alliance
FX This research was funded by Google and the Rockefeller foundation
through EcoHealth Alliance. icddr,b acknowledges with gratitude the
commitment of Google and the Rockefeller foundation to its research
efforts. We acknowledge the Department of Livestock Services (DLS) of
Bangladesh and the veterinarians Dr. Asma-Al-Hoseneara and Dr. Rashidul
Hoque and Dr. Shama Ranjan Barua from DLS, Dr. Abdul Mannan and Dr.
Shahneaz Ali Khan, from Chittagong Veterinary and Animal Sciences
University, and Tahmina Sultana from icddr, b who were involved with
this project. We are grateful to Ms. Diana DiazGranados, icddr, b, for
her constructive support in editing this manuscript.
NR 25
TC 12
Z9 15
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1865-1674
EI 1865-1682
J9 TRANSBOUND EMERG DIS
JI Transbound. Emerg. Dis.
PD JUN
PY 2014
VL 61
IS 3
BP 193
EP 198
DI 10.1111/tbed.12218
PG 6
WC Infectious Diseases; Veterinary Sciences
SC Infectious Diseases; Veterinary Sciences
GA AE9BH
UT WOS:000334298300001
PM 24650238
ER
PT J
AU Kostova, D
Andes, L
Erguder, T
Yurekli, A
Keskinkilic, B
Polat, S
Culha, G
Kilinc, EA
Tasti, E
Ersahin, Y
Ozmen, M
San, R
Ozcebe, H
Bilir, N
Asma, S
AF Kostova, Deliana
Andes, Linda
Erguder, Toker
Yurekli, Ayda
Keskinkilic, Bekir
Polat, Sertac
Culha, Gonul
Kilinc, Evin Aras
Tasti, Enver
Ersahin, Yilmaz
Ozmen, Mehmet
San, Ramazan
Ozcebe, Hilal
Bilir, Nazmi
Asma, Samira
TI Cigarette Prices and Smoking Prevalence After a Tobacco Tax Increase -
Turkey, 2008 and 2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Kostova, Deliana; Andes, Linda; Asma, Samira] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Erguder, Toker; Yurekli, Ayda] WHO, CH-1211 Geneva, Switzerland.
[Keskinkilic, Bekir; Polat, Sertac; Culha, Gonul; Kilinc, Evin Aras] Turkey Minist Hlth, Ankara, Turkey.
[Keskinkilic, Bekir; Polat, Sertac; Culha, Gonul; Kilinc, Evin Aras] Turkey Minist Hlth, Ankara, Turkey.
[Tasti, Enver; Ersahin, Yilmaz; Ozmen, Mehmet; San, Ramazan] Turkish Stat Inst, Ankara, Turkey.
[Ozcebe, Hilal; Bilir, Nazmi] Hacettepe Univ, Inst Publ Hlth, Ankara, Turkey.
RP Kostova, D (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM kiv0@cdc.gov
NR 7
TC 8
Z9 8
U1 0
U2 8
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 30
PY 2014
VL 63
IS 21
BP 457
EP 461
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI5OD
UT WOS:000336917400002
PM 24871250
ER
PT J
AU Ritchey, MD
Wall, HK
Gillespie, C
George, MG
Jamal, A
AF Ritchey, Matthew D.
Wall, Hilary K.
Gillespie, Cathleen
George, Mary G.
Jamal, Ahmed
TI Million Hearts: Prevalence of Leading Cardiovascular Disease Risk
Factors - United States, 2005-2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID PROGRESS; GOAL
C1 [Ritchey, Matthew D.; Wall, Hilary K.; Gillespie, Cathleen; George, Mary G.] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Jamal, Ahmed] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Ritchey, MD (reprint author), CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM mritchey@cdc.gov
NR 10
TC 12
Z9 12
U1 0
U2 3
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 30
PY 2014
VL 63
IS 21
BP 462
EP 467
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI5OD
UT WOS:000336917400003
PM 24871251
ER
PT J
AU Moturi, EK
Porter, KA
Wassilak, SGF
Tangermann, RH
Diop, OM
Burns, CC
Jafari, H
AF Moturi, Edna K.
Porter, Kimberly A.
Wassilak, Steven G. F.
Tangermann, Rudolf H.
Diop, Ousmane M.
Burns, Cara C.
Jafari, Hamid
TI Progress Toward Polio Eradication - Worldwide, 2013-2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Moturi, Edna K.] CDC, Atlanta, GA 30333 USA.
[Porter, Kimberly A.; Wassilak, Steven G. F.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Tangermann, Rudolf H.; Diop, Ousmane M.; Jafari, Hamid] WHO, Polio Eradicat Dept, Geneva, Switzerland.
[Burns, Cara C.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Moturi, EK (reprint author), CDC, Atlanta, GA 30333 USA.
EM emoturi@cdc.gov
RI Moturi, Edna/P-2835-2015
OI Moturi, Edna/0000-0002-1694-1476
NR 9
TC 38
Z9 38
U1 1
U2 10
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 30
PY 2014
VL 63
IS 21
BP 468
EP 472
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI5OD
UT WOS:000336917400004
PM 24871252
ER
PT J
AU Naleway, AL
Irving, SA
Henninger, ML
Li, DK
Shifflett, P
Ball, S
Williams, JL
Cragan, J
Gee, J
Thompson, MG
AF Naleway, Allison L.
Irving, Stephanie A.
Henninger, Michelle L.
Li, De-Kun
Shifflett, Pat
Ball, Sarah
Williams, Jennifer L.
Cragan, Janet
Gee, Julianne
Thompson, Mark G.
CA Vaccine Safety Datalink Pregnancy
TI Safety of influenza vaccination during pregnancy: A review of subsequent
maternal obstetric events and findings from two recent cohort studies
SO VACCINE
LA English
DT Review
DE Pregnancy; Influenza vaccine; Safety; Obstetric outcomes
ID GESTATIONAL DIABETES-MELLITUS; H1N1 INFLUENZA; WOMEN; OUTCOMES;
CHORIOAMNIONITIS; HYPERTENSION; DELIVERY; RISKS
AB Pregnant women and their infants are vulnerable to severe disease and secondary complications from influenza infection. For this reason, annual influenza vaccination is recommended for all pregnant women in the United States. Women frequently cite concerns about vaccine safety as a barrier to vaccination. This review describes the safety of inactivated influenza vaccination during pregnancy with a focus on maternal obstetric events, including hypertensive disorders, gestational diabetes, and chorioamnionitis. Included in the review are new findings from two studies which examined the safety of seasonal inactivated influenza vaccination during pregnancy. The first study enrolled 641 pregnant women during the 2010-2011 season and prospectively followed them until delivery or pregnancy termination. The second study enrolled 1616 pregnant women during the 2010-2011 influenza season, and followed the women and their infants for six months after delivery. No associations between inactivated influenza vaccination and gestational diabetes, gestational hypertension, preeclampsia/eclampsia, or chorioamnionitis were observed in either cohort. When considered as a whole, these studies should further reassure women and clinicians that influenza vaccination during pregnancy is safe for mothers. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Naleway, Allison L.; Irving, Stephanie A.; Henninger, Michelle L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR 97227 USA.
[Li, De-Kun] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA.
[Shifflett, Pat; Ball, Sarah] Abt Associates Inc, Cambridge, MA 02138 USA.
[Williams, Jennifer L.; Cragan, Janet; Gee, Julianne; Thompson, Mark G.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Naleway, AL (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA.
EM allison.naleway@kpchr.org; stephanie.irving@kpchr.org;
michelle.henninger@kpchr.org; de-kun.li@kp.org;
pat_shifflett@abtassoc.com; sarah_ball@abtassoc.com; znv8@cdc.gov;
jdc9@cdc.gov; dzg2@cdc.gov; isq8@cdc.gov
OI Naleway, Allison/0000-0001-5747-4643; Irving,
Stephanie/0000-0001-7437-6797; Shay, David/0000-0001-9619-4820
FU Centers for Disease Control and Prevention through America's Health
Insurance Plans [200-2010-F-33132, 200-2002-00732]
FX This work was supported by the Centers for Disease Control and
Prevention (contract 200-2010-F-33132 through Abt Associates and
contract 200-2002-00732 through America's Health Insurance Plans).
Conflict of interest: The findings and conclusions reported in this
article are those of the authors and do not necessarily represent the
views of CDC, Abt Associates, AHIP, or Kaiser Foundation Research
Institute. Each author reviewed and approved the final version of the
article. A.N. reports receiving research funding from GlaxoSmithKline
for an unrelated study. None of the remaining authors report any
conflicts of interest.
NR 40
TC 16
Z9 16
U1 2
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 30
PY 2014
VL 32
IS 26
BP 3122
EP 3127
DI 10.1016/j.vaccine.2014.04.021
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI4YL
UT WOS:000336872500002
PM 24742490
ER
PT J
AU Gessner, BD
Feikin, DR
AF Gessner, Bradford D.
Feikin, Daniel R.
TI Vaccine preventable disease incidence as a complement to vaccine
efficacy for setting vaccine policy
SO VACCINE
LA English
DT Review
DE Cholera; Epidemiology; Haemophilus influenzae type b; Hib; Immunization;
Malaria; Rotavirus; RTS,S; Pneumococcus; Streptococcus pneumoniae;
Vaccine; Vaccine efficacy; Vaccine effectiveness
ID PLACEBO-CONTROLLED TRIAL; DEVELOPING-COUNTRIES; ROTAVIRUS VACCINE;
CONJUGATE VACCINE; DOUBLE-BLIND; CHILDREN; POPULATION; PREVALENCE;
PNEUMONIA; INFLUENZA
AB Traditionally, vaccines have been evaluated in clinical trials that establish vaccine efficacy (VE) against etiology-confirmed disease outcomes, a measure important for licensure. Yet, VE does not reflect a vaccine's public health impact because it does not account for relative disease incidence. An additional measure that more directly establishes a vaccine's public health value is the vaccine preventable disease incidence (VPDI), which is the incidence of disease preventable by vaccine in a given context. We describe how VE and VPDI can vary, sometimes in inverse directions, across disease outcomes and vaccinated populations. We provide examples of how VPDI can be used to reveal the relative public health impact of vaccines in developing countries, which can be masked by focus on VE alone. We recommend that VPDI be incorporated along with VE into the analytic plans of vaccine trials, as well as decisions by funders, ministries of health, and regulatory authorities. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Gessner, Bradford D.] Agence Med Prevent, F-75015 Paris, France.
[Feikin, Daniel R.] Johns Hopkins Sch Publ Hlth, Dept Int Hlth, Int Vaccine Access Ctr, Baltimore, MD USA.
[Feikin, Daniel R.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
RP Gessner, BD (reprint author), Agence Med Prevent, 164 Rue Vaugirard, F-75015 Paris, France.
EM bgessner@aamp.org; dfeikin@jhsph.edu
FU Intramural CDC HHS [CC999999]
NR 24
TC 10
Z9 10
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 30
PY 2014
VL 32
IS 26
BP 3133
EP 3138
DI 10.1016/j.vaccine.2014.04.019
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI4YL
UT WOS:000336872500004
PM 24731817
ER
PT J
AU Lu, PJ
O'Halloran, A
Ding, HL
Williams, WW
Bridges, CB
Kennedy, ED
AF Lu, Peng-jun
O'Halloran, Alissa
Ding, Helen
Williams, Walter W.
Bridges, Carolyn B.
Kennedy, Erin D.
TI National and state-specific estimates of place of influenza vaccination
among adult populations - United States, 2011-12 influenza season
SO VACCINE
LA English
DT Article
DE Influenza vaccination; Place of influenza vaccination; Medical setting;
Nonmedical setting; Behavioral Risk Factor Surveillance System (BRFSS)
ID IMMUNIZATION PRACTICES; PROJECT VIVA; COVERAGE; HEALTH
AB Background: Annual influenza vaccination has been recommended for all persons >= 6 months since the 2010-11 season. New partnerships between public health agencies and medical and nonmedical vaccination providers have increased the number of vaccination providers and locations where vaccination services are delivered.
Methods: Data from the 2011-12 Behavioral Risk Factor Surveillance System (BRFSS) were analyzed. Point estimates of place of vaccination and 95% confidence intervals were calculated. Multivariable logistic regression and predictive marginal modeling were conducted to identify factors associated with vaccination settings.
Results: Among adults vaccinated during the 2011-12 influenza season, a doctor's office was the most common place (38.4%) for receipt of influenza vaccination, with stores (e.g., supermarkets or drug stores) (20.1%) the next common, and workplaces (17.6%) the third common. Overall, reported vaccination in nonmedical settings by state ranged from 32.2% in California to 60.4% in Nevada, with a median of 45.8%. Characteristics significantly associated with an increased likelihood of receipt of vaccination in nonmedical settings were higher education, not having certain identified high-risk conditions, not having had a routine checkup in the previous 12 months, and not having a primary doctor for health care. Being a member of a racial/ethnic minority group, unemployed or not in the work force were significantly associated with a decreased likelihood of receipt of vaccination in nonmedical settings.
Conclusion: Doctor's offices were the most common medical setting for adult influenza vaccination; workplaces and stores were important nonmedical settings. Increasing access to vaccination services in medical and nonmedical settings should be considered as important strategies for improving vaccination coverage. These results also can help guide development of strategies for achieving Healthy People 2020 objectives for influenza vaccination of adult populations. Published by Elsevier Ltd.
C1 [Lu, Peng-jun; O'Halloran, Alissa; Ding, Helen; Williams, Walter W.; Bridges, Carolyn B.; Kennedy, Erin D.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Lu, PJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Mail Stop A-19, Atlanta, GA 30333 USA.
EM lhp8@cdc.gov
NR 25
TC 14
Z9 16
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 30
PY 2014
VL 32
IS 26
BP 3198
EP 3204
DI 10.1016/j.vaccine.2014.04.003
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI4YL
UT WOS:000336872500013
PM 24731815
ER
PT J
AU Haberle, SG
Bowman, DMJS
Newnham, RM
Johnston, FH
Beggs, PJ
Buters, J
Campbell, B
Erbas, B
Godwin, I
Green, BJ
Huete, A
Jaggard, AK
Medek, D
Murray, F
Newbigin, E
Thibaudon, M
Vicendese, D
Williamson, GJ
Davies, JM
AF Haberle, Simon G.
Bowman, David M. J. S.
Newnham, Rewi M.
Johnston, Fay H.
Beggs, Paul J.
Buters, Jeroen
Campbell, Bradley
Erbas, Bircan
Godwin, Ian
Green, Brett J.
Huete, Alfredo
Jaggard, Alison K.
Medek, Danielle
Murray, Frank
Newbigin, Ed
Thibaudon, Michel
Vicendese, Don
Williamson, Grant J.
Davies, Janet M.
TI The Macroecology of Airborne Pollen in Australian and New Zealand Urban
Areas
SO PLOS ONE
LA English
DT Article
ID ANTHROPOGENIC CLIMATE-CHANGE; BIRCH POLLEN; GRASS-POLLEN; SEASONAL
DISTRIBUTION; EASTERN AUSTRALIA; NORTH-AMERICA; BETULA POLLEN;
ATMOSPHERE; EUROPE; SOUTH
AB The composition and relative abundance of airborne pollen in urban areas of Australia and New Zealand are strongly influenced by geographical location, climate and land use. There is mounting evidence that the diversity and quality of airborne pollen is substantially modified by climate change and land-use yet there are insufficient data to project the future nature of these changes. Our study highlights the need for long-term aerobiological monitoring in Australian and New Zealand urban areas in a systematic, standardised, and sustained way, and provides a framework for targeting the most clinically significant taxa in terms of abundance, allergenic effects and public health burden.
C1 [Haberle, Simon G.] Australian Natl Univ, Coll Asia & Pacific, Dept Archaeol & Nat Hist, Canberra, ACT, Australia.
[Bowman, David M. J. S.; Williamson, Grant J.] Univ Tasmania, Sch Plant Sci, Hobart, Tas, Australia.
[Newnham, Rewi M.] Victoria Univ Wellington, Sch Geog Environm & Earth Sci, Wellington, New Zealand.
[Johnston, Fay H.] Univ Tasmania, Menzies Res Inst Tasmania, Hobart, Tas, Australia.
[Beggs, Paul J.; Jaggard, Alison K.] Macquarie Univ, Fac Sci, Dept Geog & Environm, Sydney, NSW 2109, Australia.
[Buters, Jeroen] Tech Univ Munich, Ctr Allergy & Environm, D-80290 Munich, Germany.
[Campbell, Bradley; Godwin, Ian] Univ Queensland, Sch Agr & Food Sci, St Lucia, Qld, Australia.
[Erbas, Bircan; Vicendese, Don] La Trobe Univ, Sch Publ Hlth & Human Biosci, Bundoora, Vic, Australia.
[Green, Brett J.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA.
[Huete, Alfredo] Univ Technol Sydney, Sydney, NSW 2007, Australia.
[Medek, Danielle] Australian Natl Univ, Sch Med, Canberra, ACT, Australia.
[Murray, Frank] Murdoch Univ, Sch Environm Sci, Murdoch, WA 6150, Australia.
[Newbigin, Ed] Univ Melbourne, Sch Bot, Melbourne, Vic, Australia.
[Thibaudon, Michel] European Aerobiol Soc, Reseau Natl Surveillance Aerobiol, Lyon, Rhone Alpes, France.
[Davies, Janet M.] Univ Queensland, Sch Med, Lung & Allergy Res Ctr, Woolloongabba, Qld, Australia.
[Davies, Janet M.] Univ Queensland, Translat Res Inst, Woolloongabba, Qld, Australia.
RP Haberle, SG (reprint author), Australian Natl Univ, Coll Asia & Pacific, Dept Archaeol & Nat Hist, Canberra, ACT, Australia.
EM simon.haberle@anu.edu.au
RI Davies, Janet/C-7989-2009; Buters, Jeroen/G-5070-2011; Huete,
Alfredo/C-1294-2008; Bowman, David/A-2930-2011;
OI Huete, Alfredo/0000-0003-2809-2376; Bowman, David/0000-0001-8075-124X;
Haberle, Simon/0000-0001-5802-6535; Newbigin, Ed/0000-0002-9644-302X
FU Australian Centre for Ecological Analysis and Synthesis (ACEAS)
FX Funding support for the Working Group came from the Australian Centre
for Ecological Analysis and Synthesis (ACEAS). Terrestrial Ecosystem
Research Network ( TERN). Merck Sharp and Dohme provided additional
independent untied co-sponsorship for the Working Group. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 63
TC 10
Z9 10
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2014
VL 9
IS 5
AR e97925
DI 10.1371/journal.pone.0097925
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI3UR
UT WOS:000336790800015
PM 24874807
ER
PT J
AU Volkow, ND
Frieden, TR
Hyde, PS
Cha, SS
AF Volkow, Nora D.
Frieden, Thomas R.
Hyde, Pamela S.
Cha, Stephen S.
TI Medication-Assisted Therapies - Tackling the Opioid-Overdose Epidemic
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID DEATHS
C1 [Volkow, Nora D.] NIDA, NIH, Bethesda, MD 20892 USA.
[Hyde, Pamela S.] Subst Abuse & Mental Hlth Serv Adm, Rockville, MD USA.
[Cha, Stephen S.] Ctr Medicare Serv, Ctr Medicaid & CHIP Serv, Baltimore, MD USA.
[Cha, Stephen S.] Ctr Medicaid Serv, Ctr Medicaid & CHIP Serv, Baltimore, MD USA.
[Frieden, Thomas R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Volkow, ND (reprint author), NIDA, NIH, Bethesda, MD 20892 USA.
NR 5
TC 133
Z9 133
U1 3
U2 14
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 29
PY 2014
VL 370
IS 22
BP 2063
EP 2066
DI 10.1056/NEJMp1402780
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH9BM
UT WOS:000336434000003
PM 24758595
ER
PT J
AU Ma, JB
Cai, JZ
Ma, JW
Feng, YY
Xiao, LH
AF Ma, Jingbo
Cai, Jinzhong
Ma, Jiawen
Feng, Yaoyu
Xiao, Lihua
TI Occurrence and molecular characterization of Cryptosporidium spp. in
yaks (Bos grunniens) in China
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cryptosporidium; Qinghai; Yaks; 18S rRNA gene; Nested PCR; Genotype
ID COW-CALF OPERATIONS; DEER-LIKE GENOTYPE; DAIRY-CATTLE; BEEF-CALVES;
PREVALENCE; TRANSMISSION; INFECTION; DIARRHEA; QINGHAI; HEALTH
AB Compared with dairy and beef cattle, few data are available on the occurrence and distribution of Cryptosporidium species in yaks, which live in a very different habitat. In this study, 327 fecal specimens were collected from yaks in 4 counties in Qinghai Province of China and screened for Cryptosporidium by nested PCR analysis of the 18S rRNA gene. A total of 98 (30.0%) specimens were positive for Cryptosporidium. The occurrence of Cryptosporidium varied significantly among age groups; infection rates were 49.3% in weaned calves, 31.7% in yearlings, and 17.4% in adults. PCR products of all Cryptosporidium-positive specimens were successfully sequenced, with 56 specimens (57.1%) having C. bovis, 33 (33.7%) having C. ryanae, 2 (2.0%) having C. andersoni, 1 (1.0%) having C. ubiquitum, 1 (1.0%) having C xiaoi, 2 (2.0%) having a novel genotype, and 3 (3.1%) having mixed infections of C bovis and C ryanae. There were some age-related differences in the distribution of Cryptosporidium species in post-weaned yaks examined. To our knowledge, this is the first report of C. andersoni, C. ubiquitum, C xiaoi and a novel Cryptosporidium genotype in yaks. Published by Elsevier B.V.
C1 [Ma, Jingbo; Ma, Jiawen; Feng, Yaoyu] E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China.
[Cai, Jinzhong] Qinghai Acad Vet Med & Anim Sci, Xining 810016, Peoples R China.
[Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Xiao, LH (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
EM yyfeng@ecust.edu.cn; lxiao@cdc.gov
RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014
OI Xiao, Lihua/0000-0001-8532-2727;
FU National Natural Science Foundation of China [31110103901, 31229005];
National Special Fund for State Key Laboratory of Bioreactor Engineering
[2060204]; Fundamental Research Funds for the Central Universities,
China [WB1214073]
FX This work was supported by National Natural Science Foundation of China
(31110103901 and 31229005), National Special Fund for State Key
Laboratory of Bioreactor Engineering (No. 2060204), and Fundamental
Research Funds for the Central Universities, China (No. WB1214073).
NR 43
TC 12
Z9 16
U1 1
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY 28
PY 2014
VL 202
IS 3-4
BP 113
EP 118
DI 10.1016/j.vetpar.2014.03.030
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA AI4XT
UT WOS:000336870600004
PM 24768316
ER
PT J
AU Auld, AF
Ekra, KA
Shiraishi, RW
Tuho, MZ
Kouakou, JS
Mohamed, F
Ettiegne-Traore, V
Sabatier, J
Essombo, J
Adjorlolo-Johnson, G
Marlink, R
Ellerbrock, TV
AF Auld, Andrew F.
Ekra, Kunomboa A.
Shiraishi, Ray W.
Tuho, Moise Z.
Kouakou, Joseph S.
Mohamed, Fayama
Ettiegne-Traore, Virginie
Sabatier, Jennifer
Essombo, Joseph
Adjorlolo-Johnson, Georgette
Marlink, Richard
Ellerbrock, Tedd V.
TI Temporal Trends in Treatment Outcomes for HIV-1 and HIV-2-Infected
Adults Enrolled in Cote d'Ivoire's National Antiretroviral Therapy
Program
SO PLOS ONE
LA English
DT Article
ID SUB-SAHARAN AFRICA; REVERSE-TRANSCRIPTASE INHIBITORS; PHYSICIAN-PATIENT
RELATIONSHIPS; SCALE-UP; DRUG-RESISTANCE; INFECTED ADULTS; SOUTH-AFRICA;
COTRIMOXAZOLE PROPHYLAXIS; MULTIPLE IMPUTATION; FOOD INSECURITY
AB Background: In C (o) over cap te d'Ivoire during 2004-2007, numbers of ART enrollees increased from,5,000 to 36,943. Trends in nationally representative ART program outcomes have not yet been reported.
Methodology/Principal Findings: We conducted a retrospective chart review to assess trends in patient characteristics and attrition [death or loss to follow-up (LTFU)] over time, among a nationally representative sample of 3,682 adults (>= 15 years) initiating ART during 2004-2007 at 34 health facilities. Among ART enrollees during 2004-2007, median age was 36, the proportion female was 67%, the proportion HIV-2-infected or dually HIV-1&2 reactive was 5%, and median baseline CD4(+) T-cell (CD4) count was 135 cells/mu L. Comparing cohorts initiating ART in 2004 with cohorts initiating ART in 2007, median baseline weight declined from 55 kg to 52 kg (p = 0.008) and the proportion weighing <45 kg increased from 17% to 22% (p = 0.014). During 2004-2007, pharmacy-based estimates of the percentage of new ART enrollees >= 95% adherent to ART declined from 74% to 60% (p = 0.026), and twelve-month retention declined from 86% to 69%, due to increases in 12-month mortality from 2%-4% and LTFU from 12%-28%. In univariate analysis, year of ART initiation was associated with increasing rates of both LTFU and mortality. Controlling for baseline CD4, weight, adherence, and other risk factors, year of ART initiation was still strongly associated with LTFU but not mortality. In multivariate analysis, weight <45 kg and adherence <95% remained strong predictors of LTFU and mortality.
Conclusions: During 2004-2007, increasing prevalence among ART enrollees of measured mortality risk factors, including weight <45 kg and ART adherence <95%, might explain increases in mortality over time. However, the association between later calendar year and increasing LTFU is not explained by risk factors evaluated in this analysis. Undocumented transfers, political instability, and patient dissatisfaction with crowded facilities might explain increasing LTFU.
C1 [Auld, Andrew F.; Shiraishi, Ray W.; Sabatier, Jennifer; Ellerbrock, Tedd V.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA.
[Ekra, Kunomboa A.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Abidjan, Cote Ivoire.
[Tuho, Moise Z.; Ettiegne-Traore, Virginie] Minist Hlth, Natl Program Med Care Persons Living HIV AIDS, Abidjan, Cote Ivoire.
[Kouakou, Joseph S.; Mohamed, Fayama; Essombo, Joseph] Elizabeth Glaser Pediat AIDS Fdn, Abidjan, Cote Ivoire.
[Mohamed, Fayama] Directorate Gen Budget & Finance, Dept Econ & Finance, Abidjan, Cote Ivoire.
[Adjorlolo-Johnson, Georgette; Marlink, Richard] Elizabeth Glaser Pediat AIDS Fdn, Los Angeles, CA USA.
RP Auld, AF (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA.
EM aauld@cdc.gov
OI Auld, Andrew/0000-0001-5089-9163
FU President's Emergency Plan for AIDS Relief (PEPFAR) through the United
States Centers for Disease Control and Prevention (CDC)
FX This research has been supported by the President's Emergency Plan for
AIDS Relief (PEPFAR) (http://www.pepfar.gov/) through the United States
Centers for Disease Control and Prevention (CDC) (http://www.cdc.gov/).
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 78
TC 7
Z9 7
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 27
PY 2014
VL 9
IS 5
AR e98183
DI 10.1371/journal.pone.0098183
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI5NG
UT WOS:000336914100038
PM 24866468
ER
PT J
AU Miller, AH
Jones, JF
Drake, DF
Tian, H
Unger, ER
Pagnoni, G
AF Miller, Andrew H.
Jones, James F.
Drake, Daniel F.
Tian, Hao
Unger, Elizabeth R.
Pagnoni, Giuseppe
TI Decreased Basal Ganglia Activation in Subjects with Chronic Fatigue
Syndrome: Association with Symptoms of Fatigue
SO PLOS ONE
LA English
DT Article
ID DEEP-BRAIN-STIMULATION; INTERFERON-ALPHA; PARKINSONS-DISEASE;
FUNCTIONAL-ANATOMY; GLOBUS-PALLIDUS; DISORDERS; REWARD; CIRCUITS;
PATHOGENESIS; DEFINITION
AB Reduced basal ganglia function has been associated with fatigue in neurologic disorders, as well as in patients exposed to chronic immune stimulation. Patients with chronic fatigue syndrome (CFS) have been shown to exhibit symptoms suggestive of decreased basal ganglia function including psychomotor slowing, which in turn was correlated with fatigue. In addition, CFS patients have been found to exhibit increased markers of immune activation. In order to directly test the hypothesis of decreased basal ganglia function in CFS, we used functional magnetic resonance imaging to examine neural activation in the basal ganglia to a reward-processing (monetary gambling) task in a community sample of 59 male and female subjects, including 18 patients diagnosed with CFS according to 1994 CDC criteria and 41 non-fatigued healthy controls. For each subject, the average effect of winning vs. losing during the gambling task in regions of interest (ROI) corresponding to the caudate nucleus, putamen, and globus pallidus was extracted for group comparisons and correlational analyses. Compared to non-fatigued controls, patients with CFS exhibited significantly decreased activation in the right caudate (p = 0.01) and right globus pallidus (p = 0.02). Decreased activation in the right globus pallidus was significantly correlated with increased mental fatigue (r(2) = 0.49, p = 0.001), general fatigue (r(2) = 0.34, p = 0.01) and reduced activity (r(2) = 0.29, p = 0.02) as measured by the Multidimensional Fatigue Inventory. No such relationships were found in control subjects. These data suggest that symptoms of fatigue in CFS subjects were associated with reduced responsivity of the basal ganglia, possibly involving the disruption of projections from the globus pallidus to thalamic and cortical networks.
C1 [Miller, Andrew H.; Drake, Daniel F.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
[Jones, James F.; Tian, Hao; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Atlanta, GA USA.
[Pagnoni, Giuseppe] Univ Modena & Reggio Emilia, Dept Neurosci, Modena, Italy.
RP Miller, AH (reprint author), Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
EM amill02@emory.edu
RI Pagnoni, Giuseppe/F-3398-2015
OI Pagnoni, Giuseppe/0000-0002-8272-8091
FU Centers for Disease Control and Prevention
FX This study was funded by the Centers for Disease Control and Prevention.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 51
TC 8
Z9 8
U1 3
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 23
PY 2014
VL 9
IS 5
AR e98156
DI 10.1371/journal.pone.0098156
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI4ML
UT WOS:000336839400047
PM 24858857
ER
PT J
AU Nelson, NP
Murphy, TV
McMahon, BJ
AF Nelson, Noele P.
Murphy, Trudy V.
McMahon, Brian J.
TI Hepatitis A vaccination for post-exposure prophylaxis in persons aged 40
years and older
SO VACCINE
LA English
DT Letter
C1 [Nelson, Noele P.; Murphy, Trudy V.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Vaccine Res & Policy Team, Natl Ctr HIVAIDS Viral Hepatitis STD & TB Prevent, Atlanta, GA USA.
[McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Alaska Native Med Ctr, Anchorage, AK 99508 USA.
RP McMahon, BJ (reprint author), Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Alaska Native Med Ctr, Anchorage, AK 99508 USA.
EM nnelson@cdc.gov; tkm4@cdc.gov; bmcmahon@anthc.org
OI Nelson, Noele/0000-0001-9831-0717
FU Intramural CDC HHS [CC999999]
NR 4
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 23
PY 2014
VL 32
IS 25
BP 2939
EP 2939
DI 10.1016/j.vaccine.2014.01.086
PG 1
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI2UG
UT WOS:000336713000001
PM 24530928
ER
PT J
AU Daley, MF
Yih, WK
Glanz, JM
Hambidge, SJ
Narwaney, KJ
Yin, RH
Li, LL
Nelson, JC
Nordin, JD
Klein, NP
Jacobsen, SJ
Weintraub, E
AF Daley, Matthew F.
Yih, W. Katherine
Glanz, Jason M.
Hambidge, Simon J.
Narwaney, Komal J.
Yin, Ruihua
Li, Lingling
Nelson, Jennifer C.
Nordin, James D.
Klein, Nicola P.
Jacobsen, Steven J.
Weintraub, Eric
TI Safety of diphtheria, tetanus, acellular pertussis and inactivated
poliovirus (DTaP-IPV) vaccine
SO VACCINE
LA English
DT Article
DE Vaccine safety; Immunization; Vaccine; Surveillance; Diphtheria;
Tetanus; Acellular pertussis; Inactivated poliovirus combined vaccine
ID STEVENS-JOHNSON-SYNDROME; EVENT REPORTING SYSTEM; PROBABILITY RATIO
TEST; ADVERSE EVENTS; IMMUNIZATION SAFETY; ACTIVE SURVEILLANCE;
UNITED-STATES; RISK; CHILDREN; DATALINK
AB Background: In 2008, a diphtheria, tetanus, acellular pertussis, and inactivated poliovirus combined vaccine (DTaP-IPV) was licensed for use in children 4 through 6 years of age. While pre-licensure studies did not demonstrate significant safety concerns, the number vaccinated in these studies was not sufficient to examine the risk of uncommon but serious adverse events.
Objective: To assess the risk of serious adverse events following DTaP-IPV vaccination.
Methods: The study was conducted from January 2009 through September 2012 in the Vaccine Safety Datalink (VSD) project. In the VSD, electronic vaccination and encounter data are updated and aggregated weekly as part of ongoing surveillance activities. Based on previous reports and biologic plausibility, eight potential adverse events were monitored: meningitis/encephalitis; seizures; stroke; Guillain-Barre syndrome; Stevens-Johnson syndrome; anaphylaxis; serious allergic reactions other than anaphylaxis; and serious local reactions. Adverse event rates in DTaP-IPV recipients were compared to historical incidence rates in the VSD population prior to 2009. Sequential probability ratio testing was used to analyze the data on a weekly basis.
Results: During the study period, 201,116 children received DTaP-IPV vaccine. Ninety-seven percent of DTaP-IPV recipients also received other vaccines on the same day, typically measles-mumps-rubella and varicella vaccines. There was no statistically significant increased risk of any of the eight pre-specified adverse events among DTaP-IPV recipients when compared to historical incidence rates.
Conclusions: In this safety surveillance study of more than 200,000 DTaP-IPV vaccine recipients, there was no evidence of increased risk for any of the pre-specified adverse events monitored. Continued surveillance of DTaP-IPV vaccine safety may be warranted to monitor for rare adverse events, such as Guillain-Barre syndrome. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Daley, Matthew F.; Glanz, Jason M.; Hambidge, Simon J.; Narwaney, Komal J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80231 USA.
[Daley, Matthew F.; Hambidge, Simon J.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO 80045 USA.
[Yih, W. Katherine; Yin, Ruihua; Li, Lingling] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA.
[Yih, W. Katherine; Yin, Ruihua; Li, Lingling] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA.
[Hambidge, Simon J.] Denver Hlth, Community Hlth Serv, Denver, CO 80204 USA.
[Nelson, Jennifer C.] Grp Hlth Res Inst, Biostat Unit, Seattle, WA 98101 USA.
[Nelson, Jennifer C.] Univ Washington, Dept Biostat, Seattle, WA 98105 USA.
[Nordin, James D.] HealthPartners Inst Educ & Res, Minneapolis, MN 55440 USA.
[Klein, Nicola P.] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA.
[Jacobsen, Steven J.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.
[Weintraub, Eric] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA.
RP Daley, MF (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, 10065 E Harvard Ave 300, Denver, CO 80231 USA.
EM matthew.f.daley@kp.org; katherine_yih@harvardpilgrim.org;
jason.m.glanz@kp.org; simon.hambidge@dhha.org; komal.j.narwaney@kp.org;
ryin1000@yahoo.com; lingling_li@harvardpilgrim.org; nelson.jl@ghc.org;
james.d.nordin@healthpartner.scom; nicola.klein@kp.org;
steven.j.jacobsen@kp.org; eiw8@cdc.gov
OI Jacobsen, Steven/0000-0002-8174-8533
FU Vaccine Safety Surveillance and Assessment Projects [200-2002-00732];
American's Health Insurance Plans; Centers for Disease Control and
Prevention (CDC)
FX This study was supported through the Vaccine Safety Surveillance and
Assessment Projects contract (contract #200-2002-00732) with American's
Health Insurance Plans, funded by the Centers for Disease Control and
Prevention (CDC). CDC co-authors were involved in the design and conduct
of the study; collection, management, analysis, and interpretation of
the data; and review and approval of the manuscript.
NR 38
TC 6
Z9 6
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 23
PY 2014
VL 32
IS 25
BP 3019
EP 3024
DI 10.1016/j.vaccine.2014.03.063
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI2UG
UT WOS:000336713000016
PM 24699471
ER
PT J
AU Cotes-Cantillo, K
Paternina-Caicedo, A
Coronell-Rodriguez, W
Alvis-Guzman, N
Parashar, UD
Patel, M
De la Hoz-Restrepo, F
AF Cotes-Cantillo, Karol
Paternina-Caicedo, Angel
Coronell-Rodriguez, Wilfrido
Alvis-Guzman, Nelson
Parashar, Umesh D.
Patel, Manish
De la Hoz-Restrepo, Fernando
TI Effectiveness of the monovalent rotavirus vaccine in Colombia: A
case-control study
SO VACCINE
LA English
DT Article
DE Rotavirus; Vaccine; Diarrhea; Vaccine effectiveness
ID UNITED-STATES; EFFICACY; GASTROENTERITIS; CHILDREN; DISEASE; MORTALITY;
DIARRHEA; SAFETY
AB Objective: To assess the effectiveness of the monovalent rotavirus vaccine (RV1) to prevent rotavirus diarrhea admissions to emergency departments (ED) in Colombia.
Methods: A multicenter case-control study was carried out in six Colombian cities from 2011 to January, 2013. Cases were laboratory confirmed rotavirus diarrhea patients admitted to ED of selected health centers. Controls were patients with non-rotavirus diarrhea. Vaccination status was card-confirmed. Vaccine effectiveness and 95% confidence intervals (Cl) were calculated from the conditional logistic regression models using the formula 1 - adjusted odds ratio x 100.
Results: 1051 fecal samples were collected from 193 cases and 858 controls. Vaccination history was confirmed on 173 cases (90%) and 801 controls (93%). Among the rotavirus-positive samples with vaccination history, 57% were G2P[4], 9.8% G9P[8], 6% G9P[6]. Median age of cases (17 months) was greater than controls (15 months) (P < 0.001), and mothers of cases had lower level of education (P = 0.025). The adjusted effectiveness was 79.19% (95% CI, 23.7 to 94.32) among children 6-11 months of age and -39.75% (95% CI, -270.67 to 47.24) among those >12 months of age. Against overnight rotavirus hospitalizations, RV1 provided protection of 84.42% (95% CI, 22.68 to 96.86) among children 6-11 months of age, and -79.49% (95% CI, -555.8 to 51.08) among those >12 months.
Conclusions: RV1 provided significant protection against rotavirus hospitalization among children under 1 year of age in the Colombian setting. The observation of lower effectiveness in children >12 months requires further assessment. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Cotes-Cantillo, Karol; De la Hoz-Restrepo, Fernando] Univ Nacl Colombia, Bogota, Colombia.
[Paternina-Caicedo, Angel; Coronell-Rodriguez, Wilfrido; Alvis-Guzman, Nelson] Univ Cartagena, Grp Invest Econ Salud, Cartagena De Indias, Bolivar, Colombia.
[Parashar, Umesh D.; Patel, Manish] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Paternina-Caicedo, A (reprint author), Univ Cartagena, Fac Ciencias Econ, Sede Piedra Bolivar, Calle 30 48-152,Bloque B,Sotano 1, Cartagena De Indias, Bolivar, Colombia.
EM angel.paternina@gmail.com
RI Paternina-Caicedo, Angel/N-4496-2015
OI Paternina-Caicedo, Angel/0000-0002-6332-5174
FU Administrative Department of Science Technology and Innovation of
Colombia (COLCIENCIAS) [304]
FX This study was funded by Administrative Department of Science Technology
and Innovation of Colombia (COLCIENCIAS) through contract 304, 2010.
NR 24
TC 9
Z9 11
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 23
PY 2014
VL 32
IS 25
BP 3035
EP 3040
DI 10.1016/j.vaccine.2014.03.064
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI2UG
UT WOS:000336713000018
PM 24699470
ER
PT J
AU Khodyakov, D
Uscher-Pines, L
Lorick, SA
Lindley, MC
Shier, V
Harris, K
AF Khodyakov, Dmitry
Uscher-Pines, Lori
Lorick, Suchita A.
Lindley, Megan C.
Shier, Victoria
Harris, Katherine
TI A qualitative analysis of the impact of healthcare personnel influenza
vaccination requirements in California
SO VACCINE
LA English
DT Article
DE Health care personnel; Influenza vaccination; Mandatory vaccination;
State influenza vaccination requirements of healthcare personnel
ID INSTITUTIONAL REQUIREMENTS; UNITED-STATES; HOSPITALS; WORKERS; LAW
AB Objective: Using qualitative methods, we explored the implementation of California's 2007 influenza immunization requirements of hospital-based health care personnel (HCP).
Methods: We conducted nine case studies of California hospitals with different HCP vaccination rates and policies. Case studies consisted of interviewing 13 hospital representatives and analyzing relevant hospital documents, including influenza policies. We also conducted 13 semi-structured phone interviews with key state and county public health officials, union representatives, and officials of various professional healthcare organizations.
Results: Our qualitative results suggest that California's vaccination requirements likely did not increase influenza vaccination uptake among HCP. The law was not strong enough to compel hospitals with low and medium vaccination rates to improve their vaccination efforts, and hospitals with high vaccination rates were able to comply fully with the law by continuing to do what they were already doing - namely offering vaccinations to HCP, providing education about the risks of influenza and the benefits of vaccination, and obtaining signed declinations from those who refuse vaccination. Nonetheless, we found that by publicly raising the issue of influenza vaccination in the context of public safety and healthcare quality, California's law encouraged hospitals to develop and implement data systems to monitor the effectiveness of vaccination promotion efforts and prompted discussions, and, in some cases, adoption of stricter vaccination requirements at hospital or county levels.
Conclusions: Our findings generally support the literature that suggests that permissive influenza vaccination requirements, though politically feasible, provide little direct incentive for hospitals to focus efforts on increasing HCP vaccination rates. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Khodyakov, Dmitry; Shier, Victoria] RAND Corp, Santa Monica, CA 90401 USA.
[Uscher-Pines, Lori; Harris, Katherine] RAND Corp, Arlington, VA USA.
[Lorick, Suchita A.; Lindley, Megan C.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Khodyakov, D (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90401 USA.
EM Dmitry_Khodyakov@rand.org
FU Centers for Disease Control and Prevention [U01 IP000416]
FX This journal article was supported by the Cooperative Agreement Number
U01 IP000416 from the Centers for Disease Control and Prevention. Its
contents are solely the responsibility of the authors and do not
represent the official views of the Centers for Disease Control and
Prevention.
NR 41
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 23
PY 2014
VL 32
IS 25
BP 3082
EP 3087
DI 10.1016/j.vaccine.2013.06.077
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI2UG
UT WOS:000336713000024
PM 23845810
ER
PT J
AU Davila-Payan, C
Swann, J
Wortley, PM
AF Davila-Payan, Carlo
Swann, Julie
Wortley, Pascale M.
TI System factors to explain H1N1 state vaccination rates for adults in US
emergency response to pandemic
SO VACCINE
LA English
DT Article
DE Pandemic; Coverage; State-specific; Factors; Estimates; Adults
ID UNITED-STATES; INFLUENZA VACCINATION; WATER FLUORIDATION; TOOTH-DECAY;
PREDICTORS; COVERAGE; ACCEPTANCE; CHILDREN
AB Introduction: During the 2009-2010 H1N1 pandemic, vaccine in short supply was allocated to states pro rata by population, yet the vaccination rates of adults differed by state. States also differed in their campaign processes and decisions. Analyzing the campaign provides an opportunity to identify specific approaches that may result in higher vaccine uptake in a future event of this nature.
Objective: To determine supply chain and system factors associated with higher state H1N1 vaccination coverage for adults in a system where vaccine was in short supply.
Methods: Regression analysis of factors predicting state-specific H1N1 vaccination coverage in adults. Independent variables included state campaign information, demographics, preventive or health-seeking behavior, preparedness funding, providers, state characteristics, and H1N1-specific state data.
Results: The best model explained the variation in state-specific adult vaccination coverage with an adjusted R-squared of 0.76. We found that higher H1N1 coverage of adults is associated with program aspects including shorter lead-times (i.e., the number of days between when doses were allocated to a state and were shipped, including the time for states to order the doses) and less vaccine directed to specialist locations. Higher vaccination coverage is also positively associated with the maximum number of ship-to locations, past seasonal influenza vaccination coverage, the percentage of women with a Pap smear, the percentage of the population that is Hispanic, and negatively associated with a long duration of the epidemic peak.
Conclusion: Long lead-times may be a function of system structure or of efficiency and may suggest monitoring or redesign of distribution processes. Sending vaccine to sites with broad access could be useful when covering a general population. Existing infrastructure may be reflected in the maximum number of ship-to locations, so strengthening routine influenza vaccination programs may help during emergency vaccinations also. Future research could continue to inform program decisions. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
C1 [Davila-Payan, Carlo; Swann, Julie] Georgia Inst Technol, Sch Ind & Syst Engn, Atlanta, GA 30332 USA.
[Swann, Julie] Georgia Inst Technol, Sch Publ Policy, Atlanta, GA 30332 USA.
[Wortley, Pascale M.] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA 30329 USA.
RP Swann, J (reprint author), Georgia Inst Technol, Sch Ind & Syst Engn, 755 Ferst Dr, Atlanta, GA 30332 USA.
EM carlo.davila@gatech.edu; jswann@isye.gatech.edu; pmw1@cdc.gov
OI Davila Payan, Carlo/0000-0003-0722-4587; Swann,
Julie/0000-0003-2151-4396
FU Centers for Disease Control and Prevention (CDC)
FX C. Davila-Payan collected data, performed statistical analysis, and
aided in drafting the manuscript. J. Swann designed the study, advised
on methodology and logistical factors, and drafted the manuscript. P.
Wortley advised on public health and vaccination programs, assisted in
acquisition of data, aided in interpretation of results, and editing the
manuscript. All authors approved the final manuscript. C. Davila-Payan
was partially supported by the ORISE Fellows program during the
research. J. Swann was partially supported as the Harold R. and Mary
Anne Nash professor, by the Zalesky Family, and by Andrea Laliberte in
gifts to the Georgia Institute of Technology, and was partially
supported by the Centers for Disease Control and Prevention (CDC) in an
Intergovernmental Personnel Act agreement between the CDC and Georgia
Tech. The ORISE Fellows program and the donors to Georgia Tech had no
role in this research. Participants at the CDC gave feedback on
preliminary results including potential interpretations and reviewed the
final manuscript for confidentiality and accuracy. The findings and
conclusions in this paper are those of the authors and do not
necessarily represent the official position of the CDC.
NR 41
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 23
PY 2014
VL 32
IS 25
BP 3088
EP 3093
DI 10.1016/j.vaccine.2013.05.069
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI2UG
UT WOS:000336713000025
PM 23727421
ER
PT J
AU Harrison, C
Jorder, M
Stern, H
Stavinsky, F
Reddy, V
Hanson, H
Waechter, H
Lowe, L
Gravano, L
Balter, S
AF Harrison, Cassandra
Jorder, Mohip
Stern, Henri
Stavinsky, Faina
Reddy, Vasudha
Hanson, Heather
Waechter, HaeNa
Lowe, Luther
Gravano, Luis
Balter, Sharon
TI Using Online Reviews by Restaurant Patrons to Identify Unreported Cases
of Foodborne Illness - New York City, 2012-2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Harrison, Cassandra; Stavinsky, Faina; Reddy, Vasudha; Hanson, Heather; Waechter, HaeNa; Balter, Sharon] New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA.
[Harrison, Cassandra] CDC, Atlanta, GA 30333 USA.
[Jorder, Mohip; Stern, Henri; Gravano, Luis] Columbia Univ, New York, NY 10027 USA.
[Lowe, Luther] Yelp, San Francisco, CA USA.
RP Reddy, V (reprint author), New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA.
EM vreddy@health.nyc.gov
NR 9
TC 10
Z9 10
U1 1
U2 4
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 23
PY 2014
VL 63
IS 20
BP 441
EP 445
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH9ND
UT WOS:000336468200001
PM 24848215
ER
PT J
AU Wallace, RM
Bhavnani, D
Russell, J
Zaki, S
Muehlenbachs, A
Hayden-Pinneri, K
Aplicano, RM
Peruski, L
Vora, NM
Elson, D
Lederman, E
Leeson, B
McLaughlin, T
Waterman, S
Fonseca-Ford, M
Blanton, J
Franka, R
Velasco-Villa, A
Niezgoda, M
Orciari, L
Recuenco, S
Damon, I
Hanlon, C
Jackson, F
Dyer, J
Wadhwa, A
Robinson, L
AF Wallace, Ryan M.
Bhavnani, Darlene
Russell, John
Zaki, Sherif
Muehlenbachs, Atis
Hayden-Pinneri, Kathryn
Aplicano, Ricardo Mena
Peruski, Leonard
Vora, Neil M.
Elson, Diana
Lederman, Edith
Leeson, Ben
McLaughlin, Thomas
Waterman, Steve
Fonseca-Ford, Maureen
Blanton, Jesse
Franka, Richard
Velasco-Villa, Andres
Niezgoda, Michael
Orciari, Lillian
Recuenco, Sergio
Damon, Inger
Hanlon, Cathleen
Jackson, Felix
Dyer, Jessie
Wadhwa, Ashutosh
Robinson, Laura
TI Rabies Death Attributed to Exposure in Central America with Symptom
Onset in a US Detention Facility - Texas, 2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Wallace, Ryan M.; Vora, Neil M.] CDC, Atlanta, GA 30333 USA.
[Bhavnani, Darlene; Fonseca-Ford, Maureen; Blanton, Jesse] CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Russell, John; Leeson, Ben; McLaughlin, Thomas] Christus Spohn Hosp, Texas A&M Hlth Sci Ctr, Corpus Christi, TX USA.
[Zaki, Sherif; Muehlenbachs, Atis; Waterman, Steve; Franka, Richard; Velasco-Villa, Andres; Niezgoda, Michael; Orciari, Lillian; Recuenco, Sergio; Damon, Inger; Hanlon, Cathleen; Jackson, Felix; Dyer, Jessie; Wadhwa, Ashutosh] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Hayden-Pinneri, Kathryn] Harris Cty Med Examiners Off, Houston, TX USA.
[Aplicano, Ricardo Mena] Guatemala Minist Hlth, Guatemala City, Guatemala.
[Peruski, Leonard] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Elson, Diana; Lederman, Edith] Publ Hlth Safety & Preparedness Unit, Yuba, CA USA.
[Robinson, Laura] Texas Dept State Hlth Serv, Austin, TX USA.
RP Wallace, RM (reprint author), CDC, Atlanta, GA 30333 USA.
EM euk5@cdc.gov
OI Recuenco-Cabrera, Sergio/0000-0002-8446-7411
NR 7
TC 3
Z9 3
U1 0
U2 1
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 23
PY 2014
VL 63
IS 20
BP 446
EP 449
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH9ND
UT WOS:000336468200002
PM 24848216
ER
PT J
AU Marsden-Haug, N
Hill, H
Litvintseva, AP
Engelthaler, DM
Driebe, EM
Roe, CC
Ralston, C
Hurst, S
Goldoft, M
Gade, L
Wohrle, R
Thompson, GR
Brandt, ME
Chiller, T
AF Marsden-Haug, Nicola
Hill, Heather
Litvintseva, Anastasia P.
Engelthaler, David M.
Driebe, Elizabeth M.
Roe, Chandler C.
Ralston, Cindy
Hurst, Steven
Goldoft, Marcia
Gade, Lalitha
Wohrle, Ron
Thompson, George R., III
Brandt, Mary E.
Chiller, Tom
TI Coccidioides immitis Identified in Soil Outside of Its Known Range -
Washington, 2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Marsden-Haug, Nicola; Goldoft, Marcia; Wohrle, Ron] Univ Calif Davis, Coccidioidomycosis Serol Lab, Davis, CA 95616 USA.
[Hill, Heather; Ralston, Cindy] Benton Franklin Hlth Dist, Kennewick, WA USA.
[Litvintseva, Anastasia P.; Hurst, Steven; Gade, Lalitha; Brandt, Mary E.; Chiller, Tom] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
[Engelthaler, David M.; Driebe, Elizabeth M.; Roe, Chandler C.] Translat Genom Res Inst, Flagstaff, AZ USA.
[Thompson, George R., III] Univ Calif Davis, Coccidioidomycosis Serol Lab, Davis, CA USA.
RP Marsden-Haug, N (reprint author), Univ Calif Davis, Coccidioidomycosis Serol Lab, Davis, CA 95616 USA.
EM nicola.marsden-haug@doh.wa.gov
NR 1
TC 9
Z9 9
U1 0
U2 3
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 23
PY 2014
VL 63
IS 20
BP 450
EP 450
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH9ND
UT WOS:000336468200003
PM 24848217
ER
PT J
AU Greene, YG
Padovani, T
Rudroff, JA
Hall, R
Austin, C
Vernon, M
AF Greene, Yoran Grant
Padovani, Thomas
Rudroff, Jo Ann
Hall, Rebecca
Austin, Connie
Vernon, Michael
TI Trichinellosis Caused by Consumption of Wild Boar Meat - Illinois, 2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Greene, Yoran Grant] CDC, Atlanta, GA 30333 USA.
[Greene, Yoran Grant; Austin, Connie; Vernon, Michael] Illinois Dept Publ Hlth, Springfield, IL 62761 USA.
[Padovani, Thomas] Cook Cty Dept Publ Hlth, Chicago, IL USA.
[Rudroff, Jo Ann] Missouri Dept Hlth & Senior Serv, Jefferson City, MO USA.
[Hall, Rebecca] CDC, Div Parasit & Malarial Dis, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Greene, YG (reprint author), CDC, Atlanta, GA 30333 USA.
EM exu4@cdc.gov
NR 2
TC 3
Z9 3
U1 0
U2 3
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 23
PY 2014
VL 63
IS 20
BP 451
EP 451
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH9ND
UT WOS:000336468200004
PM 24848218
ER
PT J
AU Reynolds, CA
Finkelstein, JA
Ray, GT
Moore, MR
Huang, SS
AF Reynolds, Courtney A.
Finkelstein, Jonathan A.
Ray, G. Thomas
Moore, Matthew R.
Huang, Susan S.
TI Attributable healthcare utilization and cost of pneumoniae due to
drug-resistant Streptococcus pneumoniae: a cost analysis
SO ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL
LA English
DT Article
DE Streptococcus pneumoniae; Antibiotic resistance; Healthcare utilization;
DRSP
ID INVASIVE PNEUMOCOCCAL DISEASE; COMMUNITY-ACQUIRED PNEUMONIA;
POLYSACCHARIDE VACCINE; CONJUGATE VACCINE; UNITED-STATES; CHILDREN;
ADULTS; REPLACEMENT; GUIDELINES; MANAGEMENT
AB Background: The burden of disease due to S. pneumoniae (pneumococcus), particularly pneumonia, remains high despite the widespread use of vaccines. Drug resistant strains complicate clinical treatment and may increase costs. We estimated the annual burden and incremental costs attributable to antibiotic resistance in pneumococcal pneumonia.
Methods: We derived estimates of healthcare utilization and cost (in 2012 dollars) attributable to penicillin, erythromycin and fluoroquinolone resistance by taking the estimate of disease burden from a previously described decision tree model of pneumococcal pneumonia in the U.S. We analyzed model outputs assuming only the existence of susceptible strains and calculating the resulting differences in cost and utilization. We modeled the cost of resistance from delayed resolution of illness and the resulting additional health services.
Results: Our model estimated that non-susceptibility to penicillin, erythromycin and fluoroquinolones directly caused 32,398 additional outpatient visits and 19,336 hospitalizations for pneumococcal pneumonia. The incremental cost of antibiotic resistance was estimated to account for 4% ($91 million) of direct medical costs and 5% ($233 million) of total costs including work and productivity loss. Most of the incremental medical cost ($82 million) was related to hospitalizations resulting from erythromycin non-susceptibility. Among patients under age 18 years, erythromycin non-susceptibility was estimated to cause 17% of hospitalizations for pneumonia and $38 million in costs, or 39% of pneumococcal pneumonia costs attributable to resistance.
Conclusions: We estimate that antibiotic resistance in pneumococcal pneumonia leads to substantial healthcare utilization and cost, with more than one-third driven by macrolide resistance in children. With 5% of total pneumococcal costs directly attributable to resistance, strategies to reduce antibiotic resistance or improve antibiotic selection could lead to substantial savings.
C1 [Reynolds, Courtney A.; Huang, Susan S.] Univ Calif Irvine, Sch Med, Div Infect Dis, Irvine, CA 92697 USA.
[Reynolds, Courtney A.; Huang, Susan S.] Univ Calif Irvine, Sch Med, Hlth Policy Res Inst, Irvine, CA 92697 USA.
[Finkelstein, Jonathan A.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA.
[Finkelstein, Jonathan A.] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA.
[Finkelstein, Jonathan A.] Boston Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA.
[Ray, G. Thomas] Kaiser Permanente, Div Res, Oakland, CA 94612 USA.
[Moore, Matthew R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Reynolds, CA (reprint author), Univ Calif Irvine, Sch Med, Div Infect Dis, 100 Theory Ave,Suite 110, Irvine, CA 92697 USA.
EM courtner@uci.edu
FU Centers for Disease Control and Prevention (CDC) [TS-1363]
FX This study was funded by the Centers for Disease Control and Prevention
(CDC) (TS-1363, Finkelstein).
NR 24
TC 10
Z9 10
U1 2
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2047-2994
J9 ANTIMICROB RESIST IN
JI Antimicrob. Resist. Infect. Control
PD MAY 21
PY 2014
VL 3
AR 16
DI 10.1186/2047-2994-3-16
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases;
Microbiology
SC Public, Environmental & Occupational Health; Infectious Diseases;
Microbiology
GA CZ6OG
UT WOS:000367220000001
PM 24851182
ER
PT J
AU Li, W
Li, YJ
Li, WZ
Yang, JP
Song, MX
Diao, RN
Jia, HL
Lu, YX
Zheng, J
Zhang, XC
Xiao, LH
AF Li, Wei
Li, Yijing
Li, Weizhi
Yang, Jinping
Song, Mingxin
Diao, Ruinan
Jia, Honglin
Lu, Yixin
Zheng, Jun
Zhang, Xichen
Xiao, Lihua
TI Genotypes of Enterocytozoon bieneusi in Livestock in China: High
Prevalence and Zoonotic Potential
SO PLOS ONE
LA English
DT Article
ID VIRUS-INFECTED PATIENTS; GIARDIA-DUODENALIS; MICROSPORIDIOSIS; ANIMALS;
EPIDEMIOLOGY; IDENTIFICATION; PARASITES; THERAPY; SAMPLES; HUMANS
AB Despite many recent advances in genotype characterization of Enterocytozoon bieneusi worldwide and the exploration of the extent of cross-species transmission of microsporidiosis between humans and animals, the epidemiology of this neglected disease in China is poorly understood. In this study, a very high prevalence (60.3%; 94/156) of E. bieneusi infections in farmed pigs in Jilin province was detected by PCR of the ribosomal internal transcribed spacer (ITS). DNA sequence analysis of 88 E. bieneusi-positive specimens identified 12 distinct genotypes (11 known: CHN7, CS-1, CS-4, CS-6, EbpA, EbpB, EbpC, EbpD, EBITS3, G, and Henan-I; one novel: CS-9). Frequent appearance of mixed genotype infections was seen in the study animals. Weaned (74.6%; 53/71) or pre-weaned (68.8%; 22/32) pigs have infection rates significantly higher than growing pigs (35.8%; 19/53) (p<0.01). Likewise, E. bieneusi was detected in 2 of 45 sheep fecal specimens (4.4%) in Heilongjiang province, belonging to the known genotype BEB6. Genotypes EbpA, EbpC, EbpD, and Henan-I examined herein have been documented in the cases of human infections and BEB6, EbpA, EbpC, and EbpD in wastewater in central China. Infections of EbpA and EbpC in humans were also reported in other areas of the world. The other known genotypes (CHN7, CS-1, CS-4, CS-6, EBITS3, EbpB, and G) and the new genotype CS-9 were genetically clustered into a group of existing E. bieneusi genotypes with zoonotic potential. Thus, pigs could be a potential source of human E. bieneusi infections in China.
C1 [Li, Wei; Jia, Honglin; Zheng, Jun] Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin, Heilongjiang, Peoples R China.
[Li, Wei; Li, Yijing; Yang, Jinping; Song, Mingxin; Diao, Ruinan; Lu, Yixin] Northeast Agr Univ, Coll Vet Med, Harbin, Heilongjiang, Peoples R China.
[Li, Weizhi; Zhang, Xichen] Jilin Univ, Coll Vet Med, Minist Educ, Key Lab Zoonosis Res, Changchun 130023, Jilin, Peoples R China.
[Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
RP Zhang, XC (reprint author), Jilin Univ, Coll Vet Med, Minist Educ, Key Lab Zoonosis Res, Changchun 130023, Jilin, Peoples R China.
EM xczhang@jlu.edu.cn; lax0@cdc.gov
RI Xiao, Lihua/B-1704-2013;
OI Xiao, Lihua/0000-0001-8532-2727; Li, Wei/0000-0002-4264-1864
FU State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary
Research Institute [SKLVBF201307]; National Natural Science Foundation
of China [31302081]; Natural Science Foundation of Heilongjiang Province
[QC2013C015]; 54th Postdoctoral Scientific Foundation of China
[2013M540266]; Heilongjiang Postdoctoral Research Fund [LBH-Z13024]
FX This study was supported by the State Key Laboratory of Veterinary
Biotechnology, Harbin Veterinary Research Institute (SKLVBF201307), the
National Natural Science Foundation of China (No. 31302081), the Natural
Science Foundation of Heilongjiang Province (No. QC2013C015), the 54th
Postdoctoral Scientific Foundation of China (No. 2013M540266), and the
Heilongjiang Postdoctoral Research Fund (No. LBH-Z13024). The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 31
TC 20
Z9 20
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2014
VL 9
IS 5
AR e97623
DI 10.1371/journal.pone.0097623
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM0UW
UT WOS:000339563400040
PM 24845247
ER
PT J
AU Lobo, ML
Augusto, J
Antunes, F
Ceita, J
Xiao, LH
Codices, V
Matos, O
AF Lobo, Maria Luisa
Augusto, Joao
Antunes, Francisco
Ceita, Jose
Xiao, Lihua
Codices, Vera
Matos, Olga
TI Cryptosporidium spp., Giardia duodenalis, Enterocytozoon bieneusi and
Other Intestinal Parasites in Young Children in Lobata Province,
Democratic Republic of Sao Tome and Principe
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; HIV-INFECTED
PERSONS; MOLECULAR EPIDEMIOLOGY; SOUTH-AFRICA; CLINICAL-MANIFESTATIONS;
ZOONOTIC TRANSMISSION; CHILDHOOD DIARRHEA; UGANDAN CHILDREN; PREVALENCE
AB Rare systemic studies concerning prevalence of intestinal parasites in children have been conducted in the second smallest country in Africa, the Democratic Republic of Sao Tome and Principe. Fecal specimens from 348 children (214 in-hospital attending the Aires de Menezes Hospital and 134 from Agostinho Neto village) in Sao Tome Island were studied by parasitological and molecular methods. Of the 134 children from Agostinho Neto, 52.2% presented intestinal parasites. 32.1% and 20.2% of these children had monoparasitism and polyparasitism, respectively. Ascaris lumbricoides (27.6%), G. duodenalis (7.5%), T. trichiura (4.5%) and Entamoeba coli (10.5%) were the more frequent species identified in the children of this village. Giardia duodenalis (7.5%) and E. bieneusi (5.2%) were identified by PCR. Nested-PCR targeting G. duodenalis TPI identified Assemblage A (60%) and Assemblage B (40%). The E. bieneusi ITS-based sequence identified genotypes K (57.1%), KIN1 (28.6%) and KIN3 (14.3%). Among the 214 in-hospital children, 29.4% presented intestinal parasites. In 22.4% and 7.0% of the parasitized children, respectively, one or more species were concurrently detected. By microscopy, A. lumbricoides (10.3%) and Trichiuris trichiura (6.5%) were the most prevalent species among these children, and Cryptosporidium was detected by PCR in 8.9% of children. GP60 locus analysis identified 6.5% of C. hominis (subtypes IaA27R3 [35.7%], IaA23R3 [14.3%], IeA11G3T3 [28.6%] and IeA11G3T3R1 [21.4%]) and 2.3% of C. parvum (subtypes IIaA16G2R1 [20.0%], IIaA15G2R1 [20.0%], IIdA26G1 [40.0%] and IIdA21G1a [20.0%]). G. duodenalis and E. bieneusi were identified in 0.5% and 8.9% of the in-hospital children, respectively. G. duodenalis Assemblage B was characterized. The E. bieneusi genotypes K (52.6%), D (26.4%), A (10.5%) and KIN1 (10.5%) were identified. Although further studies are required to clarify the epidemiology of these infectious diseases in this endemic region the significance of the present results highlights that it is crucial to strength surveillance on intestinal pathogens.
C1 [Lobo, Maria Luisa; Codices, Vera; Matos, Olga] Univ Nova Lisboa, Inst Higiene & Med Trop, Grp Protozoarios Oportunistas VIH & Outros Protoz, Unidade Parasitol Med,CMDT, P-1200 Lisbon, Portugal.
[Augusto, Joao] Hosp Portimao, Ctr Hosp Algarve, Portimao, Portugal.
[Antunes, Francisco] Univ Lisbon, Fac Med, P-1699 Lisbon, Portugal.
[Ceita, Jose] Hosp Aires Menezes, Sao Tome, Sao Tome & Prin.
[Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
RP Matos, O (reprint author), Univ Nova Lisboa, Inst Higiene & Med Trop, Grp Protozoarios Oportunistas VIH & Outros Protoz, Unidade Parasitol Med,CMDT, P-1200 Lisbon, Portugal.
EM omatos@ihmt.unl.pt
RI Xiao, Lihua/B-1704-2013; Lobo, Maria/I-3527-2012;
OI Xiao, Lihua/0000-0001-8532-2727; Lobo, Maria/0000-0001-5811-7568;
Antunes, Francisco/0000-0001-7932-1154
NR 71
TC 9
Z9 10
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2014
VL 9
IS 5
AR e97708
DI 10.1371/journal.pone.0097708
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM0UW
UT WOS:000339563400047
PM 24846205
ER
PT J
AU Murphy, JL
Haas, CN
Arrowood, MJ
Hlavsa, MC
Beach, MJ
Hill, VR
AF Murphy, Jennifer L.
Haas, Charles N.
Arrowood, Michael J.
Hlavsa, Michele C.
Beach, Michael J.
Hill, Vincent R.
TI Efficacy of Chlorine Dioxide Tablets on Inactivation of Cryptosporidium
Oocysts
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article
ID ESCHERICHIA-COLI INACTIVATION; PARVUM OOCYSTS; SEQUENTIAL DISINFECTION;
DRINKING-WATER; UNITED-STATES; OZONE; VIABILITY; ASSAYS; MONOCHLORAMINE;
INFECTIVITY
AB The ability of chlorine dioxide (ClO2) to achieve 2-log inactivation of Cryptosporidium in drinking water has been documented. No studies have specifically addressed the effects of ClO2 on C. parvum oocyst infectivity in chlorinated recreational water venues (e.g., pools). The aim of this research was to determine the efficacy of ClO2 as an alternative to existing hyperchlorination protocols that are used to achieve a 3-log inactivation of Cryptosporidium in such venues. To obtain a 3-log inactivation of C. parvum Iowa oocysts, contact times of 105 and 128 min for a solution containing 5 mg/L ClO2 with and without the addition of 2.6 mg/L free chlorine, respectively, were required. Contact times of 294 and 857 min for a solution containing 1.4 mg/L ClO2 with and without the addition of 3.6 mg/L free chlorine, respectively, were required. The hyperchlorination control (21 mg/L free chlorine only) required 455 min for a 3-log inactivation. Use of a solution containing S mg/L ClO2 and solutions containing 5 or 1.4 mg/L ClO2 with the addition of free chlorine appears to be a promising alternative to hyperchlorination for inactivating Cryptosporidium in chlorinated recreational water venues, but further studies are required to evaluate safety constraints on use.
C1 [Murphy, Jennifer L.; Arrowood, Michael J.; Hlavsa, Michele C.; Beach, Michael J.; Hill, Vincent R.] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA.
[Haas, Charles N.] Drexel Univ, Philadelphia, PA 19104 USA.
RP Murphy, JL (reprint author), Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA.
EM iod7@cdc.gov
FU Buena Vista Construction Company
FX This study was supported in part by funding from Buena Vista
Construction Company. The findings and conclusions in this report are
those of the authors and do not necessarily represent the views of the
Centers for Disease Control and Prevention.
NR 41
TC 4
Z9 4
U1 4
U2 35
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
EI 1520-5851
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD MAY 20
PY 2014
VL 48
IS 10
BP 5849
EP 5856
DI 10.1021/es500644d
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA AH8VB
UT WOS:000336415200060
PM 24797292
ER
PT J
AU Oberste, MS
Lipton, HL
AF Oberste, M. Steven
Lipton, Howard L.
TI Global polio perspective
SO NEUROLOGY
LA English
DT Article
ID VACCINE-DERIVED POLIOVIRUSES
AB The results of the Global Polio Eradication Initiative that began in 1988 when there was transmission of 350,000 polio cases in 125 countries and has culminated in endemic transmission of only 223 polio cases in 3 countries in 2012 are reviewed.
C1 [Oberste, M. Steven] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Lipton, Howard L.] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60680 USA.
RP Lipton, HL (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
EM hlipton@uic.edu
FU NINDS (NIH)
FX H.L.L. supported by grants from NINDS (NIH).
NR 9
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAY 20
PY 2014
VL 82
IS 20
BP 1831
EP 1832
DI 10.1212/WNL.0000000000000426
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AI3EN
UT WOS:000336742700015
PM 24843034
ER
PT J
AU Li, J
Berkowitz, Z
Richards, TB
Hall, IJ
AF Li, Jun
Berkowitz, Zahava
Richards, Thomas B.
Hall, Ingrid J.
TI Prostate-specific antigen testing and shared decision making for
prostate cancer screening
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 30-JUN 03, 2014
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 [Li, Jun; Berkowitz, Zahava; Richards, Thomas B.; Hall, Ingrid J.] Ctr Dis Control, Atlanta, GA 30333 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2014
VL 32
IS 15
SU S
MA e12512
PG 1
WC Oncology
SC Oncology
GA CN7KL
UT WOS:000358613200145
ER
PT J
AU Lansky, A
Finlayson, T
Johnson, C
Holtzman, D
Wejnert, C
Mitsch, A
Gust, D
Chen, R
Mizuno, Y
Crepaz, N
AF Lansky, Amy
Finlayson, Teresa
Johnson, Christopher
Holtzman, Deborah
Wejnert, Cyprian
Mitsch, Andrew
Gust, Deborah
Chen, Robert
Mizuno, Yuko
Crepaz, Nicole
TI Estimating the Number of Persons Who Inject Drugs in the United States
by Meta-Analysis to Calculate National Rates of HIV and Hepatitis C
Virus Infections
SO PLOS ONE
LA English
DT Article
ID US METROPOLITAN-AREAS; USERS; POPULATION; PREVALENCE
AB Background: Injection drug use provides an efficient mechanism for transmitting bloodborne viruses, including human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Effective targeting of resources for prevention of HIV and HCV infection among persons who inject drugs (PWID) is based on knowledge of the population size and disparity in disease burden among PWID. This study estimated the number of PWID in the United States to calculate rates of HIV and HCV infection.
Methods: We conducted meta-analysis using data from 4 national probability surveys that measured lifetime (3 surveys) or past-year (3 surveys) injection drug use to estimate the proportion of the United States population that has injected drugs. We then applied these proportions to census data to produce population size estimates. To estimate the disease burden among PWID by calculating rates of disease we used lifetime population size estimates of PWID as denominators and estimates of HIV and HCV infection from national HIV surveillance and survey data, respectively, as numerators. We calculated rates of HIV among PWID by gender-, age-, and race/ethnicity.
Results: Lifetime PWID comprised 2.6% (95% confidence interval: 1.8%-3.3%) of the U. S. population aged 13 years or older, representing approximately 6,612,488 PWID (range: 4,583,188-8,641,788) in 2011. The population estimate of past-year PWID was 0.30% (95% confidence interval: 0.19 %-0.41%) or 774,434 PWID (range: 494,605-1,054,263). Among lifetime PWID, the 2011 HIV diagnosis rate was 55 per 100,000 PWID; the rate of persons living with a diagnosis of HIV infection in 2010 was 2,147 per 100,000 PWID; and the 2011 HCV infection rate was 43,126 per 100,000 PWID.
Conclusion: Estimates of the number of PWID and disease rates among PWID are important for program planning and addressing health inequities.
C1 [Lansky, Amy; Finlayson, Teresa; Johnson, Christopher; Wejnert, Cyprian; Mitsch, Andrew; Gust, Deborah; Chen, Robert; Mizuno, Yuko; Crepaz, Nicole] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Holtzman, Deborah] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.
RP Lansky, A (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
EM ALansky@cdc.gov
NR 23
TC 39
Z9 39
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 19
PY 2014
VL 9
IS 5
AR e97596
DI 10.1371/journal.pone.0097596
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AN9SK
UT WOS:000340948600048
PM 24840662
ER
PT J
AU Wanzira, H
Yeka, A
Kigozi, R
Rubahika, D
Nasr, S
Sserwanga, A
Kamya, M
Filler, S
Dorsey, G
Steinhardt, L
AF Wanzira, Humphrey
Yeka, Adoke
Kigozi, Ruth
Rubahika, Denis
Nasr, Sussann
Sserwanga, Asadu
Kamya, Moses
Filler, Scott
Dorsey, Grant
Steinhardt, Laura
TI Long-lasting insecticide-treated bed net ownership and use among
children under five years of age following a targeted distribution in
central Uganda
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Long-lasting insecticide-treated bed nets; Intervention
coverage
ID WESTERN KENYA; MALARIA TRANSMISSION; HOUSEHOLDS; MORBIDITY; MORTALITY;
CAMPAIGN; INDEXES; AFRICA; DESIGN; IMPACT
AB Background: Universal coverage of long-lasting insecticide-treated bed nets (LLINs) for prevention of malaria was adopted by the Uganda National Malaria Control Programme in 2007. The first mass distribution of LLINs was implemented in 2010. Initially, a campaign targeted to households with pregnant women and children aged = 15 000 cells/mu L within 1 day of positive test), severe outcome (intensive care unit admission after positive test, colectomy for C. difficile infection, or death within 30 days of positive test), and death within 14 days of positive test.
Results. Strain typing results were available for 2057 cases. Severe disease occurred in 363 (17.7%) cases, severe outcome in 100 (4.9%), and death within 14 days in 56 (2.7%). The most common strain types were NAP1 (28.4%), NAP4 (10.2%), and NAP11 (9.1%). In unadjusted analysis, NAP1 was associated with greater odds of severe disease than other strains. After controlling for patient risk factors, healthcare exposure, and antibiotic use, NAP1 was associated with severe disease (adjusted odds ratio [AOR], 1.74; 95% confidence interval [CI], 1.36-2.22), severe outcome (AOR, 1.66; 95% CI, 1.09-2.54), and death within 14 days (AOR, 2.12; 95% CI, 1.22-3.68).
Conclusions. NAP1 was the most prevalent strain and a predictor of severe disease, severe outcome, and death. Strategies to reduce NAP1 prevalence, such as antibiotic stewardship to reduce fluoroquinolone use, might reduce CDI morbidity.
C1 [See, Isaac; Mu, Yi; Cohen, Jessica; Anderson, Lydia; Lessa, Fernanda C.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
[See, Isaac] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Cohen, Jessica] Atlanta Res & Educ Fdn, Atlanta, GA USA.
[Beldavs, Zintars G.] Oregon Hlth Author, Portland, OR USA.
[Winston, Lisa G.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Dumyati, Ghinwa] Univ Rochester, New York, NY USA.
[Holzbauer, Stacy] Ctr Dis Control & Prevent, Minnesota Dept Hlth, St Paul, MN USA.
[Dunn, John] Tennessee Dept Hlth, Nashville, TN USA.
[Farley, Monica M.] Atlanta Vet Med Ctr, Atlanta, GA USA.
[Farley, Monica M.] Emory Univ, Sch Med, Atlanta, GA 30322 USA.
[Lyons, Carol] Connecticut Emerging Infect Program, New Haven, CT USA.
[Johnston, Helen] Colorado Dept Publ Hlth & Environm, Denver, CO USA.
[Phipps, Erin] Univ New Mexico, Albuquerque, NM 87131 USA.
[Perlmutter, Rebecca] Maryland Emerging Infect Program, Baltimore, MD USA.
[Gerding, Dale N.] Loyola Univ, Stritch Sch Med, Chicago, IL 60611 USA.
[Gerding, Dale N.] Hines Vet Affairs Hosp, Chicago, IL USA.
RP See, I (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE A-24, Atlanta, GA 30333 USA.
EM isee@cdc.gov
FU CDC EIP [U50CK000201, U50CK000194, U50CK000195, U50CK000196,
U50CK000203, U50CK000204, U50CK000205, U50CK000199, U50CK000197,
U50CK000198]
FX This work was supported by the CDC EIP Cooperative Agreement with
California (U50CK000201), Colorado (U50CK000194), Connecticut
(U50CK000195), Georgia (U50CK000196), Maryland (U50CK000203), Minnesota
(U50CK000204), New Mexico (U50CK000205), New York (U50CK000199), Oregon
(U50CK000197), and Tennessee (U50CK000198).
NR 33
TC 46
Z9 46
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2014
VL 58
IS 10
BP 1394
EP 1400
DI 10.1093/cid/ciu125
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AH3RZ
UT WOS:000336044200011
PM 24604900
ER
PT J
AU Behravesh, CB
Brinson, D
Hopkins, BA
Gomez, TM
AF Behravesh, Casey Barton
Brinson, Denise
Hopkins, Brett A.
Gomez, Thomas M.
TI Backyard Poultry Flocks and Salmonellosis: A Recurring, Yet Preventable
Public Health Challenge
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Salmonella; zoonoses; outbreak; backyard poultry; mail-order hatchery
ID MAIL-ORDER HATCHERY; UNITED-STATES; MULTISTATE OUTBREAK; LIVE POULTRY;
CONTACT; SURVEILLANCE; TYPHIMURIUM; MANAGEMENT; PATHOGENS; CHILDREN
AB Poultry are well recognized as possible carriers of Salmonella species. As part of the local foods movement, backyard poultry flocks have increased in popularity in recent years. Between 1996 and 2012, 45 outbreaks of human Salmonella infections linked to live poultry from mail-order hatcheries were documented. This review examines the history of live poultry-associated salmonellosis in humans in the United States, the current status of the issue, and what can be done to help prevent these illnesses. An integrated One Health approach involving the mail-order hatchery industry, feed stores, healthcare providers, veterinarians, and backyard flock owners is needed to help prevent live poultry-associated salmonellosis.
C1 [Behravesh, Casey Barton] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30329 USA.
[Brinson, Denise] USDA, Natl Poultry Improvement Plan, Conyers, GA USA.
[Hopkins, Brett A.] Int Tech Anim Prod & Proc Solut, Overland Pk, KS USA.
[Gomez, Thomas M.] USDA, Vet Serv, Anim & Plant Hlth Inspect Serv, Atlanta, GA USA.
RP Behravesh, CB (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd NE,MS A38, Atlanta, GA 30329 USA.
EM cbartonbehravesh@cdc.gov
FU Centers for Disease Control and Prevention
FX This work was supported by the Centers for Disease Control and
Prevention.
NR 34
TC 18
Z9 19
U1 2
U2 17
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2014
VL 58
IS 10
BP 1432
EP 1438
DI 10.1093/cid/ciu067
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AH3RZ
UT WOS:000336044200018
PM 24501387
ER
PT J
AU Kuniholm, MH
Jung, M
Everhart, JE
Cotler, S
Heiss, G
McQuillan, G
Kim, RS
Strickler, HD
Thyagarajan, B
Youngblood, M
Kaplan, RC
Ho, GYF
AF Kuniholm, Mark H.
Jung, Molly
Everhart, James E.
Cotler, Scott
Heiss, Gerardo
McQuillan, Geraldine
Kim, Ryung S.
Strickler, Howard D.
Thyagarajan, Bharat
Youngblood, Marston
Kaplan, Robert C.
Ho, Gloria Y. F.
TI Prevalence of Hepatitis C Virus Infection in US Hispanic/Latino Adults:
Results From the NHANES 2007-2010 and HCHS/SOL Studies
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE hepatitis C virus; HCV; Hispanic; Latino; United States; prevalence;
antibody; RNA; risk factor
ID UNITED-STATES; LATINOS; DESIGN
AB Prevalence of hepatitis C virus (HCV) antibody has been reported in Mexican Americans, but its prevalence in other US Hispanic/Latino groups is unknown. We studied 2 populations of US Hispanic/Latino adults; 3210 from the National Health and Nutrition Examination Survey (NHANES) 2007-2010 and 11 964 from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Age-standardized prevalence of HCV antibody was similar in NHANES 2007-2010 (1.5%) and HCHS/SOL (2.0%) but differed significantly by Hispanic/Latino background in HCHS/SOL (eg, 11.6% in Puerto Rican men vs 0.4% in South American men). These findings suggest that the HCV epidemic among US Hispanics/Latinos is heterogeneous.
C1 [Kuniholm, Mark H.; Jung, Molly; Kim, Ryung S.; Strickler, Howard D.; Kaplan, Robert C.; Ho, Gloria Y. F.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA.
[Everhart, James E.] NIDDK, Epidemiol & Data Syst Program, Div Digest Dis & Nutr, Bethesda, MD 20892 USA.
[Cotler, Scott] Loyola Univ, Med Ctr, Dept Med, Div Hepatol, Maywood, IL 60153 USA.
[Heiss, Gerardo; Youngblood, Marston] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[McQuillan, Geraldine] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Hyattsville, MD USA.
[Thyagarajan, Bharat] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
RP Kuniholm, MH (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Belfer Bldg,Rm 1308C,1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM mark.kuniholm@einstein.yu.edu
FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC65233];
University of Miami [N01-HC65234]; Albert Einstein College of Medicine
[N01-HC65235]; Northwestern University [N01-HC65236]; San Diego State
University [N01-HC65237]; National Center for Advancing Translational
Sciences (NCATS), through CTSA [UL1RR025750, KL2RR025749]
FX The Hispanic Community Health Study/Study of Latinos was carried out as
a collaborative study supported by contracts from the National Heart,
Lung, and Blood Institute (NHLBI) to the University of North Carolina
(N01-HC65233), University of Miami (N01-HC65234), Albert Einstein
College of Medicine (N01-HC65235), Northwestern University
(N01-HC65236), and San Diego State University (N01-HC65237). The
following Institutes/Centers/Offices contribute to the HCHS/SOL through
a transfer of funds to the NHLBI: National Institute on Minority Health
and Health Disparities, National Institute on Deafness and Other
Communication Disorders, National Institute of Dental and Craniofacial
Research, National Institute of Diabetes and Digestive and Kidney
Diseases, National Institute of Neurological Disorders and Stroke, NIH
Institution-Office of Dietary Supplements. M. H. K. is supported in part
by the National Center for Advancing Translational Sciences (NCATS),
through CTSA grants UL1RR025750 and KL2RR025749.
NR 8
TC 14
Z9 14
U1 2
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2014
VL 209
IS 10
BP 1585
EP 1590
DI 10.1093/infdis/jit672
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AH4CJ
UT WOS:000336073000012
PM 24423693
ER
PT J
AU Wright, PF
Wieland-Alter, W
Ilyushina, NA
Hoen, AG
Arita, M
Boesch, AW
Ackerman, ME
van der Avoort, H
Oberste, MS
Pallansch, MA
Burton, AH
Jaffar, MA
Sutter, RW
AF Wright, Peter F.
Wieland-Alter, Wendy
Ilyushina, Natalia A.
Hoen, Anne G.
Arita, Minetaro
Boesch, Austin W.
Ackerman, Margaret E.
van der Avoort, Harrie
Oberste, M. Steven
Pallansch, Mark A.
Burton, Anthony H.
Jaffar, Mohammad A.
Sutter, Roland W.
TI Intestinal Immunity Is a Determinant of Clearance of Poliovirus After
Oral Vaccination
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE polio; vaccine; IgA; mucosal immunity
ID IMMUNIZATION SCHEDULES; MUCOSAL IMMUNITY; INFECTION; POLIOVACCINE;
CIRCULATION; SECRETIONS; CHILDREN; ANTIBODY; INFANTS; SERUM
AB Background. Response to challenge with live, attenuated, oral polio vaccine (OPV) is a measure of immunity induced by prior immunization.
Methods. Using stool samples from a study from Oman in which an initial schedule of inactivated polio vaccine (IPV) was followed by an OPV type 1 challenge, we quantitated virus shed, sequenced capsid proteins of recovered virus, and developed assays for neutralization of poliovirus and mucosal immunoglobulin A (IgA) detection.
Results. Neutralizing activity correlated with detection of polio-specific IgA in stool suspensions collected 7 days after OPV type 1 challenge. Both neutralization and IgA in stool were associated with cessation of virus shedding by day 7. Rapid development of an IgA response with cessation of shedding suggests that IPV primed for the early response to challenge. Correlation of neutralization activity and IgA detection provides evidence that polio-specific IgA intestinal antibody is a determinant of mucosal shedding/transmission and that IgA functions through neutralization of virus. In contrast, neither presence nor quantity of serum or intestinal antibody induced by IPV prior to challenge correlated with cessation of shedding.
Conclusions. These assays provide an opportunity to study other immunization schedules to gain a broader understanding of the appearance and duration of a protective mucosal response to polio vaccination.
C1 [Wright, Peter F.; Wieland-Alter, Wendy; Ilyushina, Natalia A.] Geisel Med Sch Dartmouth, Div Infect Dis & Int Med, Lebanon, NH 03756 USA.
[Hoen, Anne G.] Geisel Med Sch Dartmouth, Dept Community & Family Med, Sect Biostat & Epidemiol, Lebanon, NH 03756 USA.
[Arita, Minetaro] Natl Inst Infect Dis, Tokyo, Japan.
[Boesch, Austin W.; Ackerman, Margaret E.] Thayer Sch Engn Dartmouth, Hanover, NH USA.
[van der Avoort, Harrie] Ctr Infect Dis Res, RIVM IDS, Bilthoven, Netherlands.
[Oberste, M. Steven; Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
[Burton, Anthony H.] WHO, CH-1211 Geneva, Switzerland.
[Sutter, Roland W.] WHO, Global Polio Eradicat Initiat, CH-1211 Geneva, Switzerland.
RP Wright, PF (reprint author), Geisel Med Sch Dartmouth, Dept Pediat, 1 Med Ctr Dr,Borwell 330 W, Lebanon, NH 03756 USA.
EM peter.f.wright@hitchcock.org
OI arita, minetaro/0000-0002-3314-6626
FU Bill & Melinda Gates Foundation [OPP1039141, OPP1032817]
FX This work was supported by the Bill & Melinda Gates Foundation Grand
Challenges Exploration Grant (grant number OPP1039141 to P. F. W.) and
also from the Bill and Melinda Gates Foundation Collaboration for AIDS
Vaccine Discovery Grant (grant number OPP1032817 to M. E. A.).
NR 26
TC 8
Z9 8
U1 4
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2014
VL 209
IS 10
BP 1628
EP 1634
DI 10.1093/infdis/jit671
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AH4CJ
UT WOS:000336073000018
PM 24459191
ER
PT J
AU Kelley, EJ
Driebe, EM
Etienne, K
Brandt, ME
Schupp, JM
Gillece, JD
Trujillo, JS
Lockhart, SR
Deak, E
Keim, PS
Engelthaler, DM
AF Kelley, Erin J.
Driebe, Elizabeth M.
Etienne, Kizee
Brandt, Mary E.
Schupp, James M.
Gillece, John D.
Trujillo, Jesse S.
Lockhart, Shawn R.
Deak, Eszter
Keim, Paul S.
Engelthaler, David M.
TI Real-time PCR assays for genotyping of Cryptococcus gattii in North
America
SO BMC MICROBIOLOGY
LA English
DT Article
DE Cryptococcus gattii; Genotyping; Real-time PCR; Epidemiology
ID VANCOUVER-ISLAND; BRITISH-COLUMBIA; NEOFORMANS; OUTBREAK;
SUSCEPTIBILITIES; STRAINS
AB Background: Cryptococcus gattii has been the cause of an ongoing outbreak starting in 1999 on Vancouver Island, British Columbia and spreading to mainland Canada and the US Pacific Northwest. In the course of the outbreak, C. gattii has been identified outside of its previously documented climate, habitat, and host disease. Genotyping of C. gattii is essential to understand the ecological and geographical expansion of this emerging pathogen.
Methods: We developed and validated a mismatch amplification mutation assay (MAMA) real-time PCR panel for genotyping C. gattii molecular types VGI-VGIV and VGII subtypes a,b,c. Subtype assays were designed based on whole-genome sequence of 20 C. gattii strains. Publically available multilocus sequence typing (MLST) data from a study of 202 strains was used for the molecular type (VGI-VGIV) assay design. All assays were validated across DNA from 112 strains of diverse international origin and sample types, including animal, environmental and human.
Results: Validation revealed each assay on the panel is 100% sensitive, specific and concordant with MLST. The assay panel can detect down to 0.5 picograms of template DNA.
Conclusions: The (MAMA) real-time PCR panel for C. gattii accurately typed a collection of 112 diverse strains and demonstrated high sensitivity. This is a time and cost efficient method of genotyping C. gattii best suited for application in large-scale epidemiological studies.
C1 [Kelley, Erin J.; Driebe, Elizabeth M.; Schupp, James M.; Gillece, John D.; Trujillo, Jesse S.; Keim, Paul S.; Engelthaler, David M.] Translat Genom Res Inst, Flagstaff, AZ 86001 USA.
[Etienne, Kizee; Brandt, Mary E.; Lockhart, Shawn R.; Deak, Eszter] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Deak, Eszter] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Keim, Paul S.] No Arizona Univ, Ctr Microbial Genet & Genom, Flagstaff, AZ 86011 USA.
RP Kelley, EJ (reprint author), Translat Genom Res Inst, 3051 W Shamrell Blvd Ste 106, Flagstaff, AZ 86001 USA.
EM ekelley@tgen.org
FU National Institutes of Health [R21AI098059]
FX The authors wish to thank the members of the Cryptococcus gattii Public
Health Working Group for submission of many of the isolates used in this
study. This work was supported by funds from the National Institutes of
Health: R21AI098059.
NR 23
TC 0
Z9 0
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2180
J9 BMC MICROBIOL
JI BMC Microbiol.
PD MAY 13
PY 2014
VL 14
AR 125
DI 10.1186/1471-2180-14-125
PG 15
WC Microbiology
SC Microbiology
GA AI2HD
UT WOS:000336677400001
PM 24886039
ER
PT J
AU Noronha, AS
Markowitz, LE
Dunne, EF
AF Noronha, Alinea S.
Markowitz, Lauri E.
Dunne, Eileen F.
TI Systematic review of human papillomavirus vaccine coadministration
SO VACCINE
LA English
DT Review
DE Coadministration; Concomitant; HPV vaccination; Immunogenicity; Safety
ID CERVICAL-CANCER VACCINE; MENINGOCOCCAL GLYCOCONJUGATE VACCINE; ACELLULAR
PERTUSSIS-VACCINE; HEPATITIS-B-VACCINE; AS04-ADJUVANTED VACCINE;
RANDOMIZED-TRIAL; REDUCED DIPHTHERIA; HEALTHY GIRLS; MENACWY-CRM;
IMMUNOGENICITY
AB Human papillomavirus (HPV) vaccination is recommended in early adolescence, at an age when other vaccines are also recommended. Administration of multiple vaccines during one visit is an opportunity to improve uptake of adolescent vaccines. We conducted a systematic review of safety and immunogenicity of HPV vaccines coadministered with other vaccines. Our review included 9 studies, 4 of quadrivalent HPV vaccine and 5 of bivalent HPV vaccine; coadministered vaccines included: meningococcal conjugate, hepatitis A, hepatitis B, combined hepatitis A and B, tetanus, diphtheria, acellular pertussis, and inactivated poliovirus vaccines. Studies varied in methods of data collection and measurement of immunogenicity and safety. Noninferiority of immune response and an acceptable safety profile were demonstrated when HPV vaccine was coadministered with other vaccines. Published by Elsevier Ltd.
C1 [Noronha, Alinea S.; Markowitz, Lauri E.; Dunne, Eileen F.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Dunne, EF (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA.
EM dde9@cdc.gov
NR 19
TC 19
Z9 19
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 13
PY 2014
VL 32
IS 23
BP 2670
EP 2674
DI 10.1016/j.vaccine.2013.12.037
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI3QG
UT WOS:000336776400003
PM 24412351
ER
PT J
AU Young, HS
Dirzo, R
Helgen, KM
McCauley, DJ
Billeter, SA
Kosoy, MY
Osikowicz, LM
Salkeld, DJ
Young, TP
Dittmar, K
AF Young, Hillary S.
Dirzo, Rodolfo
Helgen, Kristofer M.
McCauley, Douglas J.
Billeter, Sarah A.
Kosoy, Michael Y.
Osikowicz, Lynn M.
Salkeld, Daniel J.
Young, Truman P.
Dittmar, Katharina
TI Declines in large wildlife increase landscape-level prevalence of
rodent-borne disease in Africa
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE Kenya; dilution effect
ID INFECTIOUS-DISEASE; SMALL MAMMALS; LYME-DISEASE; SPECIES-DIVERSITY;
COMMUNITY COMPOSITION; FLEAS SIPHONAPTERA; LARGE HERBIVORES; EXTINCTION
RISK; BARTONELLA SPP.; HOST DIVERSITY
AB Populations of large wildlife are declining on local and global scales. The impacts of this pulse of size-selective defaunation include cascading changes to smaller animals, particularly rodents, and alteration of many ecosystem processes and services, potentially involving changes to prevalence and transmission of zoonotic disease. Understanding linkages between biodiversity loss and zoonotic disease is important for both public health and nature conservation programs, and has been a source of much recent scientific debate. In the case of rodent-borne zoonoses, there is strong conceptual support, but limited empirical evidence, for the hypothesis that defaunation, the loss of large wildlife, increases zoonotic disease risk by directly or indirectly releasing controls on rodent density. We tested this hypothesis by experimentally excluding large wildlife from a savanna ecosystem in East Africa, and examining changes in prevalence and abundance of Bartonella spp. infection in rodents and their flea vectors. We found no effect of wildlife removal on per capita prevalence of Bartonella infection in either rodents or fleas. However, because rodent and, consequently, flea abundance doubled following experimental defaunation, the density of infected hosts and infected fleas was roughly twofold higher in sites where large wildlife was absent. Thus, defaunation represents an elevated risk in Bartonella transmission to humans (bartonellosis). Our results (i) provide experimental evidence of large wildlife defaunation increasing landscape-level disease prevalence, (ii) highlight the importance of susceptible host regulation pathways and host/vector density responses in biodiversity-disease relationships, and (iii) suggest that rodent-borne disease responses to large wildlife loss may represent an important context where this relationship is largely negative.
C1 [Young, Hillary S.; McCauley, Douglas J.] Univ Calif Santa Barbara, Dept Ecol Evolut & Marine Biol, Santa Barbara, CA 93106 USA.
[Young, Hillary S.; Dirzo, Rodolfo; McCauley, Douglas J.] Stanford Univ, Dept Biol, Stanford, CA 94305 USA.
[Salkeld, Daniel J.] Stanford Univ, Woods Inst Environm, Stanford, CA 94305 USA.
[Young, Hillary S.; Helgen, Kristofer M.] Smithsonian Inst, Natl Museum Nat Hist, Div Mammals, Washington, DC 20013 USA.
[Billeter, Sarah A.; Kosoy, Michael Y.; Osikowicz, Lynn M.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO 80521 USA.
[Salkeld, Daniel J.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.
[Young, Truman P.] Univ Calif Davis, Dept Plant Sci, Davis, CA 95616 USA.
[Dittmar, Katharina] SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.
RP Dirzo, R (reprint author), Stanford Univ, Dept Biol, Stanford, CA 94305 USA.
EM rdirzo@stanford.edu
FU James Smithson Fund of the Smithsonian Institution; National Geographic
Society; National Science Foundation [BSR-97-07477, 03-16402, 08-16453,
12-56034, DEB-09-09670, DEB-1213740]; Natural Sciences and Engineering
Council of Canada; African Elephant Program of the US Fish and Wildlife
Service [98210-0-G563]; Woods Institute for the Environment; Smithsonian
Institution Women's Committee
FX We thank Cara Brook, Ralph Eckerlin, Jackson Ekadeli, Frederick Erii,
Lauren Gillespie, Lauren Helgen, Ashley Hintz, Helen Kafka, Felicia
Keesing, John Lochikuya, Margaret Kinnaird, Peter Lokeny, Darrin Lunde,
Scott Miller, Mathew Namoni, Everlyn Ndinda, John Ososky, John
Montenieri, Jack Silange, Michael Hastriter, and Michael Whiting for
help in this project. Financial support for this project came from the
James Smithson Fund of the Smithsonian Institution, the National
Geographic Society, the National Science Foundation (Long Term Research
in Environmental Biology Grants BSR-97-07477, 03-16402, 08-16453,
12-56034, DEB-09-09670, and DEB-1213740), the Natural Sciences and
Engineering Council of Canada, the African Elephant Program of the US
Fish and Wildlife Service (Grant 98210-0-G563), the Woods Institute for
the Environment, and the Smithsonian Institution Women's Committee.
Vector images were provided courtesy of the Integration and Application
Network, University of Maryland Center for Environmental Science
(http://ian.umces.edu/imagelibrary).
NR 68
TC 25
Z9 26
U1 12
U2 132
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 13
PY 2014
VL 111
IS 19
BP 7036
EP 7041
DI 10.1073/pnas.1404958111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AH0GS
UT WOS:000335798000068
PM 24778215
ER
PT J
AU deCastro, BR
AF deCastro, B. Rey
TI Acrolein and Asthma Attack Prevalence in a Representative Sample of the
United States Adult Population 2000-2009
SO PLOS ONE
LA English
DT Article
ID HAZARDOUS AIR-POLLUTANTS; AUTISM SPECTRUM DISORDERS; HEALTH INTERVIEW
SURVEY; TOXICS CONCENTRATIONS; OXIDATIVE STRESS; INHALED ACROLEIN;
RISK-ASSESSMENT; LUNG-FUNCTION; MAIN ROAD; POLLUTION
AB Background: Acrolein is an air toxic and highly potent respiratory irritant. There is little epidemiology available, but US EPA estimates that outdoor acrolein is responsible for about 75 percent of non-cancer respiratory health effects attributable to air toxics in the United States, based on the Agency's 2005 NATA (National-Scale Air Toxics Assessment) and acrolein's comparatively potent inhalation reference concentration of 0.02 mu g/m(3).
Objectives: Assess the association between estimated outdoor acrolein exposure and asthma attack reported by a representative cross-sectional sample of the adult United States population.
Methods: NATA 2005 chronic outdoor acrolein exposure estimates at the census tract were linked with residences oif adults (>= 18 years old) in the NHIS (National Health Interview Survey) 2000 - 2009 (n = 271,348 subjects). A sample-weighted logistic regression model characterized the association between the prevalence of reporting at least one asthma attack in the 12 months prior to survey interview and quintiles of exposure to outdoor acrolein, controlling for potential confounders.
Results: In the highest quintile of outdoor acrolein exposure (0.05 - 0.46 mu g/m(3)), there was a marginally significant increase in the asthma attack pOR (prevalence-odds ratio [95% CI] = 1.08 [0.98: 1.19]) relative to the lowest quintile. The highest quintile was also associated with a marginally significant increase in prevalence-odds (1.13 [0.98: 1.29]) in a model limited to never smokers (n = 153,820).
Conclusions: Chronic exposure to outdoor acrolein of 0.05 - 0.46 mg/m(3) appears to increase the prevalence-odds of having at least one asthma attack in the previous year by 8 percent in a representative cross-sectional sample of the adult United States population.
C1 Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30333 USA.
RP deCastro, BR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30333 USA.
EM rdecastro@cdc.gov
RI deCastro, Rey/G-2874-2011
OI deCastro, Rey/0000-0002-1610-5849
NR 96
TC 6
Z9 6
U1 1
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 9
PY 2014
VL 9
IS 5
AR e96926
DI 10.1371/journal.pone.0096926
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI4LX
UT WOS:000336838000080
PM 24816802
ER
PT J
AU Thomson, R
Festo, C
Johanes, B
Kalolella, A
Bruxvoort, K
Nchimbi, H
Tougher, S
Cairns, M
Taylor, M
Kleinschmidt, I
Ye, Y
Mann, A
Ren, RL
Willey, B
Arnold, F
Hanson, K
Kachur, SP
Goodman, C
AF Thomson, Rebecca
Festo, Charles
Johanes, Boniface
Kalolella, Admirabilis
Bruxvoort, Katia
Nchimbi, Happy
Tougher, Sarah
Cairns, Matthew
Taylor, Mark
Kleinschmidt, Immo
Ye, Yazoume
Mann, Andrea
Ren, Ruilin
Willey, Barbara
Arnold, Fred
Hanson, Kara
Kachur, S. Patrick
Goodman, Catherine
TI Has Tanzania Embraced the Green Leaf? Results from Outlet and Household
Surveys before and after Implementation of the Affordable Medicines
Facility - Malaria
SO PLOS ONE
LA English
DT Article
ID RAPID DIAGNOSTIC-TESTS; COMBINATION THERAPIES; MARKET SHARE; 7
COUNTRIES; AVAILABILITY; REGIONS; IMPACT; PRICE; AMFM; ACT
AB Background: The Affordable Medicines Facility - malaria (AMFm) is primarily an artemisinin combination therapy (ACT) subsidy, aimed at increasing availability, affordability, market share and use of quality-assured ACTs (QAACTs). Mainland Tanzania was one of eight national scale programmes where AMFm was introduced in 2010. Here we present findings from outlet and household surveys before and after AMFm implementation to evaluate its impact from both the supply and demand side.
Methods: Outlet surveys were conducted in 49 randomly selected wards throughout mainland Tanzania in 2010 and 2011, and data on outlet characteristics and stocking patterns were collected from outlets stocking antimalarials. Household surveys were conducted in 240 randomly selected enumeration areas in three regions in 2010 and 2012. Questions about treatment seeking for fever and drugs obtained were asked of individuals reporting fever in the previous two weeks.
Results: The availability of QAACTs increased from 25.5% to 69.5% among all outlet types, with the greatest increase among pharmacies and drug stores, together termed specialised drug sellers (SDSs), where the median QAACT price fell from $5.63 to $0.94. The market share of QAACTs increased from 26.2% to 42.2%, again with the greatest increase in SDSs. Household survey results showed a shift in treatment seeking away from the public sector towards SDSs. Overall, there was no change in the proportion of people with fever obtaining an antimalarial or ACT from baseline to endline. However, when broken down by treatment source, ACT use increased significantly among clients visiting SDSs.
Discussion: Unchanged ACT use overall, despite increases in QAACT availability, affordability and market share in the private sector, reflected a shift in treatment seeking towards private providers. The reasons for this shift are unclear, but likely reflect both persistent stockouts in public facilities, and the increased availability of subsidised ACTs in the private sector.
C1 [Thomson, Rebecca; Bruxvoort, Katia; Tougher, Sarah; Cairns, Matthew; Taylor, Mark; Kleinschmidt, Immo; Mann, Andrea; Willey, Barbara; Hanson, Kara; Goodman, Catherine] London Sch Hyg & Trop Med, London WC1, England.
[Thomson, Rebecca; Festo, Charles; Johanes, Boniface; Kalolella, Admirabilis; Bruxvoort, Katia; Nchimbi, Happy] Ifakara Hlth Inst, Dar Es Salaam, Tanzania.
[Taylor, Mark] Trnava Univ, Dept Publ Hlth, Trnava, Slovakia.
[Ye, Yazoume; Ren, Ruilin; Arnold, Fred] ICF Int, Int Hlth Div, Calverton, MD USA.
[Kachur, S. Patrick] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA.
RP Thomson, R (reprint author), London Sch Hyg & Trop Med, London WC1, England.
EM Rebecca.thomson@lshtm.ac.uk
OI Taylor, Mark/0000-0002-7646-7905
FU Bill and Melinda Gates Foundation through ACT Consortium [PHGB VG0410];
Global Fund to Fight AIDS, Tuberculosis and Malaria
FX The study was funded by the Bill and Melinda Gates Foundation
(www.gatesfoundation.org), through a grant with the ACT Consortium
(actconsortium.org), project code PHGB VG0410. The Independent
Evaluation of AMFm was funded by the Global Fund to Fight AIDS,
Tuberculosis and Malaria. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 30
TC 5
Z9 5
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 9
PY 2014
VL 9
IS 5
AR e95607
DI 10.1371/journal.pone.0095607
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI4LX
UT WOS:000336838000016
PM 24816649
ER
PT J
AU Johnson, LEA
Clara, W
Gambhir, M
Chacon-Fuentes, R
Marin-Correa, C
Jara, J
Minaya, P
Rodriguez, D
Blanco, N
Iihoshi, N
Orozco, M
Lange, C
Perez, SV
Amador, N
Widdowson, MA
Moen, AC
Azziz-Baumgartner, E
AF Johnson, Lucinda E. A.
Clara, Wilfrido
Gambhir, Manoj
Chacon-Fuentes, Rafael
Marin-Correa, Carlos
Jara, Jorge
Minaya, Percy
Rodriguez, David
Blanco, Natalia
Iihoshi, Naomi
Orozco, Maribel
Lange, Carmen
Vinicio Perez, Sergio
Amador, Nydia
Widdowson, Marc-Alain
Moen, Ann C.
Azziz-Baumgartner, Eduardo
TI Improvements in pandemic preparedness in 8 Central American countries,
2008-2012
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
DE Pandemic; Influenza; Preparedness; IHR; Central America;
Capacity-building; Technical assistance
ID INFLUENZA PREPAREDNESS; CHALLENGE; MORTALITY; REGION; PLANS
AB Background: In view of ongoing pandemic threats such as the recent human cases of novel avian influenza A (H7N9) in China, it is important that all countries continue their preparedness efforts. Since 2006, Central American countries have received donor funding and technical assistance from the U. S. Centers for Disease Control and Prevention (CDC) to build and improve their capacity for influenza surveillance and pandemic preparedness. Our objective was to measure changes in pandemic preparedness in this region, and explore factors associated with these changes, using evaluations conducted between 2008 and 2012.
Methods: Eight Central American countries scored their pandemic preparedness across 12 capabilities in 2008, 2010 and 2012, using a standardized tool developed by CDC. Scores were calculated by country and capability and compared between evaluation years using the Student's t-test and Wilcoxon Rank Sum test, respectively. Virological data reported to WHO were used to assess changes in testing capacity between evaluation years. Linear regression was used to examine associations between scores, donor funding, technical assistance and WHO reporting.
Results: All countries improved their pandemic preparedness between 2008 and 2012 and seven made statistically significant gains (p < 0.05). Increases in median scores were observed for all 12 capabilities over the same period and were statistically significant for eight of these (p < 0.05): country planning, communications, routine influenza surveillance, national respiratory disease surveillance, outbreak response, resources for containment, community interventions and health sector response. We found a positive association between preparedness scores and cumulative funding between 2006 and 2011 (R-2 = 0.5, p < 0.01). The number of specimens reported to WHO from participating countries increased significantly from 5,551 (2008) to 18,172 (2012) (p < 0.01).
Conclusions: Central America has made significant improvements in influenza pandemic preparedness between 2008 and 2012. U. S. donor funding and technical assistance provided to the region is likely to have contributed to the improvements we observed, although information on other sources of funding and support was unavailable to study. Gains are also likely the result of countries' response to the 2009 influenza pandemic. Further research is required to determine the degree to which pandemic improvements are sustainable.
C1 [Johnson, Lucinda E. A.; Widdowson, Marc-Alain; Moen, Ann C.; Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Clara, Wilfrido] Ctr Dis Control & Prevent, Influenza Program, Reg Off Cent Amer, San Salvador, El Salvador.
[Gambhir, Manoj] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.
[Chacon-Fuentes, Rafael; Jara, Jorge; Blanco, Natalia] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala.
[Marin-Correa, Carlos; Minaya, Percy] Training Epidemiol & Publ Hlth Intervent Network, Atlanta, GA USA.
[Rodriguez, David] Minist Hlth El Salvador, Gen Directorate Hlth Surveillance, San Salvador, El Salvador.
[Iihoshi, Naomi; Vinicio Perez, Sergio] Minist Hlth Guatemala, Natl Epidemiol Ctr, Guatemala City, Guatemala.
[Orozco, Maribel] Council Ministers Hlth Cent Amer & Dominican Rep, San Salvador, El Salvador.
[Lange, Carmen] Minist Hlth Panama, Dept Epidemiol, Panama City, Panama.
[Amador, Nydia] Minist Hlth Costa Rica, Gen Directorate Hlth Surveillance, San Jose, Costa Rica.
RP Azziz-Baumgartner, E (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA.
EM eha9@cdc.gov
NR 13
TC 4
Z9 4
U1 1
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD MAY 9
PY 2014
VL 14
AR 209
DI 10.1186/1472-6963-14-209
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AH3WE
UT WOS:000336056100001
PM 24886275
ER
PT J
AU Mitruka, K
Thornton, K
Cusick, S
Orme, C
Moore, A
Manch, RA
Box, T
Carroll, C
Holtzman, D
Ward, JW
AF Mitruka, Kiren
Thornton, Karla
Cusick, Susanne
Orme, Christina
Moore, Ann
Manch, Richard A.
Box, Terry
Carroll, Christie
Holtzman, Deborah
Ward, John W.
TI Expanding Primary Care Capacity to Treat Hepatitis C Virus Infection
Through an Evidence-Based Care Model - Arizona and Utah, 2012-2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID UNITED-STATES; BARRIERS; OUTCOMES
C1 [Mitruka, Kiren; Holtzman, Deborah; Ward, John W.] CDC, Div Viral Hepatitis, Natl Ctr Natl Ctr HIV AIDS Viral Hepatitis STD &, Phoenix, AZ 85027 USA.
[Thornton, Karla; Carroll, Christie] Univ New Mexico, Hlth Sci Ctr, Phoenix, AZ USA.
[Cusick, Susanne; Orme, Christina; Box, Terry] Univ Utah, Sch Med, Phoenix, AZ USA.
[Moore, Ann; Manch, Richard A.] St Josephs Hosp, Phoenix, AZ USA.
RP Mitruka, K (reprint author), CDC, Div Viral Hepatitis, Natl Ctr Natl Ctr HIV AIDS Viral Hepatitis STD &, Phoenix, AZ 85027 USA.
EM kmitruka@cdc.gov
NR 10
TC 18
Z9 18
U1 0
U2 2
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 9
PY 2014
VL 63
IS 18
BP 393
EP 398
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AG6GM
UT WOS:000335517100001
PM 24807237
ER
PT J
AU Beckett, GA
Ramirez, G
Vanderhoff, A
Nichols, K
Chute, SM
Wyles, DL
Schoenbachler, BT
Bedell, DT
Cabral, R
Ward, JW
AF Beckett, Geoff A.
Ramirez, Gilberto
Vanderhoff, Aaron
Nichols, Kim
Chute, Sara M.
Wyles, David L.
Schoenbachler, Ben T.
Bedell, Deborah T.
Cabral, Rebecca
Ward, John W.
TI Early Identification and Linkage to Care of Persons with Chronic
Hepatitis B Virus Infection - Three US Sites, 2012-2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
AB In the United States, an estimated 0.8-1.4 million persons are living with chronic hepatitis B virus (HBV) infection. Among these persons, as many as 70% were born in countries of Asia, Africa, or other regions where HBV is moderately or highly endemic (hepatitis B surface antigen [HBsAg] prevalence >= 2%) (1). HBV-associated cirrhosis and liver cancer are major health problems for these populations (2,3). Most persons with HBV were infected at birth or during early childhood and are asymptomatic until advanced liver disease develops. To address these concerns, CDC recommends HBsAg testing for all persons born in these areas and linkage to medical care and preventive services for those who are infected (1). In 2012, CDC awarded funds to nine sites to implement this recommendation. This report describes programs at three sites (New York, New York; Minneapolis-St. Paul, Minnesota; and San Diego, California) that conducted HBV testing, in clinical or community settings, and referred for medical evaluation and care those persons whose HBsAg test results were positive. During October 2012-March 2014, the three sites tested 4,727 persons for HBV infection; 310 (6.6%) were HBsAg-positive. Among the HBsAg-positive persons, 94% were informed of their results, 90% were counseled, 86% were referred for care, and 66% attended their scheduled first medical visit. These projects demonstrate that community-based programs can identify infected persons among populations with a high prevalence of HBV infection and refer HBsAg-positive persons for care. Individualized efforts to assist patients with accessing and receiving health-care services ("patient navigation services") can increase the number of persons who follow up on referrals and receive recommended care.
C1 [Beckett, Geoff A.; Ramirez, Gilberto; Schoenbachler, Ben T.; Bedell, Deborah T.; Cabral, Rebecca; Ward, John W.] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
[Chute, Sara M.] Minnesota Dept Hlth, Minneapolis, MN 55414 USA.
[Wyles, David L.] Univ Calif San Diego, San Diego, CA 92103 USA.
RP Beckett, GA (reprint author), CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
EM gbeckett@cdc.gov
NR 5
TC 9
Z9 9
U1 1
U2 4
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 9
PY 2014
VL 63
IS 18
BP 399
EP 401
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AG6GM
UT WOS:000335517100002
PM 24807238
ER
PT J
AU Patton, ME
Su, JR
Nelson, R
Weinstock, H
AF Patton, Monica E.
Su, John R.
Nelson, Robert
Weinstock, Hillard
TI Primary and Secondary Syphilis - United States, 2005-2013
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID CARE; MEN; SEX
C1 [Patton, Monica E.] CDC, Atlanta, GA 30333 USA.
[Su, John R.; Nelson, Robert; Weinstock, Hillard] CDC, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Patton, ME (reprint author), CDC, Atlanta, GA 30333 USA.
EM mepatton@cdc.gov
NR 10
TC 70
Z9 71
U1 0
U2 5
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 9
PY 2014
VL 63
IS 18
BP 402
EP 406
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AG6GM
UT WOS:000335517100003
PM 24807239
ER
PT J
AU Carroll, DD
Courtney-Long, EA
Stevens, AC
Sloan, ML
Lullo, C
Visser, SN
Fox, MH
Armour, BS
Campbell, VA
Brown, DR
Dorn, JM
AF Carroll, Dianna D.
Courtney-Long, Elizabeth A.
Stevens, Alissa C.
Sloan, Michelle L.
Lullo, Carolyn
Visser, Susanna N.
Fox, Michael H.
Armour, Brian S.
Campbell, Vincent A.
Brown, David R.
Dorn, Joan M.
TI Vital Signs: Disability and Physical Activity - United States, 2009-2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID CARE; BARRIERS; ADULTS
AB Background: Adults with disabilities are less active and have higher rates of chronic disease than the general population. Given the health benefits of physical activity, understanding physical activity, its relationship with chronic disease, and health professional recommendations for physical activity among young to middle-age adults with disabilities could help increase the effectiveness of health promotion efforts.
Methods: Data from the 2009-2012 National Health Interview Survey (NHIS) were used to estimate the prevalence of, and association between, aerobic physical activity (inactive, insufficiently active, or active) and chronic diseases (heart disease, stroke, diabetes, and cancer) among adults aged 18-64 years by disability status and type (hearing, vision, cognitive, and mobility). The prevalence of, and association between, receiving a health professional recommendation for physical activity and level of aerobic physical activity was assessed using 2010 data.
Results: Overall, 11.6% of U.S. adults aged 18-64 years reported a disability, with estimates for disability type ranging from 1.7% (vision) to 5.8% (mobility). Compared with adults without disabilities, inactivity was more prevalent among adults with any disability (47.1% versus 26.1%) and for adults with each type of disability. Inactive adults with disabilities were 50% more likely to report one or more chronic diseases than those who were physically active. Approximately 44% of adults with disabilities received a recommendation from a health professional for physical activity in the past 12 months.
Conclusions: Almost half of adults with disabilities are physically inactive and are more likely to have a chronic disease. Among adults with disabilities who visited a health professional in the past 12 months, the majority (56%) did not receive a recommendation for physical activity.
Implications for Public Health: These data highlight the need for increased physical activity among persons with disabilities, which might require support across societal sectors, including government and health care.
C1 [Carroll, Dianna D.; Courtney-Long, Elizabeth A.; Stevens, Alissa C.; Sloan, Michelle L.; Lullo, Carolyn; Visser, Susanna N.; Fox, Michael H.; Armour, Brian S.; Campbell, Vincent A.] CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
[Brown, David R.; Dorn, Joan M.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
RP Carroll, DD (reprint author), CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.
EM ddcarroll@cdc.gov
NR 21
TC 24
Z9 24
U1 2
U2 6
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 9
PY 2014
VL 63
IS 18
BP 407
EP 413
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AG6GM
UT WOS:000335517100004
PM 24807240
ER
PT J
AU Dabelea, D
Mayer-Davis, EJ
Saydah, S
Imperatore, G
Linder, B
Divers, J
Bell, R
Badaru, A
Talton, JW
Crume, T
Liese, AD
Merchant, AT
Lawrence, JM
Reynolds, K
Dolan, L
Liu, LL
Hamman, RF
AF Dabelea, Dana
Mayer-Davis, Elizabeth J.
Saydah, Sharon
Imperatore, Giuseppina
Linder, Barbara
Divers, Jasmin
Bell, Ronny
Badaru, Angela
Talton, Jennifer W.
Crume, Tessa
Liese, Angela D.
Merchant, Anwar T.
Lawrence, Jean M.
Reynolds, Kristi
Dolan, Lawrence
Liu, Lenna L.
Hamman, Richard F.
CA SEARCH Diabet Youth Study
TI Prevalence of Type 1 and Type 2 Diabetes Among Children and Adolescents
From 2001 to 2009
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID CHILDHOOD TYPE-1; UNITED-STATES; INCREASING INCIDENCE; RISK-FACTORS; US
YOUTH; MELLITUS; SEARCH; POPULATION; OBESITY; COHORT
AB IMPORTANCE Despite concern about an "epidemic," there are limited data on trends in prevalence of either type 1 or type 2 diabetes across US race and ethnic groups.
OBJECTIVE To estimate changes in the prevalence of type 1 and type 2 diabetes in US youth, by sex, age, and race/ethnicity between 2001 and 2009.
DESIGN, SETTING, AND PARTICIPANTS Case patients were ascertained in 4 geographic areas and 1 managed health care plan. The study population was determined by the 2001 and 2009 bridged-race intercensal population estimates for geographic sites and membership counts for the health plan.
MAIN OUTCOMES AND MEASURES Prevalence (per 1000) of physician-diagnosed type 1 diabetes in youth aged 0 through 19 years and type 2 diabetes in youth aged 10 through 19 years.
RESULTS In 2001, 4958 of 3.3 million youth were diagnosed with type 1 diabetes for a prevalence of 1.48 per 1000 (95% CI, 1.44-1.52). In 2009, 6666 of 3.4 million youth were diagnosed with type 1 diabetes for a prevalence of 1.93 per 1000 (95% CI, 1.88-1.97). In 2009, the highest prevalence of type 1 diabetes was 2.55 per 1000 among white youth (95% CI, 2.48-2.62) and the lowest was 0.35 per 1000 in American Indian youth (95% CI, 0.26-0.47) and type 1 diabetes increased between 2001 and 2009 in all sex, age, and race/ethnic subgroups except for those with the lowest prevalence (age 0-4 years and American Indians). Adjusted for completeness of ascertainment, there was a 21.1% (95% CI, 15.6%-27.0%) increase in type 1 diabetes over 8 years. In 2001, 588 of 1.7 million youth were diagnosed with type 2 diabetes for a prevalence of 0.34 per 1000 (95% CI, 0.31-0.37). In 2009, 819 of 1.8 million were diagnosed with type 2 diabetes for a prevalence of 0.46 per 1000 (95% CI, 0.43-0.49). In 2009, the prevalence of type 2 diabetes was 1.20 per 1000 among American Indian youth (95% CI, 0.96-1.51); 1.06 per 1000 among black youth (95% CI, 0.93-1.22); 0.79 per 1000 among Hispanic youth (95% CI, 0.70-0.88); and 0.17 per 1000 among white youth (95% CI, 0.15-0.20). Significant increases occurred between 2001 and 2009 in both sexes, all age-groups, and in white, Hispanic, and black youth, with no significant changes for Asian Pacific Islanders and American Indians. Adjusted for completeness of ascertainment, there was a 30.5%(95% CI, 17.3%-45.1%) overall increase in type 2 diabetes.
CONCLUSIONS AND RELEVANCE Between 2001 and 2009 in 5 areas of the United States, the prevalence of both type 1 and type 2 diabetes among children and adolescents increased. Further studies are required to determine the causes of these increases.
C1 [Dabelea, Dana; Crume, Tessa; Hamman, Richard F.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80045 USA.
[Mayer-Davis, Elizabeth J.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA.
[Saydah, Sharon; Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA.
[Linder, Barbara] NIDDK, Childhood Diabet Res Div Diabet Endocrinol & Meta, Bethesda, MD 20892 USA.
[Divers, Jasmin; Talton, Jennifer W.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA.
[Bell, Ronny] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA.
[Badaru, Angela] Childrens Hosp & Reg Med Ctr, Dept Pediat Endocrinol & Diabet, Seattle, WA USA.
[Liese, Angela D.; Merchant, Anwar T.] Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC USA.
[Lawrence, Jean M.; Reynolds, Kristi] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.
[Dolan, Lawrence] Childrens Hosp Med Ctr, Dept Endocrinol, Cincinnati, OH USA.
[Liu, Lenna L.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
[Liu, Lenna L.] Seattle Childrens Hosp, Seattle, WA USA.
RP Dabelea, D (reprint author), Colorado Sch Publ Hlth, Dept Epidemiol, 13001 East 17th Pl,Campus Box B-119, Aurora, CO 80045 USA.
EM dana.dabelea@ucdenver.edu
FU CDC [PA00097, DP-05-069, DP-10-001]; National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK); NIDDK; National Institutes of
Health (NIH) National Center for Research Resources [UL1RR029882]; NIH
[UL1 TR00423]; Clinical and Translational Research Center [UL1
TR000154]; Diabetes and Endocrinology Research Center, NIH [P30
DK57516]; National Center for Research Resources [8 UL1 TR000077];
National Center for Advancing Translational Sciences, NIH; Children with
Medical Handicaps program; [U48/CCU919219]; [U01 DP000246];
[U18DP002714]; [U48/CCU819241-3]; [U01 DP000247]; [U18DP000247-06A1];
[U48/CCU519239]; [U01 DP000248]; [1U18DP002709]; [U48/CCU419249];
[U01 DP000254]; [U18DP002708-01]; [U58/CCU019235-4]; [U01 DP000244];
[U18DP002710-01]; [U01 DP000250]; [200-2010-35171]
FX SEARCH for Diabetes in Youth is funded by grants PA00097, DP-05-069, and
DP-10-001 from the CDC and by the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK). Additional funding was provided
to the CDC for these cooperative agreements by the NIDDK. The site
contracts grants are U48/CCU919219, U01 DP000246, and U18DP002714 to
Kaiser Permanente Southern California; U48/CCU819241-3, U01 DP000247,
and U18DP000247-06A1 to the University of Colorado Denver;
U48/CCU519239, U01 DP000248, and 1U18DP002709 to the Children's Hospital
Medical Center, Cincinnati, Ohio; U48/CCU419249, U01 DP000254, and
U18DP002708-01 to the University of North Carolina at Chapel Hill;
U58/CCU019235-4, U01 DP000244, and U18DP002710-01 to the University of
Washington School of Medicine; U48/CCU919219, U01 DP000250, and
200-2010-35171 to the Wake Forest University School of Medicine. This
project was also support by grants UL1RR029882 from the National
Institutes of Health (NIH) National Center for Research Resources to the
South Carolina Clinical & Translational Research [SCTR] Institute, at
the Medical University of South Carolina; UL1 TR00423 from the NIH
Clinical and Translational Science Award to the Seattle Children's
Hospital of the University of Washington; UL1 TR000154 from the Clinical
and Translational Research Center to the University of Colorado
Pediatric Clinical; P30 DK57516 from the Diabetes and Endocrinology
Research Center, NIH, to the Barbara Davis Center at the University of
Colorado at Denver; 8 UL1 TR000077 from the National Center for Research
Resources and the National Center for Advancing Translational Sciences,
NIH; and the Children with Medical Handicaps program managed by the Ohio
Department of Health.
NR 43
TC 232
Z9 233
U1 4
U2 62
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 7
PY 2014
VL 311
IS 17
BP 1778
EP 1786
DI 10.1001/jama.2014.3201
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA AG4IG
UT WOS:000335382300023
PM 24794371
ER
PT J
AU Lantagne, D
Person, B
Smith, N
Mayer, A
Preston, K
Blanton, E
Jellison, K
AF Lantagne, Daniele
Person, Bobbie
Smith, Natalie
Mayer, Ally
Preston, Kelsey
Blanton, Elizabeth
Jellison, Kristen
TI Emergency Water Treatment with Bleach in the United States: The Need to
Revise EPA Recommendations
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article
ID HOUSEHOLD CHLORINATION; DEVELOPING-COUNTRIES; TURBIDITY
AB During emergencies in the United States, the Environmental Protection Agency (EPA) currently recommends using bottled water, or boiling or treating water by adding 1/8 teaspoon (or 8 drops) of bleach to 1 gal of water. This bleach recommendation is internally inconsistent, a relatively high chlorine dose (5.55-8.67 mg/L), and unsupported by evidence. In this study, bleach was added in three different dosages to six waters available to emergency-affected populations in each of six states; free chlorine residual (FCR) and Escherichia coli/total conforms were measured 1-24 h after treatment. Data were analyzed using four efficacy criteria. Results indicated the dosages in the current EPA recommendation are unnecessarily high to ensure (1) maintenance of FCR for 24 h after treatment, (2) absence of E. coli/total conforms, and (3) establishment of a CT-factor sufficient to inactivate Giardia lamblia and enteric viruses 1 h after treatment. Additionally, emergency-prone populations did not have the materials to complete treatment with bleach in their household. Therefore, we recommend EPA review and revise the current recommendation to establish an internally consistent, criteria-based recommendation that is usable by emergency-affected populations. We also recommend investigating the use of, new or commercially available water treatment products for emergency response in the United States.
C1 [Lantagne, Daniele; Blanton, Elizabeth] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Atlanta, GA 30333 USA.
[Person, Bobbie] Ctr Dis Control & Prevent, Natl Ctr Zoonot & Emerging Infect Dis, Off Director, Atlanta, GA 30333 USA.
[Smith, Natalie; Mayer, Ally; Preston, Kelsey; Jellison, Kristen] Lehigh Univ, Dept Civil & Environm Engn, Bethlehem, PA 18015 USA.
RP Lantagne, D (reprint author), Tufts Univ, Medford, MA 02155 USA.
EM daniele.lantagne@tufts.edu
FU Centers for Disease Control and Prevention
FX We thank the six households who hosted this study and the Centers for
Disease Control and Prevention for funding. Disclaimer: The findings and
conclusions in this report are those of the authors and do not
necessarily represent the official position of the Centers for Disease
Control and Prevention.
NR 34
TC 2
Z9 2
U1 2
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
EI 1520-5851
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD MAY 6
PY 2014
VL 48
IS 9
BP 5093
EP 5100
DI 10.1021/es405357y
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA AG9DY
UT WOS:000335720100055
PM 24684410
ER
PT J
AU Santana, WI
Williams, TL
Winne, EK
Pirkle, JL
Barr, JR
AF Santana, Wanda I.
Williams, Tracie L.
Winne, Emily K.
Pirkle, James L.
Barr, John R.
TI Quantification of Viral Proteins of the Avian H7 Subtype of Influenza
Virus: An Isotope Dilution Mass Spectrometry Method Applicable for
Producing more Rapid Vaccines in the Case of an Influenza Pandemic
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID RISK-FACTORS; HONG-KONG; HEMAGGLUTININ; INFECTION; DIGESTION; PEPTIDES;
DISEASE; CHINA
AB Vaccination is the most effective means to prevent influenza and its serious complications. Influenza viral strains undergo rapid mutations of the surface proteins hemagglutinin (HA) and neuraminidase (NA) requiring vaccines to be frequently updated to include current circulating strains. It is nearly impossible to predict which strains will be circulating in the next influenza season. It is, therefore, imperative that the process of producing a vaccine be streamlined and as swift as possible. We have developed an isotope dilution mass spectrometry (IDMS) method to quantify HA and NA in H7N7, H7N2, and H7N9 influenza. The IDMS method involves enzymatic digestion of viral proteins and the specific detection of evolutionarily conserved target peptides. The four target peptides that were initially chosen for analysis of the HA protein of H7N2 and H7N7 subtypes were conserved and available for analysis of the H7N9 subtype that circulated in China in the spring of 2013. Thus, rapid response to the potential pandemic was realized. Quantification of a protein is performed by employing multiple peptides to ensure that the enzymatic digestion of the protein is efficient in the region of the target peptides, verify the accuracy of the measurement, and provide flexibility in the case of amino acid changes among newly emerging strains. The IDMS method is an accurate, sensitive, and selective method to quantify the amount of HA and NA antigens in primary liquid standards, crude allantoic fluid, purified virus samples, and final vaccine presentations.
C1 [Santana, Wanda I.; Williams, Tracie L.; Winne, Emily K.; Pirkle, James L.; Barr, John R.] Ctr Dis Control & Prevent, Clin Chem Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
RP Williams, TL (reprint author), Ctr Dis Control & Prevent, Clin Chem Branch, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Hwy NE, Atlanta, GA 30341 USA.
EM enn8@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 32
TC 5
Z9 5
U1 2
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD MAY 6
PY 2014
VL 86
IS 9
BP 4088
EP 4095
DI 10.1021/ac4040778
PG 8
WC Chemistry, Analytical
SC Chemistry
GA AG9DW
UT WOS:000335719900004
PM 24689548
ER
PT J
AU Baytop, C
Royal, S
McCree, DH
Simmons, R
Tregerman, R
Robinson, C
Johnson, WD
McLaughlin, M
Price, C
AF Baytop, Chanza
Royal, Scott
McCree, Donna Hubbard
Simmons, Ron
Tregerman, Rebecca
Robinson, Carolyn
Johnson, Wayne D.
McLaughlin, Mike
Price, Cristofer
TI Comparison of strategies to increase HIV testing among African-American
gay, bisexual, and other men who have sex with men in Washington, DC
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE African-American; MSM; HIV testing; outreach strategies
ID INFECTION
AB This paper presents results from a study conducted to compare the relative effectiveness of three strategies - alternate venue testing (AVT), the social network strategy (SNS), and partner counseling and referral services (PCRS; standard care) - for reaching and motivating previously undiagnosed, African-American men who have sex with men (AA MSM) to be tested for HIV. Data were collected between June 2008 and February 2010 at a gay-identified, community-based organization (CBO) serving AA MSM in Washington, DC. Men were eligible to participate if they were 18-64 years old, self-identified as black or African-American, were biologically male, and self-reported oral or anal sex with a man in the past six months. Fisher's exact test of independence was used to assess differences in demographics, testing history, HIV status and sexual behaviors across the three strategies. The final sample included 470 men who met all eligibility requirements. There were no statistically significant differences in HIV positivity rates across the three strategies. However, relative to standard care, the SNS, and (to a lesser degree) the AVT strategies were more successful in recruiting men that had never been tested. Additionally, the results indicate that each strategy recruited different subgroups of men. Specifically, heterosexually identified men and men who reported engaging in unprotected sex were most likely to be recruited via SNS. Bisexually identified men and older men were most likely to be recruited via AVT or SNS, while standard care tended to reach greater proportions of young men and homosexually identified men. These findings suggest that a combination of strategies may be the best approach for engaging African-American MSM in HIV testing.
C1 [Baytop, Chanza; Royal, Scott; Tregerman, Rebecca; Robinson, Carolyn] ABT Associates Inc, US Hlt, Bethesda, MD 20814 USA.
[McCree, Donna Hubbard; Johnson, Wayne D.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
[Simmons, Ron] People Into Living Inc, Us Helping Us, Washington, DC USA.
[McLaughlin, Mike; Price, Cristofer] ABT Associates Inc, Social & Econ Policy, Bethesda, MD USA.
RP Baytop, C (reprint author), ABT Associates Inc, US Hlt, Bethesda, MD 20814 USA.
EM chanza_baytop@abtassoc.com
FU NCHHSTP CDC HHS [1UR6 PS000330-01]
NR 8
TC 5
Z9 5
U1 1
U2 6
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0954-0121
EI 1360-0451
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PD MAY 4
PY 2014
VL 26
IS 5
BP 608
EP 612
DI 10.1080/09540121.2013.845280
PG 5
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychology, Multidisciplinary; Respiratory System; Social Sciences,
Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychology; Respiratory System; Biomedical Social Sciences
GA AA8HW
UT WOS:000331337200013
PM 24116886
ER
PT J
AU Fleming, DA
Woskie, SR
Jones, JH
Silver, SR
Luo, L
Bertke, SJ
AF Fleming, Donald A.
Woskie, Susan R.
Jones, James H.
Silver, Sharon R.
Luo, Lian
Bertke, Stephen J.
TI Retrospective Assessment of Exposure to Chemicals for a Microelectronics
and Business Machine Manufacturing Facility
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE
LA English
DT Article
DE occupational exposure; circuit board manufacture; substrate production;
exposure matrix; exposure score; chlorinated solvents;
trichloroethylene; perchloroethylene
ID BREAST-CANCER
AB A retrospective exposure assessment was performed for use in a health outcomes study of a facility manufacturing circuit boards, business machines, and other equipment during the years 1969-2002. A matrix was developed identifying chemical use by department-year based on company-provided information. Use of six chemical agents (fiberglass, lead, methylene chloride, methyl chloroform, perchloroethylene, and trichloroethylene) and six chemical classes (acid-base, aromatic hydrocarbons, chlorinated hydrocarbons, other hydrocarbons, chlorofluorocarbons, and metals), and general (including unspecified) chemicals was identified. The matrix also contained an assignment for each department-year categorizing the potential for use of chemicals as negligible, intermittent/incidental, or routine. These department-based exposure matrix data were combined with work history data to provide duration of potential chemical use for workers. Negligible, intermittent/incidental or routine extent-of-chemical-use categories comprised 42.6%, 39.4%, and 17.9%, respectively, of total person-years of employment. Cumulative exposure scores were also developed, representing a relative measure of the cumulative extent of potential exposure to the six chemical agents, six chemical classes, and general (including unspecified) chemicals. Additionally, the study period was divided into manufacturing eras showing trends in chemical use, and showing that process use of trichloroethylene and methylene chloride ended in the mid-1980s and the mid-1990s, respectively. This approach may be useful in other assessments addressing a variety of chemicals, and with data constraints common to retrospective chemical exposure studies.
C1 [Fleming, Donald A.; Silver, Sharon R.; Bertke, Stephen J.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ind Wide Studies Branch, Cincinnati, OH 45226 USA.
[Woskie, Susan R.] Univ Massachusetts, Dept Work Environm, Lowell, MA USA.
[Jones, James H.] Jones Ind Hyg Serv LLC, Loveland, OH USA.
[Luo, Lian] CACI Inc, Arlington, VA USA.
RP Fleming, DA (reprint author), 4676 Columbia Pkwy,MS R-14, Cincinnati, OH 45226 USA.
EM dmf9@cdc.gov
OI Silver, Sharon/0000-0002-7679-5028
FU National Institute for Occupational Safety and Health
FX The authors wish to acknowledge the assistance of numerous members of
the NIOSH Industry-wide Studies Branch who were instrumental in the
planning and conduct of the site visits to collect company data; to
organize, review, and store records; and to facilitate this work. In
particular we wish to recognize Chris Gersic, Jean Geiman, Denise
Giglio, Delores Montgomery, Surprese Watts, Faith Armstrong, Bill
Ehling, and Kim Jenkins for data capture and coding. Kevin L. Dunn
assisted in the document reviews, Steve Allee provided programming
assistance, and Lynne Pinkerton provided consulting on the overall study
and objectives. Funding for this research was provided by the National
Institute for Occupational Safety and Health.
NR 8
TC 2
Z9 2
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 520 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1545-9624
EI 1545-9632
J9 J OCCUP ENVIRON HYG
JI J. Occup. Environ. Hyg.
PD MAY 4
PY 2014
VL 11
IS 5
BP 292
EP 305
DI 10.1080/15459624.2013.862591
PG 14
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AE8QG
UT WOS:000334265800006
PM 24224613
ER
PT J
AU Ceballos, D
Reeb-Whitaker, C
Glazer, P
Murphy-Robinson, H
Yost, M
AF Ceballos, Diana
Reeb-Whitaker, Carolyn
Glazer, Patricia
Murphy-Robinson, Helen
Yost, Michael
TI Understanding Factors That Influence Protective Glove Use Among
Automotive Spray Painters
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE
LA English
DT Article
DE focus groups; interviews; automotive paints; spray painters; car
painters; protective glove; nitrile; latex; butyl rubber
ID COLLISION REPAIR INDUSTRY; OCCUPATIONAL-EXPOSURE; NEUROLOGICAL SYMPTOMS;
ISOCYANATE EXPOSURES; ORGANIC-SOLVENTS; SKIN EXPOSURE; ASTHMA; MIXTURES;
WORKERS; HEALTH
AB Dermal contact with isocyanate-based coatings may lead to systemic respiratory sensitization. The most common isocyanates found in sprayed automotive coatings are monomeric and oligomeric 1,6-hexamethylene diisocyanate (HDI) and isophorone diisocyanate (IPDI). Most spray painters use thin (4-5 mil) latex gloves that are not effective at preventing dermal exposures when spraying isocyanate paints. Personal interviews with collision repair industry personnel and focus groups with spray painters were held to characterize risk awareness, to examine perceptions and challenges concerning protective glove use and selection, and to generate ideas for protective glove use interventions. The most popular gloves among spray painters were thin (4-5 mil) and thick (14 mil) latex. We found that medium to thick (6-8 mil) nitrile were not always perceived as comfortable and were expected to be more expensive than thin (4-5 mil) latex gloves. Of concern is the user's difficulty in distinguishing between nitrile and latex gloves; latex gloves are now sold in different colors including blue, which has traditionally been associated with nitrile gloves. Even though spray painters were familiar with the health hazards related to working with isocyanate paints, most were not always aware that dermal exposure to isocyanates could contribute to the development of occupational asthma. There is a need for more research to identify dermal materials that are protective against sprayed automotive coatings. Automotive spray painters and their employers need to be educated in the selection and use of protective gloves, specifically on attributes such as glove material, color, and thickness.
C1 [Ceballos, Diana; Murphy-Robinson, Helen; Yost, Michael] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA.
[Reeb-Whitaker, Carolyn] Washington State Dept Labor & Ind, Safety & Hlth Assessment & Res Prevent SHARP Prog, Olympia, WA 98504 USA.
[Glazer, Patricia] Gilmore Res Grp, Seattle, WA USA.
RP Ceballos, D (reprint author), NIOSH, 4676 Columbia Pkwy,R-11, Cincinnati, OH 45226 USA.
EM DCeballos@cdc.gov
FU Automotive Service Association of Washington (ASA-WA); University of
Washington Department of Environmental and Occupational Health Sciences;
National Occupational Research Agenda Project; National Institute for
Occupational Safety and Health [R01 OH009364-01]
FX The authors are grateful to the participating spray painters, collision
repair industry personnel, and spray training facilities who volunteered
in this project. Thanks also to Mark Davey for his help with data
analysis. Special thanks for the support provided by the Automotive
Service Association of Washington (ASA-WA). The contract grant sponsors
were the University of Washington Department of Environmental and
Occupational Health Sciences and the National Occupational Research
Agenda Project. Financial support was provided by the National Institute
for Occupational Safety and Health (grant number: R01 OH009364-01).
NR 39
TC 1
Z9 1
U1 2
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 520 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1545-9624
EI 1545-9632
J9 J OCCUP ENVIRON HYG
JI J. Occup. Environ. Hyg.
PD MAY 4
PY 2014
VL 11
IS 5
BP 306
EP 313
DI 10.1080/15459624.2013.862592
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AE8QG
UT WOS:000334265800007
PM 24215135
ER
PT J
AU Roberge, RJ
Palmiero, AJ
Liu, YW
Kim, JH
Zhuang, ZQ
AF Roberge, Raymond J.
Palmiero, Andrew J.
Liu, Yuewei
Kim, Jung-Hyun
Zhuang, Ziqing
TI Effect of Upper Strap Downward Displacement on N95 Filtering Facepiece
Respirator Fit Factors: A Pilot Study
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE
LA English
DT Article
DE displacement; fit factors; N95 filtering facepiece respirators; top
strap
AB Fifteen subjects underwent three replicates of quantitative respirator fit-testing with N95 filtering facepiece respirators that were donned with the upper strap high on the occiput, as per the manufacturers' donning instructions. Each fit-test was immediately followed by repeat fit-testing with the upper strap downwardly displaced to the level of the ear sulcus to determine any change in fit factors that might occur with upper strap downward slippage. A total of 35/45 (78%) initial fit-tests had a passing score (fit factor 100) with the top strap high on the occiput and 33/35 (94%) of these passed subsequent fit-testing after the top strap was displaced downward to the ear sulcus. Geometric mean fit factors for the initial passed fit-tests, and following downward strap displacement, were 217 +/- 1.6 and 207 +/- 1.9, respectively (p = 0.64). Downward displacement of the top strap did not significantly impact fit factors of N95 FFRs that had previously passed fit-testing.
C1 [Roberge, Raymond J.; Palmiero, Andrew J.; Liu, Yuewei; Kim, Jung-Hyun; Zhuang, Ziqing] NIOSH, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, Pittsburgh, PA 15236 USA.
RP Roberge, RJ (reprint author), NIOSH, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, 626 Cochrans Mill Rd,POB 18070, Pittsburgh, PA 15236 USA.
EM dtn0@cdc.gov
RI Zhuang, Ziqing/K-5462-2012
FU Intramural CDC HHS [CC999999]
NR 20
TC 0
Z9 0
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 520 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1545-9624
EI 1545-9632
J9 J OCCUP ENVIRON HYG
JI J. Occup. Environ. Hyg.
PD MAY 4
PY 2014
VL 11
IS 5
BP 338
EP 341
DI 10.1080/15459624.2013.866716
PG 4
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AE8QG
UT WOS:000334265800010
PM 24274974
ER
PT J
AU Graham, SM
Sismanidis, C
Menzies, HJ
Marais, BJ
Detjen, AK
Black, RE
AF Graham, Stephen M.
Sismanidis, Charalambos
Menzies, Heather J.
Marais, Ben J.
Detjen, Anne K.
Black, Robert E.
TI Importance of tuberculosis control to address child survival
SO LANCET
LA English
DT Editorial Material
ID SEVERE PNEUMONIA; MORTALITY; MENINGITIS; AFRICA
C1 [Graham, Stephen M.] Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Melbourne, Vic, Australia.
[Graham, Stephen M.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
[Graham, Stephen M.; Detjen, Anne K.] Int Union TB & Lung Dis, Paris, France.
[Sismanidis, Charalambos] WHO, Global TB Programme, CH-1211 Geneva, Switzerland.
[Menzies, Heather J.] US Ctr Dis Control & Prevent, Atlanta, GA USA.
[Marais, Ben J.] Univ Sydney, Sydney Emerging Infect Dis & Biosecur Inst SEIB, Sydney Med Sch, Sydney, NSW 2006, Australia.
[Marais, Ben J.] Univ Sydney, Childrens Hosp Westmead, Sydney Med Sch, Sydney, NSW 2006, Australia.
[Black, Robert E.] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Int Programs, Baltimore, MD USA.
RP Graham, SM (reprint author), Univ Melbourne, Royal Childrens Hosp, Ctr Int Child Hlth, Dept Paediat, Flemington Rd, Parkville, Vic 3052, Australia.
EM steve.graham@rch.org.au
FU World Health Organization [001]
NR 22
TC 33
Z9 34
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAY 3
PY 2014
VL 383
IS 9928
BP 1605
EP 1607
DI 10.1016/S0140-6736(14)60420-7
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AG5YO
UT WOS:000335495400032
PM 24671079
ER
PT J
AU Mohamed, AH
Dalal, W
Nyoka, R
Burke, H
Ahmed, J
Auko, E
Shihaji, W
Ndege, I
Breiman, RF
Eidex, RB
AF Mohamed, Abdinoor Haji
Dalal, Warren
Nyoka, Raymond
Burke, Heather
Ahmed, Jamal
Auko, Erick
Shihaji, Wilbert
Ndege, Irene
Breiman, Robert F.
Eidex, Rachel B.
TI Health care utilization for acute illnesses in an urban setting with a
refugee population in Nairobi, Kenya: a cross-sectional survey
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
DE Health care utilization; Urban refugees; Eastleigh; Kenya
ID RURAL KENYA; NEEDS
AB Background: Estimates place the number of refugees in Nairobi over 100,000. The constant movement of refugees between countries of origin, refugee camps, and Nairobi poses risk of introduction and transmission of communicable diseases into Kenya. We assessed the care-seeking behavior of residents of Eastleigh, a neighborhood in Nairobi with urban refugees.
Methods: During July and August 2010, we conducted a Health Utilization Survey in Section II of Eastleigh. We used a multistage random cluster sampling design to identify households for interview. A standard questionnaire on the household demographics, water and sanitation was administered to household caretakers. Separate questionnaires were administered to household members who had one or more of the illnesses of interest.
Results: Of 785 households targeted for interview, data were obtained from 673 (85.7%) households with 3,005 residents. Of the surveyed respondents, 290 (9.7%) individuals reported acute respiratory illness (ARI) in the previous 12 months, 222 (7.4%) reported fever in the preceding 2 weeks, and 54 (1.8%) reported having diarrhea in the 30 days prior to the survey. Children <5 years old had the highest frequency of all the illnesses surveyed: 17.1% (95% CI 12.2-21.9) reported ARI, 10.0% (95% CI 6.2-13.8) reported fever, and 6.9% (3.8-10.0) reported diarrhea during the time periods specified for each syndrome. Twenty-nine [7.5% (95% CI 4.3-10.7)] hospitalizations were reported among all age groups of those who sought care. Among participants who reported >= 1 illness, 330 (77.0%) sought some form of health care; most (174 [59.8%]) sought health care services from private health care providers. Fifty-five (18.9%) participants seeking healthcare services visited a pharmacy. Few residents of Eastleigh (38 [13.1%]) sought care at government-run facilities, and 24 (8.2%) sought care from a relative, a religious leader, or a health volunteer. Of those who did not seek any health care services (99 [23.0%]), the primary reason was cost (44.8%), followed by belief that the person was not sick enough (34.6%).
Conclusion: Health care utilization in Eastleigh is high; however, a large proportion of residents opt to seek care at private clinics or pharmacies, despite the availability of accessible government-provided health care services in this area.
C1 [Mohamed, Abdinoor Haji; Auko, Erick; Ndege, Irene] Kenya Govt Med Res Ctr, Nairobi, Kenya.
[Dalal, Warren; Burke, Heather; Eidex, Rachel B.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA.
[Nyoka, Raymond; Ahmed, Jamal; Breiman, Robert F.; Eidex, Rachel B.] US Ctr Dis Control & Prevent, Refugee Hlth Program Africa, Nairobi, Kenya.
[Shihaji, Wilbert] Int Org Migrat, Nairobi, Kenya.
RP Mohamed, AH (reprint author), Kenya Govt Med Res Ctr, Mbagathi Rd Mbagathi Way,KEMRI Main Campus, Nairobi, Kenya.
EM cabeynuurdr@gmail.com
NR 31
TC 0
Z9 0
U1 1
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD MAY 2
PY 2014
VL 14
AR 200
DI 10.1186/1472-6963-14-200
PG 11
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AH3VY
UT WOS:000336055400001
PM 24885336
ER
PT J
AU Yoon, PW
Bastian, B
Anderson, RN
Collins, JL
Jaffe, HW
AF Yoon, Paula W.
Bastian, Brigham
Anderson, Robert N.
Collins, Janet L.
Jaffe, Harold W.
TI Potentially Preventable Deaths from the Five Leading Causes of Death -
United States, 2008-2010
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Bastian, Brigham; Anderson, Robert N.] Natl Ctr Hlth Stat, Div Vital Stat, Hyattsville, MD USA.
[Collins, Janet L.] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA USA.
[Jaffe, Harold W.] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA.
EM pyoon@cdc.gov
NR 9
TC 38
Z9 39
U1 3
U2 10
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 2
PY 2014
VL 63
IS 17
BP 369
EP 374
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AG6GL
UT WOS:000335517000001
PM 24785982
ER
PT J
AU Zeigler, M
Claar, C
Rice, D
Davis, J
Frazier, T
Turner, A
Kelley, C
Capps, J
Kent, A
Hubbard, V
Ritenour, C
Tuscano, C
Qiu-Shultz, Z
Leaumont, CF
AF Zeigler, Mariah
Claar, Chad
Rice, Daviesha
Davis, Jack
Frazier, Tammy
Turner, Alex
Kelley, Corinna
Capps, Jonathan
Kent, Andrea
Hubbard, Valerie
Ritenour, Christiana
Tuscano, Cristina
Qiu-Shultz, Zuwen
Leaumont, Collette Fitzgerald
TI Outbreak of Campylobacteriosis Associated with a Long-Distance Obstacle
Adventure Race - Nevada, October 2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID JEJUNI; COLI
C1 [Zeigler, Mariah; Claar, Chad; Rice, Daviesha; Davis, Jack; Frazier, Tammy; Turner, Alex; Kelley, Corinna; Capps, Jonathan; Kent, Andrea; Hubbard, Valerie; Ritenour, Christiana; Tuscano, Cristina] Nellis Air Force Base Publ Hlth Flight, Nellis Air Force Base, NV 89191 USA.
[Qiu-Shultz, Zuwen] Southern Nevada Hlth Dist, Las Vegas, NV USA.
[Leaumont, Collette Fitzgerald] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Claar, C (reprint author), Nellis Air Force Base Publ Hlth Flight, Nellis Air Force Base, NV 89191 USA.
EM chad.claar@nellis.af.mil
NR 10
TC 6
Z9 7
U1 0
U2 3
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 2
PY 2014
VL 63
IS 17
BP 375
EP 378
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AG6GL
UT WOS:000335517000002
PM 24785983
ER
PT J
AU Barbour, KE
Stevens, JA
Helmick, CG
Luo, YH
Murphy, LB
Hootman, JM
Theis, K
Anderson, LA
Baker, NA
Sugerman, DE
AF Barbour, Kamil E.
Stevens, Judy A.
Helmick, Charles G.
Luo, Yao-Hua
Murphy, Louise B.
Hootman, Jennifer M.
Theis, Kristina
Anderson, Lynda A.
Baker, Nancy A.
Sugerman, David E.
TI Falls and Fall Injuries Among Adults with Arthritis - United States,
2012
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
ID PREVALENCE
C1 [Barbour, Kamil E.; Helmick, Charles G.; Luo, Yao-Hua; Murphy, Louise B.; Hootman, Jennifer M.; Theis, Kristina; Anderson, Lynda A.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Stevens, Judy A.; Sugerman, David E.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.
[Baker, Nancy A.] Univ Pittsburgh, Dept Occupat Therapy, Pittsburgh, PA 15260 USA.
RP Barbour, KE (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
EM kbarbour@cdc.gov
NR 10
TC 13
Z9 13
U1 0
U2 4
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 2
PY 2014
VL 63
IS 17
BP 379
EP 383
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AG6GL
UT WOS:000335517000003
PM 24785984
ER
PT J
AU de Perio, MA
Bernard, BP
Delaney, LJ
Pesik, N
Cohen, NJ
AF de Perio, Marie A.
Bernard, Bruce P.
Delaney, Lisa J.
Pesik, Nicki
Cohen, Nicole J.
TI Investigation of Infectious Disease Risks Associated With a
Nontransplant Anatomical Donation Center - Arizona, 2014
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [de Perio, Marie A.; Bernard, Bruce P.; Delaney, Lisa J.] CDC, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA.
[Pesik, Nicki; Cohen, Nicole J.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP de Perio, MA (reprint author), CDC, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA.
EM mdeperio@cdc.gov
NR 3
TC 0
Z9 0
U1 0
U2 1
PU CENTER DISEASE CONTROL & PREVENTION
PI ATLANTA
PA MAILSTOP E-90, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD MAY 2
PY 2014
VL 63
IS 17
BP 384
EP 385
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AG6GL
UT WOS:000335517000004
PM 24785985
ER
PT J
AU Mitchell, T
Massoudi, M
Swerdlow, DL
Dee, DL
Gould, LH
Kutty, PK
Prime, MS
Silverman, PR
Fishbein, DB
AF Mitchell, Tarissa
Massoudi, Mehran
Swerdlow, David L.
Dee, Deborah L.
Gould, L. Hannah
Kutty, Preeta K.
Prime, Marilyn S.
Silverman, Paul R.
Fishbein, Daniel B.
TI Swine Flu in College: Early Campus Response to Outbreak Control Measures
SO AMERICAN JOURNAL OF HEALTH BEHAVIOR
LA English
DT Article
DE pandemics; H1N1Virus; universities; prevention and control
ID INFLUENZA-A H1N1; APRIL-MAY 2009; NONPHARMACEUTICAL INTERVENTIONS;
PANDEMIC INFLUENZA; PUBLIC UNIVERSITY; A(H1N1)
AB Objectives: To describe student and faculty attitudes towards and adherence to nonpharmaceutical control measures during the first-known university outbreak of 2009 pandemic influenza A (H1N1). Methods: Preferred information sources, control measure adherence and likelihood of adherence during future outbreaks, and perceived illness risk, were explored through focus groups and patient interviews. Results: We conducted 7 focus groups (N=48) and 9 patient interviews. Measures (eg, hand hygiene, self-isolation while ill) were initially heeded. Limited information regarding A(H1N1) pdm09, insufficient understanding of university decisions, and perceived university alert overuse led to reports that future outbreaks would be regarded less seriously. Conclusions: Reported concern and commitment to recommendations decreased rapidly. Initial university messaging and response was critical in shaping participants' later perceptions.
C1 [Mitchell, Tarissa; Fishbein, Daniel B.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
[Mitchell, Tarissa] Southeast Permanente Med Grp, Atlanta, GA USA.
[Massoudi, Mehran] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA USA.
[Swerdlow, David L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Dee, Deborah L.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA.
[Gould, L. Hannah] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
[Kutty, Preeta K.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA.
[Prime, Marilyn S.] Univ Delaware, Student Ctr, Newark, DE USA.
[Silverman, Paul R.] Delaware Div Publ Hlth, Delaware, OH USA.
[Fishbein, Daniel B.] Myanmar Res Int, Yangon, Myanmar.
RP Mitchell, T (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
EM TMitchell1@cdc.gov
NR 22
TC 1
Z9 1
U1 0
U2 162
PU PNG PUBLICATIONS
PI OAK RIDGE
PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA
SN 1945-7359
J9 AM J HEALTH BEHAV
JI Am. J. Health Behav.
PD MAY
PY 2014
VL 38
IS 3
BP 448
EP 464
DI 10.5993/AJHB.38.3.14
PG 17
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AS1JB
UT WOS:000344036300014
PM 25181765
ER
PT J
AU Bi, ZQ
Liang, XF
Xu, AQ
Wang, LH
Shi, XM
Zhao, WH
Ma, JX
Guo, XL
Zhang, XF
Zhang, JY
Ren, J
Yan, LX
Lu, ZL
Wang, HC
Tang, JL
Cai, XN
Dong, J
Zhang, J
Chu, J
Engelgau, M
Yang, QH
Hong, YL
Wang, Y
AF Bi, Zhenqiang
Liang, Xiaofeng
Xu, Aiqiang
Wang, Linghong
Shi, Xiaoming
Zhao, Wenhua
Ma, Jixiang
Guo, Xiaolei
Zhang, Xiaofei
Zhang, Jiyu
Ren, Jie
Yan, Liuxia
Lu, Zilong
Wang, Huicheng
Tang, Junli
Cai, Xiaoning
Dong, Jing
Zhang, Juan
Chu, Jie
Engelgau, Michael
Yang, Quanhe
Hong, Yuling
Wang, Yu
TI Hypertension Prevalence, Awareness, Treatment, and Control and Sodium
Intake in Shandong Province, China: Baseline Results From
Shandong-Ministry of Health Action on Salt Reduction and Hypertension
(SMASH), 2011
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID DIETARY; TRENDS
AB Introduction
In China, population-based blood pressure levels and prevalence of hypertension are increasing. Meanwhile, sodium intake, a major risk factor for hypertension, is high. In 2011, to develop intervention priorities for a salt reduction and hypertension control project in Shandong Province (population 96 million), a cross-sectional survey was conducted to collect information on sodium intake and hypertension prevalence, awareness, treatment, and control.
Methods
Complex, multistage sampling methods were used to select a provincial-representative adult sample. Blood pressure was measured and a survey conducted among all participants; condiments were weighed in the household, a 24-hour dietary recall was conducted, and urine was collected. Hypertension was determined by blood pressure measured on a single occasion and self-reported use of antihypertension medications.
Results
Overall, 23.4% (95% confidence interval [CI], 20.9%-26.0%) of adults in Shandong were estimated to have hypertension. Among those classified as having hypertension, approximately one-third (34.5%) reported having hypertension, approximately one-fourth (27.5%) reported taking medications, and one-seventh (14.9%) had their blood pressure controlled (<140/<90 mm Hg). Estimated total average daily dietary sodium intake was 5,745 mg (95% CI, 5,428 mg-6,063 mg). Most dietary sodium (80.8%) came from salt and high-salt condiments added during cooking: a sodium intake of 4,640 mg (95% CI, 4,360 mg-4,920 mg). The average daily urinary sodium excretion was 5,398 mg (95% CI, 5,112 mg-5,683 mg).
Conclusion
Hypertension and excessive sodium intake in adults are major public health problems in Shandong Province, China.
C1 [Liang, Xiaofeng; Shi, Xiaoming; Zhao, Wenhua; Wang, Huicheng; Zhang, Juan; Wang, Yu] Chinese Ctr Dis Control & Prevent, Beijing 102206, Peoples R China.
[Bi, Zhenqiang; Xu, Aiqiang; Guo, Xiaolei; Zhang, Jiyu; Ren, Jie; Lu, Zilong; Tang, Junli; Dong, Jing; Chu, Jie] Shandong Univ, Acad Prevent Med, Jinan 250100, Peoples R China.
[Bi, Zhenqiang; Xu, Aiqiang; Guo, Xiaolei; Zhang, Jiyu; Ren, Jie; Lu, Zilong; Tang, Junli; Dong, Jing; Chu, Jie] Shandong Ctr Dis Control & Prevent, Jinan, Peoples R China.
[Wang, Linghong; Ma, Jixiang; Yan, Liuxia; Cai, Xiaoning] Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing 102206, Peoples R China.
[Zhang, Xiaofei] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China.
[Engelgau, Michael; Yang, Quanhe; Hong, Yuling] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Wang, Y (reprint author), Chinese Ctr Dis Control & Prevent, 155 Changbai Rd, Beijing 102206, Peoples R China.
EM wangyu@chinacdc.cn
FU Chinese Center for Disease Control and Prevention (CDC); National Center
for Non-communicable and Chronic Disease Control and Prevention;
Technical Development Plan in Shandong [2012GSF11828]
FX The survey was supported by funds from Chinese Center for Disease
Control and Prevention (CDC), National Center for Non-communicable and
Chronic Disease Control and Prevention, the Technical Development Plan
in Shandong (implemented by Shandong CDC, grant no. 2012GSF11828). We
thank all investigators from the national, provincial, and county-level
CDC and all participants of the survey. We also acknowledge Ying Cai and
Sonia Angell for their review of the study design and advice on
implementation of the field intervention. The findings and conclusions
in this report are those of the authors and do not necessarily represent
the official position of the US Centers for Disease Control and
Prevention. There are no conflicts of interest relevant to this article.
NR 30
TC 5
Z9 5
U1 0
U2 16
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD MAY
PY 2014
VL 11
AR 130423
DI 10.5888/pcd11.130423
PG 15
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AR3XH
UT WOS:000343522000021
ER
PT J
AU Greer, S
Schieb, L
Schwartz, G
Onufrak, S
Park, S
AF Greer, Sophia
Schieb, Linda
Schwartz, Greg
Onufrak, Stephen
Park, Sohyun
TI Association of the Neighborhood Retail Food Environment with Sodium and
Potassium Intake Among US Adults
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID LOWER MISSISSIPPI DELTA; ATHEROSCLEROSIS RISK; UNITED-STATES; STORES;
AVAILABILITY; SUPERMARKETS; COMMUNITIES; POPULATION; VEGETABLES; OBESITY
AB Introduction
High sodium intake and low potassium intake, which can contribute to hypertension and risk of cardiovascular disease, may be related to the availability of healthful food in neighborhood stores. Despite evidence linking food environment with diet quality, this relationship has not been evaluated in the United States. The modified retail food environment index (mRFEI) provides a composite measure of the retail food environment and represents the percentage of healthful-food vendors within a 0.5 mile buffer of a census tract.
Methods
We analyzed data from 8,779 participants in the National Health and Nutrition Examination Survey, 2005-2008. By using linear regression, we assessed the relationship between mRFEI and sodium intake, potassium intake, and the sodium potassium ratio. Models were stratified by region (South and non-South) and included participant and neighborhood characteristics.
Results
In the non-South region, higher mRFEI scores (indicating a more healthful food environment) were not associated with sodium intake, were positively associated with potassium intake (P [trend] = .005), and were negatively associated with the sodium potassium ratio (P [trend] = .02); these associations diminished when neighborhood characteristics were included, but remained close to statistical significance for potassium intake (P [trend] = .05) and sodium potassium ratio (P [trend] = .07). In the South, mRFEI scores were not associated with sodium intake, were negatively associated with potassium intake (P [trend] = < .001), and were positively associated with sodium potassium ratio (P [trend] = .01). These associations also diminished after controlling for neighborhood characteristics for both potassium intake (P [trend] = .03) and sodium potassium ratio (P [trend] = .40).
Conclusion
We found no association between mRFEI and sodium intake. The association between mRFEI and potassium intake and the sodium potassium ratio varied by region. National strategies to reduce sodium in the food supply may be most effective to reduce sodium intake. Strategies aimed at the local level should consider regional context and neighborhood characteristics.
C1 [Greer, Sophia; Schieb, Linda; Onufrak, Stephen; Park, Sohyun] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA.
[Schwartz, Greg] Vet Hlth Adm, Seattle, WA USA.
RP Greer, S (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,MS F-72, Atlanta, GA 30341 USA.
EM sgreer@cdc.gov
NR 28
TC 1
Z9 1
U1 1
U2 1
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD MAY
PY 2014
VL 11
AR 130340
DI 10.5888/pcd11.130340
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AR3XH
UT WOS:000343522000014
ER
PT J
AU Valdiserri, R
Khalsa, J
Dan, C
Holmberg, S
Zibbell, J
Holtzman, D
Lubran, R
Compton, W
AF Valdiserri, Ronald
Khalsa, Jag
Dan, Corinna
Holmberg, Scott
Zibbell, Jon
Holtzman, Deborah
Lubran, Robert
Compton, Wilson
TI Confronting the Emerging Epidemic of HCV Infection Among Young Injection
Drug Users
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID HEPATITIS-C VIRUS; UNITED-STATES; USE DISORDERS; NEW-YORK; RISK; ABUSE;
ADOLESCENTS; HEALTH; ADULTS; HIV
AB Hepatitis C virus infection is a significant public health problem in the United States and an important cause of morbidity and mortality. Recent reports document HCV infection increases among young injection drug users in several US regions, associated with America's prescription opioid abuse epidemic. Incident HCV infection increases among young injectors who have recently transitioned from oral opioid abuse present an important public health challenge requiring a comprehensive, community-based response. We summarize recommendations from a 2013 Office of HIV/AIDS and Infectious Disease Policy convening of experts in epidemiology, behavioral science, drug prevention and treatment, and other research; community service providers; and federal, state, and local government representatives. Their observations highlight gaps in our surveillance, program, and research portfolios and advocate a syndemic approach to this emerging public health problem.
C1 [Valdiserri, Ronald; Dan, Corinna] US Dept HHS, Off HIV AIDS & Infect Dis Policy, Washington, DC 20201 USA.
[Khalsa, Jag; Compton, Wilson] NIDA, Bethesda, MD 20892 USA.
[Lubran, Robert] Subst Abuse & Mental Hlth Serv Adm, Rockville, MD USA.
[Holmberg, Scott; Zibbell, Jon; Holtzman, Deborah] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Valdiserri, R (reprint author), US Dept HHS, 200 Independence Ave SW,Room 443-H, Washington, DC 20201 USA.
EM ron.valdiserri@hhs.gov
OI Lubran, Robert/0000-0003-1235-5207
NR 51
TC 28
Z9 28
U1 2
U2 6
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD MAY
PY 2014
VL 104
IS 5
BP 816
EP 821
DI 10.2105/AJPH.2013.301812
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AP0XU
UT WOS:000341790600022
PM 24625174
ER
PT J
AU Anderson, AR
Welles, WL
Drew, J
Orr, MF
AF Anderson, Ayana R.
Welles, Wanda Lizak
Drew, James
Orr, Maureen F.
TI The Distribution and Public Health Consequences of Releases of Chemicals
Intended for Pool Use in 17 States, 2001-2009
SO JOURNAL OF ENVIRONMENTAL HEALTH
LA English
DT Article
ID UNITED-STATES; SWIMMING POOLS; EXPOSURE; CHLORINE; EVENTS
AB To keep swimming pool water clean and clear, consumers purchase, transport, store, use, and dispose of large amounts of potentially hazardous chemicals. Data about incidents due to the use of these chemicals and the resultant public health impacts are limited. The authors analyzed pool chemical release data from 17 states that participated in the Agency for Toxic Substances and Disease Registry's chemical event surveillance system during 2001-2009. In 400 pool chemical incidents, 60% resulted in injuries. Of the 732 injured persons, 67% were members of the public and 50% were under 18 years old. Incidents occurred most frequently in private residences (39%), but incidents with the most injured persons (34%) occurred at recreational facilities. Human error (71.9%) was the most frequent primary contributing factor, followed by equipment failure (22.8%). Interventions designed to mitigate the public health impact associated with pool chemical releases should target both private pool owners and public pool operators.
C1 [Anderson, Ayana R.; Orr, Maureen F.] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA.
[Welles, Wanda Lizak] New York State Dept Hlth, Bur Tox Subst Assessment, Albany, NY 12237 USA.
[Drew, James] Wisconsin Dept Hlth Serv, Bur Environm & Occupat Hlth, Madison, WI USA.
RP Anderson, AR (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, 4770 Buford Hwy,MS F58, Atlanta, GA 30341 USA.
EM ing9@cdc.gov
NR 18
TC 3
Z9 3
U1 0
U2 2
PU NATL ENVIRON HEALTH ASSOC
PI DENVER
PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA
SN 0022-0892
J9 J ENVIRON HEALTH
JI J. Environ. Health
PD MAY
PY 2014
VL 76
IS 9
BP 10
EP 15
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AO7NT
UT WOS:000341540600002
PM 24909007
ER
PT J
AU Blake, R
AF Blake, Robert
TI Update on the Model Aquatic Health Code
SO JOURNAL OF ENVIRONMENTAL HEALTH
LA English
DT Article
ID SWIMMING POOL
AB NEHA strives to provide up-to-date and relevant information on environmental health and to build partnerships in the profession. In pursuit of these goals, we feature a column from the Environmental Health Services Branch (EHSB) of the Centers for Disease Control and Prevention (CDC) in every issue of the Journal.
In this column, EHSB and guest authors from across CDC will highlight a variety of concerns, opportunities, challenges, and successes that we all share in environmental public health. EHSB's objective is to strengthen the role of state, local, tribal, and national environmental health programs and professionals to anticipate, identify, and respond to adverse environmental exposures and the consequences of these exposures for human health. The conclusions in this article are those of the author(s) and do not necessarily represent the views of CDC.
Robert Blake is a health scientist of the EHSB at CDC and has been working in the environmental health field for more than 30 years.
C1 CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
RP Blake, R (reprint author), CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-58, Atlanta, GA 30341 USA.
EM rgblake@cdc.gov
FU CLC NIH HHS [NIH0010192010]
NR 4
TC 0
Z9 0
U1 0
U2 1
PU NATL ENVIRON HEALTH ASSOC
PI DENVER
PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA
SN 0022-0892
J9 J ENVIRON HEALTH
JI J. Environ. Health
PD MAY
PY 2014
VL 76
IS 9
BP 34
EP +
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AO7NT
UT WOS:000341540600006
PM 24909011
ER
PT J
AU Moore, JM
AF Moore, Jennifer M.
TI CDC's National Environmental Public Health Tracking Network Classroom
Modules
SO JOURNAL OF ENVIRONMENTAL HEALTH
LA English
DT Article
AB As part of our continuing effort to highlight innovative approaches and tools to improve the health and environment of communities, the Journal is pleased to publish a bimonthly column from the Centers for Disease Control and Prevention's (CDC's) Environmental Public Health Tracking Network (Tracking Network). The Tracking Network is a system of integrated health, exposure, and hazard information and data from a variety of national, state, and city sources. The Tracking Network brings together data concerning health and environmental problems with the goal of providing information to help improve where we live, work, and play.
Environmental causes of chronic diseases are hard to identify Measuring amounts of hazardous substances in our environment in a standard way, tracing the spread of these over time and area, seeing how they show up in human tissues, and understanding how they may cause illness is critical. The Tracking Network is a tool that can help connect these efforts. Through these columns, readers will learn about the program and the resources, tools, and information available from CDC's Tracking Network.
The conclusions of this article are those of the author(s) and do not necessarily represent the views of CDC.
Jennifer Moore is a health communication specialist within CDC's Environmental Health Tracking Branch and has been with CDC for six years. She has extensive experience in health communications and education.
C1 CDC, Environm Hlth Tracking Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
RP Moore, JM (reprint author), CDC, Environm Hlth Tracking Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-60, Atlanta, GA 30341 USA.
EM JMMoore@cdc.gov
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATL ENVIRON HEALTH ASSOC
PI DENVER
PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA
SN 0022-0892
J9 J ENVIRON HEALTH
JI J. Environ. Health
PD MAY
PY 2014
VL 76
IS 9
BP 38
EP 39
PG 2
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AO7NT
UT WOS:000341540600007
PM 24909012
ER
PT J
AU Yokoe, DS
Anderson, DJ
Berenholtz, SM
Calfee, DP
Dubberke, ER
Ellingson, K
Gerding, DN
Haas, J
Kaye, KS
Klompas, M
Lo, E
Marschall, J
Mermel, LA
Nicolle, L
Salgado, C
Bryant, K
Classen, D
Crist, K
Foster, N
Humphreys, E
Padberg, J
Podgorny, K
VanAmringe, M
Weaver, T
Wise, R
Maragakis, LL
AF Yokoe, Deborah S.
Anderson, Deverick J.
Berenholtz, Sean M.
Calfee, David P.
Dubberke, Erik R.
Ellingson, Katherine
Gerding, Dale N.
Haas, Janet
Kaye, Keith S.
Klompas, Michael
Lo, Evelyn
Marschall, Jonas
Mermel, Leonard A.
Nicolle, Lindsay
Salgado, Cassandra
Bryant, Kristina
Classen, David
Crist, Katrina
Foster, Nancy
Humphreys, Eve
Padberg, Jennifer
Podgorny, Kelly
VanAmringe, Margaret
Weaver, Tom
Wise, Robert
Maragakis, Lisa L.
TI Introduction to "A Compendium of Strategies to Prevent
Healthcare-Associated Infections in Acute Care Hospitals: 2014 Updates"
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
AB Since the publication of "A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals" in 2008, prevention of healthcare-associated infections (HAIs) has become a national priority. Despite improvements, preventable HAIs continue to occur. The 2014 updates to the Compendium were created to provide acute care hospitals with up-to-date, practical, expert guidance to assist in prioritizing and implementing their HAI prevention efforts. It is the product of a highly collaborative effort led by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), the American Hospital Association (AHA), the Association for Professionals in Infection Control and Epidemiology (APIC), and The Joint Commission, with major contributions from representatives of a number of organizations and societies with content expertise, including the Centers for Disease Control and Prevention (CDC), the Institute for Healthcare Improvement (IHI), the Pediatric Infectious Diseases Society (PIDS), the Society for Critical Care Medicine (SCCM), the Society for Hospital Medicine (SHM), and the Surgical Infection Society (SIS).
C1 [Yokoe, Deborah S.; Klompas, Michael] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Yokoe, Deborah S.; Klompas, Michael] Harvard Univ, Sch Med, Boston, MA USA.
[Anderson, Deverick J.] Duke Univ, Med Ctr, Durham, NC USA.
[Berenholtz, Sean M.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Calfee, David P.] Weill Cornell Med Coll, New York, NY USA.
[Dubberke, Erik R.; Marschall, Jonas] Washington Univ, Sch Med, St Louis, MO USA.
[Ellingson, Katherine] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Gerding, Dale N.] Loyola Univ, Chicago Stritch Sch Med, Chicago, IL 60611 USA.
[Haas, Janet] Westchester Cty Med Ctr, Valhalla, NY 10595 USA.
[Haas, Janet] New York Med Coll, Valhalla, NY 10595 USA.
[Kaye, Keith S.] Detroit Med Ctr, Detroit, MI USA.
[Kaye, Keith S.] Wayne State Univ, Detroit, MI USA.
[Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Lo, Evelyn] St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada.
[Lo, Evelyn; Nicolle, Lindsay] Univ Manitoba, Winnipeg, MB, Canada.
[Marschall, Jonas] Univ Hosp Bern, CH-3010 Bern, Switzerland.
[Marschall, Jonas] Univ Bern, Bern, Switzerland.
[Mermel, Leonard A.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
[Mermel, Leonard A.] Rhode Isl Hosp, Providence, RI USA.
[Nicolle, Lindsay] Hlth Sci Ctr, Winnipeg, MB, Canada.
[Salgado, Cassandra] Med Univ S Carolina, Charleston, SC 29425 USA.
[Bryant, Kristina] Univ Louisville, Louisville, KY 40292 USA.
[Classen, David] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Crist, Katrina; Weaver, Tom] Assoc Profess Infect Control & Epidemiol, Washington, DC USA.
[Foster, Nancy] Amer Hosp Assoc, Washington, DC USA.
[Humphreys, Eve] Soc Healthcare Epidemiol Amer, Arlington, VA USA.
[Padberg, Jennifer] Infect Dis Soc Amer, Arlington, VA USA.
[Podgorny, Kelly; VanAmringe, Margaret; Wise, Robert] Joint Commiss, Oak Brook Terrace, IL USA.
[Maragakis, Lisa L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
RP Yokoe, DS (reprint author), 181 Longwood Ave, Boston, MA 02115 USA.
EM dyokoe@partners.org
FU Society for Healthcare Epidemiology of America
FX Support for this Compendium was provided by the Society for Healthcare
Epidemiology of America.
NR 14
TC 0
Z9 0
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD MAY 1
PY 2014
VL 35
IS 5
BP 455
EP 459
DI 10.1086/675819
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AE4EI
UT WOS:000333933900001
ER
PT J
AU Lo, E
Nicolle, LE
Coffin, SE
Gould, C
Maragakis, LL
Meddings, J
Pegues, DA
Pettis, AM
Saint, S
Yokoe, DS
AF Lo, Evelyn
Nicolle, Lindsay E.
Coffin, Susan E.
Gould, Carolyn
Maragakis, Lisa L.
Meddings, Jennifer
Pegues, David A.
Pettis, Ann Marie
Saint, Sanjay
Yokoe, Deborah S.
TI Strategies to Prevent Catheter-Associated Urinary Tract Infections in
Acute Care Hospitals: 2014 Update
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; CONTROL CONSORTIUM INICC; NOSOCOMIAL
INFECTIONS; DEVELOPING-COUNTRIES; UNITED-STATES; RATES; BACTERIURIA;
QUALITY; EPIDEMIOLOGY; RECOMMENDATIONS
C1 [Lo, Evelyn] St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada.
[Lo, Evelyn; Nicolle, Lindsay E.] Univ Manitoba, Winnipeg, MB, Canada.
[Nicolle, Lindsay E.] Hlth Sci Ctr, Winnipeg, MB, Canada.
[Coffin, Susan E.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Gould, Carolyn] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Maragakis, Lisa L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Meddings, Jennifer] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Pegues, David A.] Hosp Univ Penn, Philadelphia, PA 19104 USA.
[Pegues, David A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Pettis, Ann Marie] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Saint, Sanjay] Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI USA.
[Saint, Sanjay] Univ Michigan, Ann Arbor, MI 48109 USA.
[Yokoe, Deborah S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Yokoe, Deborah S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Nicolle, LE (reprint author), GG 443 Hlth Sci Ctr, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.
EM lnicolle@exchange.hsc.mb.ca
FU Cangene Corporation
FX Authors report the following. E.L.-research grants/contracts: Cangene
Corporation, antibody responses to C. difficile-associated diarrhea;
research with Virox Industries, HAI response to environmental
disinfection. L.E.N.-advisory/consultant role: Cerena, Johnson &
Johnson. D.A.P.-advisory/consultant role: InVentiv; honoraria: Health
Research and Educational Trust/American Hospital Association,
RandHealth. A.M.P.-served as a speaker for Bard; served as a speaker and
author for Covidien. S.S.-honoraria and speaking fees for lectures on
healthcare-associated infection prevention, implementation science, and
patient safety from hospitals, academic medical centers, professional
societies, and non-profit foundations (none of these activities are
related to speakers' bureaus); medical advisory board: Doximity (a new
social networking site for physicians), Jvion (a healthcare technology
company). S.E.C., C.G., L.L.M., J.M., D.S.Y.- nothing to disclose.
NR 77
TC 0
Z9 0
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD MAY 1
PY 2014
VL 35
IS 5
BP 464
EP 479
DI 10.1086/675718
PG 16
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AE4EI
UT WOS:000333933900003
ER
PT J
AU Battalora, L
Buchacz, K
Armon, C
Overton, ET
Hammer, J
Patel, P
Chmiel, JS
Wood, K
Brooks, JT
Young, B
AF Battalora, L.
Buchacz, K.
Armon, C.
Overton, E. T.
Hammer, J.
Patel, P.
Chmiel, J. S.
Wood, K.
Brooks, J. T.
Young, B.
TI NEW FRACTURE RISK AND FRAX 10-YEAR PROBABILITY OF FRACTURE IN
HIV-INFECTED ADULTS
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Battalora, L.] Colorado Sch Mines, Golden, CO 80401 USA.
[Buchacz, K.; Patel, P.; Brooks, J. T.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Armon, C.; Wood, K.] Cerner Corp, Vienna, VA USA.
[Overton, E. T.] Univ Alabama Birmingham, Birmingham, AL USA.
[Hammer, J.] Denver Infect Dis Consultants, Denver, CO USA.
[Chmiel, J. S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Young, B.] Int Assoc Providers AIDS Care, Washington, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2014
VL 17
IS 3
MA PIN20
BP A268
EP A268
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA AO1OG
UT WOS:000341082001602
ER
PT J
AU Battalora, L
Buchacz, K
Armon, C
Overton, ET
Hammer, J
Patel, P
Chmiel, JS
Bush, TJ
Brooks, JT
Young, B
AF Battalora, L.
Buchacz, K.
Armon, C.
Overton, E. T.
Hammer, J.
Patel, P.
Chmiel, J. S.
Bush, T. J.
Brooks, J. T.
Young, B.
TI LOW BONE MINERAL DENSITYIS ASOCIATED WITH INCREASED RISK OF INCIDENT
FRACTURE IN HIV plus ADULTS
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Battalora, L.] Colorado Sch Mines, Golden, CO 80401 USA.
[Buchacz, K.; Patel, P.; Bush, T. J.; Brooks, J. T.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Armon, C.] Cerner Corp, Vienna, VA USA.
[Overton, E. T.] Univ Alabama Birmingham, Birmingham, AL USA.
[Hammer, J.] Denver Infect Dis Consultants, Denver, CO USA.
[Chmiel, J. S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Young, B.] Int Assoc Providers AIDS Care, Washington, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2014
VL 17
IS 3
MA PIN18
BP A268
EP A268
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA AO1OG
UT WOS:000341082001600
ER
PT J
AU Chung, JK
Cassell, CH
Honein, MA
Olney, RS
Grosse, SD
AF Chung, J. K.
Cassell, C. H.
Honein, M. A.
Olney, R. S.
Grosse, S. D.
TI HEALTH CARE UTILIZATION AND COSTS AMONG PRIVATELY INSURED CHILDREN WITH
OROFACIAL CLEFTS
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Chung, J. K.; Cassell, C. H.; Honein, M. A.; Olney, R. S.; Grosse, S. D.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2014
VL 17
IS 3
MA PIH80
BP A167
EP A168
PG 2
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA AO1OG
UT WOS:000341082001046
ER
PT J
AU Ekwueme, DU
Trogdon, J
Khavjou, O
Guy, G
Li, C
AF Ekwueme, D. U.
Trogdon, J.
Khavjou, O.
Guy, Jr G.
Li, C.
TI ESTIMATING MORBIDITY COSTS ATTRIBUTABLE TO BREAST CANCER AMONG YOUNGER
WOMEN AGED 18 TO 44 YEARS-UNITED STATES, 2000-2010
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Ekwueme, D. U.; Guy, Jr G.; Li, C.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Trogdon, J.] Univ N Carolina, Chapel Hill, GA USA.
[Khavjou, O.] RTI Int, Chapel Hill, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2014
VL 17
IS 3
MA PHS28
BP A130
EP A130
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA AO1OG
UT WOS:000341082000709
ER
PT J
AU Ortega-Sanchez, I
AF Ortega-Sanchez, I
TI REVISITING THE COST-EFFECTIVENESS OF HERPES ZOSTER VACCINATION IN
ELDERLY PEOPLE IN THE UNITED STATES
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Ortega-Sanchez, I] Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2014
VL 17
IS 3
MA PIH31
BP A159
EP A159
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA AO1OG
UT WOS:000341082000873
ER
PT J
AU Palella, FJ
Armon, C
Chmiel, JS
Brooks, JT
Debes, R
Novak, RM
Yangco, BG
Wood, K
Durham, M
Buchacz, K
AF Palella, F. J.
Armon, C.
Chmiel, J. S.
Brooks, J. T.
Debes, R.
Novak, R. M.
Yangco, B. G.
Wood, K.
Durham, M.
Buchacz, K.
TI HIGHER CD4 AT ART INITIATION PREDICTS GREATER LONG TERM LIKELIHOOD OF
CD4 NORMALIZATION
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Palella, F. J.; Chmiel, J. S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Armon, C.; Wood, K.] Cerner Corp, Vienna, VA USA.
[Brooks, J. T.; Durham, M.; Buchacz, K.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Debes, R.] Cerner Corp, North Kansas City, MO USA.
[Novak, R. M.] Univ Illinois, Chicago, IL USA.
[Yangco, B. G.] Infect Dis Res Inst, Tampa, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2014
VL 17
IS 3
MA PIN24
BP A269
EP A269
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA AO1OG
UT WOS:000341082001606
ER
PT J
AU Peasah, SK
Purakayastha, DR
Koul, P
Dawood, F
Saha, S
Broor, S
Rastogi, V
Widdowson, MA
Lal, R
Krishnan, A
AF Peasah, S. K.
Purakayastha, Ram D.
Koul, P.
Dawood, F.
Saha, S.
Broor, S.
Rastogi, V
Widdowson, M. A.
Lal, R.
Krishnan, A.
TI THE COST OF HOSPITALIZATION DUE TO ACUTE RESPIRATORY INFECTIONS IN
NORTHERN INDIA
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Peasah, S. K.] Mercer Univ, Atlanta, GA USA.
[Purakayastha, Ram D.; Krishnan, A.] All India Inst Med Sci, New Delhi, India.
[Koul, P.] Sheri Kashmir Inst Med Sci, Srinagar, Jammu & Kashmir, India.
[Dawood, F.; Widdowson, M. A.] CDC, Atlanta, GA 30333 USA.
[Saha, S.; Lal, R.] CDC India, New Delhi, India.
[Broor, S.; Rastogi, V] Inclen Trust Labs, New Delhi, India.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2014
VL 17
IS 3
MA PHS33
BP A130
EP A131
PG 2
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA AO1OG
UT WOS:000341082000714
ER
PT J
AU Zhuo, X
AF Zhuo, X.
TI TREND OF THE UTILIZATION AND COST OF PRESCRIPTION MEDICATIONS AMONG
DIABETES PATIENTS IN THE UNITED STATES: 1987 TO 2010
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Zhuo, X.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2014
VL 17
IS 3
MA PDB133
BP A261
EP A261
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA AO1OG
UT WOS:000341082001562
ER
PT J
AU Black, MC
Basile, KC
Breiding, MJ
Ryan, GW
AF Black, Michele C.
Basile, Kathleen C.
Breiding, Matthew J.
Ryan, George W.
TI Prevalence of Sexual Violence Against Women in 23 States and Two US
Territories, BRFSS 2005
SO VIOLENCE AGAINST WOMEN
LA English
DT Article
DE prevalence; rape; sexual violence
ID DIGIT-DIAL SURVEYS; INJURY-PREVENTION; RAPE; NONRESPONSE; AGGRESSION;
SCOPE
AB Sexual violence (SV) is a significant public health problem. Using data from the 2005 Behavioral Risk Factor Surveillance System (BRFSS), this article provides state-specific 12-month SV prevalence data for women residing in 23 states and two territories. Overall, more than 500,000 women in the participating states experienced completed or attempted nonconsensual sex in the 12-month period prior to the survey. The collection of state-level data using consistent, uniform, and behaviorally specific SV definitions enables states to evaluate the magnitude of the problem within their state and informs the development and evaluation of state-level SV programs, policies, and prevention efforts.
C1 [Black, Michele C.; Basile, Kathleen C.; Breiding, Matthew J.; Ryan, George W.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA.
RP Basile, KC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE, Atlanta, GA 30341 USA.
EM ksb9@cdc.gov
NR 29
TC 1
Z9 1
U1 2
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1077-8012
EI 1552-8448
J9 VIOLENCE AGAINST WOM
JI Violence Against Women
PD MAY
PY 2014
VL 20
IS 5
BP 485
EP 499
DI 10.1177/1077801214528856
PG 15
WC Women's Studies
SC Women's Studies
GA AN8VC
UT WOS:000340882200002
PM 24759775
ER
PT J
AU Lind, JN
Perrine, CG
Li, RW
AF Lind, Jennifer N.
Perrine, Cria G.
Li, Ruowei
TI Relationship between Use of Labor Pain Medications and Delayed Onset of
Lactation
SO JOURNAL OF HUMAN LACTATION
LA English
DT Article
DE breastfeeding; lactation; labor and delivery; medication; risk factors
ID EPIDURAL ANALGESIA; LACTOGENESIS II; RISK-FACTORS; DELIVERY; BEHAVIOR;
SUCCESS
AB Background: Despite estimates that 83% of mothers in the United States receive labor pain medications, little research has been done on how use of these medications affect onset of lactation.
Objective: To investigate whether use of labor pain medications is associated with delayed onset of lactation (DOL).
Methods: We analyzed data from the 2005-2007 Infant Feeding Practices Study II, a longitudinal study of women from late pregnancy through the entire first year after birth (n = 2366). In multivariable logistic regression analyses, we assessed the relationship between mothers' use of labor pain medication/method and DOL (milk coming in > 3 days after delivery).
Results: Overall, 23.4% of women in our sample experienced DOL. Compared with women who delivered vaginally and received no labor pain medication, women who received labor pain medications had a higher odds of experiencing DOL: vaginal with spinal/epidural only (aOR 2.05; 95% CI, 1.43-2.95), vaginal with spinal/epidural plus another medication (aOR 1.79; 95% CI, 1.16-2.76), vaginal with other labor pain medications only ([not spinal/epidural]; aOR 1.84; 95% CI, 1.14-2.98), planned cesarean section with spinal/epidural only (aOR 2.13; 95% CI, 1.39-3.27), planned cesarean with spinal/epidural plus another medication (aOR 2.67; 95% CI, 1.35-5.29), emergency cesarean with spinal/epidural only (aOR 2.17; 95% CI, 1.34-3.51), and emergency cesarean with spinal/epidural plus another medication (aOR 3.03; 95% CI, 1.77-5.18).
Conclusion: Mothers who received labor pain medications were more likely to report DOL, regardless of delivery method. This information could help inform clinical decisions regarding labor/delivery.
C1 [Lind, Jennifer N.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA USA.
[Lind, Jennifer N.; Perrine, Cria G.; Li, Ruowei] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA.
[Lind, Jennifer N.; Perrine, Cria G.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA.
RP Lind, JN (reprint author), CDC, Div Nutr Phys Act & Obes, 4770 Buford Hwy NE,MS F-77, Atlanta, GA 30341 USA.
EM vox2@cdc.gov
FU Intramural CDC HHS [CC999999]; NIDDK NIH HHS [T32 DK007734]
NR 29
TC 1
Z9 2
U1 1
U2 15
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0890-3344
EI 1552-5732
J9 J HUM LACT
JI J. Hum. Lact.
PD MAY
PY 2014
VL 30
IS 2
BP 167
EP 173
DI 10.1177/0890334413520189
PG 7
WC Nursing; Obstetrics & Gynecology; Pediatrics
SC Nursing; Obstetrics & Gynecology; Pediatrics
GA AN2NM
UT WOS:000340422500008
PM 24451212
ER
PT J
AU Kay, MC
Carroll, DD
Carlson, SA
Fulton, JE
AF Kay, Melissa C.
Carroll, Dianna D.
Carlson, Susan A.
Fulton, Janet E.
TI Awareness and Knowledge of the 2008 Physical Activity Guidelines for
Americans
SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH
LA English
DT Article
DE sedentary lifestyle; exercise; health promotion; physical fitness
ID PUBLIC-HEALTH; HEART-ASSOCIATION; SPORTS-MEDICINE; MENTAL-HEALTH;
ADULTS; RECOMMENDATIONS; EXERCISE; CAMPAIGNS; COLLEGE
AB Background: To estimate the proportion of U.S. adults aware and knowledgeable of the 2008 Physical Activity Guidelines for Americans. Methods: Analysis is based on a cross-sectional national sample of adults in the 2009 (n = 4281) HealthStyles survey. We estimated the prevalence of adults who reported awareness of government physical activity guidelines and who were knowledgeable of the currently recommended moderate-intensity physical activity guideline (ie, 150 minutes per week) from the 2008 Guidelines. Results: In 2009, the percent of adults who reported being aware of government physical activity (PA) guidelines was 36.1%. The percent of adults knowledgeable of the moderate-intensity physical activity guideline was less than 1% (0.56%). Conclusions: Most U.S. adults lack sufficient awareness and knowledge of the 2008 Guidelines, putting them at risk for failure to meet them. The nation needs more effective communication strategies to translate and disseminate PA guidelines.
C1 [Kay, Melissa C.] Ctr Dis Control & Prevent, Publ Hlth Prevent Serv, Div Leadership & Practice, Sci Educ & Profess Dev Program Off,Off Surveillan, Atlanta, GA 30333 USA.
[Carroll, Dianna D.; Carlson, Susan A.; Fulton, Janet E.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA.
[Carroll, Dianna D.] Commissioned Corps, Rockville, MD USA.
RP Kay, MC (reprint author), Ctr Dis Control & Prevent, Publ Hlth Prevent Serv, Div Leadership & Practice, Sci Educ & Profess Dev Program Off,Off Surveillan, Atlanta, GA 30333 USA.
NR 34
TC 11
Z9 11
U1 2
U2 8
PU HUMAN KINETICS PUBL INC
PI CHAMPAIGN
PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA
SN 1543-3080
EI 1543-5474
J9 J PHYS ACT HEALTH
JI J. Phys. Act. Health
PD MAY
PY 2014
VL 11
IS 4
BP 693
EP 698
DI 10.1123/jpah.2012-0171
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AM6OM
UT WOS:000339984500003
PM 23493071
ER
PT J
AU Demissie, Z
Lowry, R
Eaton, DK
Hertz, MF
Lee, SM
AF Demissie, Zewditu
Lowry, Richard
Eaton, Danice K.
Hertz, Marci F.
Lee, Sarah M.
TI Associations of School Violence With Physical Activity Among US High
School Students
SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH
LA English
DT Article
DE adolescent; bullying; safety; sedentary lifestyle
ID HEALTH-RISK BEHAVIORS; BODY-MASS INDEX; SPORTS PARTICIPATION; SEDENTARY
BEHAVIOR; GENDER-DIFFERENCES; YOUTH; ADOLESCENTS; POPULATION;
PREVENTION; CHILDREN
AB Background: This study investigated associations of violence-related behaviors with physical activity (PA)-related behaviors among U.S. high school students. Methods: Data from the 2009 national Youth Risk Behavior Survey, a cross-sectional survey of a nationally representative sample of 9th-12th grade students, were analyzed. Sex-stratified, adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated for associations between violence-related behaviors and being physically active for >= 60 minutes daily, sports participation, TV watching for >= 3 hours/day, and video game/computer use for >= 3 hours/day. Results: Among male students, at-school bullying victimization was negatively associated with daily PA (aOR: 0.72; 95% CI: 0.58-0.87) and sports participation; skipping school because of safety concerns was positively associated with video game/computer use (1.42; 1.01-2.00); and physical fighting was positively associated with daily PA. Among female students, at-school bullying victimization and skipping school because of safety concerns were both positively associated with video game/computer use (1.46; 1.19-1.79 and 1.60; 1.09-2.34, respectively), and physical fighting at school was negatively associated with sports participation and positively associated with TV watching. Conclusions: Bullying victimization emerged as a potentially important risk factor for insufficient PA. Schools should consider the role of violence in initiatives designed to promote PA.
C1 [Demissie, Zewditu; Lowry, Richard; Eaton, Danice K.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30333 USA.
[Hertz, Marci F.] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA.
[Lee, Sarah M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Demissie, Z (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30333 USA.
NR 45
TC 2
Z9 2
U1 1
U2 8
PU HUMAN KINETICS PUBL INC
PI CHAMPAIGN
PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA
SN 1543-3080
EI 1543-5474
J9 J PHYS ACT HEALTH
JI J. Phys. Act. Health
PD MAY
PY 2014
VL 11
IS 4
BP 705
EP 711
DI 10.1123/jpah.2012-0191
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AM6OM
UT WOS:000339984500005
PM 25078515
ER
PT J
AU Pham, CD
Ahn, S
Turner, LA
Wohrle, R
Lockhart, SR
AF Pham, Cau D.
Ahn, Stacey
Turner, Lance A.
Wohrle, Ron
Lockhart, Shawn R.
TI Development and validation of benomyl birdseed agar for the isolation of
Cryptococcus neoformans and Cryptococcus gattii from environmental
samples
SO MEDICAL MYCOLOGY
LA English
DT Article
DE Cryptococcus gattii; Cryptococcus neoformans; benomyl; birdseed agar
ID BRITISH-COLUMBIA; PACIFIC-NORTHWEST; UNITED-STATES; MELANIN PRODUCTION;
VANCOUVER-ISLAND; CR-NEOFORMANS; SEED AGAR; CANADA; MEDIA;
IDENTIFICATION
AB One of the difficulties of isolating Cryptococcus neoformans and Cryptococcus gattii from environmental samples is the abundant overgrowth of other yeast and mold species that occurs on the plates. Here we report the application of benomyl to Guizotia abyssinica seed extract growth medium to improve the isolation of C. neoformans and C. gattii from environmental samples. We validated this medium by recovering C. neoformans and C. gattii from convenience soils and swabs from a region of the United States where these yeasts are endemic.
C1 [Pham, Cau D.; Ahn, Stacey; Turner, Lance A.; Lockhart, Shawn R.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA.
[Wohrle, Ron] Washington State Dept Hlth, Tumwater, WA USA.
RP Lockhart, SR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop G-11, Atlanta, GA 30333 USA.
EM gyi2@cdc.gov
NR 28
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1369-3786
EI 1460-2709
J9 MED MYCOL
JI Med. Mycol.
PD MAY
PY 2014
VL 52
IS 4
BP 417
EP 421
DI 10.1093/mmy/myt028
PG 5
WC Infectious Diseases; Mycology; Veterinary Sciences
SC Infectious Diseases; Mycology; Veterinary Sciences
GA AM5PX
UT WOS:000339913600012
PM 24782104
ER
PT J
AU Frederick, GM
Watson, KB
Harris, CD
Carlson, SA
Fulton, JE
AF Frederick, Ginny M.
Watson, Kathleen B.
Harris, Carmen D.
Carlson, Susan A.
Fulton, Janet E.
TI US Adults' Participation in Specific Activities, Behavioral Risk Factor
Surveillance System, 2011
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the American-College-of-Sports-Medicine
CY APR 01-04, 2014
CL Atlanta, GA
SP Amer Coll Sports Med
C1 [Frederick, Ginny M.; Watson, Kathleen B.; Harris, Carmen D.; Carlson, Susan A.; Fulton, Janet E.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2014
VL 46
IS 5
SU 1
MA 1204
BP 302
EP 302
PG 1
WC Sport Sciences
SC Sport Sciences
GA AL4PW
UT WOS:000339115902061
ER
PT J
AU Garber, MD
Lobelo, F
Sajuria, M
AF Garber, Michael D.
Lobelo, Felipe
Sajuria, Marcelo
TI Nationally Representative Estimates of Health-Related Physical Fitness
in Chilean 8th Graders
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the American-College-of-Sports-Medicine
CY APR 01-04, 2014
CL Atlanta, GA
SP Amer Coll Sports Med
C1 [Garber, Michael D.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Lobelo, Felipe] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Sajuria, Marcelo] Inst Nacl Deportes Chile, Santiago, Chile.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2014
VL 46
IS 5
SU 1
MA 1210
BP 303
EP 304
PG 2
WC Sport Sciences
SC Sport Sciences
GA AL4PW
UT WOS:000339115902067
ER
PT J
AU Soares, J
Caspersen, CJ
McMurray, RG
McCurdy, TR
AF Soares, Jesus
Caspersen, Carl J.
McMurray, Robert G.
McCurdy, Thomas R.
TI Resting Metabolic Rate and Percent Body Fat in Healthy Adult Men and
Women
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the American-College-of-Sports-Medicine
CY APR 01-04, 2014
CL Atlanta, GA
SP Amer Coll Sports Med
C1 [Soares, Jesus; Caspersen, Carl J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[McMurray, Robert G.] Univ N Carolina, Chapel Hill, NC USA.
[McCurdy, Thomas R.] US EPA, Res Triangle Pk, NC 27711 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2014
VL 46
IS 5
SU 1
MA 1823
BP 490
EP 491
PG 2
WC Sport Sciences
SC Sport Sciences
GA AL4PW
UT WOS:000339115903184
ER
PT J
AU Dai, SF
Carroll, DD
Watson, KB
Paul, P
Carlson, SA
Fulton, JE
AF Dai, Shifan
Carroll, Dianna D.
Watson, Kathleen B.
Paul, Prabasaj
Carlson, Susan A.
Fulton, Janet E.
TI Participation In Specific Types Of Physical Activity Among US Adults,
NHANES 1999-2006
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the American-College-of-Sports-Medicine
CY APR 01-04, 2014
CL Atlanta, GA
SP Amer Coll Sports Med
C1 [Dai, Shifan; Carroll, Dianna D.; Watson, Kathleen B.; Paul, Prabasaj; Carlson, Susan A.; Fulton, Janet E.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2014
VL 46
IS 5
SU 1
MA 2412
BP 649
EP 650
PG 2
WC Sport Sciences
SC Sport Sciences
GA AL4PW
UT WOS:000339115904217
ER
PT J
AU Sloan, ML
Carroll, DD
Brown, DR
AF Sloan, Michelle L.
Carroll, Dianna D.
Brown, David R.
TI Physical Activity Among US Adults With And Without Mobility Disability,
Nhanes 1999-2006
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the American-College-of-Sports-Medicine
CY APR 01-04, 2014
CL Atlanta, GA
SP Amer Coll Sports Med
C1 [Sloan, Michelle L.; Carroll, Dianna D.; Brown, David R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2014
VL 46
IS 5
SU 1
MA 2413
BP 650
EP 650
PG 1
WC Sport Sciences
SC Sport Sciences
GA AL4PW
UT WOS:000339115904218
ER
PT J
AU Githuka, G
Hladik, W
Mwalili, S
Cherutich, P
Muthui, M
Gitonga, J
Maina, WK
Kim, AA
AF Githuka, George
Hladik, Wolfgang
Mwalili, Samuel
Cherutich, Peter
Muthui, Mercy
Gitonga, Joshua
Maina, William K.
Kim, Andrea A.
CA KAIS Study Grp
TI Populations at Increased Risk for HIV Infection in Kenya: Results From a
National Population-Based Household Survey, 2012
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE high-risk populations; HIV; men who have sex with men; transactional
sex; anal intercourse; Kenya
ID MIDDLE-INCOME COUNTRIES; HUMAN-IMMUNODEFICIENCY-VIRUS; SEX; MEN; WOMEN
AB Background: Populations with higher risks for HIV exposure contribute to the HIV epidemic in Kenya. We present data from the second Kenya AIDS Indicator Survey to estimate the size and HIV prevalence of populations with high-risk characteristics.
Methods: The Kenya AIDS Indicator Survey 2012 was a national survey of Kenyans aged 18 months to 64 years which linked demographic and behavioral information with HIV results. Data were weighted to account for sampling probability. This analysis was restricted to adults aged 18 years and older.
Results: Of 5088 men and 6745 women, 0.1% [95% confidence interval (CI): 0.03 to 0.14] were persons who inject drugs (PWID). Among men, 0.6% (CI: 0.3 to 0.8) had ever had sex with other men, and 3.1% (CI: 2.4 to 3.7) were males who had ever engaged in transactional sex work (MTSW). Among women, 1.9% (CI: 1.3 to 2.5) had ever had anal sex, and 4.1% (CI: 3.5 to 4.8) were women who had ever engaged in transactional sex work (FTSW). Among men, 17.6% (CI: 15.7 to 19.6) had been male clients of transactional sex workers (TSW). HIV prevalence was 0% among men who have sex with men, 6.3% (CI: 0 to 18.1) among persons who injected drugs, 7.1% (CI: 4.8 to 9.4) among male clients of TSW, 7.6% (CI: 1.8 to 13.4) among MTSW, 12.1% (CI: 7.1 to 17.1) among FTSW, and 12.1% (CI: 5.0 to 19.2) among females who ever had engaged in anal sex.
Conclusions: Population-based data on high-risk populations can be used to set realistic targets for HIV prevention, care, and treatment for these groups. These data should inform priorities for high-risk populations in the upcoming Kenyan strategic plan on HIV/AIDS.
C1 [Githuka, George; Cherutich, Peter; Maina, William K.] Minist Hlth, Natl AIDS & Sexually Transmitted Infect Control S, Nairobi, Kenya.
[Hladik, Wolfgang] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA.
[Mwalili, Samuel; Muthui, Mercy; Kim, Andrea A.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Nairobi, Kenya.
[Gitonga, Joshua] Natl AIDS Control Council, Nairobi, Kenya.
RP Githuka, G (reprint author), Kenyatta Hosp Grounds, Natl AIDS & STI Control Programme, Off Hosp Rd,POB 19361-00202, Nairobi, Kenya.
EM ggithuka@nascop.or.ke
FU National AIDS and STI Control Programme (NASCOP); Kenya National Bureau
of Statistics (KNBS); National Public Health Laboratory Services
(NPHLS); National AIDS Control Council (NACC); National Council for
Population and Development (NCPD); Kenya Medical Research Institute
(KEMRI); US Centers for Disease Control and Prevention (CDC/Kenya); US
Centers for Disease Control and Prevention (CDC/Atlanta); United States
Agency for International Development (USAID/Kenya); University of
California, San Francisco (UCSF); Joint United Nations Team on HIV/AIDS;
Japan International Cooperation Agency (JICA); Elizabeth Glaser
Paediatric AIDS Foundation (EGPAF); Liverpool Voluntary Counselling and
Testing (LVCT); African Medical and Research Foundation (AMREF); World
Bank; Global Fund; US President's Emergency Plan for AIDS Relief through
US Centers for Disease Control and Prevention, Division of Global
HIV/AIDS [PS001805, GH,000069, PS001814]; Joint United Nations Team for
HIV/AIDS
FX Kenya AIDS Indicator Survey (KAIS) 2012 was supported by the National
AIDS and STI Control Programme (NASCOP), Kenya National Bureau of
Statistics (KNBS), National Public Health Laboratory Services (NPHLS),
National AIDS Control Council (NACC), National Council for Population
and Development (NCPD), Kenya Medical Research Institute (KEMRI), US
Centers for Disease Control and Prevention (CDC/Kenya, CDC/Atlanta),
United States Agency for International Development (USAID/Kenya),
University of California, San Francisco (UCSF), Joint United Nations
Team on HIV/AIDS, Japan International Cooperation Agency (JICA),
Elizabeth Glaser Paediatric AIDS Foundation (EGPAF), Liverpool Voluntary
Counselling and Testing (LVCT), African Medical and Research Foundation
(AMREF), World Bank, and Global Fund. This publication was made possible
by support from the US President's Emergency Plan for AIDS Relief
through cooperative agreements (#PS001805, GH,000069, and PS001814) from
the US Centers for Disease Control and Prevention, Division of Global
HIV/AIDS. This work was also funded in part by support from the Global
Fund, World Bank, and the Joint United Nations Team for HIV/AIDS.
NR 26
TC 6
Z9 6
U1 4
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAY 1
PY 2014
VL 66
SU 1
BP S46
EP S56
PG 11
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AL3LO
UT WOS:000339029600006
PM 24732821
ER
PT J
AU Lanzieri, TM
Bialek, SR
Bennett, MV
Gould, JB
AF Lanzieri, Tatiana M.
Bialek, Stephanie R.
Bennett, Mihoko V.
Gould, Jeffrey B.
TI Cytomegalovirus infection among infants in California neonatal intensive
care units, 2005-2010
SO JOURNAL OF PERINATAL MEDICINE
LA English
DT Article
DE Acquired infection; congenital infection; cytomegalovirus; premature
infant; prevalence; very low birth weight infant
ID BREAST-MILK; GANCICLOVIR THERAPY; PREMATURE-INFANTS; PRETERM INFANTS;
TRANSMISSION; DISEASE; PREVALENCE; MORTALITY; PREGNANCY; DIAGNOSIS
AB Aim: To assess the burden of congenital and perinatal cytomegalovirus (CMV) disease among infants hospitalized in neonatal intensive care units (NICUs).
Methods: CMV infection was defined as a report of positive CMV viral culture or polymerase chain reaction at any time since birth in an infant hospitalized in a NICU reporting to California Perinatal Quality Care Collaborative during 2005-2010.
Results: One hundred and fifty-six (1.7 per 1000) infants were reported with CMV infection, representing an estimated 5% of the expected number of live births with symptomatic CMV disease. Prevalence was higher among infants with younger gestational ages and lower birth weights. Infants with CMV infection had significantly longer hospital stays and 14 (9%) died.
Conclusions: Reported prevalence of CMV infection in NICUs represents a fraction of total expected disease burden from CMV in the newborn period, likely resulting from underdiagnosis and milder symptomatic cases that do not require NICU care. More complete ascertainment of infants with congenital CMV infection that would benefit from antiviral treatment may reduce the burden of CMV disease in this population.
C1 [Lanzieri, Tatiana M.] Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, Atlanta, GA USA.
[Bialek, Stephanie R.] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Bennett, Mihoko V.; Gould, Jeffrey B.] CPQCC, Stanford, CA USA.
[Bennett, Mihoko V.; Gould, Jeffrey B.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
RP Lanzieri, TM (reprint author), Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop A-34, Atlanta, GA USA.
EM tmlanzieri@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 35
TC 1
Z9 1
U1 0
U2 3
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0300-5577
EI 1619-3997
J9 J PERINAT MED
JI J. Perinat. Med.
PD MAY
PY 2014
VL 42
IS 3
BP 393
EP 399
DI 10.1515/jpm-2013-0183
PG 7
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA AL2CX
UT WOS:000338934600018
PM 24334425
ER
PT J
AU Paulozzi, LJ
Zhang, K
Jones, CM
Mack, KA
AF Paulozzi, Leonard J.
Zhang, Kun
Jones, Christopher M.
Mack, Karin A.
TI Risk of Adverse Health Outcomes with Increasing Duration and Regularity
of Opioid Therapy
SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE
LA English
DT Article
DE Analgesics; Drug Abuse; Pain Management; Poisoning
ID CHRONIC NONCANCER PAIN; UNITED-STATES; DRUG OVERDOSE; PRESCRIPTIONS;
ASSOCIATION; POPULATION; PREVALENCE; DISORDERS; PATTERNS; ABUSE
AB Purpose: The purpose of this study was to examine trends in frequency and daily dosage of opioid use and related adverse health outcomes in a commercially insured population.
Methods: We examined medical claims from the Truven Health MarketScan commercial claims database for 789,457 continuously enrolled patients ages 18 to 64 years to whom opioids were dispensed during the first half of 2008. We tracked them every 6 months until either opioid use was discontinued or the end of 2010. We compared outcomes among all opioid users with those for patients who used opioids with only limited interruptions during the index period, referred to as "daily users." We contrasted the experience of daily users, other users, and nonusers for various outcomes.
Results: Of all claimants, 10.7% had at least one opioid prescription during the first 6 months of 2008. Of these, 39.9% continued through a second 6-month period, and 18.0% continued through the end of 2010. Only 9.0% of all users qualified as daily users, but 87.1% of them continued some use of opioids through the end of 2010. Only 43.8% of all users who continued use through 2010 initially qualified as daily users. Among all users who continued use through 2010, days of use and daily dosage increased with duration of use. Among daily users, only dosage increased, rising from 101 to 114 morphine milligram equivalents/day over the 3 years. The prevalence of benzodiazepine use was greater for daily than all users, exceeding 40% among daily users who continued opioid use for 3 years. Drug abuse and overdose rates increased with longer use. Daily users accounted for 25.0%, other users for 43.6%, and nonusers for 31.4% of opioid analgesic overdoses.
Conclusions: Adverse health outcomes can increase with accumulating opioid use and increasing dosage. Existing guidelines developed by specialty societies for managing patients using opioids daily or nearly daily do not address the larger number of patients who use opioids intermittently over periods of years. Practitioners should consider applying such guidelines to patients who use opioids less frequently.
C1 [Paulozzi, Leonard J.; Zhang, Kun; Jones, Christopher M.; Mack, Karin A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA USA.
RP Paulozzi, LJ (reprint author), El Paso Quarantine Stn, 601 Sunland Pk Dr,Suite 200, El Paso, TX 79912 USA.
EM lbp4@cdc.gov
RI Mack, Karin/A-3263-2012
OI Mack, Karin/0000-0001-9274-3001
FU Centers for Disease Control and Prevention
FX All work for this manuscript was funded by the Centers for Disease
Control and Prevention.
NR 46
TC 22
Z9 23
U1 1
U2 3
PU AMER BOARD FAMILY MEDICINE
PI LEXINGTON
PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA
SN 1557-2625
EI 1558-7118
J9 J AM BOARD FAM MED
JI J. Am. Board Fam. Med.
PD MAY-JUN
PY 2014
VL 27
IS 3
BP 329
EP 338
DI 10.3122/jabfm.2014.03.130290
PG 10
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA AL5IL
UT WOS:000339167000007
PM 24808111
ER
PT J
AU Sutton, MY
Frazier, E
Short, W
Skarbinski, J
AF Sutton, Madeline Y.
Frazier, Emma
Short, William
Skarbinski, Jacek
TI Pregnancies Among Reproductive-Aged Human Immunodeficiency
Virus-Infected Women in Care, United States
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Meeting Abstract
CT 62nd Annual Clinical Meeting of the
American-College-of-Obstetricians-and-Gynecologists
CY APR 26-30, 2014
CL Chicago, IL
SP Amer Coll Obstetricians & Gynecologists
C1 [Sutton, Madeline Y.; Frazier, Emma; Short, William; Skarbinski, Jacek] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7844
EI 1873-233X
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD MAY
PY 2014
VL 123
SU 1
BP 33S
EP 34S
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AL4CG
UT WOS:000339079900069
PM 24770169
ER
PT J
AU Ershova, JV
Podewils, LJ
Bronner, LE
Stockwell, HG
Dlamini, S
Mametja, LD
AF Ershova, J. V.
Podewils, L. J.
Bronner, L. E.
Stockwell, H. G.
Dlamini, S.
Mametja, L. D.
TI Evaluation of adherence to national treatment guidelines among
tuberculosis patients in three provinces of South Africa
SO SAMJ SOUTH AFRICAN MEDICAL JOURNAL
LA English
DT Article
ID DIRECTLY OBSERVED THERAPY; ANTITUBERCULOSIS DRUGS; TB; PREVALENCE;
KNOWLEDGE
AB Background. Standardised tuberculosis (TB) treatment through directly observed therapy (DOT) is available in South Africa, but the level of adherence to standardised TB treatment and its impact on treatment outcomes is unknown.
Objectives. To describe adherence to standardised TB treatment and provision of DOT, and analyse its impact on treatment outcome.
Methods. We utilised data collected for an evaluation of the South African national TB surveillance system. A treatment regimen was considered appropriate if based on national treatment guidelines. Multivariate log-binomial regression was used to evaluate the association between treatment regimens, including DOT provision, and treatment outcome.
Results. Of 1 339 TB cases in the parent evaluation, 598 (44.7%) were excluded from analysis owing to missing outcome or treatment information. The majority (697, 94.1%) of the remaining 741 patients received an appropriate TB regimen. Almost all patients (717, 96.8%) received DOT, 443 (59.8%) throughout the treatment course and 274 (37.0%) during the intensive (256, 34.6%) or continuation (18, 2.4%) phase. Independent predictors of poor outcome were partial DOT (adjusted risk ratio (aRR) 3.1, 95% confidence interval (CI) 2.2 - 4.3) and previous treatment default (aRR 2.3, 95% CI 1.1 - 4.8).
Conclusion. Patients who received incomplete DOT or had a history of defaulting from TB treatment had an increased risk of poor outcomes.
C1 [Ershova, J. V.; Podewils, L. J.; Bronner, L. E.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA.
[Ershova, J. V.; Stockwell, H. G.] Univ S Florida, Coll Publ Hlth, Tampa, FL USA.
[Dlamini, S.; Mametja, L. D.] Natl Dept Hlth, Pretoria, South Africa.
RP Ershova, JV (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA.
EM jhe3@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 16
TC 1
Z9 2
U1 0
U2 6
PU SA MEDICAL ASSOC
PI PRETORIA
PA BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
PRETORIA, 0002, SOUTH AFRICA
SN 0256-9574
EI 2078-5135
J9 SAMJ S AFR MED J
JI SAMJ S. Afr. Med. J.
PD MAY
PY 2014
VL 104
IS 5
BP 362
EP U3368
DI 10.7196/SAMJ.7655
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA AL8KI
UT WOS:000339386900025
PM 25212205
ER
PT J
AU Korrick, S
Chen, C
Schantz, S
Calafat, A
AF Korrick, S.
Chen, C.
Schantz, S.
Calafat, A.
TI The impact of adolescent exposure to bisphenol A (BPA) and phthalates on
neurobehavior: A pilot epidemiologic study
SO NEUROTOXICOLOGY AND TERATOLOGY
LA English
DT Meeting Abstract
CT 38th Annual Meeting of the Neurobehavioral-Teratology-Society
CY JUN 28-JUL 02, 2014
CL Bellevue, WA
SP Neurobehavioral Teratol Soc
C1 [Korrick, S.; Chen, C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA.
[Korrick, S.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Schantz, S.] Univ Illinois, Urbana, IL USA.
[Calafat, A.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0892-0362
EI 1872-9738
J9 NEUROTOXICOL TERATOL
JI Neurotoxicol. Teratol.
PD MAY-JUN
PY 2014
VL 43
MA NBTS 05
BP 77
EP 77
DI 10.1016/j.ntt.2014.04.008
PG 1
WC Neurosciences; Toxicology
SC Neurosciences & Neurology; Toxicology
GA AK7QC
UT WOS:000338621800015
ER
PT J
AU Baldwin, LM
Trivers, KF
Andrilla, CHA
Matthews, B
Miller, JW
Lishner, DM
Goff, BA
AF Baldwin, Laura-Mae
Trivers, Katrina F.
Andrilla, C. Holly A.
Matthews, Barbara
Miller, Jacqueline W.
Lishner, Denise M.
Goff, Barbara A.
TI Accuracy of Ovarian and Colon Cancer Risk Assessments by U.S. Physicians
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE cancer; quality of care; risk estimation
ID PRIMARY-CARE PHYSICIANS; FORCE RECOMMENDATION STATEMENT; BREAST-CANCER;
FAMILY-HISTORY; COLORECTAL-CANCER; TRANSVAGINAL ULTRASOUND; MUTATION
CARRIERS; RANDOMIZED-TRIAL; US PHYSICIANS; WOMEN
AB BACKGROUND: Studies have shown a mismatch between published cancer screening and genetic counseling referral recommendations and physician-reported screening and referral practices. Inaccurate cancer risk assessment is one potential cause of this mismatch.
OBJECTIVE: To assess U.S. physicians' ability to accurately determine a woman's colon and ovarian cancer risk level.
DESIGN, PARTICIPANTS: Cross-sectional survey of U.S. family physicians, general internists, and obstetrician-gynecologists. A twelve-page questionnaire with a vignette of a woman's annual examination included a question about the patient's level of colon and ovarian cancer risk. The final study sample included 1,555 physicians weighted to represent practicing U.S. physicians nationally.
MAIN MEASURE: Accuracy of physicians' ovarian and colon cancer risk assessments.
KEY RESULTS: Overall, most physicians accurately assessed women's risk of ovarian (57.0 %, CI 54.3, 59.6) and colon cancer (62.0 %, CI 59.4, 64.6). However, 27.1 % (CI 23.0, 31.6) of physicians overestimated the ovarian cancer risk among women at the same risk as the general population, and 65.1 % (CI 60.2, 69.7) underestimated ovarian cancer risk among women at much higher risk than the general population. Physicians overestimated colon more than ovarian cancer risk (38.0 %, CI 35.4, 40.6 vs. 27.1 %, CI 23.0, 31.6) for women at the same risk as the general population.
CONCLUSIONS: Physicians' misestimation of patient ovarian and colon cancer risk may put average risk patients in jeopardy of unnecessary screening and higher risk patients in jeopardy of missed opportunities for prevention or early detection of cancers.
C1 [Baldwin, Laura-Mae; Andrilla, C. Holly A.; Matthews, Barbara; Lishner, Denise M.] Univ Washington, Dept Family Med, Seattle, WA 98195 USA.
[Trivers, Katrina F.; Miller, Jacqueline W.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA.
[Goff, Barbara A.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA.
RP Baldwin, LM (reprint author), Univ Washington, Dept Family Med, Box 354982, Seattle, WA 98195 USA.
EM lmb@uw.edu
FU Centers for Disease Control and Prevention (CDC) through the University
of Washington Health Promotion Research Centers Cooperative Agreement
[U48DP001911]; Alliance for Reducing Cancer, Northwest (ARC NW); Centers
for Disease Control and Prevention (CDC) [U48DP001911]; National Cancer
Institute (NCI)
FX This project was funded by the Centers for Disease Control and
Prevention (CDC) through the University of Washington Health Promotion
Research Centers Cooperative Agreement U48DP001911, and through the
Alliance for Reducing Cancer, Northwest (ARC NW), funded by both the
Centers for Disease Control and Prevention (CDC; Grant U48DP001911, V.
Taylor, PI) and the National Cancer Institute (NCI). The findings and
conclusions of this journal article are those of the authors and do not
necessarily represent the official position of the Centers for Disease
Control and Prevention.
NR 69
TC 3
Z9 3
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2014
VL 29
IS 5
BP 741
EP 749
DI 10.1007/s11606-014-2768-2
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VL
UT WOS:000338205700014
PM 24519100
ER
PT J
AU Noh, J
Rodriguez, S
Lee, YM
Handali, S
Gonzalez, AE
Gilman, RH
Tsang, VCW
Garcia, HH
Wilkins, PP
AF Noh, John
Rodriguez, Silvia
Lee, Yeuk-Mui
Handali, Sukwan
Gonzalez, Armando E.
Gilman, Robert H.
Tsang, Victor C. W.
Garcia, Hector H.
Wilkins, Patricia P.
TI Recombinant Protein- and Synthetic Peptide-Based Immunoblot Test for
Diagnosis of Neurocysticercosis
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID LINKED IMMUNOELECTROTRANSFER BLOT; TAENIA-SOLIUM CYSTICERCOSIS;
IMMUNOSORBENT-ASSAY; ANTIGENS; CLONING; SERODIAGNOSIS; ANTIBODIES;
MANAGEMENT; AGREEMENT; CRITERIA
AB One of the most well-characterized tests for diagnosing neurocysticercosis (NCC) is the enzyme-linked immunoelectrotransfer blot (EITB) assay developed at the CDC, which uses lentil lectin-bound glycoproteins (LLGP) extracted from Taenia solium cysticerci. Although the test is very reliable, the purification process for the LLGP antigens has been difficult to transfer to other laboratories because of the need for expensive equipment and technical expertise. To develop a simpler assay, we previously purified and cloned the diagnostic glycoproteins in the LLGP fraction. In this study, we evaluated three representative recombinant or synthetic antigens from the LLGP fraction, individually and in different combinations, using an immunoblot assay (recombinant EITB). Using a panel of 249 confirmed NCC-positive and 401 negative blood serum samples, the sensitivity of the recombinant EITB assay was determined to be 99% and the specificity was 99% for diagnosing NCC. We also tested a panel of 239 confirmed NCC-positive serum samples in Lima, Peru, and found similar results. Overall, our data show that the performance characteristics of the recombinant EITB assay are comparable to those of the LLGP-EITB assay. This new recombinant-and synthetic antigen-based assay is sustainable and can be easily transferred to other laboratories in the United States and throughout the world.
C1 [Noh, John; Lee, Yeuk-Mui; Handali, Sukwan; Wilkins, Patricia P.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA.
[Rodriguez, Silvia; Garcia, Hector H.] Inst Nacl Ciencias Neurol, Cysticercosis Unit, Lima, Peru.
[Gonzalez, Armando E.; Gilman, Robert H.; Garcia, Hector H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Gonzalez, Armando E.] Univ San Marcos, Sch Vet Med, Lima, Peru.
[Tsang, Victor C. W.] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA.
[Garcia, Hector H.] Univ Peruana Cayetano Heredia, Dept Microbiol, Lima, Peru.
[Garcia, Hector H.] Univ Peruana Cayetano Heredia, Ctr Global Hlth, Lima, Peru.
RP Noh, J (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA.
EM jnoh@cdc.gov
FU Fogarty International Center/NIH [D43 TW001140]; Bill and Melinda Gates
Foundation [23981]; Epilepsy Program, National Center for Chronic
Disease Prevention and Health Promotion, CDC; Wellcome Trust Senior
International Research Fellowship in public health and tropical medicine
FX This work was supported in part by the Fogarty International Center/NIH
(training grant D43 TW001140), the Bill and Melinda Gates Foundation
(grant 23981), and the Epilepsy Program, National Center for Chronic
Disease Prevention and Health Promotion, CDC. H.H.G. is supported by a
Wellcome Trust Senior International Research Fellowship in public health
and tropical medicine. The funders had no role in the study design, data
collection, analysis, or interpretation, in writing the manuscript, or
in the decision to submit the article for publication.
NR 33
TC 5
Z9 6
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAY
PY 2014
VL 52
IS 5
BP 1429
EP 1434
DI 10.1128/JCM.03260-13
PG 6
WC Microbiology
SC Microbiology
GA AJ7XV
UT WOS:000337915700018
PM 24554747
ER
PT J
AU Liu, H
Taylor, TH
Pettus, K
Trees, D
AF Liu, Hsi
Taylor, Thomas H., Jr.
Pettus, Kevin
Trees, David
TI Assessment of Etest as an Alternative to Agar Dilution for Antimicrobial
Susceptibility Testing of Neisseria gonorrhoeae
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID DISEASES-TREATMENT-GUIDELINES; GONOCOCCAL INFECTIONS; UNITED-STATES; NO
LONGER; RESISTANCE; CEPHALOSPORINS; BACTERIA; UPDATE
AB We studied whether the Etest can be used as an alternative to agar dilution to determine antimicrobial susceptibilities of ceftriaxone, cefixime, and cefpodoxime in Neisseria gonorrhoeae surveillance. One hundred fifteen clinical and laboratory isolates of N. gonorrhoeae were tested following the Clinical Laboratory Improvement Amendments (CLIA)-approved CLSI standard agar dilution method and, separately, by the Etest according to the manufacturer's recommendations. The MICs were determined and compared. Ten laboratory-generated mutants were used to simulate substantially nonsusceptible specimens. The Etest and agar dilution methods were well correlated. Statistical tests produced regression R-2 values of 88%, 82%, and 85% and Pearson correlation coefficients of 92%, 91%, and 92% for ceftriaxone, cefixime, and cefpodoxime, respectively. When paired comparisons were made, the two tests were 88.7%, 80%, and 87% within 1 log(2) dilution from each other for ceftriaxone, cefixime, and cefpodoxime, respectively. The within-2-log(2) agreements were 99.1%, 98.3%, and 94.8% for ceftriaxone, cefixime, and cefpodoxime, respectively. Notwithstanding the good correlations and the within-2-log(2) general agreement, the Etest results produced slightly lower MICs than the agar dilution results. In conclusion, we found that the Etest can be effectively used as an alternative to agar dilution testing to determine the susceptibility of N. gonorrhoeae to ceftriaxone, cefixime, and cefpodoxime, although we recommend further research into extremely resistant isolates. For isolates within the typical range of clinical MICs, reexamination of the Etest interpretation of susceptible and nonsusceptible categories would likely allow for successful transition from agar dilution to the Etest.
C1 [Liu, Hsi; Pettus, Kevin; Trees, David] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30333 USA.
[Liu, Hsi; Taylor, Thomas H., Jr.; Pettus, Kevin; Trees, David] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Taylor, Thomas H., Jr.] Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA USA.
RP Liu, H (reprint author), Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30333 USA.
EM hcl6@cdc.gov
NR 21
TC 3
Z9 3
U1 1
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAY
PY 2014
VL 52
IS 5
BP 1435
EP 1440
DI 10.1128/JCM.02131-13
PG 6
WC Microbiology
SC Microbiology
GA AJ7XV
UT WOS:000337915700019
PM 24554750
ER
PT J
AU Munoz-Jordan, JL
Santiago, GA
AF Munoz-Jordan, Jorge L.
Santiago, Gilberto A.
TI Inconclusive Reverse Transcription-PCR Assay Comparison for Dengue Virus
Detection and Serotyping
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Letter
ID TIME RT-PCR
C1 [Munoz-Jordan, Jorge L.; Santiago, Gilberto A.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00920 USA.
RP Munoz-Jordan, JL (reprint author), Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00920 USA.
EM ckq2@cdc.gov
NR 9
TC 3
Z9 3
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAY
PY 2014
VL 52
IS 5
BP 1800
EP 1800
DI 10.1128/JCM.03420-13
PG 1
WC Microbiology
SC Microbiology
GA AJ7XV
UT WOS:000337915700087
PM 24744402
ER
PT J
AU Johnson, BJB
Pilgard, MA
Russell, TM
AF Johnson, Barbara J. B.
Pilgard, Mark A.
Russell, Theresa M.
TI Reply to "No Evidence for Contamination of Borrelia Blood Cultures: a
Review of Facts"
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Letter
C1 [Johnson, Barbara J. B.; Pilgard, Mark A.; Russell, Theresa M.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
RP Johnson, BJB (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
EM BJohnson@cdc.gov
NR 3
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAY
PY 2014
VL 52
IS 5
BP 1804
EP 1804
DI 10.1128/JCM.00252-14
PG 1
WC Microbiology
SC Microbiology
GA AJ7XV
UT WOS:000337915700090
PM 24744405
ER
PT J
AU Johnson, BJB
Pilgard, MA
Russell, TM
AF Johnson, Barbara J. B.
Pilgard, Mark A.
Russell, Theresa M.
TI Assessment of New Culture Method for Detection of Borrelia Species from
Serum of Lyme Disease Patients (vol 52, pg 721, 2014)
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Correction
C1 [Johnson, Barbara J. B.; Pilgard, Mark A.; Russell, Theresa M.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
RP Johnson, BJB (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
NR 1
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAY
PY 2014
VL 52
IS 5
BP 1808
EP 1808
DI 10.1128/JCM.00504-14
PG 1
WC Microbiology
SC Microbiology
GA AJ7XV
UT WOS:000337915700093
ER
PT J
AU Damon, IK
Damaso, CR
McFadden, G
AF Damon, Inger K.
Damaso, Clarissa R.
McFadden, Grant
TI Are We There Yet? The Smallpox Research Agenda Using Variola Virus
SO PLOS PATHOGENS
LA English
DT Editorial Material
ID MONKEYPOX; VACCINE; IMMUNOGENICITY; ORTHOPOXVIRUS; EFFICACY; SAFETY;
ST-246; MOUSEPOX; CMX001
C1 [Damon, Inger K.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA 30333 USA.
[Damaso, Clarissa R.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941 Rio De Janeiro, Brazil.
[McFadden, Grant] Univ Florida, Dept Mol Genet & Microbiol, Coll Med, Gainesville, FL USA.
RP Damon, IK (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA 30333 USA.
EM IDamon@cdc.gov
NR 26
TC 4
Z9 4
U1 2
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAY
PY 2014
VL 10
IS 5
AR e1004108
DI 10.1371/journal.ppat.1004108
PG 3
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA AJ5NX
UT WOS:000337732300025
PM 24789223
ER
PT J
AU Vaz-de-Lima, LRA
Martin, MD
Pawloski, LC
Leite, D
Rocha, KCP
de Brito, CA
Vaz, TMI
Martins, LM
Alvarenga, DP
Ribeiro, AF
Carvalhanas, TRMP
Nakasaki, RMD
Oliveira, SS
Waldman, EA
Tondella, ML
AF Vaz-de-Lima, Lourdes R. A.
Martin, Monte D.
Pawloski, Lucia C.
Leite, Daniela
Rocha, Karen C. P.
de Brito, Cyro A.
Vaz, Tania M. I.
Martins, Luciano Moura
Alvarenga, Danielly P.
Ribeiro, Ana F.
Carvalhanas, Telma R. M. P.
Nakasaki, Rosa M. D.
Oliveira, Silvia S.
Waldman, Eliseu A.
Tondella, Maria Lucia
CA Clinical Epidemiological Team Work
TI Serodiagnosis as Adjunct Assay for Pertussis Infection in Sao Paulo,
Brazil
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID BORDETELLA-PERTUSSIS; UNITED-STATES; TOXIN; ANTIBODIES; VACCINATION;
PREVENTION; DIPHTHERIA; DIAGNOSIS; OUTBREAK; FIMBRIAE
AB Pertussis remains an important public health problem in many countries despite extensive immunization. Cultures and real-time PCR (RT-PCR) assays are the recommended pertussis diagnostic tests, but they lack sensitivity at the later stage of the disease. This study introduces the IgG anti-pertussis toxin enzyme-linked immunosorbent assay (PT ELISA) in our routine diagnosis to improve disease burden estimation. Serum samples and nasopharyngeal swabs (n = 503) were collected at the same time from patients presenting with cough illness suspected of being pertussis and tested by the PT ELISA and culture and/or RT-PCR, respectively. Patients were separated into three age groups: group 1,<1 year (n = 260; mean age, 3 months), group 2, 1 to 6 years (n = 81; mean age, 3 years), and group 3,>= 7 years (n = 162; mean age, 26 years). The times (means) from cough onset to specimen collection were 16, 24, and 26 days, respectively. In group 1, 83 (82.2%) of 101 positive cases were positive for pertussis by culture/RT-PCR, while 40 (39.6%) tested positive by PT ELISA. In group 2, 6 (19.4%) of 31 positive cases were culture/RT-PCR positive, and 29 (93.6%) were seropositive. In group 3, 13 (13.8%) of 94 positive cases were positive by culture/RT-PCR and 91 (96.8%) were positive by serology. Culture/RT-PCR detected more cases of pertussis in infants (P < 0.0001), whereas the PT ELISA detected more cases in adolescents and adults (P < 0.0001). The timing between cough onset and specimen collection or recent vaccination may have partially affected our results. Serology is a suitable, cost-effective, and complementary pertussis diagnostic tool, especially among older children, adolescents, and adults during the later disease phase.
C1 [Vaz-de-Lima, Lourdes R. A.; Leite, Daniela; Rocha, Karen C. P.; de Brito, Cyro A.; Vaz, Tania M. I.; Martins, Luciano Moura; Alvarenga, Danielly P.] Adolfo Lutz Inst, Bacteriol Ctr, Ctr Immunol, Sao Paulo, Brazil.
[Martin, Monte D.; Pawloski, Lucia C.; Tondella, Maria Lucia] Ctr Dis Control & Prevent, Div Bacterial Dis, NCIRD, Atlanta, GA USA.
[Ribeiro, Ana F.; Carvalhanas, Telma R. M. P.] Secretaria Estado Saude Sao Paulo, Ctr Vigilancia Epidemiol, Resp Branch, Sao Paulo, Brazil.
[Nakasaki, Rosa M. D.; Oliveira, Silvia S.] Secretaria Municipal Saude CCD COVISA, Ctr Controle Doencas, Coordenacao Vigilancia Saude, Sao Paulo, Brazil.
[Waldman, Eliseu A.] Univ Sao Paulo, Fac Saude Publ, Dept Epidemiol, BR-09500900 Sao Paulo, Brazil.
RP Vaz-de-Lima, LRA (reprint author), Adolfo Lutz Inst, Bacteriol Ctr, Ctr Immunol, Sao Paulo, Brazil.
EM lourlima@uol.com.br
RI Brito, Cyro/C-1910-2012
OI Brito, Cyro/0000-0002-9934-6102
FU Fogarty International Center Global Infectious Diseases Research
Training Program grant, National Institutes of Health, University of
Pittsburgh [D43TW006592]; Instituto Adolfo Lutz
FX We thank GlaxoSmithKline for providing the purified pertussis toxin
antigens used in this study and the Secretary of Health of Sao Paulo and
Instituto Adolfo Lutz for support. We also thank Adele Caterino de
Araujo and Suely S. Kashino for comments on and review of the
manuscript.; This work was supported in part by a Fogarty International
Center Global Infectious Diseases Research Training Program grant,
National Institutes of Health, University of Pittsburgh (D43TW006592).
NR 27
TC 1
Z9 3
U1 1
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD MAY
PY 2014
VL 21
IS 5
BP 636
EP 640
DI 10.1128/CVI.00760-13
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AJ0NU
UT WOS:000337352300005
PM 24599531
ER
PT J
AU Isakova-Sivak, I
Chen, LM
Bourgeois, M
Matsuoka, Y
Voeten, JTM
Heldens, JGM
van den Bosch, H
Klimov, A
Rudenko, L
Cox, NJ
Donis, RO
AF Isakova-Sivak, Irina
Chen, Li-Mei
Bourgeois, Melissa
Matsuoka, Yumiko
Voeten, J. Theo M.
Heldens, Jacco G. M.
van den Bosch, Han
Klimov, Alexander
Rudenko, Larisa
Cox, Nancy J.
Donis, Ruben O.
TI Characterization of Reverse Genetics-Derived Cold-Adapted Master Donor
Virus A/Leningrad/134/17/57 (H2N2) and Reassortants with H5N1 Surface
Genes in a Mouse Model
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID INFLUENZA-A VIRUS; AVIAN-INFLUENZA; INACTIVATED VACCINES;
IMMUNE-RESPONSES; HEALTHY-ADULTS; LIVE; INFECTION; IMMUNOGENICITY;
PROTECTION; FERRETS
AB Live attenuated influenza vaccines (LAIV) offer significant advantages over subunit or split inactivated vaccines to mitigate an eventual influenza pandemic, including simpler manufacturing processes and more cross-protective immune responses. Using an established reverse genetics (rg) system for wild-type (wt) A/Leningrad/134/1957 and cold-adapted (ca) A/Leningrad/134/17/1957 (Len17) master donor virus (MDV), we produced and characterized three rg H5N1 reassortant viruses carrying modified HA and intact NA genes from either A/Vietnam/1203/2004 (H5N1, VN1203, clade 1) or A/Egypt/321/2007 (H5N1, EG321, clade 2) virus. A mouse model of infection was used to determine the infectivity and tissue tropism of the parental wt viruses compared to the ca master donor viruses as well as the H5N1 reassortants. All ca viruses showed reduced replication in lungs and enhanced replication in nasal epithelium. In addition, the H5N1 HA and NA enhanced replication in lungs unless it was restricted by the internal genes of the ca MDV. Mice inoculated twice 4 weeks apart with the H5N1 reassortant LAIV candidate viruses developed serum hemagglutination inhibition HI and IgA antibody titers to the homologous and heterologous viruses consistent with protective immunity. These animals remained healthy after challenge inoculation with a lethal dose with homologous or heterologous wt H5N1 highly pathogenic avian influenza (HPAI) viruses. The profiles of viral replication in respiratory tissues and the immunogenicity and protective efficacy characteristics of the two ca H5N1 candidate LAIV viruses warrant further development into a vaccine for human use.
C1 [Isakova-Sivak, Irina; Chen, Li-Mei; Bourgeois, Melissa; Matsuoka, Yumiko; Klimov, Alexander; Cox, Nancy J.; Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Dept Hlth & Human Serv, Atlanta, GA 30333 USA.
[Isakova-Sivak, Irina; Rudenko, Larisa] Russian Acad Med Sci, Inst Expt Med, St Petersburg, Russia.
[Voeten, J. Theo M.; Heldens, Jacco G. M.; van den Bosch, Han] Nobilon Int BV, Boxmeer, Netherlands.
RP Donis, RO (reprint author), Ctr Dis Control & Prevent, Influenza Div, Dept Hlth & Human Serv, Atlanta, GA 30333 USA.
EM rvd6@cdc.gov
RI Rudenko, Larisa/B-5169-2015; Isakova-Sivak, Irina/C-1034-2014
OI Rudenko, Larisa/0000-0002-0107-9959; Isakova-Sivak,
Irina/0000-0002-2801-1508
NR 53
TC 4
Z9 4
U1 1
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD MAY
PY 2014
VL 21
IS 5
BP 722
EP 731
DI 10.1128/CVI.00819-13
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AJ0NU
UT WOS:000337352300016
PM 24648485
ER
PT J
AU Braun, JM
Kalkbrenner, AE
Just, AC
Yolton, K
Calafat, AM
Sjodin, A
Hauser, R
Webster, GM
Chen, AM
Lanphear, BP
AF Braun, Joseph M.
Kalkbrenner, Amy E.
Just, Allan C.
Yolton, Kimberly
Calafat, Antonia M.
Sjodin, Andreas
Hauser, Russ
Webster, Glenys M.
Chen, Aimin
Lanphear, Bruce P.
TI Gestational Exposure to Endocrine-Disrupting Chemicals and Reciprocal
Social, Repetitive, and Stereotypic Behaviors in 4-and 5-Year-Old
Children: The HOME Study
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID ATTENTION DEFICIT/HYPERACTIVITY DISORDER; POLYBROMINATED DIPHENYL
ETHERS; PERSISTENT ORGANIC POLLUTANTS; AUTISM SPECTRUM DISORDERS;
BISPHENOL-A EXPOSURE; POLYFLUOROALKYL CHEMICALS; HIERARCHICAL
REGRESSION; ORGANOCHLORINE EXPOSURE; CHILDHOOD BEHAVIOR; PERINATAL
EXPOSURE
AB Background: Endocrine-disrupting chemicals (EDCs) may be involved in the etiology of autism spectrum disorders, but identifying relevant chemicals within mixtures of EDCs is difficult.
Objective: Our goal was to identify gestational EDC exposures associated with autistic behaviors.
Methods: We measured the concentrations of 8 phthalate metabolites, bisphenol A, 25 polychlorinated biphenyls (PCBs), 6 organochlorine pesticides, 8 brominated flame retardants, and 4 perfluoroalkyl substances in blood or urine samples from 175 pregnant women in the HOME (Health Outcomes and Measures of the Environment) Study (Cincinnati, OH). When children were 4 and 5 years old, mothers completed the Social Responsiveness Scale (SRS), a measure of autistic behaviors. We examined confounder-adjusted associations between 52 EDCs and SRS scores using a two-stage hierarchical analysis to account for repeated measures and confounding by correlated EDCs.
Results: Most of the EDCs were associated with negligible absolute differences in SRS scores (<= 1.5). Each 2-SD increase in serum concentrations of polybrominated diphenyl ether-28 (PBDE-28) (beta = 2.5; 95% CI: -0.6, 5.6) or trans-nonachlor (beta = 4.1; 95% CI: 0.8-7.3) was associated with more autistic behaviors. In contrast, fewer autistic behaviors were observed among children born to women with detectable versus nondetectable concentrations of PCB-178 (beta = -3.0; 95% CI: -6.3, 0.2), beta-hexachlorocyclohexane (beta = -3.3; 95% CI: -6.1, -0.5), or PBDE-85 (beta = -3.2; 95% CI: -5.9, -0.5). Increasing perfluorooctanoate (PFOA) concentrations were also associated with fewer autistic behaviors (beta = -2.0; 95% CI: -4.4, 0.4).
Conclusions: Some EDCs were associated with autistic behaviors in this cohort, but our modest sample size precludes us from dismissing chemicals with null associations. PFOA, beta-hexachlorocyclohexane, PCB-178, PBDE-28, PBDE-85, and trans-nonachlor deserve additional scrutiny as factors that may be associated with childhood autistic behaviors.
C1 [Braun, Joseph M.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA.
[Kalkbrenner, Amy E.] Univ Wisconsin, Zilber Sch Publ Hlth, Milwaukee, WI 53201 USA.
[Just, Allan C.; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Yolton, Kimberly] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA.
[Calafat, Antonia M.; Sjodin, Andreas] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA.
[Webster, Glenys M.; Lanphear, Bruce P.] Simon Fraser Univ, Fac Hlth & Sci, Burnaby, BC V5A 1S6, Canada.
[Webster, Glenys M.; Lanphear, Bruce P.] BC Childrens & Womens Hosp, Child & Family Res Inst, Vancouver, BC, Canada.
[Chen, Aimin] Univ Cincinnati, Dept Environm Hlth, Div Epidemiol & Biostat, Cincinnati, OH USA.
RP Braun, JM (reprint author), Brown Univ, Dept Epidemiol, Box G S121-2, Providence, RI 02912 USA.
EM joseph_braun_1@brown.edu
RI Sjodin, Andreas/F-2464-2010; Braun, Joseph/H-8649-2014;
OI Just, Allan/0000-0003-4312-5957
FU NIEHS NIH HHS [R01 ES020349, P01 ES011261, P01 ES11261, P30 ES006096,
R00 ES020346, R01 ES014575]
NR 63
TC 46
Z9 48
U1 7
U2 54
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD MAY
PY 2014
VL 122
IS 5
BP 513
EP 520
DI 10.1289/ehp.1307261
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA AJ3ZC
UT WOS:000337606300022
PM 24622245
ER
PT J
AU Kobrosly, RW
Evans, S
Miodovnik, A
Barrett, ES
Thurston, SW
Calafat, AM
Swan, SH
AF Kobrosly, Roni W.
Evans, Sarah
Miodovnik, Amir
Barrett, Emily S.
Thurston, Sally W.
Calafat, Antonia M.
Swan, Shanna H.
TI Prenatal Phthalate Exposures and Neurobehavioral Development Scores in
Boys and Girls at 6-10 Years of Age
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID CHILD-BEHAVIOR CHECKLIST; URINARY PHTHALATE; BISPHENOL-A; METABOLITE
CONCENTRATIONS; ENVIRONMENTAL CHEMICALS; REPRODUCTIVE AGE;
NATIONAL-HEALTH; PREGNANT-WOMEN; US POPULATION; YOUNG-ADULTS
AB Background: There is concern over potential neurobehavioral effects of prenatal phthalate exposures, but available data are inconsistent.
Objectives: We examined associations between prenatal urinary concentrations of phthalate metabolites and neurobehavioral scores among children.
Methods: We measured phthalate metabolite concentrations in urine samples from 153 pregnant participants in the Study for Future Families, a multicenter cohort study. Mothers completed the Child Behavior Checklist when the children were 6-10 years of age. We estimated overall and sexspecific associations between phthalate concentrations and behavior using adjusted multiple regression interaction models.
Results: In boys, concentrations of monoisobutyl phthalate were associated with higher scores for inattention (beta = 0.27; 95% CI: 0.04, 0.50), rule-breaking behavior (beta = 0.20; 95% CI: 0.01, 0.38), aggression (beta = 0.34; 95% CI: 0.09, 0.59), and conduct problems (beta = 0.39; 95% CI: 0.20, 0.58), whereas the molar sum of di(2-ethylhexyl) phthalate metabolites was associated with higher scores for somatic problems (beta = 0.15; 95% CI: 0.03, 0.28). Higher monobenzyl phthalate concentrations were associated with higher scores for oppositional behavior (beta = 0.16; 95% CI: 0.01, 0.32) and conduct problems (beta = 0.21; 95% CI: 0.06, 0.37) in boys, but with reduced anxiety scores in girls (beta = -0.20; 95% CI: -0.39, -0.01). In general, the associations reported above were close to the null among girls. Model coefficients represent the difference in the square root-transformed outcome score associated with a 1-unit increase in log-transformed metabolites.
Conclusions: Our results suggest associations between exposure to certain phthalates in late pregnancy and behavioral problems in boys. Given the few studies on this topic and methodological and population differences among studies, additional research is warranted.
C1 [Kobrosly, Roni W.; Evans, Sarah; Miodovnik, Amir; Swan, Shanna H.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY USA.
[Barrett, Emily S.] Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, Rochester, NY 14642 USA.
[Thurston, Sally W.] Univ Rochester, Sch Med & Dent, Dept Biostat & Computat Biol, Rochester, NY USA.
[Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA.
RP Kobrosly, RW (reprint author), Mt Sinai Sch Med, Dept Prevent Med, One Gustave L Levy Pl,Box 1057, New York, NY 10029 USA.
EM roni.kobrosly@mssm.edu
FU NCATS NIH HHS [KL2 TR000095, TL1 TR000096, UL1 TR000042]; NCRR NIH HHS
[M01 RR000425, M01 RR000400, M01-RR00400, M01-RR0425, UL1 RR024160];
NICHD NIH HHS [T32 HD049311]; NIEHS NIH HHS [K12 ES019852, P30 ES023515,
R01 ES009916, R01-ES09916]
NR 49
TC 25
Z9 26
U1 1
U2 20
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD MAY
PY 2014
VL 122
IS 5
BP 521
EP 528
DI 10.1289/ehp.1307063
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA AJ3ZC
UT WOS:000337606300023
PM 24577876
ER
PT J
AU Golding, J
Steer, CD
Lowery, T
Jones, R
Hibbeln, JR
AF Golding, Jean
Steer, Colin D.
Lowery, Tony
Jones, Robert
Hibbeln, Joseph R.
TI Fish Consumption and Blood Mercury Levels: Golding et al. Respond
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Letter
ID UK TOTAL DIET
C1 [Golding, Jean; Steer, Colin D.] Univ Bristol, Ctr Child & Adolescent Hlth, Bristol, RI 02809 USA.
[Lowery, Tony] Natl Ocean & Atmospher Adm, Natl Marine Fisheries Serv, Natl Seafood Inspect Lab, Pascagoula, MS USA.
[Jones, Robert] Ctr Dis Control & Prevent, Inorgan & Radiat Analyt Toxicol Branch, Atlanta, GA USA.
[Hibbeln, Joseph R.] NIAAA, NIH, Dept Hlth & Human Serv, Bethesda, MD USA.
RP Golding, J (reprint author), Univ Bristol, Ctr Child & Adolescent Hlth, Bristol, RI 02809 USA.
EM Jean.Golding@bristol.ac.uk
OI Golding, Jean/0000-0003-2826-3307
NR 3
TC 0
Z9 0
U1 0
U2 10
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD MAY
PY 2014
VL 122
IS 5
BP A120
EP A121
DI 10.1289/ehp.1307997R
PG 2
WC Environmental Sciences; Public, Environmental & Occupational Health;
Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Toxicology
GA AJ3ZC
UT WOS:000337606300004
PM 24787643
ER
PT J
AU Guh, AY
Limbago, BM
Kallen, AJ
AF Guh, Alice Y.
Limbago, Brandi M.
Kallen, Alexander J.
TI Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae
in the United States
SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
LA English
DT Review
DE carbapenem-resistant Enterobacteriaceae; infection prevention;
Klebsiella pneumoniae carbapenemase; multidrug-resistant organism; New
Delhi metallo-beta-lactamase
ID KLEBSIELLA-PNEUMONIAE CARBAPENEMASE; METALLO-BETA-LACTAMASE;
INTENSIVE-CARE-UNIT; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY;
OUTER-MEMBRANE PROTEIN; INFECTION-CONTROL; ESCHERICHIA-COLI;
RISK-FACTORS; GASTROINTESTINAL COLONIZATION; ENVIRONMENTAL CONTAMINATION
AB Carbapenem-resistant Enterobacteriaceae (CRE) are multidrug-resistant organisms with few treatment options that cause infections associated with substantial morbidity and mortality. CRE outbreaks have been increasingly reported worldwide and are mainly due to the emergence and spread of strains that produce carbapenemases. In the United States, transmission of CRE is primarily driven by the spread of organisms carrying the Klebsiella pneumoniae carbapenemase enzyme, but other carbapenemase enzymes, such as the New-Delhi metallo-beta-lactamase, have also emerged. Currently recommended control strategies for healthcare facilities include the detection of patients infected or colonized with CRE and implementation of measures to prevent further spread. In addition to efforts in individual facilities, effective CRE control requires coordination across all healthcare facilities in a region. This review describes the current epidemiology and surveillance of CRE in the United States and the recommended approach to prevention.
C1 [Guh, Alice Y.; Limbago, Brandi M.; Kallen, Alexander J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
RP Guh, AY (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
EM ggt4@cdc.gov
NR 138
TC 20
Z9 23
U1 2
U2 18
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1478-7210
EI 1744-8336
J9 EXPERT REV ANTI-INFE
JI Expert Rev. Anti-Infect. Ther.
PD MAY
PY 2014
VL 12
IS 5
BP 565
EP 580
DI 10.1586/14787210.2014.902306
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AJ2NO
UT WOS:000337493200007
PM 24666262
ER
PT J
AU Hughes, AJ
Mattson, CL
Scheer, S
Beer, L
Skarbinski, J
AF Hughes, Alison J.
Mattson, Christine L.
Scheer, Susan
Beer, Linda
Skarbinski, Jacek
TI Discontinuation of Antiretroviral Therapy Among Adults Receiving HIV
Care in the United States
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV/AIDS; antiretroviral therapy; discontinuation; HIV care
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INJECTION-DRUG USERS; MEDICATION
ADHERENCE; INFECTED INDIVIDUALS; PROSPECTIVE COHORT; AIDS DIAGNOSIS;
HEALTH BELIEFS; CELL COUNTS; HAART; TRANSMISSION
AB Background: Continuous antiretroviral therapy (ART) is important for maintaining viral suppression. This analysis estimates prevalence of and reason for ART discontinuation.
Methods: Three-stage sampling was used to obtain a nationally representative, cross-sectional sample of HIV-infected adults receiving HIV care. Face-to-face interviews and medical record abstractions were collected from June 2009 to May 2010. Data were weighted based on known probabilities of selection and adjusted for nonresponse. Patient characteristics of ART discontinuation, defined as not currently taking ART, stratified by provider-initiated versus non-provider-initiated discontinuation, were examined. Weighted logistic regression models predicted factors associated with ART discontinuation.
Results: Of adults receiving HIV care in the United States who reported ever initiating ART, 5.6% discontinued treatment. Half of those who discontinued treatment reported provider-initiated discontinuation. Provider-initiated ART discontinuation patients were more likely to have a nadir CD4 >= 200 cells per cubic millimeter. Non-provider-initiated ART discontinuation patients were more likely to have unmet need for supportive services and to have not received HIV care in the past 3 months. Among all patients who discontinued, younger age, female gender, not having continuous health insurance, incarceration, injection drug use, nadir CD4 count >= 200 cells per cubic millimeter, unmet need for supportive services, no care in the past 3 months and HIV diagnosis >= 5 years before interview were independently associated with ART discontinuation.
Conclusions: These findings inform development of interventions to increase ART persistence by identifying groups at increased risk of ART discontinuation. Evidence-based interventions targeting vulnerable populations are needed and are increasingly important as recent HIV treatment guidelines have recommended universal ART.
C1 [Hughes, Alison J.; Scheer, Susan] San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA.
[Mattson, Christine L.; Beer, Linda; Skarbinski, Jacek] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.
RP Hughes, AJ (reprint author), San Francisco Dept Publ Hlth, 25 Van Ness Ave,Suite 500, San Francisco, CA 94102 USA.
EM alison.hughes@sfdph.org
FU US Government
FX Supported by US Government work.
NR 55
TC 7
Z9 7
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAY 1
PY 2014
VL 66
IS 1
BP 80
EP 89
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AJ4YF
UT WOS:000337685400016
PM 24326608
ER
PT J
AU Wallace, A
Kimambo, S
Dafrossa, L
Rusibamayila, N
Rwebembera, A
Songoro, J
Arthur, G
Luman, E
Finkbeiner, T
Goodson, JL
AF Wallace, Aaron
Kimambo, Sajida
Dafrossa, Lyimo
Rusibamayila, Neema
Rwebembera, Anath
Songoro, Juma
Arthur, Gilly
Luman, Elizabeth
Finkbeiner, Thomas
Goodson, James L.
TI Qualitative Assessment of the Integration of HIV Services With Infant
Routine Immunization Visits in Tanzania
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; AIDS; immunization; integration
ID TO-CHILD TRANSMISSION; PREGNANT-WOMEN; FOLLOW-UP; PREVENTION; ATTITUDES;
THERAPY; MOTHERS; STIGMA
AB Background: In 2009, a project was implemented in 8 primary health clinics throughout Tanzania to explore the feasibility of integrating pediatric HIV prevention services with routine infant immunization visits.
Methods: We conducted interviews with 64 conveniently sampled mothers of infants who had received integrated HIV and immunization services and 16 providers who delivered the integrated services to qualitatively identify benefits and challenges of the intervention midway through project implementation.
Findings: Mothers' perceived benefits of the integrated services included time savings, opportunity to learn their child's HIV status and receive HIV treatment, if necessary. Providers' perceived benefits included reaching mothers who usually would not come for only HIV testing. Mothers and providers reported similar challenges, including mothers' fear of HIV testing, poor spousal support, perceived mandatory HIV testing, poor patient flow affecting confidentiality of service delivery, heavier provider workloads, and community stigma against HIV-infected persons; the latter a more frequent theme in rural compared with urban locations.
Interpretation: Future scale-up should ensure privacy of these integrated services received at clinics and community outreach to address stigma and perceived mandatory testing. Increasing human resources for health to address higher workloads and longer waiting times for proper patient flow is necessary in the long term.
C1 [Wallace, Aaron; Luman, Elizabeth; Goodson, James L.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA.
[Kimambo, Sajida; Arthur, Gilly; Finkbeiner, Thomas] Ctr Dis Control & Prevent, Div Global HIV AIDS, Dar Es Salaam, Tanzania.
[Dafrossa, Lyimo] Minist Hlth & Social Welf, Expanded Programme Immunizat, Dar Es Salaam, Tanzania.
[Rusibamayila, Neema] Minist Hlth & Social Welf, Reprod Child Hlth Serv, Dar Es Salaam, Tanzania.
[Rwebembera, Anath] Minist Hlth & Social Welf, Natl AIDS Control Programme, Dar Es Salaam, Tanzania.
[Songoro, Juma] Elizabeth Glaser Pediat AIDS Fdn, Dar Es Salaam, Tanzania.
RP Wallace, A (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS E05, Atlanta, GA 30333 USA.
EM awallace@cdc.gov
FU President's Emergency Plan for AIDS Relief (PEP-FAR) through the US
Centers for Disease Control and Prevention
FX Supported in part by the President's Emergency Plan for AIDS Relief
(PEP-FAR) through the US Centers for Disease Control and Prevention.
NR 28
TC 2
Z9 2
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAY 1
PY 2014
VL 66
IS 1
BP E8
EP E14
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AJ4YF
UT WOS:000337685400002
PM 24326602
ER
PT J
AU Garske, T
Van Kerkhove, MD
Yactayo, S
Ronveaux, O
Lewis, RF
Staples, JE
Perea, W
Ferguson, NM
AF Garske, Tini
Van Kerkhove, Maria D.
Yactayo, Sergio
Ronveaux, Olivier
Lewis, Rosamund F.
Staples, J. Erin
Perea, William
Ferguson, Neil M.
CA Yellow Fever Expert Comm
TI Yellow Fever in Africa: Estimating the Burden of Disease and Impact of
Mass Vaccination from Outbreak and Serological Data
SO PLOS MEDICINE
LA English
DT Article
ID INFECTIONS; EPIDEMIC; NIGERIA; ANTIBODIES; RISK; IMMUNIZATION;
REEMERGENCE; PERSISTENCE; MORTALITY; PROGRAM
AB Background: Yellow fever is a vector-borne disease affecting humans and non-human primates in tropical areas of Africa and South America. While eradication is not feasible due to the wildlife reservoir, large scale vaccination activities in Africa during the 1940s to 1960s reduced yellow fever incidence for several decades. However, after a period of low vaccination coverage, yellow fever has resurged in the continent. Since 2006 there has been substantial funding for large preventive mass vaccination campaigns in the most affected countries in Africa to curb the rising burden of disease and control future outbreaks. Contemporary estimates of the yellow fever disease burden are lacking, and the present study aimed to update the previous estimates on the basis of more recent yellow fever occurrence data and improved estimation methods.
Methods and Findings: Generalised linear regression models were fitted to a dataset of the locations of yellow fever outbreaks within the last 25 years to estimate the probability of outbreak reports across the endemic zone. Environmental variables and indicators for the surveillance quality in the affected countries were used as covariates. By comparing probabilities of outbreak reports estimated in the regression with the force of infection estimated for a limited set of locations for which serological surveys were available, the detection probability per case and the force of infection were estimated across the endemic zone. The yellow fever burden in Africa was estimated for the year 2013 as 130,000 (95% CI 51,000-380,000) cases with fever and jaundice or haemorrhage including 78,000 (95% CI 19,000-180,000) deaths, taking into account the current level of vaccination coverage. The impact of the recent mass vaccination campaigns was assessed by evaluating the difference between the estimates obtained for the current vaccination coverage and for a hypothetical scenario excluding these vaccination campaigns. Vaccination campaigns were estimated to have reduced the number of cases and deaths by 27% (95% CI 22%-31%) across the region, achieving up to an 82% reduction in countries targeted by these campaigns. A limitation of our study is the high level of uncertainty in our estimates arising from the sparseness of data available from both surveillance and serological surveys.
Conclusions: With the estimation method presented here, spatial estimates of transmission intensity can be combined with vaccination coverage levels to evaluate the impact of past or proposed vaccination campaigns, thereby helping to allocate resources efficiently for yellow fever control. This method has been used by the Global Alliance for Vaccines and Immunization (GAVI Alliance) to estimate the potential impact of future vaccination campaigns.
C1 [Garske, Tini; Van Kerkhove, Maria D.; Ferguson, Neil M.] Imperial Coll London, Dept Infect Dis Epidemiol, MRC Ctr Outbreak Anal, London, England.
[Yactayo, Sergio; Perea, William] World Hlth Org, Geneva, Switzerland.
[Ronveaux, Olivier] World Hlth Org, Ouagadougou, Burkina Faso.
[Lewis, Rosamund F.] Ottawa Publ Hlth, Ottawa, ON, Canada.
[Staples, J. Erin] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO USA.
RP Garske, T (reprint author), Imperial Coll London, Dept Infect Dis Epidemiol, MRC Ctr Outbreak Anal, London, England.
EM neil.ferguson@imperial.ac.uk
RI Ferguson, Neil/B-8578-2008;
OI Ferguson, Neil/0000-0002-1154-8093; /0000-0002-5704-8094
FU Medical Research Council; Bill & Melinda Gates Foundation; European
Union [278433-PREDEMICS]
FX The research leading to these results has received funding from the
Medical Research Council, the Bill & Melinda Gates Foundation, and the
European Union Seventh Framework Programme [FP7/2007-2013] under Grant
Agreement no 278433-PREDEMICS. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 52
TC 27
Z9 27
U1 1
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD MAY
PY 2014
VL 11
IS 5
AR e1001638
DI 10.1371/journal.pmed.1001638
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA AJ0MY
UT WOS:000337349300001
PM 24800812
ER
PT J
AU Gautret, P
Blanton, J
Dacheux, L
Ribadeau-Dumas, F
Brouqui, P
Parola, P
Esposito, DH
Bourhy, H
AF Gautret, Philippe
Blanton, Jesse
Dacheux, Laurent
Ribadeau-Dumas, Florence
Brouqui, Philippe
Parola, Philippe
Esposito, Douglas H.
Bourhy, Herve
TI Rabies in Nonhuman Primates and Potential for Transmission to Humans: A
Literature Review and Examination of Selected French National Data
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Review
ID POSTEXPOSURE PROPHYLAXIS; NEW-ZEALAND; TRAVELERS; EXPOSURE; VIRUS;
BITES; SURVEILLANCE; INJURIES; WILDLIFE; MONKEY
AB Background: The nonhuman primate (NHP)-related injuries in rabies-enzootic countries is a public health problem of increasing importance. The aims of this work are to collect data concerning rabies transmission from NHPs to humans; to collate medical practices regarding rabies postexposure prophylaxis (PEP) in different countries, and to provide an evidence base to support the decision to apply rabies PEP in this context.
Methodology: To retrieve information, we conducted a literature search from 1960 to January 2013. All reports of rabies in NHPs and rabies transmission to humans by infected NHPs were included. Also included were studies of travelers seeking care for rabies PEP in various settings. Data collected by the French National Reference Centre for Rabies concerning NHPs submitted for rabies diagnosis in France and human rabies exposure to NHPs in travelers returning to France were analyzed for the periods 1999-2012 and 1994-2011, respectively.
Principal findings: A total of 159 reports of rabies in NHPs have been retrieved from various sources in South America, Africa, and Asia, including 13 cases in animals imported to Europe and the US. 134 were laboratory confirmed cases. 25 cases of human rabies following NHP-related injuries were reported, including 20 from Brazil. Among more than 2000 international travelers from various settings, the proportion of injuries related to NHP exposures was about 31%. NHPs rank second, following dogs in most studies and first in studies conducted in travelers returning from Southeast Asia. In France, 15.6% of 1606 travelers seeking PEP for exposure to any animal were injured by monkeys.
Conclusions/significance: Although less frequently reported in published literature than human rabies, confirmed rabies cases in NHPs occur. The occurrence of documented transmission of rabies from NHPs to human suggests that rabies PEP is indicated in patients injured by NHPs in rabies-enzootic countries.
C1 [Gautret, Philippe; Brouqui, Philippe; Parola, Philippe] CHU Nord, Inst Hosp Univ Mediterranee Infect, Assistance Publ Hop Marseille, Marseille, France.
[Gautret, Philippe; Brouqui, Philippe; Parola, Philippe] Aix Marseille Univ, URMITE, UM63, CNRS 7278,IRD 198,Inserm 1095,Fac Med, Marseille, France.
[Blanton, Jesse] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
[Dacheux, Laurent; Ribadeau-Dumas, Florence; Bourhy, Herve] WHO Collaborating Ctr Reference & Res Rabies, Inst Pasteur, Unite Dynam Lyssavirus & Adaptat Hote, Natl Reference Ctr Rabies, Paris, France.
[Esposito, Douglas H.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
RP Gautret, P (reprint author), CHU Nord, Inst Hosp Univ Mediterranee Infect, Assistance Publ Hop Marseille, Marseille, France.
EM philippe.gautret@club-internet.fr
RI Brouqui, Philippe/P-5771-2016
NR 40
TC 10
Z9 10
U1 4
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2014
VL 8
IS 5
AR e2863
DI 10.1371/journal.pntd.0002863
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AJ5OS
UT WOS:000337735100051
PM 24831694
ER
PT J
AU Kamuyu, G
Bottomley, C
Mageto, J
Lowe, B
Wilkins, PP
Noh, JC
Nutman, TB
Ngugi, AK
Odhiambo, R
Wagner, RG
Kakooza-Mwesige, A
Owusu-Agyei, S
Ae-Ngibise, K
Masanja, H
Osier, FHA
Odermatt, P
Newton, CR
AF Kamuyu, Gathoni
Bottomley, Christian
Mageto, James
Lowe, Brett
Wilkins, Patricia P.
Noh, John C.
Nutman, Thomas B.
Ngugi, Anthony K.
Odhiambo, Rachael
Wagner, Ryan G.
Kakooza-Mwesige, Angelina
Owusu-Agyei, Seth
Ae-Ngibise, Kenneth
Masanja, Honorati
Osier, Faith H. A.
Odermatt, Peter
Newton, Charles R.
CA Epidemiology Epilepsy Demographic
TI Exposure to Multiple Parasites Is Associated with the Prevalence of
Active Convulsive Epilepsy in Sub-Saharan Africa
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID TOXOPLASMA-GONDII; ONCHOCERCA-VOLVULUS; CRYPTOGENIC EPILEPSY; RURAL
TANZANIA; RISK-FACTORS; NEUROCYSTICERCOSIS; TOXOCARIASIS; CYSTICERCOSIS;
INFECTION; RESPONSES
AB Background: Epilepsy is common in developing countries, and it is often associated with parasitic infections. We investigated the relationship between exposure to parasitic infections, particularly multiple infections and active convulsive epilepsy (ACE), in five sites across sub-Saharan Africa.
Methods and Findings: A case-control design that matched on age and location was used. Blood samples were collected from 986 prevalent cases and 1,313 age-matched community controls and tested for presence of antibodies to Onchocerca volvulus, Toxocara canis, Toxoplasma gondii, Plasmodium falciparum, Taenia solium and HIV. Exposure (seropositivity) to Onchocerca volvulus (OR = 1.98; 95% CI: 1.52-2.58, p<0.001), Toxocara canis (OR = 1.52; 95% CI: 1.23-1.87, p<0.001), Toxoplasma gondii (OR = 1.28; 95% CI: 1.04-1.56, p=0.018) and higher antibody levels (top tertile) to Toxocara canis (OR = 1.70; 95% CI: 1.30-2.24, p<0.001) were associated with an increased prevalence of ACE. Exposure to multiple infections was common (73.8% of cases and 65.5% of controls had been exposed to two or more infections), and for T. gondii and O. volvulus co-infection, their combined effect on the prevalence of ACE, as determined by the relative excess risk due to interaction (RERI), was more than additive (T. gondii and O. volvulus, RERI = 1.19). The prevalence of T. solium antibodies was low (2.8% of cases and 2.2% of controls) and was not associated with ACE in the study areas.
Conclusion: This study investigates how the degree of exposure to parasites and multiple parasitic infections are associated with ACE and may explain conflicting results obtained when only seropositivity is considered. The findings from this study should be further validated.
C1 [Kamuyu, Gathoni; Mageto, James; Lowe, Brett; Ngugi, Anthony K.; Odhiambo, Rachael; Osier, Faith H. A.; Newton, Charles R.] KEMRI Wellcome Trust Res Programme, Ctr Geog Med Res Coast, Kilifi, Kenya.
[Kamuyu, Gathoni; Lowe, Brett; Ngugi, Anthony K.; Kakooza-Mwesige, Angelina; Newton, Charles R.] Studies Epidemiol Epilepsy Demog Surveillance Sys, Accra, Ghana.
[Bottomley, Christian] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, London WC1, England.
[Bottomley, Christian] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, MRC Trop Epidemiol Grp, London WC1, England.
[Bottomley, Christian] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.
[Mageto, James] Egerton Univ, Nakuru, Kenya.
[Lowe, Brett] Univ Oxford, Nuffield Dept Clin Med, Oxford, England.
[Wilkins, Patricia P.; Noh, John C.] Ctr Dis Control & Prevent CDC, Div Parasit Dis & Malaria, Atlanta, GA USA.
[Nutman, Thomas B.] NIAID, Parasit Dis Lab, Bethesda, MD 20892 USA.
[Ngugi, Anthony K.] Aga Khan Univ East Africa, Fac Hlth Sci, Res Support Unit, Nairobi, Kenya.
[Wagner, Ryan G.] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, MRC Wits Rural Publ Hlth & Hlth Transit Res Unit, Johannesburg, South Africa.
[Wagner, Ryan G.] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
[Kakooza-Mwesige, Angelina] Iganga Mayuge Hlth & Demog Surveillance Syst, Iganga, Uganda.
[Kakooza-Mwesige, Angelina] Makerere Univ, Coll Hlth Sci, Dept Paediat & Child Hlth, Kampala, Uganda.
[Owusu-Agyei, Seth; Ae-Ngibise, Kenneth] Kintampo Hlth Res Ctr, Kintampo, Ghana.
[Masanja, Honorati] Ifakara Hlth Inst, Ifakara, Tanzania.
[Odermatt, Peter] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
[Odermatt, Peter] Unvers Basel, Basel, Switzerland.
[Newton, Charles R.] UCL Inst Child Hlth, Neurosci Unit, London, England.
[Newton, Charles R.] London Sch Hyg & Trop Med, Clin Res Unit, London WC1, England.
[Newton, Charles R.] Univ Oxford, Dept Psychiat, Oxford, England.
RP Kamuyu, G (reprint author), KEMRI Wellcome Trust Res Programme, Ctr Geog Med Res Coast, Kilifi, Kenya.
EM GKamuyu@kemri-wellcome.org
RI Sander, Josemir/C-1576-2008; Odermatt, Peter/K-7727-2015;
OI Sander, Josemir/0000-0001-6041-9661; Odermatt,
Peter/0000-0002-0296-2508; Osier, Faith/0000-0001-7133-5375; Newton,
Charles/0000-0002-6999-5507
FU Wellcome Trust through a Wellcome Trust Senior Fellowship in Clinical
Tropical Medicine [083744]; Wellcome Trust through a strategic training
award [084538]; Wellcome Trust Master's Training Fellowship [096392]
FX The Wellcome Trust funded this research through a Wellcome Trust Senior
Fellowship in Clinical Tropical Medicine (No. 083744 to CRN), and
supported GK to write up this work through a strategic training award
(No. 084538) and a Wellcome Trust Master's Training Fellowship (No.
096392) to KEMRI-Wellcome Trust Research Programme. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 52
TC 20
Z9 20
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2014
VL 8
IS 5
AR e2908
DI 10.1371/journal.pntd.0002908
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AJ5OS
UT WOS:000337735100075
PM 24875312
ER
PT J
AU Jacobson, EU
Inglesby, T
Khan, AS
Rajotte, JC
Burhans, RL
Slemp, CC
Links, JM
AF Jacobson, Evin Uzun
Inglesby, Tom
Khan, Ali S.
Rajotte, James C.
Burhans, Robert L.
Slemp, Catherine C.
Links, Jonathan M.
TI DESIGN OF THE NATIONAL HEALTH SECURITY PREPAREDNESS INDEX
SO BIOSECURITY AND BIOTERRORISM-BIODEFENSE STRATEGY PRACTICE AND SCIENCE
LA English
DT Article
AB The importance of health security in the United States has been highlighted by recent emergencies such as the H1N1 influenza pandemic, Superstorm Sandy, and the Boston Marathon bombing. The nation's health security remains a high priority today, with federal, state, territorial, tribal, and local governments, as well as nongovernment organizations and the private sector, engaging in activities that prevent, protect, mitigate, respond to, and recover from health threats. The Association of State and Territorial Health Officials (ASTHO), through a cooperative agreement with the Centers for Disease Control and Prevention (CDC) Office of Public Health Preparedness and Response (OPHPR), led an effort to create an annual measure of health security preparedness at the national level. The collaborative released the National Health Security Preparedness Index (NHSPI (TM)) in December 2013 and provided composite results for the 50 states and for the nation as a whole. The Index results represent current levels of health security preparedness in a consistent format and provide actionable information to drive decision making for continuous improvement of the nation's health security. The overall 2013 National Index result was 7.2 on the reported base-10 scale, with areas of greater strength in the domains of health surveillance, incident and information management, and countermeasure management. The strength of the Index relies on the interdependencies of the many elements in health security preparedness, making the sum greater than its parts. Moving forward, additional health security-related disciplines and measures will be included alongside continued validation efforts.
C1 [Jacobson, Evin Uzun; Khan, Ali S.; Rajotte, James C.] Ctr Dis Control & Prevent, Off Policy Planning & Evaluat, Atlanta, GA 30333 USA.
[Jacobson, Evin Uzun; Khan, Ali S.; Rajotte, James C.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA.
[Inglesby, Tom] UPMC Ctr Hlth Secur, Baltimore, MD USA.
[Burhans, Robert L.] New York State Dept Hlth, Woodstock, NY USA.
[Slemp, Catherine C.] West Virginia Bur Publ Hlth, Huntington, WV USA.
[Links, Jonathan M.] Johns Hopkins Univ, Ctr Publ Hlth Preparedness, Baltimore, MD USA.
RP Jacobson, EU (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, 1600 Clifton Rd,Mailstop D-44, Atlanta, GA 30333 USA.
EM wqm4@cdc.gov
NR 3
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1538-7135
EI 1557-850X
J9 BIOSECUR BIOTERROR
JI Biosecur. Bioterror.
PD MAY-JUN
PY 2014
VL 12
IS 3
BP 122
EP 131
DI 10.1089/bsp.2014.0024
PG 10
WC Public, Environmental & Occupational Health; International Relations
SC Public, Environmental & Occupational Health; International Relations
GA AI9BP
UT WOS:000337221900002
ER
PT J
AU Uhrig, JD
Friedman, A
Poehlman, J
Scales, M
Forsythe, A
AF Uhrig, Jennifer D.
Friedman, Allison
Poehlman, Jon
Scales, Monica
Forsythe, Ann
TI Knowledge, beliefs and behaviours related to STD risk, prevention, and
screening among a sample of African American men and women
SO HEALTH EDUCATION JOURNAL
LA English
DT Article
DE African American; health communication; health disparities; STD; USA
ID HIV; DISPARITIES; COMMUNICATION; INTERVENTIONS; INFECTIONS; HIV/AIDS
AB Objective: Current data on sexually transmitted disease (STD) among African Americans show significant racial/ethnic disparities. The purpose of this study was to explore knowledge, attitudes, beliefs, and behaviours related to STD risk, prevention, and testing among African American adults to help inform the development of a health communication intervention to address the high rates of STDs in this community.
Design: Cross-sectional survey.
Setting: Four United States (US) communities with high cumulative incidence of STDs.
Method: We administered a 44-item structured survey.
Results: Participants were 185 sexually active heterosexual African Americans aged 18 to 45. Most participants (84.2%) had been tested for an STD at least once. Most participants (75.8%) perceived STDs to be a problem in their community, and almost all (91.2%) felt that people needed education to learn how to avoid STDs. Nonetheless, only half of participants (49.5%) agreed that they should get tested for STDs because they may be at risk. Misconceptions related to STD prevention and testing were identified. Results suggest that STDs remain highly stigmatized with concerns related to social and interpersonal consequences. Participants' perceived personal risk was low, despite acknowledging high STD rates in their communities.
Conclusion: Findings suggest that health communication may play an important role in addressing STD disparities by increasing perceptions of personal risk, minimizing STD-associated stigma, and marketing STD prevention and testing behaviours.
C1 [Friedman, Allison; Forsythe, Ann] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Uhrig, JD (reprint author), Hlth Commun Program, RTI 3040 Cornwallis Rd, Res Triangle Pk, NC 27709 USA.
EM uhrig@rti.org
NR 20
TC 1
Z9 1
U1 1
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0017-8969
EI 1748-8176
J9 HEALTH EDUC J
JI Health Educ. J.
PD MAY
PY 2014
VL 73
IS 3
BP 332
EP 340
DI 10.1177/0017896912471054
PG 9
WC Education & Educational Research; Public, Environmental & Occupational
Health
SC Education & Educational Research; Public, Environmental & Occupational
Health
GA AI9VD
UT WOS:000337288200009
ER
PT J
AU Chotiwan, N
Roehrig, JT
Schlesinger, JJ
Blair, CD
Huang, CYH
AF Chotiwan, Nunya
Roehrig, John T.
Schlesinger, Jacob J.
Blair, Carol D.
Huang, Claire Y. -H.
TI Molecular determinants of dengue virus 2 envelope protein important for
virus entry in Fc gamma RIIA-Mediated antibody-dependent enhancement of
infection
SO VIROLOGY
LA English
DT Article
DE Dengue virus; Envelope protein; Antibody-dependent enhancement; Fc gamma
RIIA; Virus entry
ID HEMORRHAGIC-FEVER; DOMAIN-III; MEMBRANE-FUSION; HEPARAN-SULFATE; VERO
CELLS; GLYCOPROTEIN; PATHOGENESIS; COMPLEX; BINDING; EPITOPES
AB Antibody-dependent enhancement (ADE) of infection may cause severe illness in patients suffering a secondary infection by a heterologous dengue virus (DENV) serotype. During ADE of infection, cross-reactive non- or poorly-neutralizing antibodies form infectious virus-Ab complexes with the newly infecting serotype and enhance virus infection by binding to the Fc gamma receptors (Fc gamma R) on Fc gamma R-bearing cells. In this study, we determined that molecular determinants of DENV2 envelope protein critical for virus entry during non-ADE infection are also required for ADE infection mediated by Fc gamma RIIA, and binding of virus-Ab complexes with Fc gamma RIIA alone is not sufficient for ADE of infection. The Fc gamma RIIA mainly plays an auxiliary role in concentrating the virus-Ab complex to the cell surface, and other primary cellular receptors are required for virus entry. Understanding the viral entry pathway in ADE of DENV infection will greatly facilitate rational designs of anti-viral therapeutics against severe dengue disease associated with ADE. Published by Elsevier Inc.
C1 [Chotiwan, Nunya; Roehrig, John T.; Huang, Claire Y. -H.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Arboviral Dis Branch, Ft Collins, CO 80521 USA.
[Schlesinger, Jacob J.] Univ Rochester, Dept Med, Rochester, NY 14642 USA.
[Blair, Carol D.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Arthropod Borne & Infect Dis Lab, Ft Collins, CO 80523 USA.
RP Huang, CYH (reprint author), CDC, DVBD, Arboviral Dis Branch, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
EM yxh0@cdc.gov
FU Thailand-United States Educational Foundation (Fulbright Thailand)
scholarship for a MS degree education at Colorado State University
FX We thank Karen Boroughs, Janae Stovall, Kandice Dixon, as well as Drs.
Siritorn Butrapet, Amanda Calvert, and Amy Ullmann for their technical
assistance. We appreciate all the constructive comments provided by Drs.
Richard Kinney and Chaoping Chen. N.C. was supported by the
Thailand-United States Educational Foundation (Fulbright Thailand)
scholarship for a MS degree education at Colorado State University.
NR 43
TC 2
Z9 2
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAY
PY 2014
VL 456
BP 238
EP 246
DI 10.1016/j.virol.2014.03.031
PG 9
WC Virology
SC Virology
GA AI9NF
UT WOS:000337258600024
PM 24889243
ER
PT J
AU Gu, SH
Lim, BK
Kadjo, B
Arai, S
Kim, JA
Nicolas, V
Lalis, A
Denys, C
Cook, JA
Dominguez, SR
Holmes, KV
Urushadze, L
Sidamonidze, K
Putkaradze, D
Kuzmin, IV
Kosoy, MY
Song, JW
Yanagihara, R
AF Gu, Se Hun
Lim, Burton K.
Kadjo, Blaise
Arai, Satoru
Kim, Jeong-Ah
Nicolas, Violaine
Lalis, Aude
Denys, Christiane
Cook, Joseph A.
Dominguez, Samuel R.
Holmes, Kathryn V.
Urushadze, Lela
Sidamonidze, Ketevan
Putkaradze, Davit
Kuzmin, Ivan V.
Kosoy, Michael Y.
Song, Jin-Won
Yanagihara, Richard
TI Molecular Phylogeny of Hantaviruses Harbored by Insectivorous Bats in
Cote d'Ivoire and Vietnam
SO VIRUSES-BASEL
LA English
DT Article
DE hantavirus; Chiroptera; evolution
ID GENETICALLY DISTINCT HANTAVIRUS; NEWFOUND HANTAVIRUS; BORNE HANTAVIRUS;
UNITED-STATES; SHREW; VIRUS; EVOLUTION; SEQUENCES; RESERVOIR; GUINEA
AB The recent discovery of genetically distinct hantaviruses in multiple species of shrews and moles prompted a further exploration of their host diversification by analyzing frozen, ethanol-fixed and RNAlater (R)-preserved archival tissues and fecal samples from 533 bats (representing seven families, 28 genera and 53 species in the order Chiroptera), captured in Asia, Africa and the Americas in 1981-2012, using RT-PCR. Hantavirus RNA was detected in Pomona roundleaf bats (Hipposideros pomona) (family Hipposideridae), captured in Vietnam in 1997 and 1999, and in banana pipistrelles (Neoromicia nanus) (family Vespertilionidae), captured in Cote d'Ivoire in 2011. Phylogenetic analysis, based on the full-length S- and partial M- and L-segment sequences using maximum likelihood and Bayesian methods, demonstrated that the newfound hantaviruses formed highly divergent lineages, comprising other recently recognized batborne hantaviruses in Sierra Leone and China. The detection of bat-associated hantaviruses opens a new era in hantavirology and provides insights into their evolutionary origins.
C1 [Gu, Se Hun; Yanagihara, Richard] Univ Hawaii Manoa, John A Burns Sch Med, Pacific Ctr Emerging Infect Dis Res, Honolulu, HI 96813 USA.
[Lim, Burton K.] Royal Ontario Museum, Dept Nat Hist, Toronto, ON M5S 2C6, Canada.
[Kadjo, Blaise] Univ Cocody, Dept Biol, Abidjan 22, Cote Ivoire.
[Arai, Satoru] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo 1628640, Japan.
[Kim, Jeong-Ah; Song, Jin-Won] Korea Univ, Coll Med, Dept Microbiol, Seoul 136705, South Korea.
[Nicolas, Violaine; Lalis, Aude; Denys, Christiane] Museum Natl Hist Nat, CNRS, UMR 7205, Dept Systemat & Evolut, F-75005 Paris, France.
[Cook, Joseph A.] Univ New Mexico, Dept Biol, Museum Southwestern Biol, Albuquerque, NM 87131 USA.
[Dominguez, Samuel R.; Holmes, Kathryn V.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO 80045 USA.
[Urushadze, Lela; Sidamonidze, Ketevan; Putkaradze, Davit] Natl Ctr Dis Control & Publ Hlth, GE-0177 Tbilisi, Rep of Georgia.
[Urushadze, Lela] Ilia State Univ, Inst Chem Biol, GE-0162 Tbilisi, Rep of Georgia.
[Kuzmin, Ivan V.] Global Alliance Rabies Control, Manhattan, KS 66502 USA.
[Kosoy, Michael Y.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
RP Yanagihara, R (reprint author), Univ Hawaii Manoa, John A Burns Sch Med, Pacific Ctr Emerging Infect Dis Res, Honolulu, HI 96813 USA.
EM sehungu@hawaii.edu; burtonl@rom.on.ca; blaisekadjo1@hotmail.com;
arais@nih.go.jp; youminlove3@hotmail.com; vnicolas@mnhn.fr;
lalis@mnhn.fr; denys@mnhn.fr; cookjose@unm.edu;
samuel.dominguez@ucdenver.edu; Kathryn.Holmes@ucdenver.edu;
lelincdc@gmail.com; keti_sida@yahoo.com; dato.putkaradze@yahoo.com;
ivkuzmin@yandex.ru; mck3@cdc.gov; jwsong@korea.ac.kr;
ryanagih@hawaii.edu
FU U.S. Public Health Service grants from the National Institutes of Health
[R01AI075057, P20GM103516]; Japan Society for the Promotion of Science
[24405045]; Agency for Defense Development of Korea [UE134020ID];
Centers of Biomedical Research Excellence program [P30GM103341];
[H25-Shinko-Ippan-008]
FX This work was supported by U.S. Public Health Service grants R01AI075057
and P20GM103516 from the National Institutes of Health, grant 24405045
from the Japan Society for the Promotion of Science, grant
H25-Shinko-Ippan-008 for Research on Emerging and Re-emerging Infectious
Diseases, and grant UE134020ID from the Agency for Defense Development
of Korea. The services provided by the Genomics Core Facility, funded
partially by the Centers of Biomedical Research Excellence program
(P30GM103341), are gratefully acknowledged.
NR 39
TC 9
Z9 9
U1 2
U2 14
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAY
PY 2014
VL 6
IS 5
BP 1897
EP 1910
DI 10.3390/v6051897
PG 14
WC Virology
SC Virology
GA AI8JY
UT WOS:000337160900002
PM 24784569
ER
PT J
AU Goodman, RA
Boyd, C
Tinetti, ME
Von Kohorn, I
Parekh, AK
McGinnis, JM
AF Goodman, Richard A.
Boyd, Cynthia
Tinetti, Mary E.
Von Kohorn, Isabelle
Parekh, Anand K.
McGinnis, J. Michael
TI IOM and DHHS Meeting on Making Clinical Practice Guidelines Appropriate
for Patients with Multiple Chronic Conditions
SO ANNALS OF FAMILY MEDICINE
LA English
DT Article
DE practice guidelines; multiple chronic conditions; comorbidities;
institute of Medicine; IOM; Department of Health and Human Services;
DHHS
ID RANDOMIZED CONTROLLED-TRIALS; DISEASES; CONTEXT; CARE
AB BACKGROUND The increasing prevalence of Americans with multiple (2 or more) chronic conditions raises concerns about the appropriateness and applicability of clinical practice guidelines for patient management. Most guidelines clinicians currently rely on have been designed with a single chronic condition in mind, and many such guidelines are inattentive to issues related to comorbidities.
PURPOSE In response to the need for guideline developers to address comorbidities in guidelines, the Department of Health and Human Services convened a meeting in May 2012 in partnership with the Institute of Medicine to identify principles and action options.
RESULTS Eleven principles to improve guidelines' attentiveness to the population with multiple chronic conditions were identified during the meeting. They are grouped into 3 interrelated categories: (1) principles intended to improve the stakeholder technical process for developing guidelines; (2) principles intended to strengthen content of guidelines in terms of multiple chronic conditions; and (3) principles intended to increase focus on patient-centered care.
CONCLUSION This meeting built upon previously recommended actions by identifying additional principles and options for government, guideline developers, and others to use in strengthening the applicability of clinical practice guidelines to the growing population of people with multiple chronic conditions. The suggested principles are helping professional societies to improve guidelines' attentiveness to persons with multiple chronic conditions.
C1 [Goodman, Richard A.; Parekh, Anand K.] US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Washington, DC USA.
[Goodman, Richard A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA.
[Goodman, Richard A.] Emory Univ, Div Gen Med & Geriatr, Atlanta, GA 30322 USA.
[Boyd, Cynthia] Johns Hopkins Univ, Div Geriatr Med & Gerontol, Baltimore, MD USA.
[Tinetti, Mary E.] Yale Univ, Sch Med, Dept Internal Med Geriatr, New Haven, CT USA.
[Tinetti, Mary E.] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
[Von Kohorn, Isabelle] Holy Cross Hlth, Silver Spring, MD USA.
[McGinnis, J. Michael] Natl Acad Sci, Inst Med, Washington, DC 20418 USA.
RP Goodman, RA (reprint author), Ctr Dis Control & Prevent, Mailstop K40,4770 Buford Hwy NE, Atlanta, GA 30341 USA.
EM rag4@cdc.gov
FU AHRQ HHS [R21 HS018597]; NIA NIH HHS [K23 AG032910]
NR 30
TC 12
Z9 13
U1 2
U2 5
PU ANNALS FAMILY MEDICINE
PI LEAWOOD
PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA
SN 1544-1709
EI 1544-1717
J9 ANN FAM MED
JI Ann. Fam. Med.
PD MAY-JUN
PY 2014
VL 12
IS 3
BP 256
EP 259
DI 10.1370/afm.1646
PG 4
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA AI3YM
UT WOS:000336801800010
PM 24821897
ER
PT J
AU Bayliss, EA
Bonds, DE
Boyd, CM
Davis, MM
Finke, B
Fox, MH
Glasgow, RE
Goodman, RA
Heurtin-Roberts, S
Lachenmayr, S
Lind, C
Madigan, EA
Meyers, DS
Mintz, S
Nilsen, WJ
Okun, S
Ruiz, S
Salive, ME
Stange, KC
AF Bayliss, Elizabeth A.
Bonds, Denise E.
Boyd, Cynthia M.
Davis, Melinda M.
Finke, Bruce
Fox, Michael H.
Glasgow, Russell E.
Goodman, Richard A.
Heurtin-Roberts, Suzanne
Lachenmayr, Sue
Lind, Cristin
Madigan, Elizabeth A.
Meyers, David S.
Mintz, Suzanne
Nilsen, Wendy J.
Okun, Sally
Ruiz, Sarah
Salive, Marcel E.
Stange, Kurt C.
TI Understanding the Context of Health for Persons With Multiple Chronic
Conditions: Moving From What Is the Matter to What Matters
SO ANNALS OF FAMILY MEDICINE
LA English
DT Article
DE multiple chronic conditions; chronic illness; health services research
ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIALS; TEAM SCIENCE;
PRIMARY-CARE; EXTERNAL VALIDITY; BIOPSYCHOSOCIAL MODEL; COMPLEXITY
SCIENCE; PATIENT-CARE; NEED; MULTIMORBIDITY
AB PURPOSE An isolated focus on 1 disease at a time is insufficient to generate the scientific evidence needed to improve the health of persons living with more than 1 chronic condition. This article explores how to bring context into research efforts to improve the health of persons living with multiple chronic conditions (MCC).
METHODS Forty-five experts, including persons with MCC, family and friend caregivers, researchers, policy makers, funders, and clinicians met to critically consider 4 aspects of incorporating context into research on MCC: key contextual factors, needed research, essential research methods for understanding important contextual factors, and necessary partnerships for catalyzing collaborative action in conducting and applying research.
RESULTS Key contextual factors involve complementary perspectives across multiple levels: public policy, community, health care systems, family, and person, as well as the cellular and molecular levels where most research currently is focused. Needed research involves moving from a disease focus toward a person-driven, goal-directed research agenda. Relevant research methods are participatory, flexible, multilevel, quantitative and qualitative, conducive to longitudinal dynamic measurement from diverse data sources, sufficiently detailed to consider what works for whom in which situation, and generative of ongoing communities of learning, living and practice. Important partnerships for collaborative action include cooperation among members of the research enterprise, health care providers, community-based support, persons with MCC and their family and friend caregivers, policy makers, and payers, including government, public health, philanthropic organizations, and the business community.
CONCLUSION Consistent attention to contextual factors is needed to enhance health research for persons with MCC. Rigorous, integrated, participatory, multimethod approaches to generate new knowledge and diverse partnerships can be used to increase the relevance of research to make health care more sustainable, safe, equitable and effective, to reduce suffering, and to improve quality of life.
C1 [Bayliss, Elizabeth A.] Kaiser Permanente, Denver, CO USA.
[Bonds, Denise E.] NHLBI, Bethesda, MD 20892 USA.
[Boyd, Cynthia M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Boyd, Cynthia M.] Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Davis, Melinda M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Finke, Bruce] Indian Hlth Serv, Nashville, TN USA.
[Fox, Michael H.; Goodman, Richard A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Glasgow, Russell E.; Heurtin-Roberts, Suzanne] NCI, NIH, Bethesda, MD 20892 USA.
[Glasgow, Russell E.] Univ Colorado, Sch Med, Denver, CO USA.
[Goodman, Richard A.] Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Atlanta, GA USA.
[Lachenmayr, Sue; Ruiz, Sarah] Natl Council Aging, Washington, DC USA.
[Lind, Cristin] Karolinska Inst, Stockholm, Sweden.
[Meyers, David S.] Agcy Healthcare Res & Qual, Rockville, MD USA.
[Nilsen, Wendy J.] NIH, Off Behav & Social Sci Res, Bethesda, MD 20892 USA.
[Okun, Sally] PatientsLikeMe, Cambridge, MA USA.
[Ruiz, Sarah] Univ Chicago, Chicago, IL 60637 USA.
[Salive, Marcel E.] NIA, Bethesda, MD USA.
RP Stange, KC (reprint author), Case Western Reserve Univ, 11000 Cedar Ave,Suite 402, Cleveland, OH 44106 USA.
EM kcs@case.edu
RI Ruiz, Sarah/B-3456-2017
OI Ruiz, Sarah/0000-0002-6428-2321
FU Clinical Research Professorship from the American Cancer Society;
National Cancer Society
FX Dr Stange's time is supported in part by a Clinical Research
Professorship from the American Cancer Society and by the National
Cancer Society through the Intergovernmental Personnel Act.
NR 99
TC 36
Z9 36
U1 7
U2 45
PU ANNALS FAMILY MEDICINE
PI LEAWOOD
PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA
SN 1544-1709
EI 1544-1717
J9 ANN FAM MED
JI Ann. Fam. Med.
PD MAY-JUN
PY 2014
VL 12
IS 3
BP 260
EP 269
DI 10.1370/afm.1643
PG 10
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA AI3YM
UT WOS:000336801800011
PM 24821898
ER
PT J
AU Ross, TM
Lin, CJ
Nowalk, MP
Huang, HH
Spencer, SM
Shay, DK
Sambhara, S
Sundaram, ME
Friedrich, T
Sauereisen, S
Bloom, CE
Zimmerman, RK
AF Ross, Ted M.
Lin, Chyongchiou Jeng
Nowalk, Mary Patricia
Huang, Hsin-Hui
Spencer, Sarah M.
Shay, David K.
Sambhara, Suryaprakash
Sundaram, Maria E.
Friedrich, Thomas
Sauereisen, Sandy
Bloom, Chalise E.
Zimmerman, Richard K.
TI Influence of pre-existing hemagglutination inhibition titers against
historical influenza strains on antibody response to inactivated
trivalent influenza vaccine in adults 50-80 years of age
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE Human influenza; antibodies; immune response; immunogenicity
ID UNITED-STATES; SEASONAL INFLUENZA; ADAMANTANE RESISTANCE;
IMMUNE-RESPONSE; VIRUS; HUMANS; MEMORY; HOSPITALIZATIONS;
IMMUNOGENICITY; IMMUNIZATION
AB Background: Concerns about influenza vaccine effectiveness in older adults and the role of influenza strains encountered earlier in life led to this study.
Methods: Antibody responses against antigens in the 2011-2012 influenza vaccine at 21 days post vaccination were analyzed in 264 individuals aged 50-80 years. At Days 0 and 21, sera were tested for hemagglutination-inhibition titers against these vaccine strains and at Day 0 against a panel of 15 historical seasonal strains.
Results: The proportions of participants with seroprotective titers >= 1:40 to the vaccine strains at Days 0 and 21, respectively, were 37% and 66% for A(H1N1) and 28% and 63% for A(H3N2). An increasing number of responses >= 1.40 against historical strains was associated with seroprotective responses after vaccination among participants with a titer <1.40 at Day 0 for A(H1N1) and A(H3N2) vaccine strains (P < 0.01). In multivariable regression analyses among those with Day 0 titer <1.40, after controlling for age, sex, race, site and diabetes, Day 21 titers >= 1.40 for the vaccine A strains were significantly more likely as the number of seroprotective responses against historical strains increased (A(H1N1) odds ratio [OR] = 1.41, 95% confidence interval [CI] = 1.09-1.82 and A(H3N2) OR = 1.32, 95% CI = 1.07-1.62). The likelihood of seroconversion was significantly higher with an increasing number of responses to historical strains for A(H3N2) only (OR = 1.24, 95% CI = 1.01-1.52). Seroconversion was significantly less likely as Day 0 vaccine strain titers increased.
Conclusions: Seroprotective titers after influenza vaccination increased as the number of responses to historical strains increased.
C1 [Ross, Ted M.; Bloom, Chalise E.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
[Lin, Chyongchiou Jeng; Nowalk, Mary Patricia; Huang, Hsin-Hui; Zimmerman, Richard K.] Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA 15260 USA.
[Sundaram, Maria E.] Marshfield Clin Res Fdn, Marshfield, WI USA.
[Friedrich, Thomas] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA.
[Spencer, Sarah M.; Shay, David K.; Sambhara, Suryaprakash] NCIRD, Influenza Div, Ctr Dis Control & Prevent, Atlanta, GA USA.
[Ross, Ted M.; Bloom, Chalise E.] Vaccine & Gene Therapy Inst Florida, Port Saint Lucie, FL USA.
[Sauereisen, Sandy] UPMC St Margarets Family Med Residency, Pittsburgh, PA USA.
[Friedrich, Thomas] Wisconsin Natl Primate Res Ctr, Madison, WI USA.
RP Zimmerman, RK (reprint author), Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA 15260 USA.
EM zimmer@pitt.edu
OI Shay, David/0000-0001-9619-4820; Zimmerman, Richard/0000-0001-5941-6092
FU Centers for Disease Control and Prevention [U01 IP000467]; US Department
of Energy; CDC
FX This investigation was supported by cooperative agreement U01 IP000467
from the Centers for Disease Control and Prevention. The findings and
conclusions in this report are those of those authors and do not
necessarily represent the views of the Centers for Disease Control and
Prevention. This research was also supported in part by an appointment
to the Research Participation Program at the Centers for Disease Control
and Prevention administered by the Oak Ridge Institute for Science and
Education through an interagency agreement between the US Department of
Energy and CDC.
NR 33
TC 5
Z9 5
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD MAY
PY 2014
VL 10
IS 5
BP 1195
EP 1203
DI 10.4161/hv.28313
PG 9
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA AI2AA
UT WOS:000336656700017
PM 24614078
ER
PT J
AU Kutty, PK
Lawler, J
Rausch-Phung, E
Ortega-Sanchez, IR
Goodell, S
Schulte, C
Pollock, L
Valure, B
Hudson, J
Gallagher, K
Blog, D
AF Kutty, Preeta Krishnan
Lawler, Jacqueline
Rausch-Phung, Elizabeth
Ortega-Sanchez, Ismael R.
Goodell, Stephen
Schulte, Cynthia
Pollock, Lynn
Valure, Barbara
Hudson, Jean
Gallagher, Kathleen
Blog, Debra
TI Epidemiology and the economic assessment of a mumps outbreak in a highly
vaccinated population, Orange County, New York, 2009-2010
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE mumps; outbreak; economic; vaccine; highly vaccinated
ID RUBELLA MMR VACCINATIONS; UNITED-STATES; UNIVERSITY-STUDENTS; NOTIFIABLE
DISEASES; MEASLES; TRANSMISSION; PERSISTENCE; ANTIBODIES; FAILURE;
IMPACT
AB Studies assessing the economic burden of a mumps outbreak in a highly vaccinated population are limited. The Orange County Health Department (OCHD), New York State Department of Health (NYS DOH), and the Centers for Disease Control and Prevention conducted a mumps investigation in an affected village with a highly vaccinated population. To understand the epidemiology, standardized mumps case definition and active surveillance were used to identify mumps cases. In addition, an economic assessment of a combined outbreak investigation and third dose measles-mumps-rubella (MMR) vaccine intervention conducted by OCHD and NYS DOH was performed; estimated by retrospectively evaluating public health response-related activities including use of a third dose of MMR vaccine. From September 24, 2009, through June 15, 2010, 790 mumps cases were reported-64% were male and highest attack rate was among 11-17 year age group (99.1 cases per 1000 individuals). Of the 658 cases with known vaccination history, 83.6% had documentation of 2 doses of mumps containing vaccine. No deaths were reported. The 2 major exposure settings were schools (71.8%) and households (22.5%). Approximately 7736 h of public health personnel time were expended with the total approximate cost of US $463 000, including US $34 392 for MMR vaccine-the estimated cost per household was US $827. Mumps continues to be endemic in many parts of the world, resulting in importations into the United States. Large mumps outbreaks similar to this in highly vaccinated populations may require considerable investigation and control activities.
C1 [Kutty, Preeta Krishnan; Ortega-Sanchez, Ismael R.; Gallagher, Kathleen] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
[Lawler, Jacqueline; Goodell, Stephen; Valure, Barbara; Hudson, Jean] Orange Cty Hlth Dept, Goshen, NY USA.
[Rausch-Phung, Elizabeth; Schulte, Cynthia; Pollock, Lynn; Blog, Debra] New York State Dept Hlth, Bur Immunizat, Albany, NY USA.
RP Kutty, PK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM pkutty@cdc.gov
NR 51
TC 3
Z9 3
U1 4
U2 11
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD MAY
PY 2014
VL 10
IS 5
BP 1373
EP 1381
DI 10.4161/hv.28389
PG 9
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA AI2AA
UT WOS:000336656700041
PM 24633360
ER
PT J
AU Geller, AI
Shehab, N
Lovegrove, MC
Kegler, SR
Weidenbach, KN
Ryan, GJ
Budnitz, DS
AF Geller, Andrew I.
Shehab, Nadine
Lovegrove, Maribeth C.
Kegler, Scott R.
Weidenbach, Kelly N.
Ryan, Gina J.
Budnitz, Daniel S.
TI National Estimates of Insulin-Related Hypoglycemia and Errors Leading to
Emergency Department Visits and Hospitalizations
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID TYPE-2 DIABETES-MELLITUS; INDIVIDUALIZING GLYCEMIC TARGETS; ADVERSE DRUG
EVENTS; MEDICAL-SERVICES; QUALITY MEASURES; GLUCOSE-CONTROL; CARE;
MANAGEMENT; IMPACT; ADULTS
AB IMPORTANCE Detailed, nationally representative data describing high-risk populations and circumstances involved in insulin-related hypoglycemia and errors (IHEs) can inform approaches to individualizing glycemic targets.
OBJECTIVE To describe the US burden, rates, and characteristics of emergency department (ED) visits and emergency hospitalizations for IHEs.
DESIGN, SETTING, AND PARTICIPANTS Nationally representative public health surveillance of adverse drug events among insulin-treated patients seeking ED care (National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project) and a national household survey of insulin use (the National Health Interview Survey) were used to obtain data from January 1, 2007, through December 31, 2011.
MAIN OUTCOMES AND MEASURES Estimated annual numbers and estimated annual rates of ED visits and hospitalizations for IHEs among insulin-treated patients with diabetes mellitus.
RESULTS Based on 8100 National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance cases, an estimated 97 648 (95% CI, 64 410-130 887) ED visits for IHEs occurred annually; almost one-third (29.3%; 95% CI, 21.8%-36.8%) resulted in hospitalization. Severe neurologic sequelae were documented in an estimated 60.6%(95% CI, 51.3%-69.9%) of ED visits for IHEs, and blood glucose levels of 50 mg/dL (to convert to millimoles per liter, multiply by 0.0555) or less were recorded in more than half of cases (53.4%). Insulin-treated patients 80 years or older were more than twice as likely to visit the ED (rate ratio, 2.5; 95% CI, 1.5-4.3) and nearly 5 times as likely to be subsequently hospitalized (rate ratio, 4.9; 95% CI, 2.6-9.1) for IHEs than those 45 to 64 years. The most commonly identified IHE precipitants were reduced food intake and administration of the wrong insulin product.
CONCLUSIONS AND RELEVANCE Rates of ED visits and subsequent hospitalizations for IHEs were highest in patients 80 years or older; the risks of hypoglycemic sequelae in this age group should be considered in decisions to prescribe and intensify insulin. Meal-planning misadventures and insulin product mix-ups are important targets for hypoglycemia prevention efforts.
C1 [Geller, Andrew I.; Shehab, Nadine; Lovegrove, Maribeth C.; Budnitz, Daniel S.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
[Kegler, Scott R.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Anal Res & Practice Integrat, Atlanta, GA 30333 USA.
[Weidenbach, Kelly N.] SRA Int, Atlanta, GA USA.
[Ryan, Gina J.] Mercer Univ, Coll Pharm & Hlth Sci, Atlanta, GA USA.
RP Geller, AI (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,Mail Stop A-24, Atlanta, GA 30333 USA.
EM AGeller@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 68
TC 52
Z9 52
U1 3
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY
PY 2014
VL 174
IS 5
BP 678
EP 686
DI 10.1001/jamainternmed.2014.136
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI4NS
UT WOS:000336842700007
PM 24615164
ER
PT J
AU Baumblatt, JAG
Wiedeman, C
Dunn, JR
Schaffner, W
Paulozzi, LJ
Jones, TF
AF Baumblatt, Jane A. Gwira
Wiedeman, Caleb
Dunn, John R.
Schaffner, William
Paulozzi, Leonard J.
Jones, Timothy F.
TI High-Risk Use by Patients Prescribed Opioids for Pain and Its Role in
Overdose Deaths
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID PRESCRIPTION DRUG OVERDOSES; UNITED-STATES; ABUSE; ANALGESICS;
DIVERSION; MORTALITY; EPIDEMIC
AB IMPORTANCE From January 1, 2003, through December 31, 2010, drug overdose deaths in Tennessee increased from 422 to 1059 per year. More of these deaths involved prescription opioids than heroin and cocaine combined.
OBJECTIVE To assess the contribution of certain opioid-prescribing patterns to the risk of overdose death.
DESIGN, SETTING, AND PARTICIPANTS We performed a matched case-control study that analyzed opioid prescription data from the Tennessee Controlled Substances Monitoring Program (TNCSMP) from January 1, 2007, through December 31, 2011, to identify risk factors associated with opioid-related overdose deaths from January 1, 2009, through December 31, 2010. Case patients were ascertained from death certificate data. Age-and sex-matched controls were randomly selected from among live patients in the TNCSMP.
MAIN OUTCOMES AND MEASURES We defined a high-risk number of prescribers or pharmacies as 4 or more per year and high-risk dosage as a daily mean of more than 100 morphine milligram equivalents (MMEs) per year. The main outcome was opioid-related overdose death.
RESULTS From January 1, 2007, through December 31, 2011, one-third of the population of Tennessee filled an opioid prescription each year, and opioid prescription rates increased from 108.3 to 142.5 per 100 population per year. Among all patients in Tennessee prescribed opioids during 2011, 7.6% used more than 4 prescribers, 2.5% used more than 4 pharmacies, and 2.8% had a mean daily dosage greater than 100 MMEs. Increased risk of opioid-related overdose death was associated with 4 or more prescribers (adjusted odds ratio [aOR], 6.5; 95% CI, 5.1-8.5), 4 or more pharmacies (aOR, 6.0; 95% CI, 4.4-8.3), and more than 100 MMEs (aOR, 11.2; 95% CI, 8.3-15.1). Persons with 1 or more risk factor accounted for 55% of all overdose deaths.
CONCLUSIONS AND RELEVANCE High-risk use of prescription opioids is frequent and increasing in Tennessee and is associated with increased overdose mortality. Use of prescription drug-monitoring program data to direct risk-reduction measures to the types of patients overrepresented among overdose deaths might reduce mortality associated with opioid abuse.
C1 [Baumblatt, Jane A. Gwira] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Tennessee Dept Hlth, Nashville, TN USA.
[Wiedeman, Caleb; Dunn, John R.; Schaffner, William; Jones, Timothy F.] Tennessee Dept Hlth, Nashville, TN USA.
[Dunn, John R.; Schaffner, William] Vanderbilt Univ, Sch Med, Dept Prevent Med & Med, Nashville, TN 37212 USA.
[Paulozzi, Leonard J.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA.
RP Baumblatt, JAG (reprint author), Agcy Healthcare Res & Qual, Ctr Qual Improvement & Patient Safety, 540 Gaither Rd, Rockville, MD 20850 USA.
NR 31
TC 44
Z9 44
U1 4
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY
PY 2014
VL 174
IS 5
BP 796
EP 801
DI 10.1001/jamainternmed.2013.12711
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI4NS
UT WOS:000336842700028
ER
PT J
AU Jones, CM
Paulozzi, LJ
Mack, KA
AF Jones, Christopher M.
Paulozzi, Leonard J.
Mack, Karin A.
TI Sources of Prescription Opioid Pain Relievers by Frequency of Past-Year
Nonmedical Use: United States, 2008-2011
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Jones, Christopher M.; Paulozzi, Leonard J.; Mack, Karin A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA.
RP Jones, CM (reprint author), Ctr Dis Control & Prevent, Chamblee Campus,4770 Buford Hwy NE,MS F-62, Atlanta, GA 30341 USA.
EM fjr0@cdc.gov
RI Mack, Karin/A-3263-2012
OI Mack, Karin/0000-0001-9274-3001
NR 6
TC 33
Z9 34
U1 2
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY
PY 2014
VL 174
IS 5
BP 802
EP 803
DI 10.1001/jamainternmed.2013.12809
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI4NS
UT WOS:000336842700029
PM 24589763
ER
PT J
AU Alexander, KT
Oduor, C
Nyothach, E
Laserson, KF
Amek, N
Eleveld, A
Mason, L
Rheingans, R
Beynon, C
Mohammed, A
Ombok, M
Obor, D
Odhiambo, F
Quick, R
Phillips-Howard, PA
AF Alexander, Kelly T.
Oduor, Clifford
Nyothach, Elizabeth
Laserson, Kayla F.
Amek, Nyaguara
Eleveld, Alie
Mason, Linda
Rheingans, Richard
Beynon, Caryl
Mohammed, Aisha
Ombok, Maurice
Obor, David
Odhiambo, Frank
Quick, Robert
Phillips-Howard, Penelope A.
TI Water, Sanitation and Hygiene Conditions in Kenyan Rural Schools: Are
Schools Meeting the Needs of Menstruating Girls?
SO WATER
LA English
DT Article
DE school; education; children; water sanitation and hygiene; NGOs; Africa;
Kenya; menstruation
ID CLUSTER-RANDOMIZED TRIAL; WESTERN KENYA; NYANZA PROVINCE; SAFE WATER;
HEALTH; IMPACT; PROGRAM; RISK; EXPERIENCES; PREVENTION
AB Water, sanitation and hygiene (WASH) programs in African schools have received increased attention, particularly around the potential impact of poor menstrual hygiene management (MHM) on equity for girls' education. This study was conducted prior to a menstrual feasibility study in rural Kenya, to examine current WASH in primary schools and the resources available for menstruating schoolgirls. Cross-sectional surveys were performed in 62 primary schools during unannounced visits. Of these, 60% had handwashing water, 13% had washing water in latrines for menstruating girls, and 2% had soap. Latrines were structurally sound and 16% were clean. Most schools (84%) had separate latrines for girls, but the majority (77%) had no lock. Non-governmental organizations (NGOs) supported WASH in 76% of schools. Schools receiving WASH interventions were more likely to have: cleaner latrines (Risk Ratio (RR) 1.5; 95% Confidence Intervals [CI] 1.0, 2.1), handwashing facilities (RR 1.6, CI 1.1, 2.5), handwashing water (RR 2.7; CI 1.4, 5.2), and water in girls' latrines (RR 4.0; CI 1.4, 11.6). Schools continue to lack essential WASH facilities for menstruating girls. While external support for school WASH interventions improved MHM quality, the impact of these contributions remains insufficient. Further support is required to meet international recommendations for healthy, gender-equitable schools.
C1 [Alexander, Kelly T.; Mason, Linda; Phillips-Howard, Penelope A.] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Studies, Liverpool L3 5QA, Merseyside, England.
[Oduor, Clifford; Nyothach, Elizabeth; Laserson, Kayla F.; Amek, Nyaguara; Ombok, Maurice; Obor, David; Odhiambo, Frank; Phillips-Howard, Penelope A.] Ctr Global Hlth Res, Kenya Med Res Inst, Kisumu 157840100, Kenya.
[Laserson, Kayla F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30333 USA.
[Eleveld, Alie] Safe Water & AIDS Project, Kisumu 40100, Kenya.
[Rheingans, Richard] Univ Florida, Dept Environm & Global Hlth, Gainesville, FL 32611 USA.
[Rheingans, Richard] Univ Florida, Ctr African Studies, Gainesville, FL 32611 USA.
[Beynon, Caryl] Liverpool John Moores Univ, Ctr Publ Hlth, Liverpool L3 2ET, Merseyside, England.
[Mohammed, Aisha] Minist Publ Hlth & Sanitat, Nairobi 10100, Kenya.
[Quick, Robert] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Alexander, KT (reprint author), Univ Liverpool Liverpool Sch Trop Med, Dept Clin Studies, Liverpool L3 5QA, Merseyside, England.
EM kelly.alexander@liverpool.ac.uk; COduor@kemricdc.org;
ENyothach@kemricdc.org; kel4@cdc.gov; NAmek@kemricdc.org;
alie@swapkenya.org; linda.mason@liverpool.ac.uk; rrheing@epi.ufl.edu;
carylbeynon@hotmail.co.uk; a_o_mohamed@yahoo.com; MOmbok@kemricdc.org;
DObor@kemricdc.org; fodhiambo@kemricdc.org; rxq1@cdc.gov.org;
P.Phillips-Howard@liverpool.ac.uk
FU UK Medical Research Council/Department for International
Development/Wellcome Trust [G1100677/1]; British Council's Prime
Ministers Initiative
FX This study is part of the preliminary phase of a proof of concept
feasibility study on menstrual solutions for schoolgirls funded by the
UK Medical Research Council/Department for International
Development/Wellcome Trust Project Protect (G1100677/1). We received
seed funding through the British Council's Prime Ministers Initiative
(2) for workshops on the overlap between water and sanitation and sexual
and reproductive health, supporting collaboration with UK and US
universities, and local partners. Funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 47
TC 9
Z9 9
U1 4
U2 33
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2073-4441
J9 WATER-SUI
JI Water
PD MAY
PY 2014
VL 6
IS 5
BP 1453
EP 1466
DI 10.3390/w6051453
PG 14
WC Water Resources
SC Water Resources
GA AI7WV
UT WOS:000337113600018
ER
PT J
AU Will, JC
Yuan, KM
Ford, E
AF Will, Julie C.
Yuan, Keming
Ford, Earl
TI National Trends in the Prevalence and Medical History of Angina: 1988 to
2012
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE epidemiology; medical history; prevalence; trends
ID CORONARY-HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; UNITED-STATES; US
ADULTS; CARDIOVASCULAR-DISEASE; CASE-FATALITY; RISK; HYPERTENSION;
OBESITY; QUESTIONNAIRE
AB Background-The prevalence of angina from 1971 to 1994 was relatively flat for whites and blacks. We ask whether the prevalence and medical history of angina have changed during 1988 to 2012.
Methods and Results-We used the National Health and Nutrition Examination Survey data from 1988 to 2004 and the data from the six 2-year surveys from 2001 to 2012. We calculated trends in both crude and standardized prevalence rates for the Rose questionnaire on angina (symptomatology) and a question asking whether the respondent had ever been told by a medical professional that they had angina (medical history). In 2009 to 2012, there were on average 3.4 million (95% confidence interval, 2.8-4.0 million) people aged >= 40 years in the United States each year with angina (Rose questionnaire) and 4.5 million (95% confidence interval, 3.5-5.1 million) people with a medical history of angina. The burden of angina varied across age, race, and sex categories, and the pattern of variation differed by whether symptomatology or medical history was assessed. Statistically significant declines in the rates for both outcomes were noted, for the most part, in people aged >= 65 years. Age and sex standardized rates declined significantly for whites but not for blacks.
Conclusions-Rates of angina symptoms and medical history of angina have declined among non-Hispanic whites and among adults aged >= 65 years. Blacks have not experienced these same declines. Clearly, additional study is required to understand these declines and to track the future cost and burden of angina in the US population.
C1 [Will, Julie C.; Yuan, Keming] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA.
[Ford, Earl] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30341 USA.
RP Will, JC (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy NE,Mailstop F-72, Atlanta, GA 30341 USA.
EM jxw6@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 32
TC 7
Z9 8
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-7705
EI 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2014
VL 7
IS 3
BP 407
EP 413
DI 10.1161/CIRCOUTCOMES.113.000779
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AI3WQ
UT WOS:000336796300010
PM 24847083
ER
PT J
AU Coon, CD
Lau, DT
AF Coon, Cheryl D.
Lau, Denys T.
TI Informing Drug Development and Clinical Practice Through
Patient-Centered Outcomes Research
SO CLINICAL THERAPEUTICS
LA English
DT Editorial Material
C1 [Lau, Denys T.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
[Lau, Denys T.] Univ Illinois, Coll Pharm, Chicago, IL USA.
NR 7
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD MAY
PY 2014
VL 36
IS 5
BP 616
EP 618
DI 10.1016/j.clinthera.2014.04.015
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AI3QY
UT WOS:000336778200002
PM 24852594
ER
PT J
AU Hopf, NB
Ruder, AM
Succop, P
Waters, MA
AF Hopf, Nancy B.
Ruder, Avima M.
Succop, Paul
Waters, Martha A.
TI Evaluation of cumulative PCB exposure estimated by a job exposure matrix
versus PCB serum concentrations
SO ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
LA English
DT Article; Proceedings Paper
CT 7th International PCB Workshop - Chemical mixtures in a complex world
CY MAY 27-31, 2012
CL Arcachon, FRANCE
DE Polychlorinated biphenyls; PCB; Serum PCB; Aroclor; Occupational
exposure
ID POLYCHLORINATED-BIPHENYLS PCBS; CAPACITOR MANUFACTURING WORKERS;
OCCUPATIONAL-EXPOSURE; HALF-LIVES; DERMAL ABSORPTION; MORTALITY;
CONGENERS; PERSISTENCE; PLANT; RISK
AB Although polychlorinated biphenyls (PCBs) have been banned in many countries for more than three decades, exposures to PCBs continue to be of concern due to their long half-lives and carcinogenic effects. In National Institute for Occupational Safety and Health studies, we are using semiquantitative plant-specific job exposure matrices (JEMs) to estimate historical PCB exposures for workers (n = 24,865) exposed to PCBs from 1938 to 1978 at three capacitor manufacturing plants. A subcohort of these workers (n = 410) employed in two of these plants had serum PCB concentrations measured at up to four times between 1976 and 1989. Our objectives were to evaluate the strength of association between an individual worker's measured serum PCB levels and the same worker's cumulative exposure estimated through 1977 with the (1) JEM and (2) duration of employment, and to calculate the explained variance the JEM provides for serum PCB levels using (3) simple linear regression. Consistent strong and statistically significant associations were observed between the cumulative exposures estimated with the JEM and serum PCB concentrations for all years. The strength of association between duration of employment and serum PCBs was good for highly chlorinated (Aroclor 1254/HPCB) but not less chlorinated (Aroclor 1242/LPCB) PCBs. In the simple regression models, cumulative occupational exposure estimated using the JEMs explained 14-24 % of the variance of the Aroclor 1242/LPCB and 22-39 % for Aroclor 1254/HPCB serum concentrations. We regard the cumulative exposure estimated with the JEM as a better estimate of PCB body burdens than serum concentrations quantified as Aroclor 1242/LPCB and Aroclor 1254/HPCB.
C1 [Hopf, Nancy B.] Inst Work & Hlth IST, CH-1066 Epalinges, Switzerland.
[Ruder, Avima M.; Waters, Martha A.] NIOSH, Ctr Dis Control & Prevent, CDC, Cincinnati, OH 45226 USA.
[Succop, Paul] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA.
RP Hopf, NB (reprint author), Inst Work & Hlth IST, Route Corniche 2, CH-1066 Epalinges, Switzerland.
EM Nancy.Hopf@hospvd.ch; amr2@cdc.gov; succopa@uc.edu; maw0@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 47
TC 1
Z9 1
U1 3
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0944-1344
EI 1614-7499
J9 ENVIRON SCI POLLUT R
JI Environ. Sci. Pollut. Res.
PD MAY
PY 2014
VL 21
IS 10
BP 6314
EP 6323
DI 10.1007/s11356-013-1574-4
PG 10
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA AH7LO
UT WOS:000336314900006
PM 23475397
ER
PT J
AU Hopf, NB
Ruder, AM
Waters, MA
AF Hopf, Nancy B.
Ruder, Avima M.
Waters, Martha A.
TI Historical reconstruction of polychlorinated biphenyl (PCB) exposures
for workers in a capacitor manufacturing plant
SO ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
LA English
DT Article; Proceedings Paper
CT 7th International PCB Workshop - Chemical mixtures in a complex world
CY MAY 27-31, 2012
CL Arcachon, FRANCE
DE Polychlorinated biphenyls (PCB); Job exposure matrix (JEM)
ID HUMAN CANCER-RISKS; OCCUPATIONAL-EXPOSURE; DERMAL ABSORPTION; MATRIX
TEM; MORTALITY; UPDATE; MISCLASSIFICATION; AGENTS
AB We developed a semiquantitative job exposure matrix (JEM) for workers exposed to polychlorinated biphenyls (PCBs) at a capacitor manufacturing plant from 1946 to 1977. In a recently updated mortality study, mortality of prostate and stomach cancer increased with increasing levels of cumulative exposure estimated with this JEM (trend p values=0.003 and 0.04, respectively). Capacitor manufacturing began with winding bales of foil and paper film, which were placed in a metal capacitor box (pre-assembly), and placed in a vacuum chamber for flood-filling (impregnation) with dielectric fluid (PCBs). Capacitors dripping with PCB residues were then transported to sealing stations where ports were soldered shut before degreasing, leak testing, and painting. Using a systematic approach, all 509 unique jobs identified in the work histories were rated by predetermined process- and plant-specific exposure determinants; then categorized based on the jobs' similarities (combination of exposure determinants) into 35 job exposure categories. The job exposure categories were ranked followed by a qualitative PCB exposure rating (baseline, low, medium, and high) for inhalation and dermal intensity. Category differences in other chemical exposures (solvents, etc.) prevented further combining of categories. The mean of all available PCB concentrations (1975 and 1977) for jobs within each intensity rating was regarded as a representative value for that intensity level. Inhalation (in microgram per cubic milligram) and dermal (unitless) exposures were regarded as equally important. Intensity was frequency adjusted for jobs with continuous or intermittent PCB exposures. Era-modifying factors were applied to the earlier time periods (1946-1974) because exposures were considered to have been greater than in later eras (1975-1977). Such interpolations, extrapolations, and modifying factors may introduce non-differential misclassification; however, we do believe our rigorous method minimized misclassification, as shown by the significant exposure-response trends in the epidemiologic analysis.
C1 [Hopf, Nancy B.] Inst Work & Hlth IST, CH-1066 Epalinges, Switzerland.
[Ruder, Avima M.; Waters, Martha A.] NIOSH, Ctr Dis Control & Prevent CDC, Cincinnati, OH 45226 USA.
RP Hopf, NB (reprint author), Inst Work & Hlth IST, Route Corniche 2, CH-1066 Epalinges, Switzerland.
EM Nancy.Hopf@hospvd.ch; amr2@cdc.gov; maw0@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 49
TC 3
Z9 3
U1 2
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0944-1344
EI 1614-7499
J9 ENVIRON SCI POLLUT R
JI Environ. Sci. Pollut. Res.
PD MAY
PY 2014
VL 21
IS 10
BP 6419
EP 6433
DI 10.1007/s11356-013-1590-4
PG 15
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA AH7LO
UT WOS:000336314900016
PM 23475444
ER
PT J
AU Okoro, CA
Dhingra, SS
Li, CY
AF Okoro, Catherine A.
Dhingra, Satvinder S.
Li, Chaoyang
TI A Triple Play: Psychological Distress, Physical Comorbidities, and
Access and Use of Health Services among US Adults with Disabilities
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Psychological distress; mental health; disability; BRFSS; surveillance
ID SERIOUS MENTAL-ILLNESS; FACTOR SURVEILLANCE SYSTEM; ASSISTIVE
TECHNOLOGY; GENERAL-POPULATION; HURRICANE KATRINA; SCREENING SCALES;
INTERVIEW SURVEY; NATIONAL-HEALTH; UNITED-STATES; OLDER-ADULTS
AB Purpose. Among adults with disabilities, we examined whether increasing levels of psychological distress were associated with higher estimated prevalences of chronic conditions, obesity, health care access, and use of preventive services. Methods. We analyzed data from the 2007 Behavioral Risk Factor Surveillance System. The Kessler-6 scale was used to assess psychological distress. Results. Increasing levels of psychological distress were associated with an increased prevalence of chronic diseases and conditions, and decreased access to health care and utilization of preventive services in keeping with what has been established for non-disabled populations. Among adults with disabilities, aged 18-64 years and 65 years or older, increasing levels of distress were also associated with increased receipt of mental health treatment. However, compared to adults aged 18-64 years, larger proportions of older adults reported non-receipt of mental health treatment (mild to moderate psychological distress: 58.0% versus 70.6%; serious psychological distress: 40.5% versus 54.5%). Conclusions. While adults with disabilities who had increased levels of psychological distress were more likely to receive mental health services, they also had higher estimated prevalences of chronic conditions, barriers to health care, and non-receipt of preventive cancer screenings.
C1 [Okoro, Catherine A.; Dhingra, Satvinder S.; Li, Chaoyang] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance & Informat Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA.
RP Okoro, CA (reprint author), Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance & Informat Program Off, Off Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE,M-S E-97, Atlanta, GA 30333 USA.
EM COkoro@cdc.gov
NR 64
TC 2
Z9 2
U1 9
U2 18
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
EI 1548-6869
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD MAY
PY 2014
VL 25
IS 2
BP 814
EP 836
PG 23
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AH7VJ
UT WOS:000336343100030
PM 24858888
ER
PT J
AU Wang, GJ
Zhang, ZF
Ayala, C
Dunet, DO
Fang, J
George, MG
AF Wang, Guijing
Zhang, Zefeng
Ayala, Carma
Dunet, Diane O.
Fang, Jing
George, Mary G.
TI Costs of Hospitalization for Stroke Patients Aged 18-64 Years in the
United States
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Cost; stroke type; diagnosis type; comorbidity
ID ACUTE ISCHEMIC-STROKE; HIP FRACTURE; DISEASE; CONSEQUENCES; POPULATION;
DIAGNOSIS; OUTCOMES; BURDEN; CARE; ICD-9-CM
AB Background: Estimates for the average cost of stroke have varied 20-fold in the United States. To provide a robust cost estimate, we conducted a comprehensive analysis of the hospitalization costs for stroke patients by diagnosis status and event type. Methods: Using the 2006-2008 MarketScan inpatient database, we identified 97,374 hospitalizations with a primary or secondary diagnosis of stroke. We analyzed the costs after stratifying the hospitalizations by stroke type (hemorrhagic, ischemic, and other strokes) and diagnosis status (primary and secondary). We employed regressions to estimate the impact of event type and diagnosis status on costs while controlling for major potential confounders. Results: Among the 97,374 hospitalizations (average cost: $20,396 +/- $23,256), the number with ischemic, hemorrhagic, or other strokes was 62,637, 16,331, and 48,208, respectively, with these types having average costs, in turn, of $18,963 +/- $21,454, $32,035 +/- $32,046, and $19,248 +/- $21,703. A majority (62%) of the hospitalizations had stroke listed as a secondary diagnosis only. Regression analysis found that, overall, hemorrhagic stroke cost $14,499 more than ischemic stroke (P < .001). For hospitalizations with a primary diagnosis of ischemic stroke, those with a secondary diagnosis of ischemic heart disease (IHD) had costs that were $9836 higher (P < .001) than those without IHD. Conclusions: The costs of hospitalizations involving stroke are high and vary greatly by type of stroke, diagnosis status, and comorbidities. These findings should be incorporated into cost-effective strategies to reduce the impact of stroke.
C1 [Wang, Guijing; Zhang, Zefeng; Ayala, Carma; Dunet, Diane O.; Fang, Jing; George, Mary G.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA.
RP Wang, GJ (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy,MS F-72, Atlanta, GA 30341 USA.
EM Gbw9@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 43
TC 11
Z9 11
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD MAY-JUN
PY 2014
VL 23
IS 5
BP 861
EP 868
DI 10.1016/j.jstrokecerebrovasdis.2013.07.017
PG 8
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA AH9SI
UT WOS:000336482000027
PM 23954598
ER
PT J
AU Fry, AM
AF Fry, Alicia M.
TI Effectiveness of neuraminidase inhibitors for severe influenza
SO LANCET RESPIRATORY MEDICINE
LA English
DT Editorial Material
ID RANDOMIZED CONTROLLED-TRIAL; SEASONAL INFLUENZA; OSELTAMIVIR; CHILDREN
C1 Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Fry, AM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM afry@cdc.gov
NR 10
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD MAY
PY 2014
VL 2
IS 5
BP 346
EP 348
DI 10.1016/S2213-2600(14)70068-2
PG 4
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AI2VN
UT WOS:000336716300008
PM 24815800
ER
PT J
AU Muthuri, SG
Venkatesan, S
Myles, PR
Leonardi-Bee, J
Al Khuwaitir, TSA
Al Mamun, A
Anovadiya, AP
Azziz-Baumgartner, E
Baez, C
Bassetti, M
Beovic, B
Bertisch, B
Bonmarin, I
Booy, R
Borja-Aburto, VH
Burgmann, H
Cao, B
Carratala, J
Denholm, JT
Dominguez, SR
Duarte, PAD
Dubnov-Raz, G
Echavarria, M
Fanella, S
Gao, ZC
Gerardin, P
Giannella, M
Gubbels, S
Herberg, J
Iglesias, ALH
Hoger, PH
Hu, XY
Islam, QT
Jimenez, MF
Kandeel, A
Keijzers, G
Khalili, H
Knight, M
Kudo, K
Kusznierz, G
Kuzman, I
Kwan, AMC
Amine, IL
Langenegger, E
Lankarani, KB
Leo, YS
Linko, R
Liu, P
Madanat, F
Mayo-Montero, E
McGeer, A
Memish, Z
Metan, G
Mickiene, A
Mikic, D
Mohn, KGI
Moradi, A
Nymadawa, P
Oliva, ME
Ozkan, M
Parekh, D
Paul, M
Polack, FP
Rath, BA
Rodriguez, AH
Sarrouf, EB
Seale, AC
Sertogullarindan, B
Siqueira, MM
Skret-Magierlo, J
Stephan, F
Talarek, E
Tang, JW
To, KKW
Torres, A
Torun, SH
Tran, D
Uyeki, TM
Van Zwol, A
Vaudry, W
Vidmar, T
Yokota, RTC
Zarogoulidis, P
Nguyen-Van-Tam, JS
AF Muthuri, Stella G.
Venkatesan, Sudhir
Myles, Puja R.
Leonardi-Bee, Jo
Al Khuwaitir, Tarig S. A.
Al Mamun, Adbullah
Anovadiya, Ashish P.
Azziz-Baumgartner, Eduardo
Baez, Clarisa
Bassetti, Matteo
Beovic, Bojana
Bertisch, Barbara
Bonmarin, Isabelle
Booy, Robert
Borja-Aburto, Victor H.
Burgmann, Heinz
Cao, Bin
Carratala, Jordi
Denholm, Justin T.
Dominguez, Samuel R.
Duarte, Pericles A. D.
Dubnov-Raz, Gal
Echavarria, Marcela
Fanella, Sergio
Gao, Zhancheng
Gerardin, Patrick
Giannella, Maddalena
Gubbels, Sophie
Herberg, Jethro
Higuera Iglesias, Anjarath L.
Hoger, Peter H.
Hu, Xiaoyun
Islam, Quazi T.
Jimenez, Mirela F.
Kandeel, Amr
Keijzers, Gerben
Khalili, Hossein
Knight, Marian
Kudo, Koichiro
Kusznierz, Gabriela
Kuzman, Ilija
Kwan, Arthur M. C.
Amine, Idriss Lahlou
Langenegger, Eduard
Lankarani, Kamran B.
Leo, Yee-Sin
Linko, Rita
Liu, Pei
Madanat, Faris
Mayo-Montero, Elga
McGeer, Allison
Memish, Ziad
Metan, Gokhan
Mickiene, Aukse
Mikic, Dragan
Mohn, Kristin G. I.
Moradi, Ahmadreza
Nymadawa, Pagbajabyn
Oliva, Maria E.
Ozkan, Mehpare
Parekh, Dhruv
Paul, Mical
Polack, Fernando P.
Rath, Barbara A.
Rodriguez, Alejandro H.
Sarrouf, Elena B.
Seale, Anna C.
Sertogullarindan, Bunyamin
Siqueira, Marilda M.
Skret-Magierlo, Joanna
Stephan, Frank
Talarek, Ewa
Tang, Julian W.
To, Kelvin K. W.
Torres, Antoni
Torun, Selda H.
Dat Tran
Uyeki, Timothy M.
Van Zwol, Annelies
Vaudry, Wendy
Vidmar, Tjasa
Yokota, Renata T. C.
Zarogoulidis, Paul
Nguyen-Van-Tam, Jonathan S.
CA PRIDE Consortium Investigators
TI Effectiveness of neuraminidase inhibitors in reducing mortality in
patients admitted to hospital with influenza A H1N1pdm09 virus
infection: a meta-analysis of individual participant data
SO LANCET RESPIRATORY MEDICINE
LA English
DT Article
ID STEM-CELL TRANSPLANTATION; PANDEMIC INFLUENZA; ANTIVIRAL TREATMENT;
RISK-FACTORS; OSELTAMIVIR; CHILDREN; OUTCOMES; THERAPY; IMPACT; ADULTS
AB Background Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, but evidence for their effectiveness in reducing mortality is uncertain. We did a meta-analysis of individual participant data to investigate the association between use of neuraminidase inhibitors and mortality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection.
Methods We assembled data for patients (all ages) admitted to hospital worldwide with laboratory confirmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. We identified potential data contributors from an earlier systematic review of reported studies addressing the same research question. In our systematic review, eligible studies were done between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010); however, we continued to receive data up to March 14, 2011, from ongoing studies. We did a meta-analysis of individual participant data to assess the association between neuraminidase inhibitor treatment and mortality (primary outcome), adjusting for both treatment propensity and potential confounders, using generalised linear mixed modelling. We assessed the association with time to treatment using time-dependent Cox regression shared frailty modelling.
Findings We included data for 29 234 patients from 78 studies of patients admitted to hospital between Jan 2, 2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio [OR] 0.81; 95% CI 0.70-0.93; p=0.0024). Compared with later treatment, early treatment (within 2 days of symptom onset) was associated with a reduction in mortality risk (adjusted OR 0.48; 95% CI 0.41-0.56; p<0.0001). Early treatment versus no treatment was also associated with a reduction in mortality (adjusted OR 0.50; 95% CI 0.37-0.67; p<0.0001). These associations with reduced mortality risk were less pronounced and not significant in children. There was an increase in the mortality hazard rate with each day's delay in initiation of treatment up to day 5 as compared with treatment initiated within 2 days of symptom onset (adjusted hazard ratio [HR 1.23] [95% CI 1.18-1.28]; p<0.0001 for the increasing HR with each day's delay).
Interpretation We advocate early instigation of neuraminidase inhibitor treatment in adults admitted to hospital with suspected or proven influenza infection.
C1 [Muthuri, Stella G.; Venkatesan, Sudhir; Myles, Puja R.; Leonardi-Bee, Jo; Nguyen-Van-Tam, Jonathan S.] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG5 1PB, England.
[Al Khuwaitir, Tarig S. A.] King Saud Med City, Dept Med, Riyadh, Saudi Arabia.
[Al Mamun, Adbullah] Res Bangladesh, Int Ctr Diarrhoeal Dis, Dhaka, Bangladesh.
[Anovadiya, Ashish P.] Govt Med Coll Bhavnagar, Dept Pharmacol, Bhavnagar, Gujarat, India.
[Anovadiya, Ashish P.] Sir Takhtsinhji Gen Hosp, Bhavnagar, Gujarat, India.
[Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Baez, Clarisa] Minist Salud Prov Buenos Aires, Buenos Aires, DF, Argentina.
[Bassetti, Matteo] Santa Maria Misericordia Hosp, Udine, Italy.
[Beovic, Bojana] Univ Med Ctr, Dept Infect Dis, Ljubljana, Slovenia.
[Bertisch, Barbara] Kantonsspital St Gallen, Div Infect Dis & Hosp Epidemiol, St Gallen, Switzerland.
[Bonmarin, Isabelle] Inst Veille Sanit, St Maurice, France.
[Booy, Robert] Univ Sydney, Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance, Sydney, NSW 2006, Australia.
[Borja-Aburto, Victor H.] Inst Mexicano Seguro Social, Mexico City, DF, Mexico.
[Burgmann, Heinz] Med Univ Vienna, Vienna, Austria.
[Cao, Bin] Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China.
[Carratala, Jordi] Univ Barcelona, Bellvitge Inst Biomed Res, Hosp Univ Bellvitge, Dept Infect Dis, Barcelona, Spain.
[Denholm, Justin T.] Peter Doherty Inst Infect & Immun, Victorian Infect Dis Serv, Parkville, Vic, Australia.
[Denholm, Justin T.] Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Parkville, Vic, Australia.
[Dominguez, Samuel R.] Univ Colorado, Sch Med, Childrens Hosp Colorado, Dept Pediat Infect Dis, Aurora, CO USA.
[Duarte, Pericles A. D.] Univ Estadual Oeste Parana, Cascavel, Brazil.
[Dubnov-Raz, Gal] Chaim Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Ramat Gan, Israel.
[Echavarria, Marcela] CEMIC Univ Hosp, Clin Virol Lab, Buenos Aires, DF, Argentina.
[Fanella, Sergio] Univ Manitoba, Sect Pediat Infect Dis, Winnipeg, MB, Canada.
[Gao, Zhancheng] Peking Univ, Peoples Hosp, Dept Resp & Crit Care Med, Beijing 100871, Peoples R China.
[Gerardin, Patrick] Grp Hosp Sud Reunion, Ctr Hosp Univ, Paediat Intens Care Unit, Neonatal Intens Care Unit, St Pierre, Reunion.
[Gerardin, Patrick] Univ La Reunion, Ctr Hosp Univ, Natl Inst Hlth & Med Res, Ctr Clin Invest 1410, St Pierre, Reunion.
[Gerardin, Patrick] Univ La Reunion, Ctr Hosp Univ, Natl Inst Hlth & Med Res,Res & Dev Inst, Cyclotron Reunion Ocean Indien,Unite Mixte Rech P, St Denis, Reunion.
[Giannella, Maddalena] Hosp Gen Univ Gregorio Maranon, Dept Clin Microbiol & Infect Dis, Madrid, Spain.
[Gubbels, Sophie] Statens Serum Inst, Dept Infect Dis Epidemiol, Sect Natl Hlth Documentat & Res, DK-2300 Copenhagen, Denmark.
[Herberg, Jethro] Univ London Imperial Coll Sci Technol & Med, Div Infect Dis, Paediat Sect, London, England.
[Higuera Iglesias, Anjarath L.] Inst Nacl Enfermedades Resp, Epidemiol Res Unit, Mexico City, DF, Mexico.
[Hoger, Peter H.] Catholic Childrens Hosp Wilhelmstift, Hamburg, Germany.
[Hu, Xiaoyun] Peking Union Med Coll, Beijing 100021, Peoples R China.
[Islam, Quazi T.] Dhaka Med Coll Hosp, Dhaka, Bangladesh.
[Jimenez, Mirela F.] Univ Fed Ciencias Saude Porto Alegre, Dept Obstet & Ginecol, Preceptora Residencia Med Hosp Femina, Porto Alegre, RS, Brazil.
[Kandeel, Amr] Minist Hlth Egypt, Cairo, Egypt.
[Keijzers, Gerben] Gold Coast Hosp, Gold Coast, Australia.
[Khalili, Hossein] Univ Tehran Med Sci, Fac Pharm, Dept Clin Pharm, Tehran, Iran.
[Knight, Marian] Univ Oxford, Nuffield Dept Populat Hlth, Natl Perinatal Epidemiol Unit, Oxford, England.
[Kudo, Koichiro] Natl Ctr Global Hlth & Med, Tokyo, Japan.
[Kusznierz, Gabriela] Natl Inst Resp Dis Dr Emilio Coni, Santa Fe, Argentina.
[Kuzman, Ilija] Univ Zagreb, Sch Med, Univ Hosp Infect Dis, Zagreb 41001, Croatia.
[Kwan, Arthur M. C.] Pamela Youde Nethersole Eastern Hosp, Dept Intens Care, Hong Kong, Hong Kong, Peoples R China.
[Amine, Idriss Lahlou] Univ Mohammed V Souissi, Fac Med & Pharm, Mohammed V Mil Teaching Hosp, Biosafety Level & Res Lab 3, Rabat, Morocco.
[Langenegger, Eduard] Univ Stellenbosch, Dept Obstet & Gynaecol, Cape Town, South Africa.
[Langenegger, Eduard] Tygerberg Hosp, Cape Town, South Africa.
[Lankarani, Kamran B.] Shiraz Univ Med Sci, Ctr Hlth Policy Res, Shiraz, Iran.
[Leo, Yee-Sin] Tan Tock Seng Hosp, Dept Infect Dis, Singapore, Singapore.
[Linko, Rita] Helsinki Univ Hosp, Helsinki, Finland.
[Liu, Pei] China Med Univ, Affiliated Hosp 1, Dept Infect Dis, Shenyang, Peoples R China.
[Madanat, Faris] King Hussein Canc Ctr, Dept Pediat, Amman, Jordan.
[Mayo-Montero, Elga] Minist Def, Inst Med Prevent Def, Madrid, Spain.
[McGeer, Allison] Univ Toronto, Toronto Invas Bacterial Dis Network, Toronto, ON, Canada.
[Memish, Ziad] Minist Hlth, Riyadh, Saudi Arabia.
[Memish, Ziad] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia.
[Metan, Gokhan] Erciyes Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Kayseri, Turkey.
[Mickiene, Aukse] Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
[Mikic, Dragan] Mil Med Acad, Clin Infect & Trop Dis, Belgrade 11002, Serbia.
[Mohn, Kristin G. I.] Haukeland Hosp, Dept Med, Infect Dis Sect, N-5021 Bergen, Norway.
[Mohn, Kristin G. I.] Haukeland Hosp, Dept Res & Dev, N-5021 Bergen, Norway.
[Mohn, Kristin G. I.] Univ Bergen, Dept Clin Sci, Influenza Ctr, Bergen, Norway.
[Moradi, Ahmadreza] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Div Ocular Immunol, Baltimore, MD 21205 USA.
[Moradi, Ahmadreza] Shahid Beheshti Univ Med Sci, Massih Daneshvari Hosp, Natl Res Inst TB & Lung Dis, Tehran, Iran.
[Nymadawa, Pagbajabyn] Minist Hlth, Natl Ctr Communicable Dis, Natl Influenza Ctr, Ulaanbaatar, Mongol Peo Rep.
[Oliva, Maria E.] Hosp San Martin de Parana, Dept Infect Control, Entre Rios, Argentina.
[Ozkan, Mehpare] Dr Sami Ulus Res & Training Hosp Womens & Childre, Clin Pediat Neurol, Ankara, Turkey.
[Parekh, Dhruv] Univ Birmingham, Sch Clin & Expt Med, Crit Care & Pain Perioperat Crit Care & Trauma Tr, Birmingham B15 2TT, W Midlands, England.
[Paul, Mical] Rambam Hlth Care Campus, Div Infect Dis, Haifa, Israel.
[Polack, Fernando P.] Vanderbilt Univ, Dept Pediat, Vanderbilt Vaccine Ctr, Nashville, TN USA.
[Polack, Fernando P.] Fdn INFANT, Buenos Aires, DF, Argentina.
[Rath, Barbara A.] Charite Univ Med Ctr, Dept Pediat, Div Pneumonol Immunol, Berlin, Germany.
[Rodriguez, Alejandro H.] Univ Rovira & Virgili, Hosp Joan 23, Crit Care Dept, Inst Invest Sanitaria Pere Virgili, E-43007 Tarragona, Spain.
[Sarrouf, Elena B.] Minist Salud Tucuman, San Miguel De Tucuman, Argentina.
[Seale, Anna C.] Bristol Childrens Hosp, Paediat Intens Care Unit, Bristol, Avon, England.
[Seale, Anna C.] Univ Bristol, Sch Clin Sci, Bristol Childrens Vaccine Ctr, Bristol, Avon, England.
[Sertogullarindan, Bunyamin] Yuzuncu Yil Univ, Fac Med, Dept Pulm Med, Van, Turkey.
[Siqueira, Marilda M.] Fiocruz MS, Inst Oswaldo Cruz, Lab Resp Viruses, BR-21045900 Rio De Janeiro, Brazil.
[Skret-Magierlo, Joanna] Uniwersytet Rzeszowski, Rzeszow, Poland.
[Stephan, Frank] Univ Basel Hosp, Dept Emergency Med, CH-4031 Basel, Switzerland.
[Talarek, Ewa] Med Univ Warsaw, Dept Childrens Infect Dis, Warsaw, Poland.
[Tang, Julian W.] Natl Univ Singapore Hosp, Div Microbiol, Mol Diagnost Ctr, Dept Lab Med, Singapore 117548, Singapore.
[Tang, Julian W.] Univ Alberta Hosp, Alberta Prov Lab Publ Hlth, Edmonton, AB T6G 2B7, Canada.
[Tang, Julian W.] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada.
[To, Kelvin K. W.] Univ Hong Kong, Queen Mary Hosp, Carol Yu Ctr Infect, Hong Kong, Hong Kong, Peoples R China.
[To, Kelvin K. W.] Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Div Infect Dis, Hong Kong, Hong Kong, Peoples R China.
[Torres, Antoni] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain.
[Torun, Selda H.] Istanbul Fac Med, Dept Pediat Infect Dis, Istanbul, Turkey.
[Dat Tran] Univ Toronto, Hosp Sick Children, Dept Paediat, Div Infect Dis, Toronto, ON M5G 1X8, Canada.
[Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
[Van Zwol, Annelies] Vrije Univ Amsterdam Med Ctr, Dept Pediat Intens Care, Amsterdam, Netherlands.
[Vaudry, Wendy] Univ Alberta, Stollery Childrens Hosp, Dept Pediat, Div Infect Dis, Edmonton, AB, Canada.
[Vidmar, Tjasa] Gen Hosp Slovenj Gradec, Slovenj Gradec, Slovenia.
[Yokota, Renata T. C.] Minist Saude, Secretaria Vigilancia Saude, Dept Vigilancia Epidemiol, Brasilia, DF, Brazil.
[Zarogoulidis, Paul] Democritus Univ Thrace, Univ Gen Hosp Alexandroupolis, Infect Dis Unit, Dragana, Greece.
RP Nguyen-Van-Tam, JS (reprint author), Univ Nottingham, City Hosp, Clin Sci Bldg, Nottingham NG5 1PB, England.
EM jvt@nottingham.ac.uk
RI Knight, Marian/B-6225-2009; mcgeer, allison /H-7747-2014; Dubnov-Raz,
Gal/L-3297-2016; Bouza, Emilio/D-8661-2014; Giannella,
Maddalena/K-9090-2016;
OI Keijzers, Gerben/0000-0003-1100-4552; Loh, Tze Ping/0000-0002-4272-0001;
Bagheri Lankarani, Kamran/0000-0002-7524-9017; El Rhaffouli,
Hicham/0000-0003-3391-1014; Hoeger, Peter/0000-0003-3268-7479; tabarsi,
payam/0000-0002-8932-5420; Viasus, Diego/0000-0001-8408-3947;
Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655; cilloniz,
catia/0000-0002-4646-9838; Myles, Puja/0000-0002-8976-890X; Knight,
Marian/0000-0002-1984-4575; mcgeer, allison /0000-0001-5647-6137;
Dubnov-Raz, Gal/0000-0003-1469-8043; Bouza, Emilio/0000-0001-6967-9267;
Cox, Rebecca Jane/0000-0002-8341-4078; Khandaker,
Gulam/0000-0002-0661-4113; Herberg, Jethro/0000-0001-6941-6491; Denholm,
Justin/0000-0002-9214-6431; Parekh, Dhruv/0000-0002-1508-8362;
Giannella, Maddalena/0000-0001-8273-7601; Seale,
Anna/0000-0002-0129-3146; To, Kelvin/0000-0002-1921-5824
FU F Hoffmann-La Roche
FX F Hoffmann-La Roche.
NR 34
TC 151
Z9 155
U1 9
U2 69
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD MAY
PY 2014
VL 2
IS 5
BP 395
EP 404
DI 10.1016/S2213-2600(14)70041-4
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AI2VN
UT WOS:000336716300022
PM 24815805
ER
PT J
AU Kane, DJ
Sappenfield, WM
AF Kane, Debra J.
Sappenfield, William M.
TI Ascertainment of Medicaid Payment for Delivery on the Iowa Birth
Certificate: Is Accuracy Sufficient for Timely Policy and Program
Relevant Analysis?
SO MATERNAL AND CHILD HEALTH JOURNAL
LA English
DT Article
DE Medicaid; Paid claims; Birth certificate data; Validity; Reliability;
Kappa statistic; Sensitivity
ID RELIABILITY; VALIDITY; AGREEMENT; INSURANCE; RECORDS
AB The Iowa Department of Public Health annually links Medicaid claims data to the birth certificate. Because the latest version of the birth certificate provides more timely and less costly information on delivery payment source, we were interested in assessing the validity and reliability of the birth certificate payment source compared to Medicaid paid claims. We linked Medicaid paid claims to birth certificates for calendar years 2007-2009 (n = 120,626). We measured reliability by Kappa statistic and validity by sensitivity, specificity, predictive value positive and negative. We examined reliability and validity overall and by maternal characteristics (e. g. age, race, ethnicity, education). The Kappa statistic for the birth certificate payment source indicated substantial agreement (0.78; 95 % CL 0.78-0.79). Sensitivity and specificity were also high, 86.3 % (95 % CL 86.0-86 6 %) and 91.9 % (95 % CL 91.7-92.1 %), respectively. The predictive value positive was 87.0 %. The predictive value negative was 91.4 %. Kappa and specificity were lower among women of racial and ethnic minorities, women younger than age 24, and women with less education. The overall Kappa, sensitivity and specificity generally suggest the birth certificate payment source is as valid and reliable as the linked data source. The birth certificate payment source is less valid and reliable for women of racial and ethnic minorities, women younger than age 24, and those with less education. Consequently caution should be exercised when using the birth certificate payment source for monitoring service use by the Medicaid population within specific population subgroups.
C1 [Kane, Debra J.] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA.
[Kane, Debra J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Sappenfield, William M.] Univ S Florida, Coll Publ Hlth, Lawton & Rhea Chiles Ctr Healthy Mothers & Babies, Div Family Hlth Serv,Dept Community & Family Hlth, Tampa, FL 33612 USA.
RP Kane, DJ (reprint author), Iowa Dept Publ Hlth, Lucas State Off Bldg,321 East 12th St, Des Moines, IA 50319 USA.
EM dkane@cdc.gov; wsappenf@health.usf.edu
NR 25
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1092-7875
EI 1573-6628
J9 MATERN CHILD HLTH J
JI Matern. Child Health J.
PD MAY
PY 2014
VL 18
IS 4
BP 970
EP 977
DI 10.1007/s10995-013-1325-7
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI3CA
UT WOS:000336735200023
PM 23832375
ER
PT J
AU Fan, L
Owusu-Edusei, K
Schillie, SF
Murphy, TV
AF Fan, Lin
Owusu-Edusei, Kwame, Jr.
Schillie, Sarah F.
Murphy, Trudy V.
TI Cost-Effectiveness of Testing Hepatitis B-Positive PregnantWomen for
Hepatitis B e Antigen or Viral Load
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article; Proceedings Paper
CT 2nd Conference of the INFORMS on Healthcare
CY JUN 23-26, 2013
CL Chicago, IL
SP INFORMS
ID TO-CHILD TRANSMISSION; VIRUS INFECTION; UNITED-STATES; PERINATAL
TRANSMISSION; VERTICAL TRANSMISSION; IMMUNE GLOBULIN; LATE PREGNANCY;
PREVENTION; LAMIVUDINE; VACCINATION
AB OBJECTIVE: To estimate the cost-effectiveness of testing pregnant women with hepatitis B (hepatitis B surface antigen [HBsAg]-positive) for hepatitis B e antigen (HBeAg) or hepatitis B virus (HBV) DNA, and administering maternal antiviral prophylaxis if indicated, to decrease breakthrough perinatal HBV transmission from the U. S. health care perspective.
METHODS: A Markov decision model was constructed for a 2010 birth cohort of 4 million neonates to estimate the cost-effectiveness of two strategies: testing HBsAg-positive pregnant women for 1) HBeAg or 2) HBV load. Maternal antiviral prophylaxis is given from 28 weeks of gestation through 4 weeks postpartum when HBeAg is positive or HBV load is high (10(8) copies/mL or greater). These strategies were compared with the current recommendation. All neonates born to HBsAg-positive women received recommended active-passive immunoprophylaxis. Effects were measured in quality-adjusted life-years (QALYs) and all costs were in 2010 U. S. dollars.
RESULTS: The HBeAg testing strategy saved $3.3 million and 3,080 QALYs and prevented 486 chronic HBV infections compared with the current recommendation. The HBV load testing strategy cost $3 million more than current recommendation, saved 2,080 QALYs, and prevented 324 chronic infections with an incremental cost-effectiveness ratio of $1,583 per QALY saved compared with the current recommendations. The results remained robust over a wide range of assumptions.
CONCLUSION: Testing HBsAg-positive pregnant women for HBeAg or HBV load followed by maternal antiviral prophylaxis if HBeAg-positive or high viral load to reduce perinatal hepatitis B transmission in the United States is cost-effective.
C1 [Fan, Lin; Owusu-Edusei, Kwame, Jr.; Schillie, Sarah F.; Murphy, Trudy V.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
RP Fan, L (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS G-37, Atlanta, GA 30333 USA.
EM Wqm3@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 50
TC 10
Z9 10
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7844
EI 1873-233X
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD MAY
PY 2014
VL 123
IS 5
BP 929
EP 937
DI 10.1097/AOG.0000000000000124
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AI4BD
UT WOS:000336809400004
PM 24785842
ER
PT J
AU Callaghan, WM
Grobman, WA
Kilpatrick, SJ
Main, EK
D'Alton, M
AF Callaghan, William M.
Grobman, William A.
Kilpatrick, Sarah J.
Main, Elliott K.
D'Alton, Mary
TI Facility-Based Identification of Women With Severe Maternal Morbidity It
Is Time to Start
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article
ID UNITED-STATES; SCORING SYSTEM; MORTALITY
AB Although maternal deaths have been the traditional indicator of maternal health, these events are the "tip of the iceberg" in that there are many women who have significant complications of pregnancy, labor, and delivery. Identifying women who experience severe maternal morbidity and reviewing their care can provide critical information to inform quality improvement in obstetrics. In this commentary, we review methods to identify women who experienced severe complications of pregnancy. We propose a simple validated approach based on transfusion of four or more units of blood products, admission to an intensive care unit, or both as a starting point for identification and review of severe maternal morbidity in health care settings for the purpose of understanding successes and failures in systems of care.
C1 [Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA.
Northwestern Univ, Dept Obstet, Feinberg Sch Med, Chicago, IL 60611 USA.
Northwestern Univ, Dept Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA.
Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
Calif Maternal Qual Care Collaborat, Palo Alto, CA USA.
RP Callaghan, WM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,MS F-74, Atlanta, GA 30341 USA.
EM wgc0@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 12
TC 30
Z9 31
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7844
EI 1873-233X
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD MAY
PY 2014
VL 123
IS 5
BP 978
EP 981
DI 10.1097/AOG.0000000000000218
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AI4BD
UT WOS:000336809400011
PM 24785849
ER
PT J
AU Tepper, NK
Boulet, SL
Whiteman, MK
Monsour, M
Marchbanks, PA
Hooper, WC
Curtis, KM
AF Tepper, Naomi K.
Boulet, Sheree L.
Whiteman, Maura K.
Monsour, Michael
Marchbanks, Polly A.
Hooper, W. Craig
Curtis, Kathryn M.
TI Postpartum Venous Thromboembolism Incidence and Risk Factors
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article
ID POPULATION-BASED COHORT; PREGNANCY; PERIOD
AB OBJECTIVE: To calculate incidence of postpartum venous thromboembolism by week after delivery and to examine potential risk factors for venous thromboembolism overall and at different times during the postpartum period.
METHODS: A deidentified health care claims information database from employers, health plans, hospitals, and Medicaid programs across the United States was used to identify delivery hospitalizations among women aged 15-44 years during the years 2005-2011. International Classification of Diseases, 9th Revision, Clinical Modification diagnosis and procedure codes were used to identify instances of venous thromboembolism and associated characteristics and conditions among women with recent delivery. Incidence proportions of venous thromboembolism by week postpartum through week 12 were calculated per 10,000 deliveries. Logistic regression was used to calculate odds ratios for selected risk factors among women with postpartum venous thromboembolism and among women with venous thromboembolism during the early or later postpartum periods.
RESULTS: The incidence proportion of postpartum venous thromboembolism was highest during the first 3 weeks after delivery, dropping from nine per 10,000 during the first week to one per 10,000 at 4 weeks after delivery and decreasing steadily through the 12th week. Certain obstetric procedures and complications such as cesarean delivery, preeclampsia, hemorrhage, and postpartum infection conferred an increased risk for venous thromboembolism (odds ratios ranging from 1.3 to 6.4), which persisted over the 12-week period compared with women without these risk factors.
CONCLUSION: Risk for postpartum venous thromboembolism is highest during the first 3 weeks after delivery. Women with obstetric complications are at highest risk for postpartum venous thromboembolism, and this risk remains elevated throughout the first 12 weeks after delivery.
C1 Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA.
Ctr Dis Control, Natl Ctr Birth Defects & Dev Disabil, Div Reprod Hlth, Atlanta, GA 30333 USA.
RP Tepper, NK (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,Mailstop F-74, Atlanta, GA 30341 USA.
EM ntepper@cdc.gov
NR 18
TC 15
Z9 15
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7844
EI 1873-233X
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD MAY
PY 2014
VL 123
IS 5
BP 987
EP 996
DI 10.1097/AOG.0000000000000230
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AI4BD
UT WOS:000336809400013
PM 24785851
ER
PT J
AU Alemnji, G
Fonjungo, P
Van Der Pol, B
Peter, T
Kantor, R
Nkengasong, J
AF Alemnji, George
Fonjungo, Peter
Van Der Pol, Barbara
Peter, Trevor
Kantor, Rami
Nkengasong, John
TI The Centrality of Laboratory Services in the HIV Treatment and
Prevention Cascade: The Need for Effective Linkages and Referrals in
Resource-Limited Settings
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID EARLY ANTIRETROVIRAL THERAPY; FOLLOW-UP; CARE; HIV/AIDS; TRANSMISSION;
INFECTION; PROGRAM; SYSTEMS; IMPACT; TUBERCULOSIS
AB Strong laboratory services and systems are critical for delivering timely and quality health services that are vital to reduce patient attrition in the HIV treatment and prevention cascade. However, challenges exist in ensuring effective laboratory health systems strengthening and linkages. In particular, linkages and referrals between laboratory testing and other services need to be considered in the context of an integrated health system that includes prevention, treatment, and strategic information. Key components of laboratory health systems that are essential for effective linkages include an adequate workforce, appropriate point-of-care (POC) technology, available financing, supply chain management systems, and quality systems improvement, including accreditation. In this review, we highlight weaknesses of and gaps between laboratory testing and other program services. We propose a model for strengthening these systems to ensure effective linkages of laboratory services for improved access and retention in care of HIV/AIDS patients, particularly in low- and middle-income countries.
C1 [Alemnji, George] Ctr Dis Control & Prevent, Caribbean Reg Off, Div Global HIV AIDS, Bridgetown Bbd, Barbados.
[Fonjungo, Peter; Nkengasong, John] Ctr Dis Control & Prevent, Div Global HIV AIDS, Int Lab Branch, Atlanta, GA USA.
[Van Der Pol, Barbara] Univ Alabama Birmingham, Sch Med, Div Infect Dis, Birmingham, AL USA.
[Peter, Trevor] Clinton Hlth Access Initiat, Gaboren, Botswana.
[Kantor, Rami] Brown Univ, Div Infect Dis, Providence, RI 02912 USA.
RP Alemnji, G (reprint author), Ctr Dis Control & Prevent, Caribbean Reg Off, Div Global HIV AIDS, Bridgetown Bbd, Barbados.
EM ikv3@cdc.gov
OI Van Der Pol, Barbara/0000-0003-3064-8564
FU President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers
for Disease Control and Prevention (CDC)
FX This research has been supported by the President's Emergency Plan for
AIDS Relief (PEPFAR) through the Centers for Disease Control and
Prevention (CDC). The findings and conclusions in this report are those
of the authors and do not necessarily represent the official position of
the CDC/Agency for Toxic Substances and Disease Registry.
NR 37
TC 10
Z9 10
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD MAY 1
PY 2014
VL 28
IS 5
BP 268
EP 273
DI 10.1089/apc.2013.0356
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AH0BF
UT WOS:000335783300007
PM 24742299
ER
PT J
AU Spindler, H
Salyuk, T
Vitek, C
Rutherford, G
AF Spindler, Hilary
Salyuk, Tetyana
Vitek, Charles
Rutherford, George
TI Underreporting of HIV Transmission Among Men Who Have Sex with Men in
the Ukraine
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Letter
C1 [Spindler, Hilary; Rutherford, George] Univ Calif San Francisco, Global Hlth Sci, San Francisco, CA 94618 USA.
[Salyuk, Tetyana] Int HIV AIDS Alliance Ukraine, Kiev, Ukraine.
[Vitek, Charles] Ctr Dis Control & Prevent, Div Global HIV AIDS, Dulles, VA USA.
RP Spindler, H (reprint author), Univ Calif San Francisco, Global Hlth Sci, 50 Beale St,Suite 1200, San Francisco, CA 94618 USA.
EM hspindler@psg.ucsf.edu
FU NIMH NIH HHS [P30 MH062246]
NR 7
TC 1
Z9 1
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY 1
PY 2014
VL 30
IS 5
BP 407
EP 408
DI 10.1089/aid.2013.0237
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AG8IL
UT WOS:000335661900002
PM 24295084
ER
PT J
AU Rasmussen, SA
AF Rasmussen, S. A.
TI Teratology and Public Health: Working Together to Make Recommendations
for Pregnant Women in the Face of Uncertainty
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Meeting Abstract
C1 [Rasmussen, S. A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD MAY
PY 2014
VL 100
IS 5
SI SI
BP 362
EP 362
PG 1
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AH7AG
UT WOS:000336283800009
ER
PT J
AU Hoyt, AT
Canfield, MA
Shaw, GM
Waller, DK
Polen, KD
Ramadhani, T
Anderka, M
Scheuerle, AE
AF Hoyt, A. T.
Canfield, M. A.
Shaw, G. M.
Waller, D. K.
Polen, K. D.
Ramadhani, T.
Anderka, M.
Scheuerle, A. E.
TI The Relationship of Sociodemographic and Hispanic Acculturation Factors
with Isolated Anotia/Microtia
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Meeting Abstract
C1 [Hoyt, A. T.; Canfield, M. A.] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA.
[Shaw, G. M.] Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA.
[Waller, D. K.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX 77030 USA.
[Polen, K. D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
[Ramadhani, T.] Texas Educ Agcy, Div Res & Anal, Austin, TX USA.
[Anderka, M.] Massachusetts Dept Publ Hlth, Boston, MA USA.
[Scheuerle, A. E.] Tesserae Genet, Dallas, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD MAY
PY 2014
VL 100
IS 5
SI SI
BP 399
EP 399
PG 1
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AH7AG
UT WOS:000336283800075
ER
PT J
AU Carmichael, SL
Rasmussen, SA
Cunningham, ML
Ma, C
Browne, ML
Lammer, EJ
Shaw, GM
AF Carmichael, S. L.
Rasmussen, S. A.
Cunningham, M. L.
Ma, C.
Browne, M. L.
Lammer, E. J.
Shaw, G. M.
TI Craniosynostosis and Exposures Related to Thyroid Function
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Meeting Abstract
C1 [Carmichael, S. L.; Ma, C.; Shaw, G. M.] Stanford Univ, Stanford, CA 94305 USA.
[Rasmussen, S. A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Lammer, E. J.] Childrens Hosp Oakland Res Inst, Oakland, CA USA.
[Cunningham, M. L.] Univ Washington, Seattle, WA 98195 USA.
[Browne, M. L.] New York State Dept Hlth, Albany, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD MAY
PY 2014
VL 100
IS 5
SI SI
BP 409
EP 409
PG 1
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AH7AG
UT WOS:000336283800095
ER
PT J
AU Dawson, AL
Riehle-Colarusso, T
Reefhuis, J
Arena, JF
AF Dawson, A. L.
Riehle-Colarusso, T.
Reefhuis, J.
Arena, J. F.
TI Maternal Exposure to Methotrexate and Birth Defects: A Population-Based
Study
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Meeting Abstract
C1 [Dawson, A. L.; Riehle-Colarusso, T.; Reefhuis, J.; Arena, J. F.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD MAY
PY 2014
VL 100
IS 5
SI SI
BP 423
EP 423
PG 1
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AH7AG
UT WOS:000336283800121
ER
PT J
AU Willis, ED
Marko, A
Marin, M
Rasmussen, SA
Bialek, SR
Redfield, A
Dana, A
AF Willis, E. D.
Marko, A.
Marin, M.
Rasmussen, S. A.
Bialek, S. R.
Redfield, A.
Dana, A.
TI Pregnancy Registry for Varicella-Zoster Virus-Containing Vaccines:
17-Year Summary of Pregnancy Outcomes
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Meeting Abstract
C1 [Willis, E. D.; Marko, A.; Redfield, A.; Dana, A.] Merck & Co Inc, N Wales, PA USA.
[Marin, M.; Rasmussen, S. A.; Bialek, S. R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD MAY
PY 2014
VL 100
IS 5
SI SI
BP 437
EP 437
PG 1
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA AH7AG
UT WOS:000336283800149
ER
PT J
AU Cox, N
AF Cox, Nancy
TI Influenza seasonality: timing and formulation of vaccines
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Editorial Material
C1 Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA.
RP Cox, N (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd, Atlanta, GA 30333 USA.
EM njc1@cdc.gov
NR 8
TC 8
Z9 8
U1 0
U2 0
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
EI 1564-0604
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD MAY
PY 2014
VL 92
IS 5
BP 311
EP 311
DI 10.2471/BLT.14.139428
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH9RB
UT WOS:000336478400002
PM 24839317
ER
PT J
AU Saha, S
Chadha, M
Al Mamun, A
Rahman, M
Sturm-Ramirez, K
Chittaganpitch, M
Pattamadilok, S
Olsen, SJ
Sampurno, OD
Setiawaty, V
Pangesti, KNA
Samaan, G
Archkhawongs, S
Vongphrachanh, P
Phonekeo, D
Corwin, A
Touch, S
Buchy, P
Chea, N
Kitsutani, P
Mai, LQ
Thiem, VD
Lin, R
Low, C
Kheong, CC
Ismail, N
Yusof, MA
Tandoc, A
Roque, V
Mishra, A
Moen, AC
Widdowson, MA
Partridge, J
Lal, RB
AF Saha, Siddhartha
Chadha, Mandeep
Al Mamun, Abdullah
Rahman, Mahmudur
Sturm-Ramirez, Katharine
Chittaganpitch, Malinee
Pattamadilok, Sirima
Olsen, Sonja J.
Sampurno, Ondri Dwi
Setiawaty, Vivi
Pangesti, Krisna Nur Andriana
Samaan, Gina
Archkhawongs, Sibounhom
Vongphrachanh, Phengta
Phonekeo, Darouny
Corwin, Andrew
Touch, Sok
Buchy, Philippe
Chea, Nora
Kitsutani, Paul
Le Quynh Mai
Vu Dinh Thiem
Lin, Raymond
Low, Constance
Kheong, Chong Chee
Ismail, Norizah
Yusof, Mohd Apandi
Tandoc, Amado, III
Roque, Vito., Jr.
Mishra, Akhilesh
Moen, Ann C.
Widdowson, Marc-Alain
Partridge, Jeffrey
Lal, Renu B.
TI Influenza seasonality and vaccination timing in tropical and subtropical
areas of southern and south-eastern Asia
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID PANDEMIC INFLUENZA; PRODUCTION CAPACITY; VIRUSES; SURVEILLANCE;
EPIDEMIOLOGY; TRANSMISSION; MORTALITY; INDONESIA; PATTERNS; VACCINES
AB Objective To characterize influenza seasonality and identify the best time of the year for vaccination against influenza in tropical and subtropical countries of southern and south-eastern Asia that lie north of the equator.
Methods Weekly influenza surveillance data for 2006 to 2011 Were obtained from Bangladesh, Cambodia, India, Indonesia, the Lao People's Democratic Republic, Malaysia, the Philippines, Singapore, Thailand and Viet Nam. Weekly rates of influenza activity were based on the percentage of all nasopharyngeal samples collected during the year that tested positive for influenza virus or viral nucleic acid on any given week. Monthly positivity rates were then calculated to define annual peaks of influenza activity in each country and across countries.
Findings Influenza activity peaked between June/July and October in seven countries, three of which showed a second peak in December to February. Countries closer to the equator had year-round circulation without discrete peaks. Viral types and subtypes varied from year to year but not across countries in a given year. The cumulative proportion of specimens that tested positive from June to November was >60% in Bangladesh, Cambodia, India, the Lao People's Democratic Republic, the Philippines, Thailand and Viet Nam. Thus, these tropical and subtropical countries exhibited earlier influenza activity peaks than temperate climate countries north of the equator.
Conclusion Most southern and south-eastern Asian countries lying north of the equator should consider vaccinating against influenza from April to June; countries near the equator without a distinct peak in influenza activity can base vaccination timing on local factors.
C1 [Saha, Siddhartha] Ctr Dis Control & Prevent, Influenza Programme, US Embassy, New Delhi, India.
[Chadha, Mandeep; Mishra, Akhilesh] Natl Inst Virol, Pune, Maharashtra, India.
[Al Mamun, Abdullah; Sturm-Ramirez, Katharine; Lal, Renu B.] Int Ctr Diarrhoea Dis Res Bangladesh, Dhaka, Bangladesh.
[Rahman, Mahmudur] Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh.
[Chittaganpitch, Malinee; Pattamadilok, Sirima] Minist Publ Hlth, Natl Inst Hlth, Nonthaburi, Thailand.
[Olsen, Sonja J.] Ctr Dis Control & Prevent, Influenza Programme, Nonthaburi, Thailand.
[Sampurno, Ondri Dwi; Setiawaty, Vivi; Pangesti, Krisna Nur Andriana] Minist Hlth, Jakarta, Indonesia.
[Samaan, Gina] Ctr Dis Control & Prevent, Jakarta, Indonesia.
[Archkhawongs, Sibounhom; Vongphrachanh, Phengta; Phonekeo, Darouny] Minist Hlth, Viangchan, Laos.
[Corwin, Andrew] Ctr Dis Control & Prevent, Influenza Programme, Viangchan, Laos.
[Touch, Sok] Minist Hlth, Phnom Penh, Cambodia.
[Buchy, Philippe] Inst Pasteur, Phnom Penh, Cambodia.
[Chea, Nora] WHO, Phnom Penh, Cambodia.
[Kitsutani, Paul] Ctr Dis Control & Prevent, Influenza Programme, Phnom Penh, Cambodia.
[Le Quynh Mai; Vu Dinh Thiem] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam.
[Lin, Raymond; Low, Constance] Minist Hlth, Singapore, Singapore.
[Kheong, Chong Chee] Minist Hlth, Kuala Lumpur, Malaysia.
[Ismail, Norizah] Natl Publ Hlth Lab, Kuala Lumpur, Malaysia.
[Yusof, Mohd Apandi] Inst Med Res, Kuala Lumpur 50588, Malaysia.
[Tandoc, Amado, III] Res Inst Trop Med, Alabang, Philippines.
[Roque, Vito., Jr.] Dept Hlth, Manila, Philippines.
[Moen, Ann C.; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Partridge, Jeffrey] Ctr Dis Control & Prevent, Influenza Programme, Hanoi, Vietnam.
RP Lal, RB (reprint author), Int Ctr Diarrhoea Dis Res Bangladesh, Dhaka, Bangladesh.
EM rbl3@cdc.gov
FU World Health Organization [001]
NR 43
TC 39
Z9 39
U1 1
U2 3
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
EI 1564-0604
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD MAY
PY 2014
VL 92
IS 5
BP 318
EP 330
DI 10.2471/BLT.13.124412
PG 13
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH9RB
UT WOS:000336478400011
PM 24839321
ER
PT J
AU Bhattacharya, A
AF Bhattacharya, Anasua
TI Costs of occupational musculoskeletal disorders (MSDs) in the United
States
SO INTERNATIONAL JOURNAL OF INDUSTRIAL ERGONOMICS
LA English
DT Article
DE Musculoskeletal disorders; Bureau of Labor Statistics; Medical costs;
Indemnity costs
ID CUMULATIVE TRAUMA DISORDERS; UPPER EXTREMITY; WORKERS; DISABILITY
AB Background: For the years 1992-2010 musculoskeletal disorders (MSDs) accounted for 29-35% of all occupational injuries and illnesses involving days away from work in the United States (US) (AFL-CIO, 2012). According to the American Federation of Labor and Congress of Industrial Organizations (AFL-CIO) 2012 report 'Death on the Job', for the years 1992 through 2010 the percent of cases involving MSDs in private industry were highest in 2000 (35%) and lowest in 2007 (29%). In 2010, the median number of days away from work for MSDs was 11 compared to 8 for all occupational injury cases involving days away from work; the median number of days away from work for Carpal Tunnel Syndrome (CTS) was 25, more than three times as high as for all other BLS injuries involving days away from work (BLS, 2011). This study estimated the costs of work related MSDs, and given that the number of days lost due to CTS is very high, it also estimated the costs of CTS separately in the United States (US) for the years 2003 through 2007.
Methods: The costs of work related MSDs and CTS in the US were estimated using the cost-of-illness, human capital method (Leigh et al., 2000), using some of the costs from the literature. This method decomposes costs into direct and indirect categories. Estimates of total cost of MSDs and CTS were obtained from the product of average costs of MSDs and CTS and the number of MSDs and CTS. The number of MSDs and CTS were obtained from BLS data.
Results: The number of reported work-related MSDs declined from 435,180 in 2003 to 335,390 in 2007 and the reported number of CTS also declined from 22,110 in 2003 to 11,920 in 2007. The direct costs of MSDs and CTS were respectively $1.5 billion and $0.1 billion for the year 2007. The indirect costs were $1.1 billion and $0.1 billion for MSDs and CTS respectively for the year 2007.
Discussion: This study found that the total costs of work-related MSDs and CTS declined during the period 2003 through 2007 but the average costs per case went up signifying that medical costs and other associated costs increased during this period.
Relevance to industry: The costs of MSDs are important to the industries too as a significant part of these costs are borne by the employers. Industries with higher prevalence of MSDs are affected more in terms of lost productivities due to the employees' days away from work because of MSDs. In cases of MSDs causing permanent disabilities, new hiring and training costs are also a part of the losses experienced by the employers. Published by Elsevier B.V.
C1 NIOSH, Ctr Dis Control & Prevent, Educ & Informat Div, Cincinnati, OH 45226 USA.
RP Bhattacharya, A (reprint author), NIOSH, Ctr Dis Control & Prevent, Educ & Informat Div, MS C-15,4676 Columbia Pkwy, Cincinnati, OH 45226 USA.
EM fwa4@cdc.gov
NR 20
TC 10
Z9 10
U1 3
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-8141
EI 1872-8219
J9 INT J IND ERGONOM
JI Int. J. Ind. Ergon.
PD MAY
PY 2014
VL 44
IS 3
BP 448
EP 454
DI 10.1016/j.ergon.2014.01.008
PG 7
WC Engineering, Industrial; Ergonomics
SC Engineering
GA AH5QV
UT WOS:000336186900014
ER
PT J
AU Rodrigues, EG
Smith, K
Maule, AL
Sjodin, A
Li, Z
Romanoff, L
Kelsey, K
Proctor, S
McClean, MD
AF Rodrigues, Ema G.
Smith, Kristen
Maule, Alexis L.
Sjodin, Andreas
Li, Zheng
Romanoff, Lovisa
Kelsey, Karl
Proctor, Susan
McClean, Michael D.
TI Urinary Polycyclic Aromatic Hydrocarbon (OH-PAH) Metabolite
Concentrations and the Effect of GST Polymorphisms Among US Air Force
Personnel Exposed to Jet Fuel
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID GENETIC POLYMORPHISMS; INHALATION EXPOSURE; NAPHTHALENE; BIOMARKERS;
1-HYDROXYPYRENE; 2-NAPHTHOL; NAPHTHOLS; CYP1A1; CYP2E1; JP-8
AB Objective: To evaluate the association between inhalation exposure to jet propulsion fuel 8 (JP-8) and urinary metabolites among US Air Force (USAF) personnel, and investigate the role of glutathione S-transferase polymorphisms.
Methods: Personal air samples were collected from 37 full-time USAF personnel during 4 consecutive workdays and analyzed for JP-8 constituents and total hydrocarbons. Pre- and postshift urine samples were collected each day and analyzed for polycyclic aromatic hydrocarbon urinary metabolites.
Results: Work shift exposure to total hydrocarbons was significantly associated with postshift urinary 1-naphthol ( = 0.17; P = <0.0001), 2-naphthol ( = 0.09; P = 0.005), and 2-hydroxyfluorene concentrations ( = 0.08; P = 0.006), and a significant gene-environment interaction was observed with glutathione S-transferase mu-1.
Conclusions: USAF personnel experience inhalation exposure to JP-8, which is associated with absorption of JP-8 constituents while performing typical job-related tasks, and in our data the glutathione S-transferase mu-1 polymorphism was associated with differential metabolism of naphthalene.
C1 [Rodrigues, Ema G.; Smith, Kristen] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Maule, Alexis L.; Proctor, Susan; McClean, Michael D.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02215 USA.
[Sjodin, Andreas; Li, Zheng; Romanoff, Lovisa] Ctr Dis Control & Prevent, Organ Analyt Toxicol Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA.
[Kelsey, Karl] Brown Univ, Sch Med, Dept Epidemiol, Providence, RI 02912 USA.
[Proctor, Susan] US Army, Mil Performance Div, Environm Med Res Inst, Natick, MA 01760 USA.
[Proctor, Susan] VA Boston Healthcare Syst, Boston, MA USA.
RP Rodrigues, EG (reprint author), 665 Huntington Ave,Bldg 1 Room 1404F, Boston, MA 02115 USA.
EM emarod@hsph.harvard.edu
RI Sjodin, Andreas/F-2464-2010; McClean, Michael/J-2934-2015
FU US Army Medical Research and Materiel Command Award [W81XWH-06-1-0105]
FX This research project was funded by the US Army Medical Research and
Materiel Command Award (W81XWH-06-1-0105; PI: SP Proctor) to the Henry
M. Jackson Foundation for the Advancement of Military Medicine, Inc.
NR 24
TC 4
Z9 4
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-2752
EI 1536-5948
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD MAY
PY 2014
VL 56
IS 5
BP 465
EP 471
DI 10.1097/JOM.0000000000000142
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH1FZ
UT WOS:000335866500003
PM 24806557
ER
PT J
AU Gu, JK
Charles, LE
Bang, KM
Ma, CC
Andrew, ME
Violanti, JM
Burchfiel, CM
AF Gu, Ja K.
Charles, Luenda E.
Bang, Ki Moon
Ma, Claudia C.
Andrew, Michael E.
Violanti, John M.
Burchfiel, Cecil M.
TI Prevalence of Obesity by Occupation Among US Workers The National Health
Interview Survey 2004-2011
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID BODY-MASS INDEX; SELF-REPORTED WEIGHT; COMMERCIAL DRIVERS; ADULTS;
HEALTH; RISK; COMPENSATION; HEIGHT; INJURY; IMPACT
AB Objective: To estimate the prevalence of obesity and the change of prevalence of obesity between 2004-2007 and 2008-20011 by occupation among US workers in the National Health Interview Survey.
Methods: Self-reported weight and height were collected and used to assess obesity (body mass index 30 kg/m(2)). Gender-, race/ethnicity-, and occupation-specific prevalence of obesity were calculated.
Results: Prevalence of obesity steadily increased from 2004 through 2008 across gender and race/ethnicity but leveled off from 2008 through 2011. Non-Hispanic black female workers in health care support (49.2%) and transportation/material moving (46.6%) had the highest prevalence of obesity. Prevalence of obesity in relatively low-obesity (white-collar) occupations significantly increased between 2004-2007 and 2008-2011, whereas it did not change significantly in high-obesity (blue-collar) occupations.
Conclusions: Workers in all occupational categories are appropriate targets for health promotion and intervention programs to reduce obesity.
C1 [Gu, Ja K.; Charles, Luenda E.; Ma, Claudia C.; Andrew, Michael E.; Burchfiel, Cecil M.] Ctr Dis Control & Prevent, Biostat & Epidemiol Branch, Hlth Effects Lab Div, NIOSH, Morgantown, WV USA.
[Bang, Ki Moon] Ctr Dis Control & Prevent, Surveillance Branch, Div Resp Dis Studies, NIOSH, Morgantown, WV USA.
[Violanti, John M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, Buffalo, NY 14260 USA.
RP Gu, JK (reprint author), NIOSH, HELD, BEB, Mailstop L-4050,1095 Willowdale Rd, Morgantown, WV 26505 USA.
EM jgu@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 36
TC 12
Z9 12
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-2752
EI 1536-5948
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD MAY
PY 2014
VL 56
IS 5
BP 516
EP 528
DI 10.1097/JOM.0000000000000133
PG 13
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH1FZ
UT WOS:000335866500011
PM 24682108
ER
PT J
AU Nordin, JD
Kharbanda, EO
Benitez, GV
Lipkind, H
Vellozzi, C
DeStefano, F
AF Nordin, James D.
Kharbanda, Elyse Olshen
Benitez, Gabriela Vazquez
Lipkind, Heather
Vellozzi, Claudia
DeStefano, Frank
CA Vaccine Safety Datalink
TI Maternal Influenza Vaccine and Risks for Preterm or Small for
Gestational Age Birth
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID CARE UTILIZATION INDEX; SAFETY DATALINK; PREGNANT-WOMEN; PERINATAL
OUTCOMES; NEONATAL OUTCOMES; H1N1 INFLUENZA; UNITED-STATES;
IMMUNIZATION; ADEQUACY; EPISODES
AB Objective To study the impact of influenza vaccine administered to pregnant women during all trimesters on the rates of preterm and small for gestational age (SGA) births, evaluating both increased and decreased risk.
Study design This retrospective observational matched cohort study involved 7 Vaccine Safety Datalink sites across the US for the 2004-05 through 2008-09 influenza seasons. Cohort eligibility and outcomes were determined from administrative, claims, medical records, and birth data. In propensity score-and vaccine exposure time-matched analyses, ORs for preterm and SGA births were calculated.
Results Among 57 554 matched vaccinated and unvaccinated pregnant women, including 16 240 women in the first trimester, maternal vaccination was not associated with increased or decreased risk for preterm birth (OR for delivery at <37 weeks gestation, 0.97 [95% CI, 0.93-1.02]; for delivery at <= 32 weeks gestation, 0.98 [95% CI, 0.86-1.12]; and for delivery at <= 34 weeks gestation, 0.96 [95% CI, 0.88-1.04]) or SGA birth (OR for <5th percentile weight for gestational age, 1.02 [95% CI, 0.96-1.09], and for <10th percentile weight for gestational age, 1.00 [95% CI, 0.96-1.04]). Similarly, first trimester vaccination was not associated with increased or decreased risk for preterm or SGA birth.
Conclusion Receipt of trivalent inactivated influenza vaccine during pregnancy was not associated with increased or decreased risk of preterm or SGA birth. These findings support the safety of vaccinating pregnant women against influenza during the first, second, and third trimesters, and suggest that a nonspecific protective effect of the influenza vaccine for these outcomes does not exist.
C1 [Nordin, James D.; Kharbanda, Elyse Olshen; Benitez, Gabriela Vazquez] HealthPartners Inst Educ & Res, Minneapolis, MN 55440 USA.
[Lipkind, Heather] Yale Univ, Dept Obstet & Gynecol, New Haven, CT USA.
[Vellozzi, Claudia; DeStefano, Frank] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Nordin, JD (reprint author), HealthPartners Inst Educ & Res, Minneapolis, MN 55440 USA.
FU America's Health Insurance Plans (Centers for Disease Control and
Prevention) [200-2002-00732]
FX Supported by a subcontract with America's Health Insurance Plans (under
200-2002-00732 from the Centers for Disease Control and Prevention). The
findings and conclusions in this study are those of the authors and do
not necessarily represent the official position of the Centers for
Disease Control and Prevention. The authors declare no conflicts of
interest.
NR 40
TC 28
Z9 28
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD MAY
PY 2014
VL 164
IS 5
BP 1051
EP +
DI 10.1016/j.jpeds.2014.01.037
PG 9
WC Pediatrics
SC Pediatrics
GA AG6GB
UT WOS:000335516000023
PM 24582484
ER
PT J
AU Neri, EM
Ballman, MR
Lu, H
Greenlund, KJ
Grunbaum, JA
AF Neri, Elizabeth M.
Ballman, Marie R.
Lu, Hua
Greenlund, Kurt J.
Grunbaum, Jo Anne
TI Academic-Health Department Collaborative Relationships Are Reciprocal
and Strengthen Public Health Practice: Results from a Study of Academic
Research Centers
SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE
LA English
DT Article
DE public health; collaboration; core functions and essential public health
services; academic health department
ID UNIVERSITY PARTNERSHIP; LOCAL HEALTH; DEPARTMENTS; COMMUNITY; MODEL;
PREPAREDNESS; LINKAGES
AB Background: Collaborations between academic institutions and state and local health departments have been shown to enhance the public health core functions of Assurance by improving the public health workforce's knowledge and skills. Few studies have analyzed how academic-health department collaborations enhance Assessment and Policy Development core functions. This qualitative study explores types of collaborations between health departments and Prevention Research Centers (PRCs) and how they align with the core functions. Prevention Research Centers are academic institutions funded by the Centers for Disease Control and Prevention to conduct public health research and translate research results for policies and practices. Methods: We reviewed each PRC's annual report from fiscal year 2011 and abstracted descriptions of PRC-health department collaborations. We identified 14 themes of PRC-health department collaborations and conducted a qualitative analysis to describe the dimensions and distribution of themes. Results: Of the 37 PRCs, 36 reported 215 collaborations with 19 city, 97 county, 31 state, and 46 tribal health departments. Themes of research, survey, and surveillance aligned with the Assessment core function and evaluation, strategic planning, technical assistance, and program implementation supported the Policy Development and Assurance core functions. Overall, health departments provided on-the-ground expertise to inform PRC research, ensuring its applicability to public health practice. Reciprocally, PRCs improved data quality, increased the scientific rigor of health department processes and programs, and filled knowledge gaps within health departments. Both PRCs and health departments enhanced the relevance of public health programs and practices by grounding implementation and evaluation in community needs and views. Conclusion: Findings from this study demonstrate that PRC-health department collaborations often enhanced multiple core functions that could lead to implementation of evidence-based interventions and continuous quality improvement of public health administration at the local, state, and tribal levels. This study highlights the value and importance of reciprocal academic-health department partnerships.
C1 [Neri, Elizabeth M.; Ballman, Marie R.; Greenlund, Kurt J.; Grunbaum, Jo Anne] Ctr Dis Control & Prevent, Prevent Res Ctr Program, Appl Res & Translat Branch, Div Populat Hlth,Natl Ctr Chron Dis Prevent & Hlt, Atlanta, GA 30341 USA.
[Lu, Hua] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
RP Neri, EM (reprint author), Ctr Dis Control & Prevent, Prevent Res Ctr Program, Appl Res & Translat Branch, Div Populat Hlth,Natl Ctr Chron Dis Prevent & Hlt, Mailstop F-78 4770 Buford Hwy, Atlanta, GA 30341 USA.
EM eneri@cdc.gov
NR 26
TC 5
Z9 5
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1078-4659
EI 1550-5022
J9 J PUBLIC HEALTH MAN
JI J. Public Health Manag. Pract.
PD MAY-JUN
PY 2014
VL 20
IS 3
BP 342
EP 348
DI 10.1097/PHH.0b013e3182a152c6
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH1FR
UT WOS:000335865700016
PM 24667197
ER
PT J
AU Lankau, EW
Turner, PV
Mullan, RJ
Galland, GG
AF Lankau, Emily W.
Turner, Patricia V.
Mullan, Robert J.
Galland, G. Gale
TI Use of Nonhuman Primates in Research in North America
SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE
LA English
DT Article
DE APV; Association of Primate Veterinarians; CDC; Centers for Disease
Control and Prevention; NHP; nonhuman primate
ID BIOMEDICAL-RESEARCH; AIDS RESEARCH; MODELS; ANIMALS; DEBATE
AB In North America, the biomedical research community faces social and economic challenges to nonhuman primate (NHP) importation that could reduce the number of NHP available for research needs. The effect of such limitations on specific biomedical research topics is unknown. The Association of Primate Veterinarians (APV), with assistance from the Centers for Disease Control and Prevention, developed a survey regarding biomedical research involving NHP in the United States and Canada. The survey sought to determine the number and species of NHP maintained at APV members' facilities, current uses of NHP to identify the types of biomedical research that rely on imported animals, and members' perceived trends in NHP research. Of the 149 members contacted, 33 (22%) replied, representing diverse facility sizes and types. Cynomolgus and rhesus macaques were the most common species housed at responding institutions and comprised the majority of newly acquired and imported NHP. The most common uses for NHP included pharmaceutical research and development and neuroscience, neurology, or neuromuscular disease research. Preclinical safety testing and cancer research projects usually involved imported NHP, whereas research on aging or degenerative disease, reproduction or reproductive disease, and organ or tissue transplantation typically used domestic-bred NHP. The current results improve our understanding of the research uses for imported NHP in North America and may facilitate estimating the potential effect of any future changes in NHP accessibility for research purposes. Ensuring that sufficient NHP are available for critical biomedical research remains a pressing concern for the biomedical research community in North America.
C1 [Lankau, Emily W.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Lankau, Emily W.; Mullan, Robert J.; Galland, G. Gale] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA.
[Lankau, Emily W.] LandCow Consulting, Athens, GA USA.
[Turner, Patricia V.] Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada.
RP Lankau, EW (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
EM landcow.ecohealth@gmail.com
RI Lankau, Emily/C-8057-2011
OI Lankau, Emily/0000-0002-7094-7780
FU CDC
FX We thank APV members for their participation in this survey and the APV
Board of Directors and the Division of Global Migration and Quarantine
at CDC for supporting this work. Thanks also to John Farrar for
assistance with survey delivery and Nicole Cohen and Adam Langer
(Division of Global Migration and Quarantine, CDC) for assistance with
survey development and data analysis.
NR 24
TC 5
Z9 5
U1 2
U2 11
PU AMER ASSOC LABORATORY ANIMAL SCIENCE
PI MEMPHIS
PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA
SN 1559-6109
J9 J AM ASSOC LAB ANIM
JI J. Amer. Assoc. Lab. Anim. Sci.
PD MAY
PY 2014
VL 53
IS 3
BP 278
EP 282
PG 5
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA AH5UJ
UT WOS:000336196300008
PM 24827570
ER
PT J
AU Henderson, ZT
Suchdev, DB
Abe, K
Johnston, EO
Callaghan, WM
AF Henderson, Zsakeba T.
Suchdev, Danielle B.
Abe, Karon
Johnston, Emily Osteen
Callaghan, William M.
TI Perinatal Quality Collaboratives: Improving Care for Mothers and Infants
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID UNITED-STATES; RATES
AB Perinatal morbidity and mortality are key indicators of a nation's health status. These measures of our nation's health are influenced by decisions made in health care facilities and by health care providers. As our health systems and health care for women and infants can be improved, there is an expectation that these measures of health will also improve. State-based perinatal quality collaboratives (PQCs) are networks of perinatal care providers including hospitals, clinicians, and public health professionals working to improve pregnancy outcomes for women and newborns through continuous quality improvement. Members of the collaborative are healthcare facilities, primarily hospitals, which identify processes of care that require improvement and then use the best available methods to effect change and improve outcomes as quickly as possible. The Division of Reproductive Health at the Centers for Disease Control and Prevention is collaborating with state-based PQCs to enhance their ability to improve perinatal care by expanding the range of neonatal and maternal health issues addressed and including higher proportions of participating hospitals in their state PQC. The work of PQCs is cross-cutting and demonstrates how partnerships can act to translate evidence-based science to clinical care.
C1 [Henderson, Zsakeba T.; Suchdev, Danielle B.; Abe, Karon; Johnston, Emily Osteen; Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA.
RP Henderson, ZT (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway Northeast,Mailstop F-74, Atlanta, GA 30333 USA.
EM zhenderson@cdc.gov
FU U.S. Federal Centers for Disease Control and Prevention
FX This work was funded by the U.S. Federal Centers for Disease Control and
Prevention. We thank the leadership of the California Perinatal Quality
Care Collaborative, California Maternal Quality Care Collaborative, the
New York State Perinatal Quality Collaborative, and the Ohio Perinatal
Quality Collaborative for their input and lessons learned during this
project.
NR 17
TC 6
Z9 6
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD MAY 1
PY 2014
VL 23
IS 5
BP 368
EP 372
DI 10.1089/jwh.2014.4744
PG 5
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA AG9KY
UT WOS:000335739300002
PM 24655150
ER
PT J
AU Hammer, GP
Auvinen, A
De Stavola, BL
Grajewski, B
Gundestrup, M
Haldorsen, T
Hammar, N
Lagorio, S
Linnersjo, A
Pinkerton, L
Pukkala, E
Rafnsson, V
dos-Santos-Silva, I
Storm, HH
Strand, TE
Tzonou, A
Zeeb, H
Blettner, M
AF Hammer, Gael P.
Auvinen, Anssi
De Stavola, Bianca L.
Grajewski, Barbara
Gundestrup, Maryanne
Haldorsen, Tor
Hammar, Niklas
Lagorio, Susanna
Linnersjo, Anette
Pinkerton, Lynne
Pukkala, Eero
Rafnsson, Vilhjalmur
dos-Santos-Silva, Isabel
Storm, Hans H.
Strand, Trond-Eirik
Tzonou, Anastasia
Zeeb, Hajo
Blettner, Maria
TI Mortality from cancer and other causes in commercial airline crews: a
joint analysis of cohorts from 10 countries
SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID COSMIC-RADIATION EXPOSURE; FEMALE FLIGHT ATTENDANTS; CABIN ATTENDANTS;
COCKPIT CREW; PILOTS; RISK; AIRCRAFT; HEALTH; DISRUPTION; EXPERIENCE
AB Background Commercial airline crew is one of the occupational groups with the highest exposures to ionising radiation. Crew members are also exposed to other physical risk factors and subject to potential disruption of circadian rhythms.
Methods This study analyses mortality in a pooled cohort of 93771 crew members from 10 countries. The cohort was followed for a mean of 21.7years (2.0 million person-years), during which 5508 deaths occurred.
Results The overall mortality was strongly reduced in male cockpit (SMR 0.56) and female cabin crews (SMR 0.73). The mortality from radiation-related cancers was also reduced in male cockpit crew (SMR 0.73), but not in female or male cabin crews (SMR 1.01 and 1.00, respectively). The mortality from female breast cancer (SMR 1.06), leukaemia and brain cancer was similar to that of the general population. The mortality from malignant melanoma was elevated, and significantly so in male cockpit crew (SMR 1.57). The mortality from cardiovascular diseases was strongly reduced (SMR 0.46). On the other hand, the mortality from aircraft accidents was exceedingly high (SMR 33.9), as was that from AIDS in male cabin crew (SMR 14.0).
Conclusions This large study with highly complete follow-up shows a reduced overall mortality in male cockpit and female cabin crews, an increased mortality of aircraft accidents and an increased mortality in malignant skin melanoma in cockpit crew. Further analysis after longer follow-up is recommended.
C1 [Hammer, Gael P.; Blettner, Maria] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Med Biostat Epidemiol & Informat, D-55122 Mainz, Germany.
[Hammer, Gael P.] Lab Natl Sante, Registre Morphol Tumeurs, Luxembourg, Luxembourg.
[Auvinen, Anssi; Pukkala, Eero] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland.
[Pukkala, Eero] Finnish Canc Registry, Inst Stat & Epidemiol Canc Res, FIN-00170 Helsinki, Finland.
[Auvinen, Anssi] STUK Radiat & Nucl Safety Author, Helsinki, Finland.
[De Stavola, Bianca L.; dos-Santos-Silva, Isabel] Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Noncommunicable Dis Epidemiol, London WC1E 7HT, England.
[De Stavola, Bianca L.; dos-Santos-Silva, Isabel] Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Med Stat, London WC1E 7HT, England.
[Grajewski, Barbara; Pinkerton, Lynne] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
[Gundestrup, Maryanne] Univ Copenhagen Hosp, Clin Aviat Med, DK-2100 Copenhagen, Denmark.
[Haldorsen, Tor] Canc Registry Norway, Inst Populat Based Canc Res, Oslo, Norway.
[Hammar, Niklas] Karolinska Inst, Inst Environm Med, Unit Epidemiol, Stockholm, Sweden.
[Lagorio, Susanna] Natl Inst Hlth, Natl Ctr Epidemiol Surveillance & Hlth Promot, Rome, Italy.
[Linnersjo, Anette] Karolinska Inst, Inst Environm Med, Unit Cardiovasc Epidemiol, Stockholm, Sweden.
[Linnersjo, Anette] Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden.
[Rafnsson, Vilhjalmur] Univ Iceland, Reykjavik, Iceland.
[Storm, Hans H.] Danish Canc Soc, Copenhagen, Denmark.
[Strand, Trond-Eirik] Norwegian Armed Forces Med Serv, Inst Aviat Med, Oslo, Norway.
[Tzonou, Anastasia] Univ Athens, Athens, Greece.
[Zeeb, Hajo] Leibniz Inst Prevent Res & Epidemiol BIPS GmbH, Bremen, Germany.
RP Auvinen, A (reprint author), Lab Natl Sante EP, Registre Morphol Tumeurs, L-3555 Dudelange, Luxembourg.
EM gael.hammer@lns.etat.lu
OI Strand, Trond-Eirik/0000-0002-7561-3501; Storm,
Hans/0000-0001-7223-8198; Auvinen, Anssi/0000-0003-1125-4818; dos Santos
Silva, Isabel/0000-0002-6596-8798
FU German Federal Office for Radiation Protection [StSch 4558]
FX This work was supported by the German Federal Office for Radiation
Protection (grant number StSch 4558) for study coordination.
NR 66
TC 13
Z9 14
U1 3
U2 17
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1351-0711
EI 1470-7926
J9 OCCUP ENVIRON MED
JI Occup. Environ. Med.
PD MAY
PY 2014
VL 71
IS 5
BP 313
EP 322
DI 10.1136/oemed-2013-101395
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AF0IM
UT WOS:000334397500004
PM 24389960
ER
PT J
AU Marcewicz, L
Clayton, J
Maenner, M
Grant, A
Odom, E
Okoroh, E
Goodman, A
Christensen, D
Traylor, J
Miller, A
Warren, M
AF Marcewicz, Lauren
Clayton, Joshua
Maenner, Matthew
Grant, Althea
Odom, Erika
Okoroh, Ekwutosi
Goodman, Alyson
Christensen, Deborah
Traylor, Julie
Miller, Angela
Warren, Michael
TI LATE VITAMIN K DEFICIENCY BLEEDING IN INFANTS NOT RECEIVING PROPHYLAXIS
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Marcewicz, Lauren; Clayton, Joshua; Maenner, Matthew; Grant, Althea; Odom, Erika; Okoroh, Ekwutosi; Goodman, Alyson; Christensen, Deborah; Traylor, Julie; Miller, Angela; Warren, Michael] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD MAY
PY 2014
VL 61
SU 1
SI SI
BP S45
EP S45
PG 1
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA AG5WT
UT WOS:000335490100157
ER
PT J
AU Tai, E
Thompson, T
Thomas, C
Fairley, T
Richardson, L
AF Tai, Eric
Thompson, Trevor
Thomas, Cheryll
Fairley, Temeika
Richardson, Lisa
TI CANCER DEATHS AVERTED AMONG CHILDREN, OLDER ADOLESCENTS, AND YOUNG
ADULTS, 1975-2010
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Tai, Eric; Thompson, Trevor; Thomas, Cheryll; Fairley, Temeika; Richardson, Lisa] Ctr Dis Control & Prevent, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD MAY
PY 2014
VL 61
SU 1
SI SI
BP S88
EP S89
PG 2
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA AG5WT
UT WOS:000335490100309
ER
PT J
AU Duffy, J
Harris, J
Gade, L
Sehulster, L
Newhouse, E
O'Connell, H
Noble-Wang, J
Rao, C
Balajee, SA
Chiller, T
AF Duffy, Jonathan
Harris, Julie
Gade, Lalitha
Sehulster, Lynne
Newhouse, Emily
O'Connell, Heather
Noble-Wang, Judith
Rao, Carol
Balajee, S. Arunmozhi
Chiller, Tom
TI Mucormycosis Outbreak Associated With Hospital Linens
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE mycoses; mucormycosis; cross infection; bedding and linens
ID FUNGAL-INFECTIONS; MOLD INFECTIONS; CARE-UNITS; RHIZOPUS; EPIDEMIOLOGY;
ZYGOMYCOSIS; DISEASE; LAUNDRY; IMPACT; TISSUE
AB Background: Mucormycosis is an invasive fungal infection with a high fatality rate. We investigated an outbreak of mucormycosis in a pediatric hospital to determine routes of pathogen transmission from the environment and prevent additional infections.
Methods: A case was defined as a hospital-onset illness consistent with mucormycosis, confirmed by culture or histopathology. Case-patient medical records were reviewed for clinical course and exposure to items and locations within the hospital. Environmental samples were collected from air and surfaces. Fungal isolates collected from case-patients and the environmental samples were identified using DNA sequencing.
Results: Five case-patients had hospital-associated cutaneous mucormycosis over an 11-month period; all subsequently died. Three case-patients had conditions known to be associated with susceptibility to mucormycosis, while 2 had cardiac conditions with persistent acidosis. The cases occurred on several different wards throughout the hospital, and hospital linens were the only exposure identified as common to the case-patients. Rhizopus species were recovered from 26 (42%) of 62 environmental samples from clean linens and associated areas and from 1 (4%) of 25 samples from nonlinen-related items. Case-patients were infected with Rhizopus delemar, which was also isolated from cultures of clean linens and clean linen delivery bins from the off-site laundry facility.
Conclusions: Hospital linens were identified as a vehicle that carried R. delemar into contact with susceptible patients. Fungal species identification using DNA-based methods is useful for corroborating epidemiologic links in hospital outbreak investigations. Hospital linens should be laundered, packaged, shipped and stored in a manner that minimizes exposure to environmental contaminants.
C1 [Duffy, Jonathan] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
[Duffy, Jonathan; Sehulster, Lynne; O'Connell, Heather; Noble-Wang, Judith; Rao, Carol] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA.
[Harris, Julie; Gade, Lalitha; Balajee, S. Arunmozhi; Chiller, Tom] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA.
[Newhouse, Emily] Ctr Dis Control & Prevent, Epidemiol Elect Program, Atlanta, GA 30333 USA.
RP Duffy, J (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA.
EM jduffy@cdc.gov
NR 34
TC 13
Z9 14
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAY
PY 2014
VL 33
IS 5
BP 472
EP 476
DI 10.1097/INF.0000000000000261
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AG9PC
UT WOS:000335750600012
PM 24667485
ER
PT J
AU Breuner, CC
Miller, RJ
Braverman, PK
Adelman, WP
Breuner, CC
Levine, DA
Marcell, AV
Murray, PJ
O'Brien, RF
Gavin, LE
Pinzon, JL
Shain, B
Smith, KS
Baumberger, J
AF Breuner, Cora C.
Miller, Rachel J.
Braverman, Paula K.
Adelman, William P.
Breuner, Cora C.
Levine, David A.
Marcell, Arik V.
Murray, Pamela J.
O'Brien, Rebecca F.
Gavin, Loretta E.
Pinzon, Jorge L.
Shain, Benjamin
Smith, Karen S.
Baumberger, James
CA Comm Adolescence
TI Addendum-Adolescent Pregnancy: Current Trends and Issues
SO PEDIATRICS
LA English
DT Article
DE adolescent health; medicine; teen pregnancy
ID RISK BEHAVIOR SURVEILLANCE; UNITED-STATES; UNINTENDED PREGNANCY
C1 [Gavin, Loretta E.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Miller, Rachel J.] Amer Coll Obstetricians & Gynecologists, Washington, DC USA.
[Shain, Benjamin] Amer Acad Child & Adolescent Psychiat, Washington, DC USA.
NR 16
TC 3
Z9 3
U1 1
U2 7
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD MAY
PY 2014
VL 133
IS 5
BP 954
EP 957
DI 10.1542/peds.2014-0450
PG 4
WC Pediatrics
SC Pediatrics
GA AG2HK
UT WOS:000335236800028
ER
PT J
AU Stephens, SC
Fann, CK
Strona, FV
Wolf, W
Cohen, SE
Philip, SS
Bernstein, KT
AF Stephens, Sally C.
Fann, Charles K.
Strona, Frank V.
Wolf, Wendy
Cohen, Stephanie E.
Philip, Susan S.
Bernstein, Kyle T.
TI Identifying Syphilis Risk Networks Through Venue Attendance in San
Francisco
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID ELIMINATION; SPACE; HIV; MEN; SEX; GAY
AB Background Prioritizing interventions for patients with syphilis who are part of large or interconnected sexual networks may be high yield for partner services, and identifying venues named by patients with syphilis who report high numbers of partners may help identify such networks. In this analysis, we explore differences between interviewed patients with early syphilis regarding where they met sex partners.
Methods With a cross-sectional design, we examined the distribution of total reported sex partners from male index patients with early syphilis interviewed through the San Francisco Department of Public Health partner services program and the self-reported venues named as places they met sex partners. Based on the median number of total partners among male cases of syphilis who named each venue, we categorized venues into 3 levels of partner frequency: high (>15 partners reported), medium (6-15 partners reported), and low (<6 partners reported). Interviewed patients with early syphilis were then classified into these venue categories, and sociodemographic and risk behaviors from electronic medical records and interviews were compared using (2) tests.
Results In 2011, 433 male patients with early syphilis named 32 venues. One hundred forty-three (32.3%) patients were categorized as high, 226 (51.0%) as medium, and 74 (16.7%) as low partner frequency venue users. Patients with early syphilis who reported meeting partners at high partner frequency venues were generally older, more likely to be white, have a previous syphilis infection, use methamphetamines in the previous year, and be HIV infected (all P < 0.05) compared with those who reported meeting partners at medium-frequency and low-frequency venues.
Conclusions Venues where partners are met may be an appropriate proxy for network membership. Targeting additional resources, outreach, and services to clients who attend high-frequency venues may have a positive impact on syphilis prevention efforts.
C1 [Stephens, Sally C.; Fann, Charles K.; Strona, Frank V.; Wolf, Wendy; Cohen, Stephanie E.; Philip, Susan S.; Bernstein, Kyle T.] San Francisco Dept Publ Hlth, STD Prevent & Control Serv Sect, San Francisco, CA 94103 USA.
[Strona, Frank V.; Wolf, Wendy] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Bernstein, Kyle T.] Univ Calif Berkeley, Berkeley Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA.
RP Stephens, SC (reprint author), San Francisco Dept Publ Hlth, 1360 Mission St,Suite 401, San Francisco, CA 94103 USA.
EM Sally.Stephens@sfdph.org
FU Comprehensive STD Prevention Projects Centers for Disease Control and
Prevention [1H25PS001354-01]
FX This work was funded in part by the Comprehensive STD Prevention
Projects (1H25PS001354-01) Centers for Disease Control and Prevention.
NR 25
TC 1
Z9 1
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD MAY
PY 2014
VL 41
IS 5
BP 333
EP 337
DI 10.1097/OLQ.0000000000000116
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA AF6AR
UT WOS:000334797300012
PM 24722390
ER
PT J
AU Kuhn, JH
Bao, YM
Bavari, S
Becker, S
Bradfute, S
Brauburger, K
Brister, JR
Bukreyev, AA
Cai, YY
Chandran, K
Davey, RA
Dolnik, O
Dye, JM
Enterlein, S
Gonzalez, JP
Formenty, P
Freiberg, AN
Hensley, LE
Hoenen, T
Honko, AN
Ignatyev, GM
Jahrling, PB
Johnson, KM
Klenk, HD
Kobinger, G
Lackemeyer, MG
Leroy, EM
Lever, MS
Muhlberger, E
Netesov, SV
Olinger, GG
Palacios, G
Patterson, JL
Paweska, JT
Pitt, L
Radoshitzky, SR
Ryabchikova, EI
Saphire, EO
Shestopalov, AM
Smither, SJ
Sullivan, NJ
Swanepoel, R
Takada, A
Towner, JS
van der Groen, G
Volchkov, VE
Volchkova, VA
Wahl-Jensen, V
Warren, TK
Warfield, KL
Weidmann, M
Nichol, ST
AF Kuhn, Jens H.
Bao, Yiming
Bavari, Sina
Becker, Stephan
Bradfute, Steven
Brauburger, Kristina
Brister, J. Rodney
Bukreyev, Alexander A.
Cai, Yingyun
Chandran, Kartik
Davey, Robert A.
Dolnik, Olga
Dye, John M.
Enterlein, Sven
Gonzalez, Jean-Paul
Formenty, Pierre
Freiberg, Alexander N.
Hensley, Lisa E.
Hoenen, Thomas
Honko, Anna N.
Ignatyev, Georgy M.
Jahrling, Peter B.
Johnson, Karl M.
Klenk, Hans-Dieter
Kobinger, Gary
Lackemeyer, Matthew G.
Leroy, Eric M.
Lever, Mark S.
Muehlberger, Elke
Netesov, Sergey V.
Olinger, Gene G.
Palacios, Gustavo
Patterson, Jean L.
Paweska, Janusz T.
Pitt, Louise
Radoshitzky, Sheli R.
Ryabchikova, Elena I.
Saphire, Erica Ollmann
Shestopalov, Aleksandr M.
Smither, Sophie J.
Sullivan, Nancy J.
Swanepoel, Robert
Takada, Ayato
Towner, Jonathan S.
van der Groen, Guido
Volchkov, Viktor E.
Volchkova, Valentina A.
Wahl-Jensen, Victoria
Warren, Travis K.
Warfield, Kelly L.
Weidmann, Manfred
Nichol, Stuart T.
TI Virus nomenclature below the species level: a standardized nomenclature
for filovirus strains and variants rescued from cDNA
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID RECOMBINANT MARBURG VIRUS; EBOLA-VIRUS; FAMILY FILOVIRIDAE;
CELL-CULTURE; GUINEA-PIGS; IRF-3 ACTIVATION; IN-VITRO; REPLICATION;
TRANSCRIPTION; DOMAINS
AB Specific alterations (mutations, deletions, insertions) of virus genomes are crucial for the functional characterization of their regulatory elements and their expression products, as well as a prerequisite for the creation of attenuated viruses that could serve as vaccine candidates. Virus genome tailoring can be performed either by using traditionally cloned genomes as starting materials, followed by site-directed mutagenesis, or by de novo synthesis of modified virus genomes or parts thereof. A systematic nomenclature for such recombinant viruses is necessary to set them apart from wild-type and laboratory-adapted viruses, and to improve communication and collaborations among researchers who may want to use recombinant viruses or create novel viruses based on them. A large group of filovirus experts has recently proposed nomenclatures for natural and laboratory animal-adapted filoviruses that aim to simplify the retrieval of sequence data from electronic databases. Here, this work is extended to include nomenclature for filoviruses obtained in the laboratory via reverse genetics systems. The previously developed template for natural filovirus genetic variant naming, < virus name > (< strain >/)< isolation host-suffix >/< country of sampling >/< year of sampling >/< genetic variant designation >-< isolate designation >, is retained, but we propose to adapt the type of information added to each field for cDNA clone-derived filoviruses. For instance, the full-length designation of an Ebola virus Kikwit variant rescued from a plasmid developed at the US Centers for Disease Control and Prevention could be akin to "Ebola virus H.sapiens-rec/COD/1995/Kikwit-abc1" (with the suffix "rec" identifying the recombinant nature of the virus and "abc1" being a placeholder for any meaningful isolate designator). Such a full-length designation should be used in databases and the methods section of publications. Shortened designations (such as "EBOV H.sap/COD/95/Kik-abc1") and abbreviations (such as "EBOV/Kik-abc1") could be used in the remainder of the text, depending on how critical it is to convey information contained in the full-length name. "EBOV" would suffice if only one EBOV strain/variant/isolate is addressed.
C1 [Kuhn, Jens H.; Cai, Yingyun; Hensley, Lisa E.; Jahrling, Peter B.; Lackemeyer, Matthew G.; Wahl-Jensen, Victoria] NIAID, Integrated Res Facil Ft Detrick IRF Frederick, DCR, NIH, Frederick, MD 21702 USA.
[Bao, Yiming; Brister, J. Rodney] NIH, Informat Engn Branch, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA.
[Bavari, Sina; Dye, John M.; Honko, Anna N.; Olinger, Gene G.; Palacios, Gustavo; Pitt, Louise; Radoshitzky, Sheli R.; Warren, Travis K.] United States Army Med Res Inst Infect Dis, Frederick, MD USA.
[Becker, Stephan; Dolnik, Olga; Klenk, Hans-Dieter] Univ Marburg, Inst Virol, D-35032 Marburg, Germany.
[Bradfute, Steven] Univ New Mexico, Albuquerque, NM 87131 USA.
[Brauburger, Kristina; Muehlberger, Elke] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.
[Brauburger, Kristina; Muehlberger, Elke] Boston Univ, Sch Med, Natl Emerging Infect Dis Lab, Boston, MA 02118 USA.
[Bukreyev, Alexander A.; Freiberg, Alexander N.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
[Bukreyev, Alexander A.; Freiberg, Alexander N.] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA.
[Chandran, Kartik] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
[Davey, Robert A.; Patterson, Jean L.] Texas Biomed Res Inst, Dept Virol & Immunol, San Antonio, TX USA.
[Enterlein, Sven; Warfield, Kelly L.] Integrated BioTherapeut Inc, Gaithersburg, MD USA.
[Gonzalez, Jean-Paul] Inst Rech Dev, Dept Hlth, Marseille, France.
[Gonzalez, Jean-Paul] Metabiota Inc, San Francisco, CA USA.
[Formenty, Pierre] World Hlth Org, Geneva, Switzerland.
[Hoenen, Thomas] NIAID, Virol Lab, Div Intramural Res, NIH, Hamilton, MT USA.
[Ignatyev, Georgy M.] Minist Hlth Russian Federat, Fed State Unitary Co Microgen Sci Ind Co Immunobi, Moscow, Russia.
[Kobinger, Gary] Publ Hlth Agcy Canada, Natl Microbiol Lab, Special Pathogens Program, Winnipeg, MB, Canada.
[Leroy, Eric M.] Ctr Int Rech Med Franceville, Franceville, Gabon.
[Lever, Mark S.; Smither, Sophie J.] Dstl, Dept Biomed Sci, Salisbury, Wilts, England.
[Netesov, Sergey V.; Shestopalov, Aleksandr M.] Novosibirsk State Univ, Novosibirsk 630090, Novosibirsk Reg, Russia.
[Paweska, Janusz T.] Natl Inst Communicable Dis, Ctr Emerging & Zoonot Dis, Natl Hlth Lab Serv, Sandringham Johannesburg, Gauteng, South Africa.
[Ryabchikova, Elena I.] Russian Acad Sci, Siberian Branch, Inst Chem Biol & Fundamental Med, Novosibirsk, Novosibirsk Reg, Russia.
[Saphire, Erica Ollmann] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
[Saphire, Erica Ollmann] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
[Shestopalov, Aleksandr M.] State Res Ctr Virol & Biotechnol Vector, Koltsov, Novosibirsk Reg, Russia.
[Sullivan, Nancy J.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Swanepoel, Robert] Univ Pretoria, Zoonoses Res Unit, ZA-0002 Pretoria, South Africa.
[Takada, Ayato] Hokkaido Univ, Res Ctr Zoonosis Control, Div Global Epidemiol, Sapporo, Hokkaido, Japan.
[Towner, Jonathan S.; Nichol, Stuart T.] Ctr Dis Control & Prevent CDC, Natl Ctr Emerging & Zoonot Infect Dis NCEZID, Div High Consequence Pathogens Pathol DHCPP, Viral Special Pathogens Branch VSPB, Atlanta, GA 30333 USA.
[van der Groen, Guido] Prins Leopold Inst Trop Geneeskunde, Antwerp, Belgium.
[Volchkov, Viktor E.; Volchkova, Valentina A.] Univ Lyon, Lab Filovirus, INSERM, U758,UCB Lyon 1,Ecole Normale Super Lyon, Lyon, France.
[Weidmann, Manfred] Univ Med Gottingen, Abt Virol, Gottingen, Germany.
RP Kuhn, JH (reprint author), NIAID, Integrated Res Facil Ft Detrick IRF Frederick, DCR, NIH, B-8200 Res Plaza, Frederick, MD 21702 USA.
EM kuhnjens@mail.nih.gov; stn1@cdc.gov
RI Volchkov, Viktor/M-7846-2014; Kuhn, Jens H./B-7615-2011; Ryabchikova,
Elena /G-3089-2013; Netesov, Sergey/A-3751-2013; Becker,
Stephan/A-1065-2010; Palacios, Gustavo/I-7773-2015; Weidmann,
Manfred/G-1817-2015; LEROY, Eric/I-4347-2016;
OI Volchkov, Viktor/0000-0001-7896-8706; Kuhn, Jens H./0000-0002-7800-6045;
Ryabchikova, Elena /0000-0003-4714-1524; Netesov,
Sergey/0000-0002-7786-2464; Becker, Stephan/0000-0002-2794-5659;
Palacios, Gustavo/0000-0001-5062-1938; Weidmann,
Manfred/0000-0002-7063-7491; Shestopalov, Alexander/0000-0002-9734-0620;
LEROY, Eric/0000-0003-0022-0890; Hoenen, Thomas/0000-0002-5829-6305;
Honko, Anna/0000-0001-9165-148X
FU Joint Science and Technology Office for Chem Bio Defense
[TMTI0048_09_RD_T]; NIAID [HHSN272200700016I]; Intramural Research
Program of the NIH, National Library of Medicine; Intramural Research
Program of the NIH, NIAID
FX The content of this publication does not necessarily reflect the views
or policies of the US Department of the Army, the US Department of
Defense or the US Department of Health and Human Services or of the
institutions and companies affiliated with the authors. This work was
funded in part by the Joint Science and Technology Office for Chem Bio
Defense (proposal #TMTI0048_09_RD_T to SB). YC, JHK, and VWJ performed
this work as employees of Tunnell Consulting, Inc., and MGL as an
employee of Lovelace Respiratory Research Institute, both subcontractors
to Battelle Memorial Institute under its prime contract with NIAID,
under Contract No. HHSN272200700016I. This research was also supported
in part by the Intramural Research Program of the NIH, National Library
of Medicine (YB and JRB), and the Intramural Research Program of the
NIH, NIAID (TH).
NR 35
TC 26
Z9 28
U1 0
U2 21
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD MAY
PY 2014
VL 159
IS 5
BP 1229
EP 1237
DI 10.1007/s00705-013-1877-2
PG 9
WC Virology
SC Virology
GA AG9ZB
UT WOS:000335777600048
PM 24190508
ER
PT J
AU Seo, SC
Choung, JT
Chen, BT
Lindsley, WG
Kim, KY
AF Seo, SungChul
Choung, Ji Tae
Chen, Bean T.
Lindsley, William G.
Kim, Ki Youn
TI The level of submicron fungal fragments in homes with asthmatic children
SO ENVIRONMENTAL RESEARCH
LA English
DT Article
DE Bioaerosols; Fine particles; Fungal fragments; Childhood asthmatics;
Mold exposure
ID RELATIVE MOLDINESS INDEX; AIR-POLLUTION; ULTRAFINE PARTICLES;
RESPIRATORY HEALTH; URBAN AIR; MOLD; EXPOSURE; AEROSOLIZATION;
MICROORGANISMS; ASSOCIATIONS
AB Objectives: Much scientific evidence indicates a positive association between moldy environments and respiratory illnesses and/or symptoms (e.g., asthma). Recently, submicron fungal fragments (< 1.0 mu m) have been suggested as a potential contributor to adverse health effects due to their biological composition (e.g., antigens, mycotoxins, and (1,3)-beta-D-glucan) as well as their small size. However, the contribution of exposure to fine fungal particles on adverse health outcomes has been poorly characterized, particularly in homes with asthmatic children. We characterized the airborne level of smaller-sized fungal particles between homes with and without asthmatic children.
Methods: We visited 29 homes with (n=15) and without (n=14) an asthmatic child and sampled submicron fungal fragments in a living room and child's bedroom, along with outdoor sampling, using the NIOSH two-stage sampler. (1,3)-beta-D-glucan of fungal fragments analyzed by Limulus Amebocyte lysate assay (LAL) was used for quantifying their exposure.
Results: Overall, the geometric mean (GM) concentration of (1,3)-beta-D-glucan in submicron fungal fragments in indoor air was two-fold higher in homes with asthmatic children (50.9 pg/m(3)) compared to homes with non-asthmatic children (26.7 pg/m(3)) (P < 0.001). The GM concentration of these particles in child's bedroom in homes with an asthmatic child (66.1 pg/m(3)) was about three times higher than that in homes with non-asthmatic children (23.0 pg/m(3)) (P < 0.001). The relative humidity had a negative correlation with the concentration of (1,3)-beta-D-glucan in submicron fungal fragments (Pearson coefficient=-0.257, P=0.046).
Conclusions: Our findings indicate that homes with asthmatic children have a higher concentration of submicron fungal fragments compared to homes with non-asthmatic children. A greater exposure to smaller-sized fungal particles may occur in homes with an asthmatic child as relative humidity decreases. The very careful control of relative humidity in indoor air is necessary for reducing exposure to fine fungal particles and inhibiting the growth of microorganisms in homes with allergic diseases. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Seo, SungChul; Choung, Ji Tae] Korea Univ, Environm Hlth Ctr Asthma, Seoul, South Korea.
[Choung, Ji Tae] Korea Univ, Coll Med, Dept Pediat, Seoul 136705, South Korea.
[Chen, Bean T.; Lindsley, William G.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA.
[Kim, Ki Youn] Catholic Univ Pusan, Dept Ind Hlth, Pusan, South Korea.
RP Kim, KY (reprint author), Catholic Univ Pusan, Dept Ind Hlth, Pusan, South Korea.
EM kky5@cup.ac.kr
OI Lindsley, William/0000-0003-0720-5829
FU Ministry of Environment, Republic of Korea (MOE)
FX This research was supported by the Ministry of Environment, Republic of
Korea (MOE) as "the Environmental Health Action Program." This support
is greatly appreciated. We are also grateful to all of those who were
involved in data collection at homes.
NR 45
TC 11
Z9 11
U1 0
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD MAY
PY 2014
VL 131
BP 71
EP 76
DI 10.1016/j.envres.2014.02.015
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AH3HU
UT WOS:000336015100011
PM 24657943
ER
PT J
AU Jung, KH
Liu, B
Lovinsky-Desir, S
Yan, BZ
Camann, D
Sjodin, A
Li, Z
Perera, F
Kinney, P
Chillrud, S
Miller, RL
AF Jung, Kyung Hwa
Liu, Bian
Lovinsky-Desir, Stephanie
Yan, Beizhan
Camann, David
Sjodin, Andreas
Li, Zheng
Perera, Frederica
Kinney, Patrick
Chillrud, Steven
Miller, Rachel L.
TI Time trends of polycyclic aromatic hydrocarbon exposure in New York city
from 2001 to 2012: Assessed by repeat air and urine samples
SO ENVIRONMENTAL RESEARCH
LA English
DT Article
DE Temporal variations; Polycyclic aromatic hydrocarbons; Urinary
metabolites; Repeat exposure; Trafficemission; Heating oil combustion
ID FINE PARTICULATE MATTER; BLACK CARBON; RESIDENTIAL INDOOR; METABOLITE
LEVELS; BIRTH COHORT; CHILDREN; VARIABILITY; PREGNANCY; POLLUTION;
ASTHMA
AB Background: Exposure to air pollutants including polycyclic aromatic hydrocarbons (PAH), and specifically pyrene from combustion of fuel oil, coal, traffic and indoor sources, has been associated with adverse respiratory health outcomes. However, time trends of airborne PAR and metabolite levels detected via repeat measures over time have not yet been characterized. We hypothesized that PAH levels, measured repeatedly from residential indoor and outdoor monitors, and children's urinary concentrations of PAR metabolites, would decrease following policy interventions to reduce traffic-related air pollution.
Methods: Indoor PAH (particle- and gas-phase) were collected for two weeks prenatally (n=98), at age 5/6 years (n=397) and age 9/10 years (n=198) since 2001 and at all three age-points (n=27). Other traffic-related air pollutants (black carbon and PM2.5) were monitored indoors simultaneous with PAH monitoring at ages 5/6 (n=403) and 9/10 (n=257) between 2005 and 2012. One third of the homes were selected across seasons for outdoor PAR, BC and PM2.5 sampling. Using the same sampling method, ambient PAR, BC and PM2.5 also were monitored every two weeks at a central site between 2007 and 2012. PAR were analyzed as semivolatile PAM (e.g., pyrene; MW 178-206) (Sigma(8)PAH(semivolatile): Including pyrene (PYR), phenanthrene (PHEN), 1-methylphenanthrene (1-MEPH), 2-methylphenanthrene (2-MEPH), 3-methylphenanthrene (3-MEPH), 9-methylphenanthrene (9-MEPH), 1,7-dimethylphenanthrene (1,7-DMEPH), and 3,6-dimethyl-phenanthrene (3,6-DMEPH)) and the sum of eight nonvolatile PAR (Sigma 8PAH(rionvoiatlie): Including benzo[a]-anthracene (BaA), chrysene/iso-chrysene (Chry), benzo[b]fluoranthene (BbFA), benzo[k]fluoranthene (BkFA), benzo[alpyrene (BaP), indeno[1,2,3-c,d] pyrene (IP), dibenzo[a,h] anthracene (DahA), and benzo[g,h,i]perylene (BghiP); MW 228-278). A spot urine sample was collected from children at child ages 3, 5, 7 and 9 between 2001 and 2012 and analyzed for 10 PAM metabolites.
Results: Modest declines were detected in indoor BC and PM25 levels between 2005 and 2012 (Annual percent change [APC] = -2.08% [p=0.010] and -2.18% [p=0.059] for BC and PM25, respectively), while a trend of increasing pyrene levels was observed in indoor and outdoor samples, and at the central site during the comparable time periods (APC=4.81%, 3.77% and 7.90%, respectively; p < 0.05 for all). No significant time trend was observed in indoor Sigma 8PAH(nonvolatile) levels between 2005 and 2012; however, significant opposite trends were detected when analyzed seasonally (APC= 8.06% [p < 0.01], 3.87% [p < 0.05] for nonheating and heating season, respectively). Similarly, heating season also affected the annual trends (2005-2012) of other air pollutants: the decreasing BC trend (in indoor/outdoor air) was observed only in the nonheating season, consistent with dominating traffic sources that decreased with time; the increasing pyrene trend was more apparent in the heating season. Outdoor PM2.5 levels persistently decreased over time across the seasons. With the analyses of data collected over a longer period of time (2001-2012), a decreasing trend was observed in pyrene (APC= 2.76%; p < 0.01), mostly driven by measures from the nonheating season (APC= 3.54%; p < 0.01). In contrast levels of pyrene and naphthalene metabolites, 1-hydroxypyrene and 2-naphthol, increased from 2001 to 2012 (APC= 6.29% and 7.90% for 1-hydroxypyrene and 2-naphthol, respectively; p < 0.01 for both).
Conclusions: Multiple NYC legislative regulations targeting traffic-related air pollution may have led to decreases in Sigma(8)PAH(nonvolatne) and BC, especially in the nonheating season. Despite the overall decrease in pyrene over the 2001-2012 periods, a rise in pyrene levels in recent years (2005-2012), that was particularly evident for measures collected during the heating season, and 2-naphthol, indicates the contribution of heating oil combustion and other indoor sources to airborne pyrene and urinary 2-naphthol. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Jung, Kyung Hwa; Liu, Bian; Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care Med, New York, NY 10032 USA.
[Lovinsky-Desir, Stephanie] Columbia Univ, Coll Phys & Surg, Dept Pediat, Div Pediat Pulm, New York, NY 10032 USA.
[Yan, Beizhan; Chillrud, Steven] Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.
[Camann, David] Southwest Res Inst, Chem & Chem Engn Div, San Antonio, TX 78228 USA.
[Sjodin, Andreas; Li, Zheng] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hlth Lab Sci, Organ Analyt Toxicol Branch, Atlanta, GA USA.
[Perera, Frederica; Kinney, Patrick; Miller, Rachel L.] Columbia Univ, Columbia Ctr Childrens Environm Hlth, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA.
[Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Dept Pediat, Div Pediat Allergy & Immunol, New York, NY 10032 USA.
RP Miller, RL (reprint author), Columbia Univ, Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care Med, PH8E-101,630W 168 St, New York, NY 10032 USA.
EM rlm14@cumc.columbia.edu
RI Sjodin, Andreas/F-2464-2010;
OI Lovinsky-Desir, Stephanie/0000-0003-2272-4387
FU NIH [R01 ES013163, P50ES015905, P01ES09600, R01ES08977, P30ES09089]; EPA
[R827027, RD832096, RD832141, RD834509]; Educational Foundation of
America; New York Community Trust; Trustees of the Blanchette Hooker
Rockefeller Fund; John & Wendy Neu Family Foundation
FX This work was supported by NIH (R01 ES013163, P50ES015905, P01ES09600,
R01ES08977, P30ES09089), EPA (R827027, RD832096, RD832141, RD834509),
the Educational Foundation of America, the John & Wendy Neu Family
Foundation, the New York Community Trust, and the Trustees of the
Blanchette Hooker Rockefeller Fund.
NR 33
TC 11
Z9 11
U1 4
U2 44
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD MAY
PY 2014
VL 131
BP 95
EP 103
DI 10.1016/j.envres.2014.02.017
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AH3HU
UT WOS:000336015100014
PM 24709094
ER
PT J
AU Spector, JT
De Roos, AJ
Ulrich, CM
Sheppard, L
Sjodin, A
Wener, MH
Wood, B
McTiernan, A
AF Spector, June T.
De Roos, Anneclaire J.
Ulrich, Cornelia M.
Sheppard, Lianne
Sjoedin, Andreas
Wener, Mark H.
Wood, Brent
McTiernan, Anne
TI Plasma polychlorinated biphenyl concentrations and immune function in
postmenopausal women
SO ENVIRONMENTAL RESEARCH
LA English
DT Article
DE Cytotoxicity; Immune function; Lymphocyte proliferation; Persistent
organic pollutants; Polychlorinated biphenyls
ID NON-HODGKIN-LYMPHOMA; KILLER-CELL CYTOTOXICITY; IN-VITRO; ENVIRONMENTAL
CONTAMINANTS; ORGANOCHLORINE LEVELS; PERIPHERAL-BLOOD; CONTROLLED-TRIAL;
ADIPOSE-TISSUE; HUMAN HEALTH; SEAL PUPS
AB Background: Polychlorinated biphenyl (PCB) exposure has been associated with non-Hodgkin lymphoma in several studies, and the immune system is a potential mediator.
Objectives: We analyzed associations of plasma PCBs with immune function measures. We hypothesized that higher plasma PCB concentrations are associated with lower immune function cross-sectionally, and that increases in PCB concentrations over a one year period are associated with decreases in immune function.
Methods: Plasma PCB concentrations and immune function [natural killer (NK) cell cytotoxicity and PHA-induced T-lymphocyte proliferation (PHA-TLP)] were measured at baseline and one year in 109 postmenopausal overweight women participating in an exercise intervention study in the Seattle, Washington (USA) area. Mixed models, with adjustment for body mass index and other potential confounders, were used to estimate associations of PCBs with immune function cross-sectionally and longitudinally.
Results: Associations of PCBs with immune function measures differed across groups of PCBs (e.g., medium- and high-chlorinated and dioxin-like [mono-ortho-substituted]) and by the time frame for the comparison (cross-sectional vs. longitudinal). Higher concentrations of medium- and high-chlorinated PCBs were associated with higher PHA-TLP cross-sectionally but not longitudinally. The mean decrease in 0.5 mu g/mL PHA-TLP/50.0 pmol/g-lipid increase in dioxin-like PCBs over one year was 51.6 (95% confidence interval 2.7, 100.5; P=0.039). There was no association between plasma PCBs and NK cytotoxicity.
Conclusions: These results do not provide strong evidence of impaired cellular immunity from PCB exposure. Larger longitudinal studies with greater variability in PCB exposures are needed to further examine temporal associations of PCBs with immune function. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Spector, June T.; Sheppard, Lianne] Univ Washington, Dept Environm & Occupat Hlth Sci, Sch Publ Hlth, Seattle, WA 98105 USA.
[Spector, June T.; Wener, Mark H.; Wood, Brent; McTiernan, Anne] Univ Washington, Sch Med, Dept Med, Seattle, WA 98105 USA.
[De Roos, Anneclaire J.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Seattle, WA 98109 USA.
[De Roos, Anneclaire J.; Ulrich, Cornelia M.; McTiernan, Anne] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98105 USA.
[Ulrich, Cornelia M.] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98109 USA.
[Ulrich, Cornelia M.] Natl Ctr Tumor Dis, Heidelberg, Germany.
[Ulrich, Cornelia M.] German Canc Res Ctr, Heidelberg, Germany.
[Sheppard, Lianne] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98105 USA.
[Sjoedin, Andreas] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
RP Spector, JT (reprint author), Univ Washington, Dept Environm & Occupat Hlth Sci & Med, 4225 Roosevelt Way NE,Suite 100, Seattle, WA 98105 USA.
EM spectj@uw.edu; ajd335@drexel.edu; neli.ulrich@nct-heidelberg.de;
sheppard@uw.edu; asjodin@cdc.gov; wener@u.washington.edu;
woodbi@u.washington.edu; amctiem@fficrc.org
RI Sjodin, Andreas/F-2464-2010
FU National Institutes of Health National Institute of Environmental Health
Sciences (NIEHS) [R03 ES015787]; National Cancer Institute
[R01CA/AG9334]; NIEHS [T32 ES015459]
FX this research was funded by grants from the National Institutes of
Health National Institute of Environmental Health Sciences (NIEHS) (R03
ES015787) and the National Cancer Institute (R01CA/AG9334). Support for
JTS was provided by NIEHS (T32 ES015459).
NR 55
TC 1
Z9 1
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD MAY
PY 2014
VL 131
BP 174
EP 180
DI 10.1016/j.envres.2014.03.011
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AH3HU
UT WOS:000336015100024
PM 24721136
ER
PT J
AU Guy, GP
Berkowitz, Z
Tai, E
Holman, DM
Jones, SE
Richardson, LC
AF Guy, Gery P., Jr.
Berkowitz, Zahava
Tai, Eric
Holman, Dawn M.
Jones, Sherry Everett
Richardson, Lisa C.
TI Indoor Tanning Among High School Students in the United States, 2009 and
2011
SO JAMA DERMATOLOGY
LA English
DT Article
ID NONMELANOMA SKIN-CANCER; RISK BEHAVIOR SURVEILLANCE;
ULTRAVIOLET-RADIATION; CUTANEOUS MELANOMA; ADOLESCENTS; HEALTH; US;
INTERVENTION; METAANALYSIS; ASSOCIATION
AB IMPORTANCE Indoor tanning is associated with an increased risk of skin cancer, including melanoma, and is particularly dangerous for younger and more frequent indoor tanners.
OBJECTIVE To examine the prevalence of indoor tanning and frequent indoor tanning (> 10 times during the 12 months before each survey) and their association with health-related behaviors.
DESIGN, SETTING, AND PARTICIPANTS A cross-sectional study examined data from the 2009 and 2011 national Youth Risk Behavior Surveys, which used nationally representative samples of US high school students representing approximately 15.5 million students each survey year. The study included 25 861 students who answered the indoor tanning question.
MAIN OUTCOMES AND MEASURES The prevalence of indoor tanning and frequent indoor tanning were examined as well as their association with demographic characteristics and health-related behaviors using multivariable logistic regression modeling.
RESULTS The prevalence of indoor tanning was greater among female, older, and non-Hispanic white students. Indoor tanning was highest among female students aged 18 years or older, with 31.5% engaging in indoor tanning in 2011, and among non-Hispanic white female students, with 29.3% engaging in indoor tanning in 2011. Among female students, the adjusted prevalence of indoor tanning decreased from 26.4% in 2009 to 20.7% in 2011. Among female and male students, indoor tanning was associated with other risk-taking behaviors, such as binge drinking (P <.001 and P =.006, respectively), unhealthy weight control practices (P <.001, for both), and having sexual intercourse (P <.001, for both). Additionally, indoor tanning among female students was associated with using illegal drugs (P <.001) and having sexual intercourse with 4 or more persons (P =.03); use among male students was associated with taking steroids without a physician's prescription (P <.001), smoking cigarettes daily (P =.03), and attempting suicide (P =.006). More than half of respondents engaging in indoor tanning reported frequent use of the devices.
CONCLUSIONS AND RELEVANCE Indoor tanning is common among high school students. Public health efforts are needed to change social norms regarding tanned skin and to increase awareness, knowledge, and behaviors related to indoor tanning. The clustering of risky behaviors suggests a need for coordinated, multifaceted approaches, including primary care physician counseling, to address such behaviors among adolescents.
C1 [Guy, Gery P., Jr.; Berkowitz, Zahava; Tai, Eric; Holman, Dawn M.; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Jones, Sherry Everett] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA.
RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mail Stop F-76, Atlanta, GA 30341 USA.
EM irm2@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 51
TC 20
Z9 20
U1 0
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD MAY
PY 2014
VL 150
IS 5
BP 501
EP 511
DI 10.1001/jamadermatol.2013.7124
PG 11
WC Dermatology
SC Dermatology
GA AH2NH
UT WOS:000335957700006
PM 24577222
ER
PT J
AU Merte, JL
Kroll, CM
Collins, AS
Melnick, AL
AF Merte, Jennifer L.
Kroll, Catherine M.
Collins, Amy S.
Melnick, Alan L.
TI An epidemiologic investigation of occupational transmission of
Mycobacterium tuberculosis infection to dental health care personnel
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Article
DE Mycobacterium tuberculosis; infection prevention and control; contact
investigation; dental office; occupational infection; delayed diagnosis
ID FOR-DISEASE-CONTROL; UNITED-STATES; PREVENTION; GUIDELINES; SETTINGS;
WORKERS
AB Background. The authors describe an investigation of a dental hygienist who developed active pulmonary tuberculosis (TB), worked for several months while infectious and likely transmitted Mycobacterium tuberculosis in a dental setting in Washington state.
Methods. Clark County Public Health (CCPH) conducted an epidemiologic investigation of 20 potentially exposed close contacts and 734 direct-care dental patients in 2010.
Results. Of 20 close contacts, one family member and two coworkers, all of whom were from countries in which TB is endemic, had latent TB infection (LTBI). One U.S.-born coworker experienced a tuberculin skin test (TST) conversion from 0 to 8 millimeters. Of the 305 of 731 (41.7 percent) potentially exposed patients who received a single TST, 23 (7.5 percent) had a positive TST result of at least 5 mm. Among the subset of 157 patients tested by CCPH staff, 16 (10.2 percent) had a positive TST result. The dental office did not have infection prevention and control policies related to TB identification, prevention or education.
Conclusions. The coworker's TST conversion indicated a recent infection, likely owed to occupational transmission. The proportion of dental patients with positive TST results was greater than the 1999-2000 National Health and Nutrition Examination Survey prevalence estimate in the general population, and it may reflect transmission from the hygienist with active TB or a prevalence of LTBI in the community.
C1 [Merte, Jennifer L.] Ctr Dis Control & Prevent, Vancouver, WA USA.
[Merte, Jennifer L.; Melnick, Alan L.] Clark Cty Publ Hlth, Vancouver, WA 98666 USA.
[Kroll, Catherine M.] Clark Cty Publ Hlth, Communicable Dis Program, Vancouver, WA 98666 USA.
[Collins, Amy S.] Ctr Dis Control & Prevent, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
[Melnick, Alan L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Melnick, AL (reprint author), Clark Cty Publ Hlth, 1601 E Fourth Plain Blvd,POB 9825, Vancouver, WA 98666 USA.
EM Alan.Melnick@clark.wa.gov
FU appointment of Jennifer Merte to the Applied Epidemiology Fellowship
Program; U.S. Centers for Disease Control and Prevention
[5U38HM000414-5]
FX This study was supported in part by the appointment of Jennifer Merte to
the Applied Epidemiology Fellowship Program administered by the Council
of State and Territorial Epidemiologists and funded by the U.S. Centers
for Disease Control and Prevention Cooperative Agreement 5U38HM000414-5.
NR 15
TC 4
Z9 4
U1 1
U2 14
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
EI 1943-4723
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD MAY
PY 2014
VL 145
IS 5
BP 464
EP 471
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA AH1YG
UT WOS:000335917200014
PM 24789240
ER
PT J
AU Iliaki, E
Chen, LH
Hamer, DH
Macleod, WB
Jentes, ES
Barnett, ED
Wilson, ME
AF Iliaki, Eirini
Chen, Lin H.
Hamer, Davidson H.
Macleod, William B.
Jentes, Emily S.
Barnett, Elizabeth D.
Wilson, Mary E.
CA Boston Area Travel Med Network
TI Travel to Brazil: Analysis of Data From the Boston Area Travel Medicine
Network (BATMN) and Relevance to Travelers Attending World Cup and
Olympics
SO JOURNAL OF TRAVEL MEDICINE
LA English
DT Article
ID UNITED-STATES; INFECTION; REGIONS; HEALTH; DENGUE; FEVER; RISK
C1 [Iliaki, Eirini] Cambridge Hlth Alliance, Cambridge, England.
[Chen, Lin H.] Mt Auburn Hosp, Cambridge, MA 02138 USA.
[Chen, Lin H.] Harvard Univ, Sch Med, Boston, MA USA.
[Hamer, Davidson H.; Macleod, William B.] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA.
[Hamer, Davidson H.; Macleod, William B.] Boston Univ, Sch Publ Hlth, Dept Int Hlth, Boston, MA USA.
[Hamer, Davidson H.] Boston Univ, Sch Med, Infect Dis Sect, Boston, MA 02118 USA.
[Jentes, Emily S.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA.
[Barnett, Elizabeth D.] Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA USA.
[Wilson, Mary E.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
RP Chen, LH (reprint author), Mt Auburn Hosp, 330 Mt Auburn St, Cambridge, MA 02138 USA.
EM lchen@hms.harvard.edu
FU CDC [1 U19CI000508-01]; Boston Medical Center [1 U19CI000508-01]
FX In addition to the authors, members of the Boston Area Travel Medicine
Network who contributed data include A. W. Karchmer, MD, Beth Israel
Deaconess Medical Center and Harvard Medical School, L. Kogelman, MD,
Tufts Medical Center, and W. W. Ooi, MD, Lahey Clinic Medical Center.
The authors also thank E. Gleva, C. Benoit, R. Dufur, D. Gannon, and M.
Bhussar for their assistance with data collection and entry, and M.
Pfaff for data analysis. This research was funded by a cooperative
agreement (1 U19CI000508-01) between CDC and Boston Medical Center. The
findings and conclusions in this report are those of the authors and do
not necessarily represent the official position of CDC.
NR 16
TC 2
Z9 2
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1195-1982
EI 1708-8305
J9 J TRAVEL MED
JI J. Travel Med.
PD MAY
PY 2014
VL 21
IS 3
BP 214
EP 217
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA AF0ZZ
UT WOS:000334445200012
PM 24673916
ER
PT J
AU Torres, C
Lema, C
Dohmen, FG
Beltran, F
Novaro, L
Russo, S
Freire, MC
Velasco-Villa, A
Mbayed, VA
Cisterna, DM
AF Torres, C.
Lema, C.
Gury Dohmen, F.
Beltran, F.
Novaro, L.
Russo, S.
Freire, M. C.
Velasco-Villa, A.
Mbayed, V. A.
Cisterna, D. M.
TI Phylodynamics of vampire bat-transmitted rabies in Argentina
SO MOLECULAR ECOLOGY
LA English
DT Article
DE Argentina; phylodynamics; phylogeography; rabies virus; vampire bats
ID STATISTICAL PHYLOGENETICS; GENETIC-CHARACTERIZATION; LATIN-AMERICA;
VIRUS; DYNAMICS; BRAZIL; UNCERTAINTY; SEQUENCES; HISTORY; SKYLINE
AB Common vampire bat populations distributed from Mexico to Argentina are important rabies reservoir hosts in Latin America. The aim of this work was to analyse the population structure of the rabies virus (RABV) variants associated with vampire bats in the Americas and to study their phylodynamic pattern within Argentina. The phylogenetic analysis based on all available vampire bat-related N gene sequences showed both a geographical and a temporal structure. The two largest groups of RABV variants from Argentina were isolated from northwestern Argentina and from the central western zone of northeastern Argentina, corresponding to livestock areas with different climatic, topographic and biogeographical conditions, which determined their dissemination and evolutionary patterns. In addition, multiple introductions of the infection into Argentina, possibly from Brazil, were detected. The phylodynamic analysis suggests that RABV transmission dynamics is characterized by initial epizootic waves followed by local enzootic cycles with variable persistence. Anthropogenic interventions in the ecosystem should be assessed taking into account not only the environmental impact but also the potential risk of disease spreading through dissemination of current RABV lineages or the emergence of novel ones associated with vampire bats.
C1 [Torres, C.; Mbayed, V. A.] Univ Buenos Aires, Fac Farm & Bioquim, Catedra Virol, RA-1113 Buenos Aires, DF, Argentina.
[Torres, C.; Mbayed, V. A.] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina.
[Lema, C.; Freire, M. C.; Cisterna, D. M.] Adm Nacl Labs & Inst Salud ANLIS Dr Carlos G Malb, Inst Nacl Enfermedades Infecciosas, Serv Neurovirosis, Buenos Aires, DF, Argentina.
[Gury Dohmen, F.; Beltran, F.] Inst Zoonosis Dr Luis Pasteur, Buenos Aires, DF, Argentina.
[Novaro, L.; Russo, S.] DILAB, SENASA, Buenos Aires, DF, Argentina.
[Velasco-Villa, A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Cisterna, DM (reprint author), Adm Nacl Labs & Inst Salud ANLIS Dr Carlos G Malb, Inst Nacl Enfermedades Infecciosas, Serv Neurovirosis, Av Velez Sarsfield 563,C1282AFF, Buenos Aires, DF, Argentina.
EM dcisterna@anlis.gov.ar
OI Torres, Carolina/0000-0001-6786-8769
FU INEI-ANLIS; Centers for Disease Control and Prevention, Atlanta GA, USA;
American Fellows Program, Partners of the Americas of the USA
Government'
FX This study was supported by INEI-ANLIS 'Dr. Carlos G. Malbran, the
Centers for Disease Control and Prevention, Atlanta GA, USA; and the
American Fellows Program, Partners of the Americas of the USA
Government'.
NR 46
TC 3
Z9 3
U1 2
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1083
EI 1365-294X
J9 MOL ECOL
JI Mol. Ecol.
PD MAY
PY 2014
VL 23
IS 9
BP 2340
EP 2352
DI 10.1111/mec.12728
PG 13
WC Biochemistry & Molecular Biology; Ecology; Evolutionary Biology
SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology;
Evolutionary Biology
GA AF7PX
UT WOS:000334908100018
PM 24661865
ER
EF